FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Bohnert, KM Sripada, RK Mach, J McCarthy, JF AF Bohnert, Kipling M. Sripada, Rebecca K. Mach, Jennifer McCarthy, John F. TI Same-Day Integrated Mental Health Care and PTSD Diagnosis and Treatment Among VHA Primary Care Patients With Positive PTSD Screens SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COLLABORATIVE CARE; RANDOMIZED-TRIAL; MEDICAL HOME; DEPRESSION; VETERANS; SERVICES; INITIATION; OUTCOMES; ACCESS AB Objective: The study examined whether same-day integrated mental health services are associated with increased diagnosis and treatment initiation among primary care patients with positive posttraumatic stress disorder (PTSD) screens. Methods: Data were from a national sample of Veterans Health Administration (VHA) primary care patients with a positive PTSD screen (N=21,427). Patients were assessed for PTSD diagnosis and treatment initiation on the screening day and <= 7 days, <= 12 weeks, <= 6 months, and <= 1 year after screening positive. The service setting on screening day was categorized as primary care only, same-day primary care-mental health integration (PC-MHI), or same-day specialty mental health care. Multivariable generalized estimating equations logistic regression was used to estimate associations between category of screening day services and diagnosis and treatment initiation, with adjustment for demographic characteristics, prior psychiatric diagnoses, prior VHA service utilization, and PTSD screen score. Results: Of the 21,427 patients with positive PTSD screens, 10,809 (50.4%) received a diagnosis within one year of screening positive. Same-day PC-MHI services were associated with greater odds of PTSD diagnosis, both on the same day as (odds ratio [OR]= 2.23) and one year (OR=1.67) after screening positive compared with primary care-only services (p<.001). Among those who received a diagnosis on the same day as their positive screen, same-day PC-MHI services were associated with increased odds of initiating PTSD treatment (OR=3.39) within 12 weeks of diagnosis, compared with primary care only (p<.001). Conclusions: Same-day integrated mental health services may help facilitate PTSD diagnosis and treatment initiation after a positive screen. C1 [Bohnert, Kipling M.; Sripada, Rebecca K.] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Bohnert, Kipling M.; Sripada, Rebecca K.; Mach, Jennifer; McCarthy, John F.] US Dept Vet Affairs, SMITREC, Ann Arbor, MI 48105 USA. [Bohnert, Kipling M.; Sripada, Rebecca K.; McCarthy, John F.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Bohnert, KM (reprint author), US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48105 USA.; Bohnert, KM (reprint author), US Dept Vet Affairs, SMITREC, Ann Arbor, MI 48105 USA.; Bohnert, KM (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. EM kiplingb@med.umich.edu OI Sripada, Rebecca/0000-0002-2844-3458 FU VA Health Services Research & Development Career Development Award [CDA 11-245]; SMITREC Advanced Fellowship Program in Mental Illness Research and Treatment from the VA Office of Academic Affiliations FX Study analyses were conducted as part of the VA National Primary Care-Mental Health Integration Evaluation (Dr. Mach and Dr. McCarthy). Dr. Bohnert is supported by a VA Health Services Research & Development Career Development Award (CDA 11-245). Dr. Sripada is supported by the SMITREC Advanced Fellowship Program in Mental Illness Research and Treatment from the VA Office of Academic Affiliations. NR 28 TC 1 Z9 1 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2016 VL 67 IS 1 BP 94 EP 100 DI 10.1176/appi.ps.201500035 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4SX UT WOS:000377775000016 PM 26423103 ER PT J AU Cunningham, KF Beeson, GC Beeson, CC McDermott, PJ AF Cunningham, Kathryn F. Beeson, Gyda C. Beeson, Craig C. McDermott, Paul J. TI Increased expression of estrogen-related receptor beta during adaptation of adult cardiomyocytes to sustained hypoxia SO AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE LA English DT Article DE Cardiomyocyte; hypoxia; estrogen-related receptor; estrogen-related receptor beta; peroxisome proliferator-activated receptor gamma coactivator-1 ID ELECTRICALLY STIMULATED CONTRACTION; PROMOTES CARDIAC MITOCHONDRIAL; ACID-BINDING PROTEIN; ERR-ALPHA; GENE-EXPRESSION; TRANSCRIPTIONAL NETWORK; PGC-1 COACTIVATORS; FELINE CARDIOCYTES; GAMMA; HEART AB Estrogen-related Receptors (ERR) are members of the steroid hormone receptor superfamily of transcription factors that regulate expression of genes required for energy metabolism including mitochondrial biogenesis, fatty acid oxidation and oxidative phosphorylation. While ERR alpha and EPP gamma isoforms are known to share a wide array of target genes in the adult myocardium, the function of ERR beta has not been characterized in cardiomyocytes. The purpose of this study was to determine the role of ERR beta in regulating energy metabolism in adult cardiomyocytes in primary culture. Adult feline cardiomyocytes were electrically stimulated to contract in either hypoxia (0.5% O-2) or normoxia (21% O-2). As compared to baseline values measured in normoxia, ERR beta mRNA levels increased significantly after 8 hours of hypoxia and remained elevated over 24 h. Conversely, ERR beta mRNA decreased to normoxic levels after 4 hours of reoxygenation. Hypoxia increased expression of the alpha and beta isoforms of Peroxisome Proliferator-Activated Receptor. Coactivator-1 (PGC-1) mRNA by 6-fold and 3-fold, respectively. Knockdown of ERR beta expression via adenoviral-mediated delivery of ERR beta shRNA blocked hypoxia-induced increases in PGC-1 beta mRNA, but not PGC-1 alpha mRNA. Loss of ERR beta had no effect on mtDNA content as measured after 24 h of hypoxia. To determine whether loss of ERR beta affected mitochondrial function, oxygen consumption rates (OCR) were measured in contracting versus quiescent cardiomyocytes in normoxia. OCR was significantly lower in contracting cardiomyocytes expressing ERR beta shRNA than scrambled shRNA controls. Maximal OCR also was reduced by ERR beta knockdown. In conclusion: 1) hypoxia increases in ERR beta mRNA expression in contracting cardiomyocytes; 2) ERR beta is required for induction of the PGC-1 beta isoform in response to hypoxia; 3) ERR beta expression is required to sustain OCR in normoxic conditions. C1 [Cunningham, Kathryn F.; McDermott, Paul J.] Med Univ S Carolina, Dept Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Beeson, Gyda C.; Beeson, Craig C.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [McDermott, Paul J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 301 Strom Thurmond Bldg,114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM mcdermp@musc.edu FU NHLBI NIH HHS [T32 HL007260] NR 41 TC 0 Z9 0 U1 0 U2 0 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2160-200X J9 AM J CARDIOVASC DIS JI Am. J. Cardiovasc. Dis. PY 2016 VL 6 IS 2 BP 46 EP 54 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DO3JQ UT WOS:000377678300004 PM 27335690 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI Pain Medicine and Oxford University Press: Building a Scholarly Pain Community Together SO PAIN MEDICINE LA English DT Editorial Material C1 [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Pain Med, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Pain Med, Philadelphia, PA 19104 USA. EM rgallagher@mail.med.upenn.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 1 EP 2 DI 10.1093/pm/pnv049 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500001 PM 26768182 ER PT J AU DiNapoli, EA Craine, M Dougherty, P Gentili, A Kochersberger, G Morone, NE Murphy, JL Rodakowski, J Rodriguez, E Thielke, S Weiner, DK AF DiNapoli, Elizabeth A. Craine, Michael Dougherty, Paul Gentili, Angela Kochersberger, Gary Morone, Natalia E. Murphy, Jennifer L. Rodakowski, Juleen Rodriguez, Eric Thielke, Stephen Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult - Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment. Part V: Maladaptive Coping SO PAIN MEDICINE LA English DT Review DE Aged; Assessment; Maladaptive Coping; Chronic Pain; Elderly; Low Back Pain; Primary Care; Chronic Low Back Pain ID FEAR-AVOIDANCE BELIEFS; BEHAVIORAL TREATMENT; PERSISTENT PAIN; DISABILITY; DEPRESSION; STRATEGIES; IMPACT; EXPERIENCE; MANAGEMENT; DEMENTIA AB Objective. As part of a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults, this article focuses on maladaptive copinga significant contributor of psychological distress, increased pain, and heightened disability in older adults with CLBP. Methods. A modified Delphi technique was used to develop a maladaptive coping algorithm and table providing the rationale for the various components of the algorithm. A seven-member content expert panel and a nine-member primary care panel were involved in the iterative development of the materials. While the algorithm was developed keeping in mind resources available within the Veterans Health Administration (VHA) facilities, panelists were not exclusive to the VHA, and therefore, materials can be applied in both VHA and civilian settings. The illustrative clinical case was taken from one of the contributors' clinical practice. Results. We present a treatment algorithm and supporting table to be used by providers treating older adults who have CLBP and engage in maladaptive coping strategies. A case of an older adult with CLBP and maladaptive coping is provided to illustrate the approach to management. Conclusions. To promote early engagement in skill-focused treatments, providers can routinely evaluate pain coping strategies in older adults with CLBP using a treatment algorithm. C1 [DiNapoli, Elizabeth A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Craine, Michael] VA Eastern Colorado Healthcare Syst, Denver, CO USA. [Craine, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO 80202 USA. [Dougherty, Paul; Kochersberger, Gary] Canandaigua VA Med Ctr, Canandaigua, NY USA. [Dougherty, Paul] New York Chiropract Coll, Seneca Falls, NY USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [DiNapoli, Elizabeth A.; Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Murphy, Jennifer L.] James A Haley Vet Hosp, Tampa, FL USA. [Murphy, Jennifer L.] Univ S Florida, Tampa, FL USA. [Rodakowski, Juleen] Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA USA. [Rodriguez, Eric; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Thielke, Stephen] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. RP Weiner, DK (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.; Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov OI Rodakowski, Juleen/0000-0002-6397-8124 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 43 TC 2 Z9 2 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 64 EP 73 DI 10.1093/pm/pnv055 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500011 PM 26768183 ER PT J AU Miller, MB Borsari, B Fernandez, AC Yurasek, AM Hustad, JTP AF Miller, Mary Beth Borsari, Brian Fernandez, Anne C. Yurasek, Ali M. Hustad, John T. P. TI Drinking Location and Pregaming as Predictors of Alcohol Intoxication Among Mandated College Students SO SUBSTANCE USE & MISUSE LA English DT Article DE Alcohol; college students; drinking; location; pregaming ID DESCRIPTIVE NORMS; INJUNCTIVE NORMS; BINGE DRINKING; CONSUMPTION; PREVENTION; OUTCOMES; MISPERCEPTIONS; INTERVENTIONS; VALIDATION; BEHAVIOR AB Background: Both drinking location and pregaming have been associated with heavy alcohol use among college students, yet the manner by which they uniquely contribute to alcohol intoxication remains unclear. Objective: The current study examined the unique utility of drinking location and pregaming in predicting alcohol intoxication among college students who violated campus alcohol policy. Method: Eietween 2011 and 2012, mandated college students who reported drinking prior to heir referral events (N = 212, 41% female, 80% White, A4 =19.4 y) completed a computerized assessment of drinking location arid related behaviors as part of larger research trial Chi-squared statistics, tests, one-way analyses of covariance, and regression were used to examine study aims. Results: Parcipants were most likely (44%) to report drinking in off-campus housing prior to the referral event, and approximately half (47%) reported pregaming. Alcohol intoxication on the night of the referral event differed significantly as a function of both drinking location and pregaming, but pregaming did not moderate the association between drinking location arid alcohol intoxication among marl dated students. Female birth sex, pregaming, arid drinking at either fraternities or off-campus housng predicted greater levels of alcohol intoxication on the night of the referral incident, while drinking n a residence hall/dorm predicted lovver intoxication. Fonclusions/fmportance: Drinking location and pregaming are distinct predictors of alcohol intoxication among mandated college students. Future n e veritions may benefitfrom targeting both where arid how college students consume alcohol C1 [Miller, Mary Beth; Borsari, Brian; Fernandez, Anne C.; Yurasek, Ali M.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Borsari, Brian] San Francisco VA Med Ctr, Mental Hlth & Behav Sci Serv, San Francisco, CA USA. [Hustad, John T. P.] Penn State Univ, Coll Med, Dept Med & Publ Hlth Sci, Hershey, PA USA. RP Miller, MB (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Dept Behav & Social Sci, Box G-S121-5, Providence, RI 02912 USA. EM mary_miller@brown.edu FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01-AA015518, 01-AA017874]; VISN1 Career Development Award [V1CDA2012-18]; National Institute on Drug Abuse (NIDA) [T32 DA016184]; National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH) [UL1 TR000127, KL2 TR000126] FX Brian Borsari's contribution to this manuscript was supported by National Institute on Alcohol Abuse and Alcoholism (NIAAA) Grants R01-AA015518 and 01-AA017874 and VISN1 Career Development Award V1CDA2012-18. Anne Fernandez's and Ali Yurasek's contributions to this manuscript were supported by the National Institute on Drug Abuse (NIDA) grant T32 DA016184. John Hustad's contribution was supported by the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health (NIH) through Grants UL1 TR000127 and KL2 TR000126 to Lawrence Sinoway. The contents of this article do not represent the views of the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 39 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2016 VL 51 IS 8 BP 983 EP 992 DI 10.3109/10826084.2016.1152496 PG 10 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA DN8AR UT WOS:000377301800004 PM 27070480 ER PT J AU Yurasek, A Miller, MB Mastroleo, N Lazar, V Borsari, B AF Yurasek, Ali Miller, Mary Beth Mastroleo, Nadine Lazar, Vanessa Borsari, Brian TI Pregaming, Drinking Duration, and Movement as Unique Predictors of Alcohol Use and Cognitions Among Mandated College Students SO SUBSTANCE USE & MISUSE LA English DT Article DE Pregaming; duration of drinking; movement; event-related cognitions; mandated college students; alcohol ID EVENT-LEVEL ASSOCIATIONS; RISK-FACTORS; CONSUMPTION; ADOLESCENTS; AGGRESSION; MOTIVATION; HEALTH; TRENDS; PARTY AB Background: Pregaming is a common phenomenon among college students and is associated with increased risks such as heavy drinking, alcohol-related consequences, and violating campus alcohol policies. However, the mechanism by which pregaming increases student risk is unclear. Objectives: The current study aimed to delineate, the role of personal endorsement of pregaming; duration of an entire drinking episode on the night of an alcohol violation, and movement from one ()cation to another in predicting alcohol use and violation-related cognitions. Methods: Participants (N = 113) were college students who had received an alcohol violation. Hierarchical multiple regressions were conducted to investigate the predictive value of pregaming endorsement, duration of drinking, and movement on drinking behaviors (number of drinks consumed and estimated blood alcohol content (eBAC)] on the night of the alcohol violation as well as violation-related cognitions (responsibility, aversiveness). Results: Pregaming and duration of drinking were significant predictors of alcohol consumption and eBAC on the night of the violation, whereas movement was not, Duration of the drinking episode was significantly related to increased perceived responsibility for the alcohol violation. Conclusions/importance: Self-reported pregaming and the duration of the drinking episode appear to be better targets than movement for prevention and intervention efforts addressing pregaming on college campuses. Interventions should continue focusing on reducing pregaming and its associated consequences, especially for those who report a longer duration of drinking following a pregaming episode C1 [Yurasek, Ali; Miller, Mary Beth; Lazar, Vanessa] Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Mastroleo, Nadine] Binghamton Univ, Community & Publ Affairs Dept, Binghamton, NY USA. [Borsari, Brian] San Francisco VA Med Ctr, Mental Hlth & Behav Sci Serv, San Francisco, CA USA. [Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Yurasek, A (reprint author), Brown Univ, Dept Publ Hlth, Ctr Alcohol & Addict Studies, 121 South Main St, Providence, RI 02906 USA. EM ali_yurasek@brown.edu FU National Institute on Alcohol Abuse and Alcoholism [R01 AA015518] FX This work was supported by the National Institute on Alcohol Abuse and Alcoholism [Grant number R01 AA015518]. NR 37 TC 2 Z9 2 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2016 VL 51 IS 8 BP 993 EP 1001 DI 10.3109/10826084.2016.1152491 PG 9 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA DN8AR UT WOS:000377301800005 PM 27070369 ER PT J AU Silbert, LC Dodge, HH Lahna, D Promjunyakul, NO Austin, D Mattek, N Erten-Lyons, D Kaye, JA AF Silbert, Lisa C. Dodge, Hiroko H. Lahna, David Promjunyakul, Nutta-on Austin, Daniel Mattek, Nora Erten-Lyons, Deniz Kaye, Jeffrey A. TI Less Daily Computer Use is Related to Smaller Hippocampal Volumes in Cognitively Intact Elderly SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; assessment of cognitive disorders/dementia; cognitive aging; MRI; volumetric MRI ID ALZHEIMERS-DISEASE; IMPAIRMENT AB Background: Computer use is becoming a common activity in the daily life of older individuals and declines over time in those with mild cognitive impairment (MCI). The relationship between daily computer use (DCU) and imaging markers of neurodegeneration is unknown. Objective: The objective of this study was to examine the relationship between average DCU and volumetric markers of neurodegeneration on brain MRI. Methods: Cognitively intact volunteers enrolled in the Intelligent Systems for Assessing Aging Change study underwent MRI. Total in-home computer use per day was calculated using mouse movement detection and averaged over a one-month period surrounding the MRI. Spearman's rank order correlation (univariate analysis) and linear regression models (multivariate analysis) examined hippocampal, gray matter (GM), white matter hyperintensity (WMH), and ventricular cerebral spinal fluid (vCSF) volumes in relation to DCU. A voxel-based morphometry analysis identified relationships between regional GM density and DCU. Results: Twenty-seven cognitively intact participants used their computer for 51.3 minutes per day on average. Less DCU was associated with smaller hippocampal volumes (r= 0.48, p = 0.01), but not total GM, WMH, or vCSF volumes. After adjusting for age, education, and gender, less DCU remained associated with smaller hippocampal volume (p = 0.01). Voxel-wise analysis demonstrated that less daily computer use was associated with decreased GM density in the bilateral hippocampi and temporal lobes. Conclusions: Less daily computer use is associated with smaller brain volume in regions that are integral to memory function and known to be involved early with Alzheimer's pathology and conversion to dementia. Continuous monitoring of daily computer use may detect signs of preclinical neurodegeneration in older individuals at risk for dementia. C1 [Silbert, Lisa C.; Dodge, Hiroko H.; Lahna, David; Promjunyakul, Nutta-on; Austin, Daniel; Mattek, Nora; Erten-Lyons, Deniz; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, NIA Layton Aging & Alzheimers Dis Ctr, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Dodge, Hiroko H.; Austin, Daniel; Mattek, Nora; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, NIA Oregon Ctr Aging & Technol ORCATECH, Portland, OR 97239 USA. [Dodge, Hiroko H.] Univ Michigan, Dept Neurol, Michigan Alzheimers Dis Ctr, Ann Arbor, MI USA. [Silbert, Lisa C.; Erten-Lyons, Deniz; Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA. RP Silbert, LC (reprint author), Oregon Hlth & Sci Univ, NIA Layton Aging & Alzheimers Dis Ctr, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM silbertl@ohsu.edu FU NIH [1RO1AG036772, P30 AG008017, P30 AG024978, RO1 AG024059, R01 AG042191] FX This study was sponsored by the NIH (1RO1AG036772, P30 AG008017, P30 AG024978; RO1 AG024059; R01 AG042191). NR 16 TC 2 Z9 2 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 52 IS 2 BP 713 EP 717 DI 10.3233/JAD-160079 PG 5 WC Neurosciences SC Neurosciences & Neurology GA DN1PU UT WOS:000376838700027 PM 26967228 ER PT J AU McAllister, T Zafonte, R Jain, S Flashman, L George, M Grant, G He, F Lohr, J Andaluz, N Summerall, L Paulus, M Raman, R Stein, M AF McAllister, Thomas Zafonte, Ross Jain, Sonia Flashman, Laura George, Mark Grant, Gerald He, Feng Lohr, James Andaluz, Norberto Summerall, Lanier Paulus, Martin Raman, Rema Stein, Murray TI Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with TBI and PTSD SO BRAIN INJURY LA English DT Meeting Abstract C1 [McAllister, Thomas] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA. [Jain, Sonia; He, Feng; Lohr, James; Raman, Rema; Stein, Murray] Univ Calif San Diego, San Diego, CA 92103 USA. [Flashman, Laura] Geisel Sch Med Dartmouth, Lebanon, NH USA. [George, Mark; Summerall, Lanier] Ralph H Johnson VAMC, Charleston, SC USA. [Grant, Gerald] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Andaluz, Norberto] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Paulus, Martin] Laureate Inst Brain Res, Tulsa, OK USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0306 BP 594 EP 595 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200260 ER PT J AU Pape, T Rosenow, J Herrold, A Harton, B Patil, V Guernon, A AF Pape, Therea Rosenow, Joshua Herrold, Amy Harton, Brett Patil, Vijaya Guernon, Ann TI Neurobiological model for use of rTMS plus amantadine as a treatment to modulate and shape neural repair for persons in states of disordered consciousness SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pape, Therea; Herrold, Amy; Harton, Brett] US Dept Vet Affairs, Hines, VA USA. [Pape, Therea; Rosenow, Joshua; Herrold, Amy; Harton, Brett] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Patil, Vijaya] Hines VA & Loyola Stritch Sch Med, Hines, IL USA. [Guernon, Ann] Hines VA & Marianjoy Rehabil Hosp, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0357 BP 615 EP 616 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200308 ER PT J AU Pape, T Harton, B Bhaumik, D Guernon, A Mallinson, T AF Pape, Theresa Harton, Brett Bhaumik, Dulal Guernon, Ann Mallinson, Trudy TI Functional connectivity of networks supporting arousal and awareness: VS versus MCS and clinically meaningful gain from VS and MCS SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pape, Theresa] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Hines, IL USA. [Harton, Brett; Bhaumik, Dulal; Guernon, Ann] Hines VA, Hines, IL USA. [Bhaumik, Dulal] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Guernon, Ann] Marianjoy Rehabil Hosp, Hines, IL USA. [Mallinson, Trudy] George Washington Univ, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0380 BP 625 EP 626 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200331 ER PT J AU McAllister, T Temkin, N Dikmen, S Flashman, L Pagulayan, K Cissell, S Duncan, C Thomas, E Grant, G Summerall, L Stein, M AF McAllister, Thomas Temkin, Nancy Dikmen, Sureyya Flashman, Laura Pagulayan, Kathleen Cissell, Shadha Duncan, Connie Thomas, Elissa Grant, Gerald Summerall, Lanier Stein, Murray TI The structured assessment for evaluation of TBI (SAFE-TBI): A new instrument for assessing previous exposure to TBI SO BRAIN INJURY LA English DT Meeting Abstract C1 [McAllister, Thomas] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Temkin, Nancy; Dikmen, Sureyya; Pagulayan, Kathleen] Univ Washington, Sch Med, Seattle, WA USA. [Flashman, Laura] Geisel Sch Med Dartmouth, Dartmouth, NS, Lebanon. [Cissell, Shadha; Stein, Murray] Univ Calif San Diego, San Diego, CA 92103 USA. [Duncan, Connie] Uniform Serv Univ Hlth Sci, Bethesda, MD USA. [Thomas, Elissa] Madigan Army Med Ctr, Tacoma, WA 98431 USA. [Grant, Gerald] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Summerall, Lanier] Ralph Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0603 BP 714 EP 715 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200519 ER PT J AU Byoj, L Duff, M Turkstra, L AF Byoj, Lindsey Duff, Melissa Turkstra, Lyn TI Emotion recognition of older and younger adults with traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Byoj, Lindsey] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Duff, Melissa] Univ Iowa, Iowa City, IA USA. [Turkstra, Lyn] Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0624 BP 722 EP 723 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200537 ER PT J AU Strigo, I Simmons, A AF Strigo, Irina Simmons, Alan TI Avoiding pain: Compromised pain processing after combat trauma SO BRAIN INJURY LA English DT Meeting Abstract C1 [Strigo, Irina] San Francisco VA Med Ctr, San Francisco, CA USA. [Strigo, Irina] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Simmons, Alan] San Diego Vet Healthcare Syst, San Diego, CA USA. [Simmons, Alan] Univ Calif San Diego, San Diego, CA 92103 USA. RI strigo, irina/L-9882-2016 OI strigo, irina/0000-0002-8799-716X NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0625 BP 723 EP 723 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200538 ER PT J AU Bhaumik, D Bhaumik, R Pape, T AF Bhaumik, Dulal Bhaumik, Runa Pape, Theresa TI Statistical methods for analysing advanced imaging data for traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Bhaumik, Dulal; Bhaumik, Runa] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Bhaumik, Dulal; Bhaumik, Runa] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Pape, Theresa] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0634 BP 726 EP 727 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200546 ER PT J AU Mallinson, T Pape, T Guernon, A AF Mallinson, Trudy Pape, Theresa Guernon, Ann TI Identifying patterns of clinically meaningful recovery of NBF in persons in states of disordered consciousness due to TBI SO BRAIN INJURY LA English DT Meeting Abstract C1 [Mallinson, Trudy] George Washington Univ, Washington, DC USA. [Pape, Theresa] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Hines, IL USA. [Guernon, Ann] Hines VA & Marianjoy Rehabil Hosp, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0633 BP 726 EP 726 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200545 ER PT J AU Coleman, RR Starr, PA Katz, M Glass, GA Volz, M Khandhar, SM Ostrem, JL AF Coleman, Robert R. Starr, Philip A. Katz, Maya Glass, Graham A. Volz, Monica Khandhar, Suketu M. Ostrem, Jill L. TI Bilateral Ventral Intermediate Nucleus Thalamic Deep Brain Stimulation in Orthostatic Tremor SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY LA English DT Article DE Orthostatic tremor; Deep brain stimulation; Tremor; Ventral intermediate nucleus; Outcome; Surgical treatment; Thalamic stimulation AB Background: Orthostatic tremor (OT) is characterized by high-frequency leg tremor when standing still, resulting in a sense of imbalance, with limited treatment options. Ventral intermediate (Vim) nucleus thalamic deep brain stimulation (DBS) has been reported as beneficial in a few cases. Objective: To report clinical outcomes, lead locations, and stimulation parameters in 2 patients with severe medication-refractory OT treated with Vim DBS. Methods: The patients underwent surface electromyography (EMG) to confirm the OT diagnosis. Outcomes were measured as change in tolerated standing time at the last follow-up. Lead locations were quantified using postoperative MRI. Results: Vim DBS was well tolerated and resulted in improvement in standing time (patient 1: 50 s at baseline to 15 min 16 months after surgery; patient 2: 34 s at baseline to 4.2 min 7 months after surgery). Postoperative surface EMG for patient 1 demonstrated a delayed onset of tremor, lower-amplitude tremor, and periods of quiescence, but an unchanged tremor frequency. Conclusion: These cases provide further support for Vim DBS to improve standing time in severe medication-refractory OT. The location of the effective thalamic target for OT does not differ from the effective target for essential tremor. (C) 2016 S. Karger AG, Basel C1 [Coleman, Robert R.; Katz, Maya; Glass, Graham A.; Volz, Monica; Ostrem, Jill L.] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA. [Starr, Philip A.] Univ Calif San Francisco, Neurosurg, San Francisco, CA 94143 USA. [Coleman, Robert R.; Starr, Philip A.; Katz, Maya; Glass, Graham A.; Ostrem, Jill L.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Khandhar, Suketu M.] Kaiser Fdn Hosp, Neurol, Sacramento, CA USA. RP Coleman, RR (reprint author), Univ Calif San Francisco, 1635 Divisadero St,Suite 520-530, San Francisco, CA 94115 USA. EM robert.coleman@ucsf.edu NR 12 TC 2 Z9 2 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1011-6125 EI 1423-0372 J9 STEREOT FUNCT NEUROS JI Stereotact. Funct. Neurosurg. PY 2016 VL 94 IS 2 BP 69 EP 74 DI 10.1159/000444127 PG 6 WC Neurosciences; Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA DM7WQ UT WOS:000376571100001 PM 27002536 ER PT J AU Nguyen, VHV Wong, BM Shen, DD Woo, DT Vu, AV Lie, JD AF Nguyen, Viet-Huong V. Wong, Bonnie M. Shen, Diana D. Woo, Denny T. Vu, Amanda V. Lie, Janette D. TI Early Management of Acute Ischemic Stroke: Focus on IV tPA and Timely Reperfusion SO US PHARMACIST LA English DT Article AB Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approved thrombolytic agent for acute ischemic stroke (AIS). Recently updated American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients with Acute Ischemic Stroke and revisions to Activase labeling have expanded the time window eligibility for tPA treatment and have loosened contraindications surrounding tPA treatment. These changes should promote increased utilization of tPA in AIS, resulting in more instances of timely reperfusion and reduction of neurologic sequelae. C1 [Nguyen, Viet-Huong V.] Chapman Univ, Sch Pharm, Dept Pharm Practice, Pharm Practice, Irvine, CA USA. [Wong, Bonnie M.; Shen, Diana D.; Woo, Denny T.; Vu, Amanda V.] Univ So Calif, Sch Pharm, Los Angeles, CA USA. [Wong, Bonnie M.; Shen, Diana D.; Woo, Denny T.; Vu, Amanda V.] Vet Affairs Greater Los Angeles Healthcare Syst, Pharm VA Learning Opportun Residency VALOR, Los Angeles, CA USA. [Lie, Janette D.] Vet Affairs Greater Los Angeles Healthcare Syst, Pharm Educ & Training, Los Angeles, CA USA. RP Nguyen, VHV (reprint author), Chapman Univ, Sch Pharm, Dept Pharm Practice, Pharm Practice, Irvine, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU JOBSON PUBLISHING LLC PI NEW YORK PA 100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA SN 0148-4818 EI 2331-3501 J9 US PHARM JI US Pharm. PD JAN PY 2016 VL 41 IS 1 BP HS9 EP HS12 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DN0KC UT WOS:000376751800004 ER PT J AU Chen, H Ding, P Geng, Z Zhou, XH AF Chen, Hua Ding, Peng Geng, Zhi Zhou, Xiao-Hua TI Semiparametric Inference of the Complier Average Causal Effect with Nonignorable Missing Outcomes SO ACM TRANSACTIONS ON INTELLIGENT SYSTEMS AND TECHNOLOGY LA English DT Article DE Experimentation; Measurement; Theory; Causal inference; instrumental variable; missing not at random; noncompliance; outcome-dependent missing; principal stratification ID RANDOMIZED EXPERIMENTS; PRINCIPAL STRATIFICATION; TREATMENT-NONCOMPLIANCE; ENCOURAGEMENT DESIGN; CLINICAL-TRIALS; IDENTIFIABILITY; LIKELIHOOD AB Noncompliance and missing data often occur in randomized trials, which complicate the inference of causal effects. When both noncompliance and missing data are present, previous papers proposed moment and maximum likelihood estimators for binary and normally distributed continuous outcomes under the latent ignorable missing data mechanism. However, the latent ignorable missing data mechanism may be violated in practice, because the missing data mechanism may depend directly on the missing outcome itself. Under noncompliance and an outcome-dependent nonignorable missing data mechanism, previous studies showed the identifiability of complier average causal effect for discrete outcomes. In this article, we study the semiparametric identifiability and estimation of complier average causal effect in randomized clinical trials with both all-or-none noncompliance and outcome-dependent nonignorable missing continuous outcomes, and propose a two-step maximum likelihood estimator in order to eliminate the infinite dimensional nuisance parameter. Our method does not need to specify a parametric form for the missing data mechanism. We also evaluate the finite sample property of our method via extensive simulation studies and sensitivity analysis, with an application to a double-blinded psychiatric clinical trial. C1 [Chen, Hua] Inst Appl Phys & Computat Math, POB 8009, Beijing 100088, Peoples R China. [Ding, Peng] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Geng, Zhi] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA. RP Chen, H (reprint author), Inst Appl Phys & Computat Math, POB 8009, Beijing 100088, Peoples R China.; Ding, P (reprint author), Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.; Geng, Z (reprint author), Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China.; Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98101 USA.; Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA. EM chen_hua@iapcm.ac.cn; pengdingpku@gmail.com; zhigeng@pku.edu.cn; azhou@uw.edu FU NSFC [11101045, 11021463, 10931002, 11171365]; CAEP [2012A0201011, 2013A0101004]; Department of Veterans Affairs HSRD RCS Award [05-196] FX Chen's research was supported in part by NSFC 11101045, CAEP 2012A0201011 and CAEP 2013A0101004. Geng's research was supported by NSFC 11021463, 10931002, and 11171365. Zhou's research was supported in part by the Department of Veterans Affairs HSR&D RCS Award 05-196. It does not necessarily represent the views of the VA HSR&D Service. NR 21 TC 0 Z9 0 U1 1 U2 1 PU ASSOC COMPUTING MACHINERY PI NEW YORK PA 2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA SN 2157-6904 EI 2157-6912 J9 ACM T INTEL SYST TEC JI ACM Trans. Intell. Syst. Technol. PD JAN PY 2016 VL 7 IS 2 SI SI AR 19 DI 10.1145/2668135 PG 15 WC Computer Science, Artificial Intelligence; Computer Science, Information Systems SC Computer Science GA DJ8FB UT WOS:000374446800007 ER PT J AU Winter, L Moriarty, HJ Robinson, K Piersol, CV Vause-Earland, T Newhart, B Iacovone, DB Hodgson, N Gitlin, LN AF Winter, Laraine Moriarty, Helene J. Robinson, Keith Piersol, Catherine V. Vause-Earland, Tracey Newhart, Brian Iacovone, Delores Blazer Hodgson, Nancy Gitlin, Laura N. TI Efficacy and acceptability of a home-based, family-inclusive intervention for veterans with TBI: A randomized controlled trial SO BRAIN INJURY LA English DT Article DE Community reintegration; family; in-home service; rehabilitation; traumatic brain injury; veterans ID TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; COMMUNITY REINTEGRATION; SERVICE MEMBERS; NEUROREHABILITATION PROGRAM; OLDER-ADULTS; CAREGIVER; MILITARY; OUTCOMES; INTEGRATION AB Objective: Traumatic brain injury (TBI) often undermines community re-integration, impairs functioning and produces other symptoms. This study tested an innovative programme for veterans with TBI, the Veterans' In-home Programme (VIP), delivered in veterans' homes, involving a family member and targeting the environment (social and physical) to promote community re-integration, mitigate difficulty with the most troubling TBI symptoms and facilitate daily functioning. Setting: Interviews and intervention sessions were conducted in homes or by telephone. Participants: Eighty-one veterans with TBI at a VA polytrauma programme and a key family member. Design: This was a 2-group randomized controlled trial. Control-group participants received usual-care enhanced by two attention-control telephone calls. Follow-up interviews occurred up to 4 months after baseline interview. Main measures: VIP's efficacy was evaluated using measures of community re-integration, target outcomes reflecting veterans' self-identified problems and self-rated functional competence. Results: At follow-up, VIP participants had significantly higher community re-integration scores and less difficulty managing targeted outcomes, compared to controls. Self-rated functional competence did not differ between groups. In addition, VIP's acceptability was high. Conclusion: A home-based, family-inclusive service for veterans with TBI shows promise for improving meaningful outcomes and warrants further research and clinical application. C1 [Winter, Laraine] Philadelphia Res & Educ Fdn, Philadelphia, PA 19104 USA. [Winter, Laraine; Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA. [Moriarty, Helene J.] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Robinson, Keith; Newhart, Brian; Iacovone, Delores Blazer] Dept Vet Affairs Med Ctr, Med Rehabil Serv, Philadelphia, PA 19104 USA. [Robinson, Keith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Piersol, Catherine V.; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA 19107 USA. [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Ctr Innovat Care Aging, Baltimore, MD USA. RP Winter, L (reprint author), Philadelphia Res & Educ Fdn, Philadelphia VA Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM laraine.winter@gmail.com NR 69 TC 2 Z9 2 U1 5 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 4 BP 373 EP 387 DI 10.3109/02699052.2016.1144080 PG 15 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DK1BF UT WOS:000374646200002 PM 26983578 ER PT J AU Li, H McSharry, M Clambey, E Nguyen, T McNamee, E Weiser-Evans, M Nemenoff, R AF Li, Howard McSharry, Maria Clambey, Eric Nguyen, Teresa McNamee, Eoin Weiser-Evans, Mary Nemenoff, Raphael TI Non-small cell lung cancer cells induce PD-L1 expression in the tumor microenvironment in an orthotopic mouse model of lung cancer SO CANCER IMMUNOLOGY RESEARCH LA English DT Meeting Abstract C1 [Li, Howard] Denver VA Med Ctr, Denver, CO USA. [McSharry, Maria; Clambey, Eric; Nguyen, Teresa; McNamee, Eoin; Weiser-Evans, Mary; Nemenoff, Raphael] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD JAN PY 2016 VL 4 IS 1 SU S MA A122 DI 10.1158/2326-6074.CRICIMTEATIAACR15-A122 PG 2 WC Oncology; Immunology SC Oncology; Immunology GA DL2SB UT WOS:000375484400265 ER PT J AU Jiang, X Pu, H Mao, L Xia, J Wang, G Zhang, H Wu, Y Shi, Y Hu, X Gao, Y Chen, J AF Jiang, X. Pu, H. Mao, L. Xia, J. Wang, G. Zhang, H. Wu, Y. Shi, Y. Hu, X. Gao, Y. Chen, J. TI Poststroke EPA/DHA Treatment Combined With Dietary Supplementation of Omega-3 Polyunsaturated Fatty Acids Promotes Long-Term Neurological Recovery After Transient Cerebral Ischemia SO CELL TRANSPLANTATION LA English DT Meeting Abstract CT 23rd Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair (ASNTR) CY APR 29-30, 2016 CL Clearwater, FL SP Amer Soc Neural Therapy & Repair C1 [Jiang, X.; Pu, H.; Mao, L.; Xia, J.; Wang, G.; Zhang, H.; Wu, Y.; Shi, Y.; Hu, X.; Chen, J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Jiang, X.; Pu, H.; Wang, G.; Hu, X.; Gao, Y.; Chen, J.] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Jiang, X.; Pu, H.; Wang, G.; Hu, X.; Gao, Y.; Chen, J.] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Hu, X.; Chen, J.] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 NR 0 TC 0 Z9 0 U1 0 U2 1 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 4 BP 762 EP 763 PG 2 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA DK2BB UT WOS:000374718500056 ER PT J AU Shi, Y Zhang, L Pu, H Mao, L Hu, X Jiang, X Xu, N Stetler, RA Lealc, RK Keep, RF Chen, J AF Shi, Y. Zhang, L. Pu, H. Mao, L. Hu, X. Jiang, X. Xu, N. Stetler, R. A. Lealc, R. K. Keep, R. F. Chen, J. TI Rapid Endothelial Cytoskeletal Reorganization Enables Early Blood Brain Barrier Disruption and Long-Term Ischemic/Reperfusion Brain Injury SO CELL TRANSPLANTATION LA English DT Meeting Abstract CT 23rd Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair (ASNTR) CY APR 29-30, 2016 CL Clearwater, FL SP Amer Soc Neural Therapy & Repair C1 [Shi, Y.; Zhang, L.; Pu, H.; Mao, L.; Hu, X.; Jiang, X.; Xu, N.; Stetler, R. A.; Chen, J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Shi, Y.; Zhang, L.; Hu, X.; Stetler, R. A.; Chen, J.] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lealc, R. K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Keep, R. F.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 4 BP 772 EP 772 PG 1 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA DK2BB UT WOS:000374718500086 ER PT J AU Matthews, AM Fu, RW Dana, T Chou, R AF Matthews, Annette M. Fu, Rongwei Dana, Tracy Chou, Roger TI Intranasal or transdermal nicotine for the treatment of postoperative pain SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID SYSTEMATIC REVIEWS; MANAGEMENT; ANALGESIA; PATCH; SMOKING; NAUSEA; TRIAL; METAANALYSIS; EXPERIENCES; SURGERY AB Background Acute pain frequently occurs after surgical procedures. Nicotine has been explored as an adjunctive medication for management of postoperative pain. Objectives To assess the effect of transdermal or intranasal nicotine administration on postoperative pain, opioid analgesic use, and opioid-related adverse events. Search methods We searched MEDLINE (1966 to 20 March 2014), the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 3), EMBASE (1980 to 20 March 2014), and also databases of ongoing trials (www.controlled-trials.com/ and http://clinicaltrials.gov/). We re-ran the search on 28 April 2015. We will assess the one study of interest when we update the review. Selection criteria We included randomized, placebo-controlled clinical trials that evaluated the effects of perioperative (pre-, intra-, or postoperative) administration of nicotine on postoperative pain, opioid use, and opioid-related adverse events. We excluded all other studies. Data collection and analysis Two authors independently screened all titles and abstracts for eligibility and documented reasons for exclusion. In case of disagreement, a third author decided on the inclusion or exclusion of a trial report. When additional information was needed in order to decide if a trial should be included, one of the authors contacted the corresponding author of the trial in question. Main results Nine trials (666 participants) evaluated nicotine for postoperative pain. Nicotine may reduce postoperative pain scores at 24 hours by a small amount compared with placebo (eight trials, mean difference -0.88 on a 0 to 10 scale, 95% confidence interval (CI) -1.58 to 0.18; low quality evidence). The effect on pain at one hour and 12 hours postoperatively was less certain (very low quality evidence). Statistical heterogeneity was substantial and not adequately explained by stratification of trials according to type of surgical procedure, smoking status, mode of nicotine administration, timing of administration, or assessed risk of bias. Excluding one trial at high risk of bias resulted in similar findings. The effect of nicotine on postoperative opioid use was uncertain due to small number of participants in the studies. Nicotine probably increases the risk of postoperative nausea (seven trials, RR 1.24, 95% CI 1.03 to 1.50; moderate quality evidence). Three trials assessed sedation but the effect is very uncertain due to the very low quality of evidence. We found no evidence that nicotine increased the risk of vomiting (seven studies, risk difference (RD) 0.03, 95% CI -0.04 to 0.09; low quality evidence). The results from one single small trial were insufficient to establish whether nicotine led to an earlier hospital discharge (very low quality evidence). Authors' conclusions Based on evidence of generally low quality, nicotine may reduce postoperative pain at 24 hours compared with placebo, but the effects were relatively small (less than 1 point on a 10 point pain scale) and there was substantial heterogeneity in the results of our analyses. Nicotine does not appear to reduce postoperative use of opioids or opioid-related adverse events but probably increases the risk of nausea. More research is needed to determine the effectiveness of nicotine for postoperative pain and to understand the optimal timing, dose, and method of delivery of nicotine. C1 [Matthews, Annette M.] Portland VA Med Ctr, Dept Behav Hlth & Neurosci, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. [Matthews, Annette M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Matthews, Annette M.; Dana, Tracy; Chou, Roger] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97201 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Prevent Med, Portland, OR 97201 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. [Chou, Roger] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. RP Matthews, AM (reprint author), Portland VA Med Ctr, Dept Behav Hlth & Neurosci, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM Annette.Matthews@va.gov FU Oregon Health & Science University Human Investigations Program, USA; National Center for Research Resources/National Center for Advancing Translational Sciences (NCRR/NCATS) [UL1RR024140]; Veterans Affairs Clinical Sciences Research and Development (CSR&D) Career Development Award, USA FX Internal sources; Oregon Health & Science University Human Investigations Program, USA.; A draft of this protocol was first developed as part of a course on systematic reviews that was sponsored by National Center for Research Resources/National Center for Advancing Translational Sciences (NCRR/NCATS)-funded Clinical and Translational Science Award (CTSA) grant (UL1RR024140).; External sources; Veterans Affairs Clinical Sciences Research and Development (CSR&D) Career Development Award, USA. Awarded to Annette M. Matthews, MD. NR 38 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 1 AR CD009634 DI 10.1002/14651858.CD009634.pub2 PG 125 WC Medicine, General & Internal SC General & Internal Medicine GA DJ7PV UT WOS:000374404200040 PM 26756459 ER PT J AU Benmansour, S Adeniji, OS Privratsky, AA Frazer, A AF Benmansour, Saloua Adeniji, Opeyemi S. Privratsky, Anthony A. Frazer, Alan TI Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats SO NEUROENDOCRINOLOGY LA English DT Article DE Estradiol; Estrogen receptor agonists; Antidepressant; Forced swim test; Signaling pathways ID CENTRAL-NERVOUS-SYSTEM; FORCED SWIM TEST; OBJECT MEMORY CONSOLIDATION; DEPRESSIVE-LIKE BEHAVIOR; SIGNAL-REGULATED KINASE; BETA MESSENGER-RNA; ER-BETA; ANTIDEPRESSANT TREATMENTS; HIPPOCAMPAL-FORMATION; SYNAPTIC PLASTICITY AB Acute estradiol treatment was reported to slow the clearance of serotonin via activation of estrogen receptors (ER)beta and/or GPR30 and to block the ability of a selective serotonin reuptake inhibitor (SSRI) to slow serotonin clearance via activation of ER alpha. In this study, the behavioral consequences of longer-term treatments with estradiol or ER subtype-selective agonists and/or an SSRI were examined in the forced swim test (FST). Ovariectomized rats were administered the following for 2 weeks: estradiol, ER beta agonist (diarylpropionitrile, DPN), GPR30 agonist (G1), ER alpha agonist (PPT), and/or the SSRI sertraline. Similar to sertraline, longer-term treatment with estradiol, DPN or G1 induced an antidepressant-like effect. By contrast, PPT did not, even though it blocked the antidepressant-like effect of sertraline. Uterus weights, used as a peripheral measure of estrogenic activity, were increased by estradiol and PPT but not DPN or G1 treatment. A second part of this study investigated, using Western blot analyses in homogenates from hippocampus, whether these behavioral effects are accompanied by changes in the activation of specific signaling pathways and/or TrkB. Estradiol and G1 increased phosphorylation of Akt, ERK and TrkB. These effects were similar to those obtained after treatment with sertraline. Treatment with DPN increased phosphorylation of ERK and TrkB, but it did not alter that of Akt. Treatment with PPT increased phosphorylation of Akt and ERK without altering that of TrkB. In conclusion, activation of at least TrkB and possibly ERK may be involved in the antidepressant- like effect of estradiol, ER beta and GPR30 agonists whereas Akt activation may not be necessary. (C) 2015 S. Karger AG, Basel C1 [Benmansour, Saloua; Adeniji, Opeyemi S.; Privratsky, Anthony A.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol MC 7764, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Frazer, Alan] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol MC 7764, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM benmansour@uthscsa.edu FU NARSAD; Department of Veterans Affairs; National Institute of Mental Health [MH090386] FX This research was supported by funds from NARSAD, the Department of Veterans Affairs and the National Institute of Mental Health (MH090386). NR 75 TC 3 Z9 3 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 IS 3-4 BP 269 EP 281 DI 10.1159/000437268 PG 13 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA DL6RO UT WOS:000375766500009 PM 26159182 ER PT J AU Moghadam-Kia, S Oddis, CV Aggarwal, R AF Moghadam-Kia, Siamak Oddis, Chester V. Aggarwal, Rohit TI Approach to asymptomatic creatine kinase elevation SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Article ID HYPER-CK-EMIA; STATIN-INDUCED MYOPATHY; MUSCLE BIOPSY; IDIOPATHIC HYPERCKEMIA; PERSISTENT HYPERCKEMIA; LARGE POPULATION; RHABDOMYOLYSIS; HYPOTHYROIDISM; DYSTROPHY; MUTATION AB How to manage a patient who has an elevated serum creatine kinase (CK) level but no or insignificant muscle-related signs and symptoms is a clinical conundrum. The authors provide a systematic approach, including repeat testing after a period of rest, defining higher thresholds over which pursuing a diagnosis is worthwhile, and evaluating for a variety of nonneuromuscular causes. They also outline a workup for neuromuscular causes. C1 [Moghadam-Kia, Siamak; Oddis, Chester V.] Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15261 USA. [Moghadam-Kia, Siamak] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Aggarwal, Rohit] Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Med, Pittsburgh, PA 15261 USA. RP Aggarwal, R (reprint author), Univ Pittsburgh, Dept Med, Div Rheumatol & Clin Immunol, 3601 5th Ave,Suite 2B, Pittsburgh, PA 15261 USA. EM aggarwalr@upmc.edu FU NIAID NIH HHS [T32 AI089443] NR 37 TC 0 Z9 1 U1 0 U2 1 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD JAN PY 2016 VL 83 IS 1 BP 37 EP 42 DI 10.3949/ccjm.83a.14120 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DK3TL UT WOS:000374840200010 PM 26760521 ER PT J AU Wylie, KP Smucny, J Legget, KT Tregellas, JR AF Wylie, Korey P. Smucny, Jason Legget, Kristina T. Tregellas, Jason R. TI Targeting Functional Biomarkers in Schizophrenia with Neuroimaging SO CURRENT PHARMACEUTICAL DESIGN LA English DT Article DE Biomarkers; functional magnetic resonance imaging; fMRI; nicotine; alpha7 nicotinic receptor; functional connectivity; SPEM ID PURSUIT EYE-MOVEMENTS; DEFAULT-MODE NETWORK; CNS DRUG DEVELOPMENT; ACETYLCHOLINE-RECEPTOR; PHARMACOLOGICAL FMRI; TRACKING DYSFUNCTION; NICOTINIC RECEPTORS; LEADING SACCADES; BRAIN NETWORKS; MOUSE MODEL AB Many of the most debilitating symptoms for psychiatric disorders such as schizophrenia remain poorly treated. As such, the development of novel treatments is urgently needed. Unfortunately, the costs associated with high failure rates for investigational compounds as they enter clinical trials has led to pharmaceutical companies downsizing or eliminating research programs needed to develop these drugs. One way of increasing the probability of success for investigational compounds is to incorporate alternative methods of identifying biological targets in order to more effectively screen new drugs. A promising method of accomplishing this goal for psychiatric drugs is to use functional magnetic resonance imaging (fMRI). fMRI investigates neural circuits, shedding light on the biology that generates symptoms such as hallucinations. Once identified, relevant neural circuits can be targeted with pharmacologic interventions and the response to these drugs measured with fMRI. This review describes the early use of fMRI in this context, and discusses the alpha7 nicotinic receptor agonist 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A), as an example of the potential value of fMRI for psychiatric drug development. C1 [Wylie, Korey P.; Smucny, Jason; Legget, Kristina T.; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Denver, CO USA. [Smucny, Jason] Univ Colorado Anschutz Med Campus, Neurosci Program, Denver, CO USA. [Tregellas, Jason R.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA. RP Wylie, KP (reprint author), Anschutz Med Campus, Dept Psychiat, Bldg 500,Mail Stop F546,13001 East 17th Pl, Aurora, CO 80045 USA. EM Korey.Wylie@ucdenver.edu OI Smucny, Jason/0000-0001-5656-7987; Legget, Kristina/0000-0002-2948-506X FU Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service; National Institutes of Health [R01MH102224, R01DK103691, K01DK100445]; Brain and Behavior Research Foundation FX This work was supported by the Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service, the National Institutes of Health grants R01MH102224, R01DK103691, K01DK100445 and the Brain and Behavior Research Foundation. NR 80 TC 1 Z9 1 U1 3 U2 6 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 EI 1873-4286 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PY 2016 VL 22 IS 14 BP 2117 EP 2123 DI 10.2174/1381612822666160127113912 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DK7ZV UT WOS:000375146900014 PM 26818860 ER PT J AU Dai, XM Busby-Whitehead, J Forman, DE Alexander, KP AF Dai, Xuming Busby-Whitehead, Jan Forman, Daniel E. Alexander, Karen P. TI Stable ischemic heart disease in the older adults SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Article DE Aging; Coronary artery disease; Older adults; Risk assessment; Stable ischemic heart disease ID CORONARY-ARTERY-DISEASE; ELDERLY-PATIENTS; ASSOCIATION; TIME; OCTOGENARIANS; TRIAL C1 [Dai, Xuming] Univ N Carolina, Div Cardiol, Chapel Hill, NC USA. [Busby-Whitehead, Jan] Univ N Carolina, Ctr Aging & Hlth, Div Geriatr Med, Chapel Hill, NC USA. [Forman, Daniel E.] Univ Pittsburgh, Sect Geriatr Cardiol, VA Pittsburgh Healthcare Syst, Med Ctr,Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Alexander, Karen P.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. RP Alexander, KP (reprint author), Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. EM karen.alexander@duke.edu NR 20 TC 0 Z9 0 U1 1 U2 1 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2016 VL 13 IS 2 BP 109 EP 114 PG 6 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA DK2WV UT WOS:000374776000002 PM 27168734 ER PT J AU Silva, CGDE Franklin, BA Forman, DE Araujo, CGS AF de Souza e Silva, Christina G. Franklin, Barry A. Forman, Daniel E. Araujo, Claudio Gil S. TI Influence of age in estimating maximal oxygen uptake SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Article DE Aging; Cardiopulmonary exercise testing; Error of measurement ID CYCLE ERGOMETRY EQUATION; ALL-CAUSE MORTALITY; HEALTHY-MEN; CARDIAC REHABILITATION; EXERCISE; HEART; EFFICIENCY; DISEASE; WOMEN; METAANALYSIS AB Objective To assess the influence of age on the error of estimate (EE) of maximal oxygen uptake (VO(2)max) using sex and population specific-equations in cycle ergometer exercise testing, since estimated VO(2)max is associated with a substantial EE, often exceeding 20%, possibly due to intrinsic variability of mechanical efficiency. Methods 1850 adults (68% men), aged 18 to 91 years, underwent maximal cycle ergometer cardiopulmonary exercise testing. Cardiorespiratory fitness (CRF) was assessed relative to sex and age [younger (18 to 35 years), middle-aged (36 to 60 years) and older (>60 years)]. VO(2)max [mL.(kg.min)(-1)] was directly measured by assessment of gas exchange and estimated using sex and population specific-equations. Measured and estimated values of VO(2)max and related EE were compared among the three age-and sex-specific groups. Results Directly measured VO(2)max of men and women were 29.5 +/- 10.5 mL.(kg.min)(-1) and 24.2 +/- 9.0 mL.(kg.min)(-1) (P < 0.01). EE [mL.(kg.min)(-1)] and percent errors (%E) for men and women had similar values, 0.5 +/- 3.2 and 0.4 +/- 2.9 mL.(kg.min)(-1), and -0.8 +/- 13.1% and -1.7 +/- 15.4% (P > 0.05), respectively. EE and %E for each age-group were, respectively, for men: younger = 1.9 +/- 4.1 mL.(kg.min)(-1) and 3.8 +/- 10.5%, middle-aged = 0.6 +/- 3.1 mL.(kg.min)(-1) and 0.4 +/- 10.3%, older = -0.2 +/- 2.7 mL.(kg.min)(-1) and -4.2 +/- 16.6% (P < 0.01); and for women: younger = 1.2 +/- 3.1 mL.(kg.min)(-1) and 2.7 +/- 10.0%, middle-aged = 0.7 +/- 2.8 mL.(kg.min)(-1) and 0.5 +/- 11.1%, older = -0.8 +/- 2.3 mL.(kg.min)(-1) and -9.5 +/- 22.4% (P < 0.01). Conclusion VO(2)max were underestimated in younger age-groups and were overestimated in older age groups. Age significantly influences the magnitude of the EE of VO(2)max in both men and women and should be considered when CRF is estimated using population specific equations, rather than directly measured. C1 [de Souza e Silva, Christina G.; Araujo, Claudio Gil S.] Univ Fed Rio de Janeiro, Heart Inst Edson Saad & Med Sch, Rio De Janeiro, RJ, Brazil. [de Souza e Silva, Christina G.; Araujo, Claudio Gil S.] CLINIMEX, Exercise Med Clin, Rua Siqueira Campos 93-101, BR-22031070 Rio De Janeiro, RJ, Brazil. [Franklin, Barry A.] William Beaumont Hosp, Prevent Cardiol & Cardiac Rehabil, Royal Oak, MI 48072 USA. [Forman, Daniel E.] Univ Pittsburgh, Sect Geriatr Cardiol, Geriatr Res Educ & Clin Ctr, Med Ctr,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Araujo, CGS (reprint author), CLINIMEX, Exercise Med Clin, Rua Siqueira Campos 93-101, BR-22031070 Rio De Janeiro, RJ, Brazil. EM cgaraujo@iis.com.br RI Araujo, Claudio/A-7027-2008 OI Araujo, Claudio/0000-0001-6679-6695 FU CNPq; FAPERJ FX Partial financial support for this study was provided by CNPq and FAPERJ. NR 37 TC 1 Z9 1 U1 0 U2 1 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2016 VL 13 IS 2 BP 126 EP 131 PG 6 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA DK2WV UT WOS:000374776000005 ER PT J AU Kearns, WD Fozard, JL Ray, RD Scott, S Jasiewicz, JM Craighead, JD Pagano, CV AF Kearns, William D. Fozard, James L. Ray, Roger D. Scott, Steven Jasiewicz, Jan M. Craighead, Jeffrey D. Pagano, Craig V. TI Movement Path Tortuosity Predicts Compliance With Therapeutic Behavioral Prompts in Patients With Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE location aware technology; memory prompting and spatial disorientation; movement path tortuosity; traumatic brain injury ID PAGING SYSTEM; MEMORY; PEOPLE; TRIAL; ADULTS AB Objective: Rehabilitation of patients with traumatic brain injury typically includes therapeutic prompts for keeping appointments and adhering to medication regimens. Level of cognitive impairment may significantly affect a traumatic brain injury victim's ability to benefit from text-based prompting. We tested the hypothesis that spatial disorientation as measured by movement path tortuosity during ambulation would be associated with poorer compliance with automated prompts by veterans actively being treated for traumatic brain injury. Setting: Clinical polytrauma center. Participants: Ten (1 female) veteran patients mean age = 35.4 (SD = 12.4) years. Design: Small group correlational study without random assignment. Main Measures: Fractal Dimension, a measure of movement path tortuosity derived from a GPS logging device used to record casual outdoor ambulation at the start of the study. Compliance with smart home machine-generated therapeutic prompts received during rehabilitation at the James A. Haley Veterans Administration Hospital Polytrauma Transitional Rehabilitation Program. A patient was compliant with a prompt if they transited from where the prompt was presented to the prescribed destination (both within the Polytrauma Transitional Rehabilitation Program) within 30 minutes. Noncompliance was failure to appear at the destination within the allotted time. Results: Fractal dimension was significantly inversely related to overall prompt compliance (r = -0.603, n = 10, P = .032; 1-tailed). Conclusions: The findings support the hypothesis that increased spatial disorientation adversely impacts compliance with automated prompts throughout therapy. The results are consistent with previous studies linking elevated path tortuosity to cognitive impairment and increased risk for falls in assisted living facility residents. C1 [Kearns, William D.] Univ S Florida, Coll Behav & Community Sci, Dept Rehabil & Mental Hlth Counseling, 13301 N Bruce B Downs Blvd,MHC 1601, Tampa, FL 33612 USA. [Fozard, James L.] Univ S Florida, Coll Behav & Community Sci, Sch Aging Studies, Tampa, FL 33612 USA. [Ray, Roger D.] Rollins Coll, Dept Psychol, Winter Pk, FL 32789 USA. [Scott, Steven; Pagano, Craig V.] US Dept Vet Affairs, James A Haley Vet Adm Hosp, Phys Med & Rehabil Serv, Tampa, FL USA. [Jasiewicz, Jan M.; Craighead, Jeffrey D.] US Dept Vet Affairs, James A Haley Vet Adm Hosp, Ctr Innovat Disabil & Rehabil Res CINDRR, Tampa, FL USA. RP Kearns, WD (reprint author), Univ S Florida, Coll Behav & Community Sci, Dept Rehabil & Mental Hlth Counseling, 13301 N Bruce B Downs Blvd,MHC 1601, Tampa, FL 33612 USA. EM Kearns@usf.edu RI Kearns, William/F-9810-2015 OI Kearns, William/0000-0002-0241-814X FU US Department of Defense [W81XWH-11-1-0634] FX This research was supported by the US Department of Defense under award number W81XWH-11-1-0634 to Dr Paul Sanberg "Battlefield-Related Injury Translational Research, Post-Traumatic Disease, and Disability Veterans Injury Translational Research, Post-Traumatic Disease, and Disability Veterans Re-Integration." NR 23 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2016 VL 31 IS 1 BP E20 EP E27 DI 10.1097/HTR.0000000000000126 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DK9CN UT WOS:000375228000003 PM 25931182 ER PT J AU Moriarty, HJ Robinson, JP Bunting-Perry, L Bradway, CW AF Moriarty, Helene J. Robinson, Joanne P. Bunting-Perry, Lisette Bradway, Christine W. TI Cognitive, Affective, and Behavioral Dimensions of the Lower Urinary Tract Symptom Experience in Men With Parkinson's Disease SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article DE lower urinary tract symptoms; military veterans; Parkinson's disease; symptom experience; urinary incontinence ID QUALITY-OF-LIFE; VOIDING DYSFUNCTION; INCONTINENCE; DEPRESSION; MANAGEMENT; IMPACT; ADULTS; WOMEN; STATE AB OBJECTIVE: Lower urinary tract symptoms (LUTS) in persons with Parkinson's disease (PD) have received little research attention. To address this gap in our knowledge, we examined the LUTS experience in men with PD, guided by The Theory of Unpleasant Symptoms. METHODS: A qualitative design was used to explore the LUTS experience in this population. Participants were recruited from a Veterans' Affairs PD Center. Maximum variation sampling was used to select diverse participants for audiotaped open-ended interviews. Additional data sources included field notes collected during interviews and observation of a PD support group. The template organizing analytic approach was used to code transcribed interviews and field notes. RESULTS: Cognitive, affective, and behavioral dimensions of the LUTS experience were identified. Participants attributed LUTS to aging, medications, and effects of motor symptoms on their ability to respond to the urge to void. There was little awareness of the neurologic contributions of PD to LUTS, and most viewed LUTS as "something that you have to put up with." Negative effects of LUTS on self-identity were noted, which jeopardized relationships, intimacy, participation in social activities, and travel. Affective responses to LUTS, particularly embarrassment, had a profound impact on quality of life. Behavioral strategies to manage LUTS focused on "being prepared to go when you need to go" and consisted mostly of trial-and-error efforts. CONCLUSION: Misconceptions about LUTS among men with PD may result in underreporting, missed opportunities for professional assistance, and diminished health-related quality of life. Future research should focus on developing and testing nursing interventions to address cognitive, affective, and behavioral aspects of the LUTS experience in men with PD. C1 [Moriarty, Helene J.] Villanova Univ, Coll Nursing, 800 Lancaster Ave, Villanova, PA 19085 USA. [Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA. [Robinson, Joanne P.] Rutgers State Univ, Sch Nursing, Camden, NJ 08102 USA. [Bunting-Perry, Lisette] Univ Delaware, Sch Nursing, Newark, DE 19716 USA. [Bunting-Perry, Lisette] Dept Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Bradway, Christine W.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Moriarty, HJ (reprint author), Villanova Univ, Coll Nursing, 800 Lancaster Ave, Villanova, PA 19085 USA. EM Helene.moriarty@villanova.edu FU Hollister Grant for Continence Nursing from the Wound Ostomy Continence Nursing Society's Center for Clinical Investigation FX The project described was funded by the Hollister Grant for Continence Nursing, from the Wound Ostomy Continence Nursing Society's Center for Clinical Investigation. The research team thanks the veterans with Parkinson's disease who gave of themselves and their time to share their stories and take part in this study. NR 43 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1071-5754 EI 1528-3976 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD JAN-FEB PY 2016 VL 43 IS 1 BP 80 EP 87 DI 10.1097/WON.0000000000000165 PG 8 WC Nursing SC Nursing GA DK9EO UT WOS:000375233800012 PM 26727686 ER PT J AU Milburn, E Warren, T Dickey, MW AF Milburn, Evelyn Warren, Tessa Dickey, Michael Walsh TI World knowledge affects prediction as quickly as selectional restrictions: evidence from the visual world paradigm SO LANGUAGE COGNITION AND NEUROSCIENCE LA English DT Article DE Language comprehension; plausibility; eye tracking; sentence processing; prediction ID ANTICIPATORY EYE-MOVEMENTS; LANGUAGE COMPREHENSION; EVENT KNOWLEDGE; TIME-COURSE; INTEGRATION; VERBS; VIOLATIONS; MODELS AB There has been considerable debate regarding the question of whether linguistic knowledge and world knowledge are separable and used differently during processing or not (Hagoort et al, 2004). Integration of word meaning and world knowledge in language comprehension (Matsuki et al, 2011). Event-based plausibility immediately influences on-line language comprehension (Paczynski et al, 2012). Multiple influences of semantic memory on sentence processing: Distinct effects of semantic relatedness on violations of real-world event/state knowledge and animacy selection restrictions (Warren et al, 2007). Investigating effects of selectional restriction violations and plausibility violation severity on eye movements in reading. Previous investigations into this question have provided mixed evidence as to whether violations of selectional restrictions are detected earlier than violations of world knowledge. We report a visual world eye-tracking study comparing the timing of facilitation contributed by selectional restrictions vs. world knowledge. College-aged adults (n=36) viewed photographs of natural scenes while listening to sentences. Participants anticipated upcoming direct objects similarly regardless of whether facilitation was provided by only world knowledge or a combination of selectional restrictions and world knowledge. These results suggest that selectional restrictions are not available earlier in comprehension than world knowledge. C1 [Milburn, Evelyn; Warren, Tessa] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Milburn, Evelyn; Warren, Tessa] Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Milburn, E (reprint author), Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.; Milburn, E (reprint author), Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA USA. EM eam115@pitt.edu FU National Institutes of Health [R01DC011520] FX This research was supported by the National Institutes of Health under grant R01DC011520 to the second and third authors. NR 29 TC 0 Z9 0 U1 2 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2327-3798 EI 2327-3801 J9 LANG COGN NEUROSCI JI Lang. Cogn. Neurosci. PY 2016 VL 31 IS 4 BP 536 EP 548 DI 10.1080/23273798.2015.1117117 PG 13 WC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology GA DK5VO UT WOS:000374989100017 PM 27148555 ER PT J AU Ni, A Yang, T Mesnard-Hoaglin, NA Gutierrez, R Stubbs, EB McGuire, SO Sanders, VM Jones, KJ Foecking, EM Xin, JP AF Ni, Allen Yang, Tao Mesnard-Hoaglin, Nichole A. Gutierrez, Rafael Stubbs, Evan B., Jr. McGuire, Susan O. Sanders, Virginia M. Jones, Kathryn J. Foecking, Eileen M. Xin, Junping TI Th17 Cell Response in SOD1(G93A) Mice following Motor Nerve Injury SO MEDIATORS OF INFLAMMATION LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; REGULATORY T-LYMPHOCYTES; MEDIATE NEUROPROTECTION; THERAPEUTIC-STRATEGIES; ALS; INFLAMMATION; AXOTOMY; SERUM AB An increased risk of ALS has been reported for veterans, varsity athletes, and professional football players. The mechanism underlying the increased risk in these populations has not been identified; however, it has been proposed that motor nerve injury may trigger immune responses which, in turn, can accelerate the progression of ALS. Accumulating evidence indicates that abnormal immune reactions and inflammation are involved in the pathogenesis of ALS, but the specific immune cells involved have not been clearly defined. To understand how nerve injury and immune responses may contribute to ALS development, we investigated responses of CD4(+) T cell after facial motor nerve axotomy (FNA) at a presymptomatic stage in a transgenic mouse model of ALS (B6SJL SOD1(G93A)). SOD1(G93A) mice, compared with WT mice, displayed an increase in the basal activation state of CD4(+) T cells and higher frequency of Th17 cells, which were further enhanced by FNA. In conclusion, SOD1(G93A) mice exhibit abnormal CD4(+) T cell activation with increased levels of Th17 cells prior to the onset of neurological symptoms. Motor nerve injury exacerbates Th17 cell responses and may contribute to the development of ALS, especially in those who carry genetic susceptibility to this disease. C1 [Ni, Allen; Gutierrez, Rafael; Xin, Junping] Loyola Univ Chicago, Oncol Res Inst, Maywood, IL 60153 USA. [Ni, Allen; Mesnard-Hoaglin, Nichole A.; Stubbs, Evan B., Jr.; McGuire, Susan O.; Foecking, Eileen M.; Xin, Junping] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. [Yang, Tao] Gansu Prov Chinese Tradit Med Hosp, Dept Brain Dis, Lanzhou 730050, Gansu, Peoples R China. [Stubbs, Evan B., Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Ophthalmol, Maywood, IL 60153 USA. [Sanders, Virginia M.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Jones, Kathryn J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Jones, Kathryn J.] Roudebush VA Hosp, Res & Dev Serv, Indianapolis, IN 46202 USA. [Foecking, Eileen M.] Loyola Univ, Ctr Med, Dept Otolaryngol, Maywood, IL 60153 USA. [Xin, Junping] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA. RP Xin, JP (reprint author), Loyola Univ Chicago, Oncol Res Inst, Maywood, IL 60153 USA.; Xin, JP (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.; Xin, JP (reprint author), Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA. EM researchtreg@gmail.com FU Muscular Dystrophy Association [MDA202906]; NIH [NIH 40433, R21-CA181970]; Leukemia Research Foundation; Gansu Chinese Medicine Administration [GZK-2014-11] FX This work was supported by a grant from Muscular Dystrophy Association (MDA202906 to Junping Xin) and partially by NIH grant (NIH 40433 to Kathryn J. Jones and Virginia M. Sanders). Junping Xin was also supported in part by grants from NIH (R21-CA181970) and the Leukemia Research Foundation (New Investigator Award, 8th Annual George Richard Memorial Grant). Tao Yang was supported by a grant from Gansu Chinese Medicine Administration (GZK-2014-11). The authors thank Ms. Patricia Simms and Ms. Ashley Hess for assistance with FACS analysis and Drs. Jiwang Zhang, James Walter, Gwendolyn L. Kartje, William Wolf, Keith Fargo, Haiyan Chen, and Cynthia Pervan for ongoing professional support and collaborations, as well as scientific suggestions and discussions. NR 16 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 EI 1466-1861 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2016 AR 6131234 DI 10.1155/2016/6131234 PG 7 WC Cell Biology; Immunology SC Cell Biology; Immunology GA DL0GN UT WOS:000375310500001 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Design of Clinical Trials in Acute Kidney Injury: Lessons from the Past and Future Directions SO SEMINARS IN NEPHROLOGY LA English DT Review DE Acute kidney injury; clinical trial; prevention; treatment ID CONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; ATRIAL-NATRIURETIC-PEPTIDE; GROWTH-FACTOR-I; RADIOCONTRAST-INDUCED NEPHROPATHY; RANDOMIZED-CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; ACUTE TUBULAR-NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; MELANOCYTE-STIMULATING HORMONE AB Acute kidney injury (AKI) is a common condition with multiple etiologies and variable clinical findings and pathologic manifestations. AKI is associated with serious adverse clinical outcomes, including the development of de novo chronic kidney disease, accelerated progression of pre-existing chronic kidney disease, end-stage kidney disease, and increased mortality. Past research has advanced our understanding of the pathophysiology, epidemiology, and outcomes of AKI significantly, however, little progress has been made in the development of evidence-based interventions for its prevention and treatment. In this review, we discuss key considerations in the design of clinical trials in AKI and highlight significant methodologic limitations that precluded many past studies from determining the effectiveness of preventive and therapeutic strategies for this common and serious condition. Published by Elsevier Inc. C1 [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Sect,VA Pittsburgh Healthcare Syst,Renal El, Pittsburgh, PA 15213 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Dept Med, Renal Sect, Renal Electrolyte Div, 7 East,Room 120 111F-U,Univ Dr Div, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 89 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 EI 1558-4488 J9 SEMIN NEPHROL JI Semin. Nephrol. PD JAN PY 2016 VL 36 IS 1 BP 42 EP 52 DI 10.1016/j.semnephrol.2016.01.004 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DK4TZ UT WOS:000374914500006 PM 27085734 ER PT J AU Hossein-nezhad, A Fatemi, RP Ahmad, R Peskind, ER Zabetian, CP Hu, SC Shi, M Wahlestedt, C Zhang, J Faghihi, MA AF Hossein-nezhad, Arash Fatemi, Roya Pedram Ahmad, Rili Peskind, Elaine R. Zabetian, Cyrus P. Hu, Shu-Ching Shi, Min Wahlestedt, Claes Zhang, Jing Faghihi, Mohammad Ali TI Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease SO JOURNAL OF PARKINSONS DISEASE LA English DT Article DE Parkinson disease; RNA sequencing; cerebrospinal fluid; biomarkers; long noncoding RNA ID LARGE GENE LISTS; ALPHA-SYNUCLEIN; NONCODING RNAS; BIOMARKERS; SUSCEPTIBILITY; GENERATION; NDUFV2; MIRNA AB Background: Parkinson's disease (PD) is a debilitating neurological disorder for which prognostic and diagnostic biomarkers are lacking. Cerebrospinal fluid (CSF) is an accessible body fluid that comes into direct contact with the central nervous system (CNS) and acts as a nuclease-free repository where RNA transcripts shed by brain tissues can reside for extended periods of time. Objective: We studied the RNA species present in the CSF of PD patients to identify novel diagnostic biomarkers. Methods: Small volumes of CSF from 27 PD patients and 30 healthy age-and sex-matched controls were used for RNA extraction followed by next-generation sequencing (RNA-seq) using the Illumina platform. CSF contains a number of fragmented RNA species that were individually sequenced and analyzed. Comparing PD to control subjects, we observed a pool of dysregulated sequencing tags that were further analyzed and validated by quantitative real-time PCR (qRT-PCR). Results: A total of 201 differentially expressed sequencing tags (DETs), including 92 up-regulated and 109 down-regulated DETs were identified. We validated the following DETs by real time PCR in the patient samples: Dnmt1, Ezh2, CCR3, SSTR5, PTPRC, UBC, NDUFV2, BMP7, SCN9, SCN9 antisense (AC010127.3), and long noncoding RNAs AC079630 and UC001lva. 4 (close to the LRRK2 gene locus), as potential PD biomarkers. Conclusions: The CSF is a unique environment that contains many species of RNA. Our work demonstrates that CSF can potentially be used to identify biomarkers for the detection and tracking of disease progression and evaluation of therapeutic outcomes. C1 [Hossein-nezhad, Arash; Fatemi, Roya Pedram; Ahmad, Rili; Wahlestedt, Claes; Faghihi, Mohammad Ali] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA. [Faghihi, Mohammad Ali] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. RP Faghihi, MA (reprint author), 1501 NW 10th Ave,Biomed Res Bldg,Room 508, Miami, FL 33136 USA. EM mfaghihi@med.miami.edu OI Hossein-nezhad, Arash/0000-0003-2847-4737 FU NIH [P50NS071674, U01 NS082137, P50 NS062684, P50 NIA AG05136] FX NIH grants P50NS071674 supporting AH and part of MAF as well as sequencing costs, U01 NS082137 (to JZ), P50 NS062684 (PANUC), and P50 NIA AG05136 (to EP). NR 39 TC 2 Z9 2 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 EI 1877-718X J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2016 VL 6 IS 1 BP 109 EP 117 DI 10.3233/JPD-150737 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DK0YL UT WOS:000374638600011 PM 26889637 ER PT J AU Pandhi, N Schumacher, JR Thorpe, CT Smith, MA AF Pandhi, Nancy Schumacher, Jessica R. Thorpe, Carolyn T. Smith, Maureen A. TI Cross-sectional study examining whether the extent of first-contact access to primary care differentially benefits those with certain personalities to receive preventive services SO BMJ OPEN LA English DT Article DE PRIMARY CARE; PREVENTIVE MEDICINE ID 5-FACTOR MODEL; INFLUENZA VACCINATION; UNITED-STATES; OLDER-ADULTS; PREDICTORS; MAMMOGRAPHY; VALIDATION; OBSERVERS; TRAITS; HEALTH AB Objective The extent of first-contact access to primary care (ie, easy availability when needed) is associated with receiving recommended preventive services. Whether this access benefits patients at risk of preventive services underutilisation, such as those with certain personality characteristics, is unclear. Setting Secondary analysis of the 2003-2006 round of the Wisconsin Longitudinal Study. Participants 6975 respondents who reported a usual provider whose specialty was internal medicine or family medicine. Those reporting not visiting a medical provider in the past 12months, and those who were uninsured were excluded. Primary outcome measures Receiving mammography, cholesterol testing and influenza vaccination. Adjusted predicted probabilities (aPP) of receiving these services were analysed stratified by personality characteristics overall, and if significant, then interacted with first-contact access. Results Lower conscientiousness as compared with higher conscientiousness predicted less of all 3 preventive services; mammography (aPP 80%; 95% CI (77% to 83%) vs aPP 85%; (95% CI 82% to 87%)), cholesterol testing (88%; (85% to 90%) vs 93% (91% to 94%), and influenza vaccination (62%; (59% to 64%) vs 66%; (63% to 68%)). Lower agreeableness as compared with higher agreeableness predicted less mammography (77%; (73% to 81%) vs 84%; (82% to 87%)) and less influenza vaccination (59%; (56% to 62%) vs 65%; (63% to 68%)). Lower extraversion predicted less cholesterol testing (88%; (86% to 91%) vs (92%; (90% to 94%)). Lower openness to experience predicted less influenza vaccination (59%; (56% to 63%) vs (68%; (65% to 70%)). For agreeableness, these differences in receiving preventive services did not persist when first-contact access to primary care was present. Conclusions Certain personality characteristics predicted receiving less preventive care services. For those with less agreeableness, improved first-contact access to primary care mitigated this effect. If these results are replicated in other studies, primary care offices seeking to improve population health through receiving preventive services should prioritise increasing their first-contact accessibility. C1 [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, Madison, WI USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Dept Populat Hlth Sci, Madison, WI USA. [Schumacher, Jessica R.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Philadelphia, PA USA. [Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. RP Pandhi, N (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, Madison, WI USA.; Pandhi, N (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Dept Populat Hlth Sci, Madison, WI USA. EM nancy.pandhi@fammed.wisc.edu FU Clinical and Translational Science Award (CTSA) programme; National Center for Research Resources (NCRR) [1UL1RR025011]; National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]; National Institute on Aging Mentored Clinical Scientist Research Career Development Award [1 K08 AG029527]; University of Wisconsin Carbone Cancer Center (UWCCC) Support Grant from the National Cancer Institute [P30 CA014520]; UW School of Medicine and Public Health from the Wisconsin Partnership Program FX This work was supported by the Clinical and Translational Science Award (CTSA) programme, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. The content is solely the responsibility of the authors, and does not necessarily represent the official views of the NIH, the Department of Veterans Affairs or the USA government. In addition, NP was supported by a National Institute on Aging Mentored Clinical Scientist Research Career Development Award, grant number 1 K08 AG029527. This project was also supported by the University of Wisconsin Carbone Cancer Center (UWCCC) Support Grant from the National Cancer Institute, grant number P30 CA014520. Additional support was provided by the UW School of Medicine and Public Health from the Wisconsin Partnership Program. NR 38 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 3 AR e009738 DI 10.1136/bmjopen-2015-009738 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DJ2RH UT WOS:000374052300039 PM 26951211 ER PT J AU Gray, NE Zweig, JA Kawamoto, C Quinn, JF Copenhaver, PF AF Gray, Nora E. Zweig, Jonathan A. Kawamoto, Colleen Quinn, Joseph F. Copenhaver, Philip F. TI STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-beta Toxicity SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta toxicity; mitochondrial dysfunction; neuroprotection; selective estrogen receptor modulator ID TRANSGENIC MOUSE MODEL; INDUCED NEURONAL DEATH; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; PRECURSOR PROTEIN; OXIDATIVE STRESS; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; BIOENERGETIC DEFICITS; COGNITIVE IMPAIRMENT AB Because STX is a selective ligand for membrane estrogen receptors, it may be able to confer the beneficial effects of estrogen without eliciting the deleterious side effects associated with activation of the nuclear estrogen receptors. This study evaluates the neuroprotective properties of STX in the context of amyloid-beta (A beta) exposure. MC65 and SH-SY5Y neuroblastoma cell lines, as well as primary hippocampal neurons from wild type (WT) and Tg2576 mice, were used to investigate the ability of STX to attenuate cell death, mitochondrial dysfunction, dendritic simplification, and synaptic loss induced by A beta. STX prevented A beta-induced cell death in both neuroblastoma cell lines; it also normalized the decrease in ATP and mitochondrial gene expression caused by A beta in these cells. Notably, STX also increased ATP content and mitochondrial gene expression in control neuroblastoma cells (in the absence of A beta). Likewise in primary neurons, STX increased ATP levels and mitochondrial gene expression in both genotypes. In addition, STX treatment enhanced dendritic arborization and spine densities in WT neurons and prevented the diminished outgrowth of dendrites caused by A beta exposure in Tg2576 neurons. These data suggest that STX can act as an effective neuroprotective agent in the context of A beta toxicity, improving mitochondrial function as well as dendritic growth and synaptic differentiation. In addition, since STX also improved these endpoints in the absence of A beta, this compound may have broader therapeutic value beyond Alzheimer's disease. C1 [Gray, Nora E.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. [Zweig, Jonathan A.; Kawamoto, Colleen; Copenhaver, Philip F.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR USA. RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM grayn@ohsu.edu FU Department of Veterans Affairs Merit Review grant; NIH [NS078363, AG025525, P30 NS061800]; OHSU School of Medicine Faculty Innovation Fund FX This work was funded by a Department of Veterans Affairs Merit Review grant awarded to J. Quinn, and by NIH grants NS078363 and AG025525 awarded to P. Copenhaver. The authors thank Dr. Martin Kelly for providing his expertise and the STX used in this study, and Dr. Gary Banker and Ms. Barbara Smoody for their support of our experiments with primary hippocampal neurons. We also wish to thank Ms. Jenna Fisk for her assistance with image acquisition in some of our studies. Dr. Doris Kretzschmar provided critical input on this manuscript. We gratefully acknowledge Dr. Stefanie Kaech and Ms. Aurelie Snyder for their invaluable assistance with the confocal imaging analysis that was performed in the Advanced Light Microscopy Core, Jungers Center, OHSU. Confocal imaging was supported in part by NIH P30 NS061800, and by the OHSU School of Medicine Faculty Innovation Fund (to P. Copenhaver). MC65 cells were generously provided by Randy Woltjer, MD, PhD. NR 92 TC 1 Z9 2 U1 2 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 51 IS 2 BP 391 EP 403 DI 10.3233/JAD-150756 PG 13 WC Neurosciences SC Neurosciences & Neurology GA DJ5IJ UT WOS:000374240000007 PM 26890746 ER PT J AU Gurubhagavatula, I Patil, S Meoli, A Olson, R Sullivan, S Berneking, M Watson, NF AF Gurubhagavatula, Indira Patil, Susheel Meoli, Amy Olson, Ryan Sullivan, Shannon Berneking, Michael Watson, Nathaniel F. CA Amer Acad Sleep Med TI Sleep Apnea Evaluation of Commercial Motor Vehicle Operators SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material C1 [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Div Sleep Med, Occupat Sleep Med, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Sleep Med Clin, Philadelphia, PA USA. [Patil, Susheel] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Meoli, Amy] Penn State Hershey Sleep Res & Treatment Ctr, Hummelstown, PA USA. [Olson, Ryan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sullivan, Shannon] Stanford Univ, Div Sleep Med, Dept Psychiat, Palo Alto, CA 94304 USA. [Berneking, Michael] Concentra, Grand Rapids, MI USA. [Watson, Nathaniel F.] Univ Washington, UW Med Sleep Ctr, Seattle, WA 98195 USA. Amer Acad Sleep Med, Sleep & Transportat Safety Awareness Task Force, Darien, IL 60561 USA. RP Gurubhagavatula, I (reprint author), Amer Acad Sleep Med, Sleep & Transportat Safety Awareness Task Force, 2510 N Frontage Rd, Darien, IL 60561 USA. NR 11 TC 0 Z9 0 U1 2 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 3 BP 285 EP 286 AR PII jc-00060-16 DI 10.5664/jcsm.5560 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XI UT WOS:000374139600001 PM 26857051 ER PT J AU Primeau, M Gershon, A Talbot, L Cotto, I Lotspeich, L Hardan, A Hallmayer, J O'Hara, R AF Primeau, Michelle Gershon, Anda Talbot, Lisa Cotto, Isabelle Lotspeich, Linda Hardan, Antonio Hallmayer, Joachim O'Hara, Ruth TI Individuals with Autism Spectrum Disorders Have Equal Success Rate But Require Longer Periods of Systematic Desensitization than Control Patients to Complete Ambulatory Polysomnography SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE autism spectrum disorder; polysomnography; pediatric; methodology ID RESPIRATORY INDICATIONS; PRACTICE PARAMETERS; YOUNG-CHILDREN; SLEEP-APNEA; FEASIBILITY; EVENTS; BRAIN AB Study Objectives: Polysomnography (PSG) is the gold standard for the assessment of sleep, yet the extensive apparatus required for monitoring with PSG can be difficult to tolerate, particularly in children. Clinical populations, such as those with anxiety or tactile sensitivity, may have even greater difficulty tolerating the PSG equipment. This study evaluated an innovative protocol for obtaining full PSG in individuals diagnosed autism spectrum disorders (ASD) or developmental delay (DD), as well as typically developing controls (TD). The primary aim was to assess whether this protocol was equally successful for obtaining PSG between these groups. Methods: One hundred sixty-one individuals were recruited for participation; 93 with a diagnosis of ASD, 23 with a diagnosis of DD, and 45 TD. The participants and families were instructed on a procedure of systematic desensitization to the ambulatory PSG equipment; PSG was performed in the home of the participant. Results: PSG was successfully attained in 144 (89.4%) participants. There was no difference in completion rate by diagnosis (p = 0.1), though younger age (p = 0.018) and duration of desensitization (p = 0.024) did predict PSG failure. Further, it was found that individuals with ASD took longer to desensitize to the equipment (16.08 d), than those with DD (8.04 d) or TD (0.98 d). Conclusions: Systematic desensitization to PSG equipment, in combination with PSG completed in the home, allows for individuals with ASD to be equally successful in completing PSG, though they do take longer to acclimate to the equipment. C1 [Primeau, Michelle] Palo Alto Med Fdn, Dept Sleep Med, Sunnyvale, CA 94087 USA. [Primeau, Michelle; Gershon, Anda; Cotto, Isabelle; Lotspeich, Linda; Hardan, Antonio; Hallmayer, Joachim; O'Hara, Ruth] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Talbot, Lisa; O'Hara, Ruth] San Francisco VA Med Ctr, San Francisco, CA USA. [Hardan, Antonio; Hallmayer, Joachim] Stanford Univ, Dept Psychiat & Behav Sci, Child & Adolescent Psychiat, Stanford, CA 94305 USA. [O'Hara, Ruth] Dept Vet Affairs, MIRECC, VISN Sierra Pacific Network 21, Palo Alto, CA USA. RP Primeau, M (reprint author), Palo Alto Med Fdn, 1309 S Mary Ave Ste 200, Sunnyvale, CA 94087 USA. EM primeamm@pamf.org FU Roche FX This was not an industry supported study. Dr. Hardan has recieved research support from Roche and has consulted for Integragen. The other authors have indicated no financial conflicts of interest. NR 32 TC 0 Z9 0 U1 2 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 3 BP 357 EP 362 AR PII jc-00448-14 DI 10.5664/jcsm.5584 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XI UT WOS:000374139600013 PM 26564388 ER PT J AU Kuhn, E Weiss, BJ Taylor, KL Hoffman, JE Ramsey, KM Manber, R Gehrman, P Crowley, JJ Ruzek, JI Trockel, M AF Kuhn, Eric Weiss, Brandon J. Taylor, Katherine L. Hoffman, Julia E. Ramsey, Kelly M. Manber, Rachel Gehrman, Philip Crowley, Jill J. Ruzek, Josef I. Trockel, Mickey TI CBT-I Coach: A Description and Clinician Perceptions of a Mobile App for Cognitive Behavioral Therapy for Insomnia SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Cognitive behavioral therapy for insomnia; Diffusion of Innovations; mobile apps; sleep problems ID RANDOMIZED CONTROLLED-TRIAL; COMPARATIVE METAANALYSIS; PERSISTENT INSOMNIA; BREAST-CANCER; DISSEMINATION; INTERVENTIONS; RESTRICTION; EFFICACY; OUTCOMES; MHEALTH AB Study Objectives: This paper describes CBT-I Coach, a patient-facing smartphone app designed to enhance cognitive behavioral therapy for insomnia (CBT-I). It presents findings of two surveys of U. S. Department of Veterans Affairs (VA) CBT-I trained clinicians regarding their perceptions of CBT-I Coach before it was released (n = 138) and use of it two years after it was released (n = 176). Methods: VA-trained CBT-I clinicians completed web-based surveys before and two years after CBT-I Coach was publicly released. Results: Prior to CBT-I Coach release, clinicians reported that it was moderately to very likely that the app could improve care and a majority (87.0%) intended to use it if it were available. Intention to use the app was predicted by smartphone ownership (beta = 0.116, p < 0.05) and perceptions of relative advantage to existing CBT-I practices (beta = 0.286, p < 0.01), compatibility with their own needs and values (beta = 0.307, p < 0.01), and expectations about the complexity of the app (beta = 0.245, p < 0.05). Two years after CBT-I Coach became available, 59.9% of participants reported using it with patients and had favorable impressions of its impact on homework adherence and outcomes. Conclusions: Findings suggest that before release, CBT-I Coach was perceived to have potential to enhance CBT-I and address common adherence issues and clinicians would use it. These results are reinforced by findings two years after it was released suggesting robust uptake and favorable perceptions of its value. C1 [Kuhn, Eric; Weiss, Brandon J.; Taylor, Katherine L.; Hoffman, Julia E.; Ramsey, Kelly M.; Crowley, Jill J.; Ruzek, Josef I.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Kuhn, Eric; Weiss, Brandon J.; Manber, Rachel; Ruzek, Josef I.; Trockel, Mickey] Stanford Univ, Stanford, CA 94305 USA. [Gehrman, Philip] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gehrman, Philip] Univ Penn, Philadelphia, PA 19104 USA. RP Kuhn, E (reprint author), VA Natl Ctr PTSD, D&T Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Eric.Kuhn@va.gov RI Emchi, Karma/Q-1952-2016 FU Merck Inc. FX This was not an industry supported study. Julia E. Hoffman is a consultant to Otsuka Pharmaceuticals. Rachel Manber receives royalties from New Harbinger Press. Philip Gehrman has received grant/research support from Merck Inc. The other authors have indicated no financial conflicts of interest. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 41 TC 3 Z9 3 U1 2 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 4 BP 597 EP 606 AR PII jc-00087-15 DI 10.5664/jcsm.5700 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XM UT WOS:000374140000019 PM 26888586 ER PT J AU Tong, GE Kumar, S Chong, KC Shah, N Wong, MJ Zimmet, JM Wang, ZJ Yee, J Fu, YJ Yeh, BM AF Tong, Gregory E. Kumar, Sant Chong, Karen C. Shah, Nikita Wong, Margaret J. Zimmet, Jeffrey M. Wang, Zhen Jane Yee, Judy Fu, Yanjun Yeh, Benjamin M. TI Risk of contrast-induced nephropathy for patients receiving intravenous vs. intra-arterial iodixanol administration SO ABDOMINAL RADIOLOGY LA English DT Article DE Contrast-induced nephropathy; Intra-arterial; Intravenous; Renal; CT; Cardiac catheterization ID ACUTE KIDNEY INJURY; PERCUTANEOUS CORONARY INTERVENTIONS; INDUCED NEPHROTOXICITY; METAANALYSIS; OSMOLALITY; FREQUENCY; ANEMIA; MEDIA AB Purpose: To compare the incidence of contrast-induced nephropathy (CIN) for intravenous vs. intra-arterial administration of iodixanol, compared to non-administration. Methods: We retrospectively identified 650 patients who had intravenous iodixanol-enhanced CT, 695 with intra-arterial iodixanol cardiac catheterization, 651 with unenhanced CT, and those who also had baseline and follow-up serum creatinine within 5 days of the exam. From the medical records, we recorded the gender, age, baseline and follow-up serum creatinine/eGFR; underlying renal injury risk factors; indication for imaging; contrast material administration volume, concentration, and route of administration; and use of pre-imaging prophylactic measures for CIN. Univariate and multivariate models were used to determine predictors of CIN. Results: Baseline eGFR was lower for patients undergoing unenhanced CT than intravenous or intra-arterial patients (68 vs. 74.6 and 72.2, respectively, p < 0.01) and not different between intravenous and intra-arterial patients (p = 0.735). Simple logistic regression did not show a difference in the rate of CIN in patients who received intravenous vs. intra-arterial iodixanol (28 of 650, 4%, vs. 28 of 695, 4%, respectively, p = 0.798), nor a higher rate of CIN than seen with unenhanced CT (45 of 651, 7%, p = 0.99 and p = 0.98 by one-sided t test). Multivariate regression modeling showed that only elevated baseline creatinine or decreased eGFR and low hematocrit/hemoglobin were associated with CIN incidence (odds ratio 1.28 and 2.5; p < 0.023 and < 0.006, respectively). Conclusions: Elevation in serum creatinine due to intravenous and intra-arterial iodixanol administration is infrequent and is not more common than after unenhanced CT scans. C1 [Tong, Gregory E.; Kumar, Sant; Chong, Karen C.; Shah, Nikita; Wong, Margaret J.; Wang, Zhen Jane; Yee, Judy; Fu, Yanjun; Yeh, Benjamin M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628,M-372,505 Parnassus Ave, San Francisco, CA 94143 USA. [Zimmet, Jeffrey M.] San Francisco VA Med Ctr, Div Cardiol, 4150 Clement Ave, San Francisco, CA 94121 USA. RP Yeh, BM (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628,M-372,505 Parnassus Ave, San Francisco, CA 94143 USA. EM ben.yeh@ucsf.edu FU General Electric Healthcare; NIH [1R21EB013816, 1R01EB015476]; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 TR000004] FX This study was supported by grants from General Electric Healthcare, NIH Grant Numbers 1R21EB013816 and 1R01EB015476, and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR000004. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of General Electric Healthcare or the NIH. NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2366-004X EI 2366-0058 J9 ABDOM RADIOL JI Abdom. Radiol. PD JAN PY 2016 VL 41 IS 1 BP 91 EP 99 DI 10.1007/s00261-015-0611-9 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DJ3MK UT WOS:000374109400012 PM 26830615 ER PT J AU Dzierzewski, JM Wallace, DM Wohlgemuth, WK AF Dzierzewski, Joseph M. Wallace, Douglas M. Wohlgemuth, William K. TI Adherence to Continuous Positive Airway Pressure in Existing Users: Self-Efficacy Enhances the Association between Continuous Positive Airway Pressure and Adherence SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE adherence; continuous positive airway pressure; CPAP; moderation; self-efficacy; sleep apnea ID OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE; CPAP ADHERENCE; US VETERANS; THERAPY; RISK; POPULATION; DEPRESSION; DISORDER; GENDER AB Study Objectives: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common sleep disorder associated with a myriad of sequelae. OSAHS is effectively treated with continuous positive airway pressure (CPAP) therapy. However, fewer than 50% of patients are compliant with their CPAP therapy prescriptions. The current study sought to explore an integrated, biopsychological approach to CPAP adherence among experienced CPAP users. Methods: We performed a retrospective, cross-sectional analysis of a cohort of veterans with a diagnosis of OSAHS (n = 191) who were prescribed CPAP therapy and returned for adherence download at the Miami VA Sleep Clinic. The relationships between biomedical characteristics (e.g., CPAP pressure, self-reported sleepiness, and change in sleep efficiency) and psychological factors (e.g., self-efficacy beliefs and psychological diagnoses) and objectively measured CPAP use were examined to determine whether psychological factors moderated the relationships between biomedical characteristics and CPAP adherence. Results: Hierarchical regression analyses predicting CPAP adherence (adjusting for time since CPAP prescription, age, education, prescribed CPAP pressure, daytime sleepiness, changes in sleep efficiency with CPAP, and psychiatric conditions) revealed the following: (1) CPAP self-efficacy and CPAP pressure were positively related to adherence, and (2) CPAP self-efficacy moderates the relationship between CPAP pressure and CPAP adherence. Conclusions: There was no relationship between CPAP pressure and adherence in individuals with low self-efficacy beliefs. However, for individuals with high self-efficacy beliefs, there was a significant positive relationship between CPAP pressure and adherence. Self-efficacy beliefs appear to be a prime target for focused interventions aimed at improving CPAP adherence among those individuals with higher pressure prescriptions. C1 [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 16111 Plummer St 11E, North Hills, CA 91343 USA. [Wallace, Douglas M.; Wohlgemuth, William K.] Univ Miami, Miller Sch Med, Sleep Med Div, Dept Neurol, Miami, FL 33136 USA. [Wallace, Douglas M.] Bruce W Carter VA Med Ctr, Neurol Serv, Miami, FL USA. RP Dzierzewski, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Dzierzewski, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 16111 Plummer St 11E, North Hills, CA 91343 USA. EM Joseph.Dzierzewski@va.gov FU UCLA Claude Pepper Center [5P30AG028748]; UCLA CTSI [UL1TR000124]; VA Advanced Geriatrics Fellowship FX This work was performed at the Bruce W. Carter VA Medical Center. Joseph M Dzierzewski was supported by UCLA Claude Pepper Center (5P30AG028748), UCLA CTSI (UL1TR000124), and VA Advanced Geriatrics Fellowship. The authors have indicated no financial conflicts of interest. NR 44 TC 2 Z9 2 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 2 BP 169 EP 176 DI 10.5664/jcsm.5478 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XB UT WOS:000374138900005 PM 26350607 ER PT J AU Weiner, MW Gorriz, JM Ramirez, J Castiglioni, I AF Weiner, Michael W. Gorriz, Juan M. Ramirez, Javier Castiglioni, Isabella TI Statistical Signal Processing in the Analysis, Characterization and Detection of Alzheimer's Disease SO CURRENT ALZHEIMER RESEARCH LA English DT Editorial Material C1 [Weiner, Michael W.] Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St 114M, San Francisco, CA 94121 USA. [Gorriz, Juan M.; Ramirez, Javier] Univ Granada, Dept Signal Theory Networking & Commun, Fuentenueva S-N, E-18071 Granada, Spain. [Castiglioni, Isabella] CNR, Inst Mol Bioimaging & Physiol, Rome, Italy. RP Gorriz, JM; Ramirez, J (reprint author), Univ Granada, Dept Signal Theory Networking & Commun, Fuentenueva S-N, E-18071 Granada, Spain.; Castiglioni, I (reprint author), CNR, Inst Mol Bioimaging & Physiol, Rome, Italy. EM gorriz@ugr.es; javierrp@ugr.es; isabella.castiglioni@ibfm.cnr.it RI Ramirez, Javier/B-1836-2012 OI Ramirez, Javier/0000-0002-6229-2921 NR 23 TC 1 Z9 1 U1 0 U2 3 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1567-2050 EI 1875-5828 J9 CURR ALZHEIMER RES JI Curr. Alzheimer Res. PY 2016 VL 13 IS 5 BP 466 EP 468 DI 10.2174/156720501304160325180321 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DI4GP UT WOS:000373458700001 PM 27025774 ER PT J AU Solak, S Acar, YA Uysal, E AF Solak, Suleyman Acar, Yahya Ayhan Uysal, Emin TI Bladder herniation into inguinal canal: an important differential diagnosis of inguinal hernia SO CUKUROVA MEDICAL JOURNAL LA English DT Letter ID URINARY-BLADDER; INGUINOSCROTAL HERNIATION; INCIDENTAL DEMONSTRATION; BONE-SCAN; SCROTUM C1 [Solak, Suleyman; Uysal, Emin] Bagcilar Training & Res Hosp, Dept Emergency Med, Istanbul, Turkey. [Acar, Yahya Ayhan] San Francisco VA Med Ctr, Dept Anaesthesiol, San Francisco, CA USA. RP Acar, YA (reprint author), San Francisco VA Med Ctr, Dept Anaesthesiol, San Francisco, CA USA. EM yahya_acar@yahoo.com NR 19 TC 0 Z9 0 U1 1 U2 1 PU CUKUROVA UNIV, FAC MEDICINE PI ADANA PA YAYIN VE DOKUMENTASYON KURULU, BALCALI, ADANA, 01330, TURKEY SN 0250-5150 J9 CUKUROVA MED J JI Cukurova Med. J. PY 2016 VL 41 IS 1 BP 191 EP 192 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DH9PS UT WOS:000373128700034 ER PT J AU Millstein, RA Hoerster, KD Rosenberg, DE Nelson, KM Reiber, G Saelens, BE AF Millstein, Rachel A. Hoerster, Katherine D. Rosenberg, Dori E. Nelson, Karin M. Reiber, Gayle Saelens, Brian E. TI Individual, Social, and Neighborhood Associations With Sitting Time Among Veterans SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE sedentary behavior; physical functioning; health behaviors; mental health ID PHYSICAL-ACTIVITY QUESTIONNAIRE; TELEVISION VIEWING TIME; SEDENTARY BEHAVIOR; OLDER-ADULTS; US ADULTS; HEALTH; DEPRESSION; WALKABILITY; OUTCOMES; WOMEN AB Background: Sedentary behavior is an increasingly recognized health risk factor, independent of physical activity. Although several correlates of sedentary behavior are known, little research has identified them among U.S. veterans, a population that faces disproportionate chronic disease burden. Methods: A survey was mailed to 1997 randomly selected veterans at a large urban Veterans Affairs medical center in 2012 and remailed in 2013 to nonresponders, resulting in a 40% response rate. We examined individual-, social-, and neighborhood-level factors in association with self-reported sitting time. Factors correlated with sitting time at P < .05 were included in a multiple linear regression model. Results: In the multivariate model, higher depression (B = 7.8), body mass index (B = 5.1), functional impairment (B = 4.2), and self-rated health (B = 68.5) were significantly associated with higher sitting time, and leisure time physical activity (B = -0.10) and being employed (B = -71.3) were significantly associated with lower sitting time. Conclusions: Individual-level, but not social- and neighborhood-level, variables were associated with sitting time in this population. This study identified individual-level targets for reducing sitting time and improving overall health among veterans. C1 [Millstein, Rachel A.] Univ Calif San Diego, San Diego Joint Doctoral Program Clin Psychol, San Diego State Univ, San Diego, CA 92103 USA. [Millstein, Rachel A.; Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle Div, Seattle, WA USA. [Hoerster, Katherine D.; Saelens, Brian E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rosenberg, Dori E.] Grp Hlth Res Inst, Seattle, WA USA. [Rosenberg, Dori E.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Nelson, Karin M.] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev & Gen Internal Med Serv, Seattle Div, Seattle, WA USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. [Reiber, Gayle] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Serv, Seattle Div, Seattle, WA USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Saelens, Brian E.] Seattle Childrens Res Inst, Seattle, WA USA. RP Millstein, RA (reprint author), Univ Calif San Diego, San Diego Joint Doctoral Program Clin Psychol, San Diego State Univ, San Diego, CA 92103 USA.; Millstein, RA (reprint author), VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle Div, Seattle, WA USA. EM rmillstein@gmail.com FU US Department of Veterans Affairs; VA Puget Sound, Seattle Division Mental Illness Research, Education, and Clinical Center (MIRECC); Health Services Research and Development (HSR&D) Center of Excellence FX The authors would like to acknowledge Carol Malte, Linda Guerrero, David Tice, Marie Lutton, and Jeff Rodenbaugh, all from VA Puget Sound Healthcare System, Seattle Division, for their important contributions to this study. Ms Malte identified the survey sample using VA administrative data. Ms Guerrero, Mr Tice, and Ms Lutton helped to coordinate the survey mailing. Ms Lutton performed data entry, and Mr Rodenbaugh performed the study analyses. This material is based upon work supported by the US Department of Veterans Affairs, including local funds from the VA Puget Sound, Seattle Division Mental Illness Research, Education, and Clinical Center (MIRECC) and the Health Services Research and Development (HSR&D) Center of Excellence. NR 41 TC 0 Z9 0 U1 2 U2 5 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD JAN PY 2016 VL 13 IS 1 BP 30 EP 35 DI 10.1123/jpah.2014-0369 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4QH UT WOS:000372770000005 PM 25831556 ER PT J AU Jarcho, JM Feier, NA Labus, JS Naliboff, B Smith, SR Hong, JY Colloca, L Tillisch, K Mandelkern, MA Mayer, EA London, ED AF Jarcho, Johanna M. Feier, Natasha A. Labus, Jennifer S. Naliboff, Bruce Smith, Suzanne R. Hong, Jui-Yang Colloca, Luana Tillisch, Kirsten Mandelkern, Mark A. Mayer, Emeran A. London, Edythe D. TI Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response SO NEUROIMAGE-CLINICAL LA English DT Article DE Placebo effect; Pain; PET; [F-18]fallypride; Ventrolateral prefrontal cortex ID TRANSCRANIAL MAGNETIC STIMULATION; REFERENCE TISSUE MODEL; CHRONIC PAIN; PREFRONTAL CORTEX; PARKINSONS-DISEASE; C-11 RACLOPRIDE; INDIVIDUAL-DIFFERENCES; CLINICAL IMPORTANCE; OPIOID ACTIVITY; HEALTH-CARE AB Placebo analgesia is measured by self-report, yet current, expected, and recalled efficacy may be differentially related to brain function. Here we used a human thermal pain model to compare self-reports of expected, concurrent, and recalled efficacy of a topical placebo analgesic, and tested associations of the three measures of efficacy with changes in dopamine D2/D3 receptor availability in brain using [F-18] fallypride with positron emission tomography (PET). Participants (15 healthy women) were assessed on three test days. The first test day included a laboratory visit, during which the temperature needed to evoke consistent pain was determined, placebo analgesia was induced via verbal and experience-based expectation, and the placebo response was measured. On two subsequent test days, PET scans were performed in Control and Placebo conditions, respectively, in counterbalanced order. During Visit 1, concurrent and recalled placebo efficacy were unrelated; during the Placebo PET visit, expected and recalled efficacy were highly correlated (rho = 0.68, p = 0.005), but concurrent efficacy was unrelated to expected or recalled efficacy. Region of interest analysis revealed dopamine D2/D3 receptor availability was lower in left ventrolateral prefrontal cortex in the Placebo condition (p < 0.001, uncorrected), and greater change in this measure was associated with higher levels of recalled analgesic efficacy (rho = 0.58, p = 0.02). These preliminary findings underscore the need to consider how self-reported symptom improvement is assessed in clinical trials of analgesics and suggest that dopaminergic activity in the ventrolateral prefrontal cortex may promote recalled efficacy of placebo. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Jarcho, Johanna M.; Feier, Natasha A.; Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA 90095 USA. [Jarcho, Johanna M.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA. [Feier, Natasha A.] McGill Univ, Fac Dent, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.; London, Edythe D.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, PAIN, Los Angeles, CA USA. [Colloca, Luana] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA. [Colloca, Luana] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Tillisch, Kirsten; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu OI Jarcho, Johanna/0000-0001-9075-6968 FU Intramural Research Program at National Institute of Mental Health, National Institutes of Health [F31-DA021951, T32-MH017140] FX This work was supported in part by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health Grants F31-DA021951, T32-MH017140 (JMJ), and endowments from the Thomas P and Katherine K Pike Chair of Addiction Studies (EDL) and an endowment from the Marjorie Green Trust. NR 54 TC 2 Z9 2 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 10 BP 107 EP 114 DI 10.1016/j.nicl.2015.11.009 PG 8 WC Neuroimaging SC Neurosciences & Neurology GA DI0LX UT WOS:000373189000012 PM 26759785 ER PT J AU Messamore, E Yao, JK AF Messamore, Erik Yao, Jeffrey K. TI Phospholipid, arachidonate and eicosanoid signaling in schizophrenia SO OCL-OILSEEDS AND FATS CROPS AND LIPIDS LA English DT Review DE Phospholipids; arachidonic acid; eicosanoids; niacin-induced flushing, endophenotype marker; schizophrenia ID NIACIN SKIN FLUSH; CEREBRAL-BLOOD-FLOW; OPTICAL REFLECTION SPECTROSCOPY; MAGNETIC-RESONANCE-SPECTROSCOPY; POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; CELL MEMBRANE DYNAMICS; NICOTINIC-ACID; PROSTAGLANDIN D-2; TOPICAL NIACIN AB This paper reviews the potential role of arachidonic acid in the pathophysiology of schizophrenia. We discuss how abnormal levels of arachidonic acid may arise, and how dysregulation of signaling molecules derived from it have the potential to disrupt not only dopamine signaling, but numerous other physiological processes associated with the illness. Pharmacological doses of niacin stimulate the release of arachidonic acid; and arachidonic acid-derived molecules in turn dilate blood vessels in the skin. A blunted skin flush response to niacin is reliably observed among patients with schizophrenia. The niacin response abnormality may thus serve as a biomarker to identify a physiological subtype of schizophrenia associated with defective arachidonic acid-derived signaling. C1 [Messamore, Erik] Univ Cincinnati, Cincinnati, OH USA. [Messamore, Erik] Lindner Ctr Hope, Cincinnati, OH USA. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.; Yao, JK (reprint author), Univ Pittsburgh, Med Ctr, Western Psychiat Inst Clin, Dept Psychiat, Pittsburgh, PA 15213 USA.; Yao, JK (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. EM jkyao@pitt.edu NR 95 TC 0 Z9 0 U1 2 U2 4 PU EDP SCIENCES S A PI LES ULIS CEDEX A PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A, FRANCE SN 1258-8210 EI 2257-6614 J9 OCL OILS FAT CROP LI JI OCL Oilseed.Fats Crops Lipids PD JAN-FEB PY 2016 VL 23 IS 1 AR D112 DI 10.1051/ocl/2015054 PG 8 WC Agronomy SC Agriculture GA DH9WB UT WOS:000373145600007 ER PT J AU Handtke, V Wolff, H Williams, BA AF Handtke, Violet Wolff, Hans Williams, Brie A. TI The pains of imprisonment: challenging aspects of pain management in correctional settings SO PAIN MANAGEMENT LA English DT Editorial Material DE ethics; jail; pain; prison; vulnerable patients ID PRISON HEALTH-CARE; PREVALENCE; INMATES C1 [Handtke, Violet] Univ Basel, Inst Biomed Eth, Bernoullistr 28, CH-4056 Basel, Switzerland. [Wolff, Hans] Univ Hosp Geneva, Div Correct Med & Psychiat, Geneva, Switzerland. [Wolff, Hans] Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland. [Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Handtke, V (reprint author), Univ Basel, Inst Biomed Eth, Bernoullistr 28, CH-4056 Basel, Switzerland. EM v.handtke@unibas.ch NR 19 TC 0 Z9 0 U1 2 U2 3 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-1869 EI 1758-1877 J9 PAIN MANAG JI Pain Manag. PY 2016 VL 6 IS 2 BP 133 EP 136 DI 10.2217/pmt.15.62 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA DH7TB UT WOS:000372995600008 PM 26915436 ER PT J AU Dicianno, BE Morgan, A Lieberman, J Rosen, L AF Dicianno, Brad E. Morgan, Amy Lieberman, Jenny Rosen, Lauren TI Rehabilitation Engineering & Assistive Technology Society (RESNA) position on the application of wheelchair standing devices: 2013 current state of the literature SO ASSISTIVE TECHNOLOGY LA English DT Article DE mobility limitation; rehabilitation; standing position; wheelchairs ID SPINAL-CORD-INJURY; WHOLE-BODY VIBRATION; SPASTIC CEREBRAL-PALSY; BONE-MINERAL DENSITY; WEIGHT-BEARING; ORTHOSTATIC HYPOTENSION; CHILDREN; PROGRAMS; MOBILITY; INDIVIDUALS AB This article, approved by the Rehabilitation Engineering & Assistive Technology Society of North America Board of Directors on December 23, 2013, shares typical clinical applications and provides evidence from the literature supporting the use of wheelchair standers. C1 [Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400,Bakery Sq, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.] Univ Pittsburgh, Sch Med, Dept PM&R, Pittsburgh, PA USA. [Morgan, Amy] Permobil Inc, Lebanon, TN USA. [Lieberman, Jenny] Mt Sinai Hosp, Dept Rehabil, New York, NY 10029 USA. [Rosen, Lauren] St Josephs Childrens Hosp Tampa, Mot Anal Ctr, Tampa, FL USA. RP Dicianno, BE (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400,Bakery Sq, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu NR 44 TC 0 Z9 0 U1 4 U2 7 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 EI 1949-3614 J9 ASSIST TECHNOL JI Assist. Technol. PY 2016 VL 28 IS 1 BP 57 EP 62 DI 10.1080/10400435.2015.1113837 PG 6 WC Rehabilitation SC Rehabilitation GA DH0KY UT WOS:000372474300009 PM 26910615 ER PT J AU Primack, BA Carroll, MV Weiss, PM Shihadeh, AL Shensa, A Farley, ST Fine, MJ Eissenberg, T Nayak, S AF Primack, Brian A. Carroll, Mary V. Weiss, Patricia M. Shihadeh, Alan L. Shensa, Ariel Farley, Steven T. Fine, Michael J. Eissenberg, Thomas Nayak, Smita TI Systematic Review and Meta-Analysis of Inhaled Toxicants from Waterpipe and Cigarette Smoking SO PUBLIC HEALTH REPORTS LA English DT Article ID HIGH-SCHOOL-STUDENTS; POLYCYCLIC AROMATIC-HYDROCARBONS; US UNIVERSITY-STUDENTS; PIPE TOBACCO SMOKING; MAINSTREAM SMOKE; CARBON-MONOXIDE; NARGHILE WATERPIPE; HOOKAH USE; VOLATILE ALDEHYDES; NICOTINE EXPOSURE AB Objective. Waterpipe tobacco smoking (WTS) is an emerging trend worldwide. To inform public health policy and educational programming, we systematically reviewed the biomedical literature to compute the inhaled smoke volume, nicotine, tar, and carbon monoxide (CO) associated with a single WTS session and a single cigarette. Methods. We searched seven biomedical bibliographic databases for controlled laboratory or natural environment studies designed to mimic human tobacco consumption. Included studies quantified the mainstream smoke of a single cigarette and/or single WTS session for smoke volume, nicotine, tar, and/or CO. We conducted meta-analyses to calculate summary estimates for the inhalation of each unique substance for each mode of tobacco consumption. We assessed between-study heterogeneity using chi-squared and I-squared statistics. Results. Sufficient data from 17 studies were available to derive pooled estimates for inhalation of each exposure via each smoking method. Two researchers working independently abstracted measurement of smoke volume in liters, and nicotine, tar, and CO in milligrams. All numbers included in meta analyses matched precisely between the two researchers (100% agreement, Cohen's kappa=1.00). Whereas one WTS session was associated with 74.1 liters of smoke inhalation (95% confidence interval [CI] 38.2, 110.0), one cigarette was associated with 0.6 liters of smoke (95% CI 0.5, 0.7). One WTS session was also associated with higher levels of nicotine, tar, and CO. Conclusions. One WTS session consistently exposed users to larger smoke volumes and higher levels of tobacco toxicants compared with one cigarette. These computed estimates may be valuable to emphasize in prevention programming. C1 [Primack, Brian A.; Shensa, Ariel; Farley, Steven T.] Univ Pittsburgh, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. [Carroll, Mary V.] Squirrel Hill Hlth Ctr, Pittsburgh, PA USA. [Weiss, Patricia M.] Univ Pittsburgh Hlth Sci Lib Syst, Pittsburgh, PA USA. [Shihadeh, Alan L.] Amer Univ Beirut, Beirut, Lebanon. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Eissenberg, Thomas] Virginia Commonwealth Univ, Richmond, VA USA. [Nayak, Smita] Swedish Ctr Res & Innovat, Swedish Hlth Serv, Seattle, WA USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu OI Shihadeh, Alan/0000-0001-6387-8564; Weiss, Patricia/0000-0002-5434-391X FU National Cancer Institute [R01-CA140150] FX The authors acknowledge receipt of funding from the National Cancer Institute (R01-CA140150). The fenders played no role in the conception, data collection, writing, or approval of this manuscript. NR 49 TC 9 Z9 10 U1 4 U2 9 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JAN-FEB PY 2016 VL 131 IS 1 BP 76 EP 85 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HD UT WOS:000372392500014 PM 26843673 ER PT J AU Genes, N Kim, MS Thum, FL Rivera, L Beato, R Song, C Soriano, J Kannry, J Baumlin, K Hwang, U AF Genes, Nicholas Kim, Min Soon Thum, Frederick L. Rivera, Laura Beato, Rosemary Song, Carolyn Soriano, Jared Kannry, Joseph Baumlin, Kevin Hwang, Ula TI Usability Evaluation of a Clinical Decision Support System for Geriatric ED Pain Treatment SO APPLIED CLINICAL INFORMATICS LA English DT Article DE Clinical decision support systems; decision support techniques; aged; acute pain; medical record systems; computerized; man-machine systems ID HEALTH INFORMATION-TECHNOLOGY; EMERGENCY-DEPARTMENT PATIENTS; RANDOMIZED-CONTROLLED-TRIAL; POSTOPERATIVE PAIN; ORDER ENTRY; CARE; IMPACT; ADHERENCE; INTERVENTIONS; MEDICATION AB Background: Older adults are at risk for inadequate emergency department (ED) pain care. Unrelieved acute pain is associated with poor outcomes. Clinical decision support systems (CDSS) hold promise to improve patient care, but CDSS quality varies widely, particularly when usability evaluation is not employed. Objective: To conduct an iterative usability and redesign process of a novel geriatric abdominal pain care CDSS. We hypothesized this process would result in the creation of more usable and favorable pain care interventions. Methods: Thirteen emergency physicians familiar with the Electronic Health Record (EHR) in use at the study site were recruited. Over a 10-week period, 17 1-hour usability test sessions were conducted across 3 rounds of testing. Participants were given 3 patient scenarios and provided simulated clinical care using the EHR, while interacting with the CDSS interventions. Quantitative System Usability Scores (SUS), favorability scores and qualitative narrative feedback were collected for each session. Using a multi-step review process by an interdisciplinary team, positive and negative usability issues in effectiveness, efficiency, and satisfaction were considered, prioritized and incorporated in the iterative redesign process of the CDSS. Video analysis was used to determine the appropriateness of the CDS appearances during simulated clinical care. Results: Over the 3 rounds of usability evaluations and subsequent redesign processes, mean SUS progressively improved from 74.8 to 81.2 to 88.9; mean favorability scores improved from 3.23 to 4.29 (1 worst, 5 best). Video analysis revealed that, in the course of the iterative redesign processes, rates of physicians' acknowledgment of CDS interventions increased, however most rates of desired actions by physicians (such as more frequent pain score updates) decreased. Conclusion: The iterative usability redesign process was instrumental in improving the usability of the CDSS; if implemented in practice, it could improve geriatric pain care. The usability evaluation process led to improved acknowledgement and favorability. Incorporating usability testing when designing CDSS interventions for studies may be effective to enhance clinician use. C1 [Genes, Nicholas; Thum, Frederick L.; Rivera, Laura; Beato, Rosemary; Song, Carolyn; Baumlin, Kevin] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. [Kim, Min Soon] Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO USA. [Kim, Min Soon] Univ Missouri, Inst Informat, Columbia, MO USA. [Soriano, Jared; Kannry, Joseph] Mt Sinai Hlth Syst, Informat Technol, New York, NY USA. [Kannry, Joseph] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA. [Hwang, Ula] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hwang, Ula] James J Peters VAMC, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Genes, N (reprint author), Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. EM nicholas.genes@mountsinai.org NR 35 TC 0 Z9 0 U1 2 U2 3 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 1869-0327 J9 APPL CLIN INFORM JI Appl. Clin. Inform. PY 2016 VL 7 IS 1 BP 128 EP 142 DI 10.4338/ACI-2015-08-RA-0108 PG 15 WC Medical Informatics SC Medical Informatics GA DG4SQ UT WOS:000372063200010 PM 27081412 ER PT J AU Taylor, RL Cruickshank, MN Karimi, M Ng, HL Quail, E Kaufman, KM Harley, JB Abraham, LJ Tsao, BP Boackle, SA Ulgiati, D AF Taylor, Rhonda L. Cruickshank, Mark N. Karimi, Mahdad Ng, Han Leng Quail, Elizabeth Kaufman, Kenneth M. Harley, John B. Abraham, Lawrence J. Tsao, Betty P. Boackle, Susan A. Ulgiati, Daniela TI Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells SO CELLULAR & MOLECULAR IMMUNOLOGY LA English DT Article DE B cells; core promoter; CR2/CD21; molecular biology; transcription factor ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; COMPLEMENT RECEPTOR 2; HUMAN LYMPHOCYTES-B; GENOME-WIDE ANALYSIS; GENE-EXPRESSION; PLASMA-CELL; FACTOR E2A; CR-2 GENE; T-CELLS; C3D AB Complement receptor 2 (CR2/CD21) is predominantly expressed on the surface of mature B cells where it forms part of a coreceptor complex that functions, in part, to modulate B-cell receptor signal strength. CR2/CD21 expression is tightly regulated throughout B-cell development such that CR2/CD21 cannot be detected on pre-B or terminally differentiated plasma cells. CR2/CD21 expression is upregulated at B-cell maturation and can be induced by IL-4 and CD40 signaling pathways. We have previously characterized elements in the proximal promoter and first intron of CR2/CD21 that are involved in regulating basal and tissue-specific expression. We now extend these analyses to the CR2/CD21 core promoter. We show that in mature B cells, CR2/CD21 transcription proceeds from a focused TSS regulated by a non-consensus TATA box, an initiator element and a downstream promoter element. Furthermore, occupancy of the general transcriptional machinery in pre-B versus mature B-cell lines correlate with CR2/CD21 expression level and indicate that promoter accessibility must switch from inactive to active during the transitional B-cell window. C1 [Taylor, Rhonda L.; Ng, Han Leng; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Sch Pathol & Lab Med, Crawley, WA 6009, Australia. [Taylor, Rhonda L.; Karimi, Mahdad; Quail, Elizabeth] Univ Western Australia, Sch Chem & Biochem, Biochem & Mol Biol, Crawley, WA 6009, Australia. [Cruickshank, Mark N.] Univ Western Australia, Telethon Kids Inst, Crawley, WA 6009, Australia. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA. RP Ulgiati, D (reprint author), Univ Western Australia, Sch Pathol & Lab Med, 35 Stirling Highway, Crawley, WA 6009, Australia. EM daniela.ulgiati@uwa.edu.au FU National Health and Medical Research Council of Australia [303206]; Lupus Research Institute; Alliance for Lupus Research; National Institutes of Health [R01AI070983, K24 AI078004, P01AI083194, P01AR049084, R37AI024717, U01HG006828]; US Department of Veterans Affairs FX This study was generously supported by the National Health and Medical Research Council of Australia (303206 to DU and LJA), the Lupus Research Institute (to SAB), the Alliance for Lupus Research (to SAB, DU and BPT), National Institutes of Health (R01AI070983 to SAB, DU and BPT, K24 AI078004 to SAB, and P01AI083194, P01AR049084, R37AI024717 and U01HG006828 to JBH) and the US Department of Veterans Affairs (to JBH). The authors declare that there is no conflict of interest. NR 62 TC 0 Z9 0 U1 0 U2 0 PU CHIN SOCIETY IMMUNOLOGY PI BEING PA 5 DONGDAN SANTIAO, DONGCHEN DISTRICT, BEING, 100005, PEOPLES R CHINA SN 1672-7681 EI 2042-0226 J9 CELL MOL IMMUNOL JI Cell. Mol. Immunol. PD JAN PY 2016 VL 13 IS 1 SI SI BP 119 EP 131 DI 10.1038/cmi.2014.138 PG 13 WC Immunology SC Immunology GA DG3UQ UT WOS:000371996300013 PM 25640655 ER PT J AU Zamboanga, BL Tomaso, CC Cloutier, RM Blumenthal, H Kenney, SR Borsari, B AF Zamboanga, Byron L. Tomaso, Cara C. Cloutier, Renee M. Blumenthal, Heidemarie Kenney, Shannon R. Borsari, Brian TI Drinking Game Participation Among High School and Incoming College Students A Narrative Review SO JOURNAL OF ADDICTIONS NURSING LA English DT Review DE college transition; adolescents; incoming college students; drinking games; alcohol use; high school students ID RANDOMIZED CONTROLLED-TRIAL; ILLICIT DRUG-USE; ALCOHOL-USE; HEAVY-DRINKING; MOTIVES; RISK; INTERVENTION; TRANSITION; BEHAVIORS; 1ST-YEAR AB The transition from high school to college has been characterized as a potentially vulnerable period because of decreased parental supervision and increased autonomy. This transition can increase risk for participation in high-risk behaviors such as drinking games (DGs), which are a social drinking activity that encourages intoxication and are associated with negative alcohol-related consequences. To date, there has not been a narrative review of DG research that examines this activity among high schoolers and incoming college students specifically, and thus, the current review bridges this gap. Findings indicate that DG participation is consistently linked to negative consequences (e.g., passing out, becoming sick) and other high-risk behaviors, such as prepartying (drinking before going to a social event). In addition, DG participation is linked to demographic (e.g., age, gender), psychological (e.g., personality, alcohol cognitions), and contextual/cultural factors (e.g., the college drinking culture). These findings have implications for current prevention and intervention efforts and suggest promising directions for future research. C1 [Zamboanga, Byron L.; Tomaso, Cara C.] Smith Coll, Northampton, MA 01063 USA. [Cloutier, Renee M.; Blumenthal, Heidemarie] Univ N Texas, Denton, TX 76203 USA. [Kenney, Shannon R.] Brown Univ, Providence, RI 02912 USA. [Borsari, Brian] San Francisco VA Med Ctr, San Francisco, CA USA. [Borsari, Brian] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Zamboanga, BL; Tomaso, CC (reprint author), Smith Coll, Dept Psychol, Northampton, MA 01063 USA. EM bzamboan@smith.edu; ctomaso@smith.edu FU National Institute on Alcohol Abuse and Alcoholism [R01-AA017427]; VISN1 Career Development Award [V1CDA2012-18] FX Brian Borsari's contribution to this manuscript was supported by National Institute on Alcohol Abuse and Alcoholism Grant R01-AA017427 and VISN1 Career Development Award V1CDA2012-18. The contents of this manuscript do not represent the views of the National Institute on Alcohol Abuse and Alcoholism, the Department of Veterans Affairs, or the United States Government. Byron L. Zamboanga and Cara C. Tomaso contributed equally to the writing of this manuscript. NR 54 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1088-4602 EI 1548-7148 J9 J ADDICT NURS JI J. Addict. Nurs. PD JAN-MAR PY 2016 VL 27 IS 1 BP 24 EP 31 DI 10.1097/JAN.0000000000000108 PG 8 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA DG6RV UT WOS:000372214700004 PM 26950839 ER PT J AU Merrick, DT Gao, DX Miller, YE Keith, RL Baron, AE Feser, W Kennedy, TC Blatchford, PJ Braudrick, S Hirsch, FR Heasley, L Bunn, PA Franklin, WA AF Merrick, Daniel T. Gao, Dexiang Miller, York E. Keith, Robert L. Baron, Anna E. Feser, William Kennedy, Timothy C. Blatchford, Patrick J. Braudrick, Sarah Hirsch, Fred R. Heasley, Lynn Bunn, Paul A., Jr. Franklin, Wilbur A. TI Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma SO CANCER PREVENTION RESEARCH LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; WHITE-LIGHT BRONCHOSCOPY; LUNG-CANCER; PREINVASIVE LESIONS; AUTOFLUORESCENCE BRONCHOSCOPY; IN-SITU; PRENEOPLASTIC LESIONS; FACTOR RECEPTOR; NATURAL COURSE; FOLLOW-UP AB Bronchial dysplasia (BD), a presumed precursor of pulmonary squamous cell carcinoma (SCC), rarely progresses to invasive cancer. A high-risk cohort at the University of Colorado provided an opportunity to directly sample airway epithelium at mapped sites on successive bronchoscopies. We have hypothesized that persistent dysplastic lesions showing a similar or higher level of dysplasia on follow-up biopsy, are associated with increased risk for the development of SCC. Endoscopic biopsies from 188 high-risk subjects were histologically classified according to the current WHO classification for BD using a numeric histology score ranging from 1 to 8 representing normal bronchial mucosa through invasive lung cancer. Differences in follow-up histology scores were compared between sites classified by clinical, histologic, and immunohistochemical variables. Subjects with a higher frequency of sites that persist or progress to high-grade dysplasia (>37.5% persist/progress, N = 35 versus <37.5% persist/progress, N = 114) show a significant association with development of incident invasive SCC (adjusted HR, 7.84; 95% confidence interval, 1.56-39.39), and those with incident lung SCC have adjusted mean follow-up histology scores 1.55 U higher than in subjects without lung cancer. Current smoking, elevated Ki67 growth fraction, histologic features of angiogenic squamous dysplasia (ASD) and higher histology score in baseline biopsies are significantly associated with increased follow-up histology scores. These results show that persistent BD is associated with the development of invasive SCC. Furthermore, increased expression of Ki67, the presence of angiogenic change and degree of baseline atypia are associated with persistence of BD. (C)2015 AACR. C1 [Merrick, Daniel T.; Hirsch, Fred R.; Franklin, Wilbur A.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA. [Gao, Dexiang; Blatchford, Patrick J.] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO 80045 USA. [Miller, York E.; Keith, Robert L.] Denver Vet Affairs Med Ctr, Dept Med, Div Pulm Med, Denver, CO USA. [Miller, York E.; Keith, Robert L.; Kennedy, Timothy C.] Univ Colorado, Dept Med, Div Pulm Med, Anschutz Med Campus, Aurora, CO 80045 USA. [Baron, Anna E.; Feser, William] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Heasley, Lynn] Univ Colorado, Dept Craniofacial Biol, Anschutz Med Campus, Aurora, CO 80045 USA. [Bunn, Paul A., Jr.] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA. RP Merrick, DT (reprint author), Univ Colorado, Mail Stop 8104,12801 East 17th Ave,Room 5114, Aurora, CO 80045 USA. EM dan.merrick@ucdenver.edu FU Lung Specialized Programs of Research Excellence [P50 CA058187]; Cancer Center Support grant [P30 CA046934] FX This study was supported by Lung Specialized Programs of Research Excellence P50 CA058187 and Cancer Center Support grant P30 CA046934 (all authors received P30 CA046934) NR 36 TC 3 Z9 3 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD JAN PY 2016 VL 9 IS 1 BP 96 EP 104 DI 10.1158/1940-6207.CAPR-15-0305 PG 9 WC Oncology SC Oncology GA DG3XY UT WOS:000372005700013 PM 26542061 ER PT J AU Loewenstein, G Price, J Volpp, K AF Loewenstein, George Price, Joseph Volpp, Kevin TI Habit formation in children: Evidence from incentives for healthy eating SO JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Habit formation; Incentives; School lunch; Field experiments ID INTRINSIC MOTIVATION; EXERCISE; TRIAL AB We present findings from a field experiment conducted at 40 elementary schools involving 8000 children and 400,000 child-day observations, which tested whether providing short-run incentives can create habit formation in children. Over a 3- or 5-week period, students received an incentive for eating a serving of fruits or vegetables during lunch. Relative to an average baseline rate of 39%, providing small incentives doubled the fraction of children eating at least one serving of fruits or vegetables. Two months after the end of the intervention, the consumption rate at schools remained 21% above baseline for the 3 week treatment and 44% above baseline for the 5-week treatment. These findings indicate that short-run incentives can produce changes in behavior that persist after incentives are removed. (C) 2015 Elsevier B.V. All rights reserved. C1 [Loewenstein, George] Carnegie Mellon Univ, Social & Decis Sci, Pittsburgh, PA 15213 USA. [Price, Joseph] Brigham Young Univ, 162 FOB, Provo, UT 84602 USA. [Volpp, Kevin] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Volpp, Kevin] Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Davis, CA USA. [Volpp, Kevin] Penn Med Ctr Innovat, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Perelman Sch Med, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. RP Price, J (reprint author), Brigham Young Univ, 162 FOB, Provo, UT 84602 USA. EM joseph_price@byu.edu FU USDA Economic Research Service [59-5000-1-0034] FX The authors are grateful to the USDA Economic Research Service for research funding (grant # 59-5000-1-0034) and for the many BYU undergraduates and PTA parents that helped as research assistants on the project. This paper has benefitted from the helpful comments by Sandy Black, Dan Hamermesh, Patrick Nolen, Devin Pope, Bob Slonim, Coady Wing, Jingsan Zhu and seminar participants at the Cornell University, Harris School, University of Illinois at Chicago, University of Sydney, UT-Austin, Iowa State, University of Utah, University of Oregon, University of Iowa, and Brigham Young University. NR 22 TC 1 Z9 1 U1 5 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6296 EI 1879-1646 J9 J HEALTH ECON JI J. Health Econ. PD JAN PY 2016 VL 45 BP 47 EP 54 DI 10.1016/j.jhealeco.2015.11.004 PG 8 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DG1PU UT WOS:000371840800004 PM 26717440 ER PT J AU Haidar, G Crespo, M Maximous, S Lendermon, E Clancy, CJ Nguyen, MH AF Haidar, G. Crespo, M. Maximous, S. Lendermon, E. Clancy, C. J. Nguyen, M. H. TI Invasive Tracheobronchial Aspergillosis in a Lung Transplant Recipient Receiving Belatacept as Salvage Maintenance Immunosuppression: A Case Report SO TRANSPLANTATION PROCEEDINGS LA English DT Article ID ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; COSTIMULATION BLOCKADE; PHASE-III; CYCLOSPORINE; REGIMENS; PATIENT; BENEFIT AB Introduction. The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear. Case Report. We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation. Conclusions. Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation. C1 [Haidar, G.; Crespo, M.; Maximous, S.; Lendermon, E.; Clancy, C. J.; Nguyen, M. H.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA. [Clancy, C. J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Haidar, G (reprint author), Univ Pittsburgh, Med Ctr, 3601 Fifth Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM haidarg@upmc.edu NR 22 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 EI 1873-2623 J9 TRANSPL P JI Transplant. Proc. PD JAN-FEB PY 2016 VL 48 IS 1 BP 275 EP 278 DI 10.1016/j.transproceed.2016.01.003 PG 4 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DG1TG UT WOS:000371849800051 PM 26915884 ER PT J AU Ahluwalia, SC Schreibeis-Baum, H Prendergast, TJ Reinke, LF Lorenz, KA AF Ahluwalia, Sangeeta C. Schreibeis-Baum, Hannah Prendergast, Thomas J. Reinke, Lynn F. Lorenz, Karl A. TI NURSES AS INTERMEDIARIES: HOW CRITICAL CARE NURSES PERCEIVE THEIR ROLE IN FAMILY MEETINGS SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article ID OF-LIFE CARE; PATIENT OUTCOMES; PALLIATIVE CARE; COMMUNICATION; END; UNIT; PHYSICIANS; PERSPECTIVES; ICU; PERCEPTIONS AB Background Nurses' involvement in family meetings in the intensive care unit is central to supporting consistent communication and shared understanding within the care team and with patients and patients' family members. Evidence suggests the existence of major barriers to the effective participation and contribution of nurses during family meetings. Objectives To characterize the nature and extent of nurses' involvement in family meetings in the intensive care unit, including identifying barriers to nurses' participation and opportunities for involvement. Methods Meetings with focus groups of nurses at a Veterans Affairs medical intensive care unit were recorded, transcribed, and qualitatively analyzed by using the constant comparative method. Results Thirty critical care nurses participated in 6 focus groups. Three major themes describing nurses' involvement in family meetings were identified: nurses can play multiple roles in supporting conduct in family meetings, nurses face critical barriers to fully realizing these roles, and nurses end up as intermediaries in family meetings. Subthemes pertained to being well positioned to act as the patient's advocate, yet feeling undervalued and underempowered to contribute important information in family meetings, often resulting in mixed messages about care preferences, prognosis, or goals of care that nurses did not feel able to address during the meeting. Conclusion Nurses are positioned to play essential roles in family meetings, but their full involvement remains unrealized. Communication training and greater attention to nurses' empowerment and to facilitating the nurse-physician relationship in the context of family meetings most likely would increase appropriate involvement of nurses in the meetings. C1 [Ahluwalia, Sangeeta C.] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. [Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA. [Schreibeis-Baum, Hannah; Lorenz, Karl A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Prendergast, Thomas J.] Oregon Hlth & Sci Univ, Med, Portland, OR USA. [Prendergast, Thomas J.] Portland VA Med Ctr, Pulm & Crit Care Med, Portland, OR USA. [Reinke, Lynn F.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Reinke, Lynn F.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Lorenz, Karl A.] Univ Calif Los Angeles, Sch Med, Med, Los Angeles, CA 90024 USA. RP Ahluwalia, SC (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM sahluwal@rand.org FU National Palliative Care Research Center; Implementation Research Institute, George Warren Brown School of Social Work, Washington University, St Louis, Missouri, through the National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative FX Dr Ahluwalia was supported by a career development award from the National Palliative Care Research Center. The preparation of this article was supported in part by the Implementation Research Institute, George Warren Brown School of Social Work, Washington University, St Louis, Missouri, through the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative. NR 31 TC 2 Z9 2 U1 2 U2 12 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 EI 1937-710X J9 AM J CRIT CARE JI Am. J. Crit. Care PD JAN 1 PY 2016 VL 25 IS 1 BP 33 EP 38 DI 10.4037/ajcc2016653 PG 6 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA DF3FL UT WOS:000371229200011 PM 26724291 ER PT J AU Fan, VS Gharib, SA Martin, TR Wurfel, MM AF Fan, Vincent S. Gharib, Sina A. Martin, Thomas R. Wurfel, Mark M. TI COPD disease severity and innate immune response to pathogen-associated molecular patterns SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE chronic obstructive pulmonary disease; innate immunity; inflammation; chronic bronchitis; toll-like receptors ID OBSTRUCTIVE PULMONARY-DISEASE; TOLL-LIKE RECEPTORS; TUMOR-NECROSIS-FACTOR; AIRWAY INFLAMMATION; SYSTEMIC INFLAMMATION; ALVEOLAR MACROPHAGES; BRONCHIAL LAVAGE; HUMAN MONOCYTES; EXPRESSION; CYTOKINES AB The airways of COPD patients are often colonized with bacteria leading to increased airway inflammation. This study sought to determine whether systemic cytokine responses to microbial pathogen-associated molecular patterns (PAMPs) are increased among subjects with severe COPD. In an observational cross-sectional study of COPD subjects, PAMP-induced cytokine responses were measured in whole blood ex vivo. We used PAMPs derived from microbial products recognized by toll-like receptors 1, 2, 4, 5, 6, 7, and 8. Patterns of cytokine response to PAMPs were assessed using hierarchical clustering. One-sided Student's t-tests were used to compare PAMP-induced cytokine levels in blood from patients with and without severe COPD, and for subjects with and without chronic bronchitis. Of 28 male patients, 12 had moderate COPD (FEV1 50%-80%) and 16 severe COPD (FEV1,50%); 27 participants provided data on self-reported chronic bronchitis, of which 15 endorsed chronic bronchitis symptoms and 12 did not. Cytokine responses to PAMPs in severe COPD were generally lower than in subjects with milder COPD. This finding was particularly strong for PAMP-induced interleukin (IL)-10, granulocyte colony stimulating factor, and IL-1 beta. Subjects with chronic bronchitis showed higher PAMP-induced IL-1RA responses to most of the PAMPs evaluated. COPD patients with more severe disease demonstrated a diminished cytokine response to PAMPs, suggesting that chronic colonization with bacteria may dampen the systemic innate immune response. C1 [Fan, Vincent S.; Martin, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Fan, Vincent S.; Gharib, Sina A.; Martin, Thomas R.; Wurfel, Mark M.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98195 USA. [Gharib, Sina A.] Univ Washington, Computat Med Core, Ctr Lung Biol, Seattle, WA 98195 USA. RP Fan, VS (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1660 S Columbian Way, Seattle, WA 98108 USA. EM vfan@u.washington.edu FU United States Department of Veterans Affairs Health Services Research and Development Program [02-170-2]; National Institute of Allergy and Infectious Diseases [U54 AI057141] FX Angela Horn assisted in recruitment, study visits, and data management for the study. This work was supported by Career Development Award, Award # 02-170-2, from the United States Department of Veterans Affairs Health Services Research and Development Program, as well as a grant by the National Institute of Allergy and Infectious Diseases (Award # U54 AI057141). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 45 TC 3 Z9 4 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 467 EP 477 DI 10.2147/COPD.S94410 PG 11 WC Respiratory System SC Respiratory System GA DF5GK UT WOS:000371379600001 PM 27019597 ER PT J AU Brummel-Smith, K Butler, D Frieder, M Gibbs, N Henry, M Koons, E Loggers, E Porock, D Reuben, DB Saliba, D Scanlon, WJ Tabbush, V Tinetti, M Tumlinson, A Vladeck, BC Kogan, AC Mosqueda, L Wilber, K Goodwin, C Lundebjerg, NE Mikhailovich, A Aiello, SE AF Brummel-Smith, Kenneth Butler, Dawn Frieder, Miryam Gibbs, Nancy Henry, Maureen Koons, Eileen Loggers, Elizabeth Porock, Davina Reuben, David B. Saliba, Debra Scanlon, William J. Tabbush, Victor Tinetti, Mary Tumlinson, Anne Vladeck, Bruce C. Kogan, Alexis Coulourides Mosqueda, Laura Wilber, Kate Goodwin, Carol Lundebjerg, Nancy E. Mikhailovich, Anna Aiello, Susan E. CA Amer Geriatrics Soc Expert Panel TI Person-Centered Care: A Definition and Essential Elements SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE person-centered care; patient-centered care; care delivery; care quality; care coordination AB Improving healthcare safety, quality, and coordination, as well as quality of life, are important aims of caring for older adults with multiple chronic conditions and/or functional limitations. Person-centered care is an approach to meeting these aims, but there are no standardized, agreed-upon parameters for delivering such care. The SCAN Foundation charged a team from the American Geriatrics Society (AGS) in collaboration with a research and clinical team from the Keck School of Medicine of the University of Southern California to provide the evidence base to support a definition of person-centered care and its essential elements. An interprofessional panel of experts in person-centered care principles and practices that the AGS convened developed this statement. C1 [Brummel-Smith, Kenneth] Amer Geriat Soc, 40 Fulton St 18th Floor, New York, NY 10038 USA. [Brummel-Smith, Kenneth] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA. [Butler, Dawn] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. [Frieder, Miryam] Avalere Hlth, Washington, DC USA. [Gibbs, Nancy] So Calif Permanente Med Grp, Pasadena, CA USA. [Henry, Maureen] NCQA, Washington, DC USA. [Henry, Maureen] Univ Utah, Coll Nursing, Salt Lake City, UT USA. [Koons, Eileen] Huntington Hosp Senior Care Network, Pasadena, CA USA. [Loggers, Elizabeth] Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Loggers, Elizabeth] Seattle Canc Care Alliance, Seattle, WA USA. [Porock, Davina] Lehman Coll, Bronx, NY USA. [Reuben, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Jewish Home Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] VA Greater Angeles Healthcare Syst, Geriat Res, Educ & Clin Ctr, Los Angeles, CA USA. [Saliba, Debra] RAND Hlth, Santa Monica, CA USA. [Scanlon, William J.] Natl Hlth Policy Forum, Washington, DC USA. [Tabbush, Victor] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA USA. [Tinetti, Mary] Yale Univ, Sch Med, New Haven, CT USA. [Tumlinson, Anne] Anne Tumlinson Innovat LLC, Washington, DC USA. [Vladeck, Bruce C.] Nexera Inc, New York, NY USA. [Kogan, Alexis Coulourides; Mosqueda, Laura] Univ So Calif, Family Med & Geriat, Keck Sch Med, Los Angeles, CA USA. [Wilber, Kate] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA. [Goodwin, Carol; Lundebjerg, Nancy E.; Mikhailovich, Anna] Writing & Editorial Serv, New York, NY USA. [Goodwin, Carol; Lundebjerg, Nancy E.; Mikhailovich, Anna] Amer Geriat Soc, 40 Fulton St 18th Floor, New York, NY USA. [Aiello, Susan E.] Provided Editorial Serv, Indianapolis, IN USA. RP Goodwin, C (reprint author), Writing & Editorial Serv, New York, NY USA.; Goodwin, C (reprint author), Amer Geriat Soc, 40 Fulton St 18th Floor, New York, NY USA. EM CGoodwin@americangeriatrics.org FU TSF FX This work was supported by a grant from TSF. Gretchen E. Alkema, PhD, Victoria R. Ballesteros, MA, Megan Burke, MSW, Megan Juring, Lynn Palin, MSW, Rene Seidel, Dipl. Soz. Paed. (FH), and Erin Westphal, MS, The SCAN Foundation, Long Beach, CA, and Sean Dryden, PerryUndem Research/Communication, Washington, DC, participated in the expert panel meeting. NR 4 TC 13 Z9 14 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2016 VL 64 IS 1 BP 15 EP 18 DI 10.1111/jgs.13866 PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FQ UT WOS:000371157900003 ER PT J AU Singh, JA Ramachandran, R AF Singh, Jasvinder A. Ramachandran, Rekha TI Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample SO CLINICAL RHEUMATOLOGY LA English DT Article DE Ankle arthroplasty; Outcomes; Sex; Time trends; Utilization ID UNITED-STATES; KNEE ARTHROPLASTY; SHOULDER ARTHROPLASTY; TOTAL HIP; OPEN APPENDECTOMY; NIS DATABASE; FOLLOW-UP; OUTCOMES; REPLACEMENT; SURGERY AB The objective of this study was to assess the time trends in utilization, clinical characteristics, and outcomes of patients undergoing total ankle arthroplasty (TAA) in the USA. We used the Nationwide Inpatient Sample (NIS) data from 1998 to 2010 to examine time trends in the utilization rates of TAA. We used the Cochran Armitage test for trend to assess time trends across the years and the analysis of variance (ANOVA), Wilcoxon test, or chi-squared test (as appropriate) to compare the first (1998-2000) and the last time periods (2009-2010). TAA utilization rate increased significant from 1998 to 2010: 0.13 to 0.84 per 100,000 overall, 0.14 to 0.88 per 100,000 in females, and from 0.11 to 0.81 per 100,000 in males (p<0.0001 for each comparison for time trends). Compared to the 1998-2000 period, those undergoing TAA in 2009-2010 were older (41 % fewer patients <50 years, p<0.0001), less likely to have rheumatoid arthritis as the underlying diagnosis (55 % fewer patients, p=0.0001), more likely to have Deyo-Charlson index of 2 or more (197 % more, p=0.0010), and had a shorter length of stay at 2.5 days (17 % reduction, p<0.0001). Mortality was rare ranging from 0 to 0.6 % and discharge to inpatient facility ranged 12.6-14.1 %; we noted no significant time trends in either (p>0.05). The utilization rate of TAA increased rapidly in the USA from 1998 to 2010, but post-arthroplasty mortality rate was stable. Underlying diagnosis and medical comorbidity changed over time and both can impact outcomes after TAA. Further studies should examine how the outcomes and complications of TAA have evolved over time. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; VA Medical Center at Birmingham, AL, USA FX JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110; the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891; the National Institute of Aging (NIA) U01 AG018947; the National Cancer Institute (NCI) U10 CA149950; and research contract CE-1304-6631 from Patient Centered Outcomes Research Institute (PCORI). JAS is also supported through the use of resources and facilities at the VA Medical Center at Birmingham, AL, USA. NR 25 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD JAN PY 2016 VL 35 IS 1 BP 239 EP 245 DI 10.1007/s10067-014-2703-2 PG 7 WC Rheumatology SC Rheumatology GA DE7MM UT WOS:000370821000029 PM 24907036 ER PT J AU Miedema, MD Huguelet, J Virani, SS AF Miedema, Michael D. Huguelet, Joseph Virani, Salim S. TI Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Review DE Aspirin; Primary prevention; Cardiovascular disease ID LOW-DOSE ASPIRIN; RANDOMIZED-CONTROLLED-TRIALS; ACUTE MYOCARDIAL-INFARCTION; PLACEBO-CONTROLLED TRIAL; RISK-FACTORS; EVENTS; CORONARY; METAANALYSIS; SECONDARY; STROKE AB Aspirin remains one of the most extensively studied cardiovascular medications in the history of medicine. However, despite multiple, well-designed, large randomized controlled trials evaluating the potential of aspirin to prevent cardiovascular events in individuals without known cardiovascular disease (CVD), the role of aspirin in primary prevention is currently unclear. The initial aspirin trials included largely low-risk individuals with primary outcomes mostly focused on myocardial infarction (MI) and stroke, and showed a significant reduction in these CVD outcomes, especially MI. The more recently conducted trials have focused on older, higher CVD risk populations with high rates of lipid-lowering and antihypertensive medications use. These studies have used broader CVD outcomes as their primary end points and have failed to show a significant benefit of aspirin therapy in primary prevention. The exact reasons for the lack of efficacy in these recent trials are unclear but may be related to low rate of atherothrombotic events relative to other CVD events in the populations studied. Four large randomized controlled trials are currently underway which should provide some clarity in determining the optimal use of aspirin in the primary prevention of CVD. C1 [Miedema, Michael D.] Minneapolis Heart Inst, Minneapolis, MN USA. [Miedema, Michael D.] Minneapolis Heart Inst Fdn, 920 E 28th St, Minneapolis, MN 55414 USA. [Huguelet, Joseph] Abbott NW Hosp, Minneapolis, MN 55407 USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA. RP Miedema, MD (reprint author), Minneapolis Heart Inst, Minneapolis, MN USA.; Miedema, MD (reprint author), Minneapolis Heart Inst Fdn, 920 E 28th St, Minneapolis, MN 55414 USA. EM mdm307@mail.harvard.edu OI Virani, Salim/0000-0001-9541-6954 NR 38 TC 0 Z9 0 U1 0 U2 1 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 EI 1534-6242 J9 CURR ATHEROSCLER REP JI Curr. Atheroscleros. Rep. PD JAN PY 2016 VL 18 IS 1 AR 4 DI 10.1007/s11883-015-0555-0 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DE7JF UT WOS:000370811300003 PM 26753770 ER PT S AU Lyamin, OI Korneva, SM Rozhnov, VV Mukhametov, LM AF Lyamin, Oleg I. Korneva, Svetlana M. Rozhnov, Viatcheslav V. Mukhametov, Lev M. BE Popper, AN Hawkins, A TI Cardiorespiratory Responses to Acoustic Noise in Belugas SO EFFECTS OF NOISE ON AQUATIC LIFE II SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 3rd International Conference on the Effects of Noise on Aquatic Life CY AUG, 2013 CL Budapest, HUNGARY SP Fisheries Joint Management Comm, Natl Oceanog & Atmospher Adm, Natl Sci Fdn, NAVFAC, Off Naval Res, Off Naval Res Global, Acoust Soc Amer, Aquat Noise Trust, Discovery Sound Sea, Co Biologists, Univ Maryland, Coll Chem & Life Sci, Ctr Comparat & Evolutionary Biol Hearing DE Noise; Beluga; Heart rate; Breathing; Stress ID DOLPHIN TURSIOPS-TRUNCATUS AB To date, most research on the adverse effects of anthropogenic noise on marine mammals has focused on auditory and behavioral responses. Other responses have received little attention and are often ignored. In this study, the effect of acoustic noise on heart rate was examined in captive belugas. The data suggest that (1) heart rate can be used as a measure of physiological response (including stress) to noise in belugas and other cetaceans, (2) cardiac response is influenced by parameters of noise and adaptation to repeated exposure, and (3) cetacean calves are more vulnerable to the adverse effect of noise than adults. C1 [Lyamin, Oleg I.; Rozhnov, Viatcheslav V.; Mukhametov, Lev M.] Russian Acad Sci, AN Severtsov Inst Ecol & Evolut, Moscow 119071, Russia. [Lyamin, Oleg I.; Korneva, Svetlana M.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow 119071, Russia. [Lyamin, Oleg I.] Sepulveda Res Corp, VA Greater Los Angeles Healthcare Syst, Neurobiol Res 15A03, 16111 Plummer St, North Hills, CA 91343 USA. RP Lyamin, OI (reprint author), Russian Acad Sci, AN Severtsov Inst Ecol & Evolut, Moscow 119071, Russia.; Lyamin, OI (reprint author), Utrish Dolphinarium Ltd, Moscow 119071, Russia.; Lyamin, OI (reprint author), Sepulveda Res Corp, VA Greater Los Angeles Healthcare Syst, Neurobiol Res 15A03, 16111 Plummer St, North Hills, CA 91343 USA. EM olyamin@ucla.edu; s_korneva@list.ru; rozhnov.v@gmail.com; lev.mukhametov@gmail.com RI Varghese, Ann/P-7833-2016 FU Russian Geographical Society; Utrish Dolphinarium Ltd. FX The study was funded by the Russian Geographical Society and supported by Utrish Dolphinarium Ltd. We thank the colleagues from Dr. A. Supin's laboratory (A. N. Severtsov Institute of Ecology and Evolutions, Moscow, Russia) for assistance with the presentation of noises and Dr. P. Kosenko (Utrish Dolphinarium Ltd., Moscow, Russia) for technical support. NR 14 TC 0 Z9 0 U1 9 U2 13 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4939-2981-8; 978-1-4939-2980-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 875 BP 665 EP 672 DI 10.1007/978-1-4939-2981-8_80 PG 8 WC Environmental Sciences; Marine & Freshwater Biology SC Environmental Sciences & Ecology; Marine & Freshwater Biology GA BE2TA UT WOS:000370000900081 PM 26611017 ER PT J AU Jaoude, WA Tiu, B Strieter, N Maloney, JD AF Jaoude, Wassim Abi Tiu, Brian Strieter, Nicole Maloney, James D. TI Thoracoscopic native lung pneumonectomy after single lung transplant: initial experience with 2 cases SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Editorial Material CT CHEST Annual Meeting CY OCT 29, 2013 CL Chicago, IL DE Lung-other; Experimental thoracic surgery ID COMPLICATIONS AB Single lung transplants (SLTs) leave in place a diseased lung, a potential source of complications. Native lung pneumonectomy is occasionally indicated. We present 2 cases of native lung complications (NLCs) managed with video-assisted thoracoscopic surgery (VATS) pneumonectomy at our institution, a procedure never reported in this context before. Case 1 involves a 59-year old gentleman with refractory, invasive pulmonary aspergillosis of the native lung, 5 years after SLT for idiopathic pulmonary fibrosis. Case 2 involves a 66-year old gentleman with alpha-1 antitrypsin deficiency who developed severe haemoptysis and intraparenchymal haemorrhage in the native lung 12 years after SLT. AVATS pneumonectomy was performed in both cases because we believed it would facilitate wound healing and hasten recovery in immunosuppressed patients. Our short-term results align with this hypothesis. We conclude that VATS pneumonectomy is a feasible, adequate and safe procedure in this patient population; larger series are needed to draw definitive conclusions. C1 [Jaoude, Wassim Abi; Maloney, James D.] Univ Wisconsin Hosp & Clin, Div Cardiothorac Surg, Thorac Surg Sect, Madison, WI 53792 USA. [Tiu, Brian] Suny Downstate Med Ctr, Dept Surg, 450 Clarkson Ave, Brooklyn, NY 11203 USA. [Strieter, Nicole; Maloney, James D.] William S Middleton Mem Vet Adm Med Ctr, Div Cardiothorac Surg, Thorac Surg Sect, Madison, WI USA. RP Tiu, B (reprint author), Suny Downstate Med Ctr, Dept Surg, 450 Clarkson Ave, Brooklyn, NY 11203 USA. EM brian.tiu@downstate.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD JAN PY 2016 VL 49 IS 1 BP 352 EP 354 DI 10.1093/ejcts/ezv075 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DE9SR UT WOS:000370979800095 ER PT J AU Calverley, PM Postma, DS Anzueto, AR Make, BJ Eriksson, G Peterson, S Jenkins, CR AF Calverley, Peter M. Postma, Dirkje S. Anzueto, Antonio R. Make, Barry J. Eriksson, Goeran Peterson, Stefan Jenkins, Christine R. TI Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE anti-inflammatories; bronchodilator effect; chronic obstructive pulmonary disease; predictors; risk assessment; risk factors ID OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; LUNG-FUNCTION; FLUTICASONE PROPIONATE; CLINICAL-TRIAL; HEALTH-STATUS; SALMETEROL; EFFICACY; OUTCOMES; BUDESONIDE/FORMOTEROL AB Background: Early treatment response markers, for example, improvement in forced expiratory volume in 1 second (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score, may help clinicians to better manage patients with chronic obstructive pulmonary disease (COPD). We investigated the prevalence of clinically important improvements in FEV1 and SGRQ scores after 2-month budesonide/formoterol or formoterol treatment and whether such improvements predict subsequent improvements and exacerbation rates. Methods: This post hoc analysis is based on data from three double-blind, randomized studies in patients with moderate-to-very-severe COPD receiving twice-daily budesonide/formoterol or formoterol alone for 6 or 12 months. Prebronchodilator FEV1 and SGRQ total score were measured before treatment and at 2 and 12 months; COPD exacerbation rates were measured during months 2-12. Responders were defined by >= 100 mL improvement in prebronchodilator FEV1 and >= 4-point decrease in SGRQ total score. Results: Overall, 2,331 and 1,799 patients were included in the 0-2- and 0-12-month responder analyses, respectively, and 2,360 patients in the 2-12-month exacerbation rate analysis. At 2 months, 35.1% of patients were FEV1 responders and 44.3% were SGRQ responders. The probability of response was significantly greater with budesonide/formoterol than with formoterol or placebo for both parameters. Two-month responders had a greater chance of 12-month response than 2-month nonresponders for both FEV1 (odds ratio, 5.57; 95% confidence interval, 4.14-7.50) and SGRQ (odds ratio, 3.87; 95% confidence interval, 2.83-5.31). Two-month response in FEV1 (P<0.001), but not SGRQ (P=0.11), was associated with greater reductions in exacerbation risk. Conclusion: Early FEV1 and SGRQ treatment responses relate to their changes at 12 months. FEV1 response, but not SGRQ response, at 2 months predicts the risk of a future COPD exacerbation in some, but not all patients. This is potentially useful in clinical practice, although more sensitive and specific markers of favorable treatment response are required. C1 [Calverley, Peter M.] Aintree Univ Hosp NHS Fdn Trust, Pulm & Rehabil Res Grp, Liverpool L9 7AL, Merseyside, England. [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Gronigen Res Inst Asthma, Dept Pulm Med & TB, Groningen, Netherlands. [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, COPD, Groningen, Netherlands. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Make, Barry J.] Univ Colorado, Natl Jewish Hlth, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Eriksson, Goeran] Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden. [Peterson, Stefan] StatMind AB, Lund, Sweden. [Jenkins, Christine R.] Univ Sydney, Concord Clincal Sch, George Inst Global Hlth, Sydney, NSW 2006, Australia. RP Calverley, PM (reprint author), Aintree Univ Hosp NHS Fdn Trust, Inst Ageing & Chron Dis, Dept Clin Sci, Lower Lane, Liverpool L9 7AL, Merseyside, England. EM pmacal@liverpool.ac.uk FU AstraZeneca FX This analysis was funded by AstraZeneca. Anna Mett and Shaun Foley of in Science Communications, Springer Healthcare, provided medical writing assistance, funded by AstraZeneca. The authors thank Malin Fageras of AstraZeneca R&D, Gothenburg, Sweden, and Thomas Similowski, of Groupe Hospitalier Pitie-Salpetriere, Paris, France, for their assistance with the development of this manuscript. Anders Persson of AstraZeneca R&D, Gothenburg, Sweden, performed additional statistical analyses. NR 30 TC 1 Z9 1 U1 0 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 381 EP 390 DI 10.2147/COPD.S93303 PG 10 WC Respiratory System SC Respiratory System GA DE9RK UT WOS:000370975600001 PM 26952309 ER PT J AU Burgess, DJ Gravely, AA Nelson, DB Bair, MJ Kerns, RD Higgins, DM Farmer, MM Partin, MR AF Burgess, Diana J. Gravely, Amy A. Nelson, David B. Bair, Matthew J. Kerns, Robert D. Higgins, Diana M. Farmer, Melissa M. Partin, Melissa R. TI Association between pain outcomes and race and opioid treatment: Retrospective cohort study of Veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE blacks; chronic pain; Department of Veterans Affairs; disparities; opioids; pain outcomes; pain treatment effectiveness; race; survey; Veterans ID CHRONIC NONCANCER PAIN; UNITED-STATES; PRIMARY-CARE; RACIAL-DIFFERENCES; HEALTH-CARE; PATIENT SATISFACTION; AFRICAN-AMERICAN; POPULATION; OSTEOARTHRITIS; MANAGEMENT AB We examined whether pain outcomes (pain interference, perceived pain treatment effectiveness) vary by race and then whether opioid use moderates these associations. These analyses are part of a retrospective cohort study among 3,505 black and 46,203 non-Hispanic, white Department of Veterans Affairs (VA) patients with diagnoses of chronic musculoskeletal pain who responded to the 2007 VA Survey of Healthcare Experiences of Patients (SHEP). We used electronic medical record data to identify prescriptions for pharmacologic pain treatments in the year after diagnosis (Pain Diagnosis index visit) and before the SHEP index visit (the visit that made one eligible to complete the SHEP); pain outcomes came from the SHEP. We found no significant associations between race and pain interference or perceived effectiveness of pain treatment. VA patients with opioid prescriptions between the Pain Diagnosis index visit and the SHEP index visit reported greater pain interference on the SHEP than those without opioid prescriptions during that period. Opioid prescriptions were not associated with perceived treatment effectiveness for most patients. Findings raise questions about benefits of opioids for musculoskeletal pain and point to the need for alternative treatments for addressing chronic noncancer pain. C1 [Burgess, Diana J.; Gravely, Amy A.; Nelson, David B.; Partin, Melissa R.] Minneapolis Dept Vet Affairs VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Burgess, Diana J.; Nelson, David B.; Partin, Melissa R.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Bair, Matthew J.] Richard L Roudebush VA Med Ctr, VA Hlth Serv Res & Dev, Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Bair, Matthew J.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Bair, Matthew J.] Regenstrief Inst Inc, Indianapolis, IN USA. [Kerns, Robert D.; Higgins, Diana M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kerns, Robert D.; Higgins, Diana M.] Yale Univ, Sch Med, New Haven, CT USA. [Higgins, Diana M.; Farmer, Melissa M.] VA Greater Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, VA Hlth Serv Res & Dev Serv, Sepulveda, CA USA. RP Higgins, DM (reprint author), Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, One Vet Dr, Minneapolis, MN 55419 USA. EM Diana.Burgess@va.gov FU VA Health Services Research and Development Service (HSRD) [IIR 07-071]; VA HSR&D Research Career Scientist [RCS 10-185]; Merit Review Entry Program award MRP [04-41-1] FX This material was based on work supported by three awards from VA Health Services Research and Development Service (HSR&D): investigator initiated research IIR 07-071 (D.J.B.), VA HSR&D Research Career Scientist award RCS 10-185 (M.R.P.), and Merit Review Entry Program award MRP 04-41-1 (D.J.B.). NR 48 TC 0 Z9 0 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2016 VL 53 IS 1 BP 13 EP 24 DI 10.1682/JRRD.2014.10.0252 PG 12 WC Rehabilitation SC Rehabilitation GA DE9WS UT WOS:000370991200005 PM 26933921 ER PT J AU Costa-Mallen, P Zabetian, CP Agarwal, P Hu, SC Yearout, D Samii, A Leverenz, JB Roberts, JW Checkoway, H AF Costa-Mallen, Paola Zabetian, Cyrus P. Agarwal, Pinky Hu, Shu-Ching Yearout, Dora Samii, Ali Leverenz, James B. Roberts, John W. Checkoway, Harvey TI Response to the letter "Haptoglobin phenotype and Parkinson disease risk" by Delanghe et al. SO PARKINSONISM & RELATED DISORDERS LA English DT Letter DE Haptoglobin polymorphism; Parkinson disease; Heterosis C1 [Costa-Mallen, Paola] Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA USA. [Zabetian, Cyrus P.; Yearout, Dora; Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching; Samii, Ali] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Agarwal, Pinky] Evergreen Hlth, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. RP Costa-Mallen, P (reprint author), Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA USA. EM pcostamallen@bastyr.edu FU BLRD VA [I01 BX000531]; NIEHS NIH HHS [R01 ES010750]; NINDS NIH HHS [R01 NS065070, P50 NS062684, R21 NS070202] NR 5 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JAN PY 2016 VL 22 BP 110 EP 111 DI 10.1016/j.parkreldis.2015.10.021 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DE8JU UT WOS:000370883100020 PM 26708126 ER PT J AU Hetzenecker, A Escourrou, P Kuna, ST Series, F Lewis, K Birner, C Pfeifer, M Arzt, M AF Hetzenecker, Andrea Escourrou, Pierre Kuna, Samuel T. Series, Frederic Lewis, Keir Birner, Christoph Pfeifer, Michael Arzt, Michael TI Treatment of sleep apnea in chronic heart failure patients with auto-servo ventilation improves sleep fragmentation: a randomized controlled trial SO SLEEP MEDICINE LA English DT Article DE Heart failure; Sleep disordered breathing; Auto-servo ventilation; Sleep quality; NT-pro BNP ID POSITIVE AIRWAY PRESSURE; CHEYNE-STOKES RESPIRATION; PROGNOSTIC IMPACT; ADAPTIVE SERVOVENTILATION; HYPOPNEA SYNDROME; WRIST ACTIGRAPHY; PREVALENCE; DIAGNOSIS; SYMPTOMS; EPIDEMIC AB Background: Impaired sleep efficiency is independently associated with worse prognosis in patients with chronic heart failure (CHF). Therefore, a test was conducted on whether auto-servo ventilation (ASV, biphasic positive airway pressure [BiPAP]-ASV, Philips Respironics) reduces sleep fragmentation and improves sleep efficiency in CHF patients with central sleep apnea (CSA) or obstructive sleep apnea (OSA). Methods: In this multicenter, randomized, parallel group trial, a study was conducted on 63 CHF patients (age 64 +/- 10 years; left ventricular ejection fraction 29 +/- 7%) with CSA or OSA (apnea-hypopnea Index, AHI 47 +/- 18/h; 46% CSA) referred to sleep laboratories of the four participating centers. Participants were randomized to either ASV (n = 32) or optimal medical treatment alone (control, n = 31). Results: Polysomnography (PSG) and actigraphy at home (home) with centralized blinded scoring were obtained at baseline and 12 weeks. ASV significantly reduced sleep fragmentation (total arousal indexpsc: -16.4 +/- 20.6 vs.-0.6 13.2/h, p = 0.001; sleep fragmentation index(home):-7.6 +/- 15.6 versus 4.3 +/- 13.9/h, p = 0.003, respectively) and significantly increased sleep efficiency assessed by actigraphy (SEhome) compared to controls (2.3 +/- 10.1 vs.-2.1 +/- 6.9%, p = 0.002). Effects of ASV on sleep fragmentation and efficiency were similar in patients suffering from OSA and CSA. Conclusions: At home, ASV treatment modestly improves sleep fragmentation as well as sleep efficiency in CHF patients having either CSA or OSA. (C) 2015 Elsevier B.V. All rights reserved. C1 [Hetzenecker, Andrea; Birner, Christoph; Pfeifer, Michael; Arzt, Michael] Univ Hosp Regensburg, Dept Internal Med 2, Regensburg, Germany. [Hetzenecker, Andrea; Pfeifer, Michael] Donaustauf Hosp, Ctr Pneumol, Donaustauf, Germany. [Escourrou, Pierre] Hop Antoine Beclere, Ctr Med Sommeil, Clamart, France. [Kuna, Samuel T.] Univ Penn, Perleman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Series, Frederic] Univ Laval, IUCPQ, Ctr Rech, Quebec City, PQ, Canada. [Lewis, Keir] Prince Philip Hosp, Dept Resp Med, Llanelli, Wales. [Lewis, Keir] Swansea Coll Med, Swansea, W Glam, Wales. [Pfeifer, Michael] Hosp Order St John God Regensburg, Clin Pulmonol, Regensburg, Germany. RP Arzt, M (reprint author), Univ Hosp Regensburg, Ctr Sleep Med, Dept Internal Med 2, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. EM michael.arzt@ukr.de NR 41 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD JAN PY 2016 VL 17 BP 25 EP 31 DI 10.1016/j.sleep.2015.08.020 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DE8OX UT WOS:000370897100006 PM 26847970 ER PT J AU George, MD Baker, JF AF George, Michael D. Baker, Joshua F. TI y The Obesity Epidemic and Consequences for Rheumatoid Arthritis Care SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Rheumatoid arthritis; Obesity; Adiposity ID BODY-MASS INDEX; RADIOGRAPHIC JOINT DAMAGE; TUMOR-NECROSIS-FACTOR; LONG-TERM CHANGES; RISK-FACTORS; DISEASE-ACTIVITY; AUTOIMMUNE-DISEASES; CARDIOVASCULAR RISK; ALCOHOL-CONSUMPTION; GENERAL-POPULATION AB With the prevalence of obesity increasing dramatically worldwide over the past several decades, an increasing body of literature has examined the impact of obesity in the context of rheumatoid arthritis (RA). Epidemiologic studies suggest that obesity may be associated with a modestly increased risk for the development of RA, although these studies have shown conflicting results. Among patients with established RA, obesity has been observed to be associated with greater subjective measures of disease activity and poor treatment response, but also with a decreased risk of joint damage and lower mortality. A comprehensive evaluation of the influence of obesity on the measurement of disease, response to therapies, and long-term prognosis is critical in order to understand these observations. This review therefore focuses on recent observations, potential explanations for these findings, and implications for clinicians and investigators caring for and studying patients with RA. C1 [George, Michael D.; Baker, Joshua F.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP George, MD (reprint author), Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. EM michael.george@uphs.upenn.edu FU Veterans Affairs Clinical Science Research & Development Career Development Award [IK2 CX000955] FX Dr. Baker would like to acknowledge funding through a Veterans Affairs Clinical Science Research & Development Career Development Award (IK2 CX000955). The contents of this work do not represent the views of the Department of the Veterans Affairs or the United States Government. NR 78 TC 1 Z9 1 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD JAN PY 2016 VL 18 IS 1 AR 6 DI 10.1007/s11926-015-0550-z PG 9 WC Rheumatology SC Rheumatology GA DD9HE UT WOS:000370235500006 PM 26739963 ER PT J AU May, P Garrido, MM Cassel, JB Kelley, AS Meier, DE Normand, C Stefanis, L Smith, TJ Morrison, RS AF May, Peter Garrido, Melissa M. Cassel, J. Brian Kelley, Amy S. Meier, Diane E. Normand, Charles Stefanis, Lee Smith, Thomas J. Morrison, R. Sean TI Palliative Care Teams' Cost-Saving Effect Is Larger For Cancer Patients With Higher Numbers Of Comorbidities SO HEALTH AFFAIRS LA English DT Article ID OF-LIFE DISCUSSIONS; RESEARCH PRIORITIES; AMERICAN SOCIETY; CONSULTATION; HEALTH; PREFERENCES; DEATH; END; BENEFICIARIES; OUTCOMES AB Patients with multiple serious conditions account for a high proportion of health care spending. Such spending is projected to continue to grow substantially as a result of increased insurance eligibility, the ever-rising cost of care, the continued use of nonbeneficial high-intensity treatments at the end of life, and demographic changes. We evaluated the impact of palliative care consultation on hospital costs for adults with advanced cancer, excluding those with dementia. We found that compared to usual care, the receipt of a palliative care consultation within two days of admission was associated with 22 percent lower costs for patients with a comorbidity score of 2-3 and with 32 percent lower costs for those with a score of 4 or higher. Earlier consultation was also found to be systematically associated with a larger cost-saving effect for all subsamples defined by multimorbidity. Given ongoing workforce shortages, targeting early specialist palliative care to hospitalized patients with advanced cancer and higher numbers of serious concurrent conditions could improve care while complementing strategies to curb the growth of health spending. C1 [May, Peter] Univ Dublin Trinity Coll, Ctr Hlth Policy & Management, Dublin, Ireland. [May, Peter; Garrido, Melissa M.; Kelley, Amy S.; Meier, Diane E.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Geriatr & Palliat Med, New York, NY 10029 USA. [Garrido, Melissa M.; Stefanis, Lee] James J Peters Vet Affairs VA Med Ctr, Bronx, NY USA. [Cassel, J. Brian] Virginia Commonwealth Univ, Hematol Oncol & Palliat Care, Richmond, VA 23284 USA. [Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA. [Normand, Charles] Univ Dublin Trinity Coll, Hlth Policy & Management, Dublin, Ireland. [Smith, Thomas J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Palliat Med, Baltimore, MD USA. [Morrison, R. Sean] Icahn Sch Med Mt Sinai, Natl Palliat Care Res Ctr, New York, NY 10029 USA. RP May, P (reprint author), Univ Dublin Trinity Coll, Ctr Hlth Policy & Management, Dublin, Ireland. EM mayp2@tcd.ie RI May, Peter/B-2107-2017 OI May, Peter/0000-0001-8501-6500 FU National Cancer Institute (NCI); National Institute of Nursing Research [5R01CA116227-04]; health economics fellowship from the Health Research Board of Ireland; NCI [P30 CA 006973]; Veterans Affairs Health Services Research and Development Career Development Award [CDA 11-201/CDP 12-255]; National Institute on Aging (NIA) [1K23AG040774-01A1]; National Institutes of Health [5K24AG022345]; NIA; Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741]; National Palliative Care Research Center FX An early version of these results was presented at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association, Philadelphia, Pennsylvania, February 26, 2015. The study was funded by the National Cancer Institute (NCI) and the National Institute of Nursing Research (Project No. 5R01CA116227-04). The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. All authors are independent of the study sponsors. Peter May is sponsored by a health economics fellowship from the Health Research Board of Ireland and by the NCI. Melissa Garrido is supported by a Veterans Affairs Health Services Research and Development Career Development Award (Award No. CDA 11-201/CDP 12-255). Amy Kelley was supported by the National Institute on Aging (NIA; Grant No. 1K23AG040774-01A1). Thomas Smith is supported by a grant from the NCI to the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University (Grant No. P30 CA 006973). Sean Morrison received a Midcareer Investigator Award in Patient-Oriented Research from the National Institutes of Health (Award No. 5K24AG022345) during the course of this work. This work was supported by the NIA, the Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai (Grant No. 5P30AG028741), and the National Palliative Care Research Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The authors thank Robert Arnold, Phil Santa Emma, Mary Beth Happ, Tim Smith, and David Weissman for their contributions to the Palliative Care for Cancer project. NR 42 TC 8 Z9 8 U1 3 U2 5 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN PY 2016 VL 35 IS 1 BP 44 EP 53 DI 10.1377/hlthaff.2015.0752 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD1PV UT WOS:000369694700007 PM 26733700 ER PT J AU Townsend, RR Rosendorff, C Nichols, WW Edwards, DG Chirinos, JA Fernhall, B Cushman, WC AF Townsend, Raymond R. Rosendorff, Clive Nichols, Wilmer W. Edwards, David G. Chirinos, Julio A. Fernhall, Bo Cushman, William C. TI American Society of Hypertension position paper: central blood pressure waveforms in health and disease SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Augmentation index; central arterial pressure; pulse pressure augmentation; pulse wave analysis ID CENTRAL AORTIC PRESSURE; LEFT-VENTRICULAR AFTERLOAD; CENTRAL PULSE PRESSURE; ARTERY FUNCTION EVALUATION; MOVING AVERAGE METHOD; SYSTOLIC PRESSURE; NONINVASIVE EVALUATION; CARDIOVASCULAR EVENTS; REFLECTION MAGNITUDE; AUGMENTATION INDEX AB A number of devices are available which noninvasively estimate central aortic blood pressure using a variety of approaches such as tonometry or oscillometry. In this position paper, we discuss how the central pressure waveform is generated and measured, how central pressure waveforms appear in health and disease, the predictive value of central blood pressure measurements, the effects of interventions on waveforms, and areas of future need in this field of clinical and research endeavor. (C) 2016 American Society of Hypertension. All rights reserved. C1 [Townsend, Raymond R.; Chirinos, Julio A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. [Nichols, Wilmer W.] Univ Florida, Coll Med, Dept Med, Div Med, Gainesville, FL USA. [Nichols, Wilmer W.] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL USA. [Edwards, David G.] Univ Delaware, Coll Hlth Sci, Dept Kinesiol & Appl Physiol, Newark, DE USA. [Fernhall, Bo] Univ Illinois, Coll Appl Hlth Sci, Dept Kinesiol & Nutr, Chicago, IL USA. [Cushman, William C.] Univ Tennessee, Coll Med, Vet Affairs Med Ctr, Dept Med Serv, Memphis, TN USA. RP Townsend, RR (reprint author), Univ Penn, Renal Electrolyte & Hypertens Div, Perelman Sch Med, 122 Founders Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM townsend@exchange.upenn.edu FU NIH; Fukuda Denshi; American College of Radiology Network; Department of Homeland Security; National Multiple Sclerosis Society; Merck; Eli Lilly FX R.R.T. received grants from NIH and Fukuda Denshi. D.G.E. received grants from NIH. J.A.C. received grants from NIH, American College of Radiology Network, and Fukuda Denshi. B.F. received grants from NIH, Department of Homeland Security, and the National Multiple Sclerosis Society. W.C.C. received grants from NIH, Merck, and Eli Lilly. NR 83 TC 3 Z9 3 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD JAN PY 2016 VL 10 IS 1 BP 22 EP 33 DI 10.1016/j.jash.2015.10.012 PG 12 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DE2OM UT WOS:000370466600007 PM 26612106 ER PT J AU McClatchey, PM Keller, AC Bouchard, R Knaub, LA Reusch, JEB AF McClatchey, P. Mason Keller, Amy C. Bouchard, Ron Knaub, Leslie A. Reusch, Jane E. B. TI Fully automated software for quantitative measurements of mitochondrial morphology SO MITOCHONDRION LA English DT Article DE Mitochondria; Morphology; Microscopy; Image processing ID CELL-DEATH; DYNAMICS; FISSION; NEURONS; DISEASE; CALCIUM; FIBROBLASTS; DYSFUNCTION; ACTIVATION; INCREASES AB Mitochondria undergo dynamic changes in morphology in order to adapt to changes in nutrient and oxygen availability, communicate with the nucleus, and modulate intracellular calcium dynamics. Many recent papers have been published assessing mitochondrial morphology endpoints. Although these studies have yielded valuable insights, contemporary assessment of mitochondrial morphology is typically subjective and qualitative, precluding direct comparison of outcomes between different studies and likely missing many subtle effects. In this paper, we describe a novel software technique for measuring the average length, average width, spatial density, and intracellular localization of mitochondria from a fluorescent microscope image. This method was applied to distinguish baseline characteristics of Human Umbilical Vein Endothelial Cells (HUVECs), primary Goto-Kakizaki rat aortic smooth muscle cells (GK SMCs), primary Wistar rat aortic smooth muscle cells (Wistar SMCs), and SH-SY5Ys (human neuroblastoma cell line). Consistent with direct observation, our algorithms found SH-SY5Ys to have the greatest mitochondria] density, while HUVECs were found to have the longest mitochondria. Mitochondrial morphology responses to temperature, nutrient, and oxidative stressors were characterized to test algorithm performance. Large morphology changes recorded by the software agreed with direct observation, and subtle but consistent morphology changes were found that would not otherwise have been detected. Endpoints were consistent between experimental repetitions (R = 0.93 for length, R = 0.93 for width, R = 0.89 for spatial density, and R = 0.74 for localization), and maintained reasonable agreement even when compared to images taken with compromised microscope resolution or in an alternate imaging plane. These results indicate that the automated software described herein allows quantitative and objective characterization of mitochondrial morphology from fluorescent microscope images. Published by Elsevier B.V. and Mitochondria Research Society. C1 [McClatchey, P. Mason; Keller, Amy C.; Knaub, Leslie A.; Reusch, Jane E. B.] Univ Colorado Anschutz Med Campus, Div Endocrinol, Aurora, CO USA. [McClatchey, P. Mason; Keller, Amy C.; Bouchard, Ron; Knaub, Leslie A.; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO USA. [McClatchey, P. Mason; Reusch, Jane E. B.] Univ Colorado Anschutz Med Campus, Dept Bioengn, Aurora, CO USA. [Reusch, Jane E. B.] Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO USA. RP Reusch, JEB (reprint author), Univ Colorado Anschutz Med Campus, Div Endocrinol, Aurora, CO USA. EM jane.reusch@ucdenver.edu FU VA Merit, Denver Research Institute [NIH-5T32HL007171, NIH-5P01HL014985, CCTSI-UL1RR025780]; Center for Women's Health Research; Department of Bioengineering; National Cancer Institute Cancer Center Support Grant [P30CA046934] FX Sources of funding for this study were provided by VA Merit, Denver Research Institute, NIH-5T32HL007171 (ACK), NIH-5P01HL014985 (ACK), CCTSI-UL1RR025780 (JEBR), the Center for Women's Health Research (JEBR), and the Department of Bioengineering (PMM). Flow Cytometry is supported through a National Cancer Institute Cancer Center Support Grant (P30CA046934). NR 41 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD JAN PY 2016 VL 26 BP 58 EP 71 DI 10.1016/j.mito.2015.12.003 PG 14 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA DE6UC UT WOS:000370768100007 PM 26688338 ER PT J AU Duong, TQ Watts, LT AF Duong, Timothy Q. Watts, Lora T. TI A brief report on MRI investigation of experimental traumatic brain injury SO NEURAL REGENERATION RESEARCH LA English DT Article DE MRI; traumatic brain injury; magnetic resonance imaging; diffusion tensor imaging; cerebral blood flow ID VETERANS AB Traumatic brain injury is a major cause of death and disability. This is a brief report based on a symposium presentation to the 2014 Chinese Neurotrauma Association Meeting in San Francisco, USA. It covers the work from our laboratory in applying multimodal MRI to study experimental traumatic brain injury in rats with comparisons made to behavioral tests and histology. MRI protocols include structural, perfusion, manganese-enhanced, diffusion-tensor MRI, and MRI of blood-brain barrier integrity and cerebrovascular reactivity. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Res Imaging Inst, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Res Imaging Inst, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu NR 17 TC 1 Z9 1 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD JAN PY 2016 VL 11 IS 1 BP 15 EP 17 DI 10.4103/1673-5374.169604 PG 3 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA DD7ZF UT WOS:000370142800003 PM 26981069 ER PT J AU Fujikawa, DG Pais, ES Aviles, ER Hsieh, KC Bashir, MT AF Fujikawa, Denson G. Pais, Emil S. Aviles, Ernesto R., Jr. Hsieh, Kung-Chiao Bashir, Muhammad Tariq TI Methamphetamine-induced neuronal necrosis: the role of electrographic seizure discharges SO NEUROTOXICOLOGY LA English DT Article DE Electrographic seizures; Excitotoxicity; Methamphetamine; Mouse; Necrosis; Apoptosis ID INTERNUCLEOSOMAL DNA CLEAVAGE; ELECTRON-MICROSCOPIC FINDINGS; INDUCED STATUS EPILEPTICUS; HYPOGLYCEMIC BRAIN-DAMAGE; TEMPORAL EVOLUTION; APOPTOTIC NEURODEGENERATION; RAT-BRAIN; DEATH; DEGENERATION; FRAGMENTATION AB We have evidence that methamphetamine (METH)-induced neuronal death is morphologically necrotic, not apoptotic, as is currently believed, and that electrographic seizures may be responsible. We administered 40 mg/kg i.p. to 12 male C57BL/6 mice and monitored EEGs continuously and rectal temperatures every 15 min, keeping rectal temperatures <41.0 degrees C. Seven of the 12 mice had repetitive electrographic seizure discharges (RESDs) and 5 did not. The RESDs were often not accompanied by behavioral signs of seizures-i.e., they were often not accompanied by clonic forelimb movements. The 7 mice with RESDs had acidophilic neurons (the H&E light-microscopic equivalent of necrotic neurons by ultrastructural examination) in all of 7 brain regions (hippocampal CA1, CA2, CA3 and hilus, amygdala, piriform cortex and entorhinal cortex), the same brain regions damaged following generalized seizures, 24 h after METH administration. The 5 mice without RESDs had a few acidophilic neurons in 4 of the 7 brain regions, but those with RESDs had significantly more in 6 of the 7 brain regions. Maximum rectal temperatures were comparable in mice with and without RESDs, so that cannot explain the difference between the two groups with respect to METH-induced neuronal death. Our data show that METH-induced neuronal death is morphologically necrotic, that EEGs must be recorded to detect electrographic seizure activity in rodents without behavioral evidence of seizures, and that RESDs may be responsible for METH-induced neuronal death. Published by Elsevier Inc. C1 [Fujikawa, Denson G.; Pais, Emil S.; Aviles, Ernesto R., Jr.; Hsieh, Kung-Chiao; Bashir, Muhammad Tariq] VA Greater Los Angeles Healthcare Syst, Sepulveda VA Ambulatory Care Ctr & Nursing Home, Expt Neurol Lab, North Hills, CA USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Mail Code 151B4,16111 Plummer St, North Hills, CA 91343 USA. EM dfujikaw@ucla.edu FU VA Merit Review grant [I01-BX001858]; VA Greater Los Angeles Research and Development Service; Sepulveda Research Corporation Various Donors Fund; UCLA Department of Neurology Academic Enrichment Fund FX Our study was supported by a VA Merit Review grant (I01-BX001858), the VA Greater Los Angeles Research and Development Service, the Sepulveda Research Corporation Various Donors Fund and the UCLA Department of Neurology Academic Enrichment Fund. Dr. Jeffrey Gornbein, a UCLA biomathematical statistician, provided expert assistance in the statistical analysis of data. NR 28 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD JAN PY 2016 VL 52 BP 84 EP 88 DI 10.1016/j.neuro.2015.11.001 PG 5 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA DE6TW UT WOS:000370767500009 PM 26562800 ER PT J AU Soleymani, T Daniel, S Garvey, WT AF Soleymani, T. Daniel, S. Garvey, W. T. TI Weight maintenance: challenges, tools and strategies for primary care physicians SO OBESITY REVIEWS LA English DT Review DE Maintenance; obesity; primary care; weight loss ID DIABETES-PREVENTION-PROGRAM; LIFE-STYLE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; COMPLICATIONS-CENTRIC APPROACH; CARDIOVASCULAR RISK-FACTORS; OBSTRUCTIVE SLEEP-APNEA; ALL-CAUSE MORTALITY; BARIATRIC SURGERY; CONTROL REGISTRY AB Obesity is recognized as a chronic disease and one of the major healthcare challenges facing us today. Weight loss can be achieved via lifestyle, pharmacological and surgical interventions, but weight maintenance remains a lifetime challenge for individuals with obesity. Guidelines for the management of obesity have highlighted the role of primary care providers (PCPs). This review examines the long-term outcomes of clinical trials to identify effective weight maintenance strategies that can be utilized by PCPs. Because of the broad nature of the topic, a structured PubMed search was conducted to identify relevant research articles, peer-reviewed reviews, guidelines and articles published by regulatory bodies. Trials have demonstrated the benefit of sustained weight loss in managing obesity and its comorbidities. Maintaining 5-10% weight loss for >= 1 year is known to ameliorate many comorbidities. Weight maintenance with lifestyle modification although challenging - is possible but requires long-term support to reinforce diet, physical activity and behavioural changes. The addition of pharmacotherapy to lifestyle interventions promotes greater and more sustained weight loss. Clinical evidence and recently approved pharmacotherapy has given PCPs improved strategies to support their patients with maintenance of weight loss. Further studies are needed to assess the translation of these strategies into clinical practice. C1 [Soleymani, T.; Daniel, S.; Garvey, W. T.] Univ Alabama Birmingham, Dept Nutr Sci, 1720 Second Ave South, Birmingham, AL 35294 USA. [Soleymani, T.; Garvey, W. T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1720 Second Ave South, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU Novo Nordisk A/S; Diabetes Research Center at the University of Alabama at Birmingham - National Institutes of Health [DK-079626] FX WTG acts as guarantor and takes responsibility for the content of the article. Editorial assistance was provided by Dr Ian Seymour from AXON Communications, and funded by Novo Nordisk A/S. The authors acknowledge the support of the Diabetes Research Center at the University of Alabama at Birmingham, funded by an award from the National Institutes of Health (DK-079626). NR 129 TC 1 Z9 1 U1 7 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7881 EI 1467-789X J9 OBES REV JI Obes. Rev. PD JAN PY 2016 VL 17 IS 1 BP 81 EP 93 DI 10.1111/obr.12322 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD8EZ UT WOS:000370159500007 PM 26490059 ER PT J AU Little, EC Camp, ER Wang, C Watson, PM Watson, DK Cole, DJ AF Little, E. C. Camp, E. R. Wang, C. Watson, P. M. Watson, D. K. Cole, D. J. TI The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells SO ONCOGENESIS LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; ACTIVATOR RECEPTOR UPAR; SM-LIKE PROTEIN; HIGH-RISK GROUP; PLASMINOGEN-ACTIVATOR; DUCTAL ADENOCARCINOMA; GENE-EXPRESSION; LUNG-CANCER; STEM-CELLS; GEMCITABINE AB The cancer-associated Sm-like (CaSm) oncogene is overexpressed in 87% of human pancreatic tumor samples and CaSm knockdown has demonstrated therapeutic efficacy in murine models of pancreatic cancer. Evidence indicates that CaSm modulates messenger RNA degradation; however, its target genes and the mechanisms by which CaSm promotes pancreatic cancer remain largely unknown. Here, we demonstrate that the CaSm overexpression alters several hallmarks of cancer-including transformation, proliferation, chemoresistance and metastasis. Doxycycline-induced CaSm expression enhanced proliferation and both anchorage-dependent and -independent growth of the human Panc-1 cells in vitro. CaSm induction decreased gemcitabine-induced cytotoxicity and altered the expression of apoptotic regulation genes, including Bad, E2F1 and Bcl-X-L. CaSm-overexpressing Panc-1 cells were twofold more migratory and fourfold more invasive than the driver controls and demonstrated characteristics of epithelial-to-mesenchymal transition such as morphological changes and decreased E-cadherin expression. CaSm induction resulted in changes in RNA expression of metastasis-associated genes such as MMP1, SerpinB5, uPAR and Slug. Using a murine model of metastatic pancreatic cancer, injection of CaSm-induced Panc-1 cells resulted in a higher abundance of hepatic metastatic lesions. Overall, CaSm overexpression contributed to a more aggressive cancer phenotype in Panc-1 cells, further supporting the use of CaSm as a therapeutic target against pancreatic cancer. C1 [Little, E. C.; Cole, D. J.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Little, E. C.; Camp, E. R.; Wang, C.; Watson, P. M.; Watson, D. K.; Cole, D. J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Camp, E. R.; Wang, C.; Cole, D. J.] Med Univ S Carolina, Dept Surg, 114 Doughty St,BM 241,MSC 295, Charleston, SC 29425 USA. [Camp, E. R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Watson, P. M.; Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Watson, D. K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 114 Doughty St,BM 241,MSC 295, Charleston, SC 29425 USA. EM campe@musc.edu FU National Institutes of Health [R01CA123159, K08CA142904]; South Carolina Clinical and Translational Research through NIH [UL1TR000062]; Hollings Cancer Center Medical University of South Carolina [POCA138313] FX This work was supported by funding from the National Institutes of Health (R01CA123159 (DJC, DKW) and K08CA142904 (ERC)) and the South Carolina Clinical and Translational Research through NIH grant number UL1TR000062. We thank the MUSC Hollings Cancer Center Tissue Biorepository and the Flow Cytometry core facilities for their assistance. The shared resources are supported in part by the Hollings Cancer Center Medical University of South Carolina Support Grant (POCA138313) NR 42 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2157-9024 J9 ONCOGENESIS JI Oncogenesis PD JAN PY 2016 VL 5 AR e182 DI 10.1038/oncsis.2015.45 PG 10 WC Oncology SC Oncology GA DE2TP UT WOS:000370480200003 PM 26751936 ER PT J AU Janke-Stedronsky, SR Greenawalt, DS Stock, EM Tsan, JY MacCarthy, AA MacCarthy, DJ Copeland, LA AF Janke-Stedronsky, Shonda R. Greenawalt, David S. Stock, Eileen M. Tsan, Jack Y. MacCarthy, Andrea A. MacCarthy, Daniel J. Copeland, Laurel A. TI Association of Parental Status and Diagnosis of Posttraumatic Stress Disorder Among Veterans of Operations Iraqi and Enduring Freedom SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE posttraumatic stress disorder; parenting; gender; veterans ID MALE VIETNAM VETERANS; MENTAL-HEALTH; OEF/OIF VETERANS; RISK-FACTORS; DEPLOYMENT; PTSD; COMBAT; AFGHANISTAN; RESILIENCE; FEMALE AB Research indicates that concerns about disruption of family relationships during military service may be associated with greater posttraumatic stress symptomatology. The current study sought to extend previous findings by examining the relative odds of a posttraumatic stress disorder (PTSD) diagnosis among Operations Enduring and Iraqi Freedom (OEF/OIF) veterans with dependent children versus veterans without dependent children. Administrative databases were queried to identify 36,334 OEF/OIF veterans with dependent children seeking care in the Veterans Health Administration (VA) during fiscal years 2006-2009. These veterans were matched 1: 1 on age, gender, and demobilization date to veterans without dependent children (N = 72,668). In unconditional analyses, OEF/OIF veterans with dependent children versus those without were significantly more likely to incur a PTSD diagnosis (44% vs. 28%). After controlling for demographic variables, mental health utilization, and other serious mental illness, OEF/OIF veterans with dependent children were about 40% more likely to carry a diagnosis of PTSD. The association was stronger for men than for women. It may be of value for clinicians to consider parental status when assessing and treating veterans with PTSD. In-depth study of OEF/OIF veterans is needed to determine whether disruption of family relationships leads to increased psychological stress or parents are more likely than nonparents to seek VA mental health services for PTSD symptoms. C1 [Janke-Stedronsky, Shonda R.] Univ Texas Austin, Southwestern Residency Programs, Seton Healthcare Network, Dept Psychiat, Austin, TX 78712 USA. [Greenawalt, David S.] Albany Stratton Vet Affairs Med Ctr, Albany, NY USA. [Stock, Eileen M.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Internal Med, Temple, TX USA. [Stock, Eileen M.; Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Stock, Eileen M.; Copeland, Laurel A.] Baylor Scott & White Hlth, Temple, TX USA. [Tsan, Jack Y.] Cent Texas Vet Hlth Care Syst, Psychol Serv, Austin, TX USA. [MacCarthy, Andrea A.; MacCarthy, Daniel J.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Coll Med, Internal Med, Temple, TX USA. RP Copeland, LA (reprint author), Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM LaurelACopeland@gmail.com OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs; Central Texas Veterans Health Care System; VHA HSRD [IIR-09-335]; Baylor Scott & White Health, Temple, Texas FX This research was supported by Department of Veterans Affairs, Central Texas Veterans Health Care System, and VHA HSR&D Award IIR-09-335 (Laurel A. Copeland, PI), with additional support from Baylor Scott & White Health, Temple, Texas. The views are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 43 TC 1 Z9 1 U1 3 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD JAN PY 2016 VL 8 IS 1 BP 72 EP 79 DI 10.1037/tra0000014 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DD8KW UT WOS:000370176400010 PM 25793320 ER PT J AU Baird, SO Hopkins, LB Medina, JL Rosenfield, D Powers, MB Smits, JAJ AF Baird, Scarlett O. Hopkins, Lindsey B. Medina, Johnna L. Rosenfield, David Powers, Mark B. Smits, Jasper A. J. TI Distress Tolerance as a Predictor of Adherence to a Yoga Intervention: Moderating Roles of BMI and Body Image SO BEHAVIOR MODIFICATION LA English DT Article DE yoga; adherence; intervention; distress tolerance; predictors ID PERCEIVED STRESS QUESTIONNAIRE; REDUCING ANXIETY SENSITIVITY; PHYSICAL-ACTIVITY; PANIC DISORDER; DISCOMFORT INTOLERANCE; SHAPE QUESTIONNAIRE; FUTURE-RESEARCH; EXERCISE; WOMEN; EFFICACY AB This study tested whether distress tolerance, body image, and body mass index (BMI) predicted adherence to a yoga intervention. Participants were 27 women who participated in a yoga intervention as part of a randomized controlled trial. Attendance and distress tolerance were assessed weekly, and body image and BMI were measured at baseline. Multilevel modeling revealed a three-way interaction of distress tolerance, BMI, and body image (p < .001). For participants with few body image concerns, distress tolerance was positively associated with adherence regardless of BMI (p = .009). However, for those with poor body image, increases in distress tolerance were associated with increases in adherence among overweight participants (p < .001) but lower adherence among obese participants (p = .007). Distress tolerance may be implicated in adherence to a yoga intervention, although its effects may be dependent on body image concerns, BMI, and their interaction. Research and clinical implications are discussed. C1 [Baird, Scarlett O.] Univ Texas Austin, Clin Psychol Program, Austin, TX 78712 USA. [Baird, Scarlett O.; Medina, Johnna L.; Powers, Mark B.; Smits, Jasper A. J.] Univ Texas Austin, Austin, TX 78712 USA. [Powers, Mark B.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Hopkins, Lindsey B.] San Francisco VA Med Ctr, San Francisco, CA USA. [Rosenfield, David] So Methodist Univ, Fac, Dallas, TX 75275 USA. RP Baird, SO (reprint author), Univ Texas Austin, Mental Hlth Res Inst, Dept Psychol, Austin, TX 78712 USA. EM scarlett.baird@utexas.edu OI Hopkins, Lindsey/0000-0002-0577-2961; Powers, Mark/0000-0001-7898-073X FU Pure Action, Inc., Austin, Texas, USA FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Portions of this research were funded by a grant from Pure Action, Inc., Austin, Texas, USA, a 501c3 nonprofit organization. NR 54 TC 1 Z9 1 U1 5 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-4455 EI 1552-4167 J9 BEHAV MODIF JI Behav. Modificat. PD JAN-MAR PY 2016 VL 40 IS 1-2 SI SI BP 199 EP 217 DI 10.1177/0145445515612401 PG 19 WC Psychology, Clinical SC Psychology GA DD5ZC UT WOS:000370002500011 PM 26530475 ER PT J AU Williams, JS Lynch, CP Voronca, D Egede, LE AF Williams, Joni S. Lynch, Cheryl P. Voronca, Delia Egede, Leonard E. TI Health locus of control and cardiovascular risk factors in veterans with type 2 diabetes SO ENDOCRINE LA English DT Article DE Health locus of control; Diabetes; Diabetes outcomes; Cardiovascular disease risk factors; Quality of life; Veterans ID QUALITY-OF-LIFE; PERCEIVED CONTROL; SELF-MANAGEMENT; VALIDATION; DISEASE; RELIABILITY; POPULATION; DEPRESSION; ADHERENCE; VALIDITY AB Perceptions of control impact outcomes in veterans with chronic disease. The purpose of this study was to examine the association between control orientation and clinical and quality of life (QOL) outcomes in male veterans with type 2 diabetes (T2DM). Cross-sectional study of 283 male veterans from a primary care clinic in the southeastern US. Health locus of control (LOC) was the main predictor and assessed using the Multidimensional Health LOC Scale. Clinical outcomes were glycosylated hemoglobin A1c (HbA1c), systolic and diastolic blood pressure, and low-density lipoprotein cholesterol (LDL-C). Physical (PCS) and mental (MCS) health component scores for QOL were assessed using the Veterans RAND 12-Item Health Survey. Unadjusted and adjusted multivariate analyses were performed to assess associations between LOC and outcomes. Unadjusted analyses showed internal LOC associated with HbA1c (beta = 0.036; 95 % CI 0.001, 0.071), external LOC: powerful others inversely associated with LDL-C (beta = -0.794; 95 % CI -1.483, -0.104), and external LOC: chance inversely associated with MCS QOL (beta = -0.418; 95 % CI -0.859, -0.173). These associations remained significant when adjusting for relevant covariates. Adjusted analyses also demonstrated a significant relationship between external LOC: chance and PCS QOL (beta = 0.308; 95 % CI 0.002, 0.614). In this sample of male veterans with T2DM, internal LOC was significantly associated with glycemic control, and external was significantly associated with QOL and LDL-C, when adjusting for relevant covariates. Assessments of control orientation should be performed to understand the perceptions of patients, thus better equipping physicians with information to maximize care opportunities for veterans with T2DM. C1 [Lynch, Cheryl P.; Egede, Leonard E.] Vet Affairs Med Ctr, Ralph H Johnson Dept, HEROIC, Charleston, SC 29403 USA. [Williams, Joni S.; Lynch, Cheryl P.; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Vet Affairs Med Ctr, Ralph H Johnson Dept, HEROIC, Charleston, SC 29403 USA.; Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. EM stromjl@musc.edu; lynchcp@musc.edu; voronca@musc.edu; egedel@musc.edu FU VHA Health Services Research and Development (HSRD) program [TRP 04-038] FX This study was supported by Grant #TRP 04-038 (PI: Leonard Egede) funded by the VHA Health Services Research and Development (HSR&D) program. NR 37 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD JAN PY 2016 VL 51 IS 1 BP 83 EP 90 DI 10.1007/s12020-015-0677-8 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD6WH UT WOS:000370064800011 PM 26148703 ER PT J AU Milanesi, A Lee, JW Kim, NH Liu, YY Yang, A Sedrakyan, S Kahng, A Cervantes, V Tripuraneni, N Cheng, SY Perin, L Brent, GA AF Milanesi, Anna Lee, Jang-Won Kim, Nam-Ho Liu, Yan-Yun Yang, An Sedrakyan, Sargis Kahng, Andrew Cervantes, Vanessa Tripuraneni, Nikita Cheng, Sheue-yann Perin, Laura Brent, Gregory A. TI Thyroid Hormone Receptor alpha Plays an Essential Role in Male Skeletal Muscle Myoblast Proliferation, Differentiation, and Response to Injury SO ENDOCRINOLOGY LA English DT Article ID GROWTH-PLATE CHONDROCYTES; INSULIN-RESISTANCE; SATELLITE CELLS; SOLEUS MUSCLE; GENE; MYOD; MICE; EXPRESSION; MUTATION; MOUSE AB Thyroid hormone plays an essential role in myogenesis, the process required for skeletal muscle development and repair, although the mechanisms have not been established. Skeletal muscle develops from the fusion of precursor myoblasts into myofibers. We have used the C2C12 skeletal muscle myoblast cell line, primary myoblasts, and mouse models of resistance to thyroid hormone (RTH) alpha and beta, to determine the role of thyroid hormone in the regulation of myoblast differentiation. T-3, which activates thyroid hormone receptor (TR) alpha and beta, increased myoblast differentiation whereas GC1, a selective TR beta agonist, was minimally effective. Genetic approaches confirmed that TR alpha plays an important role in normal myoblast proliferation and differentiation and acts through the Wnt/beta-catenin signaling pathway. Myoblasts with TR alpha knockdown, or derived from RTH-TR alpha PV (a frame-shift mutation) mice, displayed reduced proliferation and myogenic differentiation. Moreover, skeletal muscle from the TR alpha 1PV mutant mouse had impaired in vivo regeneration after injury. RTH-TR beta PV mutant mouse model skeletal muscle and derived primary myoblasts did not have altered proliferation, myogenic differentiation, or response to injury when compared with control. In conclusion, TR alpha plays an essential role in myoblast homeostasis and provides a potential therapeutic target to enhance skeletal muscle regeneration. C1 [Milanesi, Anna; Liu, Yan-Yun; Yang, An; Brent, Gregory A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Lee, Jang-Won; Kim, Nam-Ho; Kahng, Andrew; Cervantes, Vanessa] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA. [Sedrakyan, Sargis; Tripuraneni, Nikita; Perin, Laura] Univ So Calif, Childrens Hosp Los Angeles, Dept Urol, Los Angeles, CA 90027 USA. [Cheng, Sheue-yann] NCI, Bethesda, MD 20892 USA. RP Milanesi, A; Brent, GA (reprint author), VA Greater Angeles Healthcare Syst, Dept Med, 111,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amilanesi@mednet.ucla.edu; gbrent@mednet.ucla.edu FU National Institutes of Health (NIH) Grant [1K08DK097295]; NIH [RO1DK98576]; NIH/National Center for Advancing Translational Science University of California, Los Angeles, Clinical and Translational Science Institute [UL1TR000124] FX This work was supported by National Institutes of Health (NIH) Grant No. 1K08DK097295 (to A.M.), and NIH RO1DK98576 (to G.A.B.). The research described was supported by NIH/National Center for Advancing Translational Science University of California, Los Angeles, Clinical and Translational Science Institute Grant No. UL1TR000124. NR 61 TC 5 Z9 5 U1 2 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2016 VL 157 IS 1 BP 4 EP 15 DI 10.1210/en.2015-1443 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD5KM UT WOS:000369962600002 PM 26451739 ER PT J AU Tascau, L Gardner, T Anan, H Yongpravat, C Cardozo, CP Bauman, WA Lee, FY Oh, DS Tawfeek, HA AF Tascau, Liana Gardner, Thomas Anan, Hussein Yongpravat, Charlie Cardozo, Christopher P. Bauman, William A. Lee, Francis Y. Oh, Daniel S. Tawfeek, Hesham A. TI Activation of Protein Kinase A in Mature Osteoblasts Promotes a Major Bone Anabolic Response SO ENDOCRINOLOGY LA English DT Article ID ENGINEERED G(S)-COUPLED RECEPTOR; PARATHYROID-HORMONE RESISTANCE; SYMPATHETIC-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; MCCUNE-ALBRIGHT-SYNDROME; ELEMENT-BINDING PROTEIN; HUMAN FIBROUS DYSPLASIA; MESENCHYMAL STEM-CELLS; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN AB Protein kinase A(PKA) regulates osteoblast cell function in vitro and is activated by important bone mass modulating agents. We determined whether PKA activation in osteoblasts is sufficient to mediate a bone anabolic response. Thus, a mouse model conditionally expressing a constitutively active PKA (CA-PKA) in osteoblasts (CA-PKA-OB mouse) was developed by crossing a 2.3-kb alpha 1 (I)-collagen promoter-Cre mouse with a floxed-CA-PKA mouse. Primary osteoblasts from the CA-PKA-OB mice exhibited higher basal PKA activity than those from control mice. Microcomputed tomographic analysis revealed that CA-PKA-OB female mice hadan 8.6-fold increase in femoral but only 1.16-fold increase in lumbar 5 vertebral bone volume/total volume. Femur cortical thickness and volume were also higher in the CA-PKA-OB mice. In contrast, alterations in many femoral microcomputed tomographic parameters in male CA-PKA-OB mice were modest. Interestingly, the 3-dimensional structure model index was substantially lower both in femur and lumbar 5 of male and female CA-PKA-OB mice, reflecting an increase in the plate to rod-like structure ratio. In agreement, femurs from female CA-PKA-OB mice had greater load to failure and were stiffer compared with those of control mice. Furthermore, the CA-PKA-OB mice had higher levels of serum bone turnover markers and increased osteoblast and osteoclast numbers per total tissue area compared with control animals. In summary, constitutive activation of PKA in osteoblasts is sufficient to increase bone mass and favorably modify bone architecture and improve mechanical properties. PKA activation in mature osteoblasts is, therefore, an important target for designing anabolic drugs for treating diseases with bone loss. C1 [Cardozo, Christopher P.; Bauman, William A.; Tawfeek, Hesham A.] James J Peters VA Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, 130 West Kingsbridge Rd,Room 3F-12, Bronx, NY 10468 USA. [Gardner, Thomas; Yongpravat, Charlie; Lee, Francis Y.] Columbia Univ, Ctr Orthopaed Res, New York, NY 10029 USA. [Oh, Daniel S.] Columbia Univ, Coll Dent Med, New York, NY 10029 USA. [Tascau, Liana] Columbia Univ, Dept Mol Med, New York, NY 10029 USA. [Cardozo, Christopher P.; Bauman, William A.; Tawfeek, Hesham A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Cardozo, Christopher P.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Anan, Hussein] Temple Univ, Sacred Heart Hosp, Allentown, PA 16102 USA. RP Tawfeek, HA (reprint author), James J Peters VA Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, 130 West Kingsbridge Rd,Room 3F-12, Bronx, NY 10468 USA. EM HeshamA.Tawfeek@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service [B9212C] FX This work was supported in part by the Department of Veterans Affairs Rehabilitation Research and Development Service Grant B9212C (to W.A.B.). NR 93 TC 1 Z9 1 U1 1 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2016 VL 157 IS 1 BP 112 EP 126 DI 10.1210/en.2015-1614 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD5KM UT WOS:000369962600018 PM 26488807 ER PT J AU Smith, K Firth, K Smeeding, S Wolever, R Kaufman, J Delgado, R Bellanti, D Xenalcis, L AF Smith, Katherine Firth, Kimberly Smeeding, Sandra Wolever, Ruth Kaufman, Joanna Delgado, Roxana Bellanti, Dawn Xenalcis, Lea TI GUIDELINES FOR CREATING, IMPLEMENTING, AND EVALUATING MIND-BODY PROGRAMS IN A MILITARY HEALTHCARE SETTING SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING LA English DT Article DE Mind-body skills; Empowerment; Guidelines; Program evaluation; Healthcare; Military healthcare ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; CENTERED MEDICAL HOME; ALTERNATIVE MEDICINE; MINDFULNESS MEDITATION; VETERANS-IMPLICATIONS; INTEGRATIVE MEDICINE; PEER SUPPORT; CHRONIC PAIN AB Research suggests that the development of mind-body skills can improve individual and family resilience, particularly related to the stresses of illness, trauma, and caregiving. To operationalize the research evidence that mind body skills help with health and recovery, Samueli Institute, in partnership with experts in mind body programming, created a set of guidelines for developing and evaluating mind-body programs for service members, veterans, and their families. The Guidelines for Creating, Implementing, and Evaluating Mind-Body Programs in a Military Healthcare Setting outline key strategies and issues to consider when developing, implementing, and evaluating a mind body focused family empowerment approach in a military healthcare setting. Although these guidelines were developed specifically for a military setting, most of the same principles can be applied to the development of programs in the civilian setting as well. The guidelines particularly address issues unique to mind-body programs, such as choosing evidence-based modalities, licensure and credentialing, safety and contraindications, and choosing evaluation measures that capture the holistic nature of these types of programs. The guidelines are practical, practice-based guidelines, developed by experts in the fields of program development and evaluation, mind-body therapies, patient- and family-centered care, as well as, experts in military and veteran's health systems. They provide a flexible framework to create mind body family empowerment programs and describe important issues that program developers and evaluators are encouraged to address to ensure the development of the most impactful, successful, evidence-supported programs possible. C1 [Smith, Katherine; Firth, Kimberly; Delgado, Roxana; Bellanti, Dawn; Xenalcis, Lea] Samueli Inst, Optimal Healing Environm, 1737 King St,Suite 600, Alexandria, VA 22314 USA. [Firth, Kimberly] NIA, NIH, Bethesda, MD 20892 USA. [Smeeding, Sandra] San Francisco VA Med Ctr, San Francisco, CA USA. [Wolever, Ruth] Duke Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA. [Wolever, Ruth] Duke Integrat Med, Durham, NC USA. [Wolever, Ruth] Vanderbilt Hlth Coaching, Osher Ctr Integrat Med Vanderbilt, Nashville, TN USA. [Wolever, Ruth] Vanderbilt Univ Sch Med, Phys Med & Rehabil, Nashville, TN USA. [Wolever, Ruth] Vanderbilt Univ Sch Med, Dept Psychiat, Nashville, TN USA. [Wolever, Ruth] Vanderbilt Sch Nursing, Nashville, TN USA. [Kaufman, Joanna] Inst Patient & Family Centered Care, Bethesda, MD USA. [Smeeding, Sandra] Salt Lake City VA Healthcare Syst, Integrat Hlth Clin & Program, Salt Lake City, UT USA. [Wolever, Ruth] Duke Sch Med, Durham, NC USA. [Wolever, Ruth] Duke Integrat Med, Durham, NC USA. RP Smith, K (reprint author), Samueli Inst, Optimal Healing Environm, 1737 King St,Suite 600, Alexandria, VA 22314 USA. EM ksmith@siib.org FU US Army Medical Research and Materiel Command, United States [W81XWH-11-1-0759] FX This work is supported by the US Army Medical Research and Materiel Command, United States, under Award no. W81XWH-11-1-0759. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. NR 102 TC 0 Z9 0 U1 5 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-8307 EI 1878-7541 J9 EXPLORE-NY JI Explore-J Sci. Heal. PD JAN-FEB PY 2016 VL 12 IS 1 BP 18 EP 33 DI 10.1016/j.explore.2015.10.002 PG 16 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DD1LG UT WOS:000369682600007 PM 26686476 ER PT J AU Steward, J Holt, CL Pollio, DE Austin, EL Johnson, N Gordon, AJ Kertesz, SG AF Steward, Jocelyn Holt, Cheryl L. Pollio, David E. Austin, Erika L. Johnson, Nancy Gordon, Adam J. Kertesz, Stefan G. TI Priorities in the primary care of persons experiencing homelessness: convergence and divergence in the views of patients and provider/experts SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE homeless persons; patient-centered care; primary care; provider perspectives ID DECISION-MAKING; PATIENTS WANT; PREFERENCES; QUALITY AB Purpose: Homeless individuals face unique challenges in health care. Several US initiatives seeking to advance patient-centered primary care for homeless persons are more likely to succeed if they incorporate the priorities of the patients they are to serve. However, there has been no prior research to elicit their priorities in primary care. This study sought to identify aspects of primary care important to persons familiar with homelessness based on personal experience or professional commitment, and to highlight where the priorities of patients and professionals dedicated to their care converge or diverge. Methods: This qualitative exercise asked 26 homeless patients and ten provider/experts to rank 16 aspects of primary care using a card sort. Patient-level respondents (n= 26) were recruited from homeless service organizations across all regions of the USA and from an established board of homeless service users. Provider/expert-level respondents (n= 10) were recruited from veteran and non-veteran-focused homeless health care programs with similar geographic diversity. Results: Both groups gave high priority to accessibility, evidence-based care, coordination, and cooperation. Provider/experts endorsed patient control more strongly than patients. Patients ranked information about their care more highly than provider/experts. Conclusion: Accessibility and the perception of care based on medical evidence represent priority concerns for homeless patients and provider/experts. Patient control, a concept endorsed by experts, is not strongly endorsed by homeless patients. Understanding how to assure fluid communication, coordination, and team member cooperation could represent more worthy targets for research and quality improvement in this domain. C1 [Steward, Jocelyn] Clayton State Univ, Dept Hlth Care Management, Morrow, GA USA. [Holt, Cheryl L.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Pollio, David E.] Univ Alabama Birmingham, Dept Social Work, Birmingham, AL USA. [Austin, Erika L.; Johnson, Nancy; Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Austin, Erika L.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. [Gordon, Adam J.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. Birmingham VA Med Ctr, Hlth Serv Res & Dev Program, Birmingham, AL 35233 USA. RP Kertesz, SG (reprint author), Birmingham VA Med Ctr, Hlth Serv Res & Dev Program, 700 South 19th St, Birmingham, AL 35233 USA. EM skertesz@uabmc.edu FU Department of Veterans Affairs, Health Services Research and Development Branch, Merit Award [07-969] FX This study is sponsored by the Department of Veterans Affairs, Health Services Research and Development Branch, Merit Award 07-969. Opinions expressed within this manuscript are those of the authors alone and do not represent positions of the Veterans Health Administration or any entity within the US federal government. NR 21 TC 0 Z9 0 U1 3 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2016 VL 10 BP 153 EP 158 DI 10.2147/PPA.S75477 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DD7EA UT WOS:000370085300001 PM 26929607 ER PT S AU Pujol-Lereis, LM Schafer, N Kuhn, LB Rohrer, B Pauly, D AF Pujol-Lereis, Luciana M. Schaefer, Nicole Kuhn, Laura B. Rohrer, Baerbel Pauly, Diana BE Rickman, CB LaVail, MM Anderson, RE Grimm, C Hollyfield, J Ash, J TI Interrelation Between Oxidative Stress and Complement Activation in Models of Age-Related Macular Degeneration SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 16th International Symposium on Retinal Degeneration (RD) CY JUL 13-18, 2014 CL Pacific Grove, CA DE Oxidative stress; Complement system; Age-related macular degeneration; Oxidation-specific epitopes; Alternative pathway; Cigarette smoke model; Light-damage model; CEP-immunization model; Sodium iodate-treatment model; Knock-out mice models ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H DEFICIENCY; CHOROIDAL NEOVASCULARIZATION; PHOTORECEPTOR DEGENERATION; REGULATORY PROTEINS; CIGARETTE-SMOKE; RPE CELLS; MICE; EXPRESSION; COMPONENT AB Millions of individuals older than 50-years suffer from age-related macular degeneration (AMD). Associated with this multifactorial disease are polymorphisms of complement factor genes and a main environmental risk factoroxidative stress. Until now the linkage between these risk factors for AMD has not been fully understood. Recent studies, integrating results on oxidative stress, complement activation, epidemiology and ocular pathology suggested the following sequence in AMD-etiology: initially, chronic oxidative stress results in modification of proteins and lipids in the posterior of the eye; these tissue alterations trigger chronic inflammation, involving the complement system; and finally, invasive immune cells facilitate pathology in the retina. Here, we summarize the results for animal studies which aim to elucidate this molecular interplay of oxidative events and tissue-specific complement activation in the eye. C1 [Schaefer, Nicole; Pauly, Diana] Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. [Rohrer, Baerbel] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Ophthalmol, Charleston, SC 29401 USA. [Rohrer, Baerbel] Res Serv, Charleston, SC 29401 USA. [Pujol-Lereis, Luciana M.; Kuhn, Laura B.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. RP Pauly, D (reprint author), Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. EM Luciana.pujol@klinik.uni-regensburg.de; Nicole.schafer@klinik.uni-regensburg.de; laura.kuhn@stud.uni-regensburg.de; rohrer@musc.edu; Diana.Pauly@klinik.uni-regensburg.de OI Pujol Lereis, Luciana Mercedes/0000-0002-7009-2743 NR 33 TC 4 Z9 4 U1 5 U2 14 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-17121-0; 978-3-319-17120-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 854 BP 87 EP 93 DI 10.1007/978-3-319-17121-0_13 PG 7 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA BE2OL UT WOS:000369715400013 PM 26427398 ER PT S AU Beeson, C Lindsey, C Nasarre, C Bandyopadhyay, M Perron, N Rohrer, B AF Beeson, Craig Lindsey, Chris Nasarre, Cecile Bandyopadhyay, Mausumi Perron, Nathan Rohrer, Baerbel BE Rickman, CB LaVail, MM Anderson, RE Grimm, C Hollyfield, J Ash, J TI Small Molecules that Protect Mitochondrial Function from Metabolic Stress Decelerate Loss of Photoreceptor Cells in Murine Retinal Degeneration Models SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 16th International Symposium on Retinal Degeneration (RD) CY JUL 13-18, 2014 CL Pacific Grove, CA DE Mitochondria; Respirometry; Glycolysis; Neuroprotectant; ATP ID OXIDATIVE STRESS; RETINITIS-PIGMENTOSA; MECHANISMS; DEATH; APOPTOSIS; SURVIVAL; ENERGY; OXYGEN AB One feature common to many of the pathways implicated in retinal degeneration is increased metabolic stress leading to impaired mitochondrial function. We found that exposure of cells to calcium ionophores or oxidants as metabolic stressors diminish maximal mitochondrial capacity. A library of 50,000 structurally diverse "drug-like" molecules was screened for protection against loss of calcium-induced loss of mitochondrial capacity in 661W rod-derived cells and C6 glioblastomas. Initial protective hits were then tested for protection against IBMX-induced loss of mitochondrial capacity as measured via respirometry. Molecules that protected mitochondria were then evaluated for protection of rod photoreceptor cells in retinal explants from rd1 mice. Two of the molecules attenuated loss of photoreceptor cells in the rd1 model. In the 661W cells, exposure to calcium ionophore or tert-butylhydroperoxide caused mitochondrial fragmentation that was blocked with the both compounds. Our studies have identified molecules that protect mitochondria and attenuate loss of photoreceptors in models of retinal degeneration suggesting that they could be good leads for development of therapeutic drugs for treatment of a wide variety of retinal dystrophies. C1 [Beeson, Craig; Lindsey, Chris] MitoChem Therapeut Inc, 280 Calhoun St,MSC140, Charleston, SC 29403 USA. [Beeson, Craig; Lindsey, Chris] Med Univ S Carolina, Dept Drug Discovery, Charleston, SC 29425 USA. [Beeson, Craig; Lindsey, Chris] Med Univ S Carolina, Dept Biomed Sci, Charleston, SC 29425 USA. [Nasarre, Cecile; Bandyopadhyay, Mausumi; Perron, Nathan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC 29401 USA. RP Beeson, C (reprint author), MitoChem Therapeut Inc, 280 Calhoun St,MSC140, Charleston, SC 29403 USA.; Beeson, C (reprint author), Med Univ S Carolina, Dept Drug Discovery, Charleston, SC 29425 USA.; Beeson, C (reprint author), Med Univ S Carolina, Dept Biomed Sci, Charleston, SC 29425 USA. EM beesonc@musc.edu; lindseyc@musc.edu; nassarre@musc.edu; e-bandyom@musc.edu; perron@musc.edu; rohrer@musc.edu NR 15 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-17121-0; 978-3-319-17120-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 854 BP 449 EP 454 DI 10.1007/978-3-319-17121-0_60 PG 6 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA BE2OL UT WOS:000369715400060 PM 26427445 ER PT S AU Rohrer, B Bandyopadhyay, M Beeson, C AF Rohrer, Baebel Bandyopadhyay, Mausumi Beeson, Craig BE Rickman, CB LaVail, MM Anderson, RE Grimm, C Hollyfield, J Ash, J TI Reduced Metabolic Capacity in Aged Primary Retinal Pigment Epithelium (RPE) is Correlated with Increased Susceptibility to Oxidative Stress SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 16th International Symposium on Retinal Degeneration (RD) CY JUL 13-18, 2014 CL Pacific Grove, CA DE Retinal pigment epithelium; Mitochondria; ATP production; Oxidative stress ID MACULAR DEGENERATION; CELLS; COMPLEMENT AB One of the affected tissues in age-related macular degeneration (AMD) is the retinal pigment epithelium (RPE), a tissue that consists of terminally differentiated cells and that accumulates damage over time. In all tissues, mitochondria (mt), which play an essential role in both cell health (energy) and death (initiator of apoptosis), undergo an aging process through the accumulation of mtDNA damage, changes in mitochondrial dynamics, a reduction in biogenesis, and mitophagy, leading to an overall reduction in mitochondrial energy production and other non-energy-related functions. Here we have compared energy metabolism in primary human RPE cells isolated from aborted fetus or aged donor eyes and grown as stable monolayers. H2O2 treatment resulted in the generation of reactive oxygen species and superoxide, an effect that was significantly augmented by age. Mitochondrial metabolism, as analyzed by Seahorse respirometry, revealed reduced mitochondrial oxygen consumption (ATP production) at baseline and a complete loss of reserve capacity in aged cells. Likewise, glycolysis was blunted in aged cells. Taken together, these studies showed that RPE cells derived from aged donor eyes are more susceptible to oxidative stress, and exhibit a loss in mitochondrial respiratory reserve capacity and a reduction in glycolysis. These data suggest that while old cells may have sufficient energy at rest, they cannot mount a stress response requiring additional ATP and reducing agents. In summary, these data support the hypothesis that mitochondria or energy metabolism is a valid target for therapy in AMD. C1 [Rohrer, Baebel; Bandyopadhyay, Mausumi] Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. [Beeson, Craig] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. [Rohrer, Baebel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. EM rohrer@musc.edu FU National Institutes of Health [R01EY019320]; Veterans Affairs [I01 RX000444]; Foundation Fighting Blindness; Research to Prevent Blindness FX This work was supported in part by the National Institutes of Health (R01EY019320), Veterans Affairs (I01 RX000444), Foundation Fighting Blindness, and an unrestricted grant to MUSC from Research to Prevent Blindness. The authors have no financial conflicts of interest. NR 12 TC 5 Z9 5 U1 0 U2 3 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-17121-0; 978-3-319-17120-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 854 BP 793 EP 798 DI 10.1007/978-3-319-17121-0_106 PG 6 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA BE2OL UT WOS:000369715400106 PM 26427491 ER PT J AU Byrne, T Montgomery, AE Fargo, JD AF Byrne, Thomas Montgomery, Ann Elizabeth Fargo, Jamison D. TI Unsheltered Homelessness Among Veterans: Correlates and Profiles SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Homelessness; Veterans; Serious mental illness; Substance use disorders; Latent class analysis ID STREET OUTREACH; HEALTH; CARE; INDIVIDUALS; SERVICES; ACCESS; ADULTS AB We identified correlates of unsheltered status among Veterans experiencing homelessness and described distinct subgroups within the unsheltered homeless Veteran population using data from a screening instrument for homelessness that is administered to all Veterans accessing outpatient care at a Veterans Health Administration (VHA) facility. Correlates of unsheltered homelessness included male gender, white race, older age, lower levels of VHA eligibility, substance use disorders, frequent use of VHA inpatient and infrequent use of VHA outpatient services, and residing in the West. We identified six distinct subgroups of unsheltered Veterans; the tri-morbid frequent users represented the highest need group, but the largest group was comprised of Veterans who made highly infrequent use of VHA healthcare services. Differences between sheltered and unsheltered Veterans and heterogeneity within the unsheltered Veteran population should be considered in targeting housing and other interventions. C1 [Byrne, Thomas] Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA. [Byrne, Thomas; Montgomery, Ann Elizabeth; Fargo, Jamison D.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. [Fargo, Jamison D.] Utah State Univ, Dept Psychol, 2810 Old Main Hill, Logan, UT 84322 USA. RP Byrne, T (reprint author), Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA.; Byrne, T (reprint author), US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM tbyrne@bu.edu; Ann.montgomery@va.gov; Jamison.fargo@usu.edu NR 22 TC 1 Z9 1 U1 3 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 EI 1573-2789 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD JAN PY 2016 VL 52 IS 2 BP 148 EP 157 DI 10.1007/s10597-015-9922-0 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DC7UX UT WOS:000369427100004 PM 26289119 ER PT J AU De Luca, SM Blosnich, JR Hentschel, EAW King, E Amen, S AF De Luca, Susan M. Blosnich, John R. Hentschel, Elizabeth A. W. King, Erika Amen, Sally TI Mental Health Care Utilization: How Race, Ethnicity and Veteran Status are Associated with Seeking Help SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Veteran; Mental health; Mental health treatment utilization; Racial/ethnic disparities ID AFGHANISTAN VETERANS; CLINICAL-OUTCOMES; SERVICES; IRAQ; DIAGNOSES; ATTITUDES; MILITARY; BARRIERS; SOLDIERS; MEMBERS AB As veterans disproportionately experience higher rates of mental illness than civilians, conflicting results surround the impact of race/ethnicity on treatment utilization. This study utilized the CDC's Texas Behavioral Risk Factor Surveillance System data, a random-digit dialed telephone survey of non-institutionalized adults. A subset of Texas respondents (n = 8563) were asked questions related to mental health treatment, stigma, help-seeking attitudes and emotional support. While no differences were found in health care utilization between non-Hispanic white veterans and non-veterans, there were distinct patterns among racial/ethnic minority veterans and non-veterans. Black and Latino non-veterans reported significantly lower health care utilization compared to non-Hispanic white non-veterans. Among veterans, there were no differences in reported utilization rates comparing non-Hispanic whites and Latinos and also non-Hispanic whites and Blacks. Our study adds to the literature by examining health care utilization among a diverse group of veterans by focusing on Veterans Administration (VA) and non-VA services to veterans. C1 [De Luca, Susan M.; King, Erika] Univ Texas Austin, Sch Social Work, 1925 San Jacinto Blvd,Stop D3500, Austin, TX 78712 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Hlth Serv Res, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. [Hentschel, Elizabeth A. W.] Univ Texas Austin, Coll Educ, Dept Educ Psychol, Counseling Psychol, 1 Univ Stn D5800, Austin, TX 78712 USA. [Amen, Sally] Univ Texas Austin, Dept Stat & Data Sci, 2317 Speedway D9800, Austin, TX 78712 USA. RP De Luca, SM (reprint author), Univ Texas Austin, Sch Social Work, 1925 San Jacinto Blvd,Stop D3500, Austin, TX 78712 USA. EM sdeluca@austin.utexas.edu; John.blosnich@va.gov; elizwilson@gmail.com; sally.amen@austin.utexas.edu NR 27 TC 0 Z9 0 U1 3 U2 18 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 EI 1573-2789 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD JAN PY 2016 VL 52 IS 2 BP 174 EP 179 DI 10.1007/s10597-015-9964-3 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DC7UX UT WOS:000369427100007 PM 26659853 ER PT J AU Jensen, DM Ohning, GV Kovacs, TOG Ghassemi, KA Jutabha, R Dulai, GS Machicado, GA AF Jensen, Dennis M. Ohning, Gordon V. Kovacs, Thomas O. G. Ghassemi, Kevin A. Jutabha, Rome Dulai, Gareth S. Machicado, Gustavo A. TI Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID RANDOMIZED-TRIAL; ADRENALINE INJECTION; VISIBLE VESSEL; HEATER PROBE; HEMORRHAGE; MANAGEMENT; THERAPY; COAGULATION; ULTRASOUND; CONSENSUS AB Background and Aims: For more than 4 decades endoscopists have relied on ulcer stigmata for risk stratification and as a guide to hemostasis. None used arterial blood flow underneath stigmata to predict outcomes. For patients with severe peptic ulcer bleeding (PUB), we used a Doppler endoscopic probe (DEP) for (1) detection of blood flow underlying stigmata of recent hemorrhage (SRH), (2) quantitating rates of residual arterial blood flow under SRH after visually directed standard endoscopic treatment, and (3) comparing risks of rebleeding and actual 30-day rebleed rates for spurting arterial bleeding (Forrest [F] IA) and oozing bleeding (F IB). Methods: Prospective cohort study of 163 consecutive patients with severe PUB and different SRH. Results: All blood flow detected by the DEP was arterial. Detection rates were 87.4% in major SRH-spurting arterial bleeding (F IA), non-bleeding visible vessel (F IIA), clot (F IIB)-and were significantly lower at 42.3% (P <.0001) for an intermediate group of oozing bleeding (F IB) or flat spot (F IIC). For spurting bleeding (F IA) versus oozing (F IB), baseline DEP arterial flow was 100% versus 46.7%, residual blood flow detected after endoscopic hemostasis was 35.7% versus 0%, and 30-day rebleed rates were 28.6% versus 0% (all P <.05). Conclusions: (1) For major SRH versus oozing or spot, the arterial blood flow detection rate by the DEP was significantly higher, indicating a higher rebleed risk. (2) Before and after endoscopic treatment, spurting (F IA) PUB had significantly higher rates of blood flow detection than oozing (F IB) PUB and a significantly higher 30-day rebleed rate. (3) The DEP is recommended as a new endoscopic guide with SRH to improve risk stratification and potentially definitive hemostasis for PUB. C1 [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O. G.; Ghassemi, Kevin A.; Jutabha, Rome; Dulai, Gareth S.; Machicado, Gustavo A.] Univ Calif Los Angeles, Div Digest Dis, CURE Digest Dis Res Ctr, CURE Hemostasis Res Grp, Los Angeles, CA USA. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O. G.; Ghassemi, Kevin A.; Jutabha, Rome; Dulai, Gareth S.; Machicado, Gustavo A.] Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan Univ Calif Los Angeles, Dept Med,Med Ctr, Los Angeles, CA 90095 USA. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O. G.; Dulai, Gareth S.; Machicado, Gustavo A.] West Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. RP Jensen, DM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, CURE DDRC, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU AstraZeneca; NIH CURE DDRC [41301]; VA Clinical Merit Review Grant; AstraZeneca USA; Vascular Technology Inc (VTI) FX D. Jensen is a consultant for Vascular Technology Incorporated and received an equipment grant for endoscopic Doppler control units to partially support this study. He was a consultant for AstraZeneca and received an investigator-initiated research grant from AstraZeneca, which partially supported a preliminary study. All other authors disclosed no financial relationships relevant to this publication. This study was partially funded by NIH CURE DDRC Grant 41301 (Human Studies Core), a VA Clinical Merit Review Grant (to Dr Jensen, PI), an Investigator Initiated Grant from AstraZeneca USA, and an equipment grant from Vascular Technology Inc (VTI). NR 37 TC 6 Z9 6 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2016 VL 83 IS 1 BP 129 EP 136 DI 10.1016/j.gie.2015.07.012 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC5AA UT WOS:000369230900019 PM 26318834 ER PT J AU Sanduleanu, S Kaltenbach, T Barkun, A McCabe, RP Velayos, F Picco, MF Laine, L Soetikno, R McQuaid, KR AF Sanduleanu, Silvia Kaltenbach, Tonya Barkun, Alan McCabe, Robert P. Velayos, Fernando Picco, Michael F. Laine, Loren Soetikno, Roy McQuaid, Kenneth R. TI A roadmap to the implementation of chromoendoscopy in inflammatory bowel disease colonoscopy surveillance practice SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID INTERNATIONAL CONSENSUS STATEMENT; DEPRESSED COLORECTAL NEOPLASMS; STANDING ULCERATIVE-COLITIS; QUALITY INDICATORS; METHYLENE-BLUE; DNA-DAMAGE; CANCER; DYSPLASIA; RISK; ENDOSCOPY C1 [Sanduleanu, Silvia] Maastricht Univ, Med Ctr, Dept Med, Div Gastroenterol, NL-6200 MD Maastricht, Netherlands. [Sanduleanu, Silvia] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands. [Kaltenbach, Tonya; Soetikno, Roy] Stanford Univ, Palo Alto, CA 94304 USA. [Kaltenbach, Tonya; Soetikno, Roy] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Barkun, Alan] McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ, Canada. [McCabe, Robert P.] Minnesota Gastroenterol, Minneapolis, MN USA. [Velayos, Fernando] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Picco, Michael F.] Mayo Clin, Dept Med, Div Gastroenterol, Jacksonville, FL 32224 USA. [Laine, Loren] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Laine, Loren] VA Connecticut Healthcare Syst, West Haven, CT USA. [McQuaid, Kenneth R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [McQuaid, Kenneth R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Sanduleanu, S (reprint author), Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Div Gastroenterol & Hepatol,Dept Internal Med, Postbox 5800, NL-6202 AZ Maastricht, Netherlands. NR 50 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2016 VL 83 IS 1 BP 213 EP 222 DI 10.1016/j.gie.2015.08.076 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC5AA UT WOS:000369230900034 PM 26364967 ER PT J AU Li, G Chen, C Laing, SD Ballard, C Biju, KC Reddick, RL Clark, RA Li, S AF Li, G. Chen, C. Laing, S. D. Ballard, C. Biju, K. C. Reddick, R. L. Clark, R. A. Li, S. TI Hematopoietic knockdown of PPAR delta reduces atherosclerosis in LDLR-/- mice SO GENE THERAPY LA English DT Article ID ACTIVATED-RECEPTOR-DELTA; PREVENTS ENDOTHELIAL DYSFUNCTION; NF-KAPPA-B; METABOLIC SYNDROME; MOLECULAR-MECHANISMS; GENE-THERAPY; BETA/DELTA; EXPRESSION; DISEASE; INFLAMMATION AB PPAR(delta) (peroxisome proliferator-activated receptor delta) mediates inflammation in response to lipid accumulation. Systemic administration of a PPAR(delta) agonist can ameliorate atherosclerosis. Paradoxically, genetic deletion of PPAR(delta) in hematopoietic cells led to a reduction of atherosclerosis in murine models, suggesting that downregulation of PPAR(delta) expression in these cells may mitigate atherogenesis. To advance this finding forward to potential clinical translation through hematopoietic stem cell transplantation-based gene therapy, we employed a microRNA (miRNA) approach to knock down PPAR(delta) expression in bone marrow cells followed by transplantation of the cells into LDLR-/- mice. We found that knockdown of PPARd expression in the hematopoietic system caused a dramatic reduction in aortic atherosclerotic lesions. In macrophages, a key component in atherogenesis, knockdown of PPAR(delta) led to decreased expression of multiple pro-inflammatory factors, including monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-1 beta and IL-6. Expression of CCR2, a receptor for MCP-1, was also decreased. The downregulation of pro-inflammatory factors is consistent with significant reduction of macrophage presence in the lesions, which may also be attributable to elevation of ABCA1 (ATP-binding cassette, subfamily A, member 1) and depression of adipocyte differentiate-related protein. Furthermore, the abundance of both MCP-1 and matrix metalloproteinase-9 proteins was reduced in plaque areas. Our results demonstrate that miRNA-mediated PPAR delta knockdown in hematopoietic cells is able to ameliorate atherosclerosis. C1 [Li, G.; Chen, C.; Laing, S. D.; Ballard, C.; Biju, K. C.; Clark, R. A.; Li, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Li, G.; Chen, C.; Laing, S. D.; Ballard, C.; Biju, K. C.; Clark, R. A.; Li, S.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Reddick, R. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Li, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. RP Li, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.; Li, S (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.; Li, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM lis1@uthscsa.edu FU Research Division of the Department of Veterans Affairs; William and Ella Owens Medical Research Foundation; Clinical and Translational Science Award from the National Institutes of Health [TR001120]; US Veterans Health Administration FX We thank Xiaoling Xue and Qiong Zhang for excellent laboratory assistance. This study was supported by a Merit Review grant from the Research Division of the Department of Veterans Affairs and by a grant from William and Ella Owens Medical Research Foundation awarded to SL. RAC is supported by Clinical and Translational Science Award TR001120 from the National Institutes of Health. This study was supported by a grant from the US Veterans Health Administration. NR 52 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 EI 1476-5462 J9 GENE THER JI Gene Ther. PD JAN PY 2016 VL 23 IS 1 BP 78 EP 85 DI 10.1038/gt.2015.78 PG 8 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA DC9ND UT WOS:000369547400009 PM 26204499 ER PT J AU Bratcher, PE Rowe, SM Reeves, G Roberts, T Szul, T Harris, WT Tirouvanziam, R Gaggar, A AF Bratcher, Preston E. Rowe, Steven M. Reeves, Ginger Roberts, Tambra Szul, Tomasz Harris, William T. Tirouvanziam, Rabindra Gaggar, Amit TI Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor SO JOURNAL OF CYSTIC FIBROSIS LA English DT Article DE CFTR; G551D; Ivacaftor; VX-770; Leukocyte; Blood ID HUMAN NEUTROPHILS; CFTR POTENTIATOR; G551D MUTATION; EXPRESSION; RECEPTORS; DISEASE; CELLS AB Background: Ivacaftor improves clinical outcome by potentiation of mutant G551D CFTR. Due to the presence of CFTR in monocytes and polymorphonuclear neutrophils (PMNs), we hypothesized that ivacaftor may impact leukocyte activation. Methods: We examined blood leukocytes from G551D CF subjects prior to and at one and six months after receiving ivacaftor. Blood leukocytes from ivacaftor-naive G551D, F508del, and healthy controls were also treated with ivacaftor ex vivo to assess mutation-specific effects. Results: Compared to healthy controls, G551D CF subjects had significantly higher expression of active CD11b on PMNs and of CD63 on monocytes, which were normalized by in vivo ivacaftor treatment. Ex vivo exposure to ivacaftor of blood cells from G551D, but not F508del and healthy subjects, resulted in changes in CXCR2 and CD16 expression on PMNs. Conclusions: In vivo and ex vivo exposure of G551D CF leukocytes to ivacaftor resulted in an altered activation profile, suggesting mutation specific leukocyte modulation. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. C1 [Bratcher, Preston E.; Rowe, Steven M.; Szul, Tomasz; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, 424 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. [Bratcher, Preston E.; Rowe, Steven M.; Szul, Tomasz; Gaggar, Amit] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, 424 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. [Rowe, Steven M.; Reeves, Ginger; Roberts, Tambra; Harris, William T.; Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, MCLM 790,1918 Univ Blvd, Birmingham, AL 35294 USA. [Rowe, Steven M.; Gaggar, Amit] Univ Alabama Birmingham, UAB Lung Hlth Ctr, 526 20th St South, Birmingham, AL 35294 USA. [Gaggar, Amit] US Dept Vet Affairs, Med Serv, Med Ctr, 700 19th St S, Birmingham, AL 35233 USA. [Rowe, Steven M.; Reeves, Ginger; Roberts, Tambra; Harris, William T.] Univ Alabama Birmingham, Dept Pediat Childrens Alabama, 1600 7th Ave South, Birmingham, AL 35233 USA. [Rowe, Steven M.] Dept Cell Dev & Integrat Biol, THT 926,1720 2nd Ave South, Birmingham, AL 35294 USA. [Bratcher, Preston E.; Szul, Tomasz; Harris, William T.; Tirouvanziam, Rabindra; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, MCLM 760,1918 Univ Blvd, Birmingham, AL 35294 USA. [Tirouvanziam, Rabindra] Emory Univ, Dept Pediat, 2015 Uppergate Dr,Room 344, Atlanta, GA 30322 USA. [Tirouvanziam, Rabindra] Childrens Healthcare Atlanta, Ctr Cyst Fibrosis & Airway Dis Res, 2015 Uppergate Dr,Room 344, Atlanta, GA 30322 USA. RP Gaggar, A (reprint author), 1918 Univ Blvd,McCallum Room 760, Birmingham, AL 35294 USA. EM bratcher@uab.edu; smrowe@uab.edu; greeves@peds.uab.edu; troberts@peds.uab.edu; szultom@uab.edu; tharris@peds.uab.edu; tirouvanziam@emory.edu; agaggar1@uab.edu FU National Institutes of Health [HL102371, 5T32HL105346-02, P30 DK072482, UL1 TR000165]; Cystic Fibrosis Foundation [GAGGAR07, GOAL13K1, TIROUV13, Harris12Q0]; Ismail Moustafa Scholar Award; Emory Children's Center FX Funding: This work is supported by the National Institutes of Health (HL102371 to AG, 5T32HL105346-02 to PEB, P30 DK072482 to SMR, UL1 TR000165 to SMR), the Cystic Fibrosis Foundation (GAGGAR07 to AG, GOAL13K1 to SMR, TIROUV13 to RT, Harris12Q0 to WTH), the Ismail Moustafa Scholar Award (to AG) and by a faculty start-up from the Emory Children's Center (RT). NR 27 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-1993 EI 1873-5010 J9 J CYST FIBROS JI J. Cyst. Fibros PD JAN PY 2016 VL 15 IS 1 BP 67 EP 73 DI 10.1016/j.jcf.2015.02.010 PG 7 WC Respiratory System SC Respiratory System GA DC8HT UT WOS:000369461200012 PM 25769931 ER PT J AU Baizano, J Fresenius, A Walker, P Berdella, M Portenoy, RK Bookbinder, M Glajchen, M Plachta, A Langfelder-Schwind, E Chen, J Dhingra, L AF Baizano, Julie Fresenius, Ashley Walker, Patricia Berdella, Maria Portenoy, Russell K. Bookbinder, Marilyn Glajchen, Myra Plachta, Amy Langfelder-Schwind, Elinor Chen, Jack Dhingra, Lara TI Web-based symptom screening in cystic fibrosis patients: A feasibility study SO JOURNAL OF CYSTIC FIBROSIS LA English DT Article DE Cystic fibrosis; Telehealth; Web-based monitoring; Symptom screening; Symptom burden; Advance care planning ID QUALITY-OF-LIFE; ADULT PATIENTS; DISTRESS; CANCER; SCALE AB Background: Cystic fibrosis (CF) causes high illness burden. Screening may identify patients who could potentially benefit from interventions for symptoms or other sources of distress. We evaluated the feasibility of a web-based system for routine monitoring. Methods: Adult CF patients enrolled in a study of palliative care service delivery completed web-based assessments every 30 days on global distress, physical and psychological symptom distress, and the perceived benefits of discussing advance care planning (ACP) with CF clinicians. Feasibility was assessed by the rate of survey completion, survey reminders, and missed surveys during a 9-month rolling enrollment period. Results: Of 74 participants (47.3% women, 94.4% white), 36.7% had comorbid diabetes, and 56.9% had an FEV1% predicted score of 40-69. In total, patients completed 456 (80.6%) of 566surveys every 30 days over the assessment period. Sixty-five (87.8%) completed 405 (79.7%) of 508 surveys online and 9 (12.2%) completed 51 (88.0%) of 58 surveys using a combination of online, telephone, and mail-based methods. Many surveys were completed without reminders (online: 261 [64.4%] of 405; combined methods: 29 [56.9%] of 51), with 166 (36.4%) surveys requiring 1 or more reminders. Further, 23.0% (17) of patients noted elevated global distress; 20.3% (15) endorsed physical symptom distress, 12.2% (9) had psychological distress, and 58.1% (43) reported that discussing ACP would be beneficial. Conclusions: Repeated web-based screening for symptom distress and ACP preferences is feasible in adult CF patients. Future studies should assess the system's generalizability and staff resources when implementing reminders and non-web methods of completion. (C) 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. C1 [Baizano, Julie] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Fresenius, Ashley; Walker, Patricia; Berdella, Maria; Plachta, Amy; Langfelder-Schwind, Elinor] Mt Sinai Beth Israel, Dept Pulm Med, Cyst Fibrosis Ctr, First Ave,16th St, New York, NY 10003 USA. [Portenoy, Russell K.; Bookbinder, Marilyn; Glajchen, Myra; Chen, Jack; Dhingra, Lara] MJHS Inst Innovat Palliat Care, 39 Broadway,3rd Floor, New York, NY 10006 USA. RP Dhingra, L (reprint author), MJHS Inst Innovat Palliat Care, 39 Broadway,3rd Floor, New York, NY 10006 USA. EM LDhingra@mjhs.org FU Cystic Fibrosis Therapeutics, Inc. [PORTEN13A0] FX This research was supported by a grant from Cystic Fibrosis Therapeutics, Inc. (PORTEN13A0). None of the authors have any conflict of interest associated with this research. NR 19 TC 0 Z9 0 U1 4 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-1993 EI 1873-5010 J9 J CYST FIBROS JI J. Cyst. Fibros PD JAN PY 2016 VL 15 IS 1 BP 102 EP 108 DI 10.1016/j.jcf.2015.11.001 PG 7 WC Respiratory System SC Respiratory System GA DC8HT UT WOS:000369461200018 ER PT J AU Terrelonge, M Marder, KS Weintraub, D Alcalay, RN AF Terrelonge, Mark, Jr. Marder, Karen S. Weintraub, Daniel Alcalay, Roy N. TI CSF beta-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE CSF beta-amyloid 1-42; Cognitive impairment; Parkinson's disease; PPMI ID CEREBROSPINAL-FLUID; DEMENTIA; TAU; A-BETA(42); ASSOCIATION; PERFORMANCE; BIOMARKERS; GUIDELINES; AUTOPSY AB Low CSF beta-amyloid 1-42 has been associated with cognitive decline in advanced Parkinson's disease; data from a single cohort suggest beta-amyloid 1-42 may be an early marker of cognitive impairment. Newly diagnosed Parkinson's participants (mean duration, 6.9 months) in the Parkinson's Progression Markers Initiative (n = 341) were assessed at baseline (untreated state) and followed for 2 years. CSF beta-amyloid 1-42, alpha-synuclein, total tau, and tau phosphorylated at threonine 181 were collected at baseline. Participants were classified as having cognitive impairment (CI) if scores on two of six cognitive tests were 1.5 standard deviations below the standardized mean based on published norms in healthy controls. Multivariable regression analyses were used to determine the association between baseline CSF markers with cognitive impairment, defined by neuropsychological testing performance at 2-year follow-up. Fifty-five participants (16.1 %) had CI at baseline and were not included in further analyses. Thirty-seven of the 286 participants without CI at baseline (12.9 %) developed CI at 2 years. Participants with CI at 2 years had significantly lower mean baseline CSF beta-amyloid 1-42 levels than non-CI participants (343.8 vs. 380.4 pg/mL, p < 0.01); no significant difference was seen for alpha-synuclein, T-tau, or P-tau 181. In a regression model of 286 participants without baseline CI adjusted for age, gender, disease duration, education, motor severity, and depression status, lower baseline beta-amyloid 1-42 levels were associated with higher odds of CI at 2 years. (OR10pg/mL = 1.04, 95 % CI 1.01-1.08, p < 0.05). CSF beta-amyloid 1-42 level at disease onset is an independent predictor of cognitive impairment in early Parkinson's disease. C1 [Terrelonge, Mark, Jr.; Marder, Karen S.; Alcalay, Roy N.] Columbia Univ, Dept Neurol, 710 W 168th St, New York, NY 10032 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Alcalay, RN (reprint author), Columbia Univ, Dept Neurol, 710 W 168th St, New York, NY 10032 USA. EM RNA2104@COLUMBIA.EDU FU NIH [NS036630, 1UL1 RR024156-01, PO412196- G, PO412196-G]; Parkinson disease Foundation; MJ Fox Foundation; Michael J. Fox Foundation for Parkinson's Research; National Institutes of Health; Novartis Pharmaceuticals; Department of Veterans Affairs; Alzheimer's Disease Cooperative Study; University of Pennsylvania; Parkinson's Disease Foundation; National Institutes of Health [NS036630, K02NS080915, UL1 TR000040, UL1 RR024156]; Brookdale Foundation; [U01NS052592] FX Dr. Marder reports grants from NIH [#NS036630 (PI), 1UL1 RR024156-01(Director PCIR), PO412196- G (Co-I), and PO412196-G (Co-I)], grants from steering committee for U01NS052592, grants from Parkinson disease Foundation, and grants from MJ Fox Foundation and research funds from Teva Pharmaceuticals outside the submitted work. Dr. Weintraub received research funding from the Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health, Novartis Pharmaceuticals, Department of Veterans Affairs, and Alzheimer's Disease Cooperative Study; honoraria from Teva Pharmaceuticals, Lundbeck Inc., Pfizer, Avanir Pharmaceuticals, Merck & Co., UCB, Bristol-Myers Squibb Company, Novartis Pharmaceuticals, Eli Lilly and Company, Clintrex LLC, Theravance, Medivation, CHDI Foundation, and Alzheimer's Disease Cooperative Study; license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS; and fees for testifying in court case related to impulse controls disorders in Parkinson's disease (March 2013). Dr. Alcalay is supported by the Parkinson's Disease Foundation, the National Institutes of Health (K02NS080915, NS036630, and UL1 TR000040, formerly the National Center for Research Resources, Grant Number UL1 RR024156), and the Brookdale Foundation. He consulted for Genzyme/Sanofi and Prophase. NR 24 TC 9 Z9 9 U1 1 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 EI 1559-1166 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JAN PY 2016 VL 58 IS 1 BP 88 EP 92 DI 10.1007/s12031-015-0647-x PG 5 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DC5RF UT WOS:000369277400010 PM 26330275 ER PT J AU Chahine, LM Weintraub, D Hawkins, KA Siderowf, A Eberly, S Oakes, D Seibyl, J Stern, MB Marek, K Jennings, D AF Chahine, Lama M. Weintraub, Daniel Hawkins, Keith A. Siderowf, Andrew Eberly, Shirley Oakes, David Seibyl, John Stern, Matthew B. Marek, Kenneth Jennings, Danna CA PARS Investigators TI Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's; cognition; prodromal; dopaminergic deficit; hyposmia ID SLEEP BEHAVIOR DISORDER; EXECUTIVE DYSFUNCTION; DOPAMINE TRANSPORTERS; PRODROMAL FEATURES; DISEASE; DEPRESSION; IMPAIRMENT; CARE AB ObjectivesThe Parkinson Associated Risk Syndrome Study identified a cohort of healthy adults with hyposmia and dopamine transporter binding reduction to characterize individuals at risk for Parkinson's disease (PD). We describe the cognitive profile of this cohort. MethodsIndividuals older than 50 y without PD were recruited. Two hundred twenty-five completed cognitive testing and were included in the final analysis. A neuropsychological test battery was administered and normative scores created for global cognition, memory, executive function/working memory, processing speed/attention, visuospatial abilities, and language domains. Other non-motor symptoms (constipation, depression, anxiety, and rapid eye movement sleep behavior disorder) were assessed through questionnaires. ResultsIndividuals with both hyposmia and reduced dopamine transporter binding (n=38) had lower mean scores for global cognition, executive function/working memory, and memory compared with all other participants (n=187). In separate multivariate logistic regression models, lower global cognition (odds ratio, 1.97, P=0.004), and specifically executive function/working memory (odds ratio, 1.84, P=0.004) scores were associated with membership in the hyposmia with dopamine transporter reduction group. Combining hyposmia with relative impairment on specific cognitive domains increased the odds of dopamine transporter binding reduction compared with hyposmia alone, with the greatest increase in odds for hyposmia plus executive function/working memory relative impairment (68% increase in odds from 4.14 to 6.96). ConclusionChanges in global cognitive abilities, and specifically executive function/working memory, are present in individuals at risk for PD. Combining non-motor features, including cognition, improves prediction of dopamine transporter binding reduction. (c) 2015 International Parkinson and Movement Disorder Society C1 [Chahine, Lama M.; Weintraub, Daniel; Stern, Matthew B.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Educ & Clin Ctr, PD Res, Philadelphia, PA USA. [Hawkins, Keith A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Eberly, Shirley; Oakes, David] Univ Rochester, Sch Med, Dept Biostat, Rochester, NY USA. [Seibyl, John; Marek, Kenneth; Jennings, Danna] Inst Neurodegenerat Disorders, New Haven, CT USA. RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM Daniel.Weintraub@uphs.upenn.edu FU Department of Defense [W81XWH-06-067] FX Support for this study is provided by the Department of Defense award number W81XWH-06-067 NR 43 TC 12 Z9 12 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2016 VL 31 IS 1 BP 86 EP 94 DI 10.1002/mds.26373 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DC7WL UT WOS:000369431300017 PM 26293177 ER PT J AU Mata, IF Leverenz, JB Weintraub, D Trojanowski, JQ Chen-Plotkin, A Van Deerlin, VM Ritz, B Rausch, R Factor, SA Wood-Siverio, C Quinn, JF Chung, KA Peterson-Hiller, AL Goldman, JG Stebbins, GT Bernard, B Espay, AJ Revilla, FJ Devoto, J Rosenthal, LS Dawson, TM Albert, MS Tsuang, D Huston, H Yearout, D Hu, SC Cholerton, BA Montine, TJ Edwards, KL Zabetian, CP AF Mata, Ignacio F. Leverenz, James B. Weintraub, Daniel Trojanowski, John Q. Chen-Plotkin, Alice Van Deerlin, Vivianna M. Ritz, Beate Rausch, Rebecca Factor, Stewart A. Wood-Siverio, Cathy Quinn, Joseph F. Chung, Kathryn A. Peterson-Hiller, Amie L. Goldman, Jennifer G. Stebbins, Glenn T. Bernard, Bryan Espay, Alberto J. Revilla, Fredy J. Devoto, Johnna Rosenthal, Liana S. Dawson, Ted M. Albert, Marilyn S. Tsuang, Debby Huston, Haley Yearout, Dora Hu, Shu-Ching Cholerton, Brenna A. Montine, Thomas J. Edwards, Karen L. Zabetian, Cyrus P. TI GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE cognition; GBA; neuropsychological tests; visuospatial; working memory ID APOLIPOPROTEIN-E GENOTYPE; GAUCHER-DISEASE; GLUCOCEREBROSIDASE MUTATIONS; DEMENTIA; RISK; PERFORMANCE; IMPAIRMENT; INCIDENT; ONSET; GENE AB BackgroundLoss-of-function mutations in the GBA gene are associated with more severe cognitive impairment in PD, but the nature of these deficits is not well understood and whether common GBA polymorphisms influence cognitive performance in PD is not yet known. MethodsWe screened the GBA coding region for mutations and the E326K polymorphism in 1,369 PD patients enrolled at eight sites from the PD Cognitive Genetics Consortium. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised), working memory/executive function (Letter-Number Sequencing Test and Trail Making Test A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation), and global cognitive function (MoCA). We used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates and accounted for multiple testing using Bonferroni's corrections. ResultsMutation carriers (n=60; 4.4%) and E326K carriers (n=65; 4.7%) had a higher prevalence of dementia (mutations, odds ratio=5.1; P=9.7x10(-6); E326K, odds ratio=6.4; P=5.7x10(-7)) and lower performance on Letter-Number Sequencing (mutations, corrected P[P-c]=9.0x10(-4); E326K, P-c=0.036), Trail Making B-A (mutations, P-c=0.018; E326K, P-c=0.018), and Benton Judgment of Line Orientation (mutations, P-c=0.0045; E326K, P-c=0.0013). ConclusionsBoth GBA mutations and E326K are associated with a distinct cognitive profile characterized by greater impairment in working memory/executive function and visuospatial abilities in PD patients. The discovery that E326K negatively impacts cognitive performance approximately doubles the proportion of PD patients we now recognize are at risk for more severe GBA-related cognitive deficits. (c) 2015 International Parkinson and Movement Disorder Society C1 [Mata, Ignacio F.; Tsuang, Debby; Huston, Haley; Yearout, Dora; Hu, Shu-Ching; Cholerton, Brenna A.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Mata, Ignacio F.; Huston, Haley; Yearout, Dora; Hu, Shu-Ching; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Neurol Inst, Cleveland, OH 44106 USA. [Weintraub, Daniel; Chen-Plotkin, Alice] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Trojanowski, John Q.; Van Deerlin, Vivianna M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA 90024 USA. [Ritz, Beate; Rausch, Rebecca] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Factor, Stewart A.; Wood-Siverio, Cathy] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson-Hiller, Amie L.] Portland VA Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson-Hiller, Amie L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Goldman, Jennifer G.; Stebbins, Glenn T.; Bernard, Bryan] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Espay, Alberto J.; Revilla, Fredy J.; Devoto, Johnna] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA. [Revilla, Fredy J.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Rosenthal, Liana S.; Dawson, Ted M.; Albert, Marilyn S.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Neuroregenerat & Stem Cell Programs, Baltimore, MD USA. [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA. [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA. [Tsuang, Debby; Cholerton, Brenna A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92717 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU National Institutes of Health [K23 NS060949, P01 AG017586, P01 ES016732, P30 AG010124, P50 AG005136, P50 NS038367, P50 NS038377, P50 NS053488, P50 NS062684, R01 ES010544, R01 NS065070, U01 NS082133, U54 ES012078]; Department of Veterans Affairs [1I01BX000531]; Consolidated Anti-Aging Foundation; Dolsen Foundation; Jane and Lee Seidman Fund; Nancy and Buster Alvord Endowment; Parkinson's Disease Foundation; Sartain Lanier Family Foundation; Office of Research and Development Medical Research Service, Department of Veterans Affairs FX This work was supported by grants from the National Institutes of Health (K23 NS060949, P01 AG017586, P01 ES016732, P30 AG010124, P50 AG005136, P50 NS038367, P50 NS038377, P50 NS053488, P50 NS062684, R01 ES010544, R01 NS065070, U01 NS082133, and U54 ES012078), the Department of Veterans Affairs (1I01BX000531), the Consolidated Anti-Aging Foundation, the Dolsen Foundation, the Jane and Lee Seidman Fund, the Nancy and Buster Alvord Endowment, the Parkinson's Disease Foundation, and the Sartain Lanier Family Foundation. This material is based upon work supported, in part, by the Office of Research and Development Medical Research Service, Department of Veterans Affairs. NR 41 TC 17 Z9 17 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2016 VL 31 IS 1 BP 95 EP 102 DI 10.1002/mds.26359 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DC7WL UT WOS:000369431300018 PM 26296077 ER PT J AU Brennan, L Siderowf, A Rubright, JD Rick, J Dahodwala, N Duda, JE Hurtig, H Stern, M Xie, SX Rennert, L Karlawish, J Shea, JA Trojanowski, JQ Weintraub, D AF Brennan, Laura Siderowf, Andrew Rubright, Jonathan D. Rick, Jacqueline Dahodwala, Nabila Duda, John E. Hurtig, Howard Stern, Matthew Xie, Sharon X. Rennert, Lior Karlawish, Jason Shea, Judy A. Trojanowski, John Q. Weintraub, Daniel TI Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; instrumental activities of daily living; cognition; item response theory ID MILD COGNITIVE IMPAIRMENT; SOCIETY TASK-FORCE; INSTRUMENTAL ACTIVITIES; ALZHEIMERS-DISEASE; RATING-SCALE; DEMENTIA; RIVASTIGMINE; AGREEMENT; PATIENT AB ObjectiveThe aim of this work was to describe the development and psychometric analysis of the Penn Parkinson's Daily Activities Questionnaire. The questionnaire is an item response theory-based tool for rating cognitive instrumental activities of daily living in PD. MethodsCandidate items for the Penn Parkinson's Daily Activities Questionnaire were developed through literature review and focus groups of patients and knowledgeable informants. Item selection and calibration of item-response theory parameters were performed using responses from a cohort of PD patients and knowledgeable informants (n = 388). In independent cohorts of PD patients and knowledgeable informants, assessments of test-retest reliability (n = 50), and construct validity (n = 68) of the questionnaire were subsequently performed. Construct validity was assessed by correlating questionnaire scores with measures of motor function, cognition, an existing activities of daily living measure, and directly observed daily function. ResultsFifty items were retained in the final questionnaire item bank. Items were excluded owing to redundancy, difficult reading level, and when item-response theory parameters could not be calculated. Test-retest reliability was high (intraclass correlation coefficient = 0.97; P < 0.001). The questionnaire correlated strongly with cognition (r = 0.68; P < 0.001) and directly observed daily function (r = 0.87; P < 0.001), but not with motor impairment (r = 0.08; P = 0.53). The questionnaire score accurately discriminated between PD patients with and without dementia (receiver operating characteristic curve = 0.91; 95% confidence interval: 0.85-0.97). ConclusionsThe Penn Parkinson's Daily Activities Questionnaire shows strong evidence of reliability and validity. Item response theory-based psychometric analysis suggests that this questionnaire can discriminate across a range of daily functions. (c) 2015 International Parkinson and Movement Disorder Society C1 [Brennan, Laura; Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Brennan, Laura; Duda, John E.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Rubright, Jonathan D.] Amer Inst Certified Publ Accountants, Ewing, NJ USA. [Rick, Jacqueline; Dahodwala, Nabila; Duda, John E.; Hurtig, Howard; Stern, Matthew; Trojanowski, John Q.; Weintraub, Daniel] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Xie, Sharon X.; Rennert, Lior] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Sch Med, PENN CMU Roybal Ctr Behav Econ & Hlth, LDI Ctr Hlth Incent,Dept Med Eth, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Sch Med, PENN CMU Roybal Ctr Behav Econ & Hlth, Dept Med,LDI Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Sch Med, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. [Shea, Judy A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Morris K. Udall Parkinson's Disease Research Center of Excellence grant from the National Institute of Neurological Disorders and Stroke [NS-053488]; Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement [SAP4100027296, Act 2001-77] FX This study was funded by a Morris K. Udall Parkinson's Disease Research Center of Excellence grant from the National Institute of Neurological Disorders and Stroke (NS-053488) and by SAP4100027296, a health research grant awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77. NR 36 TC 2 Z9 2 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2016 VL 31 IS 1 BP 126 EP 134 DI 10.1002/mds.26339 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DC7WL UT WOS:000369431300022 PM 26249849 ER PT J AU Hanlon, CA Owens, MM Joseph, JE Zhu, X George, MS Brady, KT Hartwell, KJ AF Hanlon, Colleen A. Owens, Max M. Joseph, Jane E. Zhu, Xun George, Mark S. Brady, Kathleen T. Hartwell, Karen J. TI Lower subcortical gray matter volume in both younger smokers and established smokers relative to non-smokers SO ADDICTION BIOLOGY LA English DT Article DE Gray matter; nicotine; smoking; voxel-based morphometry ID CIGARETTE-SMOKING; HUMAN-BRAIN; COGNITIVE PERFORMANCE; VISUAL-ATTENTION; RECEPTOR-BINDING; NICOTINE; TOBACCO; DEPENDENCE; AGE; MORPHOMETRY AB Although established adult smokers with long histories of nicotine dependence have lower neural tissue volume than non-smokers, it is not clear if lower regional brain volume is also observed in younger, less established smokers. The primary goal of this study was to investigate neural tissue volume in a large group of smokers and non-smokers, with a secondary goal of measuring the impact of age on these effects. We used voxel-based morphometry to compare regional gray matter volume in 118 individuals (59 smokers, 59 age- and gender-matched non-smokers). Younger smokers had significantly lower gray matter volume in the left thalamus and the left amygdala than their non-smoking peers (family-wise error-corrected clusters, P<0.05). There was no correlation between smoking use variables and tissue volume among younger smokers. Established smokers had significantly lower gray matter volume than age-matched non-smokers in the insula, parahippocampal gyrus and pallidum. Medial prefrontal cortex gray matter volume was negatively correlated with pack-years of smoking among the established smokers, but not the younger smokers. These data reveal that regional tissue volume differences are not limited exclusively to established smokers. Deficits in young adults indicate that cigarette smoking may either be deleterious to the thalamus and amygdala at an earlier age than previously reported, or that pre-existing differences in these areas may predispose individuals to the development of nicotine dependence. C1 [Hanlon, Colleen A.; Owens, Max M.; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat, 67 President St, Charleston, SC 29425 USA. [Hanlon, Colleen A.; Joseph, Jane E.; Zhu, Xun] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Joseph, Jane E.] Univ Kentucky, Lexington, KY USA. [George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA. [George, Mark S.; Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St, Charleston, SC 29425 USA.; Hanlon, CA (reprint author), Med Univ S Carolina, Dept Neurosci, 67 President St, Charleston, SC 29425 USA. EM hanlon@musc.edu FU GRAND [GA30523K]; NICHD [K12HD055885, UL1 RR029882]; [K01DA027756]; [DA036085-03]; [5R21DA026085-02] FX Funding was provided by K01DA027756 (CAH), R33 (DA036085-03), GRAND (GA30523K), 5R21DA026085-02, NICHD K12HD055885 and UL1 RR029882 NR 47 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD JAN PY 2016 VL 21 IS 1 BP 185 EP 195 DI 10.1111/adb.12171 PG 11 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA DC2ST UT WOS:000369067300016 PM 25125263 ER PT J AU Lee, AP Roth, MY Nya-Ngatchou, JJ Lin, K Walsh, TJ Page, ST Matsumoto, AM Bremner, WJ Amory, JK Anawalt, BD AF Lee, Ada P. Roth, Mara Y. Nya-Ngatchou, Jean-Jacques Lin, Kat Walsh, Thomas J. Page, Stephanie T. Matsumoto, Alvin M. Bremner, William J. Amory, John K. Anawalt, Bradley D. TI Testicular fine-needle aspiration for the assessment of intratesticular hormone concentrations SO ASIAN JOURNAL OF ANDROLOGY LA English DT Article DE male contraception; physiology; reproductive and urinary; testis ID TESTOSTERONE CONCENTRATIONS; NONOBSTRUCTIVE AZOOSPERMIA; GONADOTROPIN SUPPRESSION; SPERM ASPIRATION; HUMAN TESTIS; NORMAL MEN; BIOPSY AB Measurement of intratesticular sex steroid concentrations in men informs both the development of male hormonal contraceptives and the understanding of male infertility. Given the challenges of using invasive techniques to measure testicular hormone physiology, our group has used a minimally-invasive fine-needle aspiration technique to measure intratesticular hormones in normal healthy men. Herein, we present a post-hoc analysis of the safety and efficacy of testicular fine-needle aspiration (FNA) completed as part of six clinical trials. From 2001 through 2011, a total of 404 procedures were conducted among 163 research volunteers, 85.9% of which were successful in obtaining sufficient fluid for the measurement of intratesticular steroid concentrations. Pain was the most common side effect, with 36.8% of procedures associated with moderate procedural pain and 4.7% with severe procedural pain. Postprocedural pain was uncommon and abated within a few days. Mild local bruising occurred with 14.9% of procedures. Two serious adverse events (0.5%) required surgical intervention. The risk of an adverse event was not associated with age, body mass index, testicular size, or the volume of fluid aspirated. Testicular FNA to obtain fluid for measurement of intratesticular steroid concentrations frequently causes mild to moderate procedural pain, but serious adverse events occur rarely. Testicular FNA has been instrumental for defining human intratesticular hormone physiology and is a minimally-invasive, safe, effective method for obtaining fluid for research on testicular physiology and pathology. C1 [Lee, Ada P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Roth, Mara Y.; Nya-Ngatchou, Jean-Jacques; Page, Stephanie T.; Matsumoto, Alvin M.; Bremner, William J.; Amory, John K.; Anawalt, Bradley D.] Univ Washington, Dept Med, Seattle, WA USA. [Roth, Mara Y.; Nya-Ngatchou, Jean-Jacques; Page, Stephanie T.; Matsumoto, Alvin M.; Bremner, William J.; Amory, John K.; Anawalt, Bradley D.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Lin, Kat] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Walsh, Thomas J.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Dept Med, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Lin, Kat] Univ Washington, Seattle, WA 98195 USA. RP Anawalt, BD (reprint author), Univ Washington, Dept Med, Seattle, WA USA.; Anawalt, BD (reprint author), Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. EM banawalt@medicine.washington.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development grants [U54 HD-42454]; National Institute of Diabetes and Digestive Kidney Diseases training grant [5T32 DK007247-35, K23 HD073164-02]; Veterans Administration Research and Development FX Funding provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development grants U54 HD-42454 (STP, WJB, JKA, BDA), the National Institute of Diabetes and Digestive Kidney Diseases training grant 5T32 DK007247-35 (JJNN) and K23 HD073164-02 (MYR), and by the Veterans Administration Research and Development (AMM, BDA). NR 17 TC 0 Z9 0 U1 1 U2 2 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1008-682X EI 1745-7262 J9 ASIAN J ANDROL JI Asian J. Androl. PD JAN PY 2016 VL 18 IS 1 BP 21 EP 24 DI 10.4103/1008-682X.156637 PG 4 WC Andrology; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA DA5MJ UT WOS:000367846900004 PM 26208394 ER PT J AU Zhang, C Meermeier, NP Terker, AS Blankenstein, KI Singer, JD Hadchouel, J Ellison, DH Yang, CL AF Zhang, Chong Meermeier, Nicholas P. Terker, Andrew S. Blankenstein, Katharina I. Singer, Jeffrey D. Hadchouel, Juliette Ellison, David H. Yang, Chao-Ling TI Degradation by Cullin 3 and effect on WNK kinases suggest a role of KLHL2 in the pathogenesis of Familial Hyperkalemic Hypertension SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Kelch-like protein 2; Cullin 3; WNK kinase; Degradation; Familial Hyperkalemic Hypertension ID PSEUDOHYPOALDOSTERONISM TYPE-II; DISEASE-CAUSING MUTATIONS; NA-CL COTRANSPORTER; UBIQUITINATION; SPAK; HOMEOSTASIS; INTERACTS; COMPLEX; NKCC2; CUL3 AB Mutations in WNK1 and WNK4, and in components of the Cullin-Ring Ligase system, kelch-like 3 (KLHL3) and Cullin 3 (CUL3), can cause the rare hereditary disease, Familial Hyperkalemic Hypertension (FHHt). The disease is characterized by overactivity of the renal sodium chloride cotransporter (NCC), which is phosphorylated and activated by the WNK-stimulated Ste20-type kinases, SPAT( and OSR1. WNK kinases themselves can be targeted for ubiquitination and degradataion by the CUL3-KLHL3 E3 ubiquitin ligase complex. It is unclear, however, why there are significant differences in phenotypic severity among FHHt patients with mutations in different genes. It was reported that kelch-like 2 (KLHL2), a homolog of KLHL3, can also target WNK kinases for ubiquitation and degradation, and may play a special role in the systemic vasculature. Our recent study revealed the disease mutant CUL3 exhibits enhanced degradation of its adaptor protein KLHL3, potentially resulting in accumulation of WNK kinases secondarily. To investigate if KLHL2 plays a role in FHHt, we studied the effect of wild type and FHHt mutant CUL3 on degradation of KLHL2 and WNK kinase proteins in HEK293 cells. Although CUL3 facilitates KLHL2 degradation, the disease mutant CUL3 is more active in this regard. KLHL2 facilitated the degradation of wild type but not disease mutant WNK4 protein. These results suggest that KLHL2 likely plays a role in the pathogenesis of FHHt, and aggravates the phenotype caused by mutations in CUL3 and WNK4. (C) 2015 Elsevier Inc. All rights reserved. C1 [Zhang, Chong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Nephrol, Shanghai 200030, Peoples R China. [Meermeier, Nicholas P.; Terker, Andrew S.; Ellison, David H.; Yang, Chao-Ling] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Blankenstein, Katharina I.] Charite, Inst Vegetat Anat, Campus Charite Mitte, D-13353 Berlin, Germany. [Hadchouel, Juliette] Portland State Univ, Dept Biol, Portland, OR 97207 USA. [Hadchouel, Juliette] Paris Cardiovasc Res Ctr, Paris, France. [Hadchouel, Juliette] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. RP Zhang, C (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Nephrol, Shanghai 200030, Peoples R China.; Yang, CL (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. EM zhangchongzc@gmail.com; yangch@ohsu.edu RI Hadchouel, Juliette/K-4593-2016 FU National Natural Science Foundation of China [81570634]; Shanghai Municipal Education Commission [15zz054]; NIH [R01 DK51496, 5T32DK067864-10] FX This work was supported by National Natural Science Foundation of China 81570634 and Shanghai Municipal Education Commission 15zz054 (to C. Zhang), and NIH grant R01 DK51496 (to C.-L. Yang and D.H. Ellison). A.S. Terker was supported by NIH 5T32DK067864-10. NR 25 TC 2 Z9 3 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JAN 1 PY 2016 VL 469 IS 1 BP 44 EP 48 DI 10.1016/j.bbrc.2015.11.067 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA DB9WI UT WOS:000368868000007 PM 26607111 ER PT J AU Tuomela, JM Sandholm, JA Kaakinen, M Hayden, KL Haapasaari, KM Jukkola-Vuorinen, A Kauppila, JH Lehenkari, PP Harris, KW Graves, DE Selander, KS AF Tuomela, Johanna M. Sandholm, Jouko A. Kaakinen, Mika Hayden, Katherine L. Haapasaari, Kirsi-Maria Jukkola-Vuorinen, Arja Kauppila, Joonas H. Lehenkari, Petri P. Harris, Kevin W. Graves, David E. Selander, Katri S. TI Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Toll-like receptor 9; Invasion; LL-37; Telomeric G-quadruplex DNA; 9-mer hairpin DNA ID TOLL-LIKE RECEPTOR-9; ANTIMICROBIAL PROTEIN HCAP18/LL-37; SUBCELLULAR-LOCALIZATION; HELICOBACTER-PYLORI; NUCLEASE RESISTANCE; CELLULAR INVASION; GENE-EXPRESSION; DENDRITIC CELLS; BACTERIAL-DNA; HUMAN GENOME AB Toll-like receptor 9 (TLR9) is a cellular DNA-receptor widely expressed in cancers. We previously showed that synthetic and self-derived DNA fragments induce TLR9-mediated breast cancer cell invasion in vitro. We investigated here the invasive effects of two nuclease-resistant DNA fragments, a 9-mer hairpin, and a G-quadruplex DNA based on the human telomere sequence, both having native phosphodiester backbone. Cellular uptake of DNAs was investigated with immunofluorescence, invasion was studied with Matrigel-assays, and mRNA and protein expression were studied with qPCR and Western blotting and protease activity with zymograms. TLR9 expression was suppressed through siRNA. Although both DNAs induced TLR9-mediated changes in pro-invasive mRNA expression, only the telomeric G-quadruplex DNA significantly increased cellular invasion. This was inhibited with GM6001 and aprotinin, suggesting MMP- and serine protease mediation. Furthermore, complexing with LL-37, a cathelicidin-peptide present in breast cancers, increased 9-mer hairpin and G-quadruplex DNA uptake into the cancer cells. However, DNA/LL-37 complexes decreased invasion, as compared with DNA-treatment alone. Invasion studies were conducted also with DNA fragments isolated from neoadjuvant chemotherapy-treated breast tumors. Also such DNA induced breast cancer cell invasion in vitro. As with the synthetic DNAs, this invasive effect was reduced by complexing the neoadjuvant tumor-derived DNAs with LL-37. We conclude that 9-mer hairpin and G-quadruplex DNA fragments are nuclease-resistant DNA structures that can act as invasion-inducing TLR9 ligands. Their cellular uptake and the invasive effects are regulated via LL-37. Although such structures may be present in chemotherapy-treated tumors, the clinical significance of this finding requires further studying. C1 [Tuomela, Johanna M.; Sandholm, Jouko A.; Harris, Kevin W.; Selander, Katri S.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Tuomela, Johanna M.; Sandholm, Jouko A.; Harris, Kevin W.; Graves, David E.; Selander, Katri S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Tuomela, Johanna M.] Univ Turku, Inst Biomed, Dept Cell Biol & Anat, Turku, Finland. [Sandholm, Jouko A.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland. [Sandholm, Jouko A.] Abo Akad Univ, Turku, Finland. [Kaakinen, Mika; Kauppila, Joonas H.; Lehenkari, Petri P.] Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland. [Kaakinen, Mika] Univ Oulu, Fac Biochem & Mol Med, Oulu Ctr Cell Matrix Res, Bioctr Oulu, Oulu, Finland. [Hayden, Katherine L.; Graves, David E.] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Haapasaari, Kirsi-Maria; Kauppila, Joonas H.; Lehenkari, Petri P.] Univ Oulu, Dept Pathol, Oulu, Finland. [Jukkola-Vuorinen, Arja] Univ Hosp Oulu, Dept Oncol, Oulu, Finland. [Lehenkari, Petri P.] Oulu Univ Hosp, Dept Surg, Oulu, Finland. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Selander, Katri S.] Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland. [Selander, Katri S.] UAB, Dept Chem, CHEM 201 1720 2nd Ave South, Birmingham, AL 35294 USA. RP Selander, KS (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.; Selander, KS (reprint author), Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.; Selander, KS (reprint author), Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland.; Selander, KS (reprint author), UAB, Dept Chem, CHEM 201 1720 2nd Ave South, Birmingham, AL 35294 USA. EM Katriselander@uabmc.edu RI Lehenkari, Petri/O-3009-2016 OI Lehenkari, Petri/0000-0002-0055-5183; Kauppila, Joonas/0000-0001-6740-3726; Tuomela, Johanna/0000-0003-4390-4563 FU Department of Defense [W81XWH-10-1-0308]; Finnish Cancer Organizations; Finnish Cultural Foundation; Maud Kuistila Memorial Foundation; Orion-Farmos Research Foundation; K. Albin Johansson Foundation; Cancer Foundation of South-Western Finland FX This work was funded by grants from the Department of Defense (W81XWH-10-1-0308, K.S.S., D.G.), Finnish Cancer Organizations (J.S.), Finnish Cultural Foundation (J.T.), Maud Kuistila Memorial Foundation (J.T.), Orion-Farmos Research Foundation (J.T.), K. Albin Johansson Foundation (J.T.), and Cancer Foundation of South-Western Finland (J.T). NR 51 TC 2 Z9 2 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD JAN PY 2016 VL 155 IS 2 BP 261 EP 271 DI 10.1007/s10549-016-3683-5 PG 11 WC Oncology SC Oncology GA DC1US UT WOS:000369003100006 PM 26780557 ER PT S AU Clancy, CJ Nguyen, MH AF Clancy, Cornelius J. Nguyen, M. Hong BE Calderone, R Cihlar, R TI Diagnostic Methods for Detection of Blood-Borne Candidiasis SO CANDIDA SPECIES: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Candidemia; Invasive candidiasis; Intra-abdominal candidiasis; beta-D-glucan; Fungitell; Polymerase chain reaction (PCR); T2Candida; Diagnosis; Bayesian ID PLACEBO-CONTROLLED TRIAL; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; D-GLUCAN ASSAY; INVASIVE CANDIDIASIS; SURGICAL-PATIENTS; FUNGAL-INFECTIONS; DOUBLE-BLIND; FLUCONAZOLE PROPHYLAXIS; HIGH-RISK AB beta-D-glucan (Fungitell) and polymerase chain reaction-based (T2Candida) assays of blood samples are FDA-approved adjuncts to cultures for diagnosing candidemia and other types of invasive candidiasis, but their clinical roles are unclear. In this chapter, we describe laboratory protocols for performing Fungitell and T2Candida assays. We then discuss step-by-step methods for interpreting test results at the bedside using a Bayesian framework, and for incorporating assays into rational patient management strategies. Prior to interpreting results, clinicians must recognize that test performance varies based on the type of invasive candidiasis being diagnosed. In general, the type of invasive candidiasis that is most likely in a given patient can be identifi ed, and the pretest likelihood of disease estimated. From there, positive and negative predictive values (PPV, NPV) for an assay can be calculated. At a population level, tests can be incorporated into screening strategies for antifungal treatment. NPV and PPV thresholds can be defined for discontinuing antifungal prophylaxis or initiating preemptive treatment, respectively. Using the thresholds, it is possible to assign windows of pretest likelihood for invasive candidiasis (and corresponding patient populations) in which tests are most likely to valuable. At the individual patient level, tests may be useful outside of the windows proposed for screening populations. The interpretive and clinical decision-making processes we discuss will be applicable to other diagnostic assays as they enter the clinic, and to existing assays as more data emerge from various populations. C1 [Clancy, Cornelius J.; Nguyen, M. Hong] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. NR 36 TC 1 Z9 1 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3052-4; 978-1-4939-3051-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1356 BP 215 EP 238 DI 10.1007/978-1-4939-3052-4_16 D2 10.1007/978-1-4939-3052-4 PG 24 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Microbiology; Mycology SC Biochemistry & Molecular Biology; Microbiology; Mycology GA BE2EJ UT WOS:000369087600017 PM 26519076 ER PT J AU Brennan, JM Sketch, MH Dai, D Trilesskaya, M Al-Hejily, W Rao, SV Brilakis, E Messenger, JC Shaw, RE Anstrom, KJ Peterson, ED Douglas, PS AF Brennan, J. Matthew Sketch, Michael H., Jr. Dai, David Trilesskaya, Marina Al-Hejily, Wesam Rao, Sunil V. Brilakis, Emmanouil Messenger, John C. Shaw, Richard E. Anstrom, Kevin J. Peterson, Eric D. Douglas, Pamela S. TI Safety and Clinical Effectiveness of Drug-Eluting Stents for Saphenous Vein Graft Intervention in Older Individuals: Results From the Medicare-Linked National Cardiovascular Data Registry (R) CathPCI Registry (R) (2005-2009) SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE saphenous vein grafts; drug-eluting stents; bare metal stents; outcomes ID BARE-METAL STENTS; FOLLOW-UP; TRIAL; LESIONS AB Objectives: To evaluate the safety of drug-eluting stents (DES) when treating patients with failing saphenous vein grafts (SVG). Background: DES reduce target vessel revascularization in patients with failing SVGs; however, compared with bare metal stents (BMS), DES have been variably associated with increased mortality. Methods: Clinical records from National Cardiovascular Data Registry (R) CathPCI Registry (R) (49,325 older individuals [>= 65 years] who underwent SVG stenting 2005-2009) were linked to Medicare claims to create a longitudinal record. Death, myocardial infarction (MI), and urgent revascularization with DES versus BMS were evaluated to 3 years using propensity matching (PM). Results were stratified by clinical presentation (acute coronary syndrome [ACS], non-ACS), previous lesion treatment (in-stent, de novo), and graft segment (aortic, body, distal anastomosis). Results: In this older cohort (median age, 75 years), acute presentations were prevalent (ACS, 69%; TIMI flow <3, 45%), and adverse clinical outcomes were common by 3 years (death, 24.5%; MI, 14.6%; urgent revascularization, 29.5%). Among DES patients (n = 31,403), 3-year mortality was lower (vs. BMS) (22.7% vs. 28.0%, P < 0.001; PM hazard ratio [HR] 0.87, 95% confidence interval 0.83-0.91), and no difference was observed in the adjusted risk for MI (PM HR 0.97, 0.91 to 1.03) or urgent revascularization (PM HR 1.04, 0.99-1.08). These findings were independent of clinical presentation, previous lesion treatment, and graft segment (P interaction, ns). Conclusions: In this large SVG PCI cohort, all-cause mortality was lower among those receiving DES, and no difference in MI or urgent revascularization was observed to 3 years. (C) 2015 Wiley Periodicals, Inc. C1 [Brennan, J. Matthew; Sketch, Michael H., Jr.; Dai, David; Al-Hejily, Wesam; Rao, Sunil V.; Anstrom, Kevin J.; Peterson, Eric D.; Douglas, Pamela S.] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA. [Trilesskaya, Marina] Calif Pacific Med Ctr, Div Cardiol, Dept Internal Med, San Francisco, CA USA. [Brilakis, Emmanouil] Vet Affairs North Texas Healthcare Syst, Div Cardiol, Dept Internal Med, Dallas, TX USA. [Brilakis, Emmanouil] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Messenger, John C.] Denver Vet Affairs Med Ctr, Div Cardiol, Dept Med, Denver, CO USA. [Shaw, Richard E.] Sutter Pacif Heart Ctr, Div Cardiol, Dept Clin Informat, San Francisco, CA USA. RP Brennan, JM (reprint author), Duke Univ, Med Ctr, Div Cardiol, 2400 Pratt St,Rm 0311 Terrace Level, Durham, NC 27705 USA. EM j.matthew.brennan@dm.duke.edu FU Sanofi; Janssen; St Jude Medical; Terumo; Asahi; Abbott Vascular; Boston Scientific; Guerbet; AstraZeneca; Eli Lilly Company; Medtronic; American College of Cardiology; American Heart Association; Janssen Pharmaceuticals; Society of Thoracic Surgeons FX Dr. Brennan has no relevant disclosures to report. Dr. Sketch has no relevant disclosures to report. Dr. Dai has no relevant disclosures to report. Dr. Trilesskaya has no relevant disclosure to report. Dr. Al-Hejily has no relevant disclosure to report. Dr. Rao has non relevant disclosures to report. Dr. Brilakis reports honoraria/speaker fees from Sanofi (modest), Janssen (modest), St Jude Medical (modest), Terumo (modest), Asahi (significant), Abbott Vascular (modest), and Boston Scientific (significant); research grant from Guerbet (significant); spouse is an employee of Medtronic (significant). Dr. Messenger has no relevant disclosure to report. Dr. Shaw has no relevant disclosures to report. Dr. Anstrom reports research support from AstraZeneca (significant), Eli Lilly & Company (significant), and Medtronic (significant); has served as a consultant for Abbott Vascular (modest), AstraZeneca (modest), Bristol-Meyers Squibb (modest), Gilead (modest), Pfizer (modest), GSK (modest), Promedior (modest), and Ikaria (modest); has served on data monitoring committees for NIH (modest), University of North Carolina (modest), University of Miami (modest), Forest (modest), Pfizer (modest), GSK (modest), and Vertex (modest); and has an equity interest in Biscardia. Dr. Peterson reports research funding for the American College of Cardiology, American Heart Association, Eli Lilly & Company, Janssen Pharmaceuticals, and Society of Thoracic Surgeons (all significant); consulting (including CME) for Merck & Co. (modest), Boehringer Ingelheim, Genentech, Janssen Pharmaceuticals, and Sanofi-Aventis (all significant). Dr. Douglas has no relevant disclosures to report. NR 11 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD JAN 1 PY 2016 VL 87 IS 1 BP 43 EP 49 DI 10.1002/ccd.25979 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB7ML UT WOS:000368699500015 PM 26153480 ER PT J AU Kita, AE Long, JL AF Kita, Ashley E. Long, Jennifer L. TI Hemangioma SO ENT-EAR NOSE & THROAT JOURNAL LA English DT Editorial Material C1 [Kita, Ashley E.; Long, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Long, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Kita, AE (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU VENDOME GROUP LLC PI NEW YORK PA 6 EAST 32 ST, 8 FLOOR, NEW YORK, NY 10016 USA SN 0145-5613 EI 1942-7522 J9 ENT-EAR NOSE THROAT JI ENT-Ear Nose Throat J. PD JAN PY 2016 VL 95 IS 1 BP 19 EP 20 PG 2 WC Otorhinolaryngology SC Otorhinolaryngology GA DB8HS UT WOS:000368758400004 PM 26829680 ER PT J AU Smucny, J Olincy, A Rojas, DC Tregellas, JR AF Smucny, Jason Olincy, Ann Rojas, Donald C. Tregellas, Jason R. TI Neuronal Effects of Nicotine During Auditory Selective Attention in Schizophrenia SO HUMAN BRAIN MAPPING LA English DT Article DE attention; fMRI; hippocampus; nicotine; schizophrenia; ventral parietal cortex ID BRAIN ACTIVATION PATTERNS; PURSUIT EYE-MOVEMENT; SUSTAINED-ATTENTION; ACETYLCHOLINE-RECEPTORS; HIPPOCAMPAL-FORMATION; HEMODYNAMIC-RESPONSE; ALPHA-BUNGAROTOXIN; ANTERIOR CINGULATE; HEALTHY-VOLUNTEERS; PREFRONTAL CORTEX AB Although nicotine has been shown to improve attention deficits in schizophrenia, the neurobiological mechanisms underlying this effect are poorly understood. We hypothesized that nicotine would modulate attention-associated neuronal response in schizophrenia patients in the ventral parietal cortex (VPC), hippocampus, and anterior cingulate based on previous findings in control subjects. To test this hypothesis, the present study examined response in these regions in a cohort of nonsmoking patients and healthy control subjects using an auditory selective attention task with environmental noise distractors during placebo and nicotine administration. In agreement with our hypothesis, significant diagnosis (Control vs. Patient) X drug (Placebo vs. Nicotine) interactions were observed in the VPC and hippocampus. The interaction was driven by task-associated hyperactivity in patients (relative to healthy controls) during placebo administration, and decreased hyperactivity in patients after nicotine administration (relative to placebo). No significant interaction was observed in the anterior cingulate. Task-associated hyperactivity of the VPC predicted poor task performance in patients during placebo. Poor task performance also predicted symptoms in patients as measured by the Brief Psychiatric Rating Scale. These results are the first to suggest that nicotine may modulate brain activity in a selective attention-dependent manner in schizophrenia. (C) 2015 Wiley Periodicals, Inc. C1 [Smucny, Jason; Tregellas, Jason R.] Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO USA. [Smucny, Jason; Olincy, Ann; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Olincy, Ann; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Rojas, Donald C.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. RP Smucny, J (reprint author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO USA. EM jason.smucny@ucdenver.edu OI Smucny, Jason/0000-0001-5656-7987 FU VA Biomedical Laboratory and Clinical Science Research and Development Service [CX000459]; NIH [MH-089095, DK-103691, MH-102224, MH-102879]; Brain and Behavior Research Foundation FX Contract grant sponsor: VA Biomedical Laboratory and Clinical Science Research and Development Service; Contract grant number: CX000459; Contract grant sponsor: NIH; Contract grant numbers: MH-089095, DK-103691, MH-102224, MH-102879; Contract grant sponsor: the Brain and Behavior Research Foundation. NR 77 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JAN PY 2016 VL 37 IS 1 BP 410 EP 421 DI 10.1002/hbm.23040 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA DC3WU UT WOS:000369150500029 PM 26518728 ER PT J AU Hinchcliff, M Routson, R Segal, A Suri, P Czerniecki, J Aubin, P AF Hinchcliff, M. Routson, R. Segal, A. Suri, P. Czerniecki, J. Aubin, P. TI A BIOFEEDBACK SMART CANE TO REDUCE KNEE LOADING ASSOCIATED WITH OSTEOARTHRITIS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Hinchcliff, M.; Routson, R.; Segal, A.; Suri, P.; Czerniecki, J.; Aubin, P.] VA Puget Sound, Seattle, WA USA. [Hinchcliff, M.; Routson, R.; Suri, P.; Czerniecki, J.; Aubin, P.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 24 BP 144 EP 145 DI 10.1136/jim-d-15-00013.24 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600034 ER PT J AU Tsoi, S Vasti, E Moin, T AF Tsoi, S. Vasti, E. Moin, T. TI PRIMARY CARE PROVIDERS' PERCEPTIONS OF LIFESTYLE MODIFICATION AND MANAGEMENT FOR OBESITY AND PREDIABETES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Tsoi, S.; Moin, T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Vasti, E.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Vasti, E.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Moin, T.] HSR&D Ctr Study Healthcare Innovat Implementat &, Los Angeles, CA USA. [Moin, T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 170 BP 209 EP 209 DI 10.1136/jim-d-15-00013.170 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600180 ER PT J AU Szkudlinska, MA Neuhouser, ML Utzschneider, KM AF Szkudlinska, M. A. Neuhouser, M. L. Utzschneider, K. M. TI RELATIONSHIP BETWEEN GLYCEMIC VARIABILITY AND B-CELL FUNCTION IN ADULTS AT HIGH RISK OF TYPE 2 DIABETES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Szkudlinska, M. A.] Univ Washington, Seattle, WA 98195 USA. [Neuhouser, M. L.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Utzschneider, K. M.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 248 BP 241 EP 242 DI 10.1136/jim-d-15-00013.248 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600257 ER PT J AU Vasti, EC Tsoi, S Moin, T AF Vasti, E. C. Tsoi, S. Moin, T. TI PRIMARY CARE PROVIDERS' PERCEPTIONS OF DIABETES PREVENTION PROGRAMS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Vasti, E. C.; Tsoi, S.; Moin, T.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Tsoi, S.; Moin, T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moin, T.] HSR&D Ctr Study Healthcare Innovat Implementat &, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 449 BP 329 EP 330 DI 10.1136/jim-d-15-00013.449 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600456 ER PT J AU Ryan, JS Wang, Q Wu, D Dong, Z Wu, P AF Ryan, J. S. Wang, Q. Wu, D. Dong, Z. Wu, P. TI CHARACTERIZATION OF A CUSTOM MONOCLONAL ANTIBODY AS A NOVEL TUMOR BIOMARKER IN HUMAN GASTROINTESTINAL CANCERS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Ryan, J. S.; Wu, D.; Dong, Z.; Wu, P.] Univ Washington, Sch Med, Seattle, WA USA. [Wang, Q.; Wu, D.; Dong, Z.; Wu, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 450 BP 330 EP 330 DI 10.1136/jim-d-15-00013.450 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600457 ER PT J AU Pan, P Huang, J Morioka, C Hathout, G El-Saden, SM AF Pan, P. Huang, J. Morioka, C. Hathout, G. El-Saden, S. M. TI Cost analysis of vestibular schwannoma screening with contrast-enhanced magnetic resonance imaging in patients with asymmetrical hearing loss SO JOURNAL OF LARYNGOLOGY AND OTOLOGY LA English DT Article DE Vestibular Schwannoma; Screening; Magnetic Resonance Imaging; Hearing Loss; Cost Analysis ID FAST SPIN-ECHO; ACOUSTIC NEUROMA; RADIOSURGERY; MANAGEMENT; SURGERY; MR; MICROSURGERY; PRESERVATION; EXPERIENCE AB Background: Vestibular schwannomas are a rare cause of asymmetrical hearing loss, and routine screening with magnetic resonance imaging can be costly. This paper reports results on vestibular schwannoma screening at our institution and compares the cost of screening to a utility of hearing benefit. Method: All screening examinations with magnetic resonance imaging performed for asymmetrical hearing loss between 2006 and 2011 were retrospectively reviewed. The cost per new vestibular schwannoma diagnosis was calculated. The cost per patient for those who benefitted from intervention was estimated based on rates of hearing preservation reported in the literature. Results: Forty-five (4.3 per cent) of 1050 screening examinations with magnetic resonance imaging performed for asymmetrical hearing loss were positive for vestibular schwannoma, and the cost per new diagnosis was $11 436. The estimated screening cost per patient for those who benefitted from surgery or radiation was $147 030, while US federal compensation for unilateral hearing loss was $44 888. Conclusion: Although we achieved a lower screening cost per new diagnosis than reported in the current literature, there remains disparity between the screening cost per benefitted patient and the benefit' of hearing. C1 [Pan, P.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, 757 Westwood Blvd, Los Angeles, CA 90095 USA. [Huang, J.; Morioka, C.; Hathout, G.; El-Saden, S. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA. RP Pan, P (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Radiol, 757 Westwood Blvd, Los Angeles, CA 90095 USA. EM ppan@mednet.ucla.edu NR 30 TC 1 Z9 1 U1 4 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0022-2151 EI 1748-5460 J9 J LARYNGOL OTOL JI J. Laryngol. Otol. PD JAN PY 2016 VL 130 IS 1 BP 21 EP 24 DI 10.1017/S0022215115002431 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA DB8RI UT WOS:000368783900005 PM 26365591 ER PT J AU Pattaro, C Teumer, A Gorski, M Chu, AY Li, M Mijatovic, V Garnaas, M Tin, A Sorice, R Li, Y Taliun, D Olden, M Foster, M Yang, Q Chen, MH Pers, TH Johnson, AD Ko, YA Fuchsberger, C Tayo, B Nalls, M Feitosa, MF Isaacs, A Dehghan, A d'Adamo, P Adeyemo, A Dieffenbach, AK Zonderman, AB Nolte, IM van der Most, PJ Wright, AF Shuldiner, AR Morrison, AC Hofman, A Smith, AV Dreisbach, AW Franke, A Uitterlinden, AG Metspalu, A Tonjes, A Lupo, A Robino, A Johansson, A Demirkan, A Kollerits, B Freedman, BI Ponte, B Oostra, BA Paulweber, B Kramer, BK Mitchell, BD Buckley, BM Peralta, CA Hayward, C Helmer, C Rotimi, CN Shaffer, CM Muller, C Sala, C van Duijn, CM Saint-Pierre, A Ackermann, D Shriner, D Ruggiero, D Toniolo, D Lu, YC Cusi, D Czamara, D Ellinghaus, D Siscovick, DS Ruderfer, D Gieger, C Grallert, H Rochtchina, E Atkinson, EJ Holliday, EG Boerwinkle, E Salvi, E Bottinger, EP Murgia, F Rivadeneira, F Ernst, F Kronenberg, F Hu, FB Navis, GJ Curhan, GC Ehret, GB Homuth, G Coassin, S Thun, GA Pistis, G Gambaro, G Malerba, G Montgomery, GW Eiriksdottir, G Jacobs, G Li, G Wichmann, HE Campbell, H Schmidt, H Wallaschofski, H Volzke, H Brenner, H Kroemer, HK Kramer, H Lin, HH Leach, IM Ford, I Guessous, I Rudan, I Prokopenko, I Borecki, I Heid, IM Kolcic, I Persico, I Jukema, JW Wilson, JF Felix, JF Divers, J Lambert, JC Stafford, JM Gaspoz, JM Smith, JA Faul, JD Wang, JJ Ding, JZ Hirschhorn, JN Attia, J Whitfield, JB Chalmers, J Viikari, J Coresh, J Denny, JC Karjalainen, J Fernandes, JK Endlich, K Butterbach, K Keene, KL Lohman, K Portas, L Launer, LJ Lyytikainen, LP Yengo, L Franke, L Ferrucci, L Rose, LM Kedenko, L Rao, M Struchalin, M Kleber, ME Cavalieri, M Haun, M Cornelis, MC Ciullo, M Pirastu, M de Andrade, M McEvoy, MA Woodward, M Adam, M Cocca, M Nauck, M Imboden, M Waldenberger, M Pruijm, M Metzger, M Stumvoll, M Evans, MK Sale, MM Kahonen, M Boban, M Bochud, M Rheinberger, M Verweij, N Bouatia-Naji, N Martin, NG Hastie, N Probst-Hensch, N Soranzo, N Devuyst, O Raitakari, O Gottesman, O Franco, OH Polasek, O Gasparini, P Munroe, PB Ridker, PM Mitchell, P Muntner, P Meisinger, C Smit, JH Kovacs, P Wild, PS Froguel, P Rettig, R Magi, R Biffar, R Schmidt, R Middelberg, RPS Carroll, RJ Penninx, BW Scott, RJ Katz, R Sedaghat, S Wild, SH Kardia, SLR Ulivi, S Hwang, SJ Enroth, S Kloiber, S Trompet, S Stengel, B Hancock, SJ Turner, ST Rosas, SE Stracke, S Harris, TB Zeller, T Zemunik, T Lehtimaki, T Illig, T Aspelund, T Nikopensius, T Esko, T Tanaka, T Gyllensten, U Volker, U Emilsson, V Vitart, V Aalto, V Gudnason, V Chouraki, V Chen, WM Igl, W Marz, W Koenig, W Lieb, W Loos, RJF Liu, YM Snieder, H Pramstaller, PP Parsa, A O'Connell, JR Susztak, K Hamet, P Tremblay, J de Boer, IH Boger, CA Goessling, W Chasman, DI Kottgen, A Kao, WHL Fox, CS AF Pattaro, Cristian Teumer, Alexander Gorski, Mathias Chu, Audrey Y. Li, Man Mijatovic, Vladan Garnaas, Maija Tin, Adrienne Sorice, Rossella Li, Yong Taliun, Daniel Olden, Matthias Foster, Meredith Yang, Qiong Chen, Ming-Huei Pers, Tune H. Johnson, Andrew D. Ko, Yi-An Fuchsberger, Christian Tayo, Bamidele Nalls, Michael Feitosa, Mary F. Isaacs, Aaron Dehghan, Abbas d'Adamo, Pio Adeyemo, Adebowale Dieffenbach, Aida Karina Zonderman, Alan B. Nolte, Ilja M. van der Most, Peter J. Wright, Alan F. Shuldiner, Alan R. Morrison, Alanna C. Hofman, Albert Smith, Albert V. Dreisbach, Albert W. Franke, Andre Uitterlinden, Andre G. Metspalu, Andres Tonjes, Anke Lupo, Antonio Robino, Antonietta Johansson, Asa Demirkan, Ayse Kollerits, Barbara Freedman, Barry I. Ponte, Belen Oostra, Ben A. Paulweber, Bernhard Kraemer, Bernhard K. Mitchell, Braxton D. Buckley, Brendan M. Peralta, Carmen A. Hayward, Caroline Helmer, Catherine Rotimi, Charles N. Shaffer, Christian M. Mueller, Christian Sala, Cinzia van Duijn, Cornelia M. Saint-Pierre, Aude Ackermann, Daniel Shriner, Daniel Ruggiero, Daniela Toniolo, Daniela Lu, Yingchang Cusi, Daniele Czamara, Darina Ellinghaus, David Siscovick, David S. Ruderfer, Douglas Gieger, Christian Grallert, Harald Rochtchina, Elena Atkinson, Elizabeth J. Holliday, Elizabeth G. Boerwinkle, Eric Salvi, Erika Bottinger, Erwin P. Murgia, Federico Rivadeneira, Fernando Ernst, Florian Kronenberg, Florian Hu, Frank B. Navis, Gerjan J. Curhan, Gary C. Ehret, George B. Homuth, Georg Coassin, Stefan Thun, Gian-Andri Pistis, Giorgio Gambaro, Giovanni Malerba, Giovanni Montgomery, Grant W. Eiriksdottir, Gudny Jacobs, Gunnar Li, Guo Wichmann, H-Erich Campbell, Harry Schmidt, Helena Wallaschofski, Henri Voelzke, Henry Brenner, Hermann Kroemer, Heyo K. Kramer, Holly Lin, Honghuang Leach, I. Mateo Ford, Ian Guessous, Idris Rudan, Igor Prokopenko, Inga Borecki, Ingrid Heid, Iris M. Kolcic, Ivana Persico, Ivana Jukema, J. Wouter Wilson, James F. Felix, Janine F. Divers, Jasmin Lambert, Jean-Charles Stafford, Jeanette M. Gaspoz, Jean-Michel Smith, Jennifer A. Faul, Jessica D. Wang, Jie Jin Ding, Jingzhong Hirschhorn, Joel N. Attia, John Whitfield, John B. Chalmers, John Viikari, Jorma Coresh, Josef Denny, Joshua C. Karjalainen, Juha Fernandes, Jyotika K. Endlich, Karlhans Butterbach, Katja Keene, Keith L. Lohman, Kurt Portas, Laura Launer, Lenore J. Lyytikaeinen, Leo-Pekka Yengo, Loic Franke, Lude Ferrucci, Luigi Rose, Lynda M. Kedenko, Lyudmyla Rao, Madhumathi Struchalin, Maksim Kleber, Marcus E. Cavalieri, Margherita Haun, Margot Cornelis, Marilyn C. Ciullo, Marina Pirastu, Mario de Andrade, Mariza McEvoy, Mark A. Woodward, Mark Adam, Martin Cocca, Massimiliano Nauck, Matthias Imboden, Medea Waldenberger, Melanie Pruijm, Menno Metzger, Marie Stumvoll, Michael Evans, Michele K. Sale, Michele M. Kaehoenen, Mika Boban, Mladen Bochud, Murielle Rheinberger, Myriam Verweij, Niek Bouatia-Naji, Nabila Martin, Nicholas G. Hastie, Nick Probst-Hensch, Nicole Soranzo, Nicole Devuyst, Olivier Raitakari, Olli Gottesman, Omri Franco, Oscar H. Polasek, Ozren Gasparini, Paolo Munroe, Patricia B. Ridker, Paul M. Mitchell, Paul Muntner, Paul Meisinger, Christa Smit, Johannes H. Kovacs, Peter Wild, Philipp S. Froguel, Philippe Rettig, Rainer Maegi, Reedik Biffar, Reiner Schmidt, Reinhold Middelberg, Rita P. S. Carroll, Robert J. Penninx, Brenda W. Scott, Rodney J. Katz, Ronit Sedaghat, Sanaz Wild, Sarah H. Kardia, Sharon L. R. Ulivi, Sheila Hwang, Shih-Jen Enroth, Stefan Kloiber, Stefan Trompet, Stella Stengel, Benedicte Hancock, Stephen J. Turner, Stephen T. Rosas, Sylvia E. Stracke, Sylvia Harris, Tamara B. Zeller, Tanja Zemunik, Tatijana Lehtimaeki, Terho Illig, Thomas Aspelund, Thor Nikopensius, Tiit Esko, Tonu Tanaka, Toshiko Gyllensten, Ulf Voelker, Uwe Emilsson, Valur Vitart, Veronique Aalto, Ville Gudnason, Vilmundur Chouraki, Vincent Chen, Wei-Min Igl, Wilmar Maerz, Winfried Koenig, Wolfgang Lieb, Wolfgang Loos, Ruth J. F. Liu, Yongmei Snieder, Harold Pramstaller, Peter P. Parsa, Afshin O'Connell, Jeffrey R. Susztak, Katalin Hamet, Pavel Tremblay, Johanne de Boer, Ian H. Boeger, Carsten A. Goessling, Wolfram Chasman, Daniel I. Koettgen, Anna Kao, W. H. Linda Fox, Caroline S. CA ICBP Consortium AGEN Consortium CARDIOGRAM CHARGe-Heart Failure Grp ECHOGen Consortium TI Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function SO NATURE COMMUNICATIONS LA English DT Article ID GENOME-WIDE ASSOCIATION; FALSE DISCOVERY RATES; STAGE RENAL-DISEASE; SERUM CREATININE; METAANALYSIS; VARIANTS; INDIVIDUALS; POPULATION; RISK; HYPERTENSION AB Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways. C1 [Pattaro, Cristian; Taliun, Daniel; Fuchsberger, Christian; Saint-Pierre, Aude; Pramstaller, Peter P.] Med Univ Lubeck, European Acad Bozen Bolzano EURAC, Ctr Biomed, Via Galvani 31, I-39100 Bolzano, Italy. [Teumer, Alexander; Ernst, Florian; Homuth, Georg; Voelker, Uwe] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Friedrich Loeffler Str 15a, D-17487 Greifswald, Germany. [Teumer, Alexander; Voelzke, Henry] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Walther Rathenau Str 48, D-17487 Greifswald, Germany. [Gorski, Mathias; Olden, Matthias; Heid, Iris M.] Univ Regensburg, Inst Epidemiol & Prevent Med, Dept Genet Epidemiol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany. [Gorski, Mathias; Olden, Matthias; Rheinberger, Myriam; Boeger, Carsten A.] Univ Hosp Regensburg, Dept Nephrol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany. [Chu, Audrey Y.; Rose, Lynda M.; Chasman, Daniel I.] Brigham & Womens Hosp, Prevent Med, 900 Commonwealth Ave East, Boston, MA 02215 USA. [Li, Man; Tin, Adrienne; Coresh, Josef; Woodward, Mark; Koettgen, Anna; Kao, W. H. Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA. [Mijatovic, Vladan; Malerba, Giovanni] Univ Verona, Dept Life & Reprod Sci, Str Grazie 8, I-37134 Verona, Italy. [Garnaas, Maija; Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet,Dept Med, New Res Bldg 77 Ave Louis Pasteur,Room 458, Boston, MA 02115 USA. [Sorice, Rossella; Ruggiero, Daniela; Ciullo, Marina] Inst Genet & Biophys Adriano Buzzati Traverso CNR, Via P Castellino 111, I-80131 Naples, Italy. [Li, Yong; Koettgen, Anna] Univ Hosp Freiburg, Dept Internal Med 4, Berliner Allee 29, D-79110 Freiburg, Germany. [Foster, Meredith; Rao, Madhumathi] Tufts Univ, Sch Med, Tufts Evidence Practice Ctr, Div Nephrol,Tufts Med Ctr, Boston, MA 02111 USA. [Yang, Qiong; Chen, Ming-Huei] Boston Univ, Sch Publ Hlth, Dept Biostat, 715 Albany St, Boston, MA 02118 USA. [Chen, Ming-Huei] Boston Univ, Sch Med, Dept Neurol, 72 East Concord ST B603, Boston, MA 02118 USA. [Pers, Tune H.; Hirschhorn, Joel N.; Esko, Tonu] Boston Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. [Pers, Tune H.; Hirschhorn, Joel N.; Esko, Tonu] Boston Childrens Hosp, Ctr Basic & Translat Obes Res, 300 Longwood Ave, Boston, MA 02115 USA. [Pers, Tune H.; Hirschhorn, Joel N.] Broad Inst MIT & Harvard, Med & Populat Genet Program, Cambridge, MA USA. [Johnson, Andrew D.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBIs Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. [Johnson, Andrew D.; Hwang, Shih-Jen; Fox, Caroline S.] Ctr Populat Studies, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. [Ko, Yi-An; Rosas, Sylvia E.; Susztak, Katalin] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, 415 Curie Blvd,405B Clin Res Bldg, Philadelphia, PA 19104 USA. [Tayo, Bamidele; Kramer, Holly] Loyola Med Ctr, Dept Publ Hlth Sci, 2160 S First Ave, Maywood, IL 60153 USA. [Nalls, Michael] NIA, Neurogenet Lab, NIH, Bldg 35 Porter Bldg,1A1015, Bethesda, MD 20892 USA. [Feitosa, Mary F.; Borecki, Ingrid] Washington Univ, Sch Med, Div Stat Genom, 4444 Forest Pk Blvd,Box 8506, St Louis, MO 63108 USA. [Isaacs, Aaron; Demirkan, Ayse; van Duijn, Cornelia M.] Erasmus Univ, Med Ctr, Dept Epidemiol, Genet Epidemiol Unit, Dr Molewaterpl 50,POB 2040, NL-3000 CA Rotterdam, Netherlands. [Isaacs, Aaron] Ctr Med Syst Biol Leiden, Dr Molewaterpl 50,POB 2040, NL-3000 CA Rotterdam, Netherlands. [Dehghan, Abbas; Hofman, Albert; Felix, Janine F.; Franco, Oscar H.; Sedaghat, Sanaz] Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands. [d'Adamo, Pio; Robino, Antonietta; Gasparini, Paolo] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Via Istria 65-1, I-34137 Trieste, Italy. [d'Adamo, Pio; Robino, Antonietta; Gasparini, Paolo] Univ Trieste, Via Istria 65-1, I-34137 Trieste, Italy. [Adeyemo, Adebowale; Rotimi, Charles N.; Shriner, Daniel] NHGRI, Ctr Res Genom & Global Hlth, Bldg 12A,Room 4047,12 South Dr,MSC 5635, Bethesda, MD 20892 USA. [Dieffenbach, Aida Karina; Brenner, Hermann; Butterbach, Katja] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 581, D-69120 Heidelberg, Germany. [Dieffenbach, Aida Karina; Brenner, Hermann] German Canc Consortium DKTK, Neuenheimer Feld 581, D-69120 Heidelberg, Germany. [Zonderman, Alan B.] NIA, Lab Personal & Cognit, NIH, Biomed Ctr, 251 Bayview Blvd,Suite 100, Baltimore, MD 21224 USA. [Nolte, Ilja M.; van der Most, Peter J.; Snieder, Harold] Univ Med Ctr Groningen, Dept Epidemiol, Unit Genet Epidemiol & Bioinformat, POB 30001, NL-9700 RB Groningen, Netherlands. [Wright, Alan F.; Hayward, Caroline; Hastie, Nick; Vitart, Veronique] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland. [Shuldiner, Alan R.; Mitchell, Braxton D.; O'Connell, Jeffrey R.] Univ Maryland, Sch Med, Dept Med, 685 West Baltimore St, Baltimore, MD 21201 USA. [Shuldiner, Alan R.; Mitchell, Braxton D.] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, 10 North Greene St, Baltimore, MD 21201 USA. [Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, 1200 Pressler St Suite 453E, Houston, TX 77030 USA. [Smith, Albert V.; Eiriksdottir, Gudny; Aspelund, Thor; Emilsson, Valur; Gudnason, Vilmundur] Iceland Heart Assoc, Res Inst, Holtasmari 1, IS-201 Kopavogur, Iceland. [Smith, Albert V.; Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, Saemundargotu 2, IS-101 Reykjavik, Iceland. [Dreisbach, Albert W.] Univ Mississippi, Div Nephrol, 2500 North State St, Jackson, MS 39216 USA. [Franke, Andre; Ellinghaus, David] Univ Kiel, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany. [Uitterlinden, Andre G.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Internal Med, POB 1738, NL-3000 DR Rotterdam, Netherlands. [Metspalu, Andres; Maegi, Reedik; Nikopensius, Tiit; Esko, Tonu] Univ Tartu EGCUT, Estonian Genome Ctr, Riia 23B, EE-51010 Tartu, Estonia. [Metspalu, Andres; Nikopensius, Tiit; Esko, Tonu] Univ Tartu, Inst Mol & Cell Biol, Riia 23, EE-51010 Tartu, Estonia. [Metspalu, Andres; Nikopensius, Tiit; Esko, Tonu] Estonian Bioctr, Riia 23, EE-51010 Tartu, Estonia. [Tonjes, Anke; Stumvoll, Michael] Univ Leipzig, Dept Med, Liebigstr 18, D-04103 Leipzig, Germany. [Lupo, Antonio] Univ Verona, Dept Med, Div Nephrol, Piazzale Aristide Stefani 1, I-37126 Verona, Italy. [Johansson, Asa; Enroth, Stefan; Gyllensten, Ulf; Igl, Wilmar] Uppsala Univ, Biomed Ctr, Dept Immunol Genet & Pathol, SciLifeLab, SE-75108 Uppsala, Sweden. [Kollerits, Barbara; Kronenberg, Florian; Coassin, Stefan; Haun, Margot] Med Univ Innsbruck, Div Genet Epidemiol, Schoepfstr 41, A-6020 Innsbruck, Austria. [Freedman, Barry I.; Lohman, Kurt; Liu, Yongmei] Wake Forest Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Ponte, Belen; Ackermann, Daniel] Univ Hosp Geneva, Dept Specialties Internal Med, Div Nephrol, 4 Rue Gabrielle Perret Gentil, CH-1211 Geneva, Switzerland. [Oostra, Ben A.] Erasmus Univ, Med Ctr, Dept Clin Genet, Dr Molewaterpl 50,POB 2040, NL-3000 CA Rotterdam, Netherlands. [Paulweber, Bernhard; Kedenko, Lyudmyla] Paracelsus Med Univ, Salzburger Landeskliniken, Dept Internal Med 1, Mullner Hauptstr 48, A-5020 Salzburg, Austria. [Kraemer, Bernhard K.] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Med 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. [Buckley, Brendan M.] Univ Coll Cork, Dept Pharmacol Therapeut, Clin Invest Bldg,Western Rd, Cork, Ireland. [Peralta, Carmen A.] Univ Calif San Francisco, Sch Med, Div Nephrol, 4150 Clement St, San Francisco, CA 94121 USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Helmer, Catherine] INSERM, Epidemiol Biostat U897, Ctr INSERM, ISPED, F-33000 Bordeaux, France. [Helmer, Catherine] Univ Bordeaux, ISPED, Ctr INSERM, Epidemiol Biostat U897, F-33000 Bordeaux, France. [Shaffer, Christian M.] Vanderbilt Univ, Sch Med, 2215-B Garland Ave 1224 MRB4 Light Hall, Nashville, TN 37232 USA. [Mueller, Christian; Zeller, Tanja] Univ Heart Ctr Hamburg, Clin Gen & Intervent Cardiol, Martinistr 52, D-20246 Hamburg, Germany. [Mueller, Christian; Zeller, Tanja] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Lubeck Kiel,Martinistr 52, D-20246 Hamburg, Germany. [Sala, Cinzia; Toniolo, Daniela; Pistis, Giorgio; Cocca, Massimiliano] Ist Sci San Raffaele, Div Genet & Cell Biol, Via Olgettina 58, I-20132 Milan, Italy. [Saint-Pierre, Aude] Etab Francais Sang, INSERM, U1078, 46 Rue Felix Le Dantec,CS 51819, 29218 Brest 2, France. [Toniolo, Daniela] Inst Mol Genet CNR, Via Abbiategrasso 207, I-27100 Pavia, Italy. [Lu, Yingchang; Bottinger, Erwin P.; Gottesman, Omri; Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Cusi, Daniele; Salvi, Erika] Univ Milan, Dept Hlth Sci, Via Antonio Rudini 8, I-20142 Milan, Italy. [Czamara, Darina; Kloiber, Stefan] Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany. [Siscovick, David S.; Li, Guo] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. [Siscovick, David S.; Li, Guo] Univ Washington, Dept Med, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. [Ruderfer, Douglas] Icahn Sch Med Mt Sinai, Dept Psychiat, Div Psychiat Genom, New York, NY 10029 USA. [Gieger, Christian; Heid, Iris M.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany. [Grallert, Harald; Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany. [Grallert, Harald; Meisinger, Christa; Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, D-85764 Neuherberg, Germany. [Grallert, Harald] German Ctr Diabet Res DZD, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany. [Rochtchina, Elena] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Westmead Hosp C24, Sydney, NSW 2145, Australia. [Atkinson, Elizabeth J.; Attia, John; de Andrade, Mariza] Mayo Clin, Div Biomed Stat & Informat, 200 First St SW, Rochester, MN 55905 USA. [Holliday, Elizabeth G.; Attia, John; Hancock, Stephen J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Clin Epidemiol & Biostat, HMRI Bldg 1, New Lambton, NSW 2305, Australia. [Holliday, Elizabeth G.; Hancock, Stephen J.] Hunter Med Res Inst, Clin Res Design Informat Technol & Stat Support, 1 Kookaburra Circuit, New Lambton Hts, NSW 2305, Australia. [Murgia, Federico; Persico, Ivana; Portas, Laura; Pirastu, Mario] Inst Populat Genet CNR, Traversa La Crucca 3, I-07040 Sassari, Italy. [Hu, Frank B.; Cornelis, Marilyn C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2, Boston, MA 02115 USA. [Navis, Gerjan J.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Curhan, Gary C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA. [Curhan, Gary C.] Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA. [Ehret, George B.] Univ Hosp Geneva, Dept Specialties Internal Med, Cardiol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland. [Thun, Gian-Andri; Adam, Martin; Imboden, Medea; Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, POB 4002, Basel, Switzerland. [Thun, Gian-Andri; Adam, Martin; Imboden, Medea; Probst-Hensch, Nicole] Univ Basel, Peterspl 1, CH-4003 Basel, Switzerland. [Gambaro, Giovanni] Catholic Univ, Columbus Gemelli Univ Hosp, Dept Internal Med & Med Specialties, Div Nephrol, Via Moscati 31, I-00168 Rome, Italy. [Montgomery, Grant W.; Whitfield, John B.; Martin, Nicholas G.; Middelberg, Rita P. S.] QIMR, Genet Epidemiol, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia. [Jacobs, Gunnar; Lieb, Wolfgang] Univ Kiel, Inst Epidemiol, Niemannsweg 11, D-24105 Kiel, Germany. [Jacobs, Gunnar; Lieb, Wolfgang] Univ Kiel, Biobank Popgen, Niemannsweg 11, D-24105 Kiel, Germany. [Wichmann, H-Erich] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany. [Wichmann, H-Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany. [Wichmann, H-Erich] Klinikum Grosshadern, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany. [Campbell, Harry; Rudan, Igor; Wilson, James F.; Wild, Sarah H.] Univ Edinburgh, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland. [Schmidt, Helena] Med Univ Graz, Dept Neurol, Inst Mol Biol & Biochem, Austrian Stroke Prevent Study, Harrachgasse 21, A-8010 Graz, Austria. [Wallaschofski, Henri; Nauck, Matthias] Univ Med Greifswald, Inst Clin Chem & Lab Med, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany. [Wallaschofski, Henri; Voelzke, Henry; Nauck, Matthias; Voelker, Uwe] German Ctr Cardiovasc Res DZHK, Partner Site Greifswald,Ferdinand Sauerbruch St, D-17475 Greifswald, Germany. [Kroemer, Heyo K.] Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Friedrich Loeffler Str 23d, D-17487 Greifswald, Germany. [Lin, Honghuang] Boston Univ, Sch Med, 72 East Concord St,B-616, Boston, MA 02118 USA. [Leach, I. Mateo; Verweij, Niek] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands. [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Robertson Ctr, R1122B Level 11,Boyd Orr Bldg, Glasgow G12 8QQ, Lanark, Scotland. [Guessous, Idris; Gaspoz, Jean-Michel] Univ Geneva, Dept Community Med Primary Care & Emergency Med, Div Primary Care Med, Geneva Univ Hosp,Fac Med, CH-1211 Geneva, Switzerland. [Guessous, Idris] Univ Lausanne Hosp, Univ Inst Social & Prevent Med, Community Prevent Unit, Route Corniche 10, CH-1010 Lausanne, Switzerland. [Guessous, Idris] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. [Prokopenko, Inga] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Genom Common Dis, London W12 0NN, England. [Kolcic, Ivana; Boban, Mladen; Polasek, Ozren; Zemunik, Tatijana] Univ Split, Sch Med, Croatian Ctr Global Hlth, Soltanska 2, Split 21000, Croatia. [Jukema, J. Wouter; Trompet, Stella] Leiden Univ, Med Ctr, Dept Cardiol, POB 9600, NL-2300 RC Leiden, Netherlands. [Jukema, J. Wouter] Interuniv Cardiol Inst Netherlands ICIN, Moreelsepk 1, NL-3511 EP Utrecht, Netherlands. [Jukema, J. Wouter] Einthoven Lab Expt Vasc Med, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands. [Jukema, J. Wouter] Durrer Ctr Cardiogenet Res, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Divers, Jasmin; Stafford, Jeanette M.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Div Publ Hlth Sci, 2326 Med Ctr Blvd, Winston Salem, NC 27157 USA. [Lambert, Jean-Charles; Stracke, Sylvia; Chouraki, Vincent] Inst Pasteur, INSERM, U744, 1 Rue Pr, F-59019 Lille, France. [Smith, Jennifer A.; Kardia, Sharon L. R.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA. [Faul, Jessica D.] Univ Michigan, Inst Social Res, Survey Res Ctr, 426 Thompson St,3456, Ann Arbor, MI 48104 USA. [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Westmead Hosp C24, Sydney, NSW 2145, Australia. [Ding, Jingzhong] Wake Forest Sch Med, Dept Internal Med Geriatr, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur,NRB 0330, Boston, MA 02115 USA. [Chalmers, John; Woodward, Mark] Univ Sydney, George Inst Global Hlth, Level 10,King George V Bldg,83-117 Missenden Rd, Camperdown, NSW 2050, Australia. [Viikari, Jorma; Woodward, Mark] Univ Turku, Turku Univ Hosp, Dept Med, POB 52, Turku 20521, Finland. [Coresh, Josef; Kao, W. H. Linda] Welch Ctr Prevent Epidemiol & Clin Res, 2024 East Monument St,Suite 2-600, Baltimore, MD 21287 USA. [Denny, Joshua C.; Carroll, Robert J.] Vanderbilt Univ, Sch Med, Eskind Biomed Lib 448, 2209 Garland Ave, Nashville, TN 37212 USA. [Karjalainen, Juha; Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, POB 72, NL-9700 AB Groningen, Netherlands. [Fernandes, Jyotika K.] Med Univ S Carolina, Div Endocrinol, 171 Ashley Ave, Charleston, SC 29425 USA. [Endlich, Karlhans] Ernst Moritz Arndt Univ Greifswald, Inst Anat & Cell Biol, Friedrich Loeffler Str 23c, D-17487 Greifswald, Germany. [Keene, Keith L.] E Carolina Univ, Dept Biol, Ctr Hlth Dispar, 1001 East 10th St,N209 Howell Sci Complex, Greenville, NC 27858 USA. [Launer, Lenore J.; Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol Demog & Biometry, Gateway Bldg,3C309,7201 Winsconsin Ave, Bethesda, MD 20892 USA. [Lyytikaeinen, Leo-Pekka; Lehtimaeki, Terho] Univ Tampere, Sch Med, Dept Clin Chem, Fimlab Labs, Tampere 33520, Finland. [Yengo, Loic; Froguel, Philippe] CNRS, UMR 8199, 1 Rue Prof Calmette, F-59000 Lille, France. [Yengo, Loic; Froguel, Philippe] Lille Pasteur Inst, 1 Rue Prof Calmette, F-59000 Lille, France. [Yengo, Loic; Froguel, Philippe] Univ Lille 2, 42 Rue Paul Duez, F-59000 Lille, France. [Ferrucci, Luigi; Tanaka, Toshiko] NIA, Clin Res Branch, 251 Bayview Blvd, Baltimore, MD 21250 USA. [Struchalin, Maksim] Erasmus Univ, Dept Epidemiol & Biostat, Med Ctr, Dr Molewaterpl, NL-3000 DR Rotterdam, Netherlands. [Struchalin, Maksim] Erasmus Univ, Med Ctr, Dept Forens Mol Biol, Dr Molewaterpl, Rotterdam, Netherlands. [Kleber, Marcus E.] Heidelberg Univ, Med Fac Mannheim, Med Clin 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. [Cavalieri, Margherita; Schmidt, Reinhold] Med Univ Graz, Dept Neurol, Austrian Stroke Prevent Study, Div Special Neurol, Auenbruggerpl 22, A-8036 Graz, Austria. [McEvoy, Mark A.] Univ Newcastle, John Hunter Hosp, Hunter Med Res Inst, Ctr Clin Epidemiol & Biostat,HRMC, Locked Bag 1, Newcastle, NSW 2310, Australia. [Woodward, Mark] Univ Oxford, Nuffield Dept Populat Hlth, George Inst Global Hlth, Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England. [Pruijm, Menno] Univ Lausanne Hosp, Serv Nephrol, Rue Bugnon 17, CH-1005 Lausanne, Switzerland. [Metzger, Marie; Stengel, Benedicte] Univ Paris 11, INSERM, UMRS 1018, CESP Team 10, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. [Evans, Michele K.] NIA, Hlth Dispar Res Sect, Clin Res Branch, NIH,Biomed Ctr, 251 Bayview Blvd,Suite 100, Baltimore, MD 21224 USA. [Sale, Michele M.; Chen, Wei-Min] Univ Virginia, Dept Med Cardiovasc Med, Ctr Publ Hlth Genom, POB 800717, Charlottesville, VA 22908 USA. [Kaehoenen, Mika] Univ Tampere, Sch Med, Tampere Univ Hosp, Dept Clin Physiol, Tampere 33521, Finland. [Bochud, Murielle] Univ Lausanne, CHU Vaudois, Univ Inst Social & Prevent Med, Route Corniche 2, CH-1066 Epalinges, Switzerland. [Bouatia-Naji, Nabila] Paris Cardiovasc Res Ctr PARCC, INSERM, UMR970, 56 Rue Leblanc, F-75015 Paris, France. [Bouatia-Naji, Nabila] Paris Descartes Univ, Fac Med, Sorbonne Paris Cite, 12 Rue Ecole Med, F-75006 Paris, France. [Martin, Nicholas G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA. [Soranzo, Nicole] Wellcome Trust Sanger Inst, Hinxton CB10 1HH, England. [Devuyst, Olivier] Univ Zurich, Inst Physiol, Mech Inherited Kidney Disorders Grp, Winterthurerstr 190, CH-8057 Zurich, Switzerland. [Raitakari, Olli; Aalto, Ville] Univ Turku, Turku Univ Hosp, Dept Clin Physiol, Res Ctr Appl & Prevent Cardiovasc Med, POB 52, Turku 20521, Finland. [Munroe, Patricia B.] Queen Mary Univ London, William Harvey Res Inst, Dept Clin Pharmacol, London EC1M 6BQ, England. [Munroe, Patricia B.] Queen Mary Univ London, NIHR Barts Cardiovasc Biomed Res Unit, London EC1M 6BQ, England. [Ridker, Paul M.; Chasman, Daniel I.] Harvard Univ, Sch Med, 900 Commonwealth Ave Eeast, Boston, MA 02115 USA. [Muntner, Paul] Univ Alabama Birmingham, Dept Med, 1530 3rd Ave, South Birmingham, AL 35294 USA. [Muntner, Paul] Univ Alabama Birmingham, Dept Epidemiol, 1530 3rd Ave, South Birmingham, AL 35294 USA. [Smit, Johannes H.; Penninx, Brenda W.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, AJ Ernststr 1187, NL-1081 HL Amsterdam, Netherlands. [Smit, Johannes H.; Penninx, Brenda W.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst, AJ Ernststr 1187, NL-1081 HL Amsterdam, Netherlands. [Kovacs, Peter] Univ Leipzig, IFB AdiposityDis, Liebigstr 21, D-04103 Leipzig, Germany. [Wild, Philipp S.] Med Univ Ctr Mainz, Langenbeckstr 1, D-55131 Mainz, Germany. [Rettig, Rainer] Ernst Moritz Arndt Univ Greifswald, Inst Physiol, D-17487 Greifswald, Germany. [Biffar, Reiner] Ernst Moritz Arndt Univ Greifswald, Clin Prosthodont Dent Gerostomatol & Mat Sci, Rotgerberstr 8, D-17475 Greifswald, Germany. [Scott, Rodney J.] Univ Newcastle, Sch Biomed Sci & Pharm, Hunter Med Res Inst, John Hunter Hosp,HRMC, Locked Bag 1, Newcastle, NSW 2310, Australia. [Katz, Ronit; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA. [Ulivi, Sheila] Inst Maternal & Child Health IRCCS Burlo Garofolo, Via Istria 65, I-34137 Trieste, Italy. [Turner, Stephen T.] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55905 USA. [Stracke, Sylvia] Ernst Moritz Arndt Univ Greifswald, Clin Internal Med A, Friedrich Loeffler Str 23a, D-17475 Greifswald, Germany. [Emilsson, Valur] Univ Iceland, Fac Pharmaceut Sci, Saemundargata 2, IS-101 Reykjavik, Iceland. [Maerz, Winfried] Synlab Serv GmbH, Synlab Acad, Oberer Eselsberg 45, D-89081 Ulm, Germany. [Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, Albert Einstein Allee 23, D-89081 Ulm, Germany. [Loos, Ruth J. F.] Ichan Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA. [Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Via Lorenz Bohler 5, I-39100 Bolzano, Italy. [Pramstaller, Peter P.] Med Univ Lubeck, Dept Neurol, Ratzeburger Allee 160, D-23538 Lubeck, Germany. [Parsa, Afshin] Univ Maryland, Sch Med, Div Nephrol, 685 W Baltimore St,MSTF 314, Baltimore, MD 21201 USA. [Hamet, Pavel; Tremblay, Johanne] Univ Montreal, CHUM Res Ctr, CRCHUM, Technopole Angus, 900 St Denis, Montreal, PQ H2X 0A9, Canada. [Fox, Caroline S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol, 221 Longwood Ave, Boston, MA 02115 USA. RP Pattaro, C (reprint author), Med Univ Lubeck, European Acad Bozen Bolzano EURAC, Ctr Biomed, Via Galvani 31, I-39100 Bolzano, Italy.; Kottgen, A (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.; Kottgen, A (reprint author), Univ Hosp Freiburg, Dept Internal Med 4, Berliner Allee 29, D-79110 Freiburg, Germany.; Fox, CS (reprint author), NHLBIs Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.; Fox, CS (reprint author), Ctr Populat Studies, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.; Fox, CS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol, 221 Longwood Ave, Boston, MA 02115 USA. EM cristian.pattaro@eurac.edu; anna.koettgen@uniklinik-freiburg.de; foxca@nhlbi.nih.gov RI ; Prokopenko, Inga/H-3241-2014; Erdmann, Jeanette/P-7513-2014; Matullo, Giuseppe/K-6383-2016; Onland-Moret, N. Charlotte/G-9185-2011; Bochud, Murielle/A-3981-2010; van der Schouw, Yvonne/F-8327-2014; Ruderfer, Douglas/M-5795-2016; BOUATIA-NAJI, NABILA/D-5863-2013; d'Adamo, Adamo Pio/G-4064-2011; Schwarz, Peter/B-5127-2013; Johnson, Andrew/G-6520-2013; Franke, Lude/P-7036-2016; Karjalainen, Juha/P-8624-2016; Laan, Maris/A-4100-2011; Ellinghaus, David/G-4467-2012; Waldenberger, Melanie/B-5355-2014; Wang, Jie Jin/P-1499-2014; Singleton, Andrew/C-3010-2009; Kronenberg, Florian/B-1736-2008; Aulchenko, Yurii/M-8270-2013; Cossette, Suzanne/I-8008-2016; Lambert, jean-charles/A-9553-2014; Li, Yong/A-6283-2011; ruggiero, daniela/K-5638-2016; Lyytikainen, Leo-Pekka/C-8544-2016; Woodward, Mark/D-8492-2015; Mitchell, Paul/P-1498-2014; Grallert, Harald/B-3424-2013; Deloukas, Panos/B-2922-2013; Colaus, PsyColaus/K-6607-2013; Verweij, Niek/A-4499-2017; HELMER, Catherine/I-6581-2015; Brenner, Hermann/B-4627-2017; Franke, Andre/B-2151-2010; Lieb, Wolfgang/C-1990-2012; Yengo, Loic/D-2692-2017; Palmer, Lyle/K-3196-2014; Polasek, Ozren/B-6002-2011; Boban, Mladen/E-2777-2017; Kolcic, Ivana/E-2713-2017; Feitosa, Mary/K-8044-2012; Stengel, Benedicte/G-5730-2015 OI Wain, Louise/0000-0003-4951-1867; Peters, Annette/0000-0001-6645-0985; Johansson, Asa/0000-0002-2915-4498; Lawlor, Debbie A/0000-0002-6793-2262; Meitinger, Thomas/0000-0002-8838-8403; Magi, Reedik/0000-0002-2964-6011; Shuldiner, Alan/0000-0001-9921-4305; Smith, Albert Vernon/0000-0003-1942-5845; Ramachandran, Vasan/0000-0001-7357-5970; Goessling, Wolfram/0000-0001-9972-1569; Enroth, Stefan/0000-0002-5056-9137; Soranzo, Nicole/0000-0003-1095-3852; Chen, Wei-Min/0000-0002-2643-2333; Kumari, Meena/0000-0001-9716-1035; Meisinger, Christa/0000-0002-9026-6544; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Prokopenko, Inga/0000-0003-1624-7457; Humphries, Stephen E/0000-0002-8221-6547; Verweij, Niek/0000-0002-4303-7685; Kloiber, Stefan/0000-0002-6838-4114; Cooper, Matthew/0000-0003-1139-3682; Org, Elin/0000-0003-1451-9375; Gieger, Christian/0000-0001-6986-9554; Beckmann, Jacques S /0000-0002-9741-1900; ELOSUA, ROBERTO/0000-0001-8235-0095; Cocca, Massimiliano/0000-0002-1127-7596; Erdmann, Jeanette/0000-0002-4486-6231; Bochud, Murielle/0000-0002-5727-0218; van der Schouw, Yvonne/0000-0002-4605-435X; Ruderfer, Douglas/0000-0002-2365-386X; d'Adamo, Adamo Pio/0000-0001-9367-4909; Schwarz, Peter/0000-0001-6317-7880; Franke, Lude/0000-0002-5159-8802; Laan, Maris/0000-0002-8519-243X; Waldenberger, Melanie/0000-0003-0583-5093; Wang, Jie Jin/0000-0001-9491-4898; Kronenberg, Florian/0000-0003-2229-1120; Aulchenko, Yurii/0000-0002-7899-1575; Lambert, jean-charles/0000-0003-0829-7817; Li, Yong/0000-0003-2651-8791; ruggiero, daniela/0000-0003-3898-7827; Lyytikainen, Leo-Pekka/0000-0002-7200-5455; Deloukas, Panos/0000-0001-9251-070X; HELMER, Catherine/0000-0002-5169-7421; Brenner, Hermann/0000-0002-6129-1572; Franke, Andre/0000-0003-1530-5811; Yengo, Loic/0000-0002-4272-9305; Palmer, Lyle/0000-0002-1628-3055; Polasek, Ozren/0000-0002-5765-1862; Boban, Mladen/0000-0003-1570-9621; Kolcic, Ivana/0000-0001-7918-6052; Feitosa, Mary/0000-0002-0933-2410; Salvi, Erika/0000-0002-2724-2291; Marmot, Michael/0000-0002-2431-6419; Prabhakaran, Dorairaj/0000-0002-3172-834X; Zonderman, Alan B/0000-0002-6523-4778; Mitchell, Braxton/0000-0003-4920-4744; Smith, Jennifer/0000-0002-3575-5468; Tai, E Shyong/0000-0003-2929-8966; Morris, Richard/0000-0001-7240-4563; Kleber, Marcus/0000-0003-0663-7275; Dehghan, Abbas/0000-0001-6403-016X FU NIH [R01DK090311, R24OD017870] FX Study-specific acknowledgements and funding sources for participating studies are reported in Supplementary Note. Zebrafish work was supported by NIH R01DK090311 and R24OD017870 to W.G. NR 48 TC 23 Z9 23 U1 14 U2 30 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JAN PY 2016 VL 7 AR 10023 DI 10.1038/ncomms10023 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC2FO UT WOS:000369032800001 PM 26831199 ER PT J AU Shi, YJ Zhang, LL Pu, HJ Mao, LL Hu, XM Jiang, XY Xu, N Stetler, RA Zhang, F Liu, XR Leak, RK Keep, RF Ji, XM Chen, J AF Shi, Yejie Zhang, Lili Pu, Hongjian Mao, Leilei Hu, Xiaoming Jiang, Xiaoyan Xu, Na Stetler, R. Anne Zhang, Feng Liu, Xiangrong Leak, Rehana K. Keep, Richard F. Ji, Xunming Chen, Jun TI Rapid endothelial cytoskeletal reorganization enables early blood-brain barrier disruption and long-term ischaemic reperfusion brain injury SO NATURE COMMUNICATIONS LA English DT Article ID FOCAL CEREBRAL-ISCHEMIA; TIGHT JUNCTION PROTEINS; APPARENT DIFFUSION-COEFFICIENT; ACTIN STRESS FIBERS; MATRIX METALLOPROTEINASES; HSP27 PROTECTS; NEURONAL DEATH; STROKE; PERMEABILITY; BREAKDOWN AB The mechanism and long-term consequences of early blood-brain barrier (BBB) disruption after cerebral ischaemic/reperfusion (I/R) injury are poorly understood. Here we discover that I/R induces subtle BBB leakage within 30-60 min, likely independent of gelatinase B/MMP-9 activities. The early BBB disruption is caused by the activation of ROCK/MLC signalling, persistent actin polymerization and the disassembly of junctional proteins within microvascular endothelial cells (ECs). Furthermore, the EC alterations facilitate subsequent infiltration of peripheral immune cells, including MMP-9-producing neutrophils/macrophages, resulting in late-onset, irreversible BBB damage. Inactivation of actin depolymerizing factor (ADF) causes sustained actin polymerization in ECs, whereas EC-targeted overexpression of constitutively active mutant ADF reduces actin polymerization and junctional protein disassembly, attenuates both early-and late-onset BBB impairment, and improves long-term histological and neurological outcomes. Thus, we identify a previously unexplored role for early BBB disruption in stroke outcomes, whereby BBB rupture may be a cause rather than a consequence of parenchymal cell injury. C1 [Shi, Yejie; Zhang, Lili; Pu, Hongjian; Mao, Leilei; Hu, Xiaoming; Jiang, Xiaoyan; Stetler, R. Anne; Zhang, Feng; Liu, Xiangrong; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Shi, Yejie; Liu, Xiangrong; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing 100053, Peoples R China. [Zhang, Lili; Pu, Hongjian; Mao, Leilei; Hu, Xiaoming; Jiang, Xiaoyan; Xu, Na; Stetler, R. Anne; Zhang, Feng; Chen, Jun] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Zhang, Lili; Pu, Hongjian; Mao, Leilei; Hu, Xiaoming; Jiang, Xiaoyan; Xu, Na; Stetler, R. Anne; Chen, Jun] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China. [Zhang, Lili; Hu, Xiaoming; Stetler, R. Anne; Zhang, Feng; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Keep, Richard F.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.; Ji, XM (reprint author), Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing 100053, Peoples R China.; Chen, J (reprint author), Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. EM jixm@ccmu.edu.cn; chenj2@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU US National Institutes of Health [NS089534, NS045048, NS056118, NS092810]; US Department of Veterans Affairs Research Career Scientist Award; VA Merit Review Award [BX002495]; American Heart Association [15POST22260011]; Chinese Natural Science Foundation Outstanding Young Investigator Award [81325007]; Chang Jiang Scholars Program from the Chinese Ministry of Education [T2014251] FX This project was supported by the US National Institutes of Health grants NS089534, NS045048 and NS056118 (to J.C.), the US Department of Veterans Affairs Research Career Scientist Award and VA Merit Review Award BX002495 (to J.C.). Y.S. was supported by the American Heart Association grant 15POST22260011. X.Ji was supported by the Chinese Natural Science Foundation Outstanding Young Investigator Award (#81325007) and the Chang Jiang Scholars Program (#T2014251) from the Chinese Ministry of Education. F.Z. was supported by the US National Institutes of Health grant NS092810. We are indebted to Pat Strickler for excellent administrative support. NR 67 TC 13 Z9 13 U1 4 U2 20 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JAN PY 2016 VL 7 AR 10523 DI 10.1038/ncomms10523 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC2CJ UT WOS:000369024500002 PM 26813496 ER PT J AU Birtolo, C Go, VLW Ptasznik, A Eibl, G Pandol, SJ AF Birtolo, Chiara Go, Vay Liang W. Ptasznik, Andrzej Eibl, Guido Pandol, Stephen J. TI Phosphatidylinositol 3-Kinase A Link Between Inflammation and Pancreatic Cancer SO PANCREAS LA English DT Review DE PI3K; pancreatic cancer; chronic pancreatitis; inflammation ID ALCOHOLIC CHRONIC-PANCREATITIS; KEY PATHOLOGICAL RESPONSES; STELLATE CELLS; DUCTAL ADENOCARCINOMA; TUMOR PROGRESSION; ACINAR-CELLS; PHOSPHOINOSITIDE 3-KINASE; MACROPHAGE POLARIZATION; BREAST-CANCER; SIGNAL-TRANSDUCTION AB Even though a strong association between inflammation and cancer has been widely accepted, the underlying precise molecular mechanisms are still largely unknown. A complex signaling network between tumor and stromal cells is responsible for the infiltration of inflammatory cells into the cancer microenvironment. Tumor stromal cells such as pancreatic stellate cells (PSCs) and immune cells create a microenvironment that protects cancer cells through a complex interaction, ultimately facilitating their local proliferation and their migration to different sites. Furthermore, PSCs have multiple functions related to local immunity, angiogenesis, inflammation, and fibrosis. Recently, many studies have shown that members of the phosphoinositol-3-phosphate kinase (PI3K) family are activated in tumor cells, PSCs, and tumor-infiltrating inflammatory cells to promote cancer growth. Proinflammatory cytokines and chemokines secreted by immune cells and fibroblasts within the tumor environment can activate the PI3K pathway both in cancer and inflammatory cells. In this review, we focus on the central role of the PI3K pathway in regulating the cross talk between immune/stromal cells and cancer cells. Understanding the role of the PI3K pathway in the development of chronic pancreatitis and cancer is crucial for the discovery of novel and efficacious treatment options. C1 [Birtolo, Chiara; Ptasznik, Andrzej; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Birtolo, Chiara] Univ Bologna, S Orsola M Malpighi Hosp, Dept Internal Med, Bologna, Italy. [Go, Vay Liang W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Eibl, Guido] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Pandol, Stephen J.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. RP Pandol, SJ (reprint author), Cedars Sinai Med Ctr, Basic & Translat Pancreas Res, Gastroenterol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM stephen.pandol@cshs.org FU Department of Veterans Affairs; [P50 AA11999]; [P01 CA163200]; [P01 DK098108]; [P01AT3960] FX The study was partly supported by P50 AA11999, P01 CA163200, P01 DK098108, and P01AT3960 grants, as well as the Department of Veterans Affairs. NR 148 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD JAN PY 2016 VL 45 IS 1 BP 21 EP 31 DI 10.1097/MPA.0000000000000531 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6AZ UT WOS:000368596800004 PM 26658038 ER PT J AU Vital, P Castro, P Ittmann, M AF Vital, Paz Castro, Patricia Ittmann, Michael TI Oxidative Stress Promotes Benign Prostatic Hyperplasia SO PROSTATE LA English DT Article DE oxidative stress; benign prostatic hyperplasia; Nox4; oxidative DNA damage; transgenic ID EPITHELIAL GROWTH-FACTOR; URINARY-TRACT SYMPTOMS; CANCER PROGRESSION; PARACRINE INDUCER; NAD(P)H OXIDASE; GENE-EXPRESSION; RAT PROSTATE; CELLS; BPH; FIBROSIS AB BACKGROUND. Benign prostatic hyperplasia (BPH) is characterized by increased tissue mass in the transition zone of the prostate, which leads to obstruction of urine outflow and significant morbidity in the majority of older men. Plasma markers of oxidative stress are increased in men with BPH but it is unclear whether oxidative stress and/or oxidative DNA damage are causal in the pathogenesis of BPH. METHODS. Levels of 8-OH deoxyguanosine (8-OH dG), a marker of oxidative stress, were measured in prostate tissues from normal transition zone and BPH by ELISA. 8-OH dG was also detected in tissues by immunohistochemistry and staining quantitated by image analysis. Nox4 promotes the formation of reactive oxygen species. We therefore created and characterized transgenic mice with prostate specific expression of Nox4 under the control of the prostate specific ARR2PB promoter. RESULTS. Human BPH tissues contained significantly higher levels of 8-OH dG than control transition zone tissues and the levels of 8-OH dG were correlated with prostate weight. Cells with 8-OH dG staining were predominantly in the epithelium and were present in a patchy distribution. The total fraction of epithelial staining with 8-OH dG was significantly increased in BPH tissues by image analysis. The ARR2PB-Nox4 mice had increased oxidative DNA damage in the prostate, increased prostate weight, increased epithelial proliferation, and histological changes including epithelial proliferation, stromal thickening, and fibrosis when compared to wild type controls. CONCLUSIONS. Oxidative stress and oxidative DNA damage are important in the pathogenesis of BPH. Prostate 76: 58-67, 2016. (C) 2015 Wiley Periodicals, Inc. C1 [Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza Houston, Houston, TX 77030 USA. Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza Houston, Houston, TX 77030 USA. EM mittmann@bcm.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK083244, P20 DK097775 T32-DK007763]; National Institute on Aging [T32-AG000183]; National Cancer Institute P30 Cancer Center [P30 CA125123] FX Grant sponsor: National Institute of Diabetes and Digestive and Kidney Diseases; Grant numbers: R01 DK083244; P20 DK097775 T32-DK007763; Grant sponsor: National Institute on Aging; Grant number: T32-AG000183; Grant sponsor: National Cancer Institute P30 Cancer Center; Grant number: P30 CA125123. NR 33 TC 9 Z9 9 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD JAN 1 PY 2016 VL 76 IS 1 BP 58 EP 67 DI 10.1002/pros.23100 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA DB9AZ UT WOS:000368809600007 PM 26417670 ER PT J AU Butler, CR O'Hare, AM AF Butler, Catherine R. O'Hare, Ann M. TI Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Lipids; Cholesterol; Statin; Ezetimibe; Clinical trials; SHARP; Older adults; Kidney disease; Guidelines ID PRIMARY CARDIOVASCULAR PREVENTION; DENSITY-LIPOPROTEIN CHOLESTEROL; UNITED-STATES; PRACTICE GUIDELINE; COST-EFFECTIVENESS; RENAL PROTECTION; STATINS; CKD; HEART; DEATH AB The Study of Heart and Renal Protection (SHARP) found that treatment with ezetemibe and low-dose simvastatin reduced the incidence of major atherosclerotic events in patients with kidney disease. Due to the paucity of evidence-based interventions that lower cardiovascular morbidity in this high-risk population, the SHARP trial will likely have a large impact on clinical practice. However, applying the results of clinical trials conducted in select populations to the care of individual patients in real world settings can be fraught with difficulty. This is especially true when caring for older adults with complex comorbidity and limited life expectancy. These patients are often excluded from clinical trials, frequently have competing health priorities, and may be less likely to benefit and more likely to be harmed by medications. We discuss key considerations in applying the results of the SHARP trial to the care of older adults with CKD in real-world clinical settings using guiding principles set forth by the American Geriatrics Society's Expert Panel on the Care of Older Adults with Multimorbidity. Using this schema, we emphasize the importance of evaluating trial results in the unique context of each patient's goals, values, priorities, and circumstances. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 Dept Med, Seattle, WA USA. Univ Washington, Harborview Med Ctr, Div Hospitalist Med, 325 9Th Ave, Seattle, WA 98104 USA. VA Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Nephrol Sect, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. RP O'Hare, AM (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ann.ohare@va.gov FU NIH; CDC; VA FX A.M.O'H. receives research funding from NIH, CDC, and VA. She has received honoraria from UpToDate and the American Society of Nephrology, The Japanese Society of Dialysis, and Transplantation and Henry Ford Hospital System. NR 52 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 EI 1548-5609 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD JAN PY 2016 VL 23 IS 1 BP 29 EP 35 DI 10.1053/j.ackd.2015.11.004 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DB6UW UT WOS:000368652200006 PM 26709060 ER PT J AU Lan, CW Fiellin, DA Barry, DT Bryant, KJ Gordon, AJ Edelman, EJ Gaither, JR Maisto, SA Marshall, BDL AF Lan, Chiao-Wen Fiellin, David A. Barry, Declan T. Bryant, Kendall J. Gordon, Adam J. Edelman, E. Jennifer Gaither, Julie R. Maisto, Stephen A. Marshall, Brandon D. L. TI The Epidemiology of Substance Use Disorders in US Veterans: A Systematic Review and Analysis of Assessment Methods SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; VA HEALTH-CARE; RANDOMIZED CLINICAL-TRIAL; MAJOR DEPRESSIVE DISORDER; AMERICAN-INDIAN VETERANS; HAZARDOUS ALCOHOL-USE; SPINAL-CORD-INJURY; PSYCHIATRIC-DISORDERS; BIPOLAR DISORDER; DRUG-USE AB Background: Substance use disorders (SUDs), which encompass alcohol and drug use disorders (AUDs, DUDs), constitute a major public health challenge among US veterans. SUDs are among the most common and costly of all health conditions among veterans. Objectives: This study sought to examine the epidemiology of SUDs among US veterans, compare the prevalence of SUDs in studies using diagnostic and administrative criteria assessment methods, and summarize trends in the prevalence of SUDs reported in studies sampling US veterans over time. Methods: Comprehensive electronic database searches were conducted. A total of 3,490 studies were identified. We analyzed studies sampling US veterans and reporting prevalence, distribution, and examining AUDs and DUDs. Results: Of the studies identified, 72 met inclusion criteria. The studies were published between 1995 and 2013. Studies using diagnostic criteria reported higher prevalence of AUDs (32% vs. 10%) and DUDs (20% vs. 5%) than administrative criteria, respectively. Regardless of assessment method, both the lifetime and past year prevalence of AUDs in studies sampling US veterans has declined gradually over time. Conclusion: The prevalence of SUDs reported in studies sampling US veterans are affected by assessment method. Given the significant public health problems of SUDs among US veterans, improved guidelines for clinical screening using validated diagnostic criteria to assess AUDs and DUDs in US veteran populations are needed. Scientific Significance: These findings may inform VA and other healthcare systems in prevention, diagnosis, and intervention for SUDs among US veterans. C1 [Lan, Chiao-Wen] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA USA. [Fiellin, David A.; Edelman, E. Jennifer] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Barry, Declan T.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Barry, Declan T.] APT Fdn Inc, Pain Treatment Serv, New Haven, CT USA. [Bryant, Kendall J.] NIAAA, NIH, Bethesda, MD USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Gaither, Julie R.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Maisto, Stephen A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Marshall, Brandon D. L.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA. RP Marshall, BDL (reprint author), Brown Univ, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA. EM brandon_marshall@brown.edu OI Fiellin, David/0000-0002-4006-010X FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [U24-AA022000]; Yale Drug Abuse, Addiction and HIV Research Scholars (DAHRS) Program [K12-DA-33312-03]; Brown University; [K05-AA16928] FX This work was supported in part by grant U24-AA022000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Edelman is funded by the Yale Drug Abuse, Addiction and HIV Research Scholars (DAHRS) Program (K12-DA-33312-03). Dr. Maisto is supported by grant K05-AA16928 (NIAAA). Dr. Marshall is supported by a Richard B. Salomon Faculty Research Award from Brown University. NR 113 TC 1 Z9 1 U1 4 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2016 VL 25 IS 1 BP 7 EP 24 DI 10.1111/ajad.12319 PG 18 WC Substance Abuse SC Substance Abuse GA DB4TS UT WOS:000368506900001 PM 26693830 ER PT J AU McRae-Clark, AL Baker, NL Gray, KM Killeen, T Hartwell, KJ Simonian, SJ AF McRae-Clark, Aimee L. Baker, Nathaniel L. Gray, Kevin M. Killeen, Therese Hartwell, Karen J. Simonian, Susan J. TI Vilazodone for Cannabis Dependence: A Randomized, Controlled Pilot Trial SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; 5-HT1A RECEPTORS; FLUOXETINE; SMOKERS AB Background and Objectives: The purpose of this study was to evaluate the efficacy of vilazodone, a selective serotonin receptor inhibitor and partial 5-HT1A agonist, for treatment of cannabis dependence. Methods: Seventy-six cannabis-dependent adults were randomized to receive either up to 40 mg/day of vilazodone (n = 41) or placebo (n = 35) for 8 weeks combined with a brief motivational enhancement therapy intervention and contingency management to encourage study retention. Cannabis use outcomes were assessed via weekly urine cannabinoid tests; secondary outcomes included cannabis use self-report and cannabis craving. Results: Participants in both groups reported reduced self-reported cannabis use over the course of the study; however, vilazodone provided no advantage over placebo in reducing cannabis use. Men had significantly lower creatinine-adjusted cannabinoid levels and a trend for increased negative urine cannabinoid tests than women. Discussion and Conclusions: Vilazodone was not more efficacious than placebo in reducing cannabis use. Important gender differences were noted, with women having worse cannabis use outcomes than men. Scientific Significance: Further medication development efforts for cannabis use disorders are needed, and gender should be considered as an important variable in future trials. C1 [McRae-Clark, Aimee L.; Gray, Kevin M.; Killeen, Therese; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Baker, Nathaniel L.] Med Univ S Carolina, Dept Publ Hlth Sci, 125 Doughty St,Suite 190, Charleston, SC 29403 USA. [Hartwell, Karen J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Simonian, Susan J.] Coll Charleston, Dept Psychol, Charleston, SC 29401 USA. RP McRae-Clark, AL (reprint author), Med Univ S Carolina, 125 Doughty St,Suite 190, Charleston, SC 29403 USA. EM mcraeal@musc.edu FU NIH [R21DA34089] FX Support for this project was provided by NIH grant R21DA34089 (McRae-Clark). NR 27 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2016 VL 25 IS 1 BP 69 EP 75 DI 10.1111/ajad.12324 PG 7 WC Substance Abuse SC Substance Abuse GA DB4TS UT WOS:000368506900010 PM 26685701 ER PT S AU Whitaker, RM Corum, D Beeson, CC Schnellmann, RG AF Whitaker, Ryan M. Corum, Daniel Beeson, Craig C. Schnellmann, Rick G. BE Insel, PA TI Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 SE Annual Review of Pharmacology and Toxicology LA English DT Review; Book Chapter DE mitochondrial homeostasis; tissue bioenergetics; drug screening; high-throughput respirometry ID ISCHEMIA-REPERFUSION INJURY; ACUTE KIDNEY INJURY; THROUGHPUT RESPIROMETRIC ASSAY; ACTIVATED RECEPTOR-GAMMA; PROTEIN-QUALITY CONTROL; HIGH-FAT DIET; OXIDATIVE STRESS; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTOR; PARKINSONS-DISEASE AB Mitochondrial dysfunction is a key pathophysiological component of many acute and chronic diseases. Maintenance of mitochondrial homeostasis through the balance of mitochondrial turnover, fission and fusion, and generation of new mitochondria via mitochondrial biogenesis is critical for tissue health. Pharmacological activation of mitochondrial biogenesis can enhance oxidative metabolism and tissue bioenergetics, and improve organ function in conditions characterized by mitochondrial dysfunction. However, owing to the complexity of mitochondrial assembly and maintenance, identification of specific activators of mitochondrial biogenesis has been difficult. This review provides an overview of the role of mitochondrial dysfunction in acute and chronic diseases, details the current state of therapeutics for the stimulation of mitochondrial biogenesis and their effects on disease outcomes, describes new screening methodologies to identify novel stimulators and noncanonical pathways of mitochondrial biogenesis, and discusses potential hurdles of mitochondrial biogenesis as a therapeutic strategy. C1 [Whitaker, Ryan M.; Corum, Daniel; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Whitaker, RM; Corum, D; Beeson, CC; Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.; Schnellmann, RG (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM rmw3@musc.edu; corumd@musc.edu; beesonc@musc.edu; schnell@musc.edu FU NIDDK NIH HHS [F30 DK096964]; NIGMS NIH HHS [R01 GM084147] NR 142 TC 9 Z9 10 U1 7 U2 22 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0362-1642 BN 978-0-8243-0456-0 J9 ANNU REV PHARMACOL JI Annu. Rev. Pharmacol. Toxicol. PY 2016 VL 56 BP 229 EP 249 DI 10.1146/annurev-pharmtox-010715-103155 PG 21 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA BE1PJ UT WOS:000368345700013 PM 26566156 ER PT S AU Sharma, S Powers, A Bradley, B Ressler, KJ AF Sharma, Sumeet Powers, Abigail Bradley, Bekh Ressler, Kerry J. BE Fiske, ST TI Gene x Environment Determinants of Stress- and Anxiety-Related Disorders SO ANNUAL REVIEW OF PSYCHOLOGY, VOL 67 SE Annual Review of Psychology LA English DT Review; Book Chapter DE anxiety; depression; posttraumatic stress disorder; stress; trauma; epigenetics; gene-by-environment interaction; genome-wide association study ID GENOME-WIDE ASSOCIATION; SEROTONIN TRANSPORTER GENE; LINKED POLYMORPHIC REGION; MAJOR DEPRESSIVE DISORDER; COPY-NUMBER VARIATION; EARLY-LIFE STRESS; POSTTRAUMATIC-STRESS; CHILDHOOD-TRAUMA; PSYCHIATRIC-DISORDERS; 5-HTTLPR GENOTYPE AB The burgeoning field of gene-by-environment (G x E) interactions has revealed fascinating biological insights, particularly in the realm of stress-, anxiety-, and depression-related disorders. In this review we present an integrated view of the study of GxE interactions in stress and anxiety disorders, including the evolution of genetic association studies from genetic epidemiology to contemporary large-scale genome-wide association studies and GxE studies. We convey the importance of consortia efforts and collaboration to gain the large sample sizes needed to move the field forward. Finally, we discuss several robust and well-reproduced GxE interactions and demonstrate how epidemiological identification of GxE interactions has naturally led to a plethora of basic research elucidating the mechanisms of high-impact genetic variants. C1 [Sharma, Sumeet; Powers, Abigail; Bradley, Bekh; Ressler, Kerry J.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Sharma, Sumeet; Ressler, Kerry J.] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA. [Bradley, Bekh] US Dept Vet Affairs, Atlanta VA Med Ctr, Decatur, GA 30033 USA. RP Ressler, KJ (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.; Ressler, KJ (reprint author), Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA. EM kressler@mclean.harvard.edu FU Howard Hughes Medical Institute; NCRR NIH HHS [M01RR00039]; NICHD NIH HHS [HD071982]; NIMH NIH HHS [MH071537, MH096764, MH102890] NR 80 TC 5 Z9 5 U1 14 U2 40 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4308 BN 978-0-8243-0267-2 J9 ANNU REV PSYCHOL JI Annu. Rev. Psychol PY 2016 VL 67 BP 239 EP 261 DI 10.1146/annurev-psych-122414-033408 PG 23 WC Psychology; Psychology, Multidisciplinary SC Psychology GA BE1PH UT WOS:000368344500011 PM 26442668 ER PT J AU Bensinger, WI Becker, PS Gooley, TA Chauncey, TR Maloney, DG Gopal, AK Green, DJ Press, OW Lill, M Ifthikharuddin, JJ Vescio, R Holmberg, LA Phillips, GL AF Bensinger, W. I. Becker, P. S. Gooley, T. A. Chauncey, T. R. Maloney, D. G. Gopal, A. K. Green, D. J. Press, O. W. Lill, M. Ifthikharuddin, J. J. Vescio, R. Holmberg, L. A. Phillips, G. L. TI A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT SO BONE MARROW TRANSPLANTATION LA English DT Article ID STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; ORAL MUCOSITIS; MARROW-TRANSPLANTATION; STANDARD CHEMOTHERAPY; CONDITIONING REGIMENS; INDUCTION TREATMENT; TRIAL; BORTEZOMIB; AMIFOSTINE AB We aimed to examine whether doses of melphalan higher than 200 mg/m(2) improve response rates when used as conditioning before autologous transplant (ASCT) in multiple myeloma (MM) patients. Patients with MM, n=131, were randomized to 200 mg/m(2) (mel200) vs 280 mg/m(2) (mel280) using amifostine pretreatment. The primary end point was the proportion of patients achieving near complete response (>= nCR). No treatment-related deaths occurred in this study. Responses following ASCT were for mel200 vs mel280, respectively, >= nCR 22 vs 39%, P=0.03, >= PR 57 vs 74%, P=0.04. The hazard of mortality was not statistically significantly different between groups (mel200 vs mel280; hazard ratio (HR) = 1.15 (95% confidence interval (CI), 0.62-2.13, P=0.66)) nor was the rate of progression/mortality (HR = 0.81 (0.52-1.27, P=0.36)). The estimated PFS at 1 and 3 years were 83 and 46%, respectively, for mel200 and 78 and 54%, respectively, for mel280. Amifostine and mel280 were well tolerated, with no grade 4 regimen-related toxicities and only one grade 3 mucositis (none with mel200) and three grade 3 gastrointestinal (GI) toxicities (two in mel200). Hospitalization rates were more frequent in the mel280 group (59 vs 43%, P=0.08). Mel280 resulted in a higher major response rate (CR+nCR) and should be evaluated in larger studies. C1 [Bensinger, W. I.; Gooley, T. A.; Maloney, D. G.; Gopal, A. K.; Green, D. J.; Press, O. W.; Holmberg, L. A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Bensinger, W. I.; Becker, P. S.; Gooley, T. A.; Chauncey, T. R.; Maloney, D. G.; Gopal, A. K.; Green, D. J.; Press, O. W.; Holmberg, L. A.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, T. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lill, M.; Vescio, R.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Ifthikharuddin, J. J.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Phillips, G. L.] Wake Forest Baptist Med Ctr, Winston Salem, NC USA. [Bensinger, W. I.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D5-390, Seattle, WA 98109 USA. RP Bensinger, WI (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D5-390, Seattle, WA 98109 USA. EM wbensing@fhcrc.org FU NIH/NCI [R21 CA155911-01, P01 CA18029-28]; VA Puget Sound Health Care System, Seattle, WA FX This study was supported in part by research funds supplied by Astra-Zeneca, R21 CA155911-01, and by P01 CA18029-28 both from NIH/NCI. Previously published at the 2012 ASH Annual Meeting, Atlanta, GA December 2012. This study was supported in part by resources of the VA Puget Sound Health Care System, Seattle, WA. NR 24 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD JAN PY 2016 VL 51 IS 1 BP 67 EP 71 DI 10.1038/bmt.2015.211 PG 5 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA DB4FV UT WOS:000368469800010 PM 26367217 ER PT J AU Rose, AJ Allen, AL Minichello, T AF Rose, Adam J. Allen, Arthur L. Minichello, Tracy TI A Call to Reduce the Use of Bridging Anticoagulation SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE anticoagulants; evidence-based medicine; heparin; low-molecular weight; humans; perioperative care; practice guideline; warfarin ID VENOUS THROMBOEMBOLISM; WARFARIN INTERRUPTION; ATRIAL-FIBRILLATION; BLOOD-COAGULATION; WITHDRAWAL; REGISTRY; ABRUPT AB Because of the recent publication of several important studies, there has been a major change in how we think about perioperative management of anticoagulation. Because of these changes, existing consensus guidelines are suddenly out of date and can no longer be used as is, particularly the 2012 American College of Chest Physicians Antithrombotic Guidelines, version 9. We estimate that well over 90% of patients receiving warfarin therapy should not receive bridging anticoagulation during periprocedural interruptions of therapy, except under unusual circumstances and with appropriate justification. Accumulating evidence also suggests that bridging is not indicated among patients receiving direct-acting oral anticoagulant therapy. The large number of patients potentially affected represents an important safety concern and requires an immediate change in practice. C1 [Rose, Adam J.] Bedford VA Med Ctr, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70, Bedford, MA USA. [Rose, Adam J.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02215 USA. [Allen, Arthur L.] VA Salt Lake City Healthcare Syst, Dept Pharm, Salt Lake City, UT USA. [Minichello, Tracy] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Minichello, Tracy] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. RP Rose, AJ (reprint author), Bedford VA Med Ctr, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70, Bedford, MA USA. EM adamrose@bu.edu NR 13 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2016 VL 9 IS 1 BP 64 EP 67 DI 10.1161/CIRCOUTCOMES.115.002430 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB6FZ UT WOS:000368611000010 PM 26715651 ER PT J AU Garimella, PS Katz, R Patel, KV Kritchevsky, SB Parikh, CR Ix, JH Fried, LF Newman, AB Shlipak, MG Harris, TB Sarnak, MJ AF Garimella, Pranav S. Katz, Ronit Patel, Kushang V. Kritchevsky, Stephen B. Parikh, Chirag R. Ix, Joachim H. Fried, Linda F. Newman, Anne B. Shlipak, Michael G. Harris, Tamara B. Sarnak, Mark J. CA Hlth ABC Study TI Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality The Health Aging and Body Composition Study SO CIRCULATION-HEART FAILURE LA English DT Article DE cardiovascular outcomes; chronic kidney disease; death; erythropoietin; heart failure ID CONGESTIVE-HEART-FAILURE; EPOETIN-ALPHA; ENDOGENOUS ERYTHROPOIETIN; DARBEPOETIN-ALPHA; OLDER-ADULTS; CYSTATIN-C; INFLAMMATORY MARKERS; DISEASE; ANEMIA; RISK AB Background Studies suggest that in patients with heart failure (HF), high serum erythropoietin is associated with risk of recurrent HF and mortality. Trials of erythropoietin-stimulating agents in persons with kidney disease have also suggested an increased incidence of adverse clinical events. No large studies of which we are aware have evaluated the association of endogenous erythropoietin levels with clinical outcomes in the community-living older adults. Methods and Results Erythropoietin concentration was measured in 2488 participants aged 70-79 years in the Health, Aging and Body Composition Study. Associations of erythropoietin with incident HF, coronary heart disease, stroke, mortality, and 30% decline in estimated glomerular filtration rate were examined using Cox proportional hazards and logistic regression over 10.7 years of follow-up. Mean (SD) age was 75 (3) years and median (quartile 1, quartile 3) erythropoietin was 12.3 (9.0, 17.2) mIU/mL. There were 503 incident HF events, and each doubling of serum erythropoietin was associated with a 25% increased risk of incident HF 1.25 (95% confidence interval 1.13, 1.48) after adjusting for demographics, prevalent cardiovascular disease, cardiovascular disease risk factors, kidney function, and serum hemoglobin. There was no interaction of serum erythropoietin with chronic kidney disease or anemia (P>0.50). There were 330 incident coronary heart disease events, 161 strokes, 1112 deaths, and 698 outcomes of 30% decline in estimated glomerular filtration rate. Serum erythropoietin was not significantly associated with these outcomes. Conclusions Higher levels of endogenous erythropoietin are associated with incident HF in older adults. Studies need to elucidate the mechanisms through which endogenous erythropoietin levels associate with specific outcomes. C1 [Garimella, Pranav S.; Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA 02111 USA. [Katz, Ronit] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Kritchevsky, Stephen B.] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Parikh, Chirag R.] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA. [Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Prevent Med, San Diego, CA 92103 USA. [Fried, Linda F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15260 USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. RP Sarnak, MJ (reprint author), Tufts Med Ctr, Div Nephrol, 800 Washington St,Box 391, Boston, MA 02111 USA. EM msarnak@tuftsmedicalcenter.org OI Newman, Anne B./0000-0002-0106-1150 FU Intramural Research Program of the National Institutes of Health (NIH); National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, 5R01AG027002]; NINR [R01-NR012459]; American Heart Association [14EIA18560026]; National Center on Minority Health and Health Disparities, NIH [MD-07-080] FX This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH) and the National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. Drs Shlipak, Sarnak, Ix, and Katz were supported by NIA grant 5R01AG027002, Dr Ix by an American Heart Association Award #14EIA18560026, and Dr Patel was supported by National Center on Minority Health and Health Disparities, NIH grant MD-07-080. The study sponsors had no role in study design; collection, analysis, and interpretation of the data; writing the report; and the decision to submit the report for publication. NR 44 TC 3 Z9 3 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2016 VL 9 IS 1 AR e002124 DI 10.1161/CIRCHEARTFAILURE.115.002124 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB6HN UT WOS:000368615500001 PM 26721912 ER PT J AU McCollister, K Yang, X Mckay, JR AF McCollister, Kathryn Yang, Xuan McKay, James R. TI Cost-effectiveness analysis of a continuing care intervention for cocaine-dependent adults SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Continuing care; Cost-effectiveness analysis; Substance use disorders; Economic evaluation ID SUBSTANCE USE DISORDERS; ALCOHOL DEPENDENCE; RANDOMIZED-TRIAL; 24-MONTH OUTCOMES; MANAGEMENT; FRAMEWORK; BENEFITS; ABUSERS; DISEASE AB Introduction: The study conducts a cost-effectiveness analysis (CEA) of a continuing care Telephone Monitoring and Counseling (TMC) intervention for adults diagnosed with cocaine dependence. Participants were randomly assigned to a control condition of intensive outpatient treatment only (treatment-as usual, or TAU; N = 108), or to one of two treatment conditions featuring TMC (N=106) and TMC plus incentives (TMC-plus; N = 107). Follow-up assessments were conducted over a 2-year period. Methods: Intervention and client costs were collected with the program and client versions of the Drug Abuse Treatment Cost Analysis Program (DATCAP). Effectiveness was measured as the number of days abstinent during follow-up. Secondary analyses consider alternative measures of effectiveness and the reduced societal costs of physical and mental health problems and criminal justice involvement. Results: From the societal perspective, TMC dominates both TAU and TMC-plus as a cost-effective and cost saving intervention. Results varied by substance-using status, however, with the subgroup of participants in TMC-plus that were using drugs at intake and early in treatment having the greatest number of days of abstinence and generating similar savings during follow-up than the TMC subgroup using drugs at intake. Conclusions: Telephone monitoring and counseling appears to be a cost-effective and potentially cost saving strategy for reducing substance use among chronic substance users. Providing client incentives added to total intervention costs but did not improve overall effectiveness. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [McCollister, Kathryn; Yang, Xuan] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Clin Res Bldg,Off 1026,1120 NW 14th St, Miami, FL 33136 USA. [McKay, James R.] Univ Penn, Philadelphia, PA 19104 USA. [McKay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP McCollister, K (reprint author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Clin Res Bldg,Off 1026,1120 NW 14th St, Miami, FL 33136 USA. EM kmccolli@miami.edu FU National Institute on Drug Abuse (NIDA) [R01 DA020623, R01 DA031785] FX Financial assistance for this study was provided by the National Institute on Drug Abuse (NIDA; grant numbers R01 DA020623 & R01 DA031785). The funding sources had no involvement in the study design, in the collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the article for publication. NR 28 TC 2 Z9 2 U1 1 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2016 VL 158 BP 38 EP 44 DI 10.1016/j.drugalcdep.2015.10.032 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DB5PN UT WOS:000368566200005 PM 26621551 ER PT J AU Chavez, LJ Liu, CF Tefft, N Hebert, PL Clark, BJ Rubinsky, AD Lapham, GT Bradley, KA AF Chavez, Laura J. Liu, Chuan-Fen Tefft, Nathan Hebert, Paul L. Clark, Brendan J. Rubinsky, Anna D. Lapham, Gwen T. Bradley, Katharine A. TI Unhealthy alcohol use in older adults: Association with readmissions and emergency department use in the 30 days after hospital discharge SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol screening; Quality; Unhealthy alcohol use; Emergency department; Readmissions; Post-discharge care ID CARE TRANSITIONS INTERVENTION; VETERANS-AFFAIRS; SCREENING SCORES; USE DISORDERS; AUDIT-C; MEDICARE BENEFICIARIES; HEALTH-CARE; RISK; METAANALYSIS; CONSUMPTION AB Background: Unhealthy alcohol use could impair recovery of older patients after medical or surgical hospitalizations. However, no prior research has evaluated whether older patients who screen positive for unhealthy alcohol use are at increased risk of readmissions or emergency department (ED) visits within 30 days after discharge. This study examined the association between AUDIT-C alcohol screening results and 30-day readmissions or ED visits. Methods: Veterans Affairs (VA) patients age 65 years or older, were eligible if they were hospitalized for a medical or surgical condition (2/1/2009-10/1/2011) and had an AUDIT-C score documented in their VA electronic medical record in the year before they were hospitalized. VA and Medicare data identified VA or non-VA index hospitalizations, readmissions, and ED visits. Primary analyses adjusted for demographics, comorbid conditions, and past-year health care utilization. Results: Among 579,330 hospitalized patients, 13.7% were readmitted and 12.0% visited an ED within 30 days of discharge. In primary analyses, high-risk drinking (n = 7,167) and nondrinking (n = 357,086) were associated with increased probability of readmission (13.8%, 95% CI 13.0-14.6%; and 14.2%, 95% CI 14.1-14.3%, respectively), relative to low-risk drinking (12.9%; 95% CI 12.7-13.0%). Only nondrinkers had increased risk for ED visits. Conclusions: Alcohol screening results indicating high-risk drinking that were available in medical records were modestly associated with risk for 30-day readmissions and were not associated with risk for ED visits. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Chavez, Laura J.; Liu, Chuan-Fen; Hebert, Paul L.; Rubinsky, Anna D.; Lapham, Gwen T.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA. [Rubinsky, Anna D.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, 1660 S Columbian Way, Seattle, WA 98108 USA. [Chavez, Laura J.; Liu, Chuan-Fen; Hebert, Paul L.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA. [Tefft, Nathan] Bates Coll, 2 Andrews Rd, Lewiston, ME 04240 USA. [Clark, Brendan J.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, 12700 E 19th Ave, Aurora, CO 80045 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. RP Chavez, LJ (reprint author), Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA. EM ljchavez@uw.edu; chuan-fen.liu@va.gov; ntefft@bates.edu; paul.hebert2@va.gov; brendan.clark@ucdenver.edu; anna.rubinsky@va.gov; lapham.g@ghc.org; bradley.k@ghc.org FU Agency for Healthcare Research and Quality (AHRQ) [NIH 1R36HS022800-01]; Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound; NIAAA R21 [5R21AA020894-02]; NIH [K23 AA 021814] FX Ms. Chavez's work on this study was supported by an Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). Dr. Bradley's and Ms. Rubinsky's time on this study was supported by the Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound. Dr. Bradley's NIAAA R21 (5R21AA020894-02) supported the collection of the data used in this study. Dr. Clark is supported by NIH grant K23 AA 021814. NR 55 TC 2 Z9 2 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2016 VL 158 BP 94 EP 101 DI 10.1016/j.drugalcdep.2015.11.008 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DB5PN UT WOS:000368566200012 PM 26644137 ER PT S AU Thomas, T Seay, K Zheng, JH Zhang, C Ochsenbauer, C Kappes, JC Goldstein, H AF Thomas, Tynisha Seay, Kieran Zheng, Jian Hua Zhang, Cong Ochsenbauer, Christina Kappes, John C. Goldstein, Harris BE Prasad, VR Kalpana, GV TI High-Throughput Humanized Mouse Models for Evaluation of HIV-1 Therapeutics and Pathogenesis SO HIV PROTOCOLS, 3RD EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE HIV-1; Mouse model; Antiretroviral treatment ID IMMUNODEFICIENCY-VIRUS TYPE-1; RAG2(-/-)GAMMA(-/-)(C) MICE; CYCLIN T1; INFECTION; REPLICATION; CELLS; TAT AB Mice cannot be used as a model to evaluate HIV-1 therapeutics because they do not become infected by HIV-1 due to structural differences between several human and mouse proteins required for HIV-1 replication. This has limited their use for in vivo assessment of anti-HIV-1 therapeutics and the mechanism by which cofactors, such as illicit drug use accelerate HIV-1 replication and disease course in substance abusers. Here, we describe the development and application of two in vivo humanized mouse models that are highly sensitive and useful models for the in vivo evaluation of candidate anti-HIV therapeutics. The first model, hu-spl-PBMC-NSG mice, uses NOD-SCID IL2r gamma(-/-) (NSG) mice intrasplenically injected with human peripheral blood mononuclear cells (PBMC) which develop productive splenic HIV-1 infection after intrasplenic inoculation with a replication-competent HIV-1 expressing Renilla reniformis luciferase (HIVLucR) and enables investigators to use bioluminescence to visualize and quantitate the temporal effects of therapeutics on HIV-1 infection. The second model, hCD4/R5/cT1 mice, consists of transgenic mice carrying human CD4, CCR5 and cyclin T1 genes, which enables murine CD4-expressing cells to support HIV-1 entry, Tat-mediated LTR transcription and consequently develop productive infection. The hCD4/R5/cT1 mice develop disseminated infection of tissues including the spleen, small intestine, lymph nodes and lungs after intravenous injection with HIV-1-LucR. Because these mice can be infected with HIV-LucR expressing transmitted/founder and clade A/E and C Envs, these mouse models can also be used to evaluate the in vivo efficacy of broadly neutralizing antibodies and antibodies induced by candidate HIV-1 vaccines. Furthermore, because hCD4/R5/cT1 mice can be infected by vaginal inoculation with replication-competent HIV-1 expressing NanoLuc (HIV-nLucR)-, this mouse model can be used to evaluate the mechanisms by which substance abuse and other factors enhance mucosal transmission of HIV-1. C1 [Thomas, Tynisha; Seay, Kieran; Zheng, Jian Hua; Zhang, Cong; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. [Goldstein, Harris] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. RP Thomas, T (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. OI Ochsenbauer, Christina/0000-0003-1166-5879 FU NIAID NIH HHS [P30 AI027767]; NIDA NIH HHS [R01 DA033788, R01 DA036171] NR 25 TC 1 Z9 1 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3046-3; 978-1-4939-3045-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1354 BP 221 EP 235 DI 10.1007/978-1-4939-3046-3_15 D2 10.1007/978-1-4939-3046-3 PG 15 WC Immunology; Virology SC Immunology; Virology GA BE1XH UT WOS:000368688500016 PM 26714715 ER PT J AU Dusser, D Wise, RA Dahl, R Anzueto, A Carter, K Fowler, A Calverley, PM AF Dusser, Daniel Wise, Robert A. Dahl, Ronald Anzueto, Antonio Carter, Kerstine Fowler, Andy Calverley, Peter M. TI Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR (R) trial SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE TIOSPIR (R); GOLD; cardiovascular comorbidity; mortality; respiratory death; cardiovascular death ID OBSTRUCTIVE PULMONARY-DISEASE; ECLIPSE COHORT; CLASSIFICATION; EXACERBATION; DYSPNEA; DEATH AB Background: The aim of this study was to evaluate whether Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification could predict mortality risk factors and whether baseline treatment intensity would relate to mortality within each group, using data from TIOSPIR (R), the largest randomized clinical trial in COPD performed to date. Methods: A total of 17,135 patients from TIOSPIR (R) were pooled and grouped by GOLD grading (A-D) according to baseline Medical Research Council breathlessness score, exacerbation history, and spirometry. All-cause mortality and adjudicated cardiovascular (CV) and respiratory mortality were assessed. Results: Of the 16,326 patients classified, 1,248 died on treatment. Group B patients received proportionally more CV treatment at baseline. CV mortality risk, but not all-cause mortality risk, was significantly higher in Group B than Group C patients (CV mortality - hazard ratio [HR] = 1.74, P = 0.004; all-cause mortality - HR = 1.18, P = 0.11). Group D patients had a higher incidence of all-cause mortality than Group B patients (10.9% vs 6.6%). Similar trends were observed regardless of respiratory or CV medication at baseline. In contrast, respiratory deaths increased consistently from Groups A-D (0.3%, 0.8%, 1.6%, and 4.2% of patients, respectively). Conclusion: The data obtained from the TIOSPIR (R) trial, supporting earlier studies, suggest that proportionally more CV medication and CV deaths occur in GOLD Group B COPD patients, although deaths attributed to respiratory causes are more prevalent in Groups C and D. C1 [Dusser, Daniel] Univ Paris 05, AP HP, Hop Cochin, Sorbonne Paris Cite,Serv Pneumol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France. [Wise, Robert A.] Johns Hopkins Univ, Sch Med, Asthma & Allergy Ctr, Baltimore, MD USA. [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark. [Anzueto, Antonio] Univ Texas San Antonio, Pulm Crit Care, San Antonio, TX USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Carter, Kerstine] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA. [Fowler, Andy] Boehringer Ingelheim Pharma Ltd, Bracknell, Berks, England. [Calverley, Peter M.] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England. RP Dusser, D (reprint author), Univ Paris 05, AP HP, Hop Cochin, Sorbonne Paris Cite,Serv Pneumol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France. EM daniel.dusser@aphp.fr FU Boehringer Ingelheim; Pfizer; Novartis; Chiesi; Nycomed; Dey Pharma; GlaxoSmithKline; Pearl Therapeutics; Forest Laboratories; Bristol-Myers Squibb; Janssen; Mylan; Sunovion; Pulmonx; Spiration; Roche; Grifols; AstraZeneca; Takeda FX Daniel Dusser reports receiving consulting fees, lecture fees, and payment for the development of educational activities from Boehringer Ingelheim, Pfizer, Novartis, Chiesi, Nycomed, and Dey Pharma. Robert Wise reports receiving consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Mylan, Novartis, Pfizer, Sunovion, Pulmonx, Spiration, Roche, Grifols, and AstraZeneca, and grant support from Boehringer Ingelheim, GlaxoSmithKline, Pearl Therapeutics, and Forest Laboratories. Ronald Dahl reports receiving consulting fees, lecture fees, and grant support from Boehringer Ingelheim and Novartis. Antonio Anzueto reports receiving consulting fees, lecture fees, and travel support from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, and Novartis, and grant support from GlaxoSmithKline. Kerstine Carter and Andy Fowler report being employees of Boehringer Ingelheim. Peter Calverley reports receiving consulting fees, lecture fees, and travel support from Novartis, GlaxoSmithKline, Boehringer Ingelheim, and Takeda. The authors report no other conflicts of interest in this work. NR 15 TC 0 Z9 0 U1 0 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 133 EP 145 DI 10.2147/COPD.S97924 PG 13 WC Respiratory System SC Respiratory System GA DB3KP UT WOS:000368410400002 PM 26855568 ER PT J AU Luk, FS Kim, RY Li, K Ching, D Wong, DK Joshi, SK Imhof, I Honbo, N Hoover, H Zhu, BQ Lovett, DH Karliner, JS Raffai, RL AF Luk, Fu Sang Kim, Roy Y. Li, Kang Ching, Daniel Wong, David K. Joshi, Sunil K. Imhof, Isabella Honbo, Norman Hoover, Holly Zhu, Bo-Qing Lovett, David H. Karliner, Joel S. Raffai, Robert L. TI Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE FTY720; S1P; ApoE; coronary atherosclerosis; heart failure; cardioprotection; immunosuppression ID MATRIX METALLOPROTEINASE-2 EXPRESSION; ISCHEMIA-REPERFUSION INJURY; NFAT NUCLEAR FACTOR; SPHINGOSINE-1-PHOSPHATE ANALOG; SPHINGOSINE 1-PHOSPHATE; GENE REPAIR; IN-VIVO; HEART; CELL; PROMOTES AB Aims:We recently reported that immunosuppression with FTY720 improves cardiac function and extends longevity in Hypomorphic ApoE mice deficient in scavenger receptor Type-BI expression, also known as the HypoE/SR-BI-/- mouse model of diet-induced coronary atherosclerosis and myocardial infarction (MI). In this study, we tested the impact of FTY720 on cardiac dysfunction in HypoE/SR-BI-/- mice that survive MI and subsequently develop chronic heart failure.Methods/Results:HypoE/SR-BI-/- mice were bred to Mx1-Cre transgenic mice, and offspring were fed a high-fat diet (HFD) for 3.5 weeks to provoke hyperlipidemia, coronary atherosclerosis, and recurrent MIs. In contrast to our previous study, hyperlipidemia was rapidly reversed by inducible Cre-mediated gene repair of the HypoE allele and switching mice to a normal chow diet. Mice that survived the period of HFD were subsequently given oral FTY720 in drinking water or not, and left ventricular (LV) function was monitored using serial echocardiography for up to 15 weeks. In untreated mice, LV performance progressively deteriorated. Although FTY720 treatment did not initially prevent a decline of heart function among mice 6 weeks after Cre-mediated gene repair, it almost completely restored normal LV function in these mice by 15 weeks. Reversal of heart failure did not result from reduced atherosclerosis as the burden of aortic and coronary atherosclerosis actually increased to similar levels in both groups of mice. Rather, FTY720 caused systemic immunosuppression as assessed by reduced numbers of circulating T and B lymphocytes. In contrast, FTY720 did not enhance the loss of T cells or macrophages that accumulated in the heart during the HFD feeding period, but it did enhance the loss of B cells soon after plasma lipid lowering. Moreover, FTY720 potently reduced the expression of matrix metalloproteinase-2 and genes involved in innate immunity-associated inflammation in the heart.Conclusions:Our data demonstrate that immunosuppression with FTY720 prevents postinfarction myocardial remodeling and chronic heart failure. C1 [Luk, Fu Sang; Kim, Roy Y.; Li, Kang; Ching, Daniel; Wong, David K.; Raffai, Robert L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94121 USA. [Joshi, Sunil K.; Imhof, Isabella; Honbo, Norman; Hoover, Holly; Zhu, Bo-Qing; Lovett, David H.; Karliner, Joel S.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. RP Raffai, RL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA. EM robert.raffai@ucsf.edu FU National Institutes of Health [HL089871, HL090606]; Department of Veterans Affairs [5I01BX000532] FX This work was supported by Grants from the National Institutes of Health HL089871 (RLR) and HL090606 (JSK) which were administered by the Northern California Institute for Research and Education, and a Merit Review grant from the Department of Veterans Affairs 5I01BX000532 to RLR, and with resources of the Veterans Affairs Medical Center, San Francisco, California. NR 42 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD JAN PY 2016 VL 67 IS 1 BP 47 EP 56 DI 10.1097/FJC.0000000000000312 PG 10 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA DB4SW UT WOS:000368504500006 PM 26322923 ER PT J AU Huang, T Wang, ZH Wei, LN Kindy, M Zheng, YF Xi, TF Gao, BZ AF Huang, Ting Wang, Zhonghai Wei, Lina Kindy, Mark Zheng, Yufeng Xi, Tingfei Gao, Bruce Z. TI Microelectrode Array-evaluation of Neurotoxic Effects of Magnesium as an Implantable Biomaterial SO JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY LA English DT Article DE Magnesium; Microelectrode array; Neuroelectrophysiology; Neuron viability; Neuronal network ID NEURONAL APOPTOSIS; IN-VITRO; ALLOYS; CORROSION; CULTURE; ASSAYS; CELLS; TERM; PH AB Magnesium (Mg)-based biomaterials have shown great potential in clinical applications. However, the cytotoxic effects of excessive Mg2+ and the corrosion products from Mg-based biomaterials, particularly their effects on neurons, have been little studied. Although viability tests are most commonly used, a functional evaluation is critically needed. Here, both methyl thiazolyl tetrazolium (MTT) and lactate dehydrogenase (LDH) assays were used to test the effect of Mg2+ and Mg-extract solution on neuronal viability. Microelectrode arrays (MEAs), which provide long-term, real-time recording of extracellular electro-physiological signals of in vitro neuronal networks, were used to test for toxic effects. The minimum effective concentrations (ECmin) of Mg2+ from the MTT and LDH assays were 3 mmol/L and 100 mmol/L, respectively, while the ECmin obtained from the MEA assay was 0.1 mmol/L. MEA data revealed significant loss of neuronal network activity when the culture was exposed to 25% Mg-extract solution, a concentration that did not affect neuronal viability. For evaluating the biocompatibility of Mg-based biomaterials with neurons, MEA electrophysiological testing is a more precise method than basic cell-viability testing. Copyright (C) 2015, The editorial office of Journal of Materials Science & Technology. Published by Elsevier Limited. All rights reserved. C1 [Huang, Ting; Wei, Lina; Zheng, Yufeng; Xi, Tingfei] Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China. [Wang, Zhonghai; Kindy, Mark; Gao, Bruce Z.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci & Regenerat Med, Charleston, SC 29466 USA. [Kindy, Mark] Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29466 USA. [Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. [Zheng, Yufeng] Peking Univ, Coll Engn, Dept Mat Sci & Engn, Beijing 100871, Peoples R China. [Xi, Tingfei] Peking Univ, Shenzhen Inst, Shenzhen Key Lab Human Tissue Regenerat & Repair, Shenzhen 518057, Peoples R China. RP Xi, TF (reprint author), Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China.; Gao, BZ (reprint author), Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. EM xitingfei@pku.edu.cn; zgao@clemson.edu RI Zheng, Yufeng/A-4146-2010 OI Zheng, Yufeng/0000-0002-7402-9979 FU National Basic Research Program of China (973 Program) [2012CB619102]; National Natural Science Foundation of China [31070847, 31370956]; National Science and Technology Support Program [2012BAI18B01]; Strategic New Industry Development Special Foundation of Shenzhen, China [JCYJ20130402172114948]; Guangdong Provincial Department of Science and Technology, China [2011B050400011]; NIH NIGMS COBRE [NIH P20GM103444] FX This work was supported by the National Basic Research Program of China (973 Program, No. 2012CB619102); the National Natural Science Foundation of China (Nos. 31070847 and 31370956); the National Science and Technology Support Program (No. 2012BAI18B01); the Strategic New Industry Development Special Foundation of Shenzhen, China (No. JCYJ20130402172114948); the Guangdong Provincial Department of Science and Technology, China (No. 2011B050400011); and NIH NIGMS COBRE (No. NIH P20GM103444). NR 18 TC 1 Z9 1 U1 4 U2 9 PU JOURNAL MATER SCI TECHNOL PI SHENYANG PA 72 WENHUA RD, SHENYANG 110015, PEOPLES R CHINA SN 1005-0302 J9 J MATER SCI TECHNOL JI J. Mater. Sci. Technol. PD JAN PY 2016 VL 32 IS 1 BP 89 EP 96 DI 10.1016/j.jmst.2015.08.009 PG 8 WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering SC Materials Science; Metallurgy & Metallurgical Engineering GA DB5NI UT WOS:000368560500013 PM 27110081 ER PT J AU Kaatz, A Dattalo, M Regner, C Filut, A Carnes, M AF Kaatz, Anna Dattalo, Melissa Regner, Caitlin Filut, Amarette Carnes, Molly TI Patterns of Feedback on the Bridge to Independence: A Qualitative Thematic Analysis of NIH Mentored Career Development Award Application Critiques SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GENDER-DIFFERENCES; MEDICAL-FACULTY; SEX-DIFFERENCES; WOMENS HEALTH; DEVELOPMENT AWARDEES; ONE INSTITUTION; JOB APPLICANTS; FEMALE; DISCRIMINATION; RECOMMENDATION AB Background: NIH Mentored Career Development (K) Awards bridge investigators from mentored to independent research. A smaller proportion of women than men succeed in this transition. The aim of this qualitative study was to analyze reviewers' narrative critiques of K award applications and explore thematic content of feedback provided to male and female applicants. Method: We collected 88 critiques, 34 from 9 unfunded and 54 from 18 funded applications, from 70% (n=26) of investigators at the University of Wisconsin-Madison with K awards funded between 2005 and 2009 on the first submission or after revision. We qualitatively analyzed text in the 5 critique sections: candidate, career development plan, research plan, mentors, and environment and institutional commitment. We explored thematic content within these sections for male and female applicants and for applicants who had received a subsequent independent research award by 2014. Results: Themes revealed consistent areas of criticism for unfunded applications and praise for funded applications. Subtle variations in thematic content appeared for male and female applicants: For male applicants criticism was often followed by advice but for female applicants it was followed by questions about ability; praise recurrently characterized male but not female applicants' research as highly significant with optimism for future independence. Female K awardees that obtained subsequent independent awards stood out as having track records described as outstanding. Conclusion: This exploratory study suggests that K award reviewer feedback, particularly for female applicants, should be investigated as a potential contributor to research persistence and success in crossing the bridge to independence. C1 [Kaatz, Anna; Filut, Amarette] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Regner, Caitlin] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53715 USA. [Dattalo, Melissa] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Coll Engn, Dept Ind & Syst Engn, Madison, WI 53715 USA. RP Kaatz, A (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM akaatz@wisc.edu FU NIH [R25GM083252, R01GM111002]; Department of Medicine; Shapiro Research Scholars Program in the School of Medicine and Public Health at the University of Wisconsin-Madison; Shaprio Summer Research Program at the UW-Madison School; Medicine and Public Health FX The authors wish to thank Kristin Cox and Katherine Muratore at University of Wisconsin's Center for Women's Health Research who aided in formatting and de-identifying critiques. Dr. Carnes' and Dr. Kaatz's work on increasing scientific workforce diversity is funded by NIH grants R01GM111002 and R25GM083252, the Department of Medicine, and the Shapiro Research Scholars Program in the School of Medicine and Public Health at the University of Wisconsin-Madison. Ms. Regner received funding to participate in this research from the Shaprio Summer Research Program at the UW-Madison School or Medicine and Public Health. The funders played no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. This study was approved by the University of Wisconsin-Madison institutional review board. NR 57 TC 0 Z9 0 U1 3 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JAN 1 PY 2016 VL 25 IS 1 BP 78 EP 90 DI 10.1089/jwh.2015.5254 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA DB4YX UT WOS:000368520700013 PM 26418619 ER PT J AU Banks, WA Abrass, CK Hansen, KM AF Banks, William A. Abrass, Christine K. Hansen, Kim M. TI Differentiating the Influences of Aging and Adiposity on Brain Weights, Levels of Serum and Brain Cytokines, Gastrointestinal Hormones, and Amyloid Precursor Protein SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Aging; Cytokines; Obesity; Leptin; Amyloid precursor protein ID COLONY-STIMULATING FACTOR; ALZHEIMERS-DISEASE; CALORIC RESTRICTION; COGNITIVE IMPAIRMENT; OBESITY; INFLAMMATION; LEPTIN; INSULIN; DIET; INJECTIONS AB Aging and obesity exert important effects on disease. Differentiating these effects is difficult, however, because weight gain often accompanies aging. Here, we used a nested design of aged, calorically restricted, and refed rats to measure changes in brain and blood levels of cytokines and gastrointestinal hormones, brain amyloid precursor protein levels, and brain and body weights. By comparing groups and using path analysis, we found divergent influences of chronological aging versus body weight, our main findings being (i) changes in whole brain weight and serum macrophage colony-stimulating factor levels correlated better with body weight than with chronological aging, (ii) a decrease in brain cytokines and brain plasminogen activator inhibitor levels correlated better with chronological aging than with body weight, (iii) serum erythropoietin levels were influenced by both body weight and aging, (iv) serum plasminogen activator inhibitor, serum cytokines, and brain tumor necrosis factor were not influenced by aging or body weight, and (v) brain amyloid precursor protein more closely related to body weight and serum levels of gastrointestinal hormones than to brain weight, chronological aging, or cytokines. These findings show that although aging and body weight interact, their influences are distinct not only among various cytokines and hormones but also between the central nervous system and the peripheral tissue compartments. C1 [Banks, William A.; Hansen, Kim M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Abrass, Christine K.] Dept Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Care Med, Seattle, WA USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Rm 810A,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU Veterans Affairs Merit Reviews; AG [RO-1029839] FX The authors were supported by Veterans Affairs Merit Reviews (W.A.B.; C.K.A.) and AG RO-1029839 (W.A.B.). NR 34 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2016 VL 71 IS 1 BP 21 EP 29 DI 10.1093/gerona/glu100 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DB2UZ UT WOS:000368366900003 PM 25128822 ER PT J AU Reyes, RC Cittolin-Santos, GF Kim, JE Won, SJ Brennan-Minnella, AM Katz, M Glass, GA Swanson, RA AF Reyes, Reno C. Cittolin-Santos, Giordano Fabricio Kim, Ji-Eun Won, Seok Joon Brennan-Minnella, Angela M. Katz, Maya Glass, Graham A. Swanson, Raymond A. TI Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid SO NEUROTHERAPEUTICS LA English DT Article DE Cysteine; Parkinson's disease; oxidative stress; human; cerebrospinal fluid; target engagement ID PARKINSONS-DISEASE; OXIDATIVE STRESS; NITRIC-OXIDE; ACETYLCYSTEINE; METABOLISM; DEPLETION; BRAIN; SUPEROXIDE; NEURODEGENERATION; DEFICIENCY AB N-acetyl cysteine (NAC) supports the synthesis of glutathione (GSH), an essential substrate for fast, enzymatically catalyzed oxidant scavenging and protein repair processes. NAC is entering clinical trials for adrenoleukodystrophy, Parkinson's disease, schizophrenia, and other disorders in which oxidative stress may contribute to disease progression. However, these trials are hampered by uncertainty about the dose of NAC required to achieve biological effects in human brain. Here we describe an approach to this issue in which mice are used to establish the levels of NAC in cerebrospinal fluid (CSF) required to affect brain neurons. NAC dosing in humans can then be calibrated to achieve these NAC levels in human CSF. The mice were treated with NAC over a range of doses, followed by assessments of neuronal GSH levels and neuronal antioxidant capacity in ex vivo brain slices. Neuronal GSH levels and antioxidant capacity were augmented at NAC doses that produced peak CSF NAC concentrations of >= 50 nM. Oral NAC administration to humans produced CSF concentrations of up to 10 mu M, thus demonstrating that oral NAC administration can surpass the levels required for biological activity in brain. Variations of this approach may similarly facilitate and rationalize drug dosing for other agents targeting central nervous system disorders. C1 [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA. [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Cittolin-Santos, Giordano Fabricio] Univ Fed Rio Grande do Sul, Programa Pos Grad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil. [Cittolin-Santos, Giordano Fabricio] CNPq, Sci Borders, Brasilia, DF, Brazil. RP Swanson, RA (reprint author), San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA.; Swanson, RA (reprint author), Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. EM raymond.swanson@ucsf.edu FU Michael J. Fox Foundation; San Luis Obispo County Community Foundation; Singing Field Foundation; Department of Veterans Affairs FX We thank Drs. Caroline Tanner (University of California San Francisco) and Dean Jones (Emory University) for many helpful discussions. This study was supported by the Michael J. Fox Foundation, the San Luis Obispo County Community Foundation, the Singing Field Foundation, and the Department of Veterans Affairs. NR 39 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1933-7213 EI 1878-7479 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD JAN PY 2016 VL 13 IS 1 BP 217 EP 225 DI 10.1007/s13311-015-0404-4 PG 9 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DB5SU UT WOS:000368574700019 PM 26572666 ER PT J AU Reyes, RC Cittolin-Santos, GF Kim, JE Won, SJ Brennan-Minnella, AM Katz, M Glass, GA Swanson, RA AF Reyes, Reno C. Cittolin-Santos, Giordano Fabricio Kim, Ji-Eun Won, Seok Joon Brennan-Minnella, Angela M. Katz, Maya Glass, Graham A. Swanson, Raymond A. TI Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid (vol 13, pg 217, 2016) SO NEUROTHERAPEUTICS LA English DT Correction C1 [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA. [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Cittolin-Santos, Giordano Fabricio] Univ Fed Rio Grande do Sul, Programa Pos Grad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil. [Cittolin-Santos, Giordano Fabricio] CNPq, Sci Without Borders, Brasilia, DF, Brazil. RP Swanson, RA (reprint author), San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA.; Swanson, RA (reprint author), Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. EM raymond.swanson@ucsf.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1933-7213 EI 1878-7479 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD JAN PY 2016 VL 13 IS 1 BP 239 EP 239 DI 10.1007/s13311-015-0413-3 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DB5SU UT WOS:000368574700023 PM 26659493 ER PT J AU Keller, AC Knaub, LA McClatchey, PM Connon, CA Bouchard, R Miller, MW Geary, KE Walker, LA Klemm, DJ Reusch, JEB AF Keller, Amy C. Knaub, Leslie A. McClatchey, P. Mason Connon, Chelsea A. Bouchard, Ron Miller, Matthew W. Geary, Kate E. Walker, Lori A. Klemm, Dwight J. Reusch, Jane E. B. TI Differential Mitochondrial Adaptation in Primary Vascular Smooth Muscle Cells from a Diabetic Rat Model SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY LA English DT Article ID NITRIC-OXIDE SYNTHASE; OXYGEN SPECIES PRODUCTION; REACTIVE OXYGEN; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; INSULIN-RESISTANCE; SKELETAL-MUSCLE; BIOGENESIS; DYNAMICS; HEART AB Diabetes affects more than 330 million people worldwide and causes elevated cardiovascular disease risk. Mitochondria are critical for vascular function, generate cellular reactive oxygen species (ROS), and are perturbed by diabetes, representing a novel target for therapeutics. We hypothesized that adaptive mitochondrial plasticity in response to nutrient stress would be impaired in diabetes cellular physiology via a nitric oxide synthase- (NOS-) mediated decrease in mitochondrial function. Primary smooth muscle cells (SMCs) from aorta of the nonobese, insulin resistant rat diabetes model Goto-Kakizaki (GK) and the Wistar control rat were exposed to high glucose (25 mM). At baseline, significantly greater nitric oxide evolution, ROS production, and respiratory control ratio (RCR) were observed in GK SMCs. Upon exposure to high glucose, expression of phosphorylated eNOS, uncoupled respiration, and expression of mitochondrial complexes I, II, III, and V were significantly decreased in GK SMCs (p < 0.05). Mitochondrial superoxide increased with high glucose in Wistar SMCs (p < 0.05) with no change in the GK beyond elevated baseline concentrations. Baseline comparisons show persistent metabolic perturbations in a diabetes phenotype. Overall, nutrient stress in GK SMCs caused a persistent decline in eNOS and mitochondrial function and disrupted mitochondrial plasticity, illustrating eNOS and mitochondria as potential therapeutic targets. C1 [Keller, Amy C.; Knaub, Leslie A.; McClatchey, P. Mason; Connon, Chelsea A.; Miller, Matthew W.; Geary, Kate E.; Reusch, Jane E. B.] Univ Colorado, Div Endocrinol, Anschutz Med Campus, Aurora, CO 80045 USA. [Keller, Amy C.; Knaub, Leslie A.; McClatchey, P. Mason; Connon, Chelsea A.; Bouchard, Ron; Miller, Matthew W.; Geary, Kate E.; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA. [McClatchey, P. Mason] Univ Colorado, Dept Bioengn, Aurora, CO 80045 USA. [Walker, Lori A.] Univ Colorado, Dept Cardiol, Aurora, CO 80045 USA. [Klemm, Dwight J.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Reusch, Jane E. B.] Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO 80045 USA. RP Reusch, JEB (reprint author), Univ Colorado, Div Endocrinol, Anschutz Med Campus, Aurora, CO 80045 USA.; Reusch, JEB (reprint author), Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA.; Reusch, JEB (reprint author), Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO 80045 USA. EM jane.reusch@ucdenver.edu FU VA Merit, Denver Research Institute [NIH-5T32HL007171, NIH-5P01HL014985, CCTSI-UL1RR025780]; Center for Women's Health Research; Department of Bioengineering; National Cancer Institute Cancer Center Support Grant [P30CA046934] FX The authors wish to acknowledge Dr. Pete Watson, University of Colorado Anschutz Medical Campus, for his intellectual contributions to this work, Dr. Rebecca Scalzo, University of Colorado Anschutz Medical Campus, for critical input on the paper, and Ms. Molly McCullough for her initial mitochondrial imaging analyses. Sources of funding for this study were provided by VA Merit, Denver Research Institute, NIH-5T32HL007171 (Amy C. Keller), NIH-5P01HL014985 (Amy C. Keller), CCTSI-UL1RR025780 (Jane E. B. Reusch), the Center for Women's Health Research (Jane E. B. Reusch), and the Department of Bioengineering (P. Mason McClatchey). Flow Cytometry is supported through a National Cancer Institute Cancer Center Support Grant (P30CA046934). NR 58 TC 1 Z9 1 U1 1 U2 2 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND SN 1942-0900 EI 1942-0994 J9 OXID MED CELL LONGEV JI Oxidative Med. Cell. Longev. PY 2016 AR 8524267 DI 10.1155/2016/8524267 PG 15 WC Cell Biology SC Cell Biology GA DB9SN UT WOS:000368857300001 ER PT J AU Dale, CL Brown, EG Fisher, M Herman, AB Dowling, AF Hinkley, LB Subramaniam, K Nagarajan, SS Vinogradov, S AF Dale, Corby L. Brown, Ethan G. Fisher, Melissa Herman, Alexander B. Dowling, Anne F. Hinkley, Leighton B. Subramaniam, Karuna Nagarajan, Srikantan S. Vinogradov, Sophia TI Auditory Cortical Plasticity Drives Training-Induced Cognitive Changes in Schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article ID REMEDIATION THERAPY; MAGNETIC-FIELDS; HUMAN-BRAIN; MEMORY; LOCALIZATION; PERFORMANCE; COMPONENT; DYNAMICS; DEFICITS; SPEECH AB Schizophrenia is characterized by dysfunction in basic auditory processing, as well as higher-order operations of verbal learning and executive functions. We investigated whether targeted cognitive training of auditory processing improves neural responses to speech stimuli, and how these changes relate to higher-order cognitive functions. Patients with schizophrenia performed an auditory syllable identification task during magnetoencephalography before and after 50 hours of either targeted cognitive training or a computer games control. Healthy comparison subjects were assessed at baseline and after a 10 week no-contact interval. Prior to training, patients N = 34) showed reduced M100 response in primary auditory cortex relative to healthy participants N = 13). At reassessment, only the targeted cognitive training patient group N = 18) exhibited increased M100 responses. Additionally, this group showed increased induced high gamma band activity within left dorsolateral prefrontal cortex immediately after stimulus presentation, and later in bilateral temporal cortices. Training-related changes in neural activity correlated with changes in executive function scores but not verbal learning and memory. These data suggest that computerized cognitive training that targets auditory and verbal learning operations enhances both sensory responses in auditory cortex as well as engagement of prefrontal regions, as indexed during an auditory processing task with low demands on working memory. This neural circuit enhancement is in turn associated with better executive function but not verbal memory. C1 [Dale, Corby L.; Herman, Alexander B.; Dowling, Anne F.; Hinkley, Leighton B.; Nagarajan, Srikantan S.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Dale, Corby L.; Fisher, Melissa; Subramaniam, Karuna; Vinogradov, Sophia] San Francisco VA Med Ctr, NCIRE, San Francisco, CA USA. [Brown, Ethan G.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Fisher, Melissa; Subramaniam, Karuna; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Herman, Alexander B.; Nagarajan, Srikantan S.] Univ Calif Berkeley, UC San Francisco Grad Program Bioengn, San Francisco, CA USA. RP Dale, CL (reprint author), Biomagnet Imaging Lab, Box 0628,513 Parnassus Ave,S362, San Francisco, CA 94143 USA. EM corby.dale@ucsf.edu FU National Institutes of Health [R01DC004855, R01DC010145, R21NS076171, R01MH068725]; Howard Hughes Medical Institute Research Fellowship program; San Francisco Department of Veterans' Affairs Medical Center FX National Institutes of Health (R01DC004855, R01DC010145, R21NS076171, R01MH068725); Howard Hughes Medical Institute Research Fellowship program (to E.G.B.); San Francisco Department of Veterans' Affairs Medical Center. The cognitive training software used in this study was supplied to the senior author free of charge by Posit Science Corporation. NR 41 TC 6 Z9 6 U1 4 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2016 VL 42 IS 1 BP 220 EP 228 DI 10.1093/schbul/sbv087 PG 9 WC Psychiatry SC Psychiatry GA DB6ML UT WOS:000368629000025 PM 26152668 ER PT J AU Raugi, GJ Nelson, W Miethke, M Boyd, M Markham, C Dougall, B Bratten, D Comer, T AF Raugi, Gregory J. Nelson, William Miethke, Marion Boyd, Marvin Markham, Craig Dougall, Brittany Bratten, Dustin Comer, Tara TI Teledermatology Implementation in a VHA Secondary Treatment Facility Improves Access to Face-to-Face Care SO TELEMEDICINE AND E-HEALTH LA English DT Article DE dermatology; teledermatology; telehealth; telemedicine ID FORWARD TELEDERMATOLOGY; DERMATOLOGY AB Background:Teledermatology is a mainstream modality for delivering care in the Veterans Health Administration, especially in rural areas where access to traditional dermatology care is constrained. Previous investigations of the effect of teledermatology on improving patient access have focused largely on the metrics of visits avoided. However, the effect of teledermatology on improving patient access to face-to-face dermatology has not been well documented. The purpose of this study was to assess the impact of the implementation of store-and-forward teledermatology on access to face-to-face dermatology at the Mann-Grandstaff Spokane Veterans Administration (VA) Medical Center in Spokane, WA.Materials and Methods:Completed requests for dermatology and teledermatology consultation originating from the Spokane main facility from January 1, 2012 through June 30, 2013 were obtained from the Corporate Data Warehouse by SQL query. The numbers of consult requests and wait times for care for overall dermatology, face-to-face dermatology, and teledermatology were compared across the baseline, transition, and intervention periods.Results:Within 6 months of implementation, the total number of requests for dermatology services increased by 40%. Access to face-to-face dermatology care improved, with a decrease in the duration of the interval between consultation request and consultation completion from a mean of 64.2 days to 20.3 days; overall access to dermatology (teledermatology and face-to-face dermatology) care improved with a decrease in the duration of the same from a mean of 61.2 days to 10.3 days.Conclusions:Implementation of a teledermatology program at the Mann-Grandstaff Spokane VA Medical Center improved access to face-to-face dermatology care. C1 [Raugi, Gregory J.; Markham, Craig; Dougall, Brittany; Bratten, Dustin; Comer, Tara] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Raugi, Gregory J.] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98115 USA. [Nelson, William; Miethke, Marion; Boyd, Marvin] Spokane VA Med Ctr, Spokane, WA 99205 USA. RP Raugi, GJ (reprint author), Fed Off Bldg 909 1st Ave,Suite 630, Seattle, WA 98104 USA. EM gregory.raugi@va.gov NR 11 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD JAN 1 PY 2016 VL 22 IS 1 BP 12 EP 17 DI 10.1089/tmj.2015.0036 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DB3YE UT WOS:000368448900003 PM 26393782 ER PT J AU Kwon, I Bharmal, N Choi, S Araiza, D Moore, MR Trejo, L Sarkisian, CA AF Kwon, Ivy Bharmal, Nazleen Choi, Sarah Araiza, Daniel Moore, Mignon R. Trejo, Laura Sarkisian, Catherine A. TI Older Ethnic Minority Women's Perceptions of Stroke Prevention and Walking SO WOMENS HEALTH ISSUES LA English DT Article ID AMERICAN-HEART-ASSOCIATION; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; GENDER-DIFFERENCES; SEX-DIFFERENCES; RISK-FACTORS; HEALTH; EPIDEMIOLOGY; BARRIERS; BELIEFS AB Objective: To inform the development of a tailored behavioral stroke risk reduction intervention for ethnic minority seniors, we sought to explore gender differences in perceptions of stroke prevention and physical activity (walking). Methods: In collaboration with community-based organizations, we conducted 12 mixed-gender focus groups of African American, Latino, Chinese, and Korean seniors aged 60 years and older with a history of hypertension (89 women and 42 men). Transcripts were coded and recurring topics compared by gender. Results: Women expressed beliefs that differed from men in 4 topic areas: 1) stroke-related interest, 2) barriers to walking, 3) facilitators to walking, and 4) health behavior change attitudes. Compared with men, women were more interested in their role in response to a stroke and post-stroke care. Women described walking as an acceptable form of exercise, but cited neighborhood safety and pain as walking barriers. Fear of nursing home placement and weight loss were identified as walking facilitators. Women were more prone than men to express active/control attitudes toward health behavior change. Conclusions: Older ethnic minority women, a high-risk population for stroke, may be more receptive to behavioral interventions that address the gender-specific themes identified by this study. Published by Elsevier Inc. C1 [Kwon, Ivy; Araiza, Daniel; Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Bharmal, Nazleen] RAND Corp, Hlth Unit, Arlington, VA USA. [Choi, Sarah] Univ Calif Irvine, Coll Hlth Sci, Dept Nursing Sci, Irvine, CA USA. [Moore, Mignon R.] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90095 USA. [Trejo, Laura] City Los Angeles Dept Aging, Los Angeles, CA USA. [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. RP Sarkisian, CA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, 10945 Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM csarkisian@mednet.ucla.edu OI Kwon, Ivy/0000-0003-4160-6546 FU National Institute of Neurological Disorders and Stroke [1U54NS081764]; National Institutes of Health Office of Research on Women's Health [1U54NS081764-03S1]; National Institute on Aging [1K24AG047899-01]; National Institute on Aging UCLA Older Americans Independence Center [P30AG028747]; National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III [2P30AG021684] FX This work was supported by the National Institute of Neurological Disorders and Stroke [1U54NS081764]; National Institutes of Health Office of Research on Women's Health [1U54NS081764-03S1]; and the National Institute on Aging [1K24AG047899-01]. Additional sources of support for this project include the National Institute on Aging UCLA Older Americans Independence Center [P30AG028747] and National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III [2P30AG021684]. No competing financial interests exist. NR 41 TC 0 Z9 0 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JAN-FEB PY 2016 VL 26 IS 1 BP 80 EP 86 DI 10.1016/j.whi.2015.08.003 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DB1IS UT WOS:000368262500017 PM 26411494 ER PT J AU Blosnich, JR Nasuti, LJ Mays, VM Cochran, SD AF Blosnich, John R. Nasuti, Laura J. Mays, Vickie M. Cochran, Susan D. TI Suicidality and Sexual Orientation: Characteristics of Symptom Severity, Disclosure, and Timing Across the Life Course SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE mental disorders; gay; lesbian; bisexual; sexual minority; suicide ID NATIONAL COMORBIDITY SURVEY; WORLD-HEALTH-ORGANIZATION; MENTAL-HEALTH; RISK-FACTORS; PSYCHOLOGICAL DISTRESS; REPRESENTATIVE SAMPLE; BISEXUAL POPULATIONS; GENERAL-POPULATION; UNITED-STATES; SUBSTANCE USE AB This investigation explored suicide-related characteristics and help-seeking behavior by sexual orientation. Population-based data are from the California Quality of Life Surveys, which included 1,478 sexual minority (lesbian, gay, bisexual, and homosexually experienced individuals) and 3,465 heterosexual individuals. Bisexual women had a nearly six-fold increased risk of lifetime suicide attempts than heterosexual women (RR = 5.88, 95%CI: 3.89-8.90), and homosexually experienced men had almost 7 times higher risk of lifetime suicide attempts than heterosexual men (RR = 6.93, 95%CI: 3.65-13.15). Sexual minority men and women were more likely than heterosexual men and women to have disclosed suicide attempts to a medical professional (RR = 1.48 and RR = 1.44, respectively). Among persons who ever attempted suicide, sexual minority women had a younger age of index attempt than heterosexual women (15.9 vs. 19.6 years of age, respectively). Healthcare professionals should be aware of suicidal risk heterogeneity among sexual minority individuals, including vulnerable points of risk and evidenced-based treatments. C1 [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA. [Nasuti, Laura J.; Cochran, Susan D.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Mays, Vickie M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. [Mays, Vickie M.; Cochran, Susan D.] Univ Calif Los Angeles, Ctr Bridging Res Innovat Training & Educ Minor Hl, Los Angeles, CA 90024 USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C 151-CU,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov FU NIDA NIH HHS [R01 DA015539, R01 DA020826]; NIMHD NIH HHS [P60 MD000508]; VA [VA999999] NR 62 TC 0 Z9 0 U1 1 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PD JAN PY 2016 VL 86 IS 1 BP 69 EP 78 DI 10.1037/ort0000112 PG 10 WC Psychiatry; Social Work SC Psychiatry; Social Work GA DA9HQ UT WOS:000368120000007 PM 26752446 ER PT J AU Lawson, EH Louie, R Zingmond, DS Sacks, GD Brook, RH Hall, BL Ko, CY AF Lawson, Elise H. Louie, Rachel Zingmond, David S. Sacks, Greg D. Brook, Robert H. Hall, Bruce Lee Ko, Clifford Y. TI Using Both Clinical Registry and Administrative Claims Data to Measure Risk-adjusted Surgical Outcomes SO ANNALS OF SURGERY LA English DT Article DE ACS-NSQIP; administrative claims; clinical registry; quality measure; surgery ID QUALITY IMPROVEMENT PROGRAM; POSTOPERATIVE ADVERSE EVENTS; AMERICAN-COLLEGE; VALIDITY; CARE AB Objective:To examine the validity of hybrid quality measures that use both clinical registry and administrative claims data, capitalizing on the strengths of each data source.Background:Previous studies demonstrate substantial disagreement between clinical registry and administrative claims data on the occurrence of postoperative complications. Clinical data have greater validity than claims data for quality measurement but can be burdensome for hospitals to collect.Methods:American College of Surgeons National Surgical Quality Improvement Program records were linked to Medicare inpatient claims (2005-2008). National Quality Forum-endorsed risk-adjusted measures of 30-day postoperative complications or death assessed hospital quality for patients undergoing colectomy, lower extremity bypass, or all surgical procedures. Measures use hierarchical multivariable logistic regression to identify statistical outliers. Measures were applied using clinical data, claims data, or a hybrid of both data sources. Kappa statistics assessed agreement on determinations of hospital quality.Results:A total of 111,984 patients participated from 206 hospitals. Agreement on hospital quality between clinical and claims data was poor. Hybrid models using claims data to risk-adjust complications identified by clinical data had moderate agreement with all clinical data models, whereas hybrid models using clinical data to risk-adjust complications identified by claims data had routinely poor agreement with all clinical data models.Conclusions:Assessments of hospital quality differ substantially when using clinical registry versus administrative claims data. A hybrid approach using claims data for risk adjustment and clinical data for complications may be a valid alternative with lower data collection burden. For quality measures focused on postoperative complications to be meaningful, such policies should require, at a minimum, collection of clinical outcomes data. C1 [Lawson, Elise H.; Sacks, Greg D.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surgeons, Div Res & Optimal Patient Care, Chicago, IL USA. [Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Louie, Rachel; Zingmond, David S.; Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce Lee] BJC Healthcare, St Louis, MO USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons (ACS) through the Robert Wood Johnson Foundation Clinical Scholars Program; Centers for Medicare & Medicaid Services FX E.H.L.'s time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons (ACS) through the Robert Wood Johnson Foundation Clinical Scholars Program. R.L., D.S.Z., and B.L.H. are consultants for the ACS, and C.Y.K. is staff at the ACS. Supported by a contract from the Centers for Medicare & Medicaid Services. The remaining authors declare no conflicts of interest. NR 17 TC 4 Z9 4 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JAN PY 2016 VL 263 IS 1 BP 50 EP 57 DI 10.1097/SLA.0000000000001031 PG 8 WC Surgery SC Surgery GA DA7SN UT WOS:000368004500011 PM 25405553 ER PT J AU Dedert, EA Resick, PA McFall, ME Dennis, PA Olsen, M Beckham, JC AF Dedert, Eric A. Resick, Patricia A. McFall, Miles E. Dennis, Paul A. Olsen, Maren Beckham, Jean C. TI Pilot Cases of Combined Cognitive Processing Therapy and Smoking Cessation for Smokers With Posttraumatic Stress Disorder SO BEHAVIOR THERAPY LA English DT Article DE tobacco use cessation; posttraumatic stress disorder; cognitive therapy; comorbidity; psychotherapy ID CIGARETTE-SMOKING; CONTROLLED-TRIAL; BECK DEPRESSION; CLINICAL-TRIAL; VETERANS; PTSD; INVENTORY; SURVIVORS; SYMPTOMS; OUTCOMES AB Posttraumatic stress disorder (PTSD) and smoking are often comorbid, and both problems are in need of improved access to evidence-based treatment. The combined approach could address two high-priority problems and increase patient access to both treatments, but research is needed to determine whether this is feasible and has promise for addressing both PTSD and smoking. We collected data from 15 test cases that received a treatment combining two evidence-based treatments: cognitive processing therapy cognitive version (CPT-C) for PTSD and integrated care for smoking cessation (ICSC). We explored two combined treatment protocols including a brief (six-session) CPT-C with five follow-up in-person sessions focused on smoking cessation (n = 9) and a full 12-session CPT-C protocol with ICSC (n = 6). The combined interventions were feasible and acceptable to patients with PTSD making a quit attempt. Initial positive benefits of the combined treatments were observed. The six-session dose of CPT-C and smoking cessation resulted in 6-month bioverified smoking abstinence in two of nine participants, with clinically meaningful PTSD symptom reduction in three of nine participants. In the second cohort (full CPT-C and smoking treatment), both smoking and PTSD symptoms were improved, with three of six participants abstinent from smoking and four of six participants reporting clinically meaningful reduction in PTSD symptoms. Results suggested that individuals with PTSD who smoke are willing to engage in concurrent treatment of these problems and that combined treatment is feasible. C1 [Dedert, Eric A.; Dennis, Paul A.; Beckham, Jean C.] Durham Vet Affairs Med Ctr, 508 Fulton St,Bldg 16,2nd Floor, Durham, NC 27705 USA. [Dedert, Eric A.; Beckham, Jean C.] Vet Affairs Midatlantic Reg Mental Illness Res Ed, Durham, NC USA. [Dedert, Eric A.; Resick, Patricia A.; Dennis, Paul A.; Beckham, Jean C.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [McFall, Miles E.] VA Puget Sound Hlth Care Syst, Seattle Div, New York, NY USA. [McFall, Miles E.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Olsen, Maren] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Olsen, Maren] Duke Univ, Sch Med, Durham, NC 27706 USA. RP Dedert, EA (reprint author), Durham Vet Affairs Med Ctr, 508 Fulton St,Bldg 16,2nd Floor, Durham, NC 27705 USA. EM eric.dedert@duke.edu FU CSRAMP;D Research AMP; Development Service of the VA Office of Research and Development [1IK2CX000718] FX The authors thank all of the veterans who volunteered to participate in this study. The views expressed in this paper are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. The project described was supported by Award Number 1IK2CX000718 to Dr. Dedert from the CSR&D Research & Development Service of the VA Office of Research and Development. NR 39 TC 0 Z9 0 U1 4 U2 7 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD JAN PY 2016 VL 47 IS 1 BP 54 EP 65 PG 12 WC Psychology, Clinical SC Psychology GA DB2CF UT WOS:000368315200005 PM 26763497 ER PT J AU Eidelman, P Talbot, L Ivers, H Belanger, L Morin, CM Harvey, AG AF Eidelman, Polina Talbot, Lisa Ivers, Hans Belanger, Lynda Morin, Charles M. Harvey, Allison G. TI Change in Dysfunctional Beliefs About Sleep in Behavior Therapy, Cognitive Therapy, and Cognitive-Behavioral Therapy for Insomnia SO BEHAVIOR THERAPY LA English DT Article DE insomnia; beliefs; sleep; cognitive-behavioral therapy; behavioral experiments ID RANDOMIZED CONTROLLED-TRIAL; SOCIAL-ADJUSTMENT SCALE; PERSISTENT INSOMNIA; COMPONENT ANALYSIS; ANXIETY DISORDER; SEVERITY INDEX; OLDER-ADULTS; ATTITUDES; EFFICACY; WORK AB As part of a larger randomized controlled trial, 188 participants were randomized to behavior therapy (BT), cognitive therapy (CT), or cognitive-behavioral therapy (CBT) for insomnia. The aims of this study were threefold: (a) to determine whether change in dysfunctional beliefs about sleep was related to change in sleep, insomnia symptoms, and impairment following treatment; (b) to determine whether BT, CT, and CBT differ in their effects on dysfunctional beliefs; and (c) to determine whether the treatments differ in their effects on particular kinds of dysfunctional beliefs. Beliefs, sleep, insomnia symptoms, and sleep-related psychosocial impairment were assessed at pretreatment, posttreatment, and 6- and 12-month follow-up. Greater change in dysfunctional beliefs occurring over the course of BT, CT, or CBT was associated with greater improvement in insomnia symptoms and impairment at posttreatment and both follow-ups. All groups experienced a significant decrease in dysfunctional beliefs during treatment, which were sustained through 6- and 12-month follow-up. Compared with the BT group, a greater proportion of participants in the CT and/or CBT groups endorsed dysfunctional beliefs below a level considered clinically significant at posttreatment and 12-month follow-up. The results demonstrate the importance of targeting dysfunctional beliefs in insomnia treatment, suggest that beliefs may be significantly modified with BT alone, and indicate that cognitive interventions may be particularly powerful in enhancing belief change. C1 [Eidelman, Polina] Cognit Behav Therapy & Sci Ctr, Oakland, CA USA. [Talbot, Lisa] San Francisco VA Med Ctr, San Francisco, CA USA. [Ivers, Hans; Belanger, Lynda; Morin, Charles M.] Univ Laval, Quebec City, PQ G1K 7P4, Canada. [Harvey, Allison G.] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Harvey, AG (reprint author), Univ Calif Berkeley, Dept Psychol, 2205 Tolman Hall 1650, Berkeley, CA 94720 USA. EM aharvey@berkeley.edu FU National Institute of Mental Health [RO1MH079188] FX This project was supported by National Institute of Mental Health Grant RO1MH079188 (C.M.M., A.G.H.); clinical trial NCT 00869934. NR 51 TC 1 Z9 1 U1 4 U2 18 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD JAN PY 2016 VL 47 IS 1 BP 102 EP 115 PG 14 WC Psychology, Clinical SC Psychology GA DB2CF UT WOS:000368315200009 PM 26763501 ER PT J AU Chhatbar, PY Ramakrishnan, V Kautz, S George, MS Adams, RJ Feng, WW AF Chhatbar, Pratik Y. Ramakrishnan, Viswanathan Kautz, Steven George, Mark S. Adams, Robert J. Feng, Wuwei TI Transcranial Direct Current Stimulation Post-Stroke Upper Extremity Motor Recovery Studies Exhibit a Dose-Response Relationship SO BRAIN STIMULATION LA English DT Article DE Stroke; Transcranial direct current stimulation; tDCS; Motor recovery; Dose-response relationship; Meta-analysis; Meta-regression; Hedge's g ID INTERHEMISPHERIC INHIBITION; SUBACUTE STROKE; TDCS; METAANALYSIS; THERAPY; CORTEX; BRAIN; EXCITABILITY; MODULATION; PHASE AB Background and purpose: Transcranial direct current stimulation (tDCS) has shown mixed results in poststroke motor recovery, possibly because of tDCS dose differences. The purpose of this meta-analysis was to explore whether the outcome has a dose-response relationship with various dose-related parameters. Methods: The literature was searched for double-blind, randomized, sham-controlled clinical trials investigating the role of tDCS (= 5 sessions) in post-stroke motor recovery as measured by the Fugl-Meyer Upper Extremity (FM-UE) scale. Improvements in FM-UE scores were compared between active and sham groups by calculating standardized mean differences (Hedge's g) to derive a summary effect size. Inversevariance- weighted linear meta-regression across individual studies was performed between various tDCS parameters and Hedge's g to test for dose-response relationships. Results: Eight studies with total of 213 stroke subjects were included. Summary Hedge's g was statistically significant in favor of the active group (Hedge's g = 0.61, p = 0.02) suggesting moderate effect. Specifically, studies that used bihemispheric tDCS montage (Hedge's g = 1.30, p = 0.08) or that recruited chronic stroke patients (Hedge's g = 1.23, p = 0.02) showed large improvements in the active group. A positive dose-response relationship was found with current density (p = 0.017) and charge density (p = 0.004), but not with current amplitude. Moreover, a negative dose-response relationship was found with electrode size (p < 0.001, smaller electrodes were more effective). Conclusions: Our meta-analysis and meta-regression results suggest superior motor recovery in the active group when compared to the sham group and dose-response relationships relating to electrode size, charge density and current density. These results need to be confirmed in future dedicated studies. (C) 2015 Elsevier Inc. All rights reserved. C1 [Chhatbar, Pratik Y.; Adams, Robert J.; Feng, Wuwei] Med Univ S Carolina, Coll Med, Dept Neurol, Charleston, SC 29425 USA. [Ramakrishnan, Viswanathan] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Kautz, Steven; Feng, Wuwei] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [George, Mark S.] Med Univ S Carolina, Coll Med, Brain Stimulat Lab, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Feng, WW (reprint author), Med Univ S Carolina, Coll Med, Dept Neurol, Charleston, SC 29425 USA. EM feng@musc.edu FU National Institute of General Medical Sciences of the National Institutes of Health [P20GM109040]; American Heart Association [14SDG1829003]; Rehabilitation Research and Development Service of the VA FX All of authors are supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM109040. Dr. Feng is also supported by American Heart Association (14SDG1829003). Dr. Kautz is also funded by the Rehabilitation Research and Development Service of the VA. NR 46 TC 12 Z9 12 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD JAN-FEB PY 2016 VL 9 IS 1 BP 16 EP 26 DI 10.1016/j.brs.2015.09.002 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA8XF UT WOS:000368089500003 PM 26433609 ER PT J AU Schlosser, RJ Carroll, WW Soler, ZM Pasquini, WN Mulligan, JK AF Schlosser, Rodney J. Carroll, William W. Soler, Zachary M. Pasquini, Whitney N. Mulligan, Jennifer K. TI Reduced sinonasal levels of 1-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE vitamin D; sinusitis; 1-alpha-hydroxylase; nasal polyp; allergic fungal rhinosinusitis ID VITAMIN-D DEFICIENCY; ALLERGIC FUNGAL RHINOSINUSITIS; RANDOMIZED CLINICAL-TRIAL; 25-HYDROXYVITAMIN D; D SUPPLEMENTATION; D-METABOLISM; EXTRARENAL EXPRESSION; DENDRITIC CELLS; SINUS MUCOSA; ASTHMA AB BackgroundPatients with chronic rhinosinusitis with nasal polyps (CRSwNP) have deficiencies in circulating and sinonasal levels of the inactive form of vitamin D3, 25-hydroxycholecalciferol (25VD3). Moreover, CRSwNP patients have reduced epithelial cell-specific expression of 1-hydroxylase; the enzyme responsible for the conversion of 25VD3 to its metabolically active form, 1,25-dihydroxyvitamin D3 (1,25VD3). The objective of this work was to determine the impact of sinonasal 1-hydroxylase levels combined from all cellular sources on subjective disease severity and to identify variables influencing its expression. MethodsBlood and sinus tissue explants were collected at the time of surgery from control, chronic rhinosinusitis without nasal polyps (CRSsNP), CRSwNP, and allergic fungal rhinosinusitis (AFRS) patients. 1-Hydroxylase was measured by immunostaining with flow cytometric analysis. Subjective disease severity was measured by the 22-item Sino-Nasal Outcomes Test (SNOT-22). 1,25VD3 and 25VD3 were measured by enzyme-linked immunosorbent assay (ELISA). ResultsPatients with CRSwNP or AFRS have reduced 1-hydroxylase and 1,25VD3 compared to controls or CRSsNP. Circulating 1,25VD3 levels were the same among all groups. No differences in sinonasal 1-hydroxylase or 1,25VD3 were found between CRSwNP and AFRS. Gender, age, race, atopy, and systemic 25VD3 had no impact on sinonasal 1-hydroxylase levels in any group. However, CRSwNP patients with asthma had higher 1-hydroxylase than those without asthma. Total 1-hydroxylase levels inversely correlated with SNOT-22 in CRSwNP, but not CRSsNP. ConclusionPatients with CRSwNP and AFRS both have reduced sinonasal 1-hydroxylase and 1,25VD3 compared to controls or CRSsNP. Reductions in intracellular 1-hydroxylase combined from all sinonasal cell types were associated with more severe subjective disease severity in CRSwNP. C1 [Schlosser, Rodney J.; Carroll, William W.; Soler, Zachary M.; Pasquini, Whitney N.; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU Flight Attendant Medical Research Institute [113039, 092401]; Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award [CSRD 1I01CX000377-01A2] FX Funding sources for the study: Flight Attendant Medical Research Institute (113039 to R.J.S., 092401 to J.K.M.); Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (CSRD 1I01CX000377-01A2 to R.J.S.). NR 51 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JAN PY 2016 VL 6 IS 1 BP 58 EP 65 DI 10.1002/alr.21576 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA DA7TU UT WOS:000368007900009 PM 26575398 ER PT J AU Lee, LY Harberg, C Matkowskyj, KA Cook, S Roenneburg, D Werner, S Johnson, J Foley, DP AF Lee, Lung-Yi Harberg, Calvin Matkowskyj, Kristina A. Cook, Shelly Roenneburg, Drew Werner, Sabine Johnson, Jeffrey Foley, David P. TI Overactivation of the Nuclear Factor (Erythroid-Derived 2)-Like 2-Antioxidant Response Element Pathway in Hepatocytes Decreases Hepatic Ischemia/Reperfusion Injury in Mice SO LIVER TRANSPLANTATION LA English DT Article ID ISCHEMIA-REPERFUSION INJURY; LIVER ISCHEMIA; REACTIVE OXYGEN; RISK-FACTORS; APOPTOSIS; NRF2; ACTIVATION; PROTECTS; NECROSIS; RATS AB Hepatic ischemia/reperfusion injury (IRI) is a critical component of hepatic surgery. Oxidative stress has long been implicated as a key player in IRI. In this study, we examine the cell-specific role of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-antioxidant response element pathway in warm hepatic IRI. Nrf2 knockout (KO) and wild-type (WT) animals and novel transgenic mice expressing a constitutively active nuclear factor (erythroid-derived 2)-like 2 (caNrf2) mutant in hepatocytes (AlbCre+/caNrf2+) and their littermate controls underwent partial hepatic ischemia or sham surgery. The animals were killed 6 hours after reperfusion, and their serum and tissue were collected for analysis. As compared to WT animals after ischemia/reperfusion (IR), Nrf2 KO mice had increased hepatocellular injury with increased serum alanine aminotransferase and aspartate aminotransferase, Suzuki score, apoptosis, an increased inflammatory infiltrate, and enhanced inflammatory cytokine expression. On the other hand, AlbCre+/caNrf2+ that underwent IR had significantly reduced serum transaminases, less necrosis on histology, and a less pronounced inflammatory infiltrate and inflammatory cytokine expression as compared to the littermate controls. However, there were no differences in apoptosis. Taken together, Nrf2 plays a critical role in our murine model of warm hepatic IRI, with Nrf2 deficiency exacerbating hepatic IRI and hepatocyte-specific Nrf2 overactivation providing protection against warm hepatic IRI. (C) 2015 AASLD. C1 [Lee, Lung-Yi; Harberg, Calvin; Roenneburg, Drew; Foley, David P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Matkowskyj, Kristina A.; Cook, Shelly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Div Pharmaceut Sci, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Ctr Neurosci, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Waisman Ctr, Madison, WI 53792 USA. [Matkowskyj, Kristina A.] US Dept Vet Affairs, William S Middleton Mem Hosp, Pathol Serv, Madison, WI USA. [Foley, David P.] US Dept Vet Affairs, William S Middleton Mem Hosp, Surg Serv, Madison, WI USA. [Werner, Sabine] Swiss Fed Inst Technol, Inst Mol Hlth Sci, Dept Biol, Zurich, Switzerland. RP Foley, DP (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, 600 Highland Ave,Clin Sci Ctr H4-766, Madison, WI 53792 USA. EM foley@surgery.wisc.edu FU Clinical and Translational Science Award program through the National Institutes of Health Center for Advancing Translational Sciences [UL1TR000427]; American Society of Transplant Surgeons-Pfizer Mid-Level Faculty Award; National Institutes of Health [T32 CA0900217]; Swiss National Science Foundation [310030_132884] FX The project was supported by the Clinical and Translational Science Award program through the National Institutes of Health Center for Advancing Translational Sciences (UL1TR000427) for David P. Foley. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The project was also supported by the American Society of Transplant Surgeons-Pfizer Mid-Level Faculty Award for David P. Foley, National Institutes of Health (T32 CA0900217) for Lung-Yi Lee, and the Swiss National Science Foundation (310030_132884) for Sabine Werner. NR 33 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JAN PY 2016 VL 22 IS 1 BP 91 EP 102 DI 10.1002/lt.24303 PG 12 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA DA9PA UT WOS:000368140500011 PM 26285140 ER PT J AU Williams, GR Bethard, JR Berkaw, MN Nagel, AK Luttrell, LM Ball, LE AF Williams, Grace R. Bethard, Jennifer R. Berkaw, Mary N. Nagel, Alexis K. Luttrell, Louis M. Ball, Lauren E. TI Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics SO METHODS LA English DT Article DE G protein-coupled receptor; Mass spectrometry; Parathyroid hormone receptor; Phosphoproteomics; Osteoblast ID REVERSED-PHASE CHROMATOGRAPHY; IN-VIVO; QUANTITATIVE PROTEOMICS; MASS-SPECTROMETRY; POSTTRANSLATIONAL MODIFICATIONS; PHOSPHORYLATION NETWORKS; FRACTION CONCATENATION; FUNCTIONAL SELECTIVITY; SITE LOCALIZATION; MC3T3-E1 CELLS AB The type 1 parathyroid hormone receptor (PTH1R) is a key regulator of calcium homeostasis and bone turnover. Here, we employed SILAC-based quantitative mass spectrometry and bioinformatic pathways analysis to examine global changes in protein phosphorylation following short-term stimulation of endogenously expressed PTH1R in osteoblastic cells in vitro. Following 5 min exposure to the conventional agonist, PTH(1-34), we detected significant changes in the phosphorylation of 224 distinct proteins. Kinase substrate motif enrichment demonstrated that consensus motifs for PKA and CAMK2 were the most heavily upregulated within the phosphoproteome, while consensus motifs for mitogen-activated protein kinases were strongly downregulated. Signaling pathways analysis identified ERK1/2 and ART as important nodal kinases in the downstream network and revealed strong regulation of small GTPases involved in cytoskeletal rearrangement, cell motility, and focal adhesion complex signaling. Our data illustrate the utility of quantitative mass spectrometry in measuring dynamic changes in protein phosphorylation following GPCR activation. (C) 2015 Elsevier Inc. All rights reserved. C1 [Williams, Grace R.; Bethard, Jennifer R.; Berkaw, Mary N.; Nagel, Alexis K.; Ball, Lauren E.] Med Univ S Carolina, Dept Mol & Cellular Pharmacol, Charleston, SC 29425 USA. [Nagel, Alexis K.; Ball, Lauren E.] Med Univ S Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Ball, LE (reprint author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,BSB 358,MSC 509, Charleston, SC 29425 USA. EM ballle@musc.edu OI Ball, Lauren/0000-0001-6780-1679 FU University Research Resource Facility [P20 GM103542]; [R01 DE020925]; [S10 D010731]; [R01 DK055524]; [R01 GM095497] FX The authors thank Susana Comte-Walters, Michael Schilling and Benjamin Neely for assistance. Mass spectrometry was performed in the MUSC Mass Spectrometry Facility, a University Research Resource Facility funded through the Office of the Provost and the SC COBRE in Oxidants, Redox Balance and Signaling (P20 GM103542). This work was supported by grants R01 DE020925 (LEB), S10 D010731 (LEB), R01 DK055524 (LML) and R01 GM095497 (LML). NR 94 TC 1 Z9 1 U1 4 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 EI 1095-9130 J9 METHODS JI Methods PD JAN 1 PY 2016 VL 92 BP 36 EP 50 DI 10.1016/j.ymeth.2015.06.022 PG 15 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DB0QL UT WOS:000368212500005 PM 26160508 ER PT J AU Bilousova, T Miller, CA Poon, WW Vinters, HV Corrada, M Kawas, C Hayden, EY Tepow, DB Glabe, C Albay, R Cole, GM Teng, E Gylys, KH AF Bilousova, Tina Miller, Carol. A. Poon, Wayne W. Vinters, Harry V. Corrada, Maria Kawas, Claudia Hayden, Eric Y. Tepow, David B. Glabe, Charles Albay, Ricardo, III Cole, Gregory M. Teng, Edmond Gylys, Karen H. TI Synaptic Amyloid-beta Oligomers Precede p-Tau and Differentiate High Pathology Control Cases SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID ENDOSOMAL-LYSOSOMAL SYSTEM; ALZHEIMERS-DISEASE CORTEX; INTRANEURONAL A-BETA; TRANSGENIC RAT MODEL; IN-VIVO; MOUSE MODEL; NEUROFIBRILLARY TANGLES; COGNITIVE IMPAIRMENT; SOLUBLE OLIGOMERS; SENILE PLAQUES AB Amyloid-beta (A beta) and hyperphosphorylated tau (p-tau) aggregates form the two discrete pathologies of Alzheimer disease (AD), and oligomeric assemblies of each protein are localized to synapses. To determine the sequence by which pathology appears in synapses, A beta and p-tau were quantified across AD disease stages in parietal cortex. Nondemented cases with high Levels of AD-related pathology were included to determine factors that confer protection from clinical symptoms. Flow cytometric analysis of synaptosome preparations was used to quantify A beta and p-tau in Large populations of individual synaptic terminals. Soluble A beta oligomers were assayed by a single antibody sandwich enzyme-Linked immunosorbent assay. Total in situ A beta was elevated in patients with early- and late-stage AD dementia, but not in high pathology nondemented controls compared with age-matched normal controls. However, soluble A beta oligomers were highest in early AD synapses, and this assay distinguished early AD cases from high pathology controls. Overall, synapse-associated p-tau did not increase until Late-stage disease in human and transgenic rat cortex, and p-tau was elevated in individual A beta-positive synaptosomes in early AD. These results suggest that soluble oligomers in surviving neocortical synaptic terminals are associated with dementia onset and suggest an amyloid cascade hypothesis in which oligomeric All drives phosphorylated tau accumulation and synaptic spread. These results indicate that antiamyloid therapies will be less effective once p-tau pathology is developed. C1 [Bilousova, Tina; Gylys, Karen H.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Bilousova, Tina; Hayden, Eric Y.; Tepow, David B.; Cole, Gregory M.; Teng, Edmond; Gylys, Karen H.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Res, Los Angeles, CA USA. [Vinters, Harry V.; Hayden, Eric Y.; Tepow, David B.; Cole, Gregory M.; Teng, Edmond] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Vinters, Harry V.] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA. [Cole, Gregory M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Miller, Carol. A.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Miller, Carol. A.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Miller, Carol. A.] Univ So Calif, Keck Sch Med, Program Neurosci, Los Angeles, CA 90033 USA. [Poon, Wayne W.; Corrada, Maria; Kawas, Claudia] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA. [Corrada, Maria; Kawas, Claudia] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA. [Kawas, Claudia] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92717 USA. [Glabe, Charles; Albay, Ricardo, III] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA. [Cole, Gregory M.; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Gylys, KH (reprint author), Box 956919,Factor Bldg, Los Angeles, CA 90095 USA. EM kgylys@sonnet.ucla.edu FU NIH [AG27465, NS038328, AG041295, CA16042, AI 28697]; National Institute on Aging (NIA) [AG18879, AG34628]; NIA [R01AG21055]; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers; University of California Los Angeles Clinical and Translational Science Institute (UCLA CTSI) grant [UL1TR000124]; UCLA Older Americans Independence Center grant [P30 AG028748]; Daljit S. and Elaine Sarkaria Chair in Diagnostic Medicine; AD Research Center Neuropathology Cores NIA grants [P50 AG05142, P50 AG16970, P50 AG16573] FX Supported by NIH grants AG27465 (K.H.G.), NS038328 (D.B.T.), and AG041295 (D.B.T.); National Institute on Aging (NIA) grants AG18879 (C.A.M.) and AG34628 (jointly sponsored by the NIA, American Federation for Aging Research, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation, and an anonymous donor; to E.T.); the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers (D.B.T.); University of California Los Angeles Clinical and Translational Science Institute (UCLA CTSI) grant UL1TR000124 (U.Y.H.); UCLA Older Americans Independence Center grant P30 AG028748 (E.Y.H.); and the Daljit S. and Elaine Sarkaria Chair in Diagnostic Medicine (H.V.V.). Tissue was obtained from the AD Research Center Neuropathology Cores NIA grants P50 AG05142 (USC), P50 AG16970 (UCLA), and P50 AG16573 (UC Irvine). Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for AIDS Research Flow Cytometry Core Facility, supported by NIH grants CA16042 and AI 28697 and by the JCCC, the UCLA AIDS Institute, the David Geffen School of Medicine, and the Chancellor's Office at UCLA. Diagnosis, characterization, and follow-up of >90 study subjects was supported by NIA grant R01AG21055. NR 88 TC 10 Z9 10 U1 5 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 2016 VL 186 IS 1 BP 185 EP 198 DI 10.1016/j.ajpath.2015.09.018 PG 14 WC Pathology SC Pathology GA DA3NV UT WOS:000367705300018 PM 26718979 ER PT J AU Brady, KT McCauley, JL Back, SE AF Brady, Kathleen T. McCauley, Jenna L. Back, Sudie E. TI Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; BUPRENORPHINE-NALOXONE TREATMENT; DRUG-ABUSE; MAINTENANCE TREATMENT; ADDICTION TREATMENT; SCREENING-TEST; USE DISORDERS; CHRONIC PAIN; RISK TOOL; OVERDOSE AB Objective: Prescription opioid abuse and dependence have escalated rapidly in the United States over the past 20 years, leading to high rates of overdose deaths and a dramatic increase in the number of people seeking treatment for opioid dependence. The authors review the scope of the abuse and overdose epidemic, prescription practices, and the assessment, treatment, and prevention of prescription opioid misuse and dependence. Method: The authors provide an overview of the literature from 2006 to the present, with the twin goals of highlighting advances in prevention and treatment and identifying remaining gaps in the science. Results: A number of policy and educational initiatives at the state and federal government level have been undertaken in the past 5 years to help providers and consumers, respectively, prescribe and use opioids more responsibly. Initial reports suggest that diversion and abuse levels have begun to plateau, likely as a result of these initiatives. While there is a large body of research suggesting that opioid substitution coupled with psychosocial interventions is the best treatment option for heroin dependence, there is limited research focusing specifically on the treatment of prescription opioid dependence. In particular, the treatment of chronic pain in individuals with prescription opioid use disorders is underexplored. Conclusions: While policy and educational initiatives appear to be effective in decreasing prescription opioid abuse and misuse, research focusing on the development and evaluation of treatments specific to prescription opioid dependence and its common comorbidities (e.g., chronic pain, depression) is critically needed. C1 [Brady, Kathleen T.] Med Univ S Carolina, Addict Sci Div, Inst Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Brady, KT (reprint author), Med Univ S Carolina, Addict Sci Div, Inst Psychiat & Behav Sci, Charleston, SC 29425 USA. EM bradyk@musc.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [2 P50 DA016511]; NIDA [5 U10 DA013727, 1 K23 DA036566] FX Supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 2 P50 DA016511 and NIDA grants 5 U10 DA013727 and 1 K23 DA036566. NR 59 TC 14 Z9 14 U1 14 U2 52 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JAN PY 2016 VL 173 IS 1 BP 18 EP 26 DI 10.1176/appi.ajp.2015.15020262 PG 9 WC Psychiatry SC Psychiatry GA DA2QK UT WOS:000367640700008 PM 26337039 ER PT J AU England, BR Sayles, H Michaud, K Caplan, L Davis, LA Cannon, GW Sauer, BC Solow, EB Reimold, AM Kerr, GS Schwab, P Baker, JF Mikuls, TR AF England, Bryant R. Sayles, Harlan Michaud, Kaleb Caplan, Liron Davis, Lisa A. Cannon, Grant W. Sauer, Brian C. Solow, Elizabeth B. Reimold, Andreas M. Kerr, Gail S. Schwab, Pascale Baker, Josh F. Mikuls, Ted R. TI Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID DISEASE-ACTIVITY; INFLAMMATORY POLYARTHRITIS; CARDIOVASCULAR-DISEASE; LUNG-DISEASE; POPULATION; ASSOCIATION; CANCER; COHORT; INDEX; METHOTREXATE AB Objective. There has been limited investigation into cause-specific mortality and the associated risk factors in men with rheumatoid arthritis (RA). We investigated all-cause and cause-specific mortality in men with RA, examining determinants of survival. Methods. Men from a longitudinal RA registry were followed from enrollment until death or through 2013. Vital status and cause of death were determined using the National Death Index. Crude mortality rates and standardized mortality ratios (SMRs) were calculated for all-cause, cardiovascular disease (CVD), cancer, and respiratory mortality. Associations with all-cause and cause-specific mortality were examined using multivariable Cox proportional hazards and competing-risks regression. Results. There were 1,652 men with RA and 332 deaths. The leading causes of death were CVD (31.6%; SMR 1.77 [95% confidence interval (95% CI) 1.46-2.14]), cancer (22.9%; SMR 1.50 [95% CI 1.20-1.89]), and respiratory disease (15.1%; SMR 2.90 [95% CI 2.20-3.83]). Factors associated with all-cause mortality included older age, white race, smoking, low body weight, comorbidity, disease activity, and prednisone use. Rheumatoid factor concentration and nodules were associated with CVD mortality. There were no associations of methotrexate or biologic agent use with all-cause or cause-specific mortality. Conclusion. Men in this RA cohort experienced increased all-cause and cause-specific mortality, with a 3-fold risk of respiratory-related deaths compared to age-matched men in the general population. Further studies are needed in order to examine whether interventions targeting potentially modifiable correlates of mortality might lead to improved long-term survival in men with RA. C1 [England, Bryant R.; Sayles, Harlan; Mikuls, Ted R.] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [England, Bryant R.; Sayles, Harlan; Mikuls, Ted R.] Univ Nebraska, Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Univ Nebraska, Med Ctr, Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Caplan, Liron; Davis, Lisa A.] Denver VAMC, Denver, CO USA. [Caplan, Liron; Davis, Lisa A.] Univ Colorado, Denver, CO 80202 USA. [Davis, Lisa A.] Denver Hlth Med Ctr, Denver, CO USA. [Cannon, Grant W.; Sauer, Brian C.] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Cannon, Grant W.; Sauer, Brian C.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Solow, Elizabeth B.; Reimold, Andreas M.] Dallas Vet Affairs, Dallas, TX USA. [Solow, Elizabeth B.; Reimold, Andreas M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Kerr, Gail S.] Vet Affairs Med Ctr & Georgetown, Washington, DC USA. [Kerr, Gail S.] Howard Univ, Washington, DC 20059 USA. [Schwab, Pascale] Portland Vet Affairs Hlth Care Syst, Portland, OR USA. [Schwab, Pascale] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Baker, Josh F.] Philadelphia VAMC, Philadelphia, PA USA. [Baker, Josh F.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Mikuls, TR (reprint author), 986270 Nebraska Med Ctr, Omaha, NE 68198 USA. EM tmikuls@unmc.edu OI England, Bryant R./0000-0002-9649-3588 FU Rheumatology Research Foundation Resident Research Preceptorship; Rheumatology Research Foundation Investigator Award; Rheumatology Research Foundation Scientific Development Award; Veterans Affairs Merit Award FX Dr. England's work was supported by a Rheumatology Research Foundation Resident Research Preceptorship. Dr. Michaud's work was supported by a Rheumatology Research Foundation Investigator Award. Dr. Davis' work was supported by a Rheumatology Research Foundation Scientific Development Award. Dr. Mikuls' work was supported by a Veterans Affairs Merit Award. NR 39 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2016 VL 68 IS 1 BP 36 EP 45 DI 10.1002/acr.2264 PG 10 WC Rheumatology SC Rheumatology GA DA3FQ UT WOS:000367682800003 PM 26097231 ER PT J AU Cheng, A Owens, D AF Cheng, Andrew Owens, David TI Marfan syndrome, inherited aortopathies and exercise: What is the right answer? SO BRITISH JOURNAL OF SPORTS MEDICINE LA English DT Article ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION; CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; RECOMMENDATIONS; MANAGEMENT AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist. C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA. [Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 South Columbian Way, Seattle, WA 98108 USA. EM ACheng@cardiology.washington.edu OI Owens, David/0000-0002-7293-9688 NR 38 TC 0 Z9 0 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-3674 EI 1473-0480 J9 BRIT J SPORT MED JI Br. J. Sports Med. PD JAN PY 2016 VL 50 IS 2 BP 100 EP + DI 10.1136/bjsports-2014-306440rep PG 6 WC Sport Sciences SC Sport Sciences GA DA2FB UT WOS:000367609600009 PM 26729892 ER PT J AU Liang, KV Sileanu, FE Clermont, G Murugan, R Pike, F Palevsky, PM Kellum, JA AF Liang, Kelly V. Sileanu, Florentina E. Clermont, Gilles Murugan, Raghavan Pike, Francis Palevsky, Paul M. Kellum, John A. TI Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID RENAL REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; INTENSIVE-CARE-UNIT; RANDOMIZED CLINICAL-TRIAL; INTERMITTENT HEMODIALYSIS; RETROSPECTIVE COHORT; MULTIPLE-ORGAN; FAILURE; INJURY AB Background and objectives Observational evidence has suggested that RRT modality may affect recovery after AKI. It is unclear whether initial choice of intermittent hemodialysis or continuous RRT affects renal recovery, survival, or development of ESRD in critically ill patients when modality choice is made primarily on hemodynamics. Design, setting, participants, & measurements We performed a retrospective cohort study examining adults (>= 18 years old) admitted to intensive care units from 2000 to 2008 who received RRT for AKI and survived to hospital discharge or 90 days. We analyzed renal recovery (alive and not requiring RRT) and reasons for non-recovery (death or ESRD) at 90 and 365 days. Conditional multivariable logistic regression was used to assess differences in renal recovery at 90 and 365 days between continuous RRT and intermittent hemodialysis. Models were stratified by propensity for continuous RRT and adjusted for age and reference creatinine. Results Of 4738 patients with Kidney Disease Improving Global Outcomes stage 3 AKI, 1338 (28.2%) received RRT, and 638 (47.7%) survived to hospital discharge (353 intermittent hemodialysis and 285 continuous RRT). Recovery from AKI was lower for intermittent hemodialysis versus continuous RRT at 90 days (66.6% intermittent hemodialysis versus 75.4% continuous RRT; P=0.02) but similar at 365 days (54.1% intermittent hemodialysis versus 59.6% continuous RRT; P=0.17). In multivariable analysis, there was no difference in odds of recovery at 90 or 365 days for patients initially treated with continuous RRT versus intermittent hemodialysis (90 days: odds ratio, 1.19; 95% confidence interval, 0.91 to 1.55; P=0.20; 365 days: odds ratio, 0.93; 95% confidence interval, 0.72 to 1.2; P=0.55). Conclusions We found no significant difference in hazards for nonrecovery or reasons for nonrecovery (mortality or ESRD) with intermittent hemodialysis versus continuous RRT. These results suggest that, when initial RRT modality is chosen primarily on hemodynamics, renal recovery and clinical outcomes in survivors are similar between intermittent hemodialysis and continuous RRT. C1 [Liang, Kelly V.; Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Sileanu, Florentina E.; Murugan, Raghavan; Pike, Francis; Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Sch Med, Ctr Crit Care Nephol, Dept Crit Care Med, Pittsburgh, PA USA. [Sileanu, Florentina E.; Murugan, Raghavan; Pike, Francis; Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sileanu, Florentina E.; Clermont, Gilles; Murugan, Raghavan; Pike, Francis; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA. [Sileanu, Florentina E.; Pike, Francis] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Ctr Crit Care Nephrol, Dept Crit Care Med, 604 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu FU Gambro/Baxter, Waukegan, IL FX This work was supported by Gambro/Baxter, Waukegan, IL. NR 50 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2016 VL 11 IS 1 BP 30 EP 38 DI 10.2215/CJN.01290215 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA DA4JM UT WOS:000367766200008 PM 26681135 ER PT J AU Hoffman, W Lakkis, FG Chalasani, G AF Hoffman, William Lakkis, Fadi G. Chalasani, Geetha TI B Cells, Antibodies, and More SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RENAL-ALLOGRAFT REJECTION; GERMINAL CENTER B; IDIOPATHIC MEMBRANOUS NEPHROPATHY; MIXED CRYOGLOBULINEMIA VASCULITIS; DEPLETING INDUCTION THERAPY; RANDOMIZED CONTROLLED-TRIAL; INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; ANCA-ASSOCIATED VASCULITIS AB B cells play a central role in the immunopathogenesis of glomerulonephritides and transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple mechanisms. In addition, B cells contribute to disease pathogenesis in autoimmunity and alloimmunity by presenting antigens as well as providing costimulation and cytokines to T cells. B cells also play an immunomodulatory role in regulating the immune response by secreting cytokines that inhibit disease onset and/or progression. B cell-targeted approaches for treating immune diseases of the kidney and other organs have gained significant momentum. However, much remains to be understood about B-cell biology in order to determine the timing, duration, and context of optimal therapeutic response to B cell-targeted approaches. In this review, we discuss the multifaceted roles of B cells as enhancers and regulators of immunity with relevance to kidney disease and transplantation. C1 [Hoffman, William; Lakkis, Fadi G.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Dept Med Renal Electrolyte, Pittsburgh, PA 15261 USA. [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA. [Lakkis, Fadi G.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA. [Lakkis, Fadi G.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15261 USA. [Chalasani, Geetha] Vet Affairs Pittsburgh Hlth Care Syst, Renal Sect, Pittsburgh, PA 15261 USA. RP Chalasani, G (reprint author), Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Hlth Care Syst, Thomas E Starzl Transplantat Inst, 200 Lothrop St,W1554 Biomed Sci Tower, Pittsburgh, PA 15261 USA. EM gec12@pitt.edu FU National Institutes of Health [R01 AI079177] FX This work was supported by funds from National Institutes of Health grant R01 AI079177 (G.C.). NR 192 TC 7 Z9 7 U1 0 U2 8 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2016 VL 11 IS 1 BP 137 EP 154 DI 10.2215/CJN.09430915 PG 18 WC Urology & Nephrology SC Urology & Nephrology GA DA4JM UT WOS:000367766200020 PM 26700440 ER PT J AU Tsai, J Sippel, LM Mota, N Southwick, SM Pietrzak, RH AF Tsai, Jack Sippel, Lauren M. Mota, Natalie Southwick, Steven M. Pietrzak, Robert H. TI LONGITUDINAL COURSE OF POSTTRAUMATIC GROWTH AMONG US MILITARY VETERANS: RESULTS FROM THE NATIONAL HEALTH AND RESILIENCE IN VETERANS STUDY SO DEPRESSION AND ANXIETY LA English DT Article DE posttraumatic stress disorder; resilience; stress; spirituality; quality of life ID BREAST-CANCER; HAPPINESS; SYMPTOMS; ALTRUISM; STRESS; TRAUMA; WAR; BIBLIOTHERAPY; SATISFACTION; METAANALYSIS AB BackgroundPosttraumatic growth (PTG) is increasingly recognized as an important psychosocial phenomenon, but few studies have evaluated the longitudinal course of PTG. This study identified courses of PTG over a 2-year period in a contemporary, nationally representative sample of U.S. military veterans, and examined sociodemographic, military, trauma, medical, and psychosocial predictors of PTG course. Methods Data were based on a Web-based survey of a nationally representative sample of 1,838 U.S. veterans who reported at least one potentially traumatic event and provided data at two time points (October-December 2011 and September-October 2013). Results Five different courses of PTG were identifiedConsistently Low (33.6%), Moderately Declining (19.4%), Increasing PTG (16.8%), Dramatically Declining (15.7%), and Consistently High (14.5%). More than half (59.4%) of veterans who reported at least moderate PTG maintained that level of PTG 2 years later. Posttraumatic stress disorder symptoms, medical conditions, purpose in life, altruism, gratitude, religiosity, and an active reading lifestyle predicted maintenance or increase in PTG. Conclusions PTG has a heterogeneous course and is not only common, but can persist over time especially in the presence of posttraumatic stress and certain psychosocial factors. Clinicians and researchers should consider the personal growth that can result from trauma and help trauma survivors find ways to maintain this growth over time. C1 [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA. [Tsai, Jack; Sippel, Lauren M.; Mota, Natalie; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Sippel, Lauren M.; Mota, Natalie; Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT 06516 USA. RP Tsai, J (reprint author), US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM Jack.Tsai@yale.edu FU United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder; United States Department of Veterans Affairs, Office of Research and Development FX This work was supported in part by the United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, the United States Department of Veterans Affairs, Office of Research and Development, and a private donation. The views presented here are those of the authors alone and do not represent the position of any federal agency or of the United States Government. None of the authors report any conflicts of interest with this work. NR 47 TC 3 Z9 3 U1 7 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JAN PY 2016 VL 33 IS 1 BP 9 EP 18 DI 10.1002/da.22371 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DA3TX UT WOS:000367722900001 PM 25914061 ER PT J AU Kaz, AM Dominitz, JA AF Kaz, Andrew M. Dominitz, Jason A. TI Can individuals with colonic polyposis be managed safely with colonoscopic surveillance? SO ENDOSCOPY LA English DT Article ID FAMILIAL ADENOMATOUS POLYPOSIS; APC C1 [Kaz, Andrew M.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA. [Kaz, Andrew M.; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kaz, Andrew M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. RP Kaz, AM (reprint author), VA Puget Sound Hlth Care Syst, Gastroenterol Sect, 1660 S Columbian Way,S-111-Gastro, Seattle, WA 98108 USA. EM Andrew.Kaz@va.gov FU VA Puget Sound Health Care System FX This material is the result of work supported in part by resources from the VA Puget Sound Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 12 TC 0 Z9 0 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD JAN PY 2016 VL 48 IS 1 BP 7 EP 8 DI 10.1055/s-0034-1393637 PG 2 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CZ9YU UT WOS:000367454600003 PM 26710280 ER PT J AU Saigusa, T Dang, YJ Mullick, AE Yeh, ST Zile, MR Baicu, CF Bell, PD AF Saigusa, Takamitsu Dang, Yujing Mullick, Adam E. Yeh, Steve T. Zile, Michael R. Baicu, Catalin F. Bell, P. Darwin TI Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model SO FASEB JOURNAL LA English DT Article DE renin angiotensin system; antisense oligonucleotide; polycystic kidney disease; hypertension ID BLOOD-PRESSURE; ANTISENSE OLIGODEOXYNUCLEOTIDES; IN-VIVO; DISEASE; RENIN; SYSTEM; INHIBITOR; CELL; HYPERTENSION; RATS AB Activation of the intrarenal renin angiotensin system(RAS) is believed to play an important role in the development of hypertension and cystogenesis in autosomal dominant polycystic kidney disease (ADPKD). Results of clinical studies testing RAS inhibitors in slowing the progression of cystic disease in ADPKD are inconclusive, and we hypothesized that current RAS inhibitors do not adequately suppress intrarenal RAS. For this study, we compared a novel Gen 2 antisense oligonucleotide (ASO) that inhibits angiotensinogen (Agt) synthesis to lisinopril in adult conditional Pkd1 systemic-knockout mice, a model of ADPKD. Six weeks after Pkd1 global gene knockout, the mice were treated with Agt-ASO (66 mg/kg/wk), lisinopril (100 mg/kg/d), PBS (control), or scrambled ASO (66 mg/kg/wk) for 10 wk, followed by tissue collection. Agt ASO resulted in significant reduction in plasma, liver, and kidney Agt, and increased kidney renin compared with control treatments. Kidneys from Agt-ASO-treated mice were not as enlarged and showed reduced cystic volume compared with lisinopril or control treatments. Blood pressure was better controlled with lisinopril than with Agt-ASO. Agt-ASO suppressed cell proliferation in both cystic and noncystic cells compared with lisinopril and control treatments. However, Agt-ASO did not reduce cell proliferation in liver, which indicates that Agt-ASO targets cell signaling pathways that specifically suppresses cystogenesis in the kidney. These data suggest that Agt-ASO effectively attenuates intrarenal RAS and therefore can be a novel and effective agent for treating ADPKD. C1 [Saigusa, Takamitsu; Dang, Yujing; Bell, P. Darwin] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Zile, Michael R.; Baicu, Catalin F.] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA. [Saigusa, Takamitsu; Dang, Yujing; Zile, Michael R.; Baicu, Catalin F.; Bell, P. Darwin] Ralph Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Mullick, Adam E.; Yeh, Steve T.] ISIS Pharmaceut, Carlsbad, CA 92008 USA. RP Saigusa, T (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,CSB 829, Charleston, SC 29425 USA. EM saigusa@musc.edu; bellpd@musc.edu OI Mullick, Adam/0000-0003-4600-961X FU U.S. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [K08DK106465, P30 DK074038]; U.S. Department of Veterans Affairs Merit Award; Dialysis Clinic, Inc. (Nashville, TN, USA) FX This work was supported by U.S. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Grants K08DK106465 (to T.S.) and P30 DK074038 (to P.D.B.); U.S. Department of Veterans Affairs Merit Award (to P.D.B.); and a Dialysis Clinic, Inc. (Nashville, TN, USA) grant (to T.S. and P.D.B.). The authors declare no conflicts of interest. NR 42 TC 4 Z9 4 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD JAN PY 2016 VL 30 IS 1 BP 370 EP 379 DI 10.1096/fj.15-279299 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA DA2JL UT WOS:000367621000035 PM 26391272 ER PT J AU Good, CB Gellad, WF AF Good, Chester B. Gellad, Walid F. TI Off-label Drug Use and Adverse Drug Events Turning up the Heat on Off-label Prescribing SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Good, Chester B.; Gellad, Walid F.] Univ Pittsburgh, Dept Med, Div Gen Med, Pittsburgh, PA USA. [Good, Chester B.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Good, Chester B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. RP Good, CB (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Room 2A135,Univ Dr C, Pittsburgh, PA 15240 USA. EM chester.good@va.gov NR 9 TC 2 Z9 2 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2016 VL 176 IS 1 BP 63 EP 64 DI 10.1001/jamainternmed.2015.6068 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DA1II UT WOS:000367549100016 PM 26524668 ER PT J AU Ishida, JH Johansen, KL AF Ishida, Julie H. Johansen, Kirsten L. TI Exclusion of Patients With Kidney Disease From Cardiovascular Trials SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Ishida, Julie H.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94121 USA. [Ishida, Julie H.; Johansen, Kirsten L.] San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA USA. RP Johansen, KL (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [K23DK103963, K24DK085153, K23 DK103963, K24 DK085153] NR 6 TC 2 Z9 2 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2016 VL 176 IS 1 BP 124 EP 125 DI 10.1001/jamainternmed.2015.6403 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DA1II UT WOS:000367549100034 PM 26618994 ER PT J AU Hoang, TD Reis, J Zhu, N Jacobs, DR Launer, LJ Whitmer, RA Sidney, S Yaffe, K AF Hoang, Tina D. Reis, Jared Zhu, Na Jacobs, David R., Jr. Launer, Lenore J. Whitmer, Rachel A. Sidney, Stephen Yaffe, Kristine TI Effect of Early Adult Patterns of Physical Activity and Television Viewing on Midlife Cognitive Function SO JAMA PSYCHIATRY LA English DT Article ID YOUNG-ADULTS; SEDENTARY BEHAVIOR; ALZHEIMERS-DISEASE; OLDER-ADULTS; EXECUTIVE FUNCTION; RISK DEVELOPMENT; TEMPORAL TRENDS; LIFE-COURSE; MIDDLE-AGE; TIME USE AB IMPORTANCE Sedentary behaviors and physical inactivity are not only increasing worldwide but also are critical risk factors for adverse health outcomes. Yet, few studies have examined the effects of sedentary behavior on cognition or the long-term role of either behavior in early to middle adulthood. OBJECTIVE To investigate the association between 25-year patterns of television viewing and physical activity and midlife cognition. DESIGN, SETTING, AND PARTICIPANTS Prospective study of 3247 adults (black and white races; aged 18-30 years) enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study (March 25, 1985, to August 31, 2011). Data analysis was performed June 1, 2014, through April 15, 2015. MAIN OUTCOMES AND MEASURES We assessed television viewing and physical activity at repeated visits (>= 3 assessments) over 25 years using a validated questionnaire. A 25-year pattern of high television viewing was defined as watching TV above the upper baseline quartile (>3 hours/d) for more than two-thirds of the visits, and a 25-year pattern of low physical activity was defined as activity levels below the lower, sex-specific baseline quartile for more than two-thirds of the of the visits. We evaluated cognitive function at year 25 using the Digit Symbol Substitution Test (DSST), Stroop test, and Rey Auditory Verbal Learning Test. RESULTS At baseline, the mean (SD) age of the 3247 study participants was 25.1 (3.6) years, 1836 (56.5%) were female, 1771 (54.5%) were white, and 3015 (92.9%) had completed at least high school. Compared with participants with low television viewing, those with high television viewing during 25 years (353 of 3247 [10.9%]) were more likely to have poor cognitive performance (<1 SD below the race-specific mean) on the DSST and Stroop test, with findings reported as adjusted odds ratio (95% CI): DSST, 1.64 (1.21-2.23) and Stroop test, 1.56 (1.13-2.14), but not the Rey Auditory Verbal Learning Test, adjusted for age, race, sex, educational level, smoking, alcohol use, body mass index, and hypertension. Low physical activity during 25 years in 528 of 3247 participants (16.3%) was significantly associated with poor performance on the DSST, 1.47 (1.14-1.90). Compared with participants with low television viewing and high physical activity, the odds of poor performance were almost 2 times higher for adults with both high television viewing and low physical activity in 107 of 3247 (3.3%) (DSST, 1.95 [1.19-3.22], and Stroop test, 2.20 [1.36-3.56]). CONCLUSIONS AND RELEVANCE High television viewing and low physical activity in early adulthood were associated with worse midlife executive function and processing speed. This is one of the first studies to demonstrate that these risk behaviors may be critical targets for prevention of cognitive aging even before middle age. C1 [Hoang, Tina D.] Northern Calif Inst Res & Educ, San Francisco, CA 94121 USA. [Reis, Jared] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Zhu, Na; Jacobs, David R., Jr.] Univ Minnesota, Div Epidemiol, Sch Publ Hlth, Minneapolis, MN 55455 USA. [Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Whitmer, Rachel A.; Sidney, Stephen] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hoang, TD (reprint author), Northern Calif Inst Res & Educ, Vet Affairs Med Ctr, 4150 Clement St,116-H, San Francisco, CA 94121 USA. EM tina.hoang@va.gov RI Dey, Kamalesh/E-6568-2017 FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA [AG0005, K24 AG031155]; NHLBI [AG0005, HL122658] FX The Coronary Artery Risk Development in Young Adults (CARDIA) Study is conducted and supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and the Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between the NIA and NHLBI (AG0005). The CARDIA Cognitive Function Ancillary Study is supported by grant HL122658 from the NHLBI. Dr Yaffe is also supported by grant K24 AG031155 from the NIA. NR 66 TC 2 Z9 2 U1 7 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2016 VL 73 IS 1 BP 73 EP 79 DI 10.1001/jamapsychiatry.2015.2468 PG 7 WC Psychiatry SC Psychiatry GA DA5CP UT WOS:000367820000012 PM 26629780 ER PT J AU Schafer, AL AF Schafer, Anne L. TI Decline in Bone Mass During Weight Loss: A Cause for Concern? SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; OBESE OLDER-ADULTS; OVERWEIGHT POSTMENOPAUSAL WOMEN; LONG-DURATION SPACEFLIGHT; LIFE-STYLE INTERVENTION; MIDDLE-AGED NORWEGIANS; GASTRIC BYPASS-SURGERY; MINERAL DENSITY; HIP FRACTURE; CALORIC RESTRICTION C1 [Schafer, Anne L.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94158 USA. [Schafer, Anne L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Schafer, Anne L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA. EM anne.schafer@ucsf.edu FU CSRD VA [IK2 CX000549] NR 56 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2016 VL 31 IS 1 BP 36 EP 39 DI 10.1002/jbmr.2754 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DA3JP UT WOS:000367693300003 PM 26595270 ER PT J AU Zou, CB Synan, MJ Li, J Xiong, S Manni, ML Liu, Y Chen, BB Zhao, YT Shiva, S Tyurina, YY Jiang, JF Lee, JS Das, S Ray, A Ray, P Kagan, VE Mallampalli, RK AF Zou, Chunbin Synan, Matthew J. Li, Jin Xiong, Sheng Manni, Michelle L. Liu, Yuan Chen, Bill B. Zhao, Yutong Shiva, Sruti Tyurina, Yulia Y. Jiang, Jianfei Lee, Janet S. Das, Sudipta Ray, Anuradha Ray, Prabir Kagan, Valerian E. Mallampalli, Rama K. TI LPS impairs oxygen utilization in epithelia by triggering degradation of the mitochondrial enzyme Alcat1 SO JOURNAL OF CELL SCIENCE LA English DT Article DE Degradation; Mitochondria; Ubiquitin ID PLURIPOTENT STEM-CELL; BARTH-SYNDROME; HISTONE DEACETYLASE; LYSOCARDIOLIPIN ACYLTRANSFERASE; CARDIOLIPIN DEFICIENCY; SUBSTRATE RECOGNITION; UBIQUITIN LIGASE; LIVER-MITOCHONDRIA; OXIDATIVE STRESS; LUNG INJURY AB Cardiolipin (also known as PDL6) is an indispensable lipid required for mitochondrial respiration that is generated through de novo synthesis and remodeling. Here, the cardiolipin remodeling enzyme, acyl-CoA:lysocardiolipin-acyltransferase-1 (Alcat1; SwissProt ID, Q6UWP7) is destabilized in epithelia by lipopolysaccharide (LPS) impairing mitochondrial function. Exposure to LPS selectively decreased levels of carbon 20 (C-20)-containing cardiolipin molecular species, whereas the content of C-18 or C-16 species was not significantly altered, consistent with decreased levels of Alcat1. Alcat1 is a labile protein that is lysosomally degraded by the ubiquitin E3 ligase Skp-Cullin-F-box containing the Fbxo28 subunit (SCF-Fbxo28) that targets Alcat1 for monoubiquitylation at residue K183. Interestingly, K183 is also an acetylation-acceptor site, and acetylation conferred stability to the enzyme. Histone deacetylase 2 (HDAC2) interacted with Alcat1, and expression of a plasmid encoding HDAC2 or treatment of cells with LPS deacetylated and destabilized Alcat1, whereas treatment of cells with a pan-HDAC inhibitor increased Alcat1 levels. Alcat1 degradation was partially abrogated in LPS-treated cells that had been silenced for HDAC2 or treated with MLN4924, an inhibitor of Cullin-RING E3 ubiquitin ligases. Thus, LPS increases HDAC2-mediated Alcat1 deacetylation and facilitates SCF-Fbxo28-mediated disposal of Alcat1, thus impairing mitochondrial integrity. C1 [Zou, Chunbin; Synan, Matthew J.; Li, Jin; Manni, Michelle L.; Liu, Yuan; Chen, Bill B.; Zhao, Yutong; Lee, Janet S.; Das, Sudipta; Ray, Anuradha; Ray, Prabir; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Xiong, Sheng] Jinan Univ, Inst Biomed, Coll Life Sci & Technol, Guangzhou 510630, Guangdong, Peoples R China. [Xiong, Sheng] Jinan Univ, Natl Engn Res Ctr Genet Med, Coll Life Sci & Technol, Guangzhou 510630, Guangdong, Peoples R China. [Shiva, Sruti; Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA. [Tyurina, Yulia Y.; Jiang, Jianfei; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, 930 Scaife Hall, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; Merit Review Award from the US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01HL114453, ES020693, U19AIO68021, CA 165065, OH008282]; Human Frontier Science Program [HFSPRGP0013/2014, HL116472, HL01916, HL112791, HL125435, 12SDG12040330]; MOST of China [2012ZX09103-301-033, 2012ZX09202-301-001] FX This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs; National Institutes of Health [R01 grant numbers HL096376, HL097376, HL098174, HL081784, 1UH2HL123502 and P01HL114453 to R.K.M.; and ES020693, U19AIO68021, CA 165065, OH008282 (to V.E.K.)]; and Human Frontier Science Program [grant numbers HFSPRGP0013/2014 (to V.E.K.); HL116472 (to B.B.C.); HL01916 and HL112791 (to Y.Z.); and HL125435 and 12SDG12040330 (to C.Z.)]. S.X. was supported from the MOST of China [grant number 2012ZX09103-301-033 and 2012ZX09202-301-001]. The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. Deposited in PMC for release after 12 months. NR 93 TC 3 Z9 3 U1 1 U2 11 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 EI 1477-9137 J9 J CELL SCI JI J. Cell Sci. PD JAN 1 PY 2016 VL 129 IS 1 BP 51 EP 64 DI 10.1242/jcs.176701 PG 14 WC Cell Biology SC Cell Biology GA DA1LI UT WOS:000367556900006 PM 26604221 ER PT J AU Haas, JS Sprague, BL Klabunde, CN Tosteson, ANA Chen, JS Bitton, A Beaber, EF Onega, T Kim, JJ MacLean, CD Harris, K Yamartino, P Howe, K Pearson, L Feldman, S Brawarsky, P Schapira, MM AF Haas, Jennifer S. Sprague, Brian L. Klabunde, Carrie N. Tosteson, Anna N. A. Chen, Jane S. Bitton, Asaf Beaber, Elisabeth F. Onega, Tracy Kim, Jane J. MacLean, Charles D. Harris, Kimberly Yamartino, Phillip Howe, Kathleen Pearson, Loretta Feldman, Sarah Brawarsky, Phyllis Schapira, Marilyn M. CA PROSPR Population-Based Res Optimi TI Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE breast cancer screening; cervical cancer screening; provider practice patterns; primary care; clinical practice guidelines ID PRIMARY-CARE-PHYSICIANS; SERVICES TASK-FORCE; UNITED-STATES; MAMMOGRAPHY; RECOMMENDATIONS; CONSISTENT; ADHERENCE; SOCIETY; MODEL AB Changes to national guidelines for breast and cervical cancer screening have created confusion and controversy for women and their primary care providers. To characterize women's primary health care provider attitudes towards screening and changes in practice in response to recent revisions in guidelines for breast and cervical cancer screening. In 2014, we distributed a confidential web and mail survey to 668 women's health care providers affiliated with the four clinical care networks participating in the three PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) consortium breast cancer research centers (385 respondents; response rate 57.6 %). We assessed self-reported attitudes toward breast and cervical cancer screening, as well as practice changes in response to the most recent revisions of the U.S. Preventive Services Task Force (USPSTF) recommendations. The majority of providers believed that mammography screening was effective for reducing cancer mortality among women ages 40-74 years, and that Papanicolaou (Pap) testing was very effective for women ages 21-64 years. While the USPSTF breast and cervical cancer screening recommendations were widely perceived by the respondents as influential, 75.7 and 41.2 % of providers (for mammography and cervical cancer screening, respectively) reported screening practices in excess of those recommended by USPSTF. Provider-reported barriers to concordance with guideline recommendations included: patient concerns (74 and 36 % for breast and cervical, respectively), provider disagreement with the recommendations (50 and 14 %), health system measurement of a provider's screening practices that use conflicting measurement criteria (40 and 21 %), concern about malpractice risk (33 and 11 %), and lack of time to discuss the benefits and harms with their patients (17 and 8 %). Primary care providers do not consistently follow recent USPSTF breast and cervical cancer screening recommendations, despite noting that these guidelines are influential. C1 [Haas, Jennifer S.; Chen, Jane S.; Bitton, Asaf; Harris, Kimberly; Feldman, Sarah; Brawarsky, Phyllis] Brigham & Womens Hosp, Boston, MA 02120 USA. [Haas, Jennifer S.; Bitton, Asaf; Feldman, Sarah] Harvard Univ, Sch Med, Boston, MA USA. [Sprague, Brian L.; MacLean, Charles D.; Howe, Kathleen] Univ Vermont, Burlington, VT USA. [Tosteson, Anna N. A.; Onega, Tracy; Pearson, Loretta] Geisel Sch Med Dartmouth, Lebanon, NH USA. [Tosteson, Anna N. A.; Onega, Tracy; Pearson, Loretta] Norris Cotton Canc Ctr, Lebanon, NH USA. [Klabunde, Carrie N.] NIH, Off Dis Prevent, Off Director, Bethesda, MD 20892 USA. [Beaber, Elisabeth F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Kim, Jane J.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Yamartino, Phillip; Schapira, Marilyn M.] Univ Penn, Philadelphia, PA 19104 USA. [Yamartino, Phillip; Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA. RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. EM jhaas@partners.org FU National Cancer Institute-funded consortium, Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) [U54 CA163307, U54 CA 163313, U54 CA163303, U01CA163304, U54CA164336] FX We appreciate the input of Alan Waxman, MD, on the development of the survey. This study was conducted as part of the National Cancer Institute-funded consortium, Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) (grant numbers U54 CA163307, U54 CA 163313, U54 CA163303, U01CA163304, U54CA164336). A list of PROSPR investigators and contributing research staff is provided at: http://healthcaredelivery.cancer.gov/prospr/ NR 27 TC 8 Z9 8 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2016 VL 31 IS 1 BP 52 EP 59 DI 10.1007/s11606-015-3449-5 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DA1FB UT WOS:000367540600013 PM 26129780 ER PT J AU Berchuck, JE Patel, S AF Berchuck, Jacob E. Patel, Shalini TI An Often-Overlooked Etiology of Pleuritic Chest Pain SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE Clinical image; Diagnosis; Cardiovascular disease; Pulmonary disease C1 [Berchuck, Jacob E.; Patel, Shalini] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Patel, Shalini] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Berchuck, JE (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Room M-987, San Francisco, CA 94143 USA. EM jacob.berchuck@ucsf.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2016 VL 31 IS 1 BP 138 EP 138 DI 10.1007/s11606-015-3316-4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DA1FB UT WOS:000367540600034 PM 25869019 ER PT J AU Lapps, J Flansbaum, B Leykum, L Boswell, J Haines, L AF Lapps, Joshua Flansbaum, Bradley Leykum, Luci Boswell, Josh Haines, Luigi TI Updating threshold-based identification of hospitalists in 2012 Medicare pay data SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID CARE AB In the absence of a unique identifier, it is difficult to assess the number of practicing hospitalists. We use a variety of thresholds of billing activity to identify hospitalists in a dataset of publicly released 2012 Medicare physician pay data. Our study updates previous estimates of the number of hospitalists practicing nationwide in 2012 and suggests the field continues to grow. This research also highlights a need for a more precise system of identifying hospitalists. Journal of Hospital Medicine 2016;11:45-47. (c) 2015 Society of Hospital Medicine C1 [Lapps, Joshua; Boswell, Josh] Soc Hosp Med, Govt Relat Dept, Philadelphia, PA 19130 USA. [Flansbaum, Bradley] Lenox Hill Hosp, North Shore Long Isl Jewish Hlth Syst, New York, NY 10021 USA. [Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Leykum, Luci] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Haines, Luigi] Soc Hosp Med, Dept Informat Technol, Philadelphia, PA 19130 USA. [Haines, Luigi] Adv Solut Int Inc, Austin, TX USA. RP Lapps, J (reprint author), Soc Hosp Med, 1500 Spring Garden St,Suite 501, Philadelphia, PA 19130 USA. EM jlapps@hospitalmedicine.org FU Department of Veterans Affairs, Veterans Health Administration; South Texas Veterans Health Care System FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration. Investigator salary support is provided through the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors report no conflicts of interest. NR 9 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2016 VL 11 IS 1 BP 45 EP 47 DI 10.1002/jhm.2480 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VR UT WOS:000367728300006 PM 26381496 ER PT J AU Rao, K Safdar, N AF Rao, Krishna Safdar, Nasia TI Fecal microbiota transplantation for the treatment of Clostridium difficile infection SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID ULCERATIVE-COLITIS; INTESTINAL MICROBIOTA; BACTERIOTHERAPY; HEALTH; METAANALYSIS; DISEASE; COLONIZATION; EPIDEMIOLOGY; VANCOMYCIN; RESISTANCE AB Clostridium difficile, a major cause of healthcare-associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of C difficile infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long-term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed. Journal of Hospital Medicine 2016;11:56-61. (c) 2015 Society of Hospital Medicine C1 [Rao, Krishna] Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA. [Rao, Krishna] Vet Affairs Ann Arbor Healthcare Syst, Div Infect Dis, Ann Arbor, MI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis Sect, Dept Med, Madison, WI 53705 USA. RP Safdar, N (reprint author), Univ Wisconsin, Infect Dis Sect, Dept Med, Sch Med & Publ Hlth,MFCB, 1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU Claude D. Pepper Older Americans Independence Center [AG-024824]; Michigan Institute for Clinical and Health Research [2UL1TR000433]; VA MERIT award FX K.R. is supported by grants from the Claude D. Pepper Older Americans Independence Center (grant number AG-024824) and the Michigan Institute for Clinical and Health Research (grant number 2UL1TR000433). N.S. is supported by a VA MERIT award. The contents of this article do not necessarily represent the views of the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors report no conflicts of interest. NR 65 TC 9 Z9 9 U1 3 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2016 VL 11 IS 1 BP 56 EP 61 DI 10.1002/jhm.2449 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VR UT WOS:000367728300009 PM 26344412 ER PT J AU Silvestri, MT Bongiovanni, TR Glover, JG Gross, CP AF Silvestri, Mark T. Bongiovanni, Tasce R. Glover, Janis G. Gross, Cary P. TI Impact of price display on provider ordering: A systematic review SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID EMERGENCY-DEPARTMENT; HEALTH-CARE; LABORATORY TESTS; COST; INFORMATION; PHYSICIANS; BEHAVIOR; TRANSPARENCY; SERVICES; CHARGES AB BACKGROUNDDisplaying order prices to physicians is 1 potential strategy to reduce unnecessary health expenditures, but its impact on patterns of care is unclear. OBJECTIVETo review characteristics of previous price display interventions, impact on order costs and volume, effects on patient safety, acceptability to physicians, and the quality of this evidence. DESIGNSystematic review of studies that showed numeric prices of laboratory tests, imaging studies, or medications to providers in real time during the ordering process and evaluated the impact on provider ordering. Two investigators independently extracted data for each study and evaluated study quality using a modified Downs and Black checklist. RESULTSOf 1494 studies reviewed, 19 met inclusion criteria, including 5 randomized trials, 13 pre-post intervention studies, and 1 time series analysis. Studies were published between 1983 and 2014. Of 15 studies reporting the quantitative impact of price display on aggregate order costs or volume, 10 demonstrated a statistically significant decrease in the intervention group. Price display was found to decrease aggregate order costs (9 of 13 studies) more frequently than order volume (3 of 8 studies). Patient safety was evaluated in 5 studies and was unaffected by price display. Provider acceptability tended to be positive, although evidence was limited. Study quality was mixed, with checklist scores ranging from 5/21 to 20/21. CONCLUSIONSProvider price display likely reduces order costs to a modest degree. Patient safety appeared unchanged, though evidence was limited. More high-quality evidence is needed to confirm these findings within a modern context. Journal of Hospital Medicine 2016;11:65-76. (c) 2015 Society of Hospital Medicine C1 [Silvestri, Mark T.; Bongiovanni, Tasce R.; Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Bongiovanni, Tasce R.] US Dept Vet Affairs, Connecticut Healthcare Syst, West Haven, CT USA. [Glover, Janis G.] Yale Univ, Harvey Cushing John Hay Whitney Med Lib, New Haven, CT USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Silvestri, MT (reprint author), Robert Wood Johnson Fdn, Clin Scholars Program, POB 208088,333 Cedar St,SHM IE-61, New Haven, CT 06520 USA. EM mark.silvestri@yale.edu FU Johnson Johnson; Medtronic Inc.; 21st Century Oncology; Fair Health Inc.; ASTRO FX Dr. Silvestri, Dr. Bongiovanni, and Ms. Glover have nothing to disclose. Dr. Gross reports grants from Johnson & Johnson, Medtronic Inc., and 21st Century Oncology during the conduct of this study. In addition, he received payment from Fair Health Inc. and ASTRO outside the submitted work. NR 32 TC 2 Z9 2 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2016 VL 11 IS 1 BP 65 EP 76 DI 10.1002/jhm.2500 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VR UT WOS:000367728300011 PM 26498736 ER PT J AU McCaslin, SE Maguen, S Metzler, T Bosch, J Neylan, TC Marmar, CR AF McCaslin, Shannon E. Maguen, Shira Metzler, Thomas Bosch, Jeane Neylan, Thomas C. Marmar, Charles R. TI Assessing posttraumatic stress related impairment and well-being: The Posttraumatic Stress Related Functioning Inventory (PRFI) SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE PTSD; Functioning; Veterans; Assessment; Outcomes ID MALE VIETNAM VETERANS; ABUSE SCREENING-TEST; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; INTERPERSONAL VIOLENCE; DISORDER SYMPTOMS; HEALTH; WAR; TRAUMA; IRAQ AB Posttraumatic stress symptoms are associated with poorer social and occupational functioning and quality of life. However, general assessments of functioning do not determine the extent to which these difficulties are directly related to PTSD symptoms. This study examines the psychometric properties of a self-report measure, the 27-item Posttraumatic Stress Related Functioning Inventory (PRFI), which was developed to provide a self-report tool for clinicians and researchers to better understand the perceived impact of PTSD symptoms on functioning. The psychometric properties of the PRFI were examined utilizing data collected within a larger study examining quality of life and functioning in 251 veterans who had served in OEF/OIF/OND and endorsed the presence of subsyndromal or greater levels of PTSD symptoms at screening. One-year test-retest reliability of the measure was examined in a subset of the baseline sample who received a second administration of the PRFI (n = 109). Higher levels of PTSD symptoms were associated with poorer functioning in all domains. The PRFI demonstrated convergent validity with a measure of PTSD symptoms and was less correlated with measures of alcohol and drug use, good internal consistency and test-retest reliability from baseline to one-year follow-up. The PRFI provides self-report information regarding several domains of functioning. This initial examination of psychometric properties of the scale indicated that it may be useful for efficiently eliciting information about the ways in which PTSD symptoms in veterans impact everyday functioning. Published by Elsevier Ltd. C1 [McCaslin, Shannon E.] Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA. [McCaslin, Shannon E.; Maguen, Shira; Metzler, Thomas; Neylan, Thomas C.] San Francisco Vet Adm Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [McCaslin, Shannon E.; Maguen, Shira; Metzler, Thomas; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Bosch, Jeane] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. [Marmar, Charles R.] NYU, Steven & Alexandra Cohen Vet Ctr, New York, NY USA. [Marmar, Charles R.] NYU, Dept Psychiat, Langone Med Ctr, New York, NY 10016 USA. RP McCaslin, SE (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Shannon.McCaslin@va.gov FU United States (U.S.) Department of Veterans Affairs, Clinical Sciences Research and Development Service [CDA-2-032-06F]; United States (U.S.) Department of Veterans Affairs, Health Services Research and Development Service [RCD 06-042] FX This work was supported by Career Development Award (CDA-2-032-06F: McCaslin) from the United States (U.S.) Department of Veterans Affairs, Clinical Sciences Research and Development Service and Career Development Award (RCD 06-042: Maguen) from the United States (U.S.) Department of Veterans Affairs, Health Services Research and Development Service.The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 35 TC 0 Z9 0 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2016 VL 72 BP 104 EP 111 DI 10.1016/j.jpsychires.2015.10.016 PG 8 WC Psychiatry SC Psychiatry GA DA0KB UT WOS:000367484900016 PM 26615453 ER PT J AU Winkler, EA Yue, JK McAllister, TW Temkin, NR Oh, SS Burchard, EG Hu, DL Ferguson, AR Lingsma, HF Burke, JF Sorani, MD Rosand, J Yuh, EL Barber, J Tarapore, PE Gardner, RC Sharma, S Satris, GG Eng, C Puccio, AM Wang, KKW Mukherjee, P Valadka, AB Okonkwo, DO Diaz-Arrastia, R Manley, GT AF Winkler, Ethan A. Yue, John K. McAllister, Thomas W. Temkin, Nancy R. Oh, Sam S. Burchard, Esteban G. Hu, Donglei Ferguson, Adam R. Lingsma, Hester F. Burke, John F. Sorani, Marco D. Rosand, Jonathan Yuh, Esther L. Barber, Jason Tarapore, Phiroz E. Gardner, Raquel C. Sharma, Sourabh Satris, Gabriela G. Eng, Celeste Puccio, Ava M. Wang, Kevin K. W. Mukherjee, Pratik Valadka, Alex B. Okonkwo, David O. Diaz-Arrastia, Ramon Manley, Geoffrey T. CA TRACK-TBI Investigators TI COMT Val (158) Met polymorphism is associated with nonverbal cognition following mild traumatic brain injury SO NEUROGENETICS LA English DT Article DE Traumatic brain injury; Genetic factors; Cognitive function; Outcome measures; Human studies ID COMMON DATA ELEMENTS; CATECHOL-O-METHYLTRANSFERASE; VERBAL-LEARNING TEST; WORKING-MEMORY; GENE POLYMORPHISMS; PREFRONTAL CORTEX; PERFORMANCE; GENOTYPE; RECOMMENDATIONS; RESILIENCE AB Mild traumatic brain injury (mTBI) results in variable clinical outcomes, which may be influenced by genetic variation. A single-nucleotide polymorphism in catechol-o-methyltransferase (COMT), an enzyme which degrades catecholamine neurotransmitters, may influence cognitive deficits following moderate and/or severe head trauma. However, this has been disputed, and its role in mTBI has not been studied. Here, we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether the COMT Val (158) Met polymorphism influences outcome on a cognitive battery 6 months following mTBI-Wechsler Adult Intelligence Test Processing Speed Index Composite Score (WAIS-PSI), Trail Making Test (TMT) Trail B minus Trail A time, and California Verbal Learning Test, Second Edition Trial 1-5 Standard Score (CVLT-II). All patients had an emergency department Glasgow Coma Scale (GCS) of 13-15, no acute intracranial pathology on head CT, and no polytrauma as defined by an Abbreviated Injury Scale (AIS) score of a parts per thousand yen3 in any extracranial region. Results in 100 subjects aged 40.9 (SD 15.2) years (COMT Met (158) /Met (158) 29 %, Met (158) /Val (158) 47 %, Val (158) /Val (158) 24 %) show that the COMT Met (158) allele (mean 101.6 +/- SE 2.1) associates with higher nonverbal processing speed on the WAIS-PSI when compared to Val (158) /Val (158) homozygotes (93.8 +/- SE 3.0) after controlling for demographics and injury severity (mean increase 7.9 points, 95 % CI [1.4 to 14.3], p = 0.017). The COMT Val (158) Met polymorphism did not associate with mental flexibility on the TMT or with verbal learning on the CVLT-II. Hence, COMT Val (158) Met may preferentially modulate nonverbal cognition following uncomplicated mTBI. Registry: ClinicalTrials.gov Identifier NCT01565551. C1 Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA. [Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Burke, John F.; Sorani, Marco D.; Yuh, Esther L.; Tarapore, Phiroz E.; Sharma, Sourabh; Satris, Gabriela G.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA. [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA. [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Temkin, Nancy R.; Barber, Jason; Eng, Celeste] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Oh, Sam S.; Burchard, Esteban G.; Hu, Donglei; Eng, Celeste] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94110 USA. [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Rosand, Jonathan; Gardner, Raquel C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA. [Gardner, Raquel C.] San Francisco Vet Adm Med Ctr, Dept Neurol, San Francisco, CA USA. [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA. [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA. [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA. [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA. [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA. [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA. RP Manley, GT (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA. EM manleyg@neurosurg.ucsf.edu RI Yue, John/P-1348-2015 OI Yue, John/0000-0001-9694-7722 FU NIH [RC2 NS069409, RC2 NS069409-02S1, U01 NS086090-01]; DOD [USAMRAAW81XWH-13-1-0441, W81XWH-14-2-0176] FX This work was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS069409-02S1, NIH U01 NS086090-01, DOD USAMRAAW81XWH-13-1-0441, DOD W81XWH-14-2-0176 NR 68 TC 2 Z9 3 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1364-6745 EI 1364-6753 J9 NEUROGENETICS JI Neurogenetics PD JAN PY 2016 VL 17 IS 1 BP 31 EP 41 DI 10.1007/s10048-015-0467-8 PG 11 WC Genetics & Heredity; Clinical Neurology SC Genetics & Heredity; Neurosciences & Neurology GA DA3KJ UT WOS:000367695300005 PM 26576546 ER PT J AU Greenwood, TA Lazzeroni, LC Calkins, ME Freedman, R Green, MF Gur, RE Gur, RC Light, GA Nuechterlein, KH Olincy, A Radant, AD Seidman, LJ Siever, LJ Silverman, JM Stone, WS Sugar, CA Swerdlow, NR Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL AF Greenwood, Tiffany A. Lazzeroni, Laura C. Calkins, Monica E. Freedman, Robert Green, Michael F. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Sugar, Catherine A. Swerdlow, Neal R. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. TI Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Endophenotype; Genetics; Schizophrenia; Association; Linkage; Heritability ID GENOME-WIDE ASSOCIATION; DE-NOVO MUTATIONS; TRAIT LINKAGE ANALYSIS; BIPOLAR-DISORDER; DOPAMINE TRANSPORTER; SUSTAINED ATTENTION; CANDIDATE GENES; SCHIZOAFFECTIVE DISORDER; INTELLECTUAL DISABILITY; 1ST-DEGREE RELATIVES AB The Consortium on the Genetics of Schizophrenia Family Study (COGS-1) has previously reported our efforts to characterize the genetic architecture of 12 primary endophenotypes for schizophrenia. We now report the characterization of 13 additional measures derived from the same endophenotype test paradigms in the COGS-1 families. Nine of the measures were found to discriminate between schizophrenia patients and controls, were significantly heritable (31 to 62%), and were sufficiently independent of previously assessed endophenotypes, demonstrating utility as additional endophenotypes. Genotyping via a custom array of 1536 SNPs from 94 candidate genes identified associations for CTNNA2, ERBB4, GRID1, GRID2, GRIK3, GRIK4, GRIN2B, NOS1AP, NRG1, and RELN across multiple endophenotypes. An experiment-wide p value of 0.003 suggested that the associations across all SNPs and endophenotypes collectively exceeded chance. Linkage analyses performed using a genome-wide SNP array further identified significant or suggestive linkage for six of the candidate endophenotypes, with several genes of interest located beneath the linkage peaks (e.g., CSMD1, DISC1, DLGAP2, GRIK2, GRIN3A, and SLC6A3). While the partial convergence of the association and linkage likely reflects differences in density of gene coverage provided by the distinct genotyping platforms, it is also likely an indication of the differential contribution of rare and common variants for some genes and methodological differences in detection ability. Still, many of the genes implicated by COGS through endophenotypes have been identified by independent studies of common, rare, and de novo variation in schizophrenia, all converging on a functional genetic network related to glutamatergic neurotransmission that warrants further investigation. (C) 2015 Elsevier B. V. All rights reserved. C1 [Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Light, Gregory A.; Braff, David L.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, San Diego, CA 92161 USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Radant, Allen D.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Seidman, Larry J.; Stone, William S.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, New York, NY USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Tsuang, Ming T.] Univ Calif San Diego, Inst Genom Med, Ctr Behav Genom, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. RP Greenwood, TA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,MC 0689, La Jolla, CA 92093 USA. EM tgreenwood@ucsd.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Greenwood, Tiffany/0000-0002-6080-6503 FU National Institute of Mental Health [R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, K01-MH087889]; National Institutes of Health [HHSN268200782096C] FX The authors wish to thank all of the participants and support staff that made this study possible. This study was supported by grants R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, and K01-MH087889 (TAG) from the National Institute of Mental Health. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, Contract Number HHSN268200782096C. COGS website: http://www.npistat.com/cogs/. NR 100 TC 6 Z9 6 U1 2 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2016 VL 170 IS 1 BP 30 EP 40 DI 10.1016/j.schres.2015.11.008 PG 11 WC Psychiatry SC Psychiatry GA DA1DC UT WOS:000367535500003 PM 26597662 ER PT J AU Lizano, PL Keshavan, MS Tandon, N Mathew, IT Mothi, SS Montrose, DM Yao, JK AF Lizano, Paulo L. Keshavan, Matcheri S. Tandon, Neeraj Mathew, Ian T. Mothi, Suraj Sarvode Montrose, Debra M. Yao, Jeffrey K. TI Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE High risk; First episode psychosis; Soluble fms-like tyrosine kinase; Angiogenesis; Inflammation/immune ID ENDOTHELIAL GROWTH-FACTOR; 1ST EPISODE PSYCHOSIS; CYTOKINE ALTERATIONS; INTERFERON-GAMMA; SCHIZOPHRENIA; VEGF; SYMPTOMS; RECEPTOR; FLT-1; SFLT1 AB Schizophrenia (SZ) is a heterogeneous disorder that presents in adolescence, persists into adulthood, and has many clinical features. Recent evidence suggests that abnormalities in inflammatory, neurotrophic, and angiogenic processes may play a role in the etiology of SZ. The identification of molecular biomarkers early in the course of disease is crucial to transforming diagnostic and therapeutic avenues. We investigated 14 molecular analytes focusing on inflammatory, neurotrophic and angiogenic pathways from the plasma of antipsychotic-naive familial high risk for SZ (FHR; n = 35) and first-episode psychosis (FEP; n = 45) subjects, in comparison to healthy controls (HC, n = 39). We identified distinct alterations in molecular signatures in young relatives at FHR for SZ prior to psychosis onset and FEP subjects. Firstly, the expression of soluble fms-like tyrosine kinase (sFlt-1), an anti-angiogenic factor that binds vascular endothelial growth factor (VEGF), was significantly increased in the FHR group compared to HC, but not in FEP. Secondly, interferon gamma (IFN gamma) was significantly reduced in the FEP group compared to HC. Thirdly, network analysis revealed a positive correlation between sFlt-1 and VEGF, suggesting an activation of the angiogenic cascade in the FHR group, which persists in FEP. Our results indicate an angiogenesis and immunological dysfunction early in the course of disease, shifting the balance towards anti-angiogenesis and inflammation. Published by Elsevier B.V. C1 [Lizano, Paulo L.; Keshavan, Matcheri S.; Tandon, Neeraj; Mathew, Ian T.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Lizano, Paulo L.; Keshavan, Matcheri S.; Mothi, Suraj Sarvode] Massachusetts Mental Hlth Ctr, Div Publ Psychiat, Boston, MA 02115 USA. [Keshavan, Matcheri S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Keshavan, Matcheri S.; Montrose, Debra M.; Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Tandon, Neeraj] Baylor Coll Med, Houston, TX 77030 USA. [Yao, Jeffrey K.] Med Res Serv, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Yao, JK (reprint author), VA Pittsburg Healthcare Syst, B-1-2E-140,Univ Dr C, Pittsburgh, PA 15240 USA. EM jkyao@pitt.edu FU Department of Veterans Affairs; VA Pittsburgh Healthcare System; National Institute of Health [MH58141, MH64023, KO2 MH 01180, MH45156, c UL1 RR024153]; National Institute of Health, NIH/NCRR/GCRC [M01 RR00056]; Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University and its affiliated academic healthcare centers FX This work was supported in part by Department of Veterans Affairs [Merit Reviews (JKY) and Senior Research Career Scientist Award (JKY)] and the VA Pittsburgh Healthcare System, National Institute of Health [MH58141 (JKY), MH64023 (MSK), KO2 MH 01180 (MSK), MH45156 (MSK), c UL1 RR024153, and NIH/NCRR/GCRC Grant M01 RR00056]. Biostatistician consultation was supported by Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. NR 74 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2016 VL 170 IS 1 BP 115 EP 122 DI 10.1016/j.schres.2015.12.001 PG 8 WC Psychiatry SC Psychiatry GA DA1DC UT WOS:000367535500014 PM 26692348 ER PT J AU Szymusiak, R AF Szymusiak, Ronald TI Chapter 5 Journal SLEEP SO SLEEP LA English DT Editorial Material C1 [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Szymusiak, Ronald] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Szymusiak, R (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JAN 1 PY 2016 VL 39 IS 1 BP 5 EP 5 DI 10.5665/sleep.5298 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA0VM UT WOS:000367515700001 PM 26940459 ER PT J AU Janney, CA Kilbourne, AM Germain, A Lai, ZS Hoerster, KD Goodrich, DE Klingaman, EA Verchinina, L Richardson, CR AF Janney, Carol A. Kilbourne, Amy M. Germain, Anne Lai, Zongshan Hoerster, Katherine D. Goodrich, David E. Klingaman, Elizabeth A. Verchinina, Lilia Richardson, Caroline R. TI The Influence of Sleep Disordered Breathing on Weight Loss in a National Weight Management Program SO SLEEP LA English DT Article DE MOVE; obesity; population health; sleep apnea; veterans; weight loss ID LIFE-STYLE INTERVENTION; MENTAL-HEALTH; APNEA; OBESITY; RISK; REDUCTION; DISEASE; IMPACT; ADULTS; TRIAL AB Study Objective: To investigate the influence of sleep disordered breathing (SDB) on weight loss in overweight/obese veterans enrolled in MOVE!, a nationally implemented behavioral weight management program delivered by the National Veterans Health Administration health system. Methods: This observational study evaluated weight loss by SDB status in overweight/obese veterans enrolled in MOVE! from May 2008-February 2012 who had at least two MOVE! visits, baseline weight, and at least one follow-up weight (n = 84,770). SDB was defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Primary outcome was weight change (lb) from MOVE! enrollment to 6- and 12-mo assessments. Weight change over time was modeled with repeated-measures analyses. Results: SDB was diagnosed in one-third of the cohort (n = 28,269). At baseline, veterans with SDB weighed 29 [48] lb more than those without SDB (P < 0.001). On average, veterans attended eight MOVE! visits. Weight loss patterns over time were statistically different between veterans with and without SDB (P < 0.001); veterans with SDB lost less weight (-2.5 [0.1] lb) compared to those without SDB (-3.3 [0.1] lb; P = 0.001) at 6 months. At 12 mo, veterans with SDB continued to lose weight whereas veterans without SDB started to re-gain weight. Conclusions: Veterans with sleep disordered breathing (SDB) had significantly less weight loss over time than veterans without SDB. SDB should be considered in the development and implementation of weight loss programs due to its high prevalence and negative effect on health. C1 [Janney, Carol A.; Kilbourne, Amy M.; Lai, Zongshan; Goodrich, David E.; Verchinina, Lilia; Richardson, Caroline R.] VA Ann Arbor Healthcare Syst, CCMR, Ann Arbor, MI 48109 USA. [Kilbourne, Amy M.] VA Qual Enhancement Res Initiat QUERI, Hlth Serv Res & Dev, Washington, DC USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div Mental Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Klingaman, Elizabeth A.] VA Maryland Healthcare Syst, Baltimore, MD USA. [Klingaman, Elizabeth A.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Richardson, Caroline R.] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI USA. RP Kilbourne, AM (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, 2800 Plymouth Rd,NCRC Bldg 16, Ann Arbor, MI 48109 USA. EM amy.kilbourne@va.gov OI Goodrich, David/0000-0003-3232-2189 FU QUERI programs for Diabetes and Mental Health research as a locally initiated project [QLP 55-017]; VA Center for Clinical Management Research, Health Services Research and Development; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment FX This was not an industry supported study. This report was conducted as a joint quality improvement evaluation involving VA Health Services Research and Development Quality Enhancement Research Initiative (QUERI) programs, VHA National Center for Health Promotion & Disease Prevention (NCP), and VA Serious Mental Illness Resource and Evaluation Center (SMITREC). It is part of a larger quality improvement evaluation of MOVE! conducted by the SMITREC at the request of NCP. Funding was obtained by Dr. Janney and Dr. Goodrich from the QUERI programs for Diabetes and Mental Health research as a locally initiated project (QLP 55-017). Dr. Janney was supported by the VA Center for Clinical Management Research, Health Services Research and Development as a postdoctoral fellow at the VA Ann Arbor Healthcare System. Dr. Klingaman was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment. The funding bodies had no role in the manuscript other than financial support. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Kilbourne is a co-author of the workbook "Overcoming Bipolar Disorder: A Comprehensive Workbook for Managing Your Symptoms & Achieving Your Life Goals" (New Harbinger Publications, Inc., 2008) and receives publication royalties. The other authors have no conflicts of interest to disclose. MOVE! was developed internally by VA behavioral change experts to meet the needs of Veterans and is not a commercial product. NR 35 TC 2 Z9 2 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JAN 1 PY 2016 VL 39 IS 1 BP 59 EP 65 DI 10.5665/sleep.5318 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA0VM UT WOS:000367515700011 PM 26350475 ER PT J AU Reynolds, K Pietrzak, RH Mackenzie, CS Chou, KL Sareen, J AF Reynolds, Kristin Pietrzak, Robert H. Mackenzie, Corey S. Chou, Kee Lee Sareen, Jitender TI Post-Traumatic Stress Disorder Across the Adult Lifespan: Findings From a Nationally Representative Survey SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Epidemiology; PTSD; Characteristics; Lifespan; Older adults ID PSYCHIATRIC DIAGNOSTIC MODULES; COMORBIDITY-SURVEY-REPLICATION; GENERAL-POPULATION SAMPLE; ALCOHOL-USE-DISORDER; IV AUDADIS-IV; OLDER-ADULTS; GERMAN COMMUNITY; MENTAL-DISORDERS; TRAUMA EXPOSURE; AGE-DIFFERENCES AB Objective: There is a dearth of community-based epidemiologic literature that examines post-traumatic stress disorder (PTSD) across the adult lifespan. In the current study the authors address this gap by examining the ways in which PTSD differs among young (ages 20-34), middle-aged (ages 35-64), and older (age 65+) adults with respect to past-year prevalence, nature of "worst" stressful experience ever experienced before the onset of PTSD, all traumatic experiences, symptom expression, psychiatric comorbidities, and mental health-related quality of life. Methods: We analyzed Wave 2 data from the National Epidemiologic Survey on Alcohol and Related Conditions, including adults with past-year diagnoses of PTSD (N = 1,715). Results: The prevalence of past-year PTSD was significantly higher for young (4.3% [SE: 0.3]) and middle-aged (5.2% [SE: 0.2]) adults compared with older adults (2.6% [SE: 0.2]). Respondents in the three age groups differed with regard to their "worst" stressful experience ever experienced before the onset of PTSD and to all traumatic experiences. Older adults experienced significantly fewer traumatic experiences (mean: 5.2; SE: 0.2) compared with young (mean: 5.7; SE: 0.2) and middle-aged adults (mean: 6.4; SE: 0.1). Young and middle-aged adults had significantly greater symptom counts and greater odds of comorbid psychiatric disorders when compared with older adults. PTSD had similar effects on mental health-related quality of life across the adult lifespan. Conclusion: Results highlight key differences in the characteristics of PTSD across the adult lifespan. The overall pattern of findings indicates that increasing age is associated with less severe PTSD profiles, including lower prevalence, fewer traumatic experiences, lower symptom counts, and lower odds of psychiatric comorbidity. C1 [Reynolds, Kristin; Mackenzie, Corey S.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. [Sareen, Jitender] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, US Dept Vet Affairs,Ctr Posttraumat Stress Disord, New Haven, CT 06520 USA. [Chou, Kee Lee] Univ Hong Kong, Dept Asian & Policy Studies, Pokfulam, Hong Kong, Peoples R China. RP Pietrzak, RH (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. EM robert.pietrzak@yale.edu FU Canadian Institutes of Health Research Doctoral Research Award; Manitoba Graduate Scholarship; U.S. Department of Veterans Affairs National Center; Research Grant Council from Strategic Public Policy Research [HKIEd 7001-SPPR-11]; Humanities and Social Sciences Prestigious Fellowship Scheme [38600214]; Manitoba Health Research Council Chair Award FX Reynolds is supported by a Canadian Institutes of Health Research Doctoral Research Award and a Manitoba Graduate Scholarship, R. H. Pietrzak is supported by the U.S. Department of Veterans Affairs National Center for PTSD and a private donation, K.-L. Chou is supported by the Research Grant Council from Strategic Public Policy Research (HKIEd 7001-SPPR-11) and Humanities and Social Sciences Prestigious Fellowship Scheme (38600214), and J. Sareen is supported by a Manitoba Health Research Council Chair Award. The aforementioned funding sources did not have a role in the writing of the manuscript or the decision to submit it for publication. The NESARC was conducted and funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), with supplemental support from the National Institute on Drug Abuse. The authors thank the NIAAA and the U.S. Census Bureau field representatives who administrated the NESARC interviews and made data available to researchers. NR 42 TC 2 Z9 2 U1 4 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JAN PY 2016 VL 24 IS 1 BP 81 EP 93 DI 10.1016/j.jagp.2015.11.001 PG 13 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CZ8FA UT WOS:000367334400011 PM 26706912 ER PT J AU Basu, A Jenkins, AJ Zhang, Y Stoner, JA Klein, RL Lopes-Virella, MF Garvey, WT Lyons, TJ AF Basu, Arpita Jenkins, Alicia J. Zhang, Ying Stoner, Julie A. Klein, Richard L. Lopes-Virella, Maria F. Garvey, W. Timothy Lyons, Timothy J. CA DCCT EDIC Res Grp TI Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes SO ATHEROSCLEROSIS LA English DT Article DE Type 1 diabetes; LDL particles; Non-HDL cholesterol; Nuclear magnetic resonance-determined; lipoprotein subclass profiles ID LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; DCCT/EDIC COHORT; PARTICLE-SIZE; COMPLICATIONS TRIAL/EPIDEMIOLOGY; SUBCLINICAL ATHEROSCLEROSIS; PITTSBURGH EPIDEMIOLOGY; INSULIN-RESISTANCE; RISK-FACTOR; CHOLESTEROL AB Background: Dyslipidemia has been linked to vascular complications of Type 1 diabetes (T1DM). We investigated the prospective associations of nuclear magnetic resonance-determined lipoprotein subclass profiles (NMR-LSP) and conventional lipid profiles with carotid intima-media thickness (IMT) in T1DM. Methods: NMR-LSP and conventional lipids were measured in a subset of Diabetes Control and Complications Trial (DCCT) participants (n = 455) at study entry ('baseline', 1983-89), and were related to carotid IMT determined by ultrasonography during the observational follow-up of the DCCT, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, at EDIC Year 12 (2004-2006). Associations were defined using multiple linear regression stratified by gender, and following adjustment for HbA1c, diabetes duration, body mass index, albuminuria, DCCT randomization group, smoking status, statin use, and ultrasound devices. Results: In men, significant positive associations were observed between some baseline NMR-subclasses of LDL (total IDL/LDL and large LDL) and common and/or internal carotid IMT, and between conventional total- and LDL-cholesterol and non-HDL-cholesterol and common carotid IMT, at EDIC Year 12; these persisted in adjusted analyses (p < 0.05). Large LDL particles and conventional triglycerides were positively associated with common carotid IMT changes over 12 years (p < 0.05). Inverse associations of mean HDL diameter and large HDL concentrations, and positive associations of small LDL with common and/or internal carotid IMT (all p < 0.05) were found, but did not persist in adjusted analyses. No significant associations were observed in women. Conclusion: NMR-LSP-derived LDL particles, in addition to conventional lipid profiles, may help in identifying men with T1DM at highest risk for vascular disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. [Jenkins, Alicia J.; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA. [Jenkins, Alicia J.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. [Zhang, Ying; Stoner, Julie A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Lyons, Timothy J.] Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland. RP Lyons, TJ (reprint author), Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, ICS Block A,Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland. EM t.lyons@qub.ac.uk FU National Institutes of Health [R01DK080043]; American Diabetes Association [7-12-CT-46]; Division of Diabetes Endocrinology and Metabolic Diseases of National Institute of Diabetes and Digestive and Kidney Disease; National Eye Institute; National Institute of Neurologic Disorders and Stroke; Genetic Clinical Research Centers Program; Clinical Translational Science Center Program, Bethesda, Maryland, USA FX This project was funded by grants from the National Institutes of Health (R01DK080043) and the American Diabetes Association (7-12-CT-46).; DCCT/EDIC has been supported by U01 Cooperative Agreement grants (1982-93, 2011-2016), and contracts (1982-2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease, and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present), Bethesda, Maryland, USA. A complete list of participants in the DCCT/EDIC research group can be found in New England Journal of Medicine, 2011; 365: 2366-2376. NR 48 TC 0 Z9 0 U1 3 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD JAN PY 2016 VL 244 BP 93 EP 100 DI 10.1016/j.atherosclerosis.2015.10.106 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CZ8UR UT WOS:000367375100052 PM 26600440 ER PT J AU Fontaine, DA Davis, DB AF Fontaine, Danielle A. Davis, Dawn Belt TI Attention to Background Strain Is Essential for Metabolic Research: C57BL/6 and the International Knockout Mouse Consortium SO DIABETES LA English DT Article ID NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; DIET-INDUCED OBESITY; HIGH-FAT DIET; GENETIC-ANALYSIS; MICE; SUBSTRAINS; EXPRESSION; MUTATION; ISLETS; RELEASE AB The International Knockout Mouse Consortium (IKMC) introduces its targeted constructs into C57BL/6N embryonic stem cells. However, breeding with a Cre-recombinase and/or Flp-recombinase mouse is required for the generation of a null allele with the IKMC cassette. Many recombinase strains are in the C57BL/6J background, resulting in knockout animals on a mixed strain background. This can lead to variability in metabolic data and the use of improper control groups. While C57BL/6N and C57BL/6J are derived from the same parental C57BL/6 strain, there are key genotypic and phenotypic differences between these substrains. Many researchers may not even be aware of these differences, as the shorthand C57BL/6 is often used to describe both substrains. We found that 58% of articles involving genetically modified mouse models did not completely address background strain. This review will describe these two substrains and highlight the importance of separate consideration in mouse model development. Our aim is to increase awareness of this issue in the diabetes research community and to provide practical strategies to enable researchers to avoid mixed strain animals when using IKMC knockout mice. C1 [Fontaine, Danielle A.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Davis, DB (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. EM dbd@medicine.wisc.edu FU University of Wisconsin-Madison (UW-Madison) Institute on Aging (from the National Institute on Aging) [T32 AG000213]; UW-Madison Science and Medicine Graduate Research Scholars program; U.S. Department of Veterans Affairs [1I01BX001880]; UW-Madison Department of Medicine FX D.A.F. is supported by a training grant from the University of Wisconsin-Madison (UW-Madison) Institute on Aging (from the National Institute on Aging [T32 AG000213]) and has been supported by the UW-Madison Science and Medicine Graduate Research Scholars program. D.B.D. is supported by the U.S. Department of Veterans Affairs (1I01BX001880) and the UW-Madison Department of Medicine. NR 62 TC 13 Z9 13 U1 1 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD JAN PY 2016 VL 65 IS 1 BP 25 EP 33 DI 10.2337/db15-0982 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CZ9NS UT WOS:000367424900006 PM 26696638 ER PT J AU Fortney, JC Curran, GM Hunt, JB Cheney, AM Lu, LY Valenstein, M Eisenberg, D AF Fortney, John C. Curran, Geoffrey M. Hunt, Justin B. Cheney, Ann M. Lu, Liya Valenstein, Marcia Eisenberg, Daniel TI Prevalence of probable mental disorders and help-seeking behaviors among veteran and non-veteran community college students SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Psychiatric epidemiology; Community colleges; Veterans; Service utilization ID PSYCHIATRIC-DISORDERS; SOCIAL-CONSEQUENCES; HEALTH; INTERVENTIONS; POPULATION; DEPRESSION; ALCOHOL; SERVICE; PEERS; PTSD AB Objective: Millions of disadvantaged youth and returning veterans are enrolled in community colleges. Our objective was to determine the prevalence of mental disorders and help-seeking behaviors among community college students. Methods: Veterans (n=211) and non-veterans (n=554) were recruited from 11 community colleges and administered screeners for depression (PHQ-9), generalized anxiety (GAD-7), posttraumatic stress disorder (PC-PTSD), non-lethal self-injury, suicide ideation and suicide intent. The survey also asked about the perceived need for, barriers to and utilization of services. Regression analysis was used to compare prevalence between non-veterans and veterans adjusting for non-modifiable factors (age, gender and race/ethnicity). Results: A large proportion of student veterans and non-veterans screened positive and unadjusted bivariate comparisons indicated that student veterans had a significantly higher prevalence of positive depression screens (33.1% versus 19.5%, P<.01), positive PTSD screens (25.7% versus 12.6%, P<.01) and suicide ideation (19.2% versus 10.6%, P=.01). Adjusting for age, gender and race/ethnicity, veterans were significantly more likely than non-veterans to screen positive for depression (OR=2.10, P=.01) and suicide ideation (OR=2.31, P=.03). Student veterans had significantly higher odds of perceiving a need for treatment than non-veterans (OR=1.93, P=.02) but were more likely to perceive stigma (beta=0.28, P=.02). Despite greater need among veterans, there were no significant differences between veterans and non-veterans in use of psychotropic medications, although veterans were more likely to receive psychotherapy (OR=2.35, P=.046). Conclusions: Findings highlight the substantial gap between the prevalence of probable mental health disorders and treatment seeking among community college students. Interventions are needed to link community college students to services, especially for student veterans. (C) 2016 Published by Elsevier Inc. C1 [Fortney, John C.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. [Fortney, John C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Curran, Geoffrey M.] Univ Arkansas Med Sci, Dept Pharm Practice, Coll Pharm, Little Rock, AR 72205 USA. [Curran, Geoffrey M.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Hlth Serv Res & Dev, North Little Rock, AR 72114 USA. [Curran, Geoffrey M.; Hunt, Justin B.; Lu, Liya] Univ Arkansas Med Sci, Dept Psychiat, Coll Med, Little Rock, AR 72205 USA. [Hunt, Justin B.] Vet Hlth Care Syst Ozarks, Fayetteville, AR 72703 USA. [Cheney, Ann M.] Univ Calif Riverside, Dept Psychiat, Riverside, CA 92521 USA. [Valenstein, Marcia] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Valenstein, Marcia] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Hlth Serv Res & Dev, Ann Arbor, MI 48105 USA. [Eisenberg, Daniel] Univ Michigan, Sch Publ Hlth, Hlth Management & Policy, Ann Arbor, MI 48109 USA. RP Fortney, JC (reprint author), Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. EM fortneyj@uw.edu FU National Institute of Mental Health [MH092641]; Department of Defense [DM090465] FX This work was supported by grant number MH092641 from the National Institute of Mental Health and by grant number DM090465 from the Department of Defense. NR 31 TC 3 Z9 3 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2016 VL 38 IS 1 BP 99 EP 104 DI 10.1016/j.genhosppsych.2015.09.007 PG 6 WC Psychiatry SC Psychiatry GA CZ8OC UT WOS:000367358000019 PM 26598288 ER PT J AU Lu, MW Plagge, JM Marsiglio, MC Dobscha, SK AF Lu, Mary W. Plagge, Jane M. Marsiglio, Mary C. Dobscha, Steven K. TI Clinician Documentation on Receipt of Trauma-Focused Evidence-Based Psychotherapies in a VA PTSD Clinic SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; BEHAVIORAL THERAPY; EXPOSURE THERAPY; ASSAULT VICTIMS; VETERANS; IRAQ; AFGHANISTAN; CARE AB The U.S. Department of Veterans Affairs (VA) is implementing two trauma-focused, evidence-based psychotherapies (TF-EBPs) for posttraumatic stress disorder (PTSD): cognitive processing therapy and prolonged exposure therapy (PE). Veterans with PTSD often do not receive these treatments, and little is known about the reasons veterans may not receive TF-EBPs. The aim of this qualitative study was to summarize clinician-reported reasons in medical records for nonreceipt of TF-EBPs. All veterans (N = 63) identified through PTSD screening who were newly engaged in mental health care and received individual evaluations in a PTSD specialty clinic in fiscal year 2008 were included in the sample. Content analysis of electronic medical records revealed multiple potential reasons for nonreceipt of TF-EBPs including referral to other PTSD treatments, other clinical priorities, poor engagement in care, practical barriers, negative beliefs, and receipt of care in other settings. Eight veterans (13 %) initiated TF-EBPs. Further interventions to promote engagement in PTSD treatment are warranted. C1 [Lu, Mary W.; Plagge, Jane M.; Marsiglio, Mary C.; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA. RP Lu, MW (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, POB 1034,Mail Code P3MHDC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Mary.Lu@va.gov; Jane.Plagge@va.gov; Mary.Marsiglio@va.gov; Steven.Dobscha@va.gov FU VA Health Services Research and Development Service (HSRD) [REA 06-174]; Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC) FX This work was supported by VA Health Services Research and Development Service (HSR&D) grants REA 06-174 and the Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC). The authors acknowledge the PTSD Clinical Team at the Portland VA Medical Center, Jonathan Duckart, Anais Tuepker, Joseph Warren, Molly DeLorit, Brittany Tremblay, Sondra Long, William Minium, and Linda Ganzini. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or the U.S. government. NR 42 TC 6 Z9 6 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 EI 1556-3308 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD JAN PY 2016 VL 43 IS 1 BP 71 EP 87 DI 10.1007/s11414-013-9372-9 PG 17 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CZ8GE UT WOS:000367337400006 PM 24158464 ER PT J AU Chiu, C Feuz, MA McMahan, RD Miao, YH Sudore, RL AF Chiu, Catherine Feuz, Mariko A. McMahan, Ryan D. Miao, Yinghui Sudore, Rebecca L. TI "Doctor, Make My Decisions": Decision Control Preferences, Advance Care Planning, and Satisfaction With Communication Among Diverse Older Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Decision control preferences; advance care planning; aging; health disparities; communication ID PERCEIVED INVOLVEMENT; MEDICAL CONSULTATIONS; PATIENT PARTICIPATION; HOSPITALIZED-PATIENTS; MAKING PREFERENCES; CANCER; PHYSICIANS; LIFE; ILLNESS; END AB Context. Culturally diverse older adults may prefer varying control over medical decisions. Decision control preferences (DCPs) may profoundly affect advance care planning (ACP) and communication. Objectives. To determine the DCPs of diverse, older adults and whether DCPs are associated with participant characteristics, ACP, and communication satisfaction. Methods. A total of 146 participants were recruited from clinics and senior centers in San Francisco. We assessed DCPs using the control preferences scale: doctor makes all decisions (low), shares with doctor (medium), makes own decisions (high). We assessed associations between DCPs and demographics; prior advance directives; ability to make in-the-moment goals of care decisions; self-efficacy, readiness, and prior asked questions; and satisfaction with patient-doctor communication (on a five-point Likert scale), using Chi-square and Kruskal-Wallis analysis of variance. Results. Mean age was 71 +/- 10 years, 53% were non-white, 47% completed an advance directive, and 70% made goals of care decisions. Of the sample, 18% had low DCPs, 33% medium, and 49% high. Older age was the only characteristic associated with DCPs (low: 75 +/- 11 years, medium: 69 +/- 10 years, high: 70 +/- 9 years, P = 0.003). DCPs were not associated with ACP, in-the-moment decisions, or communication satisfaction. Readiness was the only question-asking behavior associated (low: 3.8 +/- 1.2, medium: 4.1 +/- 1.2, high: 4.3 +/- 1.2, P = 0.05). Conclusion. Nearly one-fifth of diverse, older adults want doctors to make their medical decisions. Older age and lower readiness to ask questions were the only demographic variables significantly associated with low DCPs. Yet, older adults with low DCPs still engaged in ACP, asked questions, and reported communication satisfaction. Clinicians can encourage ACP and questions for all patients, but should assess DCPs to provide the desired amount of decision support. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Chiu, Catherine; Feuz, Mariko A.; McMahan, Ryan D.; Miao, Yinghui; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Feuz, Mariko A.; McMahan, Ryan D.; Miao, Yinghui; Sudore, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Chiu, C (reprint author), 500 Parnassus Ave, San Francisco, CA 94122 USA. EM catherine.chiu@ucsf.edu FU Medical Student Training in Aging Research (MSTAR) Program; National Institute on Aging [T35AG026736]; John A. Hartford Foundation; MetLife Foundation; Lillian R. Gleitsman Foundation FX The research was supported by the Medical Student Training in Aging Research (MSTAR) Program. The MSTAR program is funded by the National Institute on Aging (T35AG026736), the John A. Hartford Foundation, the MetLife Foundation, and the Lillian R. Gleitsman Foundation. The investigators retained full independence in the conduct of this research. The authors declare no conflicts of interest. NR 43 TC 2 Z9 2 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2016 VL 51 IS 1 BP 33 EP 40 DI 10.1016/j.jpainsymman.2015.07.018 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CZ8WE UT WOS:000367379000007 PM 26342727 ER PT J AU Hartwell, KJ Hanlon, CA Li, XB Borckardt, JJ Canterberry, M Prisciandaro, JJ Moran-Santa Maria, MM LeMatty, T George, MS Brady, KT AF Hartwell, Karen J. Hanlon, Colleen A. Li, Xingbao Borckardt, Jeffrey J. Canterberry, Melanie Prisciandaro, James J. Moran-Santa Maria, Megan M. LeMatty, Todd George, Mark S. Brady, Kathleen T. TI Individualized real-time fMRI neurofeedback to attenuate craving in nicotine-dependent smokers SO JOURNAL OF PSYCHIATRY & NEUROSCIENCE LA English DT Article ID ANTERIOR CINGULATE CORTEX; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MEDIAL PREFRONTAL CORTEX; SMOKING CUES; SELF-REGULATION; ADOLESCENT SMOKERS; DECISION-MAKING; UNITED-STATES; DSM-IV; BRAIN AB Background Cue-induced craving plays an important role in relapse, and the neural correlates of cue-induced craving have been elucidated using fMRI. This study examined the utility of real-time fMRI (rtfMRI) neurofeedback to strengthen self-regulation of craving-related neural activation and cue-reactivity in cigarette smokers. Methods Nicotine-dependent smokers were randomized to rtfMRI neurofeedback or to a no-feedback control group. Participants completed 3 neuroimaging visits. Within each visit, an initial run during which smoking-related cues were used to provoke craving, an individualized craving-related region of interest (ROI) in the prefrontal cortex or anterior cingulate cortex was identified. In the rtfMRI group, activity from the ROI was fed back via a visual display during 3 subsequent runs while participants were instructed to reduce craving during cue exposure. The control group had an identical experience with no feedback provided. Results Forty-four nicotine-dependent smokers were recruited to participate in our study; data from the 33 participants who completed a 1-week follow-up visit were included in the analysis. Subjective craving ratings and cue-induced brain activation were lower in the rtfMRI group than in the control group. Limitations As participants were not seeking treatment, clinical outcomes are lacking. Conclusion Nicotine-dependent smokers receiving rtfMRI feedback from an individualized ROI attenuated smoking cue-elicited neural activation and craving, relative to a control group. Further studies are needed in treatment-seeking smokers to determine if this intervention can translate into a clinically meaningful treatment modality. C1 [Hartwell, Karen J.; Hanlon, Colleen A.; Li, Xingbao; Borckardt, Jeffrey J.; Canterberry, Melanie; Prisciandaro, James J.; Moran-Santa Maria, Megan M.; LeMatty, Todd; George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hartwell, Karen J.; George, Mark S.; Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hartwell, KJ (reprint author), 125 Doughty St,Suite 190, Charleston, SC 29403 USA. EM hartwelk@musc.edu FU National Institute of Drug Abuse [5R21DA026085, 5R33DA026085] FX The study was supported by grant 5R21DA026085 and 5R33DA026085 from the National Institute of Drug Abuse (co-primary investigators: K. Brady and M. George). The National Institute of Drug Abuse had no role in the study design nor conduct of the study, including data collection, data analysis, interpretation of the results, manuscript preparation, review, and approval or the decision to submit the manuscript for publication. The authors thank Danielle Paquette for her assistance with the laboratory cue-reactivity sessions outside of the scanner and everyone who shared their expertise and assisted in the development of the real-time fMRI neurofeedback paradigm. NR 56 TC 3 Z9 3 U1 2 U2 11 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 1180-4882 EI 1488-2434 J9 J PSYCHIATR NEUROSCI JI J. Psychiatry Neurosci. PD JAN PY 2016 VL 41 IS 1 BP 48 EP 55 DI 10.1503/jpn.140200 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CZ9SV UT WOS:000367438200006 PM 26505139 ER PT J AU Harvey, PD Aslan, M Du, MT Zhao, HY Siever, LJ Pulver, A Gaziano, JM Concato, J AF Harvey, Philip D. Aslan, Mihaela Du, Mengtian Zhao, Hongyu Siever, Larry J. Pulver, Ann Gaziano, J. Michael Concato, John TI Factor Structure of Cognition and Functional Capacity in Two Studies of Schizophrenia and Bipolar Disorder: Implications for Genomic Studies SO NEUROPSYCHOLOGY LA English DT Article DE bipolar disorder; schizophrenia; cognition; functional capacity; factor analysis ID ASHKENAZI JEWISH FAMILIES; GENOMEWIDE LINKAGE SCAN; SUSCEPTIBILITY LOCI; CANDIDATE GENES; MENTAL-ILLNESS; I DISORDER; GENETICS; ENDOPHENOTYPES; IMPAIRMENT; CONSORTIUM AB Objective: Impairments in cognition and everyday functioning are common in schizophrenia and bipolar disorder (BPD). In this article, we present factor analyses of cognitive and functional capacity (FC) measures based on 2 studies of schizophrenia (SCZ) and bipolar I disorder (BPI) using similar methods. The overall goal of these analyses was to determine whether performance-based assessments should be examined individually, or aggregated on the basis of the correlational structure of the tests, as well as to evaluate the similarity of factor structures of SCZ and BPI. Method: Veterans Affairs Cooperative Studies Program Study #572 (Harvey et al., 2014) evaluated cognitive and FC measures among 5,414 BPI and 3,942 SCZ patients. A 2nd study evaluated similar neuropsychological (NP) and FC measures among 368 BPI and 436 SCZ patients. Principal components analysis, as well as exploratory and CFAs, were used to examine the data. Results: Analyses in both datasets suggested that NP and FC measures were explained by a single underlying factor in BPI and SCZ patients, both when analyzed separately or as in a combined sample. The factor structure in both studies was similar, with or without inclusion of FC measures; homogeneous loadings were observed for that single factor across cognitive and FC domains across the samples. Conclusion: The empirically derived factor model suggests that NP performance and FC are best explained as a single latent trait applicable to people with SCZ and BPD. This single measure may enhance the robustness of the analyses relating genomic data to performance-based phenotypes. C1 [Harvey, Philip D.] Bruce W Carter Miami Vet Affairs Med Ctr, Dept Res Serv, Miami, FL USA. [Harvey, Philip D.] Univ Miami, Dept Psychiat & Behav Sci, Miller Sch Med, Miami, FL 33136 USA. [Aslan, Mihaela; Zhao, Hongyu; Concato, John] Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA. [Aslan, Mihaela; Concato, John] Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA. [Du, Mengtian] Yale Univ, Dept Stat, Grad Sch Arts & Sci, New Haven, CT 06520 USA. [Zhao, Hongyu] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT 06520 USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Dept Psychiat Serv, Bronx, NY USA. [Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Pulver, Ann] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Pulver, Ann] Johns Hopkins Univ, Dept Psychiat, Sch Med, Baltimore, MD 21218 USA. [Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Jamaica Plain, MA USA. [Gaziano, J. Michael] Harvard Univ, Dept Cardiol, Sch Med, Cambridge, MA 02138 USA. RP Harvey, PD (reprint author), Univ Miami, Dept Psychiat & Behav Sci, Miller Sch Med, 1120 Northwest 14th St,Suite 1450, Miami, FL 33136 USA. EM philip.harvey2@va.gov FU U.S. Department of Veterans Affairs Cooperative Studies Program; NIMH [R01MH079784] FX This research was supported by the U.S. Department of Veterans Affairs Cooperative Studies Program. Dr. Harvey has served as a consultant to Boeheringer Ingelheim, Forum Pharmaceuticals, Genentech, Otsuka America, Roche, Sanofi, Sunovion Pharma, and Takeda Pharma, on Phase-2 or -3 drug development; this consulting work is not related to the content of the paper. This research was also supported in part by NIMH grant R01MH079784 to Dr. Pulver. NR 39 TC 0 Z9 0 U1 6 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD JAN PY 2016 VL 30 IS 1 BP 28 EP 39 DI 10.1037/neu0000245 PG 12 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA CZ8CC UT WOS:000367326600004 PM 26710094 ER PT J AU Cheng, A Owens, D AF Cheng, Andrew Owens, David TI Republished: Marfan syndrome, inherited aortopathies and exercise: What is the right answer? SO POSTGRADUATE MEDICAL JOURNAL LA English DT Review ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION; CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; ASSOCIATION; RECOMMENDATIONS AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist. C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA. [Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ACheng@cardiology.washington.edu NR 39 TC 0 Z9 0 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0032-5473 EI 1469-0756 J9 POSTGRAD MED J JI Postgrad. Med. J. PD JAN PY 2016 VL 92 IS 1083 BP 51 EP 56 DI 10.1136/postgradmedj-2014-306440rep PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DA0HR UT WOS:000367478700009 PM 26676914 ER PT J AU Lehrner, A Flory, JD Sierer, LM Makotkine, I Marmar, CR Yehuda, R AF Lehrner, Amy Flory, Janine D. Sierer, Linda M. Makotkine, Iouri Marmar, Charles R. Yehuda, Rachel TI Sexual dysfunction and neuroendocrine correlates of posttraumatic stress disorder in combat veterans: Preliminary findings SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Sexual dysfunction; Posttraumatic stress disorder; Neurobiology; Neuroendocrinology ID WAR VETERANS; PTSD; MEN; SYMPTOMS; TRIAL AB Sexual dysfunction is not a symptom of PTSD but is a common clinical complaint in trauma survivors with this disorder. In that there are biological parallels in the neuroendocrine processes underlying both PTSD and sexual behavior, we conducted an exploratory investigation of the relationship of PTSD and related neuroendocrine indicators with sexual dysfunction in armed service veterans. Major Depressive Disorder, highly comorbid with PTSD and sexual dysfunction, was also assessed. In veterans with PTSD, sexual problems were associated with plasma DHEA and cortisol, urinary catecholamines, and glucocorticoid sensitivity, even when controlling for the effects of comorbid depression. In a subsample analysis, testosterone levels did not distinguish PTSD or sexual dysfunction, suggesting that sexual problems reported by veterans in this sample were not the result of organic disorder. PTSD did predict higher dihydrotestosterone (DHT) levels, which were associated with sexual problems. More detailed assessment of sexual dysfunction in biologically informed studies of PTSD is warranted to clarify the relationships of PTSD symptomatology and related neurobiology with sexual dysfunction. Published by Elsevier Ltd. C1 [Lehrner, Amy; Flory, Janine D.; Sierer, Linda M.; Makotkine, Iouri; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY 10468 USA. [Lehrner, Amy; Flory, Janine D.; Sierer, Linda M.; Makotkine, Iouri; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Marmar, Charles R.] NYU, Langone Sch Med, New York, NY USA. RP Lehrner, A (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM amy.lehrner@va.gov FU Lightfighter Trust [LFT2009-02-1]; US Department of Defense [DOD W81XWH-06-0032, DOD W81XWH-10-2-0072, DOD W81XWH-09-2-0044] FX Parent studies for the data included in this report were funded by the Lightfighter Trust (LFT2009-02-1) and the US Department of Defense (DOD W81XWH-06-0032, DOD W81XWH-10-2-0072, DOD W81XWH-09-2-0044). NR 24 TC 0 Z9 0 U1 6 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD JAN PY 2016 VL 63 BP 271 EP 275 DI 10.1016/j.psyneuen.2015.10.015 PG 5 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA CZ9MT UT WOS:000367422400033 PM 26529050 ER PT J AU Barry, CL Kennedy-Hendricks, A Gollust, SE Niederdeppe, J Bachhuber, MA Webster, DW McGinty, EE AF Barry, Colleen L. Kennedy-Hendricks, Alene Gollust, Sarah E. Niederdeppe, Jeff Bachhuber, Marcus A. Webster, Daniel W. McGinty, Emma E. TI Understanding Americans' views on opioid pain reliever abuse SO ADDICTION LA English DT Article DE Addiction; opioid analgesics; policy; public opinion; substance abuse; surveys ID POLICY; OPINION; SUPPORT AB AimsOpioid pain reliever abuse rates have increased sharply in the United States. This study examines Americans' personal experience with opioid pain reliever use and abuse, and views about the seriousness of the problem, factors causing it, responsibility for addressing it and support for policies to resolve it. DesignPublic opinion survey. Setting and ParticipantsA nationally representative US adult sample (n=1111). MeasuresExperiences with opioid pain relievers and views about the seriousness, causes of and responsibility for addressing the problem, and support for policies to reduce opioid pain reliever abuse. Findings28.2 per cent of Americans reported using opioid pain relievers in the last 12 months, 69.5% have used them in their life-time and 17.3% reported using these medications when not prescribed to them. Fifty-eight per cent ranked the problem as serious, on a par with other major health concerns. Individual-orientated factors, including a lack of understanding about how easy it is to become addicted (80.0%) and improper storage (65.1%) and disposal (64.1%), ranked highest as causes, and those abusing opioid pain relievers (83.8%) and their physicians (78.0%) were viewed as most responsible for solving the problem. Of the policies recommended to curb the epidemic, 14 of 16 were supported by a majority of Americans. ConclusionsAmericans view the problem of opioid pain reliever abuse as serious, and support nearly all the policies recommended by medical, law enforcement, disease control and public health experts to curb the epidemic. C1 [Barry, Colleen L.; Kennedy-Hendricks, Alene; Webster, Daniel W.; McGinty, Emma E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA. [Barry, Colleen L.; Bachhuber, Marcus A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Gollust, Sarah E.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA. [Niederdeppe, Jeff] Cornell Univ, Dept Commun, Ithaca, NY USA. [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bachhuber, Marcus A.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Webster, Daniel W.; McGinty, Emma E.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD 21205 USA. RP Barry, CL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 403, Baltimore, MD 21205 USA. EM cbarry@jhu.edu OI Bachhuber, Marcus/0000-0002-5610-8382 FU AIG, Inc. FX Funding for this study was obtained through an unrestricted research grant from AIG, Inc. The funder had no role in the study design, analysis, interpretation or drafting of this manuscript. The authors have no conflicts of interests to declare. NR 28 TC 4 Z9 4 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 85 EP 93 DI 10.1111/add.13077 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500017 PM 26212522 ER PT J AU Baker, TB Collins, LM Mermelstein, R Piper, ME Schlam, TR Cook, JW Bolt, DM Smith, SS Jorenby, DE Fraser, D Loh, WY Theobald, WE Fiore, MC AF Baker, Timothy B. Collins, Linda M. Mermelstein, Robin Piper, Megan E. Schlam, Tanya R. Cook, Jessica W. Bolt, Daniel M. Smith, Stevens S. Jorenby, Douglas E. Fraser, David Loh, Wei-Yin Theobald, Wendy E. Fiore, Michael C. TI Enhancing the effectiveness of smoking treatment research: conceptual bases and progress SO ADDICTION LA English DT Article DE Chronic care smoking treatment; cigarettes; comparative effectiveness; factorial experiment; methodology; Multiphase Optimization Strategy (MOST); phase-based model; primary care; quitting smoking; smoking cessation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; HEALTH BEHAVIOR-CHANGE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE MANAGEMENT; ELECTRONIC MEDICAL-RECORD; BUPROPION SR; STOP SMOKING; INTERVENTION COMPONENTS; CESSATION INTERVENTION; FACTORIAL-EXPERIMENTS AB Background and aimsA chronic care strategy could potentially enhance the reach and effectiveness of smoking treatment by providing effective interventions for all smokers, including those who are initially unwilling to quit. This paper describes the conceptual bases of a National Cancer Institute-funded research program designed to develop an optimized, comprehensive, chronic care smoking treatment. MethodsThis research is grounded in three methodological approaches: (1) the Phase-Based Model, which guides the selection of intervention components to be experimentally evaluated for the different phases of smoking treatment (motivation, preparation, cessation, and maintenance); (2) the Multiphase Optimization Strategy (MOST), which guides the screening of intervention components via efficient experimental designs and, ultimately, the assembly of promising components into an optimized treatment package; and (3) pragmatic research methods, such as electronic health record recruitment, that facilitate the efficient translation of research findings into clinical practice. Using this foundation and working in primary care clinics, we conducted three factorial experiments (reported in three accompanying papers) to screen 15 motivation, preparation, cessation and maintenance phase intervention components for possible inclusion in a chronic care smoking treatment program. ResultsThis research identified intervention components with relatively strong evidence of effectiveness at particular phases of smoking treatment and it demonstrated the efficiency of the MOST approach in terms both of the number of intervention components tested and of the richness of the information yielded. ConclusionsA new, synthesized research approach efficiently evaluates multiple intervention components to identify promising components for every phase of smoking treatment. Many intervention components interact with one another, supporting the use of factorial experiments in smoking treatment development. C1 [Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Cook, Jessica W.; Smith, Stevens S.; Jorenby, Douglas E.; Fraser, David; Theobald, Wendy E.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Cook, Jessica W.; Smith, Stevens S.; Jorenby, Douglas E.; Fraser, David; Theobald, Wendy E.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. RP Fiore, MC (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM mcf@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; NSF [DMS-1305725]; NIH [P50DA10075, R01DK097364] FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. W.-Y.L. is also supported by NSF grant DMS-1305725. L.M.C. is also supported by NIH grants P50DA10075 and R01DK097364. NR 88 TC 5 Z9 5 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 107 EP 116 DI 10.1111/add.13154 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500019 PM 26581974 ER PT J AU Cook, JW Collins, LM Fiore, MC Smith, SS Fraser, D Bolt, DM Baker, TB Piper, ME Schlam, TR Jorenby, D Loh, WY Mermelstein, R AF Cook, Jessica W. Collins, Linda M. Fiore, Michael C. Smith, Stevens S. Fraser, David Bolt, Daniel M. Baker, Timothy B. Piper, Megan E. Schlam, Tanya R. Jorenby, Douglas Loh, Wei-Yin Mermelstein, Robin TI Comparative effectiveness of motivation phase intervention components for use with smokers unwilling to quit: a factorial screening experiment SO ADDICTION LA English DT Article DE Chronic care smoking treatment; comparative effectiveness; factorial experiment; motivational interviewing; Multi-phase Optimization Strategy (MOST); nicotine replacement therapy; Phase-Based Model; primary care; smoking cessation; smoking reduction ID NICOTINE REPLACEMENT THERAPY; INCREASE FUTURE CESSATION; CURRENT CIGARETTE-SMOKING; RANDOMIZED-TRIAL; UNITED-STATES; ADULT SMOKERS; BEHAVIORAL INTERVENTIONS; TOBACCO DEPENDENCE; DISEASE MANAGEMENT; GENERAL-POPULATION AB AimsTo screen promising intervention components designed to reduce smoking and promote abstinence in smokers initially unwilling to quit. DesignA balanced, four-factor, randomized factorial experiment. SettingEleven primary care clinics in southern Wisconsin, USA. ParticipantsA total of 517 adult smokers (63.4% women, 91.1% white) recruited during primary care visits who were willing to reduce their smoking but not quit. InterventionsFour factors contrasted intervention components designed to reduce smoking and promote abstinence: (1) nicotine patch versus none; (2) nicotine gum versus none; (3) motivational interviewing (MI) versus none; and (4) behavioral reduction counseling (BR) versus none. Participants could request cessation treatment at any point during the study. MeasurementsThe primary outcome was percentage change in cigarettes smoked per day at 26weeks post-study enrollment; the secondary outcomes were percentage change at 12 weeks and point-prevalence abstinence at 12 and 26 weeks post-study enrollment. FindingsThere were few main effects, but a significant four-way interaction at 26weeks post-study enrollment (P=0.01, =0.12) revealed relatively large smoking reductions by two component combinations: nicotine gum combined with BR and BR combined with MI. Further, BR improved 12-week abstinence rates (P=0.04), and nicotine gum, when used without MI, increased 26-week abstinence after a subsequent aided quit attempt (P=0.01). ConclusionsMotivation-phase nicotine gum and behavioral reduction counseling are promising intervention components for smokers who are initially unwilling to quit. C1 [Cook, Jessica W.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Jorenby, Douglas] Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI 53711 USA. [Cook, Jessica W.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Jorenby, Douglas] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. RP Cook, JW (reprint author), Univ Wisconsin, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. EM jwcook@ctri.medicine.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; NSF [DMS-1305725]; NIH [P50DA10075, R01DK097364]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; Eli Lilly and Company FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. W.-Y.L. is also supported by NSF grant DMS-1305725. L. M.C. is also supported by NIH grants P50DA10075 and R01DK097364. J.W.C. is supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody funded substantially by one of these organizations. W.-Y.L. is supported partially by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment. NR 70 TC 4 Z9 4 U1 5 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 117 EP 128 DI 10.1111/add.13161 PG 12 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500020 PM 26582140 ER PT J AU Piper, ME Fiore, MC Smith, SS Fraser, D Bolt, DM Collins, LM Mermelstein, R Schlam, TR Cook, JW Jorenby, DE Loh, WY Baker, TB AF Piper, Megan E. Fiore, Michael C. Smith, Stevens S. Fraser, David Bolt, Daniel M. Collins, Linda M. Mermelstein, Robin Schlam, Tanya R. Cook, Jessica W. Jorenby, Douglas E. Loh, Wei-Yin Baker, Timothy B. TI Identifying effective intervention components for smoking cessation: a factorial screening experiment SO ADDICTION LA English DT Article DE Chronic care smoking treatment; comparative effectiveness; factorial experiment; Multiphase Optimization Strategy (MOST); nicotine replacement therapy; Phase-Based Model of smoking treatment; primary care; smoking cessation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; RANDOMIZED-TRIAL; PRECESSATION TREATMENT; WITHDRAWAL SYMPTOMS; SELF-DETERMINATION; TOBACCO CESSATION; FUTURE CESSATION; CIGARETTE USE; ABSTINENCE; PATCH AB Aim To identify promising intervention components intended to help smokers to attain and maintain abstinence in their quit smoking attempts. DesignA fully crossed, six-factor randomized fractional factorial experiment. SettingEleven primary care clinics in southern Wisconsin, USA. ParticipantsA total of 637 adult smokers (55% women, 88% white) motivated to quit smoking who visited primary care clinics. InterventionsSix intervention components designed to prepare smokers to quit, and achieve and maintain abstinence (i.e. for the preparation, cessation and maintenance phases of smoking treatment): (1) preparation nicotine patch versus none; (2) preparation nicotine gum versus none; (3) preparation counseling versus none; (4) intensive cessation in-person counseling versus minimal; (5) intensive cessation telephone counseling versus minimal; and (6) 16 versus 8weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum). MeasurementsSeven-day self-reported point-prevalence abstinence at 16weeks. FindingsPreparation counseling significantly improved week 16 abstinence rates (P = .04), while both forms of preparation nicotine replacement therapy interacted synergistically with intensive cessation in-person counseling (P<0.05). Conversely, intensive cessation phone counseling and intensive cessation in-person counseling interacted antagonistically (P<0.05)these components produced higher abstinence rates by themselves than in combination. ConclusionsPreparation counseling and the combination of intensive cessation in-person counseling with preparation nicotine gum or patch are promising intervention components for smoking and should be evaluated as an integrated treatment package. C1 [Piper, Megan E.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Schlam, Tanya R.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Piper, Megan E.; Fiore, Michael C.; Smith, Stevens S.; Schlam, Tanya R.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. RP Piper, ME (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM mep@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; NIH [P50DA10075, R01DK097364]; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; NSF [DMS-1305725]; Eli Lilly and Company FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. L.M. C. is also supported by NIH grants P50DA10075 and R01DK097364. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. J.W.C. is also supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. W.-Y.L. is also supported by NSF grant DMS-1305725. The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody substantially funded by one of these organizations. W.-Y.L. is partially supported by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment. NR 71 TC 10 Z9 11 U1 8 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 129 EP 141 DI 10.1111/add.13162 PG 13 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500021 PM 26582269 ER PT J AU Schlam, TR Fiore, MC Smith, SS Fraser, D Bolt, DM Collins, LM Mermelstein, R Piper, ME Cook, JW Jorenby, DE Loh, WY Baker, TB AF Schlam, Tanya R. Fiore, Michael C. Smith, Stevens S. Fraser, David Bolt, Daniel M. Collins, Linda M. Mermelstein, Robin Piper, Megan E. Cook, Jessica W. Jorenby, Douglas E. Loh, Wei-Yin Baker, Timothy B. TI Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment SO ADDICTION LA English DT Article DE Chronic care smoking treatment; comparative effectiveness; electronic medication monitoring; factorial experiment; medication adherence; Multiphase Optimization Strategy (MOST); nicotine replacement therapy; Phase-Based Model of smoking treatment; primary care; relapse prevention; smoking cessation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; RANDOMIZED CLINICAL-TRIAL; RELAPSE PREVENTION; QUITTING SMOKING; MEDICATION ADHERENCE; MEMS FEEDBACK; ADULT SMOKERS; CESSATION; PATCH; CIGARETTE AB AimsTo identify promising intervention components that help smokers attain and maintain abstinence during a quit attempt. DesignA 2x2x2x2x2 randomized factorial experiment. SettingEleven primary care clinics in Wisconsin, USA. ParticipantsA total of 544 smokers (59% women, 86% white) recruited during primary care visits and motivated to quit. InterventionsFive intervention components designed to help smokers attain and maintain abstinence: (1) extended medication (26 versus 8 weeks of nicotine patch+nicotine gum); (2) maintenance (phone) counseling versus none; (3) medication adherence counseling versus none; (4) automated (medication) adherence calls versus none; and (5) electronic medication monitoring with feedback and counseling versus electronic medication monitoring alone. MeasurementsThe primary outcome was 7-day self-reported point-prevalence abstinence 1 year after the target quit day. FindingsOnly extended medication produced a main effect. Twenty-six versus 8 weeks of medication improved point-prevalence abstinence rates (43 versus 34% at 6 months; 34 versus 27% at 1 year; P =0.01 for both). There were four interaction effects at 1 year, showing that an intervention component's effectiveness depended upon the components with which it was combined. ConclusionsTwenty-six weeks of nicotine patch+nicotine gum (versus 8 weeks) and maintenance counseling provided by phone are promising intervention components for the cessation and maintenance phases of smoking treatment. C1 [Schlam, Tanya R.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Piper, Megan E.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Schlam, Tanya R.; Fiore, Michael C.; Smith, Stevens S.; Piper, Megan E.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, State Coll, PA USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, State Coll, PA USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53711 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. RP Schlam, TR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM trschlam@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; National Science Foundation [DMS-1305725]; NIH [P50DA10075, R01DK097364]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; Eli Lilly and Company FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. W.-Y.L. is also supported by National Science Foundation grant DMS-1305725. L.M.C. is also supported by NIH grants P50DA10075 and R01DK097364. J.W.C. is supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs.; The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody funded substantially by one of these organizations. W.-Y.L. is supported partially by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment. NR 63 TC 6 Z9 6 U1 6 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 142 EP 155 DI 10.1111/add.13153 PG 14 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500022 PM 26581819 ER PT J AU Greenan, CW Christensen, C Wojciechowski, B Taam, R Newman, RB AF Greenan, Candice W. Christensen, Colleen Wojciechowski, Barbara Taam, Rosalea Newman, Roger B. TI Gestational weight gain in twin pregnancies: does achievement of body mass index-specific weight gain recommendations reduce preterm birth and neonatal morbidity? SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 36th Annual Pregnancy Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2016 CL Atlanta, GA SP Soc Maternal Fetal Med C1 [Greenan, Candice W.; Christensen, Colleen; Taam, Rosalea; Newman, Roger B.] Med Univ S Carolina, Charleston, SC 29425 USA. [Wojciechowski, Barbara] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2016 VL 214 IS 1 SU S MA 422 BP S233 EP S233 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CZ4SK UT WOS:000367092800416 ER PT J AU Greenan, CW Christensen, C Wojciechowski, B Taam, R Newman, R AF Greenan, Candice W. Christensen, Colleen Wojciechowski, Barbara Taam, Rosalea Newman, Roger TI Validation of body mass index (BMI)-specific weight gain recommendations for twin gestations in all maternal BMI categories SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 36th Annual Pregnancy Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2016 CL Atlanta, GA SP Soc Maternal Fetal Med C1 [Greenan, Candice W.; Christensen, Colleen; Taam, Rosalea; Newman, Roger] Med Univ S Carolina, Charleston, SC 29425 USA. [Wojciechowski, Barbara] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2016 VL 214 IS 1 SU S MA 282 BP S163 EP S163 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CZ4SK UT WOS:000367092800278 ER PT J AU Khan, M Dhammu, TS Matsuda, F Annamalai, B Dhindsa, TS Singh, I Singh, AK AF Khan, Mushfiquddin Dhammu, Tajinder S. Matsuda, Fumiyo Annamalai, Balasubramaniam Dhindsa, Tejbir Singh Singh, Inderjit Singh, Avtar K. TI Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI SO BRAIN RESEARCH LA English DT Article DE TBI; GSNO; Calpain; Peroxynitrite; nNOS; Neurodegeneration ID TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; S-NITROSOGLUTATHIONE; EXPERIMENTAL STROKE; RAT MODEL; CYTOSKELETAL DEGRADATION; PEROXYNITRITE FORMATION AB Traumatic brain injury (TB!) derails nitric oxide (NO)-based anti-inflammatory and anti-excitotoxicity mechanisms. NO is consumed by superoxide to form peroxynitrite, leading to decreased NO bioavailability for S-nitrosoglutathione (GSNO) synthesis and regulation of neuroprotective pathways. Neuronal peroxynitrite is implicated in neuronal loss and functional deficits following TBI. Using a contusion mouse model of TBI, we investigated mechanisms for the opposed roles of GSNO versus peroxynitrite for neuroprotection and functional recovery. TBI was induced by controlled cortical impact (CCI) in adult male mice. GSNO treatment at 2 h after CCI decreased the expression levels of phospho neuronal nitric oxide synthase (pnNOS), alpha II spectrin degraded products, and 3-NT, while also decreasing the activities of nNOS and calpains. Treatment of TBI with FeTPPS, a peroxynitrite scavenger, had effects similar to GSNO treatment. GSNO treatment of TBI also reduced neuronal degeneration and improved neurobehavioral function in a two-week TB! study. In a cell free system, SIN-1 (a peroxynitrite donor and 3-nitrotyrosinating agent) increased whereas GSNO (an S-nitrosylating agent) decreased calpain activity, and these activities were reversed by, respectively, FeTPPS and mercuric chloride, a cysteine-NO bond cleaving agent. These data indicate that peroxynitrite-mediated activation and GSNO-mediated inhibition of the deleterious nNOS/calpain system play critical roles in the pathobiology of neuronal protection and functional recovery in TBI disease. Given GSNO's safety record in other diseases, its neuroprotective efficacy and promotion of functional recovery in this TBI study make low-dose GSNO a potential candidate for preclinical evaluation. (C) 2015 Elsevier B.V. All rights reserved. C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Annamalai, Balasubramaniam; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu; dhammu@musc.edu; fumiyo@health.nop.kagoshima-u.ac.jp; annamal@musc.edu; dhindsat@musc.edu; singhi@musc.edu; singha@musc.edu FU NIH [NS-72511]; VA Merit Award [BX001062, BX002829]; NIH from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR018823, C06 RR015455] FX This work was supported by grants from NIH (NS-72511) and VA Merit Award (BX001062 and BX002829). This work was also supported by the NIH, Grants C06 RR018823 and No. C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan and Ms. Terry Hope for their technical help and secretarial assistance. We are grateful to Ms. Danielle Lowe (MD/PhD student at the MUSC) for statistical analysis. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript. NR 63 TC 2 Z9 2 U1 2 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD JAN 1 PY 2016 VL 1630 BP 159 EP 170 DI 10.1016/j.brainres.2015.11.015 PG 12 WC Neurosciences SC Neurosciences & Neurology GA CZ4YU UT WOS:000367109900016 PM 26596859 ER PT J AU Ijadi-Maghsoodi, R Cook, M Barnert, ES Gaboian, S Bath, E AF Ijadi-Maghsoodi, Roya Cook, Mekeila Barnert, Elizabeth S. Gaboian, Shushanik Bath, Eraka TI Understanding and Responding to the Needs of Commercially Sexually Exploited Youth Recommendations for the Mental Health Provider SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Commercially sexually exploited children; Commercial sexual exploitation of children; Sex trafficking; Human trafficking; Exploitation ID RANDOMIZED CONTROLLED-TRIAL; SEX TRAFFICKING; UNITED-STATES; TRAUMA; ABUSE; WOMEN; PROSTITUTION; SERVICES; CHILDREN; THERAPY AB Mental health providers are frequently at the forefront of addressing the multifaceted needs of commercially sexually exploited youth. This article provides an overview of the definition of commercial sexual exploitation of children and relevant legislation including the shift toward decriminalization of commercially sexually exploited youth. To provide clinicians with tools needed to deliver competent care to this population, a review of risk factors for commercial sexual exploitation of children and the role of the clinician in identification, assessment, and treatment of commercially sexually exploited youth are discussed. C1 [Ijadi-Maghsoodi, Roya] Off Healthcare Transformat & Innovat, VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA 90073 USA. [Ijadi-Maghsoodi, Roya] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Cook, Mekeila] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Integrated Subst Abuse Programs, Los Angeles, CA 90025 USA. [Barnert, Elizabeth S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Gaboian, Shushanik] Univ Calif Los Angeles, Dept Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Bath, Eraka] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Child Forens Serv, Los Angeles, CA 90095 USA. RP Ijadi-Maghsoodi, R (reprint author), Off Healthcare Transformat & Innovat, VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 11301 Wilshire Blvd,Bldg 500,Room 1601, Los Angeles, CA 90073 USA. EM rijadimaghsoodi@mednet.ucla.edu FU VA Office of Academic Affiliations through VA Advanced Fellowship in Women's Health; NIMH [2P20 MD000182]; Los Angeles County Department of Probation FX Dr R. Ijadi-Maghsoodi is supported by the VA Office of Academic Affiliations through the VA Advanced Fellowship in Women's Health. Dr E. Bath receives funding from the NIMH (2P20 MD000182) and the Los Angeles County Department of Probation. Dr R. Ijadi-Maghsoodi, Dr E.S. Barnert, Dr M. Cook, and Ms S. Gaboian have nothing to disclose. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or the United States Government. NR 37 TC 1 Z9 1 U1 8 U2 26 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1056-4993 EI 1558-0490 J9 CHILD ADOL PSYCH CL JI Child Adolesc. Psychiatr. N. Am. PD JAN PY 2016 VL 25 IS 1 BP 107 EP + DI 10.1016/j.chc.2015.08.007 PG 17 WC Psychiatry SC Psychiatry GA CZ1RE UT WOS:000366882200011 PM 26593123 ER PT J AU Pierre, JF Busch, RA Kudsk, KA AF Pierre, Joseph F. Busch, Rebecca A. Kudsk, Kenneth A. TI The Gastrointestinal Immune System: Implications for the Surgical Patient SO CURRENT PROBLEMS IN SURGERY LA English DT Review C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Pierre, Joseph F.] Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA. [Busch, Rebecca A.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Div Gen Surg, Madison, WI USA. RP Pierre, JF (reprint author), Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, 5841 S Maryland Ave, Chicago, IL 60637 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD JAN PY 2016 VL 53 IS 1 BP 6 EP 10 DI 10.1067/j.cpsurg.2015.10.006 PG 5 WC Surgery SC Surgery GA CZ6KT UT WOS:000367210900002 PM 26699623 ER PT J AU Camus, M Jensen, DM Ohning, GV Kovacs, TO Jutabha, R Ghassemi, KA Machicado, GA Dulai, GS Jensen, ME Gornbein, JA AF Camus, Marine Jensen, Dennis M. Ohning, Gordon V. Kovacs, Thomas O. Jutabha, Rome Ghassemi, Kevin A. Machicado, Gustavo A. Dulai, Gareth S. Jensen, Mary E. Gornbein, Jeffrey A. TI Comparison of Three Risk Scores to Predict Outcomes of Severe Lower Gastrointestinal Bleeding SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE prognosis score; gastrointestinal bleeding; Charlson index; ASA score; CURE Hemostasis prognosis score ID RANDOMIZED CONTROLLED-TRIAL; LENGTH-OF-STAY; OUTPATIENT CARE; HEMORRHAGE; MORTALITY; MANAGEMENT; VALIDATION; ENDOSCOPY; MORBIDITY; COST AB Background and Aims: Improved medical decisions by using a score at the initial patient triage level may lead to improvements in patient management, outcomes, and resource utilization. There is no validated score for management of lower gastrointestinal bleeding (LGIB) unlike for upper gastrointestinal bleeding. The aim of our study was to compare the accuracies of 3 different prognostic scores [Center for Ulcer Research and Education Hemostasis prognosis score, Charlson index, and American Society of Anesthesiologists (ASA) score] for the prediction of 30-day rebleeding, surgery, and death in severe LGIB. Methods: Data on consecutive patients hospitalized with severe gastrointestinal bleeding from January 2006 to October 2011 in our 2 tertiary academic referral centers were prospectively collected. Sensitivities, specificities, accuracies, and area under the receiver operator characteristic curve were computed for 3 scores for predictions of rebleeding, surgery, and mortality at 30 days. Results: Two hundred thirty-five consecutive patients with LGIB were included between 2006 and 2011. Twenty-three percent of patients rebled, 6% had surgery, and 7.7% of patients died. The accuracies of each score never reached 70% for predicting rebleeding or surgery in either. The ASA score had a highest accuracy for predicting mortality within 30 days (83.5%), whereas the Center for Ulcer Research and Education Hemostasis prognosis score and the Charlson index both had accuracies <75% for the prediction of death within 30 days. Conclusions: ASA score could be useful to predict death within 30 days. However, a new score is still warranted to predict all 30 days outcomes (rebleeding, surgery, and death) in LGIB. C1 [Camus, Marine; Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O.; Jutabha, Rome; Ghassemi, Kevin A.; Machicado, Gustavo A.; Dulai, Gareth S.; Jensen, Mary E.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, CURE Hemostasis Res Grp, Los Angeles, CA 90095 USA. [Camus, Marine; Jensen, Dennis M.; Kovacs, Thomas O.; Jutabha, Rome; Ghassemi, Kevin A.; Machicado, Gustavo A.; Dulai, Gareth S.; Jensen, Mary E.] Univ Calif Los Angeles, UCLA Ronald Reagan Med Ctr, Div Digest Dis, Los Angeles, CA 90095 USA. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O.; Machicado, Gustavo A.; Dulai, Gareth S.] Univ Calif Los Angeles, Div Gastroenterol, VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90095 USA. [Gornbein, Jeffrey A.] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA. [Camus, Marine] Univ Paris 07, Lariboisiere Hosp, AP HP, Dept Gastroenterol, Paris, France. RP Jensen, DM (reprint author), VA Greater Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM djensen@mednet.ucla.edu FU CURE Center Grant Human Studies CORE [NIH41301]; VA Clinical Merit Review Grant; Philippe Foundation FX Partially supported by NIH41301 CURE Center Grant Human Studies CORE and a VA Clinical Merit Review Grant (D.M.J.). M.C. received a grant from the Philippe Foundation for supporting her research exchange program between France and the United States. NR 28 TC 3 Z9 3 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JAN PY 2016 VL 50 IS 1 BP 52 EP 58 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CZ2ND UT WOS:000366941000010 PM 25599218 ER PT J AU Gardner, RC Hess, CP Brus-Ramer, M Possin, KL Cohn-Sheehy, BI Kramer, JH Berger, MS Yaffe, K Miller, B Rabinovici, GD AF Gardner, Raquel C. Hess, Christopher P. Brus-Ramer, Marcel Possin, Katherine L. Cohn-Sheehy, Brendan I. Kramer, Joel H. Berger, Mitchel S. Yaffe, Kristine Miller, Bruce Rabinovici, Gil D. TI Cavum Septum Pellucidum in Retired American Pro-Football Players SO JOURNAL OF NEUROTRAUMA LA English DT Article DE concussion; magnetic resonance imaging; septum pellucidum; traumatic brain injury ID TRAUMATIC BRAIN-INJURY; ENCEPHALOPATHY; DEMENTIA; DISEASE; BOXERS; MRI AB Previous studies report that cavum septum pellucidum (CSP) is frequent among athletes with a history of repeated traumatic brain injury (TBI), such as boxers. Few studies of CSP in athletes, however, have assessed detailed features of the septum pellucidum in a case-control fashion. This is important because prevalence of CSP in the general population varies widely (2% to 85%) between studies. Further, rates of CSP among American pro-football players have not been described previously. We sought to characterize MRI features of the septum pellucidum in a series of retired pro-football players with a history of repeated concussive/subconcussive head traumas compared with controls. We retrospectively assessed retired American pro-football players presenting to our memory clinic with cognitive/behavioral symptoms in whom structural MRI was available with slice thickness 2mm (n=17). Each player was matched to a memory clinic control patient with no history of TBI. Scans were interpreted by raters blinded to clinical information and TBI/football history, who measured CSP grade (0-absent, 1-equivocal, 2-mild, 3-moderate, 4-severe) and length according to a standard protocol. Sixteen of 17 (94%) players had a CSP graded 2 compared with 3 of 17 (18%) controls. CSP was significantly higher grade (p<0.001) and longer in players than controls (mean length +/- standard deviation: 10.6mm +/- 5.4 vs. 1.1mm +/- 1.3, p<0.001). Among patients presenting to a memory clinic, long high-grade CSP was more frequent in retired pro-football players compared with patients without a history of TBI. C1 [Gardner, Raquel C.; Possin, Katherine L.; Cohn-Sheehy, Brendan I.; Kramer, Joel H.; Miller, Bruce; Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94121 USA. [Gardner, Raquel C.; Yaffe, Kristine] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Hess, Christopher P.; Brus-Ramer, Marcel] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA. [Berger, Mitchel S.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. RP Gardner, RC (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St,Neurol Box 127, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU Department of Veterans Affairs Advanced Fellowship in Mental Illness Research/Treatment; UCSF Pepper Center Research Career Development Core; NIA [K24-AG031155, R01-AG045611, K23-AG037566]; Alzheimer's Association; Avid Radiopharmaceuticals; John Douglas French Alzheimer's Foundation; Hellman Family Foundation; Tau Consortium; UCSF ADRC [P50 AG023501]; State Center grants FX We thank our patients and their families for contributing to research on TBI. We acknowledge administrative and technical support from Trishna Subas and Shirley Reeder. Funding: Department of Veterans Affairs Advanced Fellowship in Mental Illness Research/Treatment (RCG); UCSF Pepper Center Research Career Development Core (RCG); NIA K24-AG031155 (KY), NIA R01-AG045611 (GDR), Alzheimer's Association (GDR), Avid Radiopharmaceuticals (GDR), John Douglas French Alzheimer's Foundation (GDR), Hellman Family Foundation (GDR), Tau Consortium (GDR), UCSF ADRC (P50 AG023501) (GDR, BM), and State Center grants (BM), NIA K23-AG037566 (KP). NR 15 TC 2 Z9 2 U1 3 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JAN 1 PY 2016 VL 33 IS 1 BP 157 EP 161 DI 10.1089/neu.2014.3805 PG 5 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CZ4EW UT WOS:000367057200018 PM 25970145 ER PT J AU Dumanovsky, T Augustin, R Rogers, M Lettang, K Meier, DE Morrison, RS AF Dumanovsky, Tamara Augustin, Rachel Rogers, Maggie Lettang, Katrina Meier, Diane E. Morrison, R. Sean TI The Growth of Palliative Care in US Hospitals: A Status Report SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID UNITED-STATES; ACCESS AB Background: Palliative care is expanding rapidly in the United States. Objective: To examine variation in access to hospital palliative care. Methods: Data were obtained from the American Hospital Association (AHA) Annual Surveys for Fiscal Years 2012 and 2013, the National Palliative Care Registry, the Dartmouth Atlas of Healthcare, the American Census Bureau's American Community Survey (ACS), web searches, and telephone interviews of hospital administrators and program directors. Multivariable logistic regression was used to examine predictors of hospital palliative care programs. Results: Sixty-seven percent of hospitals with 50 or more total facility beds reported a palliative care program. Institutional characteristics were strongly associated with the presence of a hospital palliative care program. Ninety percent of hospitals with 300 beds or more were found to have palliative care programs as compared to 56% of hospitals with fewer than 300 beds. Tax status was also a significant predictor. Not-for-profit hospitals and public hospitals were, respectively, 4.8 times and 7.1 times more likely to have a palliative care program as compared to for-profit hospitals. Palliative care penetration was highest in the New England (88% of hospitals), Pacific (77% of hospitals), and mid-Atlantic (77% of hospitals) states and lowest in the west south central (43% of hospitals) and east south central (42% of hospitals) states. Conclusions: This study demonstrates continued steady growth in the number of hospital palliative care programs in the United States, with almost universal access to services in large U.S. hospitals and academic medical centers. Nevertheless access to palliative care remains uneven and depends on accidents of geography and hospital ownership. C1 [Dumanovsky, Tamara; Augustin, Rachel; Rogers, Maggie; Lettang, Katrina; Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA. [Meier, Diane E.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Morrison, R. Sean] Icahn Sch Med Mt Sinai, Natl Palliat Care Res Ctr, New York, NY 10029 USA. [Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA. RP Morrison, RS (reprint author), Icahn Sch Med Mt Sinai, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, Box 1070, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU National Institute on Aging [R24AG044300, P30AG028741]; Cambia Health Foundation; Clinical Research Professor Award from the American Cancer Society FX This work was supported by grants from the National Institute on Aging (R24AG044300, P30AG028741) and the Cambia Health Foundation. Dr. Morrison is the recipient of a Clinical Research Professor Award from the American Cancer Society. NR 10 TC 22 Z9 22 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD JAN 1 PY 2016 VL 19 IS 1 BP 8 EP 15 DI 10.1089/jpm.2015.0351 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CZ4FB UT WOS:000367057700005 PM 26417923 ER PT J AU Collins, GT Gerak, LR Javors, MA France, CP AF Collins, Gregory T. Gerak, Lisa R. Javors, Martin A. France, Charles P. TI Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID 5-HT2C RECEPTOR AGONISTS; MEDICATION DEVELOPMENT; INDUCED REINSTATEMENT; ADDICTIVE DISORDERS; SQUIRREL-MONKEYS; SEEKING BEHAVIOR; ABUSE; DEPENDENCE; RATS; MODULATION AB Cocaine abuse and obesity are serious public health problems, and studies suggest that both dopamine and serotonin systems are involved in regulating the consumption of drugs and food. Lorcaserin has serotonin (5-HT)(2C) receptor agonist actions, is approved by the U.S. Food and Drug Administration for treating obesity, and might be effective for treating cocaine abuse. These studies characterized the pharmacokinetic and behavioral profiles of lorcaserin (intragastric administration) and determined the effectiveness of lorcaserin to alter discriminative stimulus and reinforcing effects of cocaine (intravenous administration) in rhesus monkeys. Administered acutely, lorcaserin dose-dependently increased the occurrence of yawning while decreasing spontaneous activity and operant responding for food. These effects appeared within 30-60 minutes of administration and began to dissipate by 240 minutes, a time course closely matching plasma concentrations of lorcaserin. In monkeys discriminating cocaine from saline, lorcaserin alone did not occasion cocaine-appropriate responding but shifted the cocaine dose-response curve to the right and down in two of three monkeys. When administered acutely, lorcaserin dose-dependently decreased the rate at which monkeys responded for infusions of cocaine. When administered chronically, 3.2 mg/kg lorcaserin reduced the rate of cocaine-maintained responding by 50% for the duration of a 14-day treatment period. Together, these results show that lorcaserin attenuates the discriminative stimulus effects of cocaine after acute administration and the reinforcing effects of cocaine after acute and repeated administration, consistent with the view that it might have utility in treating cocaine abuse. C1 [Collins, Gregory T.; Gerak, Lisa R.; Javors, Martin A.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Javors, Martin A.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP France, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM france@uthscsa.edu RI Collins, Gregory/K-3125-2012 FU National Institutes of Health National Institute on Drug Abuse [U01DA034992, K05DA017918] FX This research was supported by the National Institutes of Health National Institute on Drug Abuse [Grants U01DA034992 and K05DA017918]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute on Drug Abuse. NR 47 TC 4 Z9 4 U1 1 U2 6 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JAN PY 2016 VL 356 IS 1 BP 85 EP 95 DI 10.1124/jpet.115.228833 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CZ2NN UT WOS:000366942000010 PM 26534942 ER PT J AU Williams, EC Achtmeyer, CE Young, JP Rittmueller, SE Ludman, EJ Lapham, GT Lee, AK Chavez, LJ Berger, D Bradley, KA AF Williams, Emily C. Achtmeyer, Carol E. Young, Jessica P. Rittmueller, Stacey E. Ludman, Evette J. Lapham, Gwen T. Lee, Amy K. Chavez, Laura J. Berger, Douglas Bradley, Katharine A. TI Local Implementation of Alcohol Screening and Brief Intervention at Five Veterans Health Administration Primary Care Clinics: Perspectives of Clinical and Administrative Staff SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Qualitative; Alcohol; Screening; Brief intervention; Implementation ID RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; GENERAL-PRACTITIONERS; MENTAL-ILLNESS; USE DISORDERS; STRATEGIES; CONSUMPTION; PERFORMANCE; STIGMA; TRANSFORMATION AB Background and Objective: Population-based alcohol screening, followed by brief intervention for patients who screen positive for unhealthy alcohol use, is widely recommended for primary care settings and considered a top prevention priority, but is challenging to implement. However, new policy initiatives in the U.S., including the Affordable Care Act, may help launch widespread implementation. While the nationwide Veterans Health Administration (VA) has achieved high rates of documented alcohol screening and brief intervention, research has identified quality problems with both. We conducted a qualitative key informant study to describe local implementation of alcohol screening and brief intervention from the perspectives of frontline adopters in VA primary care in order to understand the process of implementation and factors underlying quality problems. Methods: A purposive snowball sampling method was used to identify and recruit key informants from 5 VA primary care clinics in the northwestern U.S. Key informants completed 20-30 minute semi-structured interviews, which were recorded, transcribed, and qualitatively analyzed using template analysis. Results: Key informants (N = 32) included: clinical staff (n = 14), providers (n = 14), and administrative informants (n = 4) with varying participation in implementation of and responsibility for alcohol screening and brief intervention at the medical center. Ten inter-related themes (5 a priori and 5 emergent) were identified and grouped into 3 applicable domains of Greenhalgh's conceptual framework for dissemination of innovations, including values of adopters (theme 1), processes of implementation (themes 2 and 3), and post-implementation consequences in care processes (themes 4-10). While key informants believed alcohol use was relevant to health and important to address, the process of implementation (in which no training was provided and electronic clinical reminders "just showed up") did not address critical training and infrastructure needs. Key informants lacked understanding of the goals of screening and brief intervention, believed referral to specialty addictions treatment (as opposed to offering brief intervention) was the only option for following up on a positive screen, reported concern regarding limited availability of treatment resources, and lacked optimism regarding patients' interest in seeking help. Conclusions: Findings suggest that the local process of implementing alcohol screening and brief intervention may have inadequately addressed important adopter needs and thus may have ultimately undermined, instead of capitalized on, staff and providers' belief in the importance of addressing alcohol use as part of primary care. Additional implementation strategies, such as training or academic detailing, may address some unmet needs and help improve the quality of both screening and brief intervention. However, these strategies may be resource-intensive and insufficient for comprehensively addressing implementation barriers. Published by Elsevier Inc. C1 [Williams, Emily C.; Achtmeyer, Carol E.; Young, Jessica P.; Lapham, Gwen T.; Lee, Amy K.; Chavez, Laura J.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr Value Driven Care, HSR&D, Seattle, WA 98108 USA. [Achtmeyer, Carol E.; Berger, Douglas] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Div, Primary & Specialty Med Care Serv, Seattle, WA 98108 USA. [Achtmeyer, Carol E.; Lapham, Gwen T.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Div, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Berger, Douglas; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Williams, Emily C.; Chavez, Laura J.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Ludman, Evette J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Emily C.; Ludman, Evette J.; Lapham, Gwen T.; Lee, Amy K.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Rittmueller, Stacey E.] Pacific Northwest Univ Sci, Coll Osteopath Med, Yakima, WA 98901 USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,HSRD S-152, Seattle, WA 98108 USA. EM Emily.Williams3@va.gov; Carol.Achtmeyer@va.gov; Jessica.Young@va.gov; stacey.ritt@gmail.com; ludman.e@ghc.org; lapham.g@ghc.org; Amy.Lee6@va.gov; Laura.Chavez2@va.gov; Douglas.Berger@va.gov; bradley.k@ghc.org FU VA Health Services Research Development; VA Quality Enhancement Research Initiative [RRP 11-268]; Career Development Award from VA Health Services Research Development [CDA 12-276]; Implementation Research Institute (IRI) at George Warren Brown School of Social Work at Washington University in St. Louis; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service; Quality Enhancement Research Initiative (QUERI); Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound; Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant [NIH 1R36HS022800-01] FX This study was funded by VA Health Services Research & Development and VA Quality Enhancement Research Initiative (RRP 11-268; Williams PI). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276) and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). Dr. Bradley's time on this study was supported by the Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound. Ms. Chavez is supported by an Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). NR 80 TC 3 Z9 3 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JAN PY 2016 VL 60 SI SI BP 27 EP 35 DI 10.1016/j.jsat.2015.07.011 PG 9 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CZ1RH UT WOS:000366882500005 PM 26297322 ER PT J AU Backhus, LM Farjah, F Liang, CKJ He, H Varghese, TK Au, DH Flum, DR Zeliadt, SB AF Backhus, Leah M. Farjah, Farhood Liang, Chao-Kang Jason He, Hao Varghese, Thomas K., Jr. Au, David H. Flum, David R. Zeliadt, Steven B. TI Imaging surveillance and survival for surgically resected non-small-cell lung cancer SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Imaging surveillance; Lung cancer survival; Cancer follow-up; Guidelines ID REGULAR FOLLOW-UP; COMPUTED-TOMOGRAPHY; SURGERY; RECURRENCE; MANAGEMENT; RELEVANCE; CHEST; CT AB Introduction: The importance of imaging surveillance after treatment for lung cancer is not well characterized. We examined the association between initial guideline recommended imaging surveillance and survival among early-stage resected nonesmall-cell lung cancer (NSCLC) patients. Methods: A retrospective study was conducted using Surveillance, Epidemiology, and End ResultseMedicare data (1995-2010). Surgically resected patients, with stage I and II NSCLC, were categorized by imaging received during the initial surveillance period (4-8 mo) after surgery. Primary outcome was overall survival. Secondary treatment interventions were examined as intermediary outcomes. Results: Most (88%) patients had at least one outpatient clinic visit, and 24% received an initial computerized tomography (CT) during the first surveillance period. Five-year survival by initial surveillance imaging was 61% for CT, 58% for chest radiography, and 60% for no imaging. After adjustment, initial CT was not associated with improved overall survival (hazard ratio [HR], 1.04; 95% confidence interval [CI] 0.96 1.14). On subgroup analysis, restricted to patients with demonstrated initial postoperative follow-up, CT was associated with a lower overall risk of death for stage I patients (HR, 0.85; 95% CI, 0.74-0.98), but not for stage II (HR, 1.01; 95% CI, 0.71-1.42). There was no significant difference in rates of secondary interventions predicted by type of initial imaging surveillance. Conclusions: Initial surveillance CT is not associated with improved overall or lung cancer -specific survival among early-stage NSCLC patients undergoing surgical resection. Stage I patients with early follow-up may represent a subpopulation that benefits from initial surveillance although this may be influenced by healthy patient selection bias. Published by Elsevier Inc. C1 [Backhus, Leah M.] VA Palo Alto Hlth Care Syst, Surg Serv, Palo Alto, CA USA. [Backhus, Leah M.] Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA. [Farjah, Farhood; He, Hao; Varghese, Thomas K., Jr.; Flum, David R.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Liang, Chao-Kang Jason; Zeliadt, Steven B.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Au, David H.; Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. [Au, David H.] Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA USA. RP Backhus, LM (reprint author), Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Res Bldg, Stanford, CA 94305 USA. EM lbackhus@stanford.edu FU NIH/NCATS [2 KL2 TR000421-06 KL2] FX Funded by NIH/NCATS National Center for Research Resources 2 KL2 TR000421-06 KL2 Scholar ITHS Multidisciplinary Clinical Research Training Program. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 33 TC 2 Z9 2 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2016 VL 200 IS 1 BP 171 EP 176 DI 10.1016/j.jss.2015.06.048 PG 6 WC Surgery SC Surgery GA CZ1BM UT WOS:000366840700025 PM 26231974 ER PT J AU Brothers, TE Zhang, JW Mauldin, PD Tonnessen, BH Robison, JG Vallabhaneni, R Hallett, JW AF Brothers, Thomas E. Zhang, Jingwen Mauldin, Patrick D. Tonnessen, Britt H. Robison, Jacob G. Vallabhaneni, Raghuveer Hallett, John W., Jr. TI Predicting outcomes for infrapopliteal limb-threatening ischemia using the Society for Vascular Surgery Vascular Quality Initiative SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ARTERIAL OCCLUSIVE DISEASE; LEG BASIL TRIAL; INFRAINGUINAL BYPASS; RISK STRATIFICATION; OF-LIFE; SURGICAL OUTCOMES; SCORING METHOD; REVASCULARIZATION; MORTALITY; MODEL AB Objective: The outcomes of open surgical or endovascular intervention for limb-threatening ischemia (LTI) involving the infrapopliteal vessels are dependent on complex anatomic, demographic, and disease factors. To assist in decision-making, we used the Vascular Quality Initiative (VQI) to derive a model using only preoperatively available factors to predict important outcomes for open or endovascular revascularization. Methods: National VQI data for the infrainguinal bypass and peripheral vascular intervention (PVI) modules were reviewed in a blinded fashion for patients who underwent intervention for LTI of the infrapopliteal vessels. Primary outcomes consisted of major adverse limb event (MALE) and amputation-free survival (AFS). Generalized linear modeling was used for the multivariate analyses, with entry of variables dependent on results of univariate analysis. Results: From January 2003 through August 2014 a total of 19,053 infrainguinal open bypass and 48,739 PVI procedures were identified, among which 5264 and 5252, respectively, represented infrapopliteal (tibial-peroneal-pedal) revascularization for LTI. From these, 3036 infrapopliteal open bypass patients and 1319 infrapopliteal PVI patients had sufficient follow-up data for study inclusion. For open surgery, the reduced generalized linear model revealed that American Society of Anesthesiologists class 4 or 5, previous major amputation, living at home, and female sex had the greatest adverse effect on MALE, and dialysis dependence, low body mass index, and lack of great saphenous vein as a conduit had the greatest negative effect on AFS. For PVI, lesion length from 10 to 15 cm, treatment of three or more arteries, and classification other than A on the Trans-Atlantic Inter-Society Consensus demonstrated the largest adverse effects on MALE, and dialysis dependence, low body mass index, and congestive heart failure most negatively affected AFS. Conclusions: This study on a cross-section of patients selected for intervention in academic and community hospitals offers a "real world" glimpse of factors predictive of outcome. The VQI can be used to derive models that predict the outcomes of open surgical bypass or PVI for LTI involving the infrapopliteal vessels. C1 [Brothers, Thomas E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Surg Serv, Charleston, SC USA. [Brothers, Thomas E.; Robison, Jacob G.] Med Univ S Carolina, Div Vasc & Endovasc Surg, Charleston, SC 29425 USA. [Zhang, Jingwen; Mauldin, Patrick D.] Med Univ S Carolina, Dept Internal Med, Charleston, SC 29425 USA. [Tonnessen, Britt H.; Hallett, John W., Jr.] Roper St Francis Heart & Vasc Ctr, Div Vasc Surg, Charleston, SC USA. [Vallabhaneni, Raghuveer] Univ N Carolina, Div Vasc Surg, Chapel Hill, NC USA. RP Brothers, TE (reprint author), 114 Doughty St,Ste BM654,MSC 295, Charleston, SC 29425 USA. EM brothete@musc.edu NR 31 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2016 VL 63 IS 1 BP 114 EP U183 DI 10.1016/j.jvs.2015.08.063 PG 16 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CZ2ON UT WOS:000366944600019 PM 26432282 ER PT J AU Davidson, BP Belcik, JT Mott, BH Landry, G Lindner, JR AF Davidson, Brian P. Belcik, J. Todd Mott, Brian H. Landry, Gregory Lindner, Jonathan R. TI Quantification of residual limb skeletal muscle perfusion with contrast-enhanced ultrasound during application of a focal junctional tourniquet SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID BLOOD-FLOW; CAPILLARY RECRUITMENT; DIABETES-MELLITUS; ISCHEMIA; EXERCISE; REST AB Objective: Focal junctional tourniquets (JTs) have been developed to control hemorrhage from proximal limb injuries. These devices may permit greater collateral perfusion than circumferential tourniquets. We hypothesized that JTs eliminate large-vessel pulse pressure yet allow a small amount of residual limb perfusion that could be useful for maintaining tissue viability. Methods: Ten healthy control subjects were studied. Transthoracic echocardiography, Doppler ultrasound of the femoral artery (FA) and posterior tibial artery, and contrast-enhanced ultrasound (CEU) perfusion imaging of the anterior thigh extensor and calf plantar flexor muscles were performed at baseline and during application of a JT over the common FA. Intramuscular arterial pulsatility index was also measured from CEU intensity variation during the cardiac cycle. Results: FA flow was eliminated by JTs in all subjects; posterior tibial flow was eliminated in all but one. Perfusion measured in the thigh and calf muscles was similar at baseline (0.33 +/- 0.29 vs 0.29 +/- 0.22 mL/min/g). Application of the JT resulted in a reduction of perfusion (P < .05) that was similar for the thigh and calf (0.08 +/- 0.07 and 0.10 +/- 0.03 mL/min/g). On CEU, microvascular flux rate was reduced by z55%, and functional microvascular blood volume was reduced by approximate to 35%. Arterial pulsatility index was reduced by approximate to 90% in the calf. JT inflation did not alter left ventricle dimensions, fractional shortening, cardiac output, or arterial elastance as a measure of total systolic load. Conclusions: Application of a JT eliminates conduit arterial pulse and markedly reduces intramuscular pulse pressure, but thigh and calf skeletal muscle perfusion is maintained at 25% to 35% of basal levels. These data suggest that JTs that are used to control limb hemorrhage allow residual tissue perfusion even when pulse pressure is absent. C1 [Davidson, Brian P.; Belcik, J. Todd; Mott, Brian H.; Landry, Gregory; Lindner, Jonathan R.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Davidson, Brian P.] Portland VA Med Ctr, Portland, OR USA. RP Lindner, JR (reprint author), Oregon Hlth & Sci Univ, Div Cardiovasc, UHN 62,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM lindnerj@ohsu.edu FU NHLBI NIH HHS [R01 HL111969, R01 HL078610, R01 HL130046] NR 26 TC 0 Z9 0 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2016 VL 63 IS 1 BP 148 EP 153 DI 10.1016/j.jvs.2014.06.107 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CZ2ON UT WOS:000366944600023 PM 25065582 ER PT J AU Korenstein, D Duan, K Diaz, MJ Ahn, R Keyhani, S AF Korenstein, Deborah Duan, Kevin Diaz, Manuel J. Ahn, Rosa Keyhani, Salomeh TI Do Health Care Delivery System Reforms Improve Value? The Jury Is Still Out SO MEDICAL CARE LA English DT Article DE care delivery system; quality of care; cost containment ID CENTERED MEDICAL HOME; PAY-FOR-PERFORMANCE; QUALITY-OF-CARE; INNOVATION PROFILE; ALTERNATIVE QUALITY; COST; OUTCOMES; PROGRAM; IMPACT; PILOT AB Background:Widespread restructuring of health delivery systems is underway in the United States to reduce costs and improve the quality of health care.Objective:To describe studies evaluating the impact of system-level interventions (incentives and delivery structures) on the value of US health care, defined as the balance between quality and cost.Research Design:We identified articles in PubMed (2003 to July 2014) using keywords identified through an iterative process, with reference and author tracking. We searched tables of contents of relevant journals from August 2014 through 11 August 2015 to update our sample.Subjects:We included prospective or retrospective studies of system-level changes, with a control, reporting both quality and either cost or utilization of resources.Measures:Data about study design, study quality, and outcomes was extracted by one reviewer and checked by a second.Results:Thirty reports of 28 interventions were included. Interventions included patient-centered medical home implementations (n=12), pay-for-performance programs (n=10), and mixed interventions (n=6); no other intervention types were identified. Most reports (n=19) described both cost and utilization outcomes. Quality, cost, and utilization outcomes varied widely; many improvements were small and process outcomes predominated. Improved value (improved quality with stable or lower cost/utilization or stable quality with lower cost/utilization) was seen in 23 reports; 1 showed decreased value, and 6 showed unchanged, unclear, or mixed results.Study limitations included variability among specific endpoints reported, inconsistent methodologies, and lack of full adjustment in some observational trials. Lack of standardized MeSH terms was also a challenge in the search.Conclusions:On balance, the literature suggests that health system reforms can improve value. However, this finding is tempered by the varying outcomes evaluated across studies with little documented improvement in outcome quality measures. Standardized measures of value would facilitate assessment of the impact of interventions across studies and better estimates of the broad impact of system change. C1 [Korenstein, Deborah] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10017 USA. [Duan, Kevin; Diaz, Manuel J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Ahn, Rosa; Keyhani, Salomeh] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Korenstein, D (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 485 Lexington Ave, New York, NY 10017 USA. EM korenstd@mskcc.org OI Korenstein, Deborah/0000-0003-1859-0574 FU NCI NIH HHS [P30 CA008748] NR 45 TC 2 Z9 2 U1 6 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JAN PY 2016 VL 54 IS 1 BP 55 EP 66 DI 10.1097/MLR.0000000000000445 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CZ2MT UT WOS:000366940000010 PM 26492216 ER PT J AU Charalambous, CC Bowden, MG Adkins, DL AF Charalambous, Charalambos C. Bowden, Mark G. Adkins, DeAnna L. TI Motor Cortex and Motor Cortical Interhemispheric Communication in Walking After Stroke: The Roles of Transcranial Magnetic Stimulation and Animal Models in Our Current and Future Understanding SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE walking; interhemispheric motor cortical communication; stroke; rehabilitation; rodent models; translational science ID ADULT SQUIRREL-MONKEYS; SENSORIMOTOR CORTEX; CORTICOMOTOR EXCITABILITY; TRANSCALLOSAL INHIBITION; POSTSTROKE HEMIPARESIS; BRAIN-STIMULATION; CORPUS-CALLOSUM; GAIT IMPAIRMENT; RATS; FORELIMB AB Despite the plethora of human neurophysiological research, the bilateral involvement of the leg motor cortical areas and their interhemispheric interaction during both normal and impaired human walking is poorly understood. Using transcranial magnetic stimulation (TMS), we have expanded our understanding of the role upper-extremity motor cortical areas play in normal movements and how stroke alters this role, and probed the efficacy of interventions to improve post-stroke arm function. However, similar investigations of the legs have lagged behind, in part, due to the anatomical difficulty in using TMS to stimulate the leg motor cortical areas. Additionally, leg movements are predominately bilaterally controlled and require interlimb coordination that may involve both hemispheres. The sensitive, but invasive, tools used in animal models of locomotion hold great potential for increasing our understanding of the bihemispheric motor cortical control of walking. In this review, we discuss 3 themes associated with the bihemispheric motor cortical control of walking after stroke: (a) what is known about the role of the bihemispheric motor cortical control in healthy and poststroke leg movements, (b) how the neural remodeling of the contralesional hemisphere can affect walking recovery after a stroke, and (c) what is the effect of behavioral rehabilitation training of walking on the neural remodeling of the motor cortical areas bilaterally. For each theme, we discuss how rodent models can enhance the present knowledge on human walking by testing hypotheses that cannot be investigated in humans, and how these findings can then be back-translated into the neurorehabilitation of poststroke walking. C1 [Charalambous, Charalambos C.; Bowden, Mark G.; Adkins, DeAnna L.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Adkins, DeAnna L.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Adkins, DL (reprint author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,CRI404D,MSC 510, Charleston, SC 29425 USA. EM adkinsdl@musc.edu FU NINDS [NS065866]; Career Development Award [2 RRD N0787-W]; Office or Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs; Ralph H. Johnson VA Medical Center, Charleston, SC; NIH [P20 GM109040-01] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This material is the result of work supported in part by NINDS NS065866 (DLA), Career Development Award-2 RR&D N0787-W (MGB) and the Office or Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs, and the Ralph H. Johnson VA Medical Center, Charleston, SC, and NIH P20 GM109040-01 (MGB and DLA). NR 75 TC 2 Z9 2 U1 2 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1545-9683 EI 1552-6844 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PD JAN PY 2016 VL 30 IS 1 BP 94 EP 102 DI 10.1177/1545968315581418 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CZ5VH UT WOS:000367169900009 PM 25878201 ER PT J AU Mathews, CA Perez, VB Roach, BJ Fekri, S Vigil, O Kupferman, E Mathalon, DH AF Mathews, C. A. Perez, V. B. Roach, B. J. Fekri, S. Vigil, O. Kupferman, E. Mathalon, D. H. TI Error-related brain activity dissociates hoarding disorder from obsessive-compulsive disorder SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Electroencephalography/event-related potentials (EEG/ERP); error monitoring; error-related negativity (ERN); hoarding; neurophysiological; obsessive-compulsive disorder (OCD) ID ANTERIOR CINGULATE CORTEX; COGNITIVE CONTROL; CLINICAL-FEATURES; DECISION-MAKING; TASK-DIFFICULTY; FRONTAL-CORTEX; NEGATIVITY; CONFLICT; SYMPTOMS; AGE AB Background. Obsessive-compulsive disorder (OCD) is associated with an abnormally large error-related negativity (ERN), an electrophysiological measure of error monitoring in response to performance errors, but it is unclear if hoarding disorder (HD) also shows this abnormality. This study aimed to determine whether the neurophysiological mechanisms underlying error monitoring are similarly compromised in HD and OCD. Method. We used a visual flanker task to assess ERN in response to performance errors in 14 individuals with HD, 27 with OCD, 10 with HD+OCD, and 45 healthy controls (HC). Age-corrected performance and ERN amplitudes were examined using analyses of variance and planned pairwise group comparisons. Results. A main effect of hoarding on ERN (p = 0.031) was observed, indicating ERN amplitudes were attenuated in HD relative to non-HD subjects. A group x age interaction effect on ERN was also evident. In HD-positive subjects, ERN amplitude deficits were significantly greater in younger individuals (r = -0.479, p = 0.018), whereas there were no significant ERN changes with increasing age in OCD and HC participants. Conclusions. The reduced ERN in HD relative to OCD and HC provides evidence that HD is neurobiologically distinct from OCD, and suggests that deficient error monitoring may be a core pathophysiological feature of HD. This effect was particularly prominent in younger HD participants, further suggesting that deficient error monitoring manifests most strongly early in the illness course and/or in individuals with a relatively early illness onset. C1 [Mathews, C. A.; Roach, B. J.; Fekri, S.; Vigil, O.; Kupferman, E.; Mathalon, D. H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mathews, C. A.] Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA. [Perez, V. B.] Alliant Int Univ, CSPP, San Diego, CA USA. [Perez, V. B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Perez, V. B.] Vet Affairs San Diego Healthcare Syst, VISN 22, La Jolla, CA USA. [Roach, B. J.; Mathalon, D. H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Mathews, CA (reprint author), Univ Florida, Dept Psychiat, 100 S Newell Dr L4-100, Gainesville, FL 32610 USA. EM carolmathews@ufl.edu FU National Institutes of Mental Health [CAM: R21MH087748]; Althea Foundation FX This study was supported by the National Institutes of Mental Health (CAM: R21MH087748) and by the Althea Foundation. NR 80 TC 3 Z9 3 U1 4 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD JAN PY 2016 VL 46 IS 2 BP 367 EP 379 DI 10.1017/S0033291715001889 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CZ5VV UT WOS:000367171300012 PM 26415671 ER PT J AU Albert, TJ Swenson, ER AF Albert, Tyler J. Swenson, Erik R. TI Circumstances When Arterial Blood Gas Analysis Can Lead Us Astray SO RESPIRATORY CARE LA English DT Editorial Material ID SAMPLE; HEPARIN; ERRORS C1 [Albert, Tyler J.] Vet Affairs Puget Sound Hlth Care Syst, Hosp & Specialty Med, Seattle, WA 98108 USA. [Albert, Tyler J.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Med, Seattle, WA 98108 USA. RP Albert, TJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111-PULM, Seattle, WA 98108 USA. EM Tyler.Albert@va.gov NR 12 TC 0 Z9 0 U1 2 U2 5 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JAN PY 2016 VL 61 IS 1 BP 119 EP 121 DI 10.4187/respcare.04556 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CZ4GU UT WOS:000367062300019 PM 26682966 ER PT J AU Webb, TN Carrisoza-Gaytan, R Montalbetti, N Rued, A Roy, A Socovich, AM Subramanya, AR Satlin, LM Kleyman, TR Carattino, MD AF Webb, Tennille N. Carrisoza-Gaytan, Rolando Montalbetti, Nicolas Rued, Anna Roy, Ankita Socovich, Alexandra M. Subramanya, Arohan R. Satlin, Lisa M. Kleyman, Thomas R. Carattino, Marcelo D. TI Cell-specific regulation of L-WNK1 by dietary K+ SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE high-conductance calcium-activated potassium channels; potassium adaptation; kidney-specific with-no-lysine kinase 1; pseudohypoaldosteronism; with-no-lysine kinase 1; long with-no-lysine kinase 1 ID CORTICAL COLLECTING DUCT; FAMILIAL HYPERKALEMIC HYPERTENSION; CONDUCTANCE POTASSIUM CHANNELS; BINDING INTERCALATED CELLS; DISTAL TUBULAR POTASSIUM; KINASE-DEFECTIVE ISOFORM; APICAL MEMBRANE; MAXI-K; BLOOD-PRESSURE; CONNECTING TUBULE AB Flow-induced K+ secretion in the aldosterone-sensitive distal nephron is mediated by high-conductance Ca2+ -activated K+ (BK) channels. Familial hyperkalemic hypertension (pseudohypoaldosteronism type II) is an inherited form of hypertension with decreased K+ secretion and increased Na+ reabsorption. This disorder is linked to mutations in genes encoding with-no-lysine kinase 1 (WNK1), WNK4, and Kelch-like 3/Cullin 3, two components of an E3 ubiquitin ligase complex that degrades WNKs. We examined whether the full-length (or "long") form of WNK1 (L-WNK1) affected the expression of BK alpha-subunits in HEK cells. Overexpression of L-WNK1 promoted a significant increase in BK alpha-subunit whole cell abundance and functional channel expression. BK alpha-subunit abundance also increased with coexpression of a kinase dead L-WNK1 mutant (K233M) and with kidney-specific WNK1 (KS-WNK1), suggesting that the catalytic activity of L-WNK1 was not required to increase BK expression. We examined whether dietary K+ intake affected L-WNK1 expression in the aldosterone-sensitive distal nephron. We found a paucity of L-WNK1 labeling in cortical collecting ducts (CCDs) from rabbits on a low-K+ diet but observed robust staining for L-WNK1 primarily in intercalated cells when rabbits were fed a high-K+ diet. Our results and previous findings suggest that L-WNK1 exerts different effects on renal K+ secretory channels, inhibiting renal outer medullary K+ channels and activating BK channels. A high-K+ diet induced an increase in L-WNK1 expression selectively in intercalated cells and may contribute to enhanced BK channel expression and K+ secretion in CCDs. C1 [Webb, Tennille N.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15261 USA. [Montalbetti, Nicolas; Rued, Anna; Roy, Ankita; Socovich, Alexandra M.; Subramanya, Arohan R.; Kleyman, Thomas R.; Carattino, Marcelo D.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.; Kleyman, Thomas R.; Carattino, Marcelo D.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA. [Kleyman, Thomas R.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Carrisoza-Gaytan, Rolando; Satlin, Lisa M.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Kleyman, TR (reprint author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kleyman@pitt.edu OI Montalbetti, Nicolas/0000-0003-2897-9540 FU National Institute of Diabetes and Digestive and Kidney Diseases Grants [R01-DK-038470, R01-DK-084184, R01-DK-098145, R37-DK-051391, T32-DK091202, P30-DK-079307]; CONACYT [232526] FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants, including R01-DK-038470 (L. M. Satlin and T. R. Kleyman), R01-DK-084184 (M. D. Carattino), R01-DK-098145 (A. R. Subramanya), R37-DK-051391 (T. R. Kleyman and L. M. Satlin), T32-DK091202, and P30-DK-079307 (Pittsburgh Center for Kidney Research). R. Carrisoza-Gaytan was supported, in part, by a CONACYT postdoctoral scholarship (232526). NR 108 TC 2 Z9 2 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN 1 PY 2016 VL 310 IS 1 BP F15 EP F26 DI 10.1152/ajprenal.00226.2015 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CY7MT UT WOS:000366593500004 PM 26662201 ER PT J AU Tsai, MH Boggs, SD AF Tsai, Mitchell H. Boggs, Steven D. TI Disruption Interrupted SO ANESTHESIA AND ANALGESIA LA English DT Letter C1 [Tsai, Mitchell H.] Univ Vermont, Coll Med, Dept Anesthesiol, Burlington, VT 05405 USA. [Boggs, Steven D.] James J Peters VA Med Ctr, Dept Anesthesiol, Bronx, NY USA. [Boggs, Steven D.] Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY USA. RP Tsai, MH (reprint author), Univ Vermont, Coll Med, Dept Anesthesiol, Burlington, VT 05405 USA. EM Mitchell.Tsai@uvmhealth.org NR 3 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD JAN PY 2016 VL 122 IS 1 BP 294 EP 295 DI 10.1213/ANE.0000000000000961 PG 2 WC Anesthesiology SC Anesthesiology GA CY9EK UT WOS:000366710000017 PM 26678481 ER PT J AU Clayburgh, DR Byrd, JK Bonfili, J Duvvuri, U AF Clayburgh, Daniel R. Byrd, J. Kenneth Bonfili, Jennifer Duvvuri, Umamaheswar TI Intraoperative Ultrasonography During Transoral Robotic Surgery SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE transoral robotic surgery; oropharynx; ultrasound ID ULTRASOUND; TORS AB Objective: This study describes the potential application of intraoperative ultrasound imaging during transoral robotic surgery (TORS). Methods: Ultrasound imaging was performed during transoral robotic resection of oropharyngeal tumors in 10 patients at a tertiary academic center. Ultrasound imaging was utilized to identify large-caliber vessels adjacent to the surgical site. Measurements were also taken on the ultrasound of tumor thickness to determine the deep margin. Following resection, the tumor was sectioned, and a gross measurement of the tumor thickness was obtained. Results: Intraoperative ultrasound use led to the identification of larger-caliber blood vessels within the operative field prior to encountering them visually. Ultrasound could also aid in defining deep tumor margins; the tumor thickness measured via ultrasound was found to be accurate within 1 to 2 mm of the grossly measured tumor thickness. This allowed for focused, careful dissection to protect and avoid blood vessels during dissection as well as improved tumor resection. Conclusions: The use of intraoperative ultrasound provides additional information to the head and neck surgeon during TORS. This may be used to identify blood vessels and assess tumor margins, thereby improving the safety and efficacy of TORS. C1 [Clayburgh, Daniel R.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Clayburgh, Daniel R.] Portland VA Med Ctr, Portland, OR USA. [Byrd, J. Kenneth] Georgia Regents Univ, Dept Otolaryngol Head & Neck Surg, Augusta, GA USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst Penn, Pittsburgh, PA USA. [Bonfili, Jennifer] Univ Pittsburgh, Med Ctr, Div Perioperat Nursing, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Career Development Award from the Department of Veterans Affairs BLRD; PNC Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded in part by a Career Development Award from the Department of Veterans Affairs BLR&D, and the PNC Foundation (U.D.). NR 8 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD JAN PY 2016 VL 125 IS 1 BP 37 EP 42 DI 10.1177/0003489415596754 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA CY7PY UT WOS:000366602000006 PM 26215725 ER PT J AU Zhao, J Giles, BM Taylor, RL Yette, GA Lough, KM Ng, HL Abraham, LJ Wu, H Kelly, JA Glenn, SB Adler, AJ Williams, AH Comeau, ME Ziegler, JT Marion, M Alarcon-Riquelme, ME Alarcon, GS Anaya, JM Bae, SC Kim, D Lee, HS Criswell, LA Freedman, BI Gilkeson, GS Guthridge, JM Jacob, CO James, JA Kamen, DL Merrill, JT Sivils, KM Niewold, TB Petri, MA Ramsey-Goldman, R Reveille, JD Scofield, RH Stevens, AM Vila, LM Vyse, TJ Kaufman, KM Harley, JB Langefeld, CD Gaffney, PM Brown, EE Edberg, JC Kimberly, RP Ulgiati, D Tsao, BP Boackle, SA AF Zhao, Jian Giles, Brendan M. Taylor, Rhonda L. Yette, Gabriel A. Lough, Kara M. Ng, Han Leng Abraham, Lawrence J. Wu, Hui Kelly, Jennifer A. Glenn, Stuart B. Adler, Adam J. Williams, Adrienne H. Comeau, Mary E. Ziegler, Julie T. Marion, Miranda Alarcon-Riquelme, Marta E. Alarcon, Graciela S. Anaya, Juan-Manuel Bae, Sang-Cheol Kim, Dam Lee, Hye-Soon Criswell, Lindsey A. Freedman, Barry I. Gilkeson, Gary S. Guthridge, Joel M. Jacob, Chaim O. James, Judith A. Kamen, Diane L. Merrill, Joan T. Sivils, Kathy Moser Niewold, Timothy B. Petri, Michelle A. Ramsey-Goldman, Rosalind Reveille, John D. Scofield, R. Hal Stevens, Anne M. Vila, Luis M. Vyse, Timothy J. Kaufman, Kenneth M. Harley, John B. Langefeld, Carl D. Gaffney, Patrick M. Brown, Elizabeth E. Edberg, Jeffrey C. Kimberly, Robert P. Ulgiati, Daniela Tsao, Betty P. Boackle, Susan A. CA BIOLUPUS GENLES Networks TI Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL ACTIVATION; MURINE CD21 GENE; CR-2; EXPRESSION; LYMPHOCYTES; ADMIXTURE; PROMOTER; DATABASE; AUTOANTIBODIES AB Objectives Systemic lupus erythematosus (SLE; OMIM 152700) is characterised by the production of antibodies to nuclear antigens. We previously identified variants in complement receptor 2 (CR2/CD21) that were associated with decreased risk of SLE. This study aimed to identify the causal variant for this association. Methods Genotyped and imputed genetic variants spanning CR2 were assessed for association with SLE in 15 750 case-control subjects from four ancestral groups. Allele-specific functional effects of associated variants were determined using quantitative real-time PCR, quantitative flow cytometry, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP)-PCR. Results The strongest association signal was detected at rs1876453 in intron 1 of CR2 (p(meta)=4.2x10(-4), OR 0.85), specifically when subjects were stratified based on the presence of dsDNA autoantibodies (case-control p(meta)=7.6x10(-7), OR 0.71; case-only p(meta)=1.9x10(-4), OR 0.75). Although allele-specific effects on B cell CR2 mRNA or protein levels were not identified, levels of complement receptor 1 (CR1/CD35) mRNA and protein were significantly higher on B cells of subjects harbouring the minor allele (p=0.0248 and p=0.0006, respectively). The minor allele altered the formation of several DNA protein complexes by EMSA, including one containing CCCTC-binding factor (CTCF), an effect that was confirmed by ChIP-PCR. Conclusions These data suggest that rs1876453 in CR2 has long-range effects on gene regulation that decrease susceptibility to lupus. Since the minor allele at rs1876453 is preferentially associated with reduced risk of the highly specific dsDNA autoantibodies that are present in preclinical, active and severe lupus, understanding its mechanisms will have important therapeutic implications. C1 [Zhao, Jian; Wu, Hui; Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Giles, Brendan M.; Yette, Gabriel A.; Lough, Kara M.; Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO 80045 USA. [Taylor, Rhonda L.; Ng, Han Leng; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Sch Pathol & Lab Med, Crawley, WA, Australia. [Kelly, Jennifer A.; Glenn, Stuart B.; Adler, Adam J.; Alarcon-Riquelme, Marta E.; Guthridge, Joel M.; James, Judith A.; Sivils, Kathy Moser; Scofield, R. Hal; Gaffney, Patrick M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Williams, Adrienne H.; Comeau, Mary E.; Ziegler, Julie T.; Marion, Miranda; Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Williams, Adrienne H.; Comeau, Mary E.; Ziegler, Julie T.; Marion, Miranda; Langefeld, Carl D.] Wake Forest Sch Med, Ctr Publ Hlth Genom, Winston Salem, NC USA. [Alarcon-Riquelme, Marta E.; Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Granada, Pfizer, Junta de Andalucia Ctr Genom & Oncol Res, Granada, Spain. [Alarcon, Graciela S.; Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Bae, Sang-Cheol; Kim, Dam; Lee, Hye-Soon] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Ephraim P Engleman Rheumatol Res, San Francisco, CA 94143 USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Gilkeson, Gary S.; Kamen, Diane L.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. [Jacob, Chaim O.] Univ So Calif, Dept Med, Los Angeles, CA USA. [James, Judith A.; Sivils, Kathy Moser] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, Oklahoma City, OK 73104 USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Div Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Dept Rheumatol & Clin Immunogenet, Houston, TX 77030 USA. [Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Vila, Luis M.] Univ Puerto Rico, Dept Med, Div Rheumatol, San Juan, PR 00936 USA. [Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med & Immunol, London WC2R 2LS, England. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Boackle, Susan A.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Boackle, SA (reprint author), Univ Colorado, Sch Med, 1775 Aurora Court,Room 3102 B,Mail Stop B115, Aurora, CO 80045 USA. EM susan.boackle@ucdenver.edu RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249; Kimberly, Robert/0000-0002-5330-3086; Niewold, Timothy/0000-0003-3532-6660 FU NIH/NCI Cancer Core Support Grant [P30 CA046934]; National Institutes of Health (NIH) [P30 DK57516]; US National Institutes of Health [R01AI070983, K24AI078004, T32AR07534, K24AR002138, LRPAI071651, K08AI083790, N01AR062277, P01AI083194, P01AR049084, P20RR020143, P30AR048311, P30AR053483, P30AR055385, P30GM103510, P60AR030692, P60AR062755, P60AR053308, R01AI063274, R01AR033062, R01AR042460, R01AR043274, R01AR43727, R01AR043814, R01AR051545, R01AR057172, R01CA141700, R21AI070304, R37AI024717, RC1AR058621, U01AI101934, U19AI082714, U54RR023417, UL1RR024999, UL1RR025014, UL1RR025741, UL1RR025777, UL1RR029882, UL1TR000004]; Alliance for Lupus Research; Lupus Research Institute; US Department of Veterans Affairs; US Department of Defense [PR094002]; Arthritis National Research Foundation; Arthritis Foundation; Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [A121983]; European Science Foundation RNP (BIOLUPUS Research Network); Wellcome Trust; Arthritis Research UK; Kirkland Scholar Award; Wake Forest School of Medicine Center for Public Health Genomics FX The quality of the RNA samples prepared from healthy human subjects was evaluated in the University of Colorado Cancer Center Microarray Core, which is supported by the NIH/NCI Cancer Core Support Grant (P30 CA046934). Flow cytometry was carried out in the Barbara Davis Center Flow Cytometry Core Facility, which was supported by National Institutes of Health (NIH) grant P30 DK57516. This work was also supported by the US National Institutes of Health [R01AI070983 (S.A.B, B.P.T., D.U.), K24AI078004 (S.A.B.), T32AR07534 (B.M.G.), K24AR002138 (R.R.G.), LRPAI071651 (T.B.N.), K08AI083790 (T.B.N.), N01AR062277 (J.B.H.), P01AI083194 (J.B.H.), P01AR049084 (R.P.K., J.B.H., J.C.E., E.E.B., G.S.A., J.D.R., R.R.G., and M.A.P.), P20RR020143 (J.B.H.), P30AR048311 (E.E.B.), P30AR053483 (J.A.J and J.M.G.), P30AR055385 (E.E.B.), P30GM103510 (J.A.J.), P60AR030692 (R.R.G.), P60AR062755 (D.L.K.), P60AR053308 (L.A.C.), R01AI063274 (P.M.G.), R01AR033062 (R.P.K.), R01AR042460 (J.B.H.), R01AR043274 (K.M.S.), R01AR43727 (M.A.P.), R01AR043814 (B.P.T.), R01AR051545 (A.M.S.), R01AR057172 (C.O.J.), R01CA141700 (M.E.A.R.), R21AI070304 (S.A.B.), R37AI024717 (J.B.H.), RC1AR058621 (M.E.A.R.), U01AI101934 (J.A.J. and J.M.G.), U19AI082714 (J.A.J. and J.M.G.), U54RR023417 (J.D.R.), UL1RR024999 (T.B.N.), UL1RR025014 (A.M.S.), UL1RR025741 (R.R.G.), UL1RR025777 (R.P.K. and J.C.E.), UL1RR029882 (D.L.K.), and UL1TR000004 (L.A.C.)], the Alliance for Lupus Research (S.A.B., B.P.T., D.U., K.M.S., T.B.N., L.A.C. and C.O.J.), the Lupus Research Institute (B.P.T., T.B.N.), the US Department of Veterans Affairs (Merit Awards; J.B.H., G.S.G.), the US Department of Defense (PR094002, J.B.H.), the Arthritis National Research Foundation (Eng Tan Scholar Award; J.Z. and T.B.N.), the Arthritis Foundation (A.M.S., and P.M.G.), the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A121983; S.C.B.), the European Science Foundation RNP (BIOLUPUS Research Network), the Wellcome Trust (T.J.V.), Arthritis Research UK (T.J.V.), a Kirkland Scholar Award (L.A.C.), and the Wake Forest School of Medicine Center for Public Health Genomics (C.D.L.). The funders had no role in study design, data collection, analysis and interpretation, writing of the report or decision to submit the paper for publication. NR 40 TC 1 Z9 1 U1 0 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JAN PY 2016 VL 75 IS 1 BP 242 EP 252 DI 10.1136/annrheumdis-2014-205584 PG 11 WC Rheumatology SC Rheumatology GA CY4TW UT WOS:000366402400033 PM 25180293 ER PT J AU Berry, K Lerrigo, R Liou, IW Ioannou, GN AF Berry, Kristin Lerrigo, Robert Liou, Iris W. Ioannou, George N. TI Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE MELD Score; Hepatorenal Syndrome; Hepatic Hydrothorax; Hepatocellular Carcinoma; Transjugular Intrahepatic Portosystemic Shunt; TIPS; Cirrhosis; Mortality; Liver Transplantation ID PARACENTESIS PLUS ALBUMIN; REFRACTORY ASCITES; HEPATORENAL-SYNDROME; HEPATIC HYDROTHORAX; RANDOMIZED-TRIAL; RENAL-FUNCTION; TIPS; PREVENTION; METAANALYSIS AB BACKGROUND & AIMS: A transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment of refractory ascites and variceal bleeding. However, it is unclear whether a TIPS affects long-term survival. We investigated whether a TIPS is associated with survival in patients with cirrhosis awaiting liver transplantation. METHODS: By using the United Network for Organ Sharing registries from 2002 to 2013, we followed up a cohort of transplant-naive adults with cirrhosis (N = 97,063) from the time of transplant listing until the time of death or transplantation. We used Cox proportional hazards and competing-risks analyses to compare these primary outcomes between patients with a TIPS (n = 7475; 7.7%) and without a TIPS (n = 89,588; 92.3%) at the time of listing, adjusting for baseline characteristics. RESULTS: During an average follow-up period of 1.61 years, 23,305 (24%) patients died before undergoing transplantation, 47,563 (49%) underwent transplantation, and the remaining 26,195 (27%) still were alive without having received a liver transplant. Compared with patients without a TIPS, patients with a TIPS had a lower risk of death (adjusted subhazard ratio, 0.95; 95% confidence interval, 0.9-0.99), transplantation (adjusted subhazard ratio, 0.92, 95% confidence interval, 0.88-0.95), or the combined outcome of death or transplantation (adjusted hazard ratio, 0.85; 95% confidence interval, 0.83-0.88). CONCLUSIONS: Among patients with cirrhosis awaiting liver transplantation, patients with a TIPS had a lower mortality rate than patients without a TIPS. C1 [Berry, Kristin; Ioannou, George N.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98195 USA. [Lerrigo, Robert] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Internal Med, Seattle, WA 98195 USA. [Liou, Iris W.; Ioannou, George N.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Research Enhancement Award Program, Office of Research and Development, Veterans Affairs; Health Resources and Services Administration [231-00-0115] FX Supported by the Research Enhancement Award Program, Office of Research and Development, Veterans Affairs, and supported in part by Health Resources and Services Administration contract 231-00-0115. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services. NR 26 TC 2 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD JAN PY 2016 VL 14 IS 1 BP 118 EP 123 DI 10.1016/j.cgh.2015.06.042 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CY8HQ UT WOS:000366649800025 PM 26192147 ER PT J AU Kurichi, JE Streim, JE Bogner, HR Xie, DW Kwong, PL Hennessy, S AF Kurichi, Jibby E. Streim, Joel E. Bogner, Hillary R. Xie, Dawei Kwong, Pui L. Hennessy, Sean TI Comparison of predictive value of activity limitation staging systems based on dichotomous versus trichotomous responses in the Medicare Current Beneficiary Survey SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Staging; Disability; Medicare Current Beneficiary Survey; Activities of daily living ID CARE AB Background: Traditional ways of measuring disability include summary indices, binary expressions, or counts of limitations. However, counts of activity of daily living (ADL) or instrumental activity of daily living (IADL) limitations do not specify which activities are limited. Activity limitation staging systems within the ADL and IADL domains depict both the severity and types of limitations experienced and specify clinically meaningful patterns of increasing difficulty with self-care. Objective: To compare the predictive value and utility of ADL and IADL stages based on dichotomous versus trichotomous responses to ADL and IADL questions based on "difficulty'' and "receive help'' responses. Methods: Data were analyzed from the 2005, 2006, and 2007 Medicare Current Beneficiary Survey (MCBS) entry panels on 11,706 beneficiaries. This was a prospective cohort study that examined time to inpatient admission, all-cause mortality, skilled nursing facility (SNF) admission, and long-term care (LTC) facility admission based on dichotomous versus trichotomous stages. Results: For both ADLs and IADLs, Akaike information criteria for most outcomes were lower (indicating better-performing models) for the trichotomous staging systems than the dichotomous staging systems. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the dichotomous ADL staging system increased as disability increased, whereas the HRs of the other staging systems fluctuated. Conclusions: Both staging systems have strong associations with each outcome. The dichotomous staging system is more clinically relevant while the trichotomous staging system may provide utility for clinicians, health care organizations, and policy makers seeking to predict death or admission to a hospital, SNF, or LTC facility. (C) 2016 Elsevier Inc. All rights reserved. C1 [Kurichi, Jibby E.; Bogner, Hillary R.; Xie, Dawei; Kwong, Pui L.; Hennessy, Sean] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA USA. [Hennessy, Sean] Univ Penn, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA. RP Kurichi, JE (reprint author), 907 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jkurichi@mailmed.upenn.edu FU National Institutes of Health [AG040105, HD074756]; NIMH [MH082799, MH047447] FX The research for this manuscript was supported by grants from the National Institutes of Health (AG040105 and HD074756) for Drs. Hennessy, Streim, and Xie, Ms. Kwong, and Ms. Kurichi. Dr. Bogner was supported by NIMH grants MH082799 and MH047447. There are no personal conflicts of interest of any of the authors, and no authors reported disclosures beyond the funding source. The opinions and conclusions of the authors are not necessarily those of the sponsoring agencies. NR 19 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD JAN PY 2016 VL 9 IS 1 BP 64 EP 73 DI 10.1016/j.dhjo.2015.08.006 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CY7AQ UT WOS:000366560600010 PM 26590119 ER PT J AU Turner, AP Roubinov, DS Atkins, DC Haselkorn, JK AF Turner, Aaron P. Roubinov, Danielle S. Atkins, David C. Haselkorn, Jodie K. TI Predicting medication adherence in multiple sclerosis using telephone-based home monitoring SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Medication adherence; Multiple sclerosis; Chronic illness self-management; Telehealth ID DISEASE-MODIFYING THERAPIES; INJECTION ANXIETY; SELF-EFFICACY; CARE-SYSTEM; IMPAIRMENT; PREVALENCE; VETERANS; UTILITY; EXPECTATIONS; DISABILITY AB Background: Poor medication adherence exerts a substantial negative impact on the health and well-being of individuals with multiple sclerosis (MS). Improving adherence rates requires a proactive approach of frequent and ongoing monitoring; however, this can be difficult to achieve within traditional, reactive health care systems that generally emphasize acute care services. Telephone-based home monitoring may circumvent these barriers and facilitate optimal care coordination and management for individuals with MS and other chronic illnesses. Objective: The current study evaluated the utility of a one-item, telephone-administered measure of adherence expectations as a prospective predictor of medication adherence across a six month period among individuals with MS. Methods: As part of a longitudinal study, Veterans with MS (N = 89) who were receiving medical services through the Veterans Health Administration completed monthly telephone-based interviews for six months. Results: Using mixed model regression analyses, adherence expectations predicted adherence after adjusting for demographic, illness-related, and psychosocial factors (B = -5.54, p < .01). Conclusions: Brief, telephone-based assessments of adherence expectations may represent an easy and efficient method for monitoring medication use among individuals with MS. The results offer an efficient method to detect and provide support for individuals who may benefit from interventions to promote medication adherence. (C) 2016 Elsevier Inc. All rights reserved. C1 [Turner, Aaron P.; Roubinov, Danielle S.; Haselkorn, Jodie K.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Roubinov, Danielle S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Turner, AP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM aaron.turner@va.gov OI Atkins, David/0000-0002-5781-9880 FU Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award [B3319VA]; VA MS Center of Excellence West FX This research was supported by Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award (B3319VA) to Aaron P. Turner. Additional support was provided by the VA MS Center of Excellence West. NR 41 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD JAN PY 2016 VL 9 IS 1 BP 83 EP 89 DI 10.1016/j.dhjo.2015.08.008 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CY7AQ UT WOS:000366560600012 PM 26454560 ER PT J AU Ladebue, AC Helfrich, CD Gerdes, ZT Fihn, SD Nelson, KM Sayre, GG AF Ladebue, Amy C. Helfrich, Christian D. Gerdes, Zachary T. Fihn, Stephan D. Nelson, Karin M. Sayre, George G. TI The experience of Patient Aligned Care Team (PACT) members SO HEALTH CARE MANAGEMENT REVIEW LA English DT Article DE evaluation; patient-centered care; patient-centered medical home (PCMH); team-based care; teamlet ID CENTERED MEDICAL HOME; SAFETY OUTCOMES; HEALTH-CARE; BURNOUT; IMPLEMENTATION; VETERANS; SURGEONS; QUALITY; ERRORS; LIFE AB Background: In April 2010, the Veterans Health Administration (VHA) launched the Patient Aligned Care Team (PACT) initiative to implement a patient-centered medical home (PCMH) model. Few evaluations have addressed the effects of PCMH on health care professionals' experiences. Purposes: The aim of this study was to contribute to evaluation of the PACT initiative and the broader literature on PCMH by assessing respondents' experiences of implementing a PCMH model and becoming a teamlet. Methodology/Approach: A retrospective qualitative analysis of open-text responses in a survey fielded to all VHA Primary Care personnel (VHA Primary Care physicians, nurse practitioners, physician assistants, nurse care managers, clinical associates, and administrative clerks) in May and June 2012 (approximately 2 years into the 5-year planned implementation of PACT) using deductive and inductive content analysis. The main measures were two open-response fields: Is there anything else you would like us to relay to the VA leadership in Central Office? and Do you have any other comments or feedback on PACT? The data consisted of free text responses of 3,868 survey participants who provided text for one or both of the open-response fields. Findings: Although respondents viewed PACT positively as a model and reported it improved relationships with patients and increased patient satisfaction, they described multiple barriers to achieving functioning teamlets and unintended consequences, including reduced time with patients, increased participant burnout, and decreased team efficacy because of low-performing team members. A central theme related to staffing being insufficient for the new model. Practice Implications: Insufficient staffing of PCMH teams is a critical barrier to realizing the benefits of the new model. Frontline staff have concrete recommendations for other problems, such as using back-up teams to cover during absences, but that will require providing more opportunities for feedback from staff to be heard. C1 [Ladebue, Amy C.] Seattle Univ, Coll Arts & Sci, Hlth Serv Res & Dev Ctr Innovat Veteran Centered, Seattle, WA 98122 USA. [Helfrich, Christian D.; Nelson, Karin M.; Sayre, George G.] Univ Washington, Hlth Serv Res & Dev Ctr Innovat Veteran Centered, Seattle, WA USA. [Helfrich, Christian D.; Fihn, Stephan D.; Sayre, George G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Gerdes, Zachary T.] Univ Akron, Hlth Serv Res andDevelopmentCenter Innovat Vetera, Akron, OH 44325 USA. [Gerdes, Zachary T.] Univ Akron, Dept Psychol, Akron, OH 44325 USA. [Fihn, Stephan D.] US Dept Vet Affairs, Off Analyt & Business Intelligence, Seattle, WA USA. [Fihn, Stephan D.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. RP Ladebue, AC (reprint author), Seattle Univ, Coll Arts & Sci, Hlth Serv Res & Dev Ctr Innovat Veteran Centered, Seattle, WA 98122 USA. RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 FU VA Office of Patient Care Services FX This work was undertaken as part of the VA's PACT Demonstration Laboratory initiative, supporting and evaluating VA's transition to a PCMH model. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.. NR 36 TC 0 Z9 0 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0361-6274 EI 1550-5030 J9 HEALTH CARE MANAGE R JI Health Care Manage. Rev. PD JAN-MAR PY 2016 VL 41 IS 1 BP 2 EP 10 DI 10.1097/HMR.0000000000000048 PG 9 WC Health Policy & Services SC Health Care Sciences & Services GA CY9GV UT WOS:000366716300002 PM 25539056 ER PT J AU Ferguson, S Trupin, L Yazdany, J Yelin, E Barton, J Katz, P AF Ferguson, S. Trupin, L. Yazdany, J. Yelin, E. Barton, J. Katz, P. TI Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication SO LUPUS LA English DT Article DE Contraception; family planning; teratogen; systemic lupus erythematosus ID UNITED-STATES; UNINTENDED PREGNANCY; RHEUMATOID-ARTHRITIS; ERYTHEMATOSUS; WOMEN; VALIDATION; HEALTH; CARE; OUTCOMES; IMPACT AB Objective Family planning discussions are an important aspect of medical care for women with systemic lupus erythematosus (SLE) as active disease is a risk factor for poor pregnancy outcomes, and the medications used for treatment can be harmful to the fetus when used during conception and pregnancy. Our objective was to examine the impact of patient perception of quality and type of communication on receiving contraception counseling. Methods Data were derived from patients enrolled in the University of California, San Francisco Lupus Outcomes Study. Individuals participate in a yearly structured telephone interview that includes assessment of contraception counseling when starting new medications, and measures of communication and decision making. Logistic regression was performed to identify predictors of not receiving contraception counseling. Results Of the 68 women included in this analysis, one-third did not receive contraception counseling when starting new medications. Older age, white race, depressive symptoms, and higher SLE disease activity were independently associated with not receiving contraception counseling. Participants who did not receive contraception counseling rated their physicians lower in shared decision-making (SDM) communication. Conclusions This study demonstrates a gap in family planning counseling among women with SLE starting new medications. Future studies to address these potential areas of intervention, including education about the need for contraception through menopause, and mechanisms to engage in SDM surrounding contraception are needed to improve quality of care for women with lupus. C1 [Ferguson, S.; Trupin, L.; Yazdany, J.; Yelin, E.; Katz, P.] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA. [Barton, J.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. RP Ferguson, S (reprint author), Univ Calif San Francisco, Div Rheumatol, Room 270,3333 Calif St,Box 0920, San Francisco, CA 94143 USA. EM sancia.ferguson@ucsf.edu FU National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-053308]; NIH/National Center for Research Resources through a University of California, San Francisco (UCSF), Clinical and Translational Science Institute grant [Ul1-RR-024131] FX This work was supported by the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant (P60-AR-053308), and the NIH/National Center for Research Resources through a University of California, San Francisco (UCSF), Clinical and Translational Science Institute grant (Ul1-RR-024131). NR 29 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD JAN PY 2016 VL 25 IS 1 BP 12 EP 17 DI 10.1177/0961203315596079 PG 6 WC Rheumatology SC Rheumatology GA CY7PV UT WOS:000366601700002 PM 26190169 ER PT J AU Aranovich, GJ McClure, SM Fryer, S Mathalon, DH AF Aranovich, Gabriel J. McClure, Samuel M. Fryer, Susanna Mathalon, Daniel H. TI The effect of cognitive challenge on delay discounting SO NEUROIMAGE LA English DT Article ID IMPULSIVE DECISION-MAKING; WORKING-MEMORY; PREFRONTAL CORTEX; SELF-CONTROL; INTERTEMPORAL CHOICE; NEURAL SYSTEMS; FMRI; REWARDS; MODEL; ADDICTION AB Recent findings suggest that the dorsolateral prefrontal cortex (DLPFC), a region consistently associated with impulse control, is vulnerable to transient suppression of its activity and attendant functions by excessive stress and/or cognitive demand. Using functional magnetic resonance imaging, we show that a capacity-exceeding cognitive challenge induced decreased DLPFC activity and correlated increases in the preference for immediately available rewards. Consistent with growing evidence of a link between working memory capacity and delay discounting, the effect was inversely proportional to baseline performance on a working memory task. Subjects who performed well on the working memory task had unchanged, or even decreased, delay discounting rates, suggesting that working memory ability may protect cognitive control from cognitive challenge. (C) 2015 Elsevier Inc. All rights reserved. C1 [Aranovich, Gabriel J.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [McClure, Samuel M.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA. [Fryer, Susanna; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fryer, Susanna; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Aranovich, GJ (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM gabe.aranovich@ucsf.edu FU NIMH [R25MH060482, R01 MH076989]; NSF [1358507]; VA CSRD [IK2 CX001028] FX This work was supported by grants NIMH R25MH060482 (to G.J. Aranovich), NSF 1358507 (to S.M. McClure), VA CSR&D: and IK2 CX001028 (S. Fryer), and NIMH R01 MH076989 (to D.H. Mathalon). NR 44 TC 0 Z9 0 U1 2 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 BP 733 EP 739 DI 10.1016/j.neuroimage.2015.09.027 PN A PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY8GL UT WOS:000366646700068 PM 26394377 ER PT J AU Bowers, ME Yehuda, R AF Bowers, Mallory E. Yehuda, Rachel TI Intergenerational Transmission of Stress in Humans SO NEUROPSYCHOPHARMACOLOGY LA English DT Review ID ANTENATAL MATERNAL ANXIETY; GLUCOCORTICOID-RECEPTOR GENE; INFANT BIRTH-WEIGHT; HOLOCAUST SURVIVORS; PRENATAL STRESS; CORTISOL-LEVELS; NURTURING RELATIONSHIPS; CHERNOBYL EXPOSURE; TRAUMA EXPOSURE; PRETERM BIRTH AB The hypothesis that offspring are affected by parental trauma or stress exposure, first noted anecdotally, is now supported empirically by data from Holocaust survivor offspring cohorts and other populations. These findings have been extended to less extreme forms of stress, where differential physical, behavioral, and cognitive outcomes are observed in affected offspring. Parental stress-mediated effects in offspring could be explained by genetics or social learning theory. Alternatively, biological variations stemming from stress exposure in parents could more directly have an impact on offspring, a concept we refer to here as 'intergenerational transmission', via changes to gametes and the gestational uterine environment. We further extend this definition to include the transmission of stress to offspring via early postnatal care, as animal studies demonstrate the importance of early maternal care of pups in affecting offsprings' long-term behavioral changes. Here, we review clinical observations in offspring, noting that offspring of stress- or trauma-exposed parents may be at greater risk for physical, behavioral, and cognitive problems, as well as psychopathology. Furthermore, we review findings concerning offspring biological correlates of parental stress, in particular, offspring neuroendocrine, epigenetic, and neuroanatomical changes, in an attempt to determine the extent of parental stress effects. Although understanding the etiology of effects in offspring is currently impeded by methodological constraints, and limitations in our knowledge, we summarize current information and conclude by presenting hypotheses that have been prompted by recent studies in the field. C1 [Bowers, Mallory E.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Bronx, NY 10468 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, JJP VAMC, 526 OOMH PTSD 116-A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov NR 104 TC 15 Z9 15 U1 9 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 232 EP 244 DI 10.1038/npp.2015.247 PG 13 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400015 PM 26279078 ER PT J AU Vinogradov, S Herman, A AF Vinogradov, Sophia Herman, Alexander TI Psychiatric Illnesses as Oscillatory Connectomopathies SO NEUROPSYCHOPHARMACOLOGY LA English DT Editorial Material ID NETWORK OSCILLATIONS C1 [Vinogradov, Sophia; Herman, Alexander] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Vinogradov, S (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM sophia.vinogradov@ucsf.edu FU NIMH NIH HHS [R01 MH068725, MH68725] NR 6 TC 2 Z9 2 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 387 EP 388 DI 10.1038/npp.2015.308 PG 3 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400039 PM 26657965 ER PT J AU Reddy, BG Dai, Q McNicholas, CM Fuller, CM Kappes, JC DeLucas, LJ AF Reddy, Bharat G. Dai, Qun McNicholas, Carmel M. Fuller, Catherine M. Kappes, John C. DeLucas, Lawrence J. TI Expression and purification of the alpha subunit of the epithelial sodium channel, ENaC SO PROTEIN EXPRESSION AND PURIFICATION LA English DT Article DE Epithelial sodium channel; ENaC; GFP; GFP Affinity Column; Membrane Protein Purification; Membrane Protein Expression ID CELL-SURFACE EXPRESSION; NA+ CHANNEL; MEMBRANE-PROTEINS; ION-CHANNEL; RETROVIRAL VECTORS; LENTIVIRAL VECTOR; GAMMA-SUBUNIT; AMILORIDE; STOICHIOMETRY; FLUORESCENCE AB The epithelial sodium channel (ENaC) plays a critical role in maintaining Na+ homeostasis in various tissues throughout the body. An understanding of the structure of the ENaC subunits has been developed from homology modeling based on the related acid sensing ion channel 1 (ASIC1) protein structure, as well as electrophysiological approaches. However, ENaC has several notable functional differences compared to ASIC1, thereby providing justification for determination of its three-dimensional structure. Unfortunately, this goal remains elusive due to several experimental challenges. Of the subunits that comprise a physiological hetero-trimeric alpha beta gamma ENaC, the alpha-subunit is unique in that it is capable of forming a homo-trimeric structure that conducts Na+ ions. Despite functional and structural interest in alpha ENaC, a key factor complicating structural studies has been its interaction with multiple other proteins, disrupting its homogeneity. In order to address this issue, a novel protocol was used to reduce the number of proteins that associate and co-purify with alpha ENaC. In this study, we describe a novel expression system coupled with a two-step affinity purification approach using NiNTA, followed by a GFP antibody column as a rapid procedure to improve the purity and yield of rat aENaC. (C) 2015 Elsevier Inc. All rights reserved. C1 [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA. [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [McNicholas, Carmel M.; Fuller, Catherine M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [DeLucas, Lawrence J.] Univ Alabama Birmingham, Dept Optometry, Birmingham, AL 35294 USA. [Reddy, Bharat G.; Fuller, Catherine M.; Kappes, John C.; DeLucas, Lawrence J.] Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL 35233 USA. RP DeLucas, LJ (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA. EM duke2@uab.edu FU NIH [NIGMS R01GM095639, NIDDK R01DK037206, P30 AR048311]; Virology, Genetic Sequencing and Flow Cytometry Cores of the UAB Center for AIDS Research [P30 AI27767]; UAB CF Research & Translational Core Center [P30 DK072482] FX This research was supported by the following NIH Grants NIGMS R01GM095639 and NIDDK R01DK037206, and the Virology, Genetic Sequencing and Flow Cytometry Cores of the UAB Center for AIDS Research (P30 AI27767), and the UAB CF Research & Translational Core Center (P30 DK072482). They antibodies were made by RDCC Analytical Imaging and Immunoreagent Core with supported from NIH P30 AR048311. We would also Casey Weaver for the use of his hybridoma and Suman Bharara and Kevin Macon for their help in culturing the hybridoma to produce the GFP antibody. Finally we would like to thank the late Dale Benos, without whom, none of this would have been done. NR 62 TC 0 Z9 0 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-5928 EI 1096-0279 J9 PROTEIN EXPRES PURIF JI Protein Expr. Purif. PD JAN PY 2016 VL 117 BP 67 EP 75 DI 10.1016/j.pep.2015.09.014 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA CZ0JU UT WOS:000366791900009 PM 26394093 ER PT J AU Bhatt, SP Wells, JM Kinney, GL Washko, GR Budoff, M Kim, YI Bailey, WC Nath, H Hokanson, JE Silverman, EK Crapo, J Dransfield, MT AF Bhatt, Surya P. Wells, James M. Kinney, Gregory L. Washko, George R., Jr. Budoff, Matthew Kim, Young-il Bailey, William C. Nath, Hrudaya Hokanson, John E. Silverman, Edwin K. Crapo, James Dransfield, Mark T. CA COPDGene Investigators TI beta-Blockers are associated with a reduction in COPD exacerbations SO THORAX LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; RISK; ASTHMA; HYPERTENSION; THERAPY; CLASSIFICATION; METAANALYSIS AB Background While some retrospective studies have suggested that beta-blocker use in patients with COPD is associated with a reduction in the frequency of acute exacerbations and lower mortality, there is concern that their use in patients with severe COPD on home oxygen may be harmful. Methods Subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2-4 COPD participating in a prospective follow-up of the COPDGene cohort, a multicentre observational cohort of current and former smokers were recruited. Total and severe exacerbation rates were compared between groups categorised by beta-blocker use on longitudinal follow-up using negative binomial regression analyses, after adjustment for demographics, airflow obstruction, % emphysema on CT, respiratory medications, presence of coronary artery disease, congestive heart failure and coronary artery calcification, and after adjustment for propensity to prescribe beta-blockers. Results 3464 subjects were included. During a median of 2.1 years of follow-up, beta-blocker use was associated with a significantly lower rate of total (incidence risk ratio (IRR) 0.73, 95% CI 0.60 to 0.90; p=0.003) and severe exacerbations (IRR 0.67, 95% CI 0.48 to 0.93; p=0.016). In those with GOLD stage 3 and 4 and on home oxygen, use of beta-blockers was again associated with a reduction in the rate of total (IRR 0.33, 95% CI 0.19 to 0.58; p<0.001) and severe exacerbations (IRR 0.35, 95% CI 0.16 to 0.76; p=0.008). Exacerbation reduction was greatest in GOLD stage B. There was no difference in all-cause mortality with beta-blocker use. Conclusions beta-Blockers are associated with a significant reduction in COPD exacerbations regardless of severity of airflow obstruction. The findings of this study should be tested in a randomised, placebo-controlled trial. C1 [Bhatt, Surya P.; Wells, James M.; Bailey, William C.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Kinney, Gregory L.; Hokanson, John E.] Univ Colorado, Dept Epidemiol, Aurora, CO USA. [Washko, George R., Jr.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Kim, Young-il] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA. [Nath, Hrudaya] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35294 USA. [Silverman, Edwin K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA. [Crapo, James] Natl Jewish Hlth, Div Pulm & Crit Care, Denver, CO USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, THT 422,1720,2nd Ave South, Birmingham, AL 35294 USA. EM spbhatt@uab.edu FU NIH [R01 HL089897, R01 HL089856, R01 HL122438]; TRDRP Award [20XT-0014] FX COPDGene is supported by NIH grant numbers R01 HL089897, R01 HL089856 and R01 HL122438. The coronary calcification data is supported by TRDRP Award No. 20XT-0014. NR 43 TC 16 Z9 18 U1 4 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 EI 1468-3296 J9 THORAX JI Thorax PD JAN PY 2016 VL 71 IS 1 BP 8 EP 14 DI 10.1136/thoraxjnl-2015-207251 PG 7 WC Respiratory System SC Respiratory System GA CY8TV UT WOS:000366682100004 PM 26283710 ER PT J AU Estock, JL Curinga, HK Li, A Grieve, LB Brackney, CR AF Estock, Jamie L. Curinga, Holly K. Li, Airan Grieve, Lorin B. Brackney, Christopher R. TI Comparison of chest compression interruption times across 2 automated devices: a randomized, crossover simulation study SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; OVER MANNEQUIN; TRIAL; SYSTEM; HELICOPTER; QUALITY; CPR AB Objective: The goal of this study was to compare chest compression interruption times required to apply, adjust, and remove 2 different automated chest compression (ACC) devices using the same evaluation protocol. Methods: Twenty-nine registered nurses and respiratory therapists used 2 ACC devices in separate resuscitation scenarios involving a patient manikin simulating a 45-year-old man in cardiac arrest in his intensive care unit room. Device presentation was randomized, with half of the participants using LUCAS 2 in the first scenario and the other half using AutoPulse in the first scenario. Results: The mean chest compression interruption time to apply the ACC device to the patient was significantly shorter for AutoPulse (mean [M] = 31.6 +/- 8.44) than for LUCAS 2 (M = 39.1 +/- 11.20; t(28) = 3.65, P = .001). The mean chest compression interruption time to remove the ACC device from the patient and resume manual compressions was also significantly shorter for AutoPulse (M = 6.5 +/- 3.65) than for LUCAS 2 (M = 10.1 +/- 3.97; t(26) = 3.36, P = .002). There was no difference in the mean chest compression interruption time to adjust the position of the ACC device on the patient between AutoPulse (M = 14.3 +/- 5.24) and LUCAS 2 (M = 12.5 +/- 3.89; t(23)= -1.45, P = .162). Conclusions: The results of this study trended in favor of AutoPulse. However, the interruption in chest compression to apply either device to the patient was notably longer than the maximum interruption time recommended by the American Heart Association. Published by Elsevier Inc. C1 [Estock, Jamie L.; Li, Airan] VA Pittsburgh Healthcare Syst, Ctr Med Prod End User Testing, Pittsburgh, PA USA. [Curinga, Holly K.; Brackney, Christopher R.] VA Pittsburgh Healthcare Syst, Crit Care Serv, Pittsburgh, PA USA. [Grieve, Lorin B.] VA Pittsburgh Healthcare Syst, Dept Educ, Pittsburgh, PA USA. RP Estock, JL (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C Res Bldg 30,G-39, Pittsburgh, PA 15240 USA. EM jamie.estock@va.gov OI Estock, Jamie/0000-0001-8279-2811 FU Medical Education and Patient Safety grant through the Veterans Research Foundation at VA Pittsburgh Healthcare System, Pittsburgh, PA FX The execution of this work was supported by a Medical Education and Patient Safety grant through the Veterans Research Foundation at VA Pittsburgh Healthcare System, Pittsburgh, PA. The sponsor of this research had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit this article for publication. NR 28 TC 0 Z9 0 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD JAN PY 2016 VL 34 IS 1 BP 57 EP 62 DI 10.1016/j.ajem.2015.09.011 PG 6 WC Emergency Medicine SC Emergency Medicine GA CY1IH UT WOS:000366159400012 PM 26472511 ER PT J AU Mancini, M Chiari, L Holmstrom, L Salarian, A Horak, FB AF Mancini, Martina Chiari, Lorenzo Holmstrom, Lars Salarian, Arash Horak, Fay B. TI Validity and reliability of an IMU-based method to detect APAs prior to gait initiation SO GAIT & POSTURE LA English DT Article DE Gait initiation; Inertial sensors; Force plates; Parkinson's disease ID ANTICIPATORY POSTURAL ADJUSTMENTS; PARKINSONS-DISEASE; STEP INITIATION; WEARABLE SENSORS; MOVEMENT; BALANCE; PERTURBATIONS; COORDINATION; STIMULATION; WALKING AB Anticipatory postural adjustments (APAs) prior to gait initiation have been largely studied in traditional, laboratory settings using force plates under the feet to characterize the displacement of the center of pressure. However clinical trials and clinical practice would benefit from a portable, inexpensive method for characterizing APAs. Therefore, the main objectives of this study were (1) to develop a novel, automatic IMU-based method to detect and characterize APAs during gait initiation and (2) to measure its test-retest reliability. Experiment I was carried out in the laboratory to determine the validity of the IMU-based method in 10 subjects with PD (OFF medication) and 12 control subjects. Experiment II was carried out in the clinic, to determine test-retest reliability of the IMU-based method in a different set of 17 early-to-moderate, treated subjects with PD (tested ON medication) and 17 age-matched control subjects. Results showed that gait initiation characteristics (both APAs and 1st step) detected with our novel method were significantly correlated to the characteristics calculated with a force plate and motion analysis system. The size of APAs measured with either inertial sensors or force plate was significantly smaller in subjects with PD than in control subjects (p < 0.05). Test-retest reliability for the gait initiation characteristics measured with inertial sensors was moderate-to-excellent (0.56 < ICC < 0.82) for both groups. Our findings support the feasibility of automatically characterizing postural preparation and gait initiation with body-worn inertial sensors that would be practical for unsupervised clinical and home settings. (C) 2015 Elsevier B.V. All rights reserved. C1 [Mancini, Martina; Salarian, Arash; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, Portland, OR 97201 USA. [Chiari, Lorenzo] Univ Bologna, Dept Elect Elect & Informat Engn Guglielmo Marcon, Bologna, Italy. [Holmstrom, Lars; Horak, Fay B.] APDM Inc, Portland, OR USA. [Horak, Fay B.] Portland VA Med Ctr, Dept Res, Portland, OR USA. RP Mancini, M (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, 3181 Sam Jackson Pk Rd, Portland, OR 97201 USA. EM mancinim@ohsu.edu; lorenzo.chiari@unibo.it; lars@apdm.com; arash.salarian@gmail.com; horakf@ohsu.edu RI Salarian, Arash/E-8311-2016 OI Salarian, Arash/0000-0001-7332-0062; Chiari, Lorenzo/0000-0002-2318-4370 FU NIH [RC1 NS068678, R42 HD071760-03] FX We thank Kelsey Priest for scheduling and helping with data collection. This publication was made possible with support from NIH RC1 NS068678 and R42 HD071760-03. NR 30 TC 4 Z9 4 U1 3 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2016 VL 43 BP 125 EP 131 DI 10.1016/j.gaitpost.2015.08.015 PG 7 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA CY1HW UT WOS:000366158300021 PM 26433913 ER PT J AU Poelke, G Ventura, MI Byers, AL Yaffe, K Sudore, R Barnes, DE AF Poelke, Gina Ventura, Maria I. Byers, Amy L. Yaffe, Kristine Sudore, Rebecca Barnes, Deborah E. TI Leisure activities and depressive symptoms in older adults with cognitive complaints SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE leisure activities; depressive symptoms; mild cognitive impairment; aging ID PHYSICAL-ACTIVITY; CARDIOVASCULAR HEALTH; CONTROLLED-TRIAL; IMPAIRMENT; EXERCISE; INTERVENTIONS; PREVALENCE; COMMUNITY; DEMENTIA; DECLINE AB Background: Depressive symptoms are common in older adults and associated with increased risk of cognitive impairment. Leisure activities are often promoted for individuals with mood symptoms but few studies compare the effects of different types of leisure activities on reducing depressive symptoms. Methods: Data were analyzed from participants enrolled from 2008-2009 in the Mental Activity and eXercise (MAX) Trial, which examined the effects of physical plus mental activity over 12 weeks in inactive older adults with cognitive complaints. There were no significant differences between intervention groups on the primary outcome of cognitive function or the secondary outcome of depressive symptoms; therefore, all participants were combined for the current analyses in which we examined changes in leisure activity engagement (Community Healthy Activities Model Program for Seniors (CHAMPS)), and changes in depressive symptoms (Geriatric Depression Scale (GDS)) as a function of changes in leisure activity engagement from baseline to post-intervention. Results: Participants' mean age was 73.0 years, 61.6% were female, and 63.6% were non-Hispanic white. There was a significant change in total hours per week engaged in leisure activities from baseline (36.7 hours, SD = 12.7) to post-intervention (40.4 hours, SD = 15.7; paired t-test p = 0.02), and mean change in depressive symptoms was significantly inversely correlated with change in leisure activity hours such that increases in total leisure activity were associated with decreases in depressive symptoms (r = -0.21, p = 0.04). Conclusions: Increasing the total amount of leisure activity levels may help lower depressive symptoms in inactive older adults with cognitive complaints. C1 [Poelke, Gina; Ventura, Maria I.; Byers, Amy L.; Yaffe, Kristine; Sudore, Rebecca; Barnes, Deborah E.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94102 USA. RP Poelke, G (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 870 Market St,Suite 1123, San Francisco, CA 94102 USA. EM gpoelke@gmail.com FU Career Development Award from the National Institute on Aging [K01-AG024069]; Alzheimer's Association [IIRG-06-27306]; University of California School of Medicine; Institutes of Health/National Center for Research Resources/University of California; San Francisco - Clinical and Translational Science Institute [KL2 RR024130]; NIH [5-T32-AG000212] FX This study was supported in part by a Career Development Award from the National Institute on Aging (grant K01-AG024069), the Alzheimer's Association (grant IIRG-06-27306), the University of California School of Medicine, the Institutes of Health/National Center for Research Resources/University of California, San Francisco - Clinical and Translational Science Institute (grant KL2 RR024130) and NIH grant 5-T32-AG000212. NR 28 TC 0 Z9 0 U1 2 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JAN PY 2016 VL 28 IS 1 BP 63 EP 69 DI 10.1017/S1041610215001246 PG 7 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CY1WM UT WOS:000366198900009 PM 26299193 ER PT J AU Keator, DB van Erp, TGM Turner, JA Glover, GH Mueller, BA Liu, TT Voyvodic, JT Rasmussen, J Calhoun, VD Lee, HJ Toga, AW McEwen, S Ford, JM Mathalon, DH Diaz, M O'Leary, DS Bockholt, HJ Gadde, S Preda, A Wible, CG Stern, HS Belger, A McCarthy, G Ozyurt, B Potkin, SG AF Keator, David B. van Erp, Theo G. M. Turner, Jessica A. Glover, Gary H. Mueller, Bryon A. Liu, Thomas T. Voyvodic, James T. Rasmussen, Jerod Calhoun, Vince D. Lee, Hyo Jong Toga, Arthur W. McEwen, Sarah Ford, Judith M. Mathalon, Daniel H. Diaz, Michele O'Leary, Daniel S. Bockholt, H. Jeremy Gadde, Syam Preda, Adrian Wible, Cynthia G. Stern, Hal S. Belger, Aysenil McCarthy, Gregory Ozyurt, Burak Potkin, Steven G. CA FBIRN TI The Function Biomedical Informatics Research Network Data Repository SO NEUROIMAGE LA English DT Article ID MULTICENTER FMRI; CORTICAL THICKNESS; RATING-SCALE; SCHIZOPHRENIA; VARIABILITY; ACTIVATION; IDENTIFICATION; ABNORMALITIES; RELIABILITY; INSTRUMENT AB The Function Biomedical Informatics Research Network (FBIRN) developed methods and tools for conducting multi-scanner functional magnetic resonance imaging (fMRI) studies. Method and tool development were based on two major goals: 1) to assess the major sources of variation in fMRI studies conducted across scanners, including instrumentation, acquisition protocols, challenge tasks, and analysis methods, and 2) to provide a distributed network infrastructure and an associated federated database to host and query large, multi-site, fMRI and clinical data sets. In the process of achieving these goals the FBIRN test bed generated several multi-scanner brain imaging data sets to be shared with the wider scientific community via the BIRN Data Repository (BDR). The FBIRN Phase 1 data set consists of a traveling subject study of 5 healthy subjects, each scanned on 10 different 1.5 to 4 T scanners. The FBIRN Phase 2 and Phase 3 data sets consist of subjects with schizophrenia or schizoaffective disorder along with healthy comparison subjects scanned at multiple sites. In this paper, we provide concise descriptions of FBIRN's multi-scanner brain imaging data sets and details about the BIRN Data Repository instance of the Human Imaging Database (HID) used to publicly share the data. (C) 2015 Elsevier Inc. All rights reserved. C1 [Keator, David B.; van Erp, Theo G. M.; Rasmussen, Jerod; Preda, Adrian; Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA. [Turner, Jessica A.; Calhoun, Vince D.] Mind Res Networlc, Albuquerque, NM USA. [Turner, Jessica A.] Georgia State Univ, Dept Psychiat, Atlanta, GA 30303 USA. [Turner, Jessica A.] Georgia State Univ, Inst Neurosci, Atlanta, GA 30303 USA. [Glover, Gary H.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA. [Mueller, Bryon A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Liu, Thomas T.] Univ Calif San Diego, Ctr Funct MRI, San Diego, CA 92103 USA. [Voyvodic, James T.; Gadde, Syam] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC USA. [Calhoun, Vince D.; Bockholt, H. Jeremy] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA. [Calhoun, Vince D.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Lee, Hyo Jong] Chonbuk Natl Univ, Dept Comp Sci & Engn, Jeonju, South Korea. [Toga, Arthur W.] Univ So Calif, Lab Neuro Imaging, Los Angeles, CA USA. [Toga, Arthur W.] Univ So Calif, Inst Neuroimaging & Informat, Los Angeles, CA USA. [Toga, Arthur W.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [McEwen, Sarah] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Brain Imaging & EEG Lab, San Francisco, CA 94143 USA. [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Diaz, Michele] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA. [O'Leary, Daniel S.; Bockholt, H. Jeremy] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [Wible, Cynthia G.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Wible, Cynthia G.] Brockton VAMC, Boston, MA USA. [Stern, Hal S.] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA. [Belger, Aysenil] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Belger, Aysenil] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [McCarthy, Gregory] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Ozyurt, Burak] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Keator, DB (reprint author), Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine Hall,Room 163, Irvine, CA 92697 USA. EM dbkeator@uci.edu RI Preda, Adrian /K-8889-2013 OI Preda, Adrian /0000-0003-3373-2438 FU National Center for Research Resources at the National Institutes of Health (Function Biomedical Informatics Research Network) [NIH 1 U24 RR021992]; National Center for Research Resources at the National Institutes of Health (Biomedical Informatics Research Network Coordinating Center) [NIH 1 U24 RR025736-01] FX We are thankful to Mrs. Liv McMillan for overall study coordination, to Ms. Shichun Ling for editorial assistance, and to the research subjects for their participation. This work was supported by the National Center for Research Resources at the National Institutes of Health (grant numbers: NIH 1 U24 RR021992) (Function Biomedical Informatics Research Network) and NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; www.birncommunity.org). The funding sources had no role in the study design, data collection, or publication of the data. NR 54 TC 3 Z9 3 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1074 EP 1079 DI 10.1016/j.neuroimage.2015.09.003 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000003 PM 26364863 ER PT J AU Labus, JS Naliboff, B Kilpatrick, L Liu, C Ashe-McNalley, C dos Santos, IR Alaverdyan, M Woodworth, D Gupta, A Ellingson, BM Tillisch, K Mayer, EA AF Labus, Jennifer S. Naliboff, Bruce Kilpatrick, Lisa Liu, Cathy Ashe-McNalley, Cody dos Santos, Ivani R. Alaverdyan, Mher Woodworth, Davis Gupta, Arpana Ellingson, Benjamin M. Tillisch, Kirsten Mayer, Emeran A. TI Pain and Interoception Imaging Network (PAIN): A multimodal, multisite, brain-imaging repository for chronic somatic and visceral pain disorders SO NEUROIMAGE LA English DT Article DE Chronic pain; Neuroimaging data repository; Archived repository; Standardized repository; Large biological datasets; Multiple sites ID MAPP RESEARCH NETWORK; CHRONIC PELVIC PAIN; MRI AB The Pain and Interoception Imaging Network (PAIN) repository (painrepository.org) is a newly created NIH (NIDA/NCCAM) funded neuroimaging data repository that aims to accelerate scientific discovery regarding brain mechanisms in pain and to provide more rapid benefits to pain patients through the harmonization of efforts and data sharing. The PAIN Repository consists of two components, an Archived Repository and a Standardized Repository. Similar to other 'open' imaging repositories, neuroimaging researchers can deposit any dataset of chronic pain patients and healthy controls into the Archived Repository. Scans in the Archived Repository can be very diverse in terms of scanning procedures and clinical metadata, complicating the merging of datasets for analyses. The Standardized Repository overcomes these limitations through the use of standardized scanning protocols along with a standardized set of clinical metadata, allowing an unprecedented ability to perform pooled analyses. The Archived Repository currently includes 741 scans and is rapidly growing. The Standardized Repository currently includes 433 scans. Pain conditions currently represented in the PAIN repository include: irritable bowel syndrome, vulvodynia, migraine, chronic back pain, and inflammatory bowel disease. Both the PAIN Archived and Standardized Repositories promise to be important resources in the field of chronic pain research. The enhanced ability of the Standardized Repository to combine imaging, clinical and other biological datasets from multiple sites in particular make it a unique resource for significant scientific discoveries. (C) 2015 Elsevier Inc. All rights reserved. C1 [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Alaverdyan, Mher; Woodworth, Davis; Gupta, Arpana; Ellingson, Benjamin M.; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Oppenheimer Family Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Gupta, Arpana; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Tillisch, Kirsten] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Gupta, Arpana; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, PAIN, Los Angeles, CA 90095 USA. [Woodworth, Davis; Ellingson, Benjamin M.] Univ Calif Los Angeles, David Geffen Sch Med, Radiol, Los Angeles, CA 90095 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Sch Med, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu FU National Institutes of Health: NCCAM/NIDA [R01 AT007137, P30 DK041301, R01 DK048351, R01 HD076756] FX This research was supported in part by grants from the National Institutes of Health: NCCAM/NIDA: R01 AT007137 (KT, BN), P30 DK041301, R01 DK048351 (EAM), and R01 HD076756 (JSL). NR 13 TC 4 Z9 4 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1232 EP 1237 DI 10.1016/j.neuroimage.2015.04.018 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000029 PM 25902408 ER PT J AU Bird, ER Gilmore, AK George, WH Lewis, MA AF Bird, Elizabeth R. Gilmore, Amanda K. George, William H. Lewis, Melissa A. TI The role of social drinking factors in the relationship between incapacitated sexual assault and drinking before sexual activity SO ADDICTIVE BEHAVIORS LA English DT Article DE Incapacitated sexual assault; Drinking motives; Drinking norms; Alcohol use; Sexual activity ID COLLEGE-STUDENTS; ALCOHOL-USE; SUBSTANCE USE; RISK-FACTORS; RECIPROCAL RELATIONSHIPS; CASUAL SEX; WOMEN; VICTIMIZATION; RAPE; CONSUMPTION AB White House Council on Women and Girls (2014) highlighted sexual assault prevention as a high priority issue in need of immediate attention. A risk factor associated with sexual assault victimization and revictimization is drinking before sexual activity. The current study examined the relationship between incapacitated sexual assault (ISA) and drinking before sexual activity. Given the typical social context of both drinking before sexual activity and sexual assault in college settings, social-related drinking factors including drinking to conform motives, social drinking motives, and perceived drinking norms were examined. Six hundred and three undergraduate college women completed a survey online assessing history of ISA, social factors associated with drinking, and frequency of drinking before sexual activity. Path analysis indicated that both ISA before college and since entering college were associated with higher perceived drinking norms, more social drinking motive endorsement, and more drinking to conform. However, only higher perceived drinking norms and more social drinking motive endorsement were associated with both more severe ISA histories and more frequent drinking before sexual activity. Thus, a more severe ISA history was indeed associated with more frequent drinking before sexual activity and social factors related to drinking played a significant role in this relationship. Social factors can be easily targeted through brief interventions and these findings can inform future programming to promote more careful use of alcohol in social and sexual situations. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Bird, Elizabeth R.; Gilmore, Amanda K.; George, William H.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Gilmore, Amanda K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lewis, Melissa A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Bird, ER (reprint author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA. EM ebird@uw.edu FU National Institute for Alcohol Abuse and Alcoholism (NIAAA) [F31AA020134]; Alcohol and Drug Abuse Institute at the University of Washington [ADAI-0311-2]; University of Washington; NIAAA [R01AA016281, R01AA021379] FX Data collection and manuscript preparation were supported by grants from the National Institute for Alcohol Abuse and Alcoholism (NIAAA) awarded to A. K. Gilmore (F31AA020134) as well as a grant from the Alcohol and Drug Abuse Institute at the University of Washington (ADAI-0311-2), as well as the Bolles Fellowship and Hunt Fellowship from the University of Washington awarded to A. K. Gilmore. Manuscript preparation was also supported by grants from NIAAA awarded to W. H. George (R01AA016281) and to M. A. Lewis (R01AA021379). NR 59 TC 1 Z9 2 U1 7 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JAN PY 2016 VL 52 BP 28 EP 33 DI 10.1016/j.addbeh.2015.08.001 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CX0HI UT WOS:000365377100005 PM 26348279 ER PT J AU Grossbard, JR Leo, NRM Geisner, IM Atkins, D Ray, AE Kilmer, JR Mallett, K Larimer, ME Turrisi, R AF Grossbard, Joel R. Leo, Nadine R. Mastro Geisner, Irene Markman Atkins, David Ray, Anne E. Kilmer, Jason R. Mallett, Kimberly Larimer, Mary E. Turrisi, Rob TI Drinking norms, readiness to change, and gender as moderators of a combined alcohol intervention for first-year college students SO ADDICTIVE BEHAVIORS LA English DT Article DE Alcohol intervention; College students; Moderators; Readiness to change; Norms ID BRIEF MOTIVATIONAL INTERVENTIONS; PERSONALIZED NORMATIVE FEEDBACK; HEAVY-DRINKING; RANDOMIZED FACTORIAL; EMERGENCY-DEPARTMENT; CHANGE QUESTIONNAIRE; CONTROLLED-TRIAL; NATIONAL-SURVEY; NONMEDICAL USE; FOLLOW-UP AB Introduction: Alcohol interventions targeting college students and their parents have been shown to be efficacious. Little research has examined moderators of intervention efficacy to help tailor interventions for subgroups of students. Method: This study is a secondary data analysis of readiness to change, drinking norms, and gender as moderators of an efficacious peer- and parent-based intervention (Turrisi et al., 2009). Students (n = 680) were randomized to the combined peer and parent intervention (n = 342) or assessment-only control (n = 338). Results: The combined intervention reduced peak blood alcohol content (BAC) compared to control. Gender and norms did not moderate the relationship between the intervention and drinking. Significant interactions were found between gender, precontemplation, and intervention. Students in the combined condition with higher precontemplation had lower weekly drinking compared to those with lower precontemplation. This pattern was also found among men for peak BAC and alcohol-related consequences but not among women, indicating a three-way interaction. Conclusion: Interventions may need to consider readiness to change and gender to optimize effectiveness. Published by Elsevier Ltd. C1 [Grossbard, Joel R.] Vet Affairs Univ Washington, Dept Hlth Serv, Seattle, WA 98108 USA. [Leo, Nadine R. Mastro] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Geisner, Irene Markman; Atkins, David; Kilmer, Jason R.; Larimer, Mary E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. [Ray, Anne E.] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA. [Mallett, Kimberly; Turrisi, Rob] Penn State Univ, Biobehav Hlth & Prevent Ctr, University Pk, PA 16802 USA. RP Grossbard, JR (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM joel.Grossbard@va.gov OI Atkins, David/0000-0002-5781-9880 FU National Institute on Alcohol Abuse and Alcoholism [R01 AA 12529] FX This research was supported in part by a grant from the National Institute on Alcohol Abuse and Alcoholism R01 AA 12529 awarded to Rob Turrisi. NR 74 TC 2 Z9 2 U1 6 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JAN PY 2016 VL 52 BP 75 EP 82 DI 10.1016/j.addbeh.2015.07.028 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CX0HI UT WOS:000365377100012 PM 26363307 ER PT J AU Leslie, RD Palmer, J Schloot, NC Lernmark, A AF Leslie, R. David Palmer, Jerry Schloot, Nanette C. Lernmark, Ake TI Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment SO DIABETOLOGIA LA English DT Review DE Autoantibodies; Genetic variants; LADA; MODY; Personalised medicine; Review; Tcells; Treatment; Type 1 diabetes; Type 2 diabetes ID BETA-CELL FUNCTION; INSULIN SENSITIVITY; GAD ANTIBODIES; RISK-FACTORS; LADA CHINA; C-PEPTIDE; TYPE-2; ONSET; ADULTS; AUTOIMMUNITY AB Diabetes is not a single homogeneous disease but composed of many diseases with hyperglycaemia as a common feature. Four factors have, historically, been used to identify this diversity: the age at onset; the severity of the disease, i.e. degree of loss of beta cell function; the degree of insulin resistance and the presence of diabetes-associated autoantibodies. Our broad understanding of the distinction between the two major types, type 1 diabetes mellitus and type 2 diabetes mellitus, are based on these factors, but it has become apparent that they do not precisely capture the different disease forms. Indeed, both major types of diabetes have common features, encapsulated by adult-onset autoimmune diabetes and maturity-onset diabetes of the young. As a result, there has been a repositioning of our understanding of diabetes. In this review, drawing on recent literature, we discuss the evidence that autoimmune type 1 diabetes has a broad clinical phenotype with diverse therapeutic options, while the term non-autoimmune type 2 diabetes obscures the optimal management strategy because it encompasses substantial heterogeneity. Underlying these developments is a general progression towards precision medicine with the need for precise patient characterisation, currently based on clinical phenotypes but in future augmented by laboratory-based tests. C1 [Leslie, R. David] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England. [Palmer, Jerry] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Schloot, Nanette C.] Univ Dusseldorf, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany. [Schloot, Nanette C.] Lilly Deutschland GmbH, Bad Homburg, Germany. [Lernmark, Ake] Lund Univ, CRC, Dept Clin Sci, Malmo, Sweden. RP Leslie, RD (reprint author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England. EM r.d.g.leslie@qmul.ac.uk NR 45 TC 11 Z9 11 U1 2 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2016 VL 59 IS 1 BP 13 EP 20 DI 10.1007/s00125-015-3789-z PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CX6IN UT WOS:000365804500004 PM 26498592 ER PT B AU Cavazos, JE AF Cavazos, Jose E. BE Husain, AM TI First-Generation Antiepileptic Drugs SO PRACTICAL EPILEPSY LA English DT Article; Book Chapter ID PARTIAL-ONSET SEIZURES; TONIC CLONIC SEIZURES; STATUS EPILEPTICUS; CARBAMAZEPINE; MONOTHERAPY; OUTCOMES; EPILEPSY; THERAPY C1 [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] South Texas Vet Hlth Care Syst, San Antonio VA Epilepsy Ctr Excellence, San Antonio, TX USA. RP Cavazos, JE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. NR 9 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-029-7 PY 2016 BP 263 EP 276 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA BD9PI UT WOS:000365049500026 ER PT J AU Ashrafioun, L Pigeon, WR Conner, KR Leong, SH Oslin, DW AF Ashrafioun, Lisham Pigeon, Wilfred R. Conner, Kenneth R. Leong, Shirley H. Oslin, David W. TI Prevalence and correlates of suicidal ideation and suicide attempts among veterans in primary care referred for a mental health evaluation SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; Suicide attempt; Primary care; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; COMPLETED SUICIDE; RECEIVING CARE; RISK-FACTORS; COMORBIDITY; DEPRESSION; SYSTEM; PTSD; METAANALYSIS; ASSOCIATION AB Background: The Veterans Health Administration has made concerted efforts to increase mental health services offered in primary care. However, few studies have evaluated correlates of suicidal ideation and suicide attempt in veterans in primary care-mental health integration (PCMHI). The purpose of the present study is to examine associations between suicidal ideation and suicide attempts as dependent variables and demographic and clinical factors as the independent variables. Methods: Veterans (n=3004) referred from primary care to PCMHI were contacted for further assessment, which included past-year severity of suicidal thoughts (none, low, high) and attempts using the Paykel Suicide Scale, mental health disorders, and illicit drug use. Multinomial logistic regression models were used to identify correlates of suicidal ideation and suicide attempts. Results: Thoughts of taking one's life was endorsed by 24% of participants and suicide attempts were reported in 2%. In adjusted models, depression, psychosis, mania, PTSD and generalized anxiety disorder were associated with high severity suicidal ideation, but not suicide attempt. Illicit drug use was not associated with suicidal ideation, but was the only variable associated with suicide attempt. Limitations: The study was cross-sectional, focused on one clinical setting, and the suicide attempt analyses had limited power. Conclusions: PCMHI is a critical setting to assess suicidal ideation and suicide attempt and researchers and clinicians should be aware that the differential correlates of these suicide-related factors. Future research is needed to identify prospective risk factors and assess the utility of follow-up care in preventing suicide. Published by Elsevier B.V. C1 [Ashrafioun, Lisham; Pigeon, Wilfred R.; Conner, Kenneth R.] Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Ashrafioun, Lisham; Pigeon, Wilfred R.; Conner, Kenneth R.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14627 USA. [Leong, Shirley H.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Leong, Shirley H.; Oslin, David W.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. RP Ashrafioun, L (reprint author), Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM Lisham.Ashrafioun@va.gov NR 50 TC 2 Z9 2 U1 6 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2016 VL 189 BP 344 EP 350 DI 10.1016/j.jad.2015.09.014 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CV3PD UT WOS:000364170200051 PM 26474375 ER PT J AU Foster, GR Afdhal, N Roberts, SK Brau, N Gane, EJ Pianko, S Lawitz, E Thompson, A Shiffman, ML Cooper, C Towner, WJ Conway, B Ruane, P Bourliere, M Asselah, T Berg, T Zeuzem, S Rosenberg, W Agarwal, K Stedman, CAM Mo, H Dvory-Sobol, H Han, L Wang, J McNally, J Osinusi, A Brainard, DM McHutchison, JG Mazzotta, F Tran, TT Gordon, SC Patel, K Reau, N Mangia, A Sulkowski, M AF Foster, G. R. Afdhal, N. Roberts, S. K. Braeu, N. Gane, E. J. Pianko, S. Lawitz, E. Thompson, A. Shiffman, M. L. Cooper, C. Towner, W. J. Conway, B. Ruane, P. Bourliere, M. Asselah, T. Berg, T. Zeuzem, S. Rosenberg, W. Agarwal, K. Stedman, C. A. M. Mo, H. Dvory-Sobol, H. Han, L. Wang, J. McNally, J. Osinusi, A. Brainard, D. M. McHutchison, J. G. Mazzotta, F. Tran, T. T. Gordon, S. C. Patel, K. Reau, N. Mangia, A. Sulkowski, M. CA ASTRAL-2 & ASTRAL-3 Investigators TI Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID C VIRUS-INFECTION; RANDOMIZED-TRIAL AB BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis. In one trial, patients with HCV genotype 2 were randomly assigned in a 1: 1 ratio to receive sofosbuvir-velpatasvir,in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus weight-based ribavirin (132 patients) for 12 weeks. In a second trial, patients with HCV genotype 3 were randomly assigned in a 1: 1 ratio to receive sofosbuvir-velpatasvir for 12 weeks (277 patients) or sofosbuvir-ribavirin for 24 weeks (275 patients). The primary end point for the two trials was a sustained virologic response at 12 weeks after the end of therapy. RESULTS Among patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P = 0.02). Among patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir-ribavirin group (P<0.001). The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia. CONCLUSIONS Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin. C1 [Foster, G. R.] Queen Mary Univ London, London E1 4AT, England. [Rosenberg, W.] UCL, London WC1E 6BT, England. [Rosenberg, W.] Kings Coll Hosp London, London SE5 8RX, England. [Agarwal, K.] Inst Liver Studies, London, England. [Afdhal, N.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Roberts, S. K.] Alfred Hlth, Melbourne, Vic, Australia. [Roberts, S. K.] Monash Univ, Melbourne, Vic 3004, Australia. [Thompson, A.] St Vincents Hosp, Melbourne, Vic, Australia. [Pianko, S.] Monash Hlth, Clayton, Vic, Australia. [Pianko, S.] Monash Univ, Clayton, Vic, Australia. [Braeu, N.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Braeu, N.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gane, E. J.] Auckland Clin Studies, Auckland, New Zealand. [Stedman, C. A. M.] Christchurch Clin Studies Trust & Univ Otago, Christchurch, New Zealand. [Lawitz, E.] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA. [Shiffman, M. L.] Liver Inst Virginia, Richmond, VA USA. [Cooper, C.] Univ Ottawa, Ottawa, ON, Canada. [Conway, B.] Vancouver Infect Dis Ctr, Vancouver, BC, Canada. [Towner, W. J.] Kaiser Permanente, Los Angeles, CA USA. [Ruane, P.] Ruane Med, Los Angeles, CA USA. [Tran, T. T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Berg, T.; Mo, H.; Dvory-Sobol, H.; Han, L.; Wang, J.; McNally, J.; Osinusi, A.; Brainard, D. M.; McHutchison, J. G.] Gilead Sci Inc, Foster City, CA 94404 USA. [Bourliere, M.] Hop St Joseph, Marseille, France. [Asselah, T.] Univ Paris Diderot, INSERM, UMR 1149, Hop Beaujon,Serv Hepatol, Clichy, France. [Berg, T.] Univ Hosp Leipzig, Leipzig, Germany. [Zeuzem, S.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. [Mazzotta, F.] Santa Maria Annunziata Hosp, Florence, Italy. [Mangia, A.] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy. [Gordon, S. C.] Henry Ford Hlth Syst, Detroit, MI USA. [Patel, K.] Duke Univ, Sch Med, Durham, NC USA. [Reau, N.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Sulkowski, M.] Johns Hopkins Univ, Baltimore, MD USA. RP Foster, GR (reprint author), Queen Mary Univ London, Liver Unit, 4 Newark St, London E1 4AT, England. EM g.r.foster@qmul.ac.uk RI Loustaud-Ratti, Veronique/A-5262-2017; Leggett, Barbara/D-3579-2011 OI Rosenberg, William/0000-0002-2732-2304 FU Gilead Sciences FX Funded by Gilead Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, NCT02201953. NR 17 TC 121 Z9 123 U1 7 U2 25 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 31 PY 2015 VL 373 IS 27 BP 2608 EP 2617 DI 10.1056/NEJMoa1512612 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CZ8UH UT WOS:000367374100006 PM 26575258 ER PT J AU Alawieh, A Elvington, A Zhu, H Yu, J Kindy, MS Atkinson, C Tomlinson, S AF Alawieh, Ali Elvington, Andrew Zhu, Hong Yu, Jin Kindy, Mark S. Atkinson, Carl Tomlinson, Stephen TI Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Ischemic stroke; Complement inhibition; Neuroinflammation; Neuroprotection ID MANNOSE-BINDING LECTIN; NEURAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; SUBVENTRICULAR ZONE; BRAIN-INJURY; IN-VITRO; STROKE; NEUROGENESIS; RECEPTOR; SYSTEM AB Background: Complement promotes neuroinflammation and injury in models of stroke. However, complement is also being increasingly implicated in repair and regeneration after central nervous system (CNS) injury, and some complement deficiencies have been shown to provide acute, but not subacute, protection after murine stroke. Here, we investigate the dual role of complement in injury and repair after cerebral ischemia and reperfusion. Methods: We used complement-deficient mice and different complement inhibitors in a model of transient middle cerebral artery occlusion to investigate complement-dependent cellular and molecular changes that occur through the subacute phase after stroke. Results: C3 deficiency and site-targeted complement inhibition with either CR2-Crry (inhibits all pathways) or CR2-fH (inhibits alternative pathway) significantly reduced infarct size, reduced apoptotic cell death, and improved neurological deficit score in the acute phase after stroke. However, only in CR2-fH-treated mice was there sustained protection with no evolution of injury in the subacute phase. Whereas both inhibitors significantly reduced microglia/macrophage activation and astrogliosis in the subacute phase, only CR2-fH improved neurological deficit and locomotor function, maintained neurogenesis markers, enhanced neuronal migration, and increased VEGF expression. These findings in CR2-fH-treated mice correlated with improved performance in spatial learning and passive avoidance tasks. The complement anaphylatoxins have been implicated in repair and regenerative mechanisms after CNS injury, and in this context CR2-fH significantly reduced, but did not eliminate the generation of C5a within the brain, unlike CR2-Crry that completely blocked C5a generation. Gene expression profiling revealed that CR2-fH treatment downregulated genes associated with apoptosis, TGF beta signaling, and neutrophil activation, and decreased neutrophil infiltration was confirmed by immunohistochemistry. CR2-fH upregulated genes for neural growth factor and mediators of neurogenesis and neuronal migration. Live animal imaging demonstrated that following intravenous injection, CR2-fH targeted specifically to the post-ischemic brain, with a tissue half-life of 48.5 h. Finally, unlike C3 deficiency, targeted complement inhibition did not increase susceptibility to lethal post-stroke infection, an important consideration for stroke patients. Conclusions: Ischemic brain tissue-targeted and selective inhibition of alternative complement pathway provide self-limiting inhibition of complement activation and reduces acute injury while maintaining complement-dependent recovery mechanisms into the subacute phase after stroke. C1 [Alawieh, Ali; Elvington, Andrew; Atkinson, Carl; Tomlinson, Stephen] Med Univ S Carolina, Childrens Res Inst, Department Microbiol & Immunol, Charleston, SC 29425 USA. [Zhu, Hong; Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Inst Neurosci, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.; Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Childrens Res Inst, Department Microbiol & Immunol, 173 Ashley Ave BSB 201, Charleston, SC 29425 USA. EM tomlinss@musc.edu OI Alawieh, Ali/0000-0003-2601-8850 FU NIH [1P20GM109040]; Department of Veterans Affairs (Merit Award) [1I01RX001141, 1BX001218]; American Heart Association [15PRE25250009] FX This work was supported by grants from the NIH (1P20GM109040), the Department of Veterans Affairs (Merit Award 1I01RX001141 and 1BX001218), and an American Heart Association Pre-doctoral Fellowship to AA (15PRE25250009). NR 40 TC 2 Z9 2 U1 1 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD DEC 30 PY 2015 VL 12 AR 247 DI 10.1186/s12974-015-0464-8 PG 15 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DA0UG UT WOS:000367512400005 PM 26714866 ER PT J AU Chen, YX Zhu, WB Zhang, WR Libal, N Murphy, SJ Offner, H Alkayed, NJ AF Chen, Yingxin Zhu, Wenbin Zhang, Wenri Libal, Nicole Murphy, Stephanie J. Offner, Halina Alkayed, Nabil J. TI A novel mouse model of thromboembolic stroke SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE Cerebral ischemia; Stroke, Thromboembolic; Mouse; tPA; Optical microangiography ID CEREBRAL-ARTERY OCCLUSION; SPONTANEOUSLY HYPERTENSIVE-RATS; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; INTRALUMINAL SUTURE; EMBOLIC STROKE; BRAIN ISCHEMIA; INFARCT SIZE; REPERFUSION; MICE AB Background: We previously demonstrated that tissue plasminogen activator (tPA) reduces infarct size after mechanical middle cerebral artery occlusion (MCAO) in wild-type (WT) mice and transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). Clinically, tPA limits ischemic damage by dissolving the clot blocking blood flow through a cerebral artery. To mimic the clinical situation, we developed a new mouse model of thromboembolic stroke, and tested the efficacy of tPA in WT and DR2-Tg mice. New Method Autologous blood is withdrawn into a PE-8 catheter filled with 2 IU alpha-thrombin. After exposing the catheter briefly to air, the catheter is reintroduced into the external (ECA) and advanced into the internal carotid artery (ICA) to allow for intravascular injection of thrombin at the MCA bifurcation. To validate the model, we tested the effect of tPA on laser-Doppler perfusion (LDP) over the MCA territory and infarct size in WT and DR2-Tg mice. Results: The procedure results in a consistent drop in LDP, and leads to a highly reproducible ischemic lesion. When administered at 15 min after thrombosis, tPA restored LDP and resulted in a significant reduction in infarct size at 24 h after thrombosis in both WT and DR2-Tg. Comparison with Existing Methods: Our model significantly reduces surgery time, requires a single anesthesia exposure, and produces a consistent and predictable infarction, with low variability and mortality. Conclusion: We validated the efficacy of tPA in restoring blood flow and reducing infarct in a new model of endovascular thromboembolic stroke in the mouse. (C) 2015 Elsevier B.V. All rights reserved. C1 [Chen, Yingxin; Zhu, Wenbin; Zhang, Wenri; Libal, Nicole; Murphy, Stephanie J.; Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res, Portland, OR USA. RP Alkayed, NJ (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Dept Anesthesiol & Perioperat Med, UHN 2,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM alkayedn@ohsu.edu FU NIH [R42NS065515, R01NS070837] FX This project was supported by NIH grants R42NS065515 (Offner & Alkayed) and R01NS070837 (Alkayed). NR 40 TC 3 Z9 3 U1 9 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 EI 1872-678X J9 J NEUROSCI METH JI J. Neurosci. Methods PD DEC 30 PY 2015 VL 256 BP 203 EP 211 DI 10.1016/j.jneumeth.2015.09.013 PG 9 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CY7VW UT WOS:000366618400021 PM 26386284 ER PT J AU Cortese, BM Uhde, TW Brady, KT McClernon, FJ Yang, QX Collins, HR LeMatty, T Hartwell, KJ AF Cortese, Bernadette M. Uhde, Thomas W. Brady, Kathleen T. McClernon, F. Joseph Yang, Qing X. Collins, Heather R. LeMatty, Todd Hartwell, Karen J. TI The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Odors; Smoking; Tobacco dependence; Craving; Cue-reactivity; Neuroimaging ID ALCOHOL CUES; OLFACTORY FUNCTION; CIGARETTE-SMOKING; PREFRONTAL CORTEX; RISK DRINKERS; DRUG CUES; IN-VIVO; REACTIVITY; RELAPSE; SMOKERS AB Given that the vast majority of functional magnetic resonance imaging (fMRI) studies of drug cue reactivity use unisensory visual cues, but that multisensory cues may elicit greater craving-related brain responses, the current study sought to compare the fMRI BOLD response to unisensory visual and multisensory, visual plus odor, smoking cues in 17 nicotine-dependent adult cigarette smokers. Brain activation to smoking-related, compared to neutral, pictures was assessed under cigarette smoke and odorless odor conditions. While smoking pictures elicited a pattern of activation consistent with the addiction literature, the multisensory (odor+picture) smoking cues elicited significantly greater and more widespread activation in mainly frontal and temporal regions. BOLD signal elicited by the multisensory, but not unisensory cues, was significantly related to participants' level of control over craving as well. Results demonstrated that the co-presentation of cigarette smoke odor with smoking-related visual cues, compared to the visual cues alone, elicited greater levels of craving-related brain activation in key regions implicated in reward. These preliminary findings support future research aimed at a better understanding of multisensory integration of drug cues and craving. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Cortese, Bernadette M.; Uhde, Thomas W.; Brady, Kathleen T.; LeMatty, Todd; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson VAMC, Charleston, SC USA. [McClernon, F. Joseph] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Yang, Qing X.] Penn State Coll Med, Dept Radiol & Neurosurg, Ctr NMR Res, Hershey, PA USA. [Collins, Heather R.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Ctr Biomed Imaging, Charleston, SC 29425 USA. RP Cortese, BM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, MSC 861, Charleston, SC 29425 USA. EM corteseb@musc.edu FU NIMH [K01MH090548]; NCATS [UL1 TR000062] FX Funding for this study was provided by NIMH Grant K01MH090548 (BMC), and by NCATS Grant UL1 TR000062 (pilot project to KJH and BMC). Study sponsors had no role in the study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication. NR 51 TC 1 Z9 1 U1 5 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD DEC 30 PY 2015 VL 234 IS 3 BP 321 EP 327 DI 10.1016/j.pscychresns.2015.10.008 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CX9FU UT WOS:000366011200006 PM 26475784 ER PT J AU Jiang, RZ Lu, YT Ho, H Li, B Chen, JF Lin, M Li, FQ Wu, K Wu, HJ Lichterman, J Wan, HL Lu, CL OuYang, W Ni, M Wang, LL Li, GB Lee, T Zhang, XQ Yang, JT Rettig, M Chung, LWK Yang, HM Li, KC Hou, Y Tseng, HR Hou, S Xu, X Wang, J Posadas, EM AF Jiang, Runze Lu, Yi-Tsung Ho, Hao Li, Bo Chen, Jie-Fu Lin, Millicent Li, Fuqiang Wu, Kui Wu, Hanjie Lichterman, Jake Wan, Haolei Lu, Chia-Lun OuYang, William Ni, Ming Wang, Linlin Li, Guibo Lee, Tom Zhang, Xiuqing Yang, Jonathan Rettig, Matthew Chung, Leland W. K. Yang, Huanming Li, Ker-Chau Hou, Yong Tseng, Hsian-Rong Hou, Shuang Xu, Xun Wang, Jun Posadas, Edwin M. TI A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer SO ONCOTARGET LA English DT Article DE circulating tumor cell; prostate cancer; whole genome sequencing; liquid biopsy; cancer heterogeneity ID METASTATIC BREAST-CANCER; COPY-NUMBER; LUNG-CANCER; SINGLE-NUCLEOTIDE; PERIPHERAL-BLOOD; PD-1 BLOCKADE; MUTATIONS; EVOLUTION; DNA; REARRANGEMENTS AB Previous studies have demonstrated focal but limited molecular similarities between circulating tumor cells (CTCs) and biopsies using isolated genetic assays. We hypothesized that molecular similarity between CTCs and tissue exists at the single cell level when characterized by whole genome sequencing (WGS). By combining the NanoVelcro CTC Chip with laser capture microdissection (LCM), we developed a platform for single-CTC WGS. We performed this procedure on CTCs and tissue samples from a patient with advanced prostate cancer who had serial biopsies over the course of his clinical history. We achieved 30X depth and >= 95% coverage. Twenty-nine percent of the somatic single nucleotide variations (SSNVs) identified were founder mutations that were also identified in CTCs. In addition, 86% of the clonal mutations identified in CTCs could be traced back to either the primary or metastatic tumors. In this patient, we identified structural variations (SVs) including an intrachromosomal rearrangement in chr3 and an interchromosomal rearrangement between chr13 and chr15. These rearrangements were shared between tumor tissues and CTCs. At the same time, highly heterogeneous short structural variants were discovered in PTEN, RB1, and BRCA2 in all tumor and CTC samples. Using high-quality WGS on single-CTCs, we identified the shared genomic alterations between CTCs and tumor tissues. This approach yielded insight into the heterogeneity of the mutational landscape of SSNVs and SVs. It may be possible to use this approach to study heterogeneity and characterize the biological evolution of a cancer during the course of its natural history. C1 [Jiang, Runze; Li, Bo; Li, Fuqiang; Wu, Kui; Wu, Hanjie; Ni, Ming; Wang, Linlin; Li, Guibo; Yang, Huanming; Hou, Yong; Xu, Xun; Wang, Jun] Beijing Genome Inst Shenzhen, Shenzhen 51803, Peoples R China. [Lu, Yi-Tsung; Chen, Jie-Fu; Lichterman, Jake; Lu, Chia-Lun; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Urol Oncol Res Program, Los Angeles, CA 90048 USA. [Ho, Hao; Li, Ker-Chau] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA. [Ho, Hao; Li, Ker-Chau] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan. [Chen, Jie-Fu; Lin, Millicent; OuYang, William; Yang, Jonathan; Tseng, Hsian-Rong; Hou, Shuang] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Wan, Haolei] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lee, Tom; Tseng, Hsian-Rong] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA. [Zhang, Xiuqing] BGI Shenzhen, Guangdong Enterprise Key Lab Human Dis Genom, Shenzhen 51803, Peoples R China. [Rettig, Matthew] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Dept Med, Los Angeles, CA 90073 USA. [Yang, Huanming; Wang, Jun] King Abdulaziz Univ, Princess Al Jawhara Ctr Excellence Res Hereditary, Jeddah 21589, Saudi Arabia. [Yang, Huanming] Zhejiang Univ, James D Watson Inst Genome Sci, Hangzhou 310058, Zhejiang, Peoples R China. [Wang, Jun] Univ Copenhagen, Dept Biol, DK-1599 Copenhagen, Denmark. [Wang, Jun] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, DK-1599 Copenhagen, Denmark. RP Posadas, EM (reprint author), Cedars Sinai Med Ctr, Urol Oncol Res Program, Los Angeles, CA 90048 USA. EM HRTseng@mednet.ucla.edu; wangj@genomics.cn; Edwin.Posadas@csmc.edu FU National High Technology Research and Development Program of China-863 Program [2012AA02A201]; National Basic Research Program of China (973 program) [2011CB809202, 2011CB809203]; Key Laboratory Project - Shenzhen City [CXB201108250096A]; Major Industrial Technology Research Program of Shenzhen [BGI20100001]; Science, Technology and Innovation Committee of Shenzhen Municipality [JSGG20140702161347218]; China National GeneBank-Shenzhen; Prostate Cancer Foundation (PCF); UCLA Prostate Cancer SPORE Program; NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program [R21 CA151159, R33 CA157396]; DoD Idea Award [W81XWH-11-1-0422]; Steven Spielberg Discovery Fund in Prostate Cancer Research; PCF Young Investigator Award; St. Anthony Fund for Prostate Cancer Research; CD McKinnon Fund; Berns Family Fund for Prostate Cancer Research; Innovative Research Team Project of Guangdong; Guangdong Enterprise Key Laboratory of Human Disease Genomics [2011A060906007]; National Natural Science Fund [81272899, 81172510]; Discipline Booster Plan of Xi Jing Hospital [XJZT12Z07]; Danish Natural Science Research Council; Danish National Research Foundation; National Natural Science Foundation of China; Shenzhen Municipal Government; Local Government of the Yantian District of Shenzhen FX The work at BGI was supported by the National High Technology Research and Development Program of China-863 Program (No. 2012AA02A201), a National Basic Research Program of China (973 program No. 2011CB809202 and 2011CB809203), the Key Laboratory Project Supported by Shenzhen City (No. CXB201108250096A), Major Industrial Technology Research Program of Shenzhen (No. BGI20100001), the Science, Technology and Innovation Committee of Shenzhen Municipality (JSGG20140702161347218), and China National GeneBank-Shenzhen. The research endeavors at UCLA were supported by a Creativity Award from the Prostate Cancer Foundation (PCF), the UCLA Prostate Cancer SPORE Program, and research grants (R21 CA151159 and R33 CA157396) from the NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program. The research endeavors at Cedars-Sinai Medical Center were supported by a DoD Idea Award (W81XWH-11-1-0422), the Steven Spielberg Discovery Fund in Prostate Cancer Research, a PCF Young Investigator Award, the St. Anthony Fund for Prostate Cancer Research, the CD McKinnon Fund, and the Berns Family Fund for Prostate Cancer Research. This project was also supported by grants from the Innovative Research Team Project of Guangdong, the Guangdong Enterprise Key Laboratory of Human Disease Genomics (No. 2011A060906007), the National Natural Science Fund (81272899 and 81172510) and Discipline Booster Plan of Xi Jing Hospital (XJZT12Z07). We also acknowledge an Ole Romer grant from the Danish Natural Science Research Council, the Danish National Research Foundation, the National Natural Science Foundation of China, and funds from the Shenzhen Municipal Government and the Local Government of the Yantian District of Shenzhen. NR 53 TC 15 Z9 15 U1 5 U2 14 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 29 PY 2015 VL 6 IS 42 BP 44781 EP 44793 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD4QX UT WOS:000369908800053 PM 26575023 ER PT J AU Londino, JD Gulick, D Isenberg, JS Mallampalli, RK AF Londino, James D. Gulick, Dexter Isenberg, Jeffrey S. Mallampalli, Rama K. TI Cleavage of Signal Regulatory Protein alpha (SIRP alpha) Enhances Inflammatory Signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYLOID PRECURSOR PROTEIN; C-TERMINAL FRAGMENT; NF-KAPPA-B; CELL-MIGRATION; SECRETASE; ACTIVATION; CD47; SHPS-1; ADAM10; GROWTH AB Signal regulatory protein alpha (SIRP alpha) is a membrane glycoprotein immunoreceptor abundant in cells of monocyte lineage. SIRP alpha ligation by a broadly expressed transmembrane protein, CD47, results in phosphorylation of the cytoplasmic immunoreceptor tyrosine-based inhibitory motifs, resulting in the inhibition of NF-kappa B signaling in macrophages. Here we observed that proteolysis of SIRP alpha during inflammation is regulated by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), resulting in the generation of a membrane-associated cleavage fragment in both THP-1 monocytes and human lung epithelia. We mapped a charge-dependent putative cleavage site near the membrane-proximal domain necessary for ADAM10-mediated cleavage. In addition, a secondary proteolytic cleavage within the membrane-associated SIRP alpha fragment by gamma-secretase was identified. Ectopic expression of a SIRP alpha mutant plasmid encoding a proteolytically resistant form in HeLa cells inhibited activation of the NF-kappa B pathway and suppressed STAT1 phosphorylation in response to TNF alpha to a greater extent than expression of wild-type SIRP alpha. Conversely, overexpression of plasmids encoding the proteolytically cleaved SIRP alpha fragments in cells resulted in enhanced STAT-1 and NF-kappa B pathway activation. Thus, the data suggest that combinatorial actions of ADAM10 and gamma-secretase on SIRP alpha cleavage promote inflammatory signaling. C1 [Londino, James D.; Gulick, Dexter; Isenberg, Jeffrey S.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA. [Isenberg, Jeffrey S.] Univ Pittsburgh, Sch Med, Div Pulm,Allergy & Crit Care Med, Vasc Med Inst,Starzl Transplantat Inst,Dept Pharm, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Pulm Allergy & Crit Care Med, Dept Med, NW628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu RI Regan, Clinton/E-6250-2012 FU United States Department of Veterans Affairs Merit Review Award; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, HL114453, T32 5T32HL007563-28] FX This work was partially supported by a United States Department of Veterans Affairs Merit Review Award and partially by National Institutes of Health R01 Grants HL096376, HL097376, HL098174, HL081784, and 1UH2HL123502 and P01 Grant HL114453 (to R. K. M.) and Grant T32 5T32HL007563-28 (to J. D. L.). The authors declare no conflict of interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 42 TC 4 Z9 4 U1 1 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 2015 VL 290 IS 52 BP 31113 EP 31125 DI 10.1074/jbc.M115.682914 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CZ6GK UT WOS:000367199000039 PM 26534964 ER PT J AU Singh, H Graber, ML AF Singh, Hardeep Graber, Mark L. TI Improving Diagnosis in Health Care - The Next Imperative for Patient Safety SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID ERRORS C1 [Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Graber, Mark L.] RTI Int, Raleigh, NC USA. [Graber, Mark L.] Soc Improve Diag Med, New York, NY USA. [Graber, Mark L.] SUNY Stony Brook, Stony Brook, NY 11794 USA. RP Singh, H (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX 77030 USA. NR 5 TC 20 Z9 20 U1 1 U2 8 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2493 EP 2495 DI 10.1056/NEJMp1512241 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700004 PM 26559457 ER PT J AU Sharma, A Hoover, DR Shi, QH Gustafson, D Plankey, MW Hershow, RC Tien, PC Golub, ET Anastos, K AF Sharma, Anjali Hoover, Donald R. Shi, Qiuhu Gustafson, Deborah Plankey, Michael W. Hershow, Ronald C. Tien, Phyllis C. Golub, Elizabeth T. Anastos, Kathryn TI Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study SO PLOS ONE LA English DT Article ID STARTING ANTIRETROVIRAL THERAPY; ALL-CAUSE MORTALITY; IMMUNE CELL COUNTS; UNITED-STATES; DISEASE PROGRESSION; NUTRITIONAL-STATUS; PROSPECTIVE COHORT; BLACK ADULTS; OBESITY; IMPACT AB Background Early HIV studies suggested protective associations of overweight against mortality, yet data are lacking for the era of potent highly active antiretroviral therapy (HAART). We evaluated associations of pre-HAART initiation body mass index (BMI) with mortality among HAART-using women. Methods Prospective study of time to death after HAART initiation among continuous HAART users in the Women's Interagency HIV Study. Unadjusted Kaplan-Meier and adjusted proportional hazards survival models assessed time to AIDS and non-AIDS death by last measured pre-HAART BMI. Results Of 1428 continuous HAART users 39 (2.7%) were underweight, 521 (36.5%) normal weight, 441 (30.9%) overweight, and 427 (29.9%) obese at time of HAART initiation. A total of 322 deaths occurred during median follow-up of 10.4 years (IQR 5.9-14.6). Censoring at non-AIDS death, the highest rate of AIDS death was observed among underweight women (p = 0.0003 for all 4 categories). In multivariate models, women underweight prior to HAART died from AIDS more than twice as rapidly vs. normal weight women (aHR 2.04, 95% CI 1.03, 4.04); but being overweight or obese (vs. normal weight) was not independently associated with AIDS death. Cumulative incidence of non-AIDS death was similar across all pre-HAART BMI categories. Conclusions Among continuous HAART-using women, being overweight prior to initiation was not associated with lower risk of AIDS or non-AIDS death. Being underweight prior to HAART was associated with over double the rate of AIDS death in adjusted analyses. Although overweight and obesity may be associated with many adverse health conditions, neither was predictive of mortality among the HAART-using women. C1 [Sharma, Anjali; Anastos, Kathryn] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Shi, Qiuhu] New York Med Coll, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA. [Gustafson, Deborah] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Plankey, Michael W.] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis, Washington, DC 20007 USA. [Hershow, Ronald C.] Univ Illinois, Dept Epidemiol, Chicago, IL USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Sharma, A (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. EM anjali.sharma@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI Grant) [UL1 RR024131]; National Institutes of Health [K23AR06199301] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. This research was also supported by National Institutes of Health K23AR06199301 (AS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 23 PY 2015 VL 10 IS 12 AR e0143740 DI 10.1371/journal.pone.0143740 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ4SI UT WOS:000367092600009 PM 26699870 ER PT J AU Olson, KA Beatty, AL Heidecker, B Regan, MC Brody, EN Foreman, T Kato, S Mehler, RE Singer, BS Hveem, K Dalen, H Sterling, DG Lawn, RM Schiller, NB Williams, SA Whooley, MA Ganz, P AF Olson, Kristoff A. Beatty, Alexis L. Heidecker, Bettina Regan, Mathilda C. Brody, Edward N. Foreman, Trudi Kato, Shintaro Mehler, Robert E. Singer, Britta S. Hveem, Kristian Dalen, Havard Sterling, David G. Lawn, Richard M. Schiller, Nelson B. Williams, Stephen A. Whooley, Mary A. Ganz, Peter TI Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts SO EUROPEAN HEART JOURNAL LA English DT Article DE Growth differentiation factor 11 and 8; Ageing; Cardiovascular outcomes; Epidemiology; Hypertrophy ID LEFT-VENTRICULAR MASS; SKELETAL-MUSCLE; DISEASE; FRAMINGHAM; FAILURE; AGE; DYSFUNCTION; SOCIETY; INDEX; RISK AB Aims Growth differentiation factor 11 and/or its homologue growth differentiation factor 8 (GDF11/8) reverses age-related cardiac hypertrophy and vascular ageing in mice. We investigated whether GDF11/8 associates with cardiovascular outcomes, left ventricular hypertrophy (LVH), or age in humans. Methods and results We measured plasma GDF11/8 levels in 928 participants with stable ischaemic heart disease in the Heart and Soul study. We adjudicated heart failure hospitalization, stroke, myocardial infarction, death, and their composite endpoint. Left ventricular hypertrophy was evaluated by echocardiography. We used multivariable Cox proportional hazards models to compare rates of cardiovascular events and death across GDF11/8 quartiles and logistic regression models to evaluate the association between GDF11/8 and LVH. Four hundred and fifty participants (48.5%) experienced a cardiovascular event or death during 8.9 years of follow-up. The adjusted risk of the composite endpoint was lower in the highest compared with the lowest GDF11/8 quartile [hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.33-0.60; P < 0.001]. We replicated this relationship of GDF11/8 to adverse events in 971 participants in the HUNT3 cohort (adjusted HR, 0.34; 95% CI, 0.23-0.51; P < 0.001). Left ventricular hypertrophy was present in 368 participants (39.7%) at baseline. Participants in the highest quartile of GDF11/8 were less likely to have LVH than those in the lowest quartile (adjusted OR, 0.55; 95% CI, 0.35-0.86; P = 0.009). GDF11/8 levels were lower in older individuals (P < 0.001). Conclusion In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice. C1 [Olson, Kristoff A.; Beatty, Alexis L.; Heidecker, Bettina; Schiller, Nelson B.; Whooley, Mary A.; Ganz, Peter] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Beatty, Alexis L.] Vet Affairs Puget Sound Hlth Care Syst, Cardiol Sect, Seattle, WA USA. [Beatty, Alexis L.] Univ Washington, Dept Med, Seattle, WA USA. [Regan, Mathilda C.] Vet Hlth Res Inst, San Francisco, CA USA. [Brody, Edward N.; Foreman, Trudi; Mehler, Robert E.; Singer, Britta S.; Sterling, David G.; Lawn, Richard M.; Williams, Stephen A.] SomaLogic Inc, Boulder, CO USA. [Kato, Shintaro] NEC Corp Amer, Irving, TX 75063 USA. [Hveem, Kristian] Lifandis AS, Levanger, Norway. [Hveem, Kristian] NTNU, Dept Publ Hlth, HUNT Res Ctr, Trondheim, Norway. [Dalen, Havard] Nord Trondelag Hlth Trust, Levanger Hosp, Dept Med, Levanger, Norway. [Dalen, Havard] Norwegian Univ Sci & Technol, MI Lab, Trondheim, Norway. [Dalen, Havard] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Trondheim, Norway. [Whooley, Mary A.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ganz, Peter] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. RP Ganz, P (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM peter.ganz@ucsf.edu FU Department of Veterans Affairs (Epidemiology Merit Review Program); National Heart, Lung and Blood Institute [R01 HL079235]; Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program); Ischemia Research and Education Foundation; National Center for Advancing Translational Sciences [KL2TR000143]; SomaLogic FX This study was supported by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program); the National Heart, Lung and Blood Institute (grant number: R01 HL079235); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program); and the Ischemia Research and Education Foundation. None of these funding sources had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The contents of this research are solely the responsibility of the investigators and do not necessarily represent the official views of the NIH. A.L.B. is supported by the National Center for Advancing Translational Sciences (grant number: KL2TR000143). This study was also supported in part by a research grant to M.A.W. from SomaLogic. NR 18 TC 18 Z9 21 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD DEC 21 PY 2015 VL 36 IS 48 BP 3426 EP 3434 DI 10.1093/eurheartj/ehv385 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DE1GD UT WOS:000370373900010 PM 26294790 ER PT J AU Shukla, SK Cook, D Meyer, J Vernon, SD Le, T Clevidence, D Robertson, CE Schrodi, SJ Yale, S Frank, DN AF Shukla, Sanjay K. Cook, Dane Meyer, Jacob Vernon, Suzanne D. Le, Thao Clevidence, Derek Robertson, Charles E. Schrodi, Steven J. Yale, Steven Frank, Daniel N. TI Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) SO PLOS ONE LA English DT Article ID NITROSATIVE STRESS PATHWAYS; GRAM-NEGATIVE ENTEROBACTERIA; SYNDROME CFS; INFLAMMATORY PATHWAYS; LEAKY GUT; TRANSLOCATION; LPS; NORMALIZATION; RESPONSES; SYMPTOMS AB Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disease characterized by intense and debilitating fatigue not due to physical activity that has persisted for at least 6 months, post-exertional malaise, unrefreshing sleep, and accompanied by a number of secondary symptoms, including sore throat, memory and concentration impairment, headache, and muscle/joint pain. In patients with post-exertional malaise, significant worsening of symptoms occurs following physical exertion and exercise challenge serves as a useful method for identifying biomarkers for exertion intolerance. Evidence suggests that intestinal dysbiosis and systemic responses to gut microorganisms may play a role in the symptomology of ME/CFS. As such, we hypothesized that post-exertion worsening of ME/CFS symptoms could be due to increased bacterial translocation from the intestine into the systemic circulation. To test this hypothesis, we collected symptom reports and blood and stool samples from ten clinically characterized ME/CFS patients and ten matched healthy controls before and 15 minutes, 48 hours, and 72 hours after a maximal exercise challenge. Microbiomes of blood and stool samples were examined. Stool sample microbiomes differed between ME/CFS patients and healthy controls in the abundance of several major bacterial phyla. Following maximal exercise challenge, there was an increase in relative abundance of 6 of the 9 major bacterial phyla/genera in ME/CFS patients from baseline to 72 hours post-exercise compared to only 2 of the 9 phyla/genera in controls (p = 0.005). There was also a significant difference in clearance of specific bacterial phyla from blood following exercise with high levels of bacterial sequences maintained at 72 hours post-exercise in ME/CFS patients versus clearance in the controls. These results provide evidence for a systemic effect of an altered gut microbiome in ME/CFS patients compared to controls. Upon exercise challenge, there were significant changes in the abundance of major bacterial phyla in the gut in ME/CFS patients not observed in healthy controls. In addition, compared to controls clearance of bacteria from the blood was delayed in ME/CFS patients following exercise. These findings suggest a role for an altered gut microbiome and increased bacterial translocation following exercise in ME/CFS patients that may account for the profound post-exertional malaise experienced by ME/CFS patients. C1 [Shukla, Sanjay K.; Le, Thao; Schrodi, Steven J.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Cook, Dane; Meyer, Jacob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Cook, Dane; Clevidence, Derek] Univ Wisconsin, Madison, WI USA. [Vernon, Suzanne D.] Bateman Horne Ctr Excellence, Salt Lake City, UT USA. [Robertson, Charles E.; Frank, Daniel N.] Univ Colorado Denver, Aurora, CO USA. [Yale, Steven] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. RP Shukla, SK (reprint author), Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. EM shukla.sanjay@mcrf.mfldclin.edu OI Schrodi, Steven/0000-0003-2304-8528 FU CFIDS Association of America; Marshfield Clinic Research Foundation FX This study was funded from a grant from The CFIDS Association of America to SKS and donors to the Marshfield Clinic Research Foundation. The funding agency has no role in the study design or in the preparation of the manuscript. NR 57 TC 7 Z9 7 U1 6 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 18 PY 2015 VL 10 IS 12 AR e0145453 DI 10.1371/journal.pone.0145453 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9KM UT WOS:000366725800078 PM 26683192 ER PT J AU Meier, DT Tu, LH Zraika, S Hogan, MF Templin, AT Hull, RL Raleigh, DP Kahn, SE AF Meier, Daniel T. Tu, Ling-Hsien Zraika, Sakeneh Hogan, Meghan F. Templin, Andrew T. Hull, Rebecca L. Raleigh, Daniel P. Kahn, Steven E. TI Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-CELL APOPTOSIS; FIBRIL FORMATION; PANCREATIC-ISLETS; TRANSGENIC MOUSE; HUMAN AMYLIN; POLYPEPTIDE; DEPOSITION; INHIBITORS; CYTOTOXICITY; MECHANISM AB Deposition of human islet amyloid polypeptide (hIAPP, also known as amylin) as islet amyloid is a characteristic feature of the pancreas in type 2 diabetes, contributing to increased beta-cell apoptosis and reduced beta-cell mass. Matrix metalloproteinase-9 (MMP-9) is active in islets and cleaves hIAPP. We investigated whether hIAPP fragments arising from MMP-9 cleavage retain the potential to aggregate and cause toxicity, and whether over-expressing MMP-9 in amyloid-prone islets reduces amyloid burden and the resulting beta-cell toxicity. Synthetic hIAPP was incubated with MMP-9 and the major hIAPP fragments observed by MS comprised residues 1-15, 1-25, 16-37, 16-25, and 26-37. The fragments 1-15, 1-25, and 26-37 did not form amyloid fibrils in vitro and they were not cytotoxic when incubated with b cells. Mixtures of these fragments with full-length hIAPP did not modulate the kinetics of fibril formation by full-length hIAPP. In contrast, the 16-37 fragment formed fibrils more rapidly than full-length hIAPP but was less cytotoxic. Co-incubation of MMP-9 and fragment 16-37 ablated amyloidogenicity, suggesting that MMP-9 cleaves hIAPP 16-37 into non-amyloidogenic fragments. Consistent with MMP-9 cleavage resulting in largely non-amyloidogenic degradation products, adenoviral overexpression of MMP-9 in amyloid-prone islets reduced amyloid deposition and beta-cell apoptosis. These findings suggest that increasing islet MMP-9 activity might be a strategy to limit beta-cell loss in type 2 diabetes. C1 [Meier, Daniel T.; Zraika, Sakeneh; Hogan, Meghan F.; Templin, Andrew T.; Hull, Rebecca L.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Meier, Daniel T.; Zraika, Sakeneh; Hogan, Meghan F.; Templin, Andrew T.; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Tu, Ling-Hsien] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan. [Tu, Ling-Hsien; Raleigh, Daniel P.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA. [Raleigh, Daniel P.] UCL, Dept Struct & Mol Biol, London WC1E 6BT, England. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@uw.edu RI Regan, Clinton/E-6250-2012 OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087; raleigh, daniel/0000-0003-3248-7493 FU Dept. of Veterans Affairs [BX001060]; NIH [DK-007247, DK-017047, DK-020595, DK-080945, DK-088082, DK-098506, GM-078114, HL-007028]; Swiss National Foundation Fellowship; Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington; American Diabetes Association FX This work was supported by the Dept. of Veterans Affairs Grant BX001060, NIH Grants DK-007247, DK-017047, DK-020595, DK-080945, DK-088082, DK-098506, GM-078114, and HL-007028. The authors declare that they have no conflict of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Supported by a Swiss National Foundation Fellowship and the Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington.; Supported by an American Diabetes Association Mentor-based Fellowship. NR 49 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 18 PY 2015 VL 290 IS 51 BP 30475 EP 30485 DI 10.1074/jbc.M115.676692 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CY9PG UT WOS:000366738200024 PM 26483547 ER PT J AU Ruegsegger, GN Company, JM Toedebusch, RG Roberts, CK Roberts, MD Booth, FW AF Ruegsegger, Gregory N. Company, Joseph M. Toedebusch, Ryan G. Roberts, Christian K. Roberts, Michael D. Booth, Frank W. TI Rapid Alterations in Perirenal Adipose Tissue Transcriptomic Networks with Cessation of Voluntary Running SO PLOS ONE LA English DT Article ID GENE-EXPRESSION; ADIPOCYTE HYPERPLASIA; INSULIN-RESISTANCE; CHILDHOOD OBESITY; WEIGHT-REDUCTION; EPIDIDYMAL FAT; CELL-CYCLE; INFLAMMATION; PROTEIN; RATS AB In maturing rats, the growth of abdominal fat is attenuated by voluntary wheel running. After the cessation of running by wheel locking, a rapid increase in adipose tissue growth to a size that is similar to rats that have never run (i.e. catch-up growth) has been previously reported by our lab. In contrast, diet-induced increases in adiposity have a slower onset with relatively delayed transcriptomic responses. The purpose of the present study was to identify molecular pathways associated with the rapid increase in adipose tissue after ending 6 wks of voluntary running at the time of puberty. Age-matched, male Wistar rats were given access to running wheels from 4 to 10 weeks of age. From the 10th to 11th week of age, one group of rats had continued wheel access, while the other group had one week of wheel locking. Perirenal adipose tissue was extracted, RNA sequencing was performed, and bioinformatics analyses were executed using Ingenuity Pathway Analysis (IPA). IPA was chosen to assist in the understanding of complex ` omics data by integrating data into networks and pathways. Wheel locked rats gained significantly more fat mass and significantly increased body fat percentage between weeks 10-11 despite having decreased food intake, as compared to rats with continued wheel access. IPA identified 646 known transcripts differentially expressed (p < 0.05) between continued wheel access and wheel locking. In wheel locked rats, IPA revealed enrichment of transcripts for the following functions: extracellular matrix, macrophage infiltration, immunity, and pro-inflammatory. These findings suggest that increases in visceral adipose tissue that accompanies the cessation of pubertal physical activity are associated with the alteration of multiple pathways, some of which may potentiate the development of pubertal obesity and obesity-associated systemic low-grade inflammation that occurs later in life. C1 [Ruegsegger, Gregory N.; Company, Joseph M.; Toedebusch, Ryan G.; Roberts, Michael D.; Booth, Frank W.] Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO 65211 USA. [Roberts, Christian K.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Booth, Frank W.] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO USA. [Booth, Frank W.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO USA. [Booth, Frank W.] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO USA. RP Booth, FW (reprint author), Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO 65211 USA. EM boothf@missouri.edu NR 47 TC 3 Z9 3 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2015 VL 10 IS 12 AR e0145229 DI 10.1371/journal.pone.0145229 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JO UT WOS:000366723400060 PM 26678390 ER PT J AU Shen, RZ Achenbach, J Shen, Y Palaia, J Rahkola, JT Nick, HJ Smythies, LE McConnell, M Fowler, MG Smith, PD Janoff, EN AF Shen, Ruizhong Achenbach, Jenna Shen, Yue Palaia, Jana Rahkola, Jeremy T. Nick, Heidi J. Smythies, Lesley E. McConnell, Michelle Fowler, Mary G. Smith, Phillip D. Janoff, Edward N. TI Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-ASSOCIATED HIV-1; TYPE-1 TRANSCYTOSIS; EPITHELIAL-CELLS; DENDRITIC CELLS; SECRETORY IGA; POSITIVE MOTHERS; FED INFANTS; R5 HIV-1; INFECTION AB Breast milk is a vehicle of infection and source of protection in post-natal mother-to-child HIV-1 transmission (MTCT). Understanding the mechanism by which breast milk limits vertical transmission will provide critical insight into the design of preventive and therapeutic approaches to interrupt HIV-1 mucosal transmission. However, characterization of the inhibitory activity of breast milk in human intestinal mucosa, the portal of entry in postnatal MTCT, has been constrained by the limited availability of primary mucosal target cells and tissues to recapitulate mucosal transmission ex vivo. Here, we characterized the impact of skimmed breast milk, breast milk antibodies (Igs) and non-Ig components from HIV-1-infected Ugandan women on the major events of HIV-1 mucosal transmission using primary human intestinal cells and tissues. HIV-1-specific IgG antibodies and non-Ig components in breast milk inhibited the uptake of Ugandan HIV-1 isolates by primary human intestinal epithelial cells, viral replication in and transport of HIV-1-bearing dendritic cells through the human intestinal mucosa. Breast milk HIV-1-specific IgG and IgA, as well as innate factors, blocked the uptake and transport of HIV-1 through intestinal mucosa. Thus, breast milk components have distinct and complementary effects in reducing HIV-1 uptake, transport through and replication in the intestinal mucosa and, therefore, likely contribute to preventing postnatal HIV-1 transmission. Our data suggests that a successful preventive or therapeutic approach would require multiple immune factors acting at multiple steps in the HIV-1 mucosal transmission process. C1 [Shen, Ruizhong; Nick, Heidi J.; Smythies, Lesley E.; Smith, Phillip D.] Univ Alabama Birmingham, Dept Med, Div Gastroenterol, Birmingham, AL 35294 USA. [Achenbach, Jenna; Palaia, Jana; Rahkola, Jeremy T.; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. [Shen, Yue] Auburn Univ, Dept Biol Sci, Auburn, AL 36849 USA. [Rahkola, Jeremy T.; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. [McConnell, Michelle] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fowler, Mary G.] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. [Smith, Phillip D.] Vet Affairs Med Ctr, Birmingham, AL USA. RP Janoff, EN (reprint author), Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. EM rshen@uab.edu; Edward.Janoff@ucdenver.edu FU National Institutes of Health [AI093151, AI106395, AI083127, DK064400, AI41361, HD059527, AI083615]; UAB Center for AIDS Research (CFAR); Comprehensive Cancer Center Pilot Grant Program; amfAR; Foundation for AIDS Research [108015-49-RGRL]; Elisabeth Glaser Pediatric AIDS Foundations [MV-00-9-900-01432-0-00]; Research Service of the Veterans Administration FX National Institutes of Health grants AI093151 and AI106395 (RS), AI083127 and DK064400 (PDS), AI41361, HD059527 and AI083615 (ENJ); UAB Center for AIDS Research (CFAR) and Comprehensive Cancer Center Pilot Grant Program (RS); amfAR, the Foundation for AIDS Research 108015-49-RGRL (PDS); the Elisabeth Glaser Pediatric AIDS Foundations MV-00-9-900-01432-0-00 (ENJ); and the Research Service of the Veterans Administration (PDS and ENJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 0 Z9 0 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2015 VL 10 IS 12 AR e0145150 DI 10.1371/journal.pone.0145150 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JO UT WOS:000366723400051 PM 26680219 ER PT J AU Singh, JA Qu, HY Yazdany, J Chatham, W Shewchuk, R AF Singh, Jasvinder A. Qu, Haiyan Yazdany, Jinoos Chatham, Winn Shewchuk, Richard TI Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Lupus; Systemic lupus erythematosus; Hispanic; African-American; Minorities; Race; Facilitators; Challenges; Immunosuppressive medication; Adherence ID QUALITY-OF-LIFE; TREATMENT ADHERENCE; RHEUMATIC-DISEASE; HEALTH-CARE; ERYTHEMATOSUS; COHORT; WOMEN AB Background: Medication decision-making poses a challenge for a significant proportion of patients. This is an even more challenging for patients who have complex, rare, immune conditions that affect them at a young age and are associated with the use of life-long treatment, perceived by some as having significant risk of side effects and toxicity. Introduction: The aim of our study was to examine the perspectives of women with lupus nephritis on facilitators to medication decision-making. Methods: We used the nominal group technique (NGT), a structured formative process to elicit patient perspectives. An NGT expert moderated eight patient group meetings. Participants (n = 52) responded to the question "What sorts of things make it easier for people to decide to take the medicines that doctors prescribe for treating their lupus kidney disease?" Patients nominated, discussed, and prioritized facilitators to medication decisional processes. Results: Fifty-two women with lupus nephritis participated in eight NGT meetings (27 African-American, 13 Hispanic, and 12 Caucasian). Average age was 40.6 years (standard deviation (SD) = 13.3), and disease duration was 11.8 years (SD = 8.3); 36.5 % obtained at least a college education, and 55.8 % had difficulty in reading health materials. Patients generated 280 decision-making facilitators (range of 26 to 42 per panel). Of these, 102 (36 %) facilitators were perceived by patients as having relatively more influence in decision-making processes than others. Prioritized facilitators included effective patient-physician communication regarding benefits/harms, patient desire to live a normal life and improve quality of life, concern for their dependents, experiencing benefits and few/infrequent/no harms with lupus medications, and their affordability. Relative to African-Americans, Caucasian and Hispanic patients endorsed a smaller percentage of facilitators as influential. Level of agreement with which patients within panels independently agreed in their selections of the three most influential facilitators ranged from 33 % to 60 %. Conclusions: We identified facilitators to lupus medication decision-making. This information will be used to populate a decision aid for lupus nephritis. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN 55905 USA. [Qu, Haiyan; Shewchuk, Richard] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL 35233 USA. [Yazdany, Jinoos] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 510,20th St South,FOT 805B, Birmingham, AL 35233 USA. EM jassingh@uab.edu FU Patient-Centered Outcomes Research Institute [CE-1304-6631]; NIH [K23 AR060259]; Rosalind Russell Medical Research Center for Arthritis FX This material is the result of work supported by research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute. JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, AL, USA. JY is also supported by NIH K23 AR060259 and the Rosalind Russell Medical Research Center for Arthritis. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 23 TC 1 Z9 1 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD DEC 17 PY 2015 VL 17 AR 367 DI 10.1186/s13075-015-0883-z PG 11 WC Rheumatology SC Rheumatology GA CY8UD UT WOS:000366682900001 PM 26680561 ER PT J AU Wang, K Smith, ZM Buxton, RB Swenson, ER Dubowitz, DJ AF Wang, Kang Smith, Zachary M. Buxton, Richard B. Swenson, Erik R. Dubowitz, David J. TI Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE cerebral oxygen metabolism; cerebral oxygenation; cerebral blood flow; acetazolamide; hypoxia; magnetic resonance imaging ID ACUTE MOUNTAIN-SICKNESS; CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; HIGH-ALTITUDE; TRUST MRI; EXERCISE; METABOLISM; PREVENTION; PERFUSION; METAANALYSIS AB Low doses of the carbonic anhydrase inhibitor acetazolamide provides accelerated acclimatization to high-altitude hypoxia and prevention of cerebral and other symptoms of acute mountain sickness. We previously observed increases in cerebral O-2 metabolism (CMRO2) during hypoxia. In this study, we investigate whether low-dose oral acetazolamide (250 mg) reduces this elevated CMRO2 and in turn might improve cerebral tissue oxygenation (Pti(O2)) during acute hypoxia. Six normal human subjects were exposed to 6 h of normobaric hypoxia with and without acetazolamide prophylaxis. We determined CMRO2 and cerebral Pti(O2) from MRI measurements of cerebral blood flow (CBF) and cerebral venous O-2 saturation. During normoxia, low-dose acetazolamide resulted in no significant change in CBF, CMRO2, or Pti(O2). During hypoxia, we observed increases in CBF [48.5 (SD 12.4) (normoxia) to 65.5 (20.4) ml.100 ml(-1).min(-1) (hypoxia), P < 0.05] and CMRO2 [1.54 (0.19) to 1.79 (0.25) mu mol.ml(-1).min(-1), P < 0.05] and a dramatic decline in Pti(O2) [25.0 to 11.4 (2.7) mmHg, P < 0.05]. Acetazolamide prophylaxis mitigated these rises in CBF [53.7 (20.7) ml.100 ml(-1).min(-1) (hypoxia + acetazolamide)] and CMRO2 [1.41 (0.09) mu mol.ml(-1).min(-1) (hypoxia + acetazolamide)] associated with acute hypoxia but also reduced O-2 delivery [6.92 (1.45) (hypoxia) to 5.60 (1.14) mmol/min (hypoxia + acetazolamide), P < 0.05]. The net effect was improved cerebral tissue Pti(O2) during acute hypoxia [11.4 (2.7) (hypoxia) to 16.5 (3.0) mmHg (hypoxia + acetazolamide), P < 0.05]. In addition to its renal effect, low-dose acetazolamide is effective at the capillary endothelium, and we hypothesize that local interruption in cerebral CO2 excretion accounts for the improvements in CMRO2 and ultimately in cerebral tissue oxygenation during hypoxia. This study suggests a potentially pivotal role of cerebral CO2 and pH in modulating CMRO2 and Pti(O2) during acute hypoxia. C1 [Wang, Kang; Smith, Zachary M.; Buxton, Richard B.; Dubowitz, David J.] Univ Calif San Diego, Dept Radiol, Ctr Funct MRI, San Diego, CA 92103 USA. [Wang, Kang] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Swenson, Erik R.] Univ Washington, Dept Med, Seattle, WA USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Dubowitz, DJ (reprint author), UCSD Ctr Funct MRI, 9500 Gilman Dr,MC 0677, La Jolla, CA 92093 USA. EM dubowitz@ucsd.edu FU National Institute of Neurological Disorders and Stroke [R01-NS-053934, R21-NS-075812, R01-NS-036722] FX This work was supported by National Institute of Neurological Disorders and Stroke Grants R01-NS-053934, R21-NS-075812, and R01-NS-036722. NR 49 TC 5 Z9 5 U1 2 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD DEC 15 PY 2015 VL 119 IS 12 BP 1494 EP 1500 DI 10.1152/japplphysiol.00117.2015 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA DA2BP UT WOS:000367600600016 PM 26472861 ER PT J AU An, NF Xiong, Y LaRue, AC Kraft, AS Cen, B AF An, Ningfei Xiong, Ying LaRue, Amanda C. Kraft, Andrew S. Cen, Bo TI Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors SO CANCER RESEARCH LA English DT Article ID ACQUIRED-RESISTANCE; PROSTATE-CANCER; GENE AMPLIFICATION; RECEPTOR; CELLS; TRANSLATION; PROTEIN; GROWTH; CRIZOTINIB; INITIATION AB Mesenchymal-epithelial transition (MET) blockade offers a new targeted therapy particularly in those cancers with MET amplification. However, the efficacy and the duration of the response to MET inhibitors are limited by the emergence of drug resistance. Here, we report that resistance to small-molecule inhibitors of MET can arise from increased expression of the prosurvival Pim protein kinases. This resistance mechanism was documented in non-small cell lung cancer and gastric cancer cells with MET amplification. Inhibition of Pim kinases enhanced cell death triggered by short-term treatment with MET inhibitors. Pim kinases control the translation of anti-apoptotic protein Bcl-2 at an internal ribosome entry site and this mechanism was identified as the basis for Pim-mediated resistance to MET inhibitors. Protein synthesis was increased in drug-resistant cells, secondary to a Pim-mediated increase in cap-independent translation. In cells rendered drug resistant by chronic treatment with MET inhibitors, genetic or pharmacologic inhibition of Pim kinases was sufficient to restore sensitivity in vitro and in vivo. Taken together, our results rationalize Pim inhibition as a strategy to augment responses and blunt acquired resistance to MET inhibitors in cancer. (C)2015 AACR. C1 [An, Ningfei; Cen, Bo] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [An, Ningfei; Xiong, Ying; LaRue, Amanda C.; Cen, Bo] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Xiong, Ying; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Kraft, Andrew S.] Univ Arizona, Ctr Canc, Tucson, AZ USA. RP Cen, B (reprint author), Med Univ S Carolina, Dept Med, 86 Jonathan Lucas St, Charleston, SC 29425 USA. EM akraft@uacc.arizona.edu; cen@musc.edu FU NIH [1K01DK085196, 1R01CA173200]; DOD [W81XWH-12-10560] FX This work was supported by NIH grants 1K01DK085196 (B. Cen), 1R01CA173200 (A.S. Kraft), and DOD grant W81XWH-12-10560 (A.S. Kraft). NR 40 TC 2 Z9 2 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2015 VL 75 IS 24 BP 5318 EP 5328 DI 10.1158/0008-5472.CAN-15-0544 PG 11 WC Oncology SC Oncology GA DA1JL UT WOS:000367552000017 PM 26670562 ER PT J AU Connor, K Cheng, E Siebens, HC Lee, ML Mittman, BS Ganz, DA Vickrey, B AF Connor, Karen Cheng, Eric Siebens, Hilary C. Lee, Martin L. Mittman, Brian S. Ganz, David A. Vickrey, Barbara TI Study protocol of "CHAPS": a randomized controlled trial protocol of Care Coordination for Health Promotion and Activities in Parkinson's Disease to improve the quality of care for individuals with Parkinson's disease SO BMC NEUROLOGY LA English DT Article DE Care coordination; Parkinson's disease; Behavioral intervention; Clinical trial; Quality of health care; Nursing care management ID DOMAIN MANAGEMENT MODEL; INCREASE FUNCTIONAL INDEPENDENCE; CHRONIC ILLNESS; INPATIENT REHABILITATION; DEMENTIA CAREGIVERS; COLLABORATIVE CARE; DISCHARGE RATE; INTERVENTION; VALIDATION; VALIDITY AB Background: Parkinson's disease, the second most common neurodegenerative disease, is diagnostically defined by motor impairments, but also includes often under-recognized impairments in cognition, mood, sleep, and the autonomic nervous system. These problems can severely affect individuals' quality of life. In our prior research, we have developed indicators to measure the quality of care delivered to patients with Parkinson's disease, and we identified gaps in delivering evidence-based treatments for this population. Effective strategies to close these gaps are needed to improve patient quality of life. Methods/design: Building on prior research we developed a multi-faceted proactive implementation program called Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS). To be eligible, patients had to have at least two visits with a primary diagnosis of idiopathic Parkinson's disease (ICD-9 code: 332.0) at one of five Veterans Affairs Medical Centers in the southwestern United States from 2010 to 2014. The program consists of telephone assessments, evidence-based protocols, and tools to enhance patient self-management, care planning, and coordination of care across providers, including an electronic database to support and track coordination of care. Our mixed-methods study employs a randomized, controlled trial design to test whether the CHAPS intervention improves performance in 38 quality measures among an analytic sample of 346 patients. The 38 qualitymeasures are categorized into overarching areas of communication, education, and continuity; regulatory reporting; diagnosis; periodic assessment; medication use; management of motor and non-motor symptoms; use of non-pharmacological approaches and therapies; palliative care; and health maintenance. Secondary outcomes are patient health-related quality of life, self-efficacy, and perceptions of care quality. We are also evaluating the extent of the CHAPS Program implementation and measuring program costs and impacts on health services utilization, in order to perform a analysis of the CHAPS program from the perspective of the Veterans Health Administration (VA). Outcomes are assessed by interviewer-administered surveys collected at baseline and at 6, 12, and 18 months, and by medical record chart abstractions. Analyses will be intention-to-treat. Discussion: The CHAPS Program is poised for dissemination within the VA National Parkinson's Disease Research, Education, and Clinical Center Consortium if demonstrated efficacious. C1 [Connor, Karen; Cheng, Eric; Vickrey, Barbara] VA Greater Los Angeles Healthcare Syst, PADRECC Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Connor, Karen; Cheng, Eric; Vickrey, Barbara] Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Siebens, Hilary C.] Siebens Patient Care Commun, Seal Beach, CA 90740 USA. [Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, Sepulveda VA Ambulatory Care Ctr, North Hills, CA 91343 USA. [Lee, Martin L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Mittman, Brian S.] Vet Affairs Greater Los Angeles Healthcare Syst 1, CIPRS, Sepulveda, CA 91343 USA. [Ganz, David A.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA 90073 USA. RP Connor, K (reprint author), VA Greater Los Angeles Healthcare Syst, PADRECC Parkinsons Dis Res Educ & Clin Ctr, 11301 Wilshire Blvd,B500,ML 127, Los Angeles, CA 90073 USA. EM Karen.Connor@va.gov FU Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service [NRI 11-126] FX The research reported here was supported by the Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service (NRI 11-126). Dr. Karen Connor is a Health Scientist at the Parkinson's Disease Research, Education, and Clinical Center (PADRECC), VA Greater Los Angeles Healthcare System. The authors wish to thank the CHAPS Advisory Board: Dr. Robert Ruff, Dr. Jeff Bronstein, Dr. Sharon Valente, Dr. Fran Weaver, Dr. Peter Schmidt, Michele Popadynec RN MPS, John Ball, Edna Ball and the CHAPS Steering Committee: Dr. Dorothee Cole, Dr. Evelyn Tecoma, Dr. Denson Fujikawa, Dr. Emad Farag, Virginia Janovsky, Dr. Steven Schreiber, Dr. Selina Parveen, Dr. Donna McNeese-Smith, Dr. Donna Benton, Ms. Jo Rosen. We wish to thank Virginia Janovsky MN, MS, RN and Erik Ernst DNP who provided nursing practice expertise in the CHAPS Program design. We wish to thank Michael McGowan and Lisa Edwards for their contributions to the ongoing research study. We wish to acknowledge Megan Connor's programming expertise in the CHAPS care management tool development. NR 59 TC 0 Z9 0 U1 10 U2 23 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD DEC 15 PY 2015 VL 15 AR 258 DI 10.1186/s12883-015-0506-y PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA CZ1WE UT WOS:000366895800002 PM 26670300 ER PT J AU Scott, JL Cunningham, MA Naga, OS Wirth, JR Eudaly, JG Gilkeson, GS AF Scott, Jennifer L. Cunningham, Melissa A. Naga, Osama S. Wirth, Jena R. Eudaly, Jackie G. Gilkeson, Gary S. TI Estrogen Receptor alpha Deficiency Modulates TLR Ligand-Mediated PDC-TREM Expression in Plasmacytoid Dendritic Cells in Lupus-Prone Mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID I INTERFERON; MURINE LUPUS; DIFFERENTIATION; ERYTHEMATOSUS; TRANSCRIPTION; PROMOTES; DISEASE; MOUSE; LY49Q; AUTOIMMUNITY AB Female lupus-prone NZM2410 estrogen receptor alpha (ER alpha)-deficient mice are protected from renal disease and have prolonged survival compared with wild-type littermates; however, the mechanism of protection is unknown. Plasmacytoid dendritic cells (pDCs) and type I IFN drive lupus pathogenesis. Estrogen acting via ER alpha enhances both pDC development and IFN production. The objectives for this study were to determine if ER alpha modulates pDC function and IFN activity in predisease NZM2410 mice as a possible protective mechanism of ER alpha deficiency in lupus-prone mice. We measured the effect of ER alpha deficiency on spleen pDC frequency, number, maturation, and activation state. ER alpha deficiency reduced type I IFN activity and the frequency of MHC class II+ pDCs in the spleen without altering overall pDC frequency, number, or maturation state. Additionally, ER alpha-deficient NZM2410 mice had a significantly decreased frequency of pDCs expressing PDC-TREM, a modulator of TLR-mediated IFN production. After in vitro TLR9 stimulation, ER alpha deficiency significantly reduced the expression of PDC-TREM on pDCs from both NZM2410 and C57BL/6 mice. Thus, we have identified a significant effect of ER alpha deficiency on pDCs in predisease NZM2410 mice, which may represent a mechanism by which ER alpha deficiency protects NZM2410 mice from lupuslike disease. C1 [Scott, Jennifer L.] Med Univ S Carolina, Coll Grad Studies, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Scott, Jennifer L.; Cunningham, Melissa A.; Naga, Osama S.; Wirth, Jena R.; Eudaly, Jackie G.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM gilkeson@musc.edu FU Veterans Affairs Merit Review Grant [BX000470]; National Institutes of Health Grant [UT1 TR000062]; American Association of Immunology Careers in Immunology Fellowship; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center; Medical University of South Carolina [P30 CA138313]; National Institutes of Health-National Institute of General Medical Sciences Grant [P30 GM103342] FX This work was supported by Veterans Affairs Merit Review Grant BX000470, the National Institutes of Health Grant UT1 TR000062, and an American Association of Immunology Careers in Immunology Fellowship. This work was supported in part by the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, and Medical University of South Carolina (Grant P30 CA138313). This study used the services of the Medical University of South Carolina Flow Cytometry Facility, which is supported by National Institutes of Health-National Institute of General Medical Sciences Grant P30 GM103342 to the South Carolina Center of Biomedical Research Excellence for Developmentally Based Cardiovascular Diseases. NR 36 TC 3 Z9 3 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD DEC 15 PY 2015 VL 195 IS 12 BP 5561 EP 5571 DI 10.4049/jimmunol.1500315 PG 11 WC Immunology SC Immunology GA CY9OB UT WOS:000366735100006 PM 26553076 ER PT J AU Heatwole, C Johnson, N Bode, R Dekdebrun, J Dilek, N Hilbert, JE Luebbe, E Martens, W McDermott, MP Quinn, C Rothrock, N Thornton, C Vickrey, BG Victorson, D Moxley, RT AF Heatwole, Chad Johnson, Nicholas Bode, Rita Dekdebrun, Jeanne Dilek, Nuran Hilbert, James E. Luebbe, Elizabeth Martens, William McDermott, Michael P. Quinn, Christine Rothrock, Nan Thornton, Charles Vickrey, Barbara G. Victorson, David Moxley, Richard T., III TI Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2) SO NEUROLOGY LA English DT Article ID FACIOSCAPULOHUMERAL DYSTROPHY; CHRONIC PAIN; CEREBRAL INVOLVEMENT; DAYTIME SLEEPINESS; WORKSHOP REPORT; DYSFUNCTION; INTENSITY AB Objective:To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with these symptoms.Methods:We conducted a cross-sectional study of adult patients with DM2 from a National Registry of DM2 Patients to assess the prevalence and relative importance of 310 symptoms and 21 symptomatic themes. Participant responses were compared by age categories, sex, educational attainment, employment status, and duration of symptoms.Results:The symptomatic themes with the highest prevalence in DM2 were the inability to do activities (94.4%), limitations with mobility or walking (89.2%), hip, thigh, or knee weakness (89.2%), fatigue (89.2%), and myotonia (82.6%). Participants identified the inability to do activities and fatigue as the symptomatic themes that have the greatest overall effect on their lives. Unemployment, a longer duration of symptoms, and less education were associated with a higher average prevalence of all symptomatic themes (p < 0.01). Unemployment, a longer duration of symptoms, sex, and increased age were associated with a higher average effect of all symptomatic themes among patients with DM2 (p < 0.01).Conclusions:The lives of patients with DM2 are affected by a variety of symptoms. These symptoms have different levels of significance and prevalence in this population and vary across DM2 subgroups in different demographic categories. C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Hilbert, James E.; Luebbe, Elizabeth; Martens, William; McDermott, Michael P.; Thornton, Charles; Moxley, Richard T., III] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [McDermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA. [Quinn, Christine] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Rochester, NY 14642 USA. [Johnson, Nicholas] Univ Utah, Salt Lake City, UT USA. [Bode, Rita; Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vickrey, Barbara G.] Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA. RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. EM Chad_Heatwole@urmc.rochester.edu FU Goldberg Nathan Foundation for Myotonic Dystrophy Type-2 Research; National Institute of Arthritis and Musculoskeletal and Skin Disorders [1K23AR055947]; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center [U54NS48843-01]; Muscular Dystrophy Association; New York State Empire Clinical Research Investigator Program; Saunders Family Fund; University of Rochester Clinical Translational Science Institute FX Support for PRISM-2 was provided by the Goldberg Nathan Foundation for Myotonic Dystrophy Type-2 Research, the National Institute of Arthritis and Musculoskeletal and Skin Disorders (1K23AR055947), the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (U54NS48843-01), the Muscular Dystrophy Association, the New York State Empire Clinical Research Investigator Program, the Saunders Family Fund, and the University of Rochester Clinical Translational Science Institute. NR 28 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 15 PY 2015 VL 85 IS 24 BP 2136 EP 2146 DI 10.1212/WNL.0000000000002225 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CY5QI UT WOS:000366461900008 PM 26581301 ER PT J AU Forsyth, JK Bachman, P Mathalon, DH Roach, BJ Asarnow, RF AF Forsyth, Jennifer K. Bachman, Peter Mathalon, Daniel H. Roach, Brian J. Asarnow, Robert F. TI Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE D-cycloserine; NMDA receptor; neuroplasticity; long-term potentiation; learning ID LONG-TERM POTENTIATION; COGNITIVE-BEHAVIORAL THERAPY; NONEMOTIONAL MEMORY TASKS; D-CYCLOSERINE; SYNAPTIC PLASTICITY; BASAL GANGLIA; PSYCHIATRIC-DISORDERS; EVOKED-POTENTIALS; VISUAL-CORTEX; SCHIZOPHRENIA AB Experience-dependent plasticity is a fundamental property of the brain. It is critical for everyday function, is impaired in a range of neurological and psychiatric disorders, and frequently depends on long-term potentiation (LTP). Preclinical studies suggest that augmenting N-methyl-D-aspartate receptor (NMDAR) signaling may promote experience-dependent plasticity; however, a lack of noninvasive methods has limited our ability to test this idea in humans until recently. We examined the effects of enhancing NMDAR signaling using D-cycloserine (DCS) on a recently developed LTP EEG paradigm that uses high-frequency visual stimulation (HFvS) to induce neural potentiation in visual cortex neurons, as well as on three cognitive tasks: a weather prediction task (WPT), an information integration task (IIT), and a n-back task. The WPT and IIT are learning tasks that require practice with feedback to reach optimal performance. The n-back assesses working memory. Healthy adults were randomized to receive DCS (100 mg; n = 32) or placebo (n = 33); groups were similar in IQ and demographic characteristics. Participants who received DCS showed enhanced potentiation of neural responses following repetitive HFvS, as well as enhanced performance on the WPT and IIT. Groups did not differ on the n-back. Augmenting NMDAR signaling using DCS therefore enhanced activity-dependent plasticity in human adults, as demonstrated by lasting enhancement of neural potentiation following repetitive HFvS and accelerated acquisition of two learning tasks. Results highlight the utility of considering cellular mechanisms underlying distinct cognitive functions when investigating potential cognitive enhancers. C1 [Forsyth, Jennifer K.; Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Bachman, Peter] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Roach, Brian J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Asarnow, RF (reprint author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. EM rasarnow@mednet.ucla.edu FU Della Martin Foundation; National Science Foundation FX We thank Dr. Gregory Ashby and Dr. Vivian Valentin for consultation on implementation and modeling of the IIT and Dr. Barbara Knowlton for consultation on implementation of the WPT. We also thank Elissa Ye, Cheryl Li, Heather Hansen, Devin Deer, and Chantelle Kinzel for assistance with data collection, data processing, and/or programming. This work was supported by the Della Martin Foundation and a National Science Foundation Graduate Research Fellowship (to J.K.F.). NR 56 TC 5 Z9 5 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 15 PY 2015 VL 112 IS 50 BP 15331 EP 15336 DI 10.1073/pnas.1509262112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY4UN UT WOS:000366404200046 PM 26621715 ER PT J AU Collins, GT France, CP AF Collins, Gregory T. France, Charles P. TI Determinants of conditioned reinforcing effectiveness: Dopamine D-2-like receptor agonist-stimulated responding for cocaine-associated stimuli SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Conditioned reinforcement; Dopamine D2-like receptors; Pramipexole; Cocaine self-administration ID DRUG-SEEKING BEHAVIOR; PROGRESSIVE-RATIO SCHEDULES; CUE-INDUCED REINSTATEMENT; EXTENDED ACCESS; IMPULSE CONTROL; D-3 RECEPTORS; ADDICTION; REWARD; PRAMIPEXOLE; ANTAGONISTS AB Environmental stimuli associated with drug use can take on conditioned properties capable of promoting drug-seeking behaviors during abstinence. This study investigated the relative importance of the amount of reinforced responding, number of cocaine-stimulus pairings, total cocaine intake, and reinforcing effectiveness of the self-administered dose of cocaine to the conditioned reinforcing effectiveness of cocaine-associated stimuli (CS). Male rats were trained to self-administer cocaine (0.1 [small] or 1.0 mg/kg/ inf [large]) under a fixed ratio schedule of reinforcement. A progressive ratio (PR) schedule was used to quantify the reinforcing effectiveness of each dose of cocaine, as well as the conditioned reinforcing effectiveness of the CS following treatment with saline or the dopamine D2-like receptor agonist pramipexole (0.1-3.2 mg/kg). The large dose of cocaine maintained larger final ratios and greater levels of cocaine intake, whereas the small dose resulted in more cocaine-CS pairings. The total amount of responding was comparable between groups. During PR tests of conditioned reinforcement, pramipexole increased responding for CS presentations in both groups; however, the final ratio completed was significantly greater in large-as compared to small-dose group. In addition to highlighting a central role for dopamine D2-like receptors in modulating the effectiveness of cocaine-paired stimuli to reinforce behavior, these results suggest that conditioned reinforcing effectiveness is primarily determined by the reinforcing effectiveness of the self-administered dose of cocaine and/or total cocaine intake, and not the total amount of responding or number cocaine-stimulus pairings. These findings have implications for understanding how different patterns of drug-taking might impact vulnerability to relapse. Published by Elsevier B.V. C1 [Collins, Gregory T.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Collins, GT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM collinsg@uthscsa.edu RI Collins, Gregory/K-3125-2012 FU National Institute on Drug Abuse Senior Scientist Award [K05 DA017918] FX CPF is supported by a National Institute on Drug Abuse Senior Scientist Award (K05 DA017918) NR 39 TC 3 Z9 3 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD DEC 15 PY 2015 VL 769 BP 242 EP 249 DI 10.1016/j.ejphar.2015.11.024 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CY1AG UT WOS:000366137800030 PM 26593427 ER PT J AU Dewey, D McDonald, MK Brown, WJ Boyd, SJ Bunnell, BE Schuldberg, D AF Dewey, Daniel McDonald, Molly K. Brown, Wilson J. Boyd, Steven J. Bunnell, Brian E. Schuldberg, David TI The impact of ecological momentary assessment on posttraumatic stress symptom trajectory SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic stress disorder; Ecological momentary assessment; Self-monitoring; Traumatic stress ID RANDOMIZED CONTROLLED-TRIAL; PSYCHOMETRIC PROPERTIES; TRAUMA EXPOSURE; DISORDER; DISTRESS AB Ecological momentary assessment includes continuous, real-time gathering of self-report data in a participant's natural environment. The current study evaluated the possible impact of this assessment strategy on severity of posttraumatic stress (PTS) in a sample of participants who reported experiencing a past traumatic event. Participants with clinically elevated PTS symptoms reported symptom severity at three time-points: during an initial screening, following an unmonitored period, and following two weeks of monitoring. During the monitoring period, participants carried an Android device which prompted them to report PTS symptoms and negative emotions six times daily. PTS severity scores were then compared across these three time-points. Results indicated that participating in the ecological momentary assessment protocol was associated with a significant reduction in PTS severity, whereas significant changes were not noted over the unmonitored control condition. The authors conclude that ecological momentary assessment may have therapeutic value even when not combined with formal intervention, and it may be a useful tool for improving the efficiency of a stepped-care approach to treating PTS symptoms. Published by Elsevier Ireland Ltd. C1 [Dewey, Daniel; Brown, Wilson J.; Boyd, Steven J.; Bunnell, Brian E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Dewey, Daniel; McDonald, Molly K.; Schuldberg, David] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. RP Dewey, D (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116,109 Bee St, Charleston, SC 29401 USA. EM daniel.dewey@va.gov NR 19 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 300 EP 303 DI 10.1016/j.psychres.2015.09.009 PG 4 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400026 PM 26381184 ER PT J AU Ballard, ME Dean, AC Mandelkern, MA London, ED AF Ballard, Michael E. Dean, Andy C. Mandelkern, Mark A. London, Edythe D. TI Striatal Dopamine D-2/D-3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users SO PLOS ONE LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; REFERENCE TISSUE MODEL; PREFRONTAL CORTEX; COGNITIVE PERFORMANCE; DISTRIBUTION VOLUME; COCAINE ADDICTION; D-2 RECEPTORS; BRAIN IMAGES; DEFICITS; ABUSERS AB Background Dopamine D-2/D-3 receptor availability in the striatum has been linked with executive function in healthy individuals, and is below control levels among drug addicts, possibly contributing to diminished executive function in the latter group. This study tested for an association of striatal D-2/D-3 receptor availability with a measure of executive function among research participants who met DSM-IV criteria for methamphetamine dependence. Methods Methamphetamine users and non-user controls (n = 18 per group) completed the Wisconsin Card Sorting Test and positron emission tomography with [F-18]fallypride. Results The methamphetamine users displayed significantly lower striatal D-2/D-3 receptor availability on average than controls after controlling for age and education (p = 0.008), but they did not register greater proportions of either perseverative or non-perseverative errors when controlling for education (both ps >= 0.622). The proportion of non-perseverative, but not perseverative, errors was negatively correlated with striatal D2/D3 receptor availability among controls (r = -0.588, p = 0.010), but not methamphetamine users (r = 0.281, p = 0.258), and the group-wise interaction was significant (p = 0.030). Conclusions These results suggest that cognitive flexibility, as measured by perseverative errors on the Wisconsin Card Sorting Test, is not determined by signaling through striatal D-2/D-3 receptors in healthy controls, and that in stimulant abusers, who have lower D-2/D-3 receptor availability, compensation can effectively maintain other executive functions, which are associated with D-2/D-3 receptor signaling in controls. C1 [Ballard, Michael E.; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Ballard, Michael E.; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP London, ED (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu RI Ballard, Michael/F-9146-2013 OI Ballard, Michael/0000-0002-2651-6588 FU National Institutes of Health [R01 DA020726, P20 DA022539, K23 DA027734, M0I RR00865]; Marjorie M. Greene Trust; Thomas P. and Katherine K. Pike Chair in Addiction Studies; [T32 DA024635] FX The research was supported by National Institutes of Health grants R01 DA020726 (EDL), P20 DA022539 (EDL), K23 DA027734 (ACD), M0I RR00865 (UCLA GCRC), by endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies (EDL), and the Marjorie M. Greene Trust. MEB was supported by T32 DA024635. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 0 Z9 0 U1 5 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 14 PY 2015 VL 10 IS 12 AR e0143510 DI 10.1371/journal.pone.0143510 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9GR UT WOS:000366715900012 PM 26657223 ER PT J AU Sudore, R Le, GM McMahon, R Feuz, M Katen, M Barnes, DE AF Sudore, Rebecca Le, Gem M. McMahon, Ryan Feuz, Mariko Katen, Mary Barnes, Deborah E. TI The advance care planning PREPARE study among older Veterans with serious and chronic illness: study protocol for a randomized controlled trial SO TRIALS LA English DT Article DE advance care planning; aging; medical decision-making; randomized trial; chronic disease management; geriatrics; veterans; health behavior; advance directive; vulnerable populations ID MENTAL STATUS QUESTIONNAIRE; LIMITED HEALTH LITERACY; QUALITY-OF-LIFE; DECISION-MAKING; ADMINISTRATIVE DATA; ADVANCED CANCER; BEHAVIOR-CHANGE; MEDICAL-CARE; ADULTS; VALIDATION AB Background: Advance care planning (ACP) is a process whereby patients prepare for medical decision-making. The traditional objective of ACP has focused on the completion of advance directives. We have developed a new paradigm of ACP focused on preparing patients and their loved ones for communication and informed medical decision-making. To operationalize this new paradigm of ACP, we created an interactive, patient-centered website called PREPARE (www.prepareforyourcare.org) designed for diverse older adults. Methods/Design: This randomized controlled trial with blinded outcome assessment is designed to determine the efficacy of PREPARE to engage older Veterans in the ACP process. Veterans who are >= 60 years of age, have >= two medical conditions, and have seen a primary care physician >= two times in the last year are being randomized to one of two study arms. The PREPARE study arm reviews the PREPARE website and an easy-to-read advance directive. The control arm only reviews the advance directive. The primary outcome is documentation of an advance directive and ACP discussions. Other clinically important outcomes using validated surveys include ACP behavior change process measures (knowledge, contemplation, self-efficacy, and readiness) and a full range of ACP action measures (identifying a surrogate, identifying values and goals, choosing leeway or flexibility for the surrogate, communicating with clinicians and surrogates, and documenting one's wishes). We will also assess satisfaction with decision-making and Veteran activation within primary care visits by direct audio recording. To examine the outcomes at 1 week, 3 months, and 6 months between the two study arms, we will use mixed effects linear, Poisson, or negative binomial regression and mixed effects logistic regression. Discussion: This study will determine whether PREPARE increases advance directive completion rates and engagement with the ACP process. If PREPARE is efficacious, it could prove to be an easy and effective intervention to help older adults engage in the ACP process within or outside of the medical environment. PREPARE may also help older adults communicate their medical wishes and goals to their loved ones and clinicians, improve medical decision-making, and ensure their wishes are honored over the life course. C1 [Sudore, Rebecca; Le, Gem M.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca; McMahon, Ryan; Feuz, Mariko; Katen, Mary] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. [Le, Gem M.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sudore, R (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM rebecca.sudore@ucsf.edu FU Veterans Affairs Health Services Research Development [11-110-2] FX The Veterans Affairs Health Services Research & Development is the primary funder of this study (#11-110-2). The funder has no role in the study design, the interpretation of data, or the publication of results. NR 60 TC 1 Z9 1 U1 5 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD DEC 12 PY 2015 VL 16 AR 570 DI 10.1186/s13063-015-1055-9 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CY2RB UT WOS:000366254700001 PM 26654250 ER PT J AU Lyons, BE Austin, D Seelye, A Petersen, J Yeargers, J Riley, T Sharma, N Mattek, N Dodge, H Wild, K Kaye, JA AF Lyons, Bayard E. Austin, Daniel Seelye, Adriana Petersen, Johanna Yeargers, Jonathan Riley, Thomas Sharma, Nicole Mattek, Nora Dodge, Hiroko Wild, Katherine Kaye, Jeffrey A. TI Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy (vol 7, 102, 2015) SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Correction DE Alzheimer's disease (AD); dementia; mild cognitive impairment (MCI); home monitoring; OHSU; ORCATECH; Layton Aging and Alzheimer's Disease Center C1 [Lyons, Bayard E.; Austin, Daniel; Seelye, Adriana; Petersen, Johanna; Yeargers, Jonathan; Riley, Thomas; Sharma, Nicole; Mattek, Nora; Dodge, Hiroko; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Lyons, Bayard E.; Seelye, Adriana; Mattek, Nora; Dodge, Hiroko; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Austin, Daniel; Petersen, Johanna; Yeargers, Jonathan; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. RP Lyons, BE (reprint author), Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. EM lyonsb@ohsu.edu FU NIA NIH HHS [R01 AG024059, R01 AG042191, P30 AG024978, R01 AG033581, P30 AG008017, K01 AG023014] NR 1 TC 0 Z9 0 U1 0 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD DEC 11 PY 2015 VL 7 AR 232 DI 10.3389/fnagi.2015.00232 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CY7ND UT WOS:000366594500001 PM 26696884 ER PT J AU Revuelta, GJ Embry, A Elm, JJ Gregory, C Delambo, A Kautz, S Hinson, VK AF Revuelta, Gonzalo J. Embry, Aaron Elm, Jordan J. Gregory, Chris Delambo, Amy Kautz, Steve Hinson, Vanessa K. TI Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait SO TRANSLATIONAL NEURODEGENERATION LA English DT Article DE Parkinson's disease; Freezing of gait; Noradrenaline; Atomoxetine; Dopa-response ID ATTENTION AB Background: Freezing of gait (FoG) is a common and debilitating condition in Parkinson's disease (PD) associated with executive dysfunction. A subtype of FoG does not respond to dopaminergic therapy and may be related to noradrenergic deficiency. This pilot study explores the effects of atomoxetine on gait in PD patients with dopaunresponsive FoG using a novel paradigm for objective gait assessment. Findings: Ten patients with PD and dopa-unresponsive FoG were enrolled in this eight-week open label pilot study. Assessments included an exploratory gait analysis protocol that quantified spatiotemporal parameters during straight-away walking and turning, while performing a dual task. Clinical, and subjective assessments of gait, quality of life, and safety were also administered. The primary outcome was a validated subjective assessment for FoG (FOG-Q). Atomoxetine was well tolerated, however, no significant change was observed in the primary outcome. The gait analysis protocol correlated well with clinical scales, but not with subjective assessments. DBS patients were more likely to increase gait velocity (p = 0.033), and improved in other clinical assessments. Conclusions: Objective gait analysis protocols assessing gait while dual tasking are feasible and useful for this patient population, and may be superior correlates of FoG severity than subjective measures. These findings can inform future trials in this population. C1 [Revuelta, Gonzalo J.; Delambo, Amy; Hinson, Vanessa K.] Med Univ S Carolina, Coll Med, Dept Neurol, Movement Disorders Div, Charleston, SC 29425 USA. [Embry, Aaron; Gregory, Chris; Kautz, Steve] Med Univ S Carolina, Coll Hlth Profess, Ctr Rehabil Res Neurol Condit, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Elm, Jordan J.] Med Univ S Carolina, Dept Publ Hlth Sci, Coll Med, Charleston, SC 29425 USA. [Gregory, Chris; Kautz, Steve] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Revuelta, GJ (reprint author), Med Univ S Carolina, Coll Med, Dept Neurol, Movement Disorders Div, 208B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. EM revuelta@musc.edu FU NCATS NIH HHS [UL1 TR000062]; NINDS NIH HHS [K23 NS091391] NR 12 TC 1 Z9 1 U1 3 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2047-9158 J9 TRANSL NEURODEGENER JI Transl. Neurodegener. PD DEC 10 PY 2015 VL 4 AR UNSP 24 DI 10.1186/s40035-015-0047-8 PG 4 WC Neurosciences SC Neurosciences & Neurology GA CY3OK UT WOS:000366318900001 PM 26693006 ER PT J AU Delgado, C Grimes, BA Glidden, DV Shlipak, M Sarnak, MJ Johansen, KL AF Delgado, Cynthia Grimes, Barbara A. Glidden, David V. Shlipak, Michael Sarnak, Mark J. Johansen, Kirsten L. TI Association of Frailty based on self-reported physical function with directly measured kidney function and mortality SO BMC NEPHROLOGY LA English DT Article DE Self-report frailty; Kidney function and mortality ID BODY-COMPOSITION; RENAL-DISEASE; OLDER-ADULTS; HEMODIALYSIS; HEALTH; PERFORMANCE; PROGRESSION; PREVALENT; PROTEIN AB Background: Use of serum creatinine to estimate GFR may lead to underestimation of the association between self-reported frailty and kidney function. Our objectives were to evaluate the association of measured GFR (mGFR) with self-reported frailty among patients with CKD and to determine whether self-reported frailty was associated with death after adjusting for mGFR. Methods: Participants in the Modification of Diet in Renal Disease study (1989-1993) had GFR measured using iothalamate clearance (mGFR), and GFR was estimated based on the CKD-EPI creatinine (eGFRcr) and cystatin C (eGFRcys) equations. We defined self-reported frailty as three or more of: exhaustion, poor physical function, low physical activity, and low body weight. Death was ascertained through 2007 using the National Death Index and the United States Renal Data System. Results: Eight hundred twelve MDRD participants (97 %) had complete data on self-reported frailty (16 % prevalence, N = 130) and mGFR (mean (SD) 33.1 +/- 11.7 ml/min/1.73 m(2)). Higher GFR was associated with lower odds of self-reported frailty based on mGFR, (OR 0.71, 95 % CI 0.60-0.86 per 10 ml/min/1.73 m(2)), eGFRcr (OR 0.80, 95 % CI 0.67-0.94 per 10 ml/min/1.73 m2), and eGFRcys (OR 0.75, 95 % CI 0.62-0.90 per 10 ml/min/1.73 m(2)). Median follow-up was 17 (IQR 11-18) years, with 371 deaths. Self-reported frailty was associated with a higher risk of death (HR 1.71, 95 % CI 1.26-2.30), which was attenuated to a similar degree when mGFR (HR 1.48, 95 % CI 1.08-2.00), eGFRcr (HR 1.57, 95 % CI 1.15-2.10), or eGFRcys (HR 1.51, 95 % CI 1.10-2.10) was included as an indicator of kidney function. Conclusions: We found an inverse association between kidney function and self-reported frailty that was similar for mGFR, eGFR and eGFRcys. In this relatively healthy cohort of clinical trial participants with CKD, using serum creatinine to estimate GFR did not substantially alter the association of GFR with self-reported frailty or of self-reported frailty with death. C1 [Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Grimes, Barbara A.; Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. RP Delgado, C (reprint author), San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. EM Cynthia.Delgado@ucsf.edu FU United States Department of Veteran Affairs, Clinical Science Research and Development Program [1IK2CX000527-01A2]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [1K24DK085153]; National Institute of Aging (NIA) [R01AG027002] FX Cynthia Delgado MD's work was supported by Career Development Award # 1IK2CX000527-01A2 from the United States Department of Veteran Affairs, Clinical Science Research and Development Program; Dr. Johansen is supported by 1K24DK085153 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).; Drs. Shlipak and Sarnak are supported by R01AG027002 from the National Institute of Aging (NIA). NR 21 TC 1 Z9 1 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD DEC 9 PY 2015 VL 16 AR 203 DI 10.1186/s12882-015-0202-6 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CY1NE UT WOS:000366173000001 PM 26645070 ER PT J AU Chen, DH Meneret, A Friedman, JR Korvatska, O Gad, A Bonkowski, ES Stessman, HA Doummar, D Mignot, C Anheim, M Bernes, S Davis, MY Damon-Perriere, N Degos, B Grabli, D Gras, D Hisama, FM Mackenzie, KM Swanson, PD Tranchant, C Vidailhet, M Winesett, S Trouillard, O Amendola, LM Dorschner, MO Weiss, M Eichler, EE Torkamani, A Roze, E Bird, TD Raskind, WH AF Chen, Dong-Hui Meneret, Aurelie Friedman, Jennifer R. Korvatska, Olena Gad, Alona Bonkowski, Emily S. Stessman, Holly A. Doummar, Diane Mignot, Cyril Anheim, Mathieu Bernes, Saunder Davis, Marie Y. Damon-Perriere, Nathalie Degos, Bertrand Grabli, David Gras, Domitille Hisama, Fuki M. Mackenzie, Katherine M. Swanson, Phillip D. Tranchant, Christine Vidailhet, Marie Winesett, Steven Trouillard, Oriane Amendola, Laura M. Dorschner, Michael O. Weiss, Michael Eichler, Evan E. Torkamani, Ali Roze, Emmanuel Bird, Thomas D. Raskind, Wendy H. TI ADCY5-related dyskinesia Broader spectrum and genotype-phenotype correlations SO NEUROLOGY LA English DT Article ID BENIGN HEREDITARY CHOREA; TYPE-5 ADENYLYL-CYCLASE; FACIAL MYOKYMIA FDFM; FAMILIAL DYSKINESIA; ADCY5 MUTATIONS; FOLLOW-UP; DYSTONIA; DYSFUNCTION; MICE AB Objective: To investigate the clinical spectrum and distinguishing features of adenylate cyclase 5 (ADCY5)-related dyskinesia and genotype-phenotype relationship. Methods: We analyzed ADCY5 in patients with choreiform or dystonic movements by exome or targeted sequencing. Suspected mosaicism was confirmed by allele-specific amplification. We evaluated clinical features in our 50 new and previously reported cases. Results: We identified 3 new families and 12 new sporadic cases with ADCY5 mutations. These mutations cause a mixed hyperkinetic disorder that includes dystonia, chorea, and myoclonus, often with facial involvement. The movements are sometimes painful and show episodic worsening on a fluctuating background. Many patients have axial hypotonia. In 2 unrelated families, a p.A726T mutation in the first cytoplasmic domain (C1) causes a relatively mild disorder of prominent facial and hand dystonia and chorea. Mutations p.R418W or p.R418Q in C1, de novo in 13 individuals and inherited in 1, produce a moderate to severe disorder with axial hypotonia, limb hypertonia, paroxysmal nocturnal or diurnal dyskinesia, chorea, myoclonus, and intermittent facial dyskinesia. Somatic mosaicism is usually associated with a less severe phenotype. In one family, a p.M1029K mutation in the C2 domain causes severe dystonia, hypotonia, and chorea. The progenitor, whose childhood-onset episodic movement disorder almost disappeared in adulthood, was mosaic for the mutation. Conclusions: ADCY5-related dyskinesia is a childhood-onset disorder with a wide range of hyperkinetic abnormal movements. Genotype-specific correlations and mosaicism play important roles in the phenotypic variability. Recurrent mutations suggest particular functional importance of residues 418 and 726 in disease pathogenesis. C1 [Chen, Dong-Hui; Bonkowski, Emily S.; Davis, Marie Y.; Swanson, Phillip D.; Weiss, Michael; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Korvatska, Olena; Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Stessman, Holly A.; Eichler, Evan E.] Univ Washington, Dept Genom Sci, Seattle, WA 98195 USA. [Hisama, Fuki M.; Amendola, Laura M.; Raskind, Wendy H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Dorschner, Michael O.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Eichler, Evan E.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] INSERM, U 1127, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] CNRS, UMR 7225, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Univ Paris 06, Sorbonne Univ, UMR S 1127, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] ICM, Inst Cerveau & Moe Epiniere, Paris, France. [Meneret, Aurelie; Degos, Bertrand; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France. [Meneret, Aurelie; Degos, Bertrand; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Hop La Pitie Salpetriere, AP HP, Dept Genet, Paris, France. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Rady Childrens Hosp, San Diego, CA USA. [Gad, Alona] Tel Aviv Med Sch, Tel Aviv Brill Community Mental Hlth Ctr, Tel Aviv, Israel. [Doummar, Diane] Hop Trousseau, AP HP, Serv Neuropediat, F-75571 Paris, France. [Doummar, Diane] Ctr Reference Mouvements Anormaux Enfant Adulte, Paris, France. [Mignot, Cyril] Ctr Deficiences Intellectuelles Causes Rares, Paris, France. [Anheim, Mathieu; Tranchant, Christine] Hospices Civils Strasbourg, Dept Neurol, Illkirch Graffenstaden, France. [Anheim, Mathieu; Tranchant, Christine] Univ Strasbourg, FMTS, Illkirch Graffenstaden, France. [Anheim, Mathieu; Tranchant, Christine] Univ Strasbourg, CNRS UMR7104, INSERM U964, IGBMC, Illkirch Graffenstaden, France. [Bernes, Saunder] Phoenix Childrens Hosp, Phoenix, AZ USA. [Damon-Perriere, Nathalie] CHU Bordeaux, Explorat Fonct Syst Nerveux, Paris, France. [Gras, Domitille] Hop Robert Debre, AP HP, Serv Neuropediat, F-75019 Paris, France. [Mackenzie, Katherine M.] Stanford Univ, Lucile Packard Childrens Hosp, Dept Child Neurol, Palo Alto, CA 94304 USA. [Winesett, Steven] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA. [Torkamani, Ali] Scripps Hlth, Scripps Translat Sci Inst, San Diego, CA USA. [Torkamani, Ali] Scripps Res Inst, San Diego, CA USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Raskind, Wendy H.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. RP Raskind, WH (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM tomnroz@uw.edu; wendyrun@uw.edu FU NIH [R01 NS069719, R01 MH101221, U01 HG006476]; NIH (Clinical and Translational Science Award (CTSA) [UL1 TR001114-03]; Journees de Neurologie en Langue Francaise; INSERM (COSSEC); AP-HP (DRC-PHRC); Fondation pour la Recherche sur le Cerveau (FRC); DHOS-INSERM; ANR (French National Institutes); AMADYS; Alliance France Dystonie; Department of Veterans Affairs FX Supported in part by funds from the NIH (R01 NS069719) to W. H. R., R01 MH101221 to E. E. E., U01 HG006476 to A. T., Clinical and Translational Science Award (CTSA; UL1 TR001114-03) to A. T., Journees de Neurologie en Langue Francaise to A. M., INSERM (COSSEC) to E. R., AP-HP (DRC-PHRC) to E. R., Fondation pour la Recherche sur le Cerveau (FRC) to E. R., DHOS-INSERM to M. V., ANR (French National Institutes) to M. V., AMADYS to M. V., Alliance France Dystonie to A. M., and the Department of Veterans Affairs (T.D.B., W.H.R.). NR 30 TC 14 Z9 14 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 8 PY 2015 VL 85 IS 23 BP 2026 EP 2035 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DF8WV UT WOS:000371642200010 PM 26537056 ER PT J AU Teerlink, JR Felker, GM McMurray, JJV Solomon, SD Monsalvo, ML Legg, J Malik, FI Honarpour, N AF Teerlink, John R. Felker, G. Michael McMurray, John J. V. Solomon, Scott D. Monsalvo, Maria Laura Legg, Jason Malik, Fady I. Honarpour, Narimon CA COSMIC-HF Investigators TI Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final Results from a Double-blind, Randomized, Placebo-controlled, Multicenter Study SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc C1 [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Felker, G. Michael] Duke Univ, Sch Med, Durham, NC USA. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. [Solomon, Scott D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Solomon, Scott D.] Harvard Univ, Sch Med, Boston, MA USA. [Monsalvo, Maria Laura; Legg, Jason; Honarpour, Narimon] Amgen Inc, Thousand Oaks, CA 91320 USA. [Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 24294 BP 2269 EP 2269 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100017 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI The Greatest Generation SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PHYSICIANS C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM gurpreet.dhaliwal@ucsf.edu NR 7 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 8 PY 2015 VL 314 IS 22 BP 2353 EP 2354 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CX8XT UT WOS:000365989100006 PM 26647253 ER PT J AU Singh, SP Schwartz, MP Tokuda, EY Luo, Y Rogers, RE Fujita, M Ahn, NG Anseth, KS AF Singh, S. P. Schwartz, M. P. Tokuda, E. Y. Luo, Y. Rogers, R. E. Fujita, M. Ahn, N. G. Anseth, K. S. TI A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression SO SCIENTIFIC REPORTS LA English DT Article ID CELL-MIGRATION; 3-DIMENSIONAL CULTURE; MALIGNANT PHENOTYPE; MATRIX STIFFNESS; DRUG-RESISTANCE; GENE-EXPRESSION; ELASTIC-MODULI; CANCER; HYDROGELS; INVASION AB Here, we demonstrate the flexibility of peptide-functionalized poly(ethylene glycol) (PEG) hydrogels for modeling tumor progression. The PEG hydrogels were formed using thiol-ene chemistry to incorporate a matrix metalloproteinase-degradable peptide crosslinker (KKCGGPQG down arrow IWGQGCKK) permissive to proteolytic remodeling and the adhesive CRGDS peptide ligand. Tumor cell function was investigated by culturing WM239A melanoma cells on PEG hydrogel surfaces or encapsulating cells within the hydrogels, and either as monocultures or indirect (non-contact) cocultures with primary human dermal fibroblasts (hDFs). WM239A cluster size and proliferation rate depended on the shear elastic modulus for cells cultured on PEG hydrogels, while growth was inhibited by coculture with hDFs regardless of hydrogel stiffness. Cluster size was also suppressed by hDFs for WM239A cells encapsulated in PEG hydrogels, which is consistent with cells seeded on top of hydrogels. Notably, encapsulated WM239A clusters and single cells adopted invasive phenotypes in the hDF coculture model, which included single cell and collective migration modes that resembled invasion from human melanoma patient-derived xenograft tumors encapsulated in equivalent PEG hydrogels. Our combined results demonstrate that peptide-functionalized PEG hydrogels provide a useful platform for investigating aspects of tumor progression in 2D and 3D microenvironments, including single cell migration, cluster growth and invasion. C1 [Singh, S. P.; Tokuda, E. Y.; Anseth, K. S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA. [Singh, S. P.; Tokuda, E. Y.; Anseth, K. S.] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA. [Schwartz, M. P.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA. [Luo, Y.; Fujita, M.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Rogers, R. E.] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA. [Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ahn, N. G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA. [Anseth, K. S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA. RP Anseth, KS (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA. EM kristi.anseth@colorado.edu RI Schwartz, Michael/B-3417-2008; Schwartz, Mike/O-7963-2016 OI Schwartz, Michael/0000-0003-3785-6606; Schwartz, Mike/0000-0003-3785-6606 FU Howard Hughes Medical Institute; National Institutes of Health [RO1 CA132633-02, T32 GM-065103] FX The authors acknowledge the Howard Hughes Medical Institute and the National Institutes of Health (RO1 CA132633-02) for funding this work. SPS acknowledges the biophysics training program (NIH grant T32 GM-065103) for fellowship support. MPS acknowledges a donation in the memory of Gerald E. Whitbeck (generously provided by his family and Follett Corp). NR 66 TC 3 Z9 3 U1 5 U2 31 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 7 PY 2015 VL 5 AR 17814 DI 10.1038/srep17814 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX7CB UT WOS:000365857300001 PM 26638791 ER PT J AU Forouzanfar, MH Alexander, L Anderson, HR Bachman, VF Biryukov, S Brauer, M Burnett, R Casey, D Coates, MM Cohen, A Delwiche, K Estep, K Frostad, JJ Astha, KC Kyu, HH Moradi-Lakeh, M Ng, M Slepak, EL Thomas, BA Wagner, J Aasvang, GM Abbafati, C Ozgoren, AA Abd-Allah, F Abera, SF Aboyans, V Abraham, B Abraham, JP Abubakar, I Abu-Rmeileh, NME Aburto, TC Achoki, T Adelekan, A Adofo, K Adou, AK Adsuar, JC Afshin, A Agardh, EE Al Khabouri, MJ Al Lami, FH Alam, SS Alasfoor, D Albittar, MI Alegretti, MA Aleman, AV Alemu, ZA Alfonso-Cristancho, R Alhabib, S Ali, R Ali, MK Alla, F Allebeck, P Allen, PJ Alsharif, U Alvarez, E Alvis-Guzman, N Amankwaa, AA Amare, AT Ameh, EA Ameli, O Amini, H Ammar, W Anderson, BO Antonio, CAT Anwari, P Cunningham, SA Arnlov, J Arsenijevic, VSA Artaman, A Asghar, RJ Assadi, R Atkins, LS Atkinson, C Avila, MA Awuah, B Badawi, A Bahit, MC Bakfalouni, T Balakrishnan, K Balalla, S Balu, RK Banerjee, A Barber, RM Barker-Collo, SL Barquera, S Barregard, L Barrero, LH Barrientos-Gutierrez, T Basto-Abreu, AC Basu, A Basu, S Basulaiman, MO Ruvalcaba, CB Beardsley, J Bedi, N Bekele, T Bell, ML Benjet, C Bennett, DA Benzian, H Bernabe, E Beyene, TJ Bhala, N Bhalla, A Bhutta, ZQA Bikbov, B Bin Abdulhak, AA Blore, JD Blyth, FM Bohensky, MA Basara, BB Borges, G Bornstein, NM Bose, D Boufous, S Bourne, RR Brainin, M Brazinova, A Breitborde, NJ Brenner, H Briggs, ADM Broday, DM Brooks, PM Bruce, NG Brugha, TS Brunekreef, B Buchbinder, R Bui, LN Bukhman, G Bulloch, AG Burch, M Burney, PGJ Campos-Nonato, IR Campuzano, JC Cantoral, AJ Caravanos, J Cardenas, R Cardis, E Carpenter, DO Caso, V Castaneda-Orjuela, CA Castro, RE Catala-Lopez, F Cavalleri, F Ccedil;avlin, A Chadha, VK Chang, JC Charlson, FJ Chen, HL Chen, WQ Chen, ZM Chiang, PP Chimed-Ochir, O Chowdhury, R Christophi, CA Chuang, TW Chugh, SS Cirillo, M Classen, TKD Colistro, V Colomar, M Colquhoun, SM Contreras, AG Cooper, C Cooperrider, K Cooper, LT Coresh, J Courville, KJ Criqui, MH Cuevas-Nasu, L Damsere-Derry, J Danawi, H Dandona, L Dandona, R Dargan, PI Davis, A Davitoiu, DV Dayama, A de Castro, EF De la Cruz-Gongora, V De Leo, D de Lima, G Degenhardt, L del Pozo-Cruz, B Dellavalle, RP Deribe, K Derrett, S Jarlais, DCD Dessalegn, M deVeber, GA Devries, KM Dharmaratne, SD Dherani, MK Dicker, D Ding, EL Dokova, K Dorsey, ER Driscoll, TR Duan, L Durrani, AM Ebel, BE Ellenbogen, RG Elshrek, YM Endres, M Ermakov, SP Erskine, HE Eshrati, B Esteghamati, A Fahimi, S Faraon, EJA Farzadfar, F Fay, DFJ Feigin, VL Feigl, AB Fereshtehnejad, SM Ferrari, AJ Ferri, CP Flaxman, AD Fleming, TD Foigt, N Foreman, KJ Paleo, UF Franklin, RC Gabbe, B Gaffikin, L Gakidou, E Gamkrelidze, A Gankpe, FG Gansevoort, RT Garcia-Guerra, FA Gasana, E Geleijnse, JM Gessner, BD Gething, P Gibney, KB Gillum, RF Ginawi, IAM Giroud, M Giussani, G Goenka, S Goginashvili, K Dantes, HG Gona, P de Cosio, TG Gonzalez-Castell, D Gotay, CC Goto, A Gouda, HN Guerrant, RL Gugnani, HC Guillemin, F Gunnell, D Gupta, R Gupta, R Gutierrez, RA Hafezi-Nejad, N Hagan, H Hagstromer, M Halasa, YA Hamadeh, RR Hammami, M Hankey, GJ Hao, YT Harb, HL Haregu, TN Haro, JM Havmoeller, R Hay, SI Hedayati, MT Heredia-Pi, IB Hernandez, L Heuton, KR Heydarpour, P Hijar, M Hoek, HW Man, HJH Hornberger, JC Hosgood, HD Hoy, DG Hsairi, M Hu, GQ Hu, H Huang, C Huang, JJ Hubbell, BJ Huiart, L Husseini, A Iannarone, ML Iburg, KM Idrisov, BT Ikeda, N Innos, K Inoue, M Islami, F Ismayilova, S Jacobsen, KH Jansen, HA Jarvis, DL Jassal, SK Jauregui, A Jayaraman, S Jeemon, P Jensen, PN Jha, V Jiang, F Jiang, GH Jiang, Y Jonas, JB Juel, K Kan, HD Roseline, SSK Karam, NE Karch, A Karema, CK Karthikeyan, G Kaul, A Kawakami, N Kazi, DS Kemp, AH Kengne, AP Keren, A Khader, YS Khalifa, SEAH Khan, EA Khang, YH Khatibzadeh, S Khonelidze, I Kieling, C Kim, D Kim, S Kim, Y Kimokoti, RW Kinfu, Y Kinge, JM Kissela, BM Kivipelto, M Knibbs, LD Knudsen, AK Kokubo, Y Kose, MR Kosen, S Kraemer, A Kravchenko, M Krishnaswami, S Kromhout, H Ku, T Defo, BK Bicer, BK Kuipers, EJ Kulkarni, C Kulkarni, VS Kumar, GA Kwan, GF Lai, T Balaji, AL Lalloo, R Lallukka, T Lam, H Lan, Q Lansingh, VC Larson, HJ Larsson, A Laryea, DO Lavados, PM Lawrynowicz, AE Leasher, JL Lee, JT Leigh, J Leung, R Levi, M Li, Y Li, Y Liang, J Liang, XF Lim, SS Lindsay, MP Lipshultz, SE Liu, SW Liu, Y Lloyd, BK Logroscino, G London, SJ Lopez, N Lortet-Tieulent, J Lotufo, PA Lozano, R Lunevicius, R Ma, JX Ma, S Machado, VMP MacIntyre, MF Magis-Rodriguez, C Mahdi, AA Majdan, M Malekzadeh, R Mangalam, S Mapoma, CC Marape, M Marcenes, W Margolis, DJ Margono, C Marks, GB Martin, RV Marzan, MB Mashal, MT Masiye, F Mason-Jones, AJ Matsushita, K Matzopoulos, R Mayosi, BM Mazorodze, TT Mckay, AC Mckee, M McLain, A Meaney, PA Medina, C Mehndiratta, MM Mejia-Rodriguez, F Mekonnen, W Melaku, YA Meltzer, M Memish, ZA Mendoza, W Mensah, GA Meretoja, A Mhimbira, FA Micha, R Miller, TR Mills, EJ Misganaw, A Mishra, S Ibrahim, NM Mohammad, KA Mokdad, AH Mola, GL Monasta, L Hernandez, JCM Montico, M Moore, AR Morawska, L Mori, R Moschandreas, J Moturi, WN Arian, DM Mueller, UO Mukaigawara, M Mullany, EC Murthy, KS Naghavi, M Nahas, Z Naheed, A Naidoo, KS Naldi, L Nand, D Nangia, V Narayan, KMV Nash, D Neal, B Nejjari, C Neupane, SP Newton, CR Ngalesoni, FN Ngirabega, JD Nguyen, G Nguyen, NT Nieuwenhuijsen, MJ Nisar, MI Nogueira, JR Nolla, JM Nolte, S Norheim, OF Norman, RE Norrving, B Nyakarahuka, L Oh, IH Ohkubo, T Olusanya, BO Omer, SB Opio, JN Orozco, R Pagcatipunan, RS Pain, AW Pandian, JD Panelo, CIA Papachristou, C Park, EK Parry, CD Caicedo, AJP Patten, SB Paul, VK Pavlin, BI Pearce, N Pedraza, LS Pedroza, A Stokic, LP Pekericli, A Pereira, DM Perez-Padilla, R Perez-Ruiz, F Perico, N Perry, SAL Pervaiz, A Pesudovs, K Peterson, CB Petzold, M Phillips, MR Phua, HP Plass, D Poenaru, D Polanczyk, GV Polinder, S Pond, CD Pope, CA Pope, D Popova, S Pourmalek, F Powles, J Prabhakaran, D Prasad, NM Qato, DM Quezada, AD Quistberg, DAA Racape L Rafay, A Rahimi, K Rahimi-Movaghar, V Rahman, SU Raju, M Rakovac, I Rana, SM Rao, M Razavi, H Reddy, KS Refaat, AH Rehm, J Remuzzi, G Ribeiro, AL Riccio, PM Richardson, L Riederer, A Robinson, M Roca, A Rodriguez, A Rojas-Rueda, D Romieu, I Ronfani, L Room, R Roy, N Ruhago, GM Rushton, L Sabin, N Sacco, RL Saha, S Sahathevan, R Sahraian, MA Salomon, JA Salvo, D Sampson, UK Sanabria, JR Sanchez, LM Sanchez-Pimienta, TG Sanchez-Riera, L Sandar, L Santos, IS Sapkota, A Satpathy, M Saunders, JE Sawhney, M Saylan, MI Scarborough, P Schmidt, JC Schneider, IJC Schottker, B Schwebel, DC Scott, JG Seedat, S Sepanlou, SG Serdar, B Servan-Mori, EE Shaddick, G Shahraz, S Levy, TS Shangguan, S She, J Sheikhbahaei, S Shibuya, K Shin, HH Shinohara, Y Shiri, R Shishani, K Shiue, I Sigfusdottir, ID Silberberg, DH Simard, EP Sindi, S Singh, A Singh, GM Singh, JA Skirbekk, V Sliwa, K Soljak, M Soneji, S Soreide, K Soshnikov, S Sposato, LA Sreeramareddy, CT Stapelberg, NJC Stathopoulou, V Steckling, N Stein, DJ Stein, MB Stephens, N Stockl, H Straif, K Stroumpoulis, K Sturua, L Sunguya, BF Swaminathan, S Swaroop, M Sykes, BL Tabb, KM Takahashi, K Talongwa, RT Tandon, N Tanne, D Tanner, M Tavakkoli, M Ao, BJT Teixeira, CM Rojo, MMT Terkawi, AS Texcalac-Sangrador, JL Thackway, SV Thomson, B Thorne-Lyman, AL Thrift, AG Thurston, GD Tillmann, T Tobollik, M Tonelli, M Topouzis, F Towbin, JRA Toyoshima, H Traebert, JE Tran, BX Trasande, L Trillini, M Trujillo, U Dimbuene, ZT Tsilimbaris, M Tuzcu, EM Uchendu, US Ukwaja, KN Uzun, SB van de Vijver, S Van Dingenen, R Van Gool, CH Van Os, J Varakin, YY Vasankari, TJ Vasconcelos, AMN Vavilala, MS Veerman, LJ Velasquez-Melendez, G Venketasubramanian, N Vijayakumar, L Villalpando, S Violante, FS Vlassov, VV Vollset, SE Wagner, GR Waller, SG Wallin, MT Wan, X Wang, HD Wang, JL Wang, LH Wang, WZ Wang, YP Warouw, TS Watts, CH Weichenthal, S Weiderpass, E Weintraub, RG Werdecker, A Wessells, KR Westerman, R Whiteford, HA Wilkinson, JD Williams, HC Williams, TN Woldeyohannes, SM Wolfe, CDA Wong, JQ Woolf, AD Wright, JL Wurtz, B Xu, G Yan, LJL Yang, GH Yano, Y Ye, PP Yenesew, M Yentur, GK Yip, P Yonemoto, N Yoon, SJ Younis, MZ Younoussi, Z Yu, CH Zaki, ME Zhao, Y Zheng, YF Zhou, MG Zhu, J Zhu, SK Zou, XN Zunt, JR Lopez, AD Vos, T Murray, CJ AF Forouzanfar, Mohammad H. Alexander, Lily Anderson, H. Ross Bachman, Victoria F. Biryukov, Stan Brauer, Michael Burnett, Richard Casey, Daniel Coates, Matthew M. Cohen, Aaron Delwiche, Kristen Estep, Kara Frostad, Joseph J. Astha, K. C. Kyu, Hmwe H. Moradi-Lakeh, Maziar Ng, Marie Slepak, Erica Leigh Thomas, Bernadette A. Wagner, Joseph Aasvang, Gunn Marit Abbafati, Cristiana Ozgoren, Ayse Abbasoglu Abd-Allah, Foad Abera, Semaw F. Aboyans, Victor Abraham, Biju Abraham, Jerry Puthenpurakal Abubakar, Ibrahim Abu-Rmeileh, Niveen M. E. Aburto, Tania C. Achoki, Tom Adelekan, Ademola Adofo, Koranteng Adou, Arsene K. Adsuar, Jose C. Afshin, Ashkan Agardh, Emilie E. Al Khabouri, Mazin J. Al Lami, Faris H. Alam, Sayed Saidul Alasfoor, Deena Albittar, Mohammed I. Alegretti, Miguel A. Aleman, Alicia V. Alemu, Zewdie A. Alfonso-Cristancho, Rafael Alhabib, Samia Ali, Raghib Ali, Mohammed K. Alla, Francois Allebeck, Peter Allen, Peter J. Alsharif, Ubai Alvarez, Elena Alvis-Guzman, Nelson Amankwaa, Adansi A. Amare, Azmeraw T. Ameh, Emmanuel A. Ameli, Omid Amini, Heresh Ammar, Walid Anderson, Benjamin O. Antonio, Carl Abelardo T. Anwari, Palwasha Cunningham, Solveig Argeseanu Arnlov, Johan Arsenijevic, Valentina S. Arsic Artaman, Al Asghar, Rana J. Assadi, Reza Atkins, Lydia S. Atkinson, Charles Avila, Marco A. Awuah, Baffour Badawi, Alaa Bahit, Maria C. Bakfalouni, Talal Balakrishnan, Kalpana Balalla, Shivanthi Balu, Ravi Kumar Banerjee, Amitava Barber, Ryan M. Barker-Collo, Suzanne L. Barquera, Simon Barregard, Lars Barrero, Lope H. Barrientos-Gutierrez, Tonatiuh Basto-Abreu, Ana C. Basu, Arindam Basu, Sanjay Basulaiman, Mohammed O. Ruvalcaba, Carolina Batis Beardsley, Justin Bedi, Neeraj Bekele, Tolesa Bell, Michelle L. Benjet, Corina Bennett, Derrick A. Benzian, Habib Bernabe, Eduardo Beyene, Tariku J. Bhala, Neeraj Bhalla, Ashish Bhutta, Zulfi Qar A. Bikbov, Boris Bin Abdulhak, Aref A. Blore, Jed D. Blyth, Fiona M. Bohensky, Megan A. Basara, Berrak Bora Borges, Guilherme Bornstein, Natan M. Bose, Dipan Boufous, Soufiane Bourne, Rupert R. Brainin, Michael Brazinova, Alexandra Breitborde, Nicholas J. Brenner, Hermann Briggs, Adam D. M. Broday, David M. Brooks, Peter M. Bruce, Nigel G. Brugha, Traolach S. Brunekreef, Bert Buchbinder, Rachelle Bui, Linh N. Bukhman, Gene Bulloch, Andrew G. Burch, Michael Burney, Peter G. J. Campos-Nonato, Ismael R. Campuzano, Julio C. Cantoral, Alejandra J. Caravanos, Jack Cardenas, Rosario Cardis, Elisabeth Carpenter, David O. Caso, Valeria Castaneda-Orjuela, Carlos A. Castro, Ruben E. Catala-Lopez, Ferran Cavalleri, Fiorella Cavlin, Alanur Chadha, Vineet K. Chang, Jung-chen Charlson, Fiona J. Chen, Honglei Chen, Wanqing Chen, Zhengming Chiang, Peggy P. Chimed-Ochir, Odgerel Chowdhury, Rajiv Christophi, Costas A. Chuang, Ting-Wu Chugh, Sumeet S. Cirillo, Massimo Classen, Thomas K. D. Colistro, Valentina Colomar, Mercedes Colquhoun, Samantha M. Contreras, Alejandra G. Cooper, Cyrus Cooperrider, Kimberly Cooper, Leslie T. Coresh, Josef Courville, Karen J. Criqui, Michael H. Cuevas-Nasu, Lucia Damsere-Derry, James Danawi, Hadi Dandona, Lalit Dandona, Rakhi Dargan, Paul I. Davis, Adrian Davitoiu, Dragos V. Dayama, Anand de Castro, E. Filipa De la Cruz-Gongora, Vanessa De Leo, Diego de Lima, Graca Degenhardt, Louisa del Pozo-Cruz, Borja Dellavalle, Robert P. Deribe, Kebede Derrett, Sarah Jarlais, Don C. Des Dessalegn, Muluken deVeber, Gabrielle A. Devries, Karen M. Dharmaratne, Samath D. Dherani, Mukesh K. Dicker, Daniel Ding, Eric L. Dokova, Klara Dorsey, E. Ray Driscoll, Tim R. Duan, Leilei Durrani, Adnan M. Ebel, Beth E. Ellenbogen, Richard G. Elshrek, Yousef M. Endres, Matthias Ermakov, Sergey P. Erskine, Holly E. Eshrati, Babak Esteghamati, Alireza Fahimi, Saman Faraon, Emerito Jose A. Farzadfar, Farshad Fay, Derek F. J. Feigin, Valery L. Feigl, Andrea B. Fereshtehnejad, Seyed-Mohammad Ferrari, Alize J. Ferri, Cleusa P. Flaxman, Abraham D. Fleming, Thomas D. Foigt, Nataliya Foreman, Kyle J. Paleo, Urbano Fra Franklin, Richard C. Gabbe, Belinda Gaffikin, Lynne Gakidou, Emmanuela Gamkrelidze, Amiran Gankpe, Fortune G. Gansevoort, Ron T. Garcia-Guerra, Francisco A. Gasana, Evariste Geleijnse, Johanna M. Gessner, Bradford D. Gething, Pete Gibney, Katherine B. Gillum, Richard F. Ginawi, Ibrahim A. M. Giroud, Maurice Giussani, Giorgia Goenka, Shifalika Goginashvili, Ketevan Dantes, Hector Gomez Gona, Philimon de Cosio, Teresita Gonzalez Gonzalez-Castell, Dinorah Gotay, Carolyn C. Goto, Atsushi Gouda, Hebe N. Guerrant, Richard L. Gugnani, Harish C. Guillemin, Francis Gunnell, David Gupta, Rahul Gupta, Rajeev Gutierrez, Reyna A. Hafezi-Nejad, Nima Hagan, Holly Hagstromer, Maria Halasa, Yara A. Hamadeh, Randah R. Hammami, Mouhanad Hankey, Graeme J. Hao, Yuantao Harb, Hilda L. Haregu, Tilahun Nigatu Haro, Josep Maria Havmoeller, Rasmus Hay, Simon I. Hedayati, Mohammad T. Heredia-Pi, Ileana B. Hernandez, Lucia Heuton, Kyle R. Heydarpour, Pouria Hijar, Martha Hoek, Hans W. Man, Howard J. Hoff Hornberger, John C. Hosgood, H. Dean Hoy, Damian G. Hsairi, Mohamed Hu, Guoqing Hu, Howard Huang, Cheng Huang, John J. Hubbell, Bryan J. Huiart, Laetitia Husseini, Abdullatif Iannarone, Marissa L. Iburg, Kim M. Idrisov, Bulat T. Ikeda, Nayu Innos, Kaire Inoue, Manami Islami, Farhad Ismayilova, Samaya Jacobsen, Kathryn H. Jansen, Henrica A. Jarvis, Deborah L. Jassal, Simerjot K. Jauregui, Alejandra Jayaraman, Sudha Jeemon, Panniyammakal Jensen, Paul N. Jha, Vivekanand Jiang, Fan Jiang, Guohong Jiang, Ying Jonas, Jost B. Juel, Knud Kan, Haidong Roseline, Sidibe S. Kany Karam, Nadim E. Karch, Andre Karema, Corine K. Karthikeyan, Ganesan Kaul, Anil Kawakami, Norito Kazi, Dhruv S. Kemp, Andrew H. Kengne, Andre P. Keren, Andre Khader, Yousef S. Khalifa, Shams Eldin Ali Hassan Khan, Ejaz A. Khang, Young-Ho Khatibzadeh, Shahab Khonelidze, Irma Kieling, Christian Kim, Daniel Kim, Sungroul Kim, Yunjin Kimokoti, Ruth W. Kinfu, Yohannes Kinge, Jonas M. Kissela, Brett M. Kivipelto, Miia Knibbs, Luke D. Knudsen, Ann Kristin Kokubo, Yoshihiro Kose, M. Rifat Kosen, Soewarta Kraemer, Alexander Kravchenko, Michael Krishnaswami, Sanjay Kromhout, Hans Ku, Tiffany Defo, Barthelemy Kuate Bicer, Burcu Kucuk Kuipers, Ernst J. Kulkarni, Chanda Kulkarni, Veena S. Kumar, G. Anil Kwan, Gene F. Lai, Taavi Balaji, Arjun Lakshmana Lalloo, Ratilal Lallukka, Tea Lam, Hilton Lan, Qing Lansingh, Van C. Larson, Heidi J. Larsson, Anders Laryea, Dennis O. Lavados, Pablo M. Lawrynowicz, Alicia E. Leasher, Janet L. Lee, Jong-Tae Leigh, James Leung, Ricky Levi, Miriam Li, Yichong Li, Yongmei Liang, Juan Liang, Xiaofeng Lim, Stephen S. Lindsay, M. Patrice Lipshultz, Steven E. Liu, Shiwei Liu, Yang Lloyd, Belinda K. Logroscino, Giancarlo London, Stephanie J. Lopez, Nancy Lortet-Tieulent, Joannie Lotufo, Paulo A. Lozano, Rafael Lunevicius, Raimundas Ma, Jixiang Ma, Stefan Machado, Vasco M. P. MacIntyre, Michael F. Magis-Rodriguez, Carlos Mahdi, Abbas A. Majdan, Marek Malekzadeh, Reza Mangalam, Srikanth Mapoma, Christopher C. Marape, Marape Marcenes, Wagner Margolis, David J. Margono, Christopher Marks, Guy B. Martin, Randall V. Marzan, Melvin B. Mashal, Mohammad T. Masiye, Felix Mason-Jones, Amanda J. Matsushita, Kunihiro Matzopoulos, Richard Mayosi, Bongani M. Mazorodze, Tasara T. Mckay, Abigail C. Mckee, Martin McLain, Abigail Meaney, Peter A. Medina, Catalina Mehndiratta, Man Mohan Mejia-Rodriguez, Fabiola Mekonnen, Wubegzier Melaku, Yohannes A. Meltzer, Michele Memish, Ziad A. Mendoza, Walter Mensah, George A. Meretoja, Atte Mhimbira, Francis Apolinary Micha, Renata Miller, Ted R. Mills, Edward J. Misganaw, Awoke Mishra, Santosh Ibrahim, Norlinah Mohamed Mohammad, Karzan A. Mokdad, Ali H. Mola, Glen L. Monasta, Lorenzo Hernandez, Julio C. Montaez Montico, Marcella Moore, Ami R. Morawska, Lidia Mori, Rintaro Moschandreas, Joanna Moturi, Wilkister N. Arian, Dariush Mozaff Mueller, Ulrich O. Mukaigawara, Mitsuru Mullany, Erin C. Murthy, Kinnari S. Naghavi, Mohsen Nahas, Ziad Naheed, Aliya Naidoo, Kovin S. Naldi, Luigi Nand, Devina Nangia, Vinay Narayan, K. M. Venkat Nash, Denis Neal, Bruce Nejjari, Chakib Neupane, Sudan P. Newton, Charles R. Ngalesoni, Frida N. Ngirabega, Jean de Dieu Nguyen, Grant Nguyen, Nhung T. Nieuwenhuijsen, Mark J. Nisar, Muhammad I. Nogueira, Jose R. Nolla, Joan M. Nolte, Sandra Norheim, Ole F. Norman, Rosana E. Norrving, Bo Nyakarahuka, Luke Oh, In-Hwan Ohkubo, Takayoshi Olusanya, Bolajoko O. Omer, Saad B. Opio, John Nelson Orozco, Ricardo Pagcatipunan, Rodolfo S., Jr. Pain, Amanda W. Pandian, Jeyaraj D. Panelo, Carlo Irwin A. Papachristou, Christina Park, Eun-Kee Parry, Charles D. Caicedo, Angel J. Paternina Patten, Scott B. Paul, Vinod K. Pavlin, Boris I. Pearce, Neil Pedraza, Lilia S. Pedroza, Andrea Stokic, Ljiljana Pejin Pekericli, Ayfer Pereira, David M. Perez-Padilla, Rogelio Perez-Ruiz, Fernando Perico, Norberto Perry, Samuel A. L. Pervaiz, Aslam Pesudovs, Konrad Peterson, Carrie B. Petzold, Max Phillips, Michael R. Phua, Hwee Pin Plass, Dietrich Poenaru, Dan Polanczyk, Guilherme V. Polinder, Suzanne Pond, Constance D. Pope, C. Arden Pope, Daniel Popova, Svetlana Pourmalek, Farshad Powles, John Prabhakaran, Dorairaj Prasad, Noela M. Qato, Dima M. Quezada, Amado D. Quistberg, D. Alex A. Racape, Lionel Rafay, Anwar Rahimi, Kazem Rahimi-Movaghar, Vafa Rahman, Sajjad Ur Raju, Murugesan Rakovac, Ivo Rana, Saleem M. Rao, Mayuree Razavi, Homie Reddy, K. Srinath Refaat, Amany H. Rehm, Juergen Remuzzi, Giuseppe Ribeiro, Antonio L. Riccio, Patricia M. Richardson, Lee Riederer, Anne Robinson, Margaret Roca, Anna Rodriguez, Alina Rojas-Rueda, David Romieu, Isabelle Ronfani, Luca Room, Robin Roy, Nobhojit Ruhago, George M. Rushton, Lesley Sabin, Nsanzimana Sacco, Ralph L. Saha, Sukanta Sahathevan, Ramesh Sahraian, Mohammad Ali Salomon, Joshua A. Salvo, Deborah Sampson, Uchechukwu K. Sanabria, Juan R. Sanchez, Luz Maria Sanchez-Pimienta, Tania G. Sanchez-Riera, Lidia Sandar, Logan Santos, Itamar S. Sapkota, Amir Satpathy, Maheswar Saunders, James E. Sawhney, Monika Saylan, Mete I. Scarborough, Peter Schmidt, Juergen C. Schneider, Ione J. C. Schoettker, Ben Schwebel, David C. Scott, James G. Seedat, Soraya Sepanlou, Sadaf G. Serdar, Berrin Servan-Mori, Edson E. Shaddick, Gavin Shahraz, Saeid Levy, Teresa Shamah Shangguan, Siyi She, Jun Sheikhbahaei, Sara Shibuya, Kenji Shin, Hwashin H. Shinohara, Yukito Shiri, Rahman Shishani, Kawkab Shiue, Ivy Sigfusdottir, Inga D. Silberberg, Donald H. Simard, Edgar P. Sindi, Shireen Singh, Abhishek Singh, Gitanjali M. Singh, Jasvinder A. Skirbekk, Vegard Sliwa, Karen Soljak, Michael Soneji, Samir Soreide, Kjetil Soshnikov, Sergey Sposato, Luciano A. Sreeramareddy, Chandrashekhar T. Stapelberg, Nicolas J. C. Stathopoulou, Vasiliki Steckling, Nadine Stein, Dan J. Stein, Murray B. Stephens, Natalie Stoeckl, Heidi Straif, Kurt Stroumpoulis, Konstantinos Sturua, Lela Sunguya, Bruno F. Swaminathan, Soumya Swaroop, Mamta Sykes, Bryan L. Tabb, Karen M. Takahashi, Ken Talongwa, Roberto T. Tandon, Nikhil Tanne, David Tanner, Marcel Tavakkoli, Mohammad Ao, Braden J. Te Teixeira, Carolina M. Rojo, Martha M. Tellez Terkawi, Abdullah S. Texcalac-Sangrador, Jose Luis Thackway, Sarah V. Thomson, Blake Thorne-Lyman, Andrew L. Thrift, Amanda G. Thurston, George D. Tillmann, Taavi Tobollik, Myriam Tonelli, Marcello Topouzis, Fotis Towbin, Jeff Rey A. Toyoshima, Hideaki Traebert, Jeff Erson Tran, Bach X. Trasande, Leonardo Trillini, Matias Trujillo, Ulises Dimbuene, Zacharie Tsala Tsilimbaris, Miltiadis Tuzcu, Emin Murat Uchendu, Uche S. Ukwaja, Kingsley N. Uzun, Selen B. van de Vijver, Steven Van Dingenen, Rita Van Gool, Coen H. Van Os, Jim Varakin, Yuri Y. Vasankari, Tommi J. Vasconcelos, Ana Maria N. Vavilala, Monica S. Veerman, Lennert J. Velasquez-Melendez, Gustavo Venketasubramanian, N. Vijayakumar, Lakshmi Villalpando, Salvador Violante, Francesco S. Vlassov, Vasiliy Victorovich Vollset, Stein Emil Wagner, Gregory R. Waller, Stephen G. Wallin, Mitchell T. Wan, Xia Wang, Haidong Wang, JianLi Wang, Linhong Wang, Wenzhi Wang, Yanping Warouw, Tati S. Watts, Charlotte H. Weichenthal, Scott Weiderpass, Elisabete Weintraub, Robert G. Werdecker, Andrea Wessells, K. Ryan Westerman, Ronny Whiteford, Harvey A. Wilkinson, James D. Williams, Hywel C. Williams, Thomas N. Woldeyohannes, Solomon M. Wolfe, Charles D. A. Wong, John Q. Woolf, Anthony D. Wright, Jonathan L. Wurtz, Brittany Xu, Gelin Yan, Lijing L. Yang, Gonghuan Yano, Yuichiro Ye, Pengpeng Yenesew, Muluken Yentuer, Goekalp K. Yip, Paul Yonemoto, Naohiro Yoon, Seok-Jun Younis, Mustafa Z. Younoussi, Zourkaleini Yu, Chuanhua Zaki, Maysaa E. Zhao, Yong Zheng, Yingfeng Zhou, Maigeng Zhu, Jun Zhu, Shankuan Zou, Xiaonong Zunt, Joseph R. Lopez, Alan D. Vos, Theo Murray, Christopher J. CA GBD 2013 Risk Factors TI Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 SO LANCET LA English DT Article ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; CAUSE-SPECIFIC MORTALITY; FINE PARTICULATE MATTER; OUTDOOR AIR-POLLUTION; MALE BRITISH DOCTORS; ALL-CAUSE MORTALITY; LONG-TERM EXPOSURE; BLOOD-PRESSURE; TOBACCO SMOKING AB Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2010 methods. Risk-outcome pairs meeting explicit evidence criteria were assessed for 188 countries for the period 1990-2013 by age and sex using three inputs: risk exposure, relative risks, and the theoretical minimum risk exposure level (TMREL). Risks are organised into a hierarchy with blocks of behavioural, environmental and occupational, and metabolic risks at the first level of the hierarchy. The next level in the hierarchy includes nine clusters of related risks and two individual risks, with more detail provided at levels 3 and 4 of the hierarchy. Compared with GBD 2010, six new risk factors have been added: handwashing practices, occupational exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration rate. For most risks, data for exposure were synthesised with a Bayesian meta-regression method, DisMod-MR 2.0, or spatial-temporal Gaussian process regression. Relative risks were based on meta-regressions of published cohort and intervention studies. Attributable burden for clusters of risks and all risks combined took into account evidence on the mediation of some risks such as high body-mass index (BMI) through other risks such as high systolic blood pressure and high cholesterol. Findings All risks combined account for 57.2% (95% uncertainty interval [UI] 55.8-58.5) of deaths and 41.6% (40.1-43.0) of DALYs. Risks quantified account for 87.9% (86.5-89.3) of cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected tropical diseases and malaria. In terms of global DALYs in 2013, six risks or clusters of risks each caused more than 5% of DALYs: dietary risks accounting for 11.3 million deaths and 241.4 million DALYs, high systolic blood pressure for 10.4 million deaths and 208.1 million DALYs, child and maternal malnutrition for 1.7 million deaths and 176.9 million DALYs, tobacco smoke for 6.1 million deaths and 143.5 million DALYs, air pollution for 5.5 million deaths and 141.5 million DALYs, and high BMI for 4.4 million deaths and 134.0 million DALYs. Risk factor patterns vary across regions and countries and with time. In sub-Saharan Africa, the leading risk factors are child and maternal malnutrition, unsafe sex, and unsafe water, sanitation, and handwashing. In women, in nearly all countries in the Americas, north Africa, and the Middle East, and in many other high-income countries, high BMI is the leading risk factor, with high systolic blood pressure as the leading risk in most of Central and Eastern Europe and south and east Asia. For men, high systolic blood pressure or tobacco use are the leading risks in nearly all high-income countries, in north Africa and the Middle East, Europe, and Asia. For men and women, unsafe sex is the leading risk in a corridor from Kenya to South Africa. Interpretation Behavioural, environmental and occupational, and metabolic risks can explain half of global mortality and more than one-third of global DALYs providing many opportunities for prevention. Of the larger risks, the attributable burden of high BMI has increased in the past 23 years. In view of the prominence of behavioural risk factors, behavioural and social science research on interventions for these risks should be strengthened. Many prevention and primary care policy options are available now to act on key risks. C1 [Forouzanfar, Mohammad H.; Alexander, Lily; Bachman, Victoria F.; Biryukov, Stan; Brauer, Michael; Casey, Daniel; Coates, Matthew M.; Cohen, Aaron; Delwiche, Kristen; Estep, Kara; Frostad, Joseph J.; Kyu, Hmwe H.; Moradi-Lakeh, Maziar; Ng, Marie; Slepak, Erica Leigh; Thomas, Bernadette A.; Wagner, Joseph; Achoki, Tom; Atkinson, Charles; Barber, Ryan M.; Cooperrider, Kimberly; Dandona, Lalit; Dicker, Daniel; Flaxman, Abraham D.; Fleming, Thomas D.; Foreman, Kyle J.; Gakidou, Emmanuela; Hay, Simon I.; Heuton, Kyle R.; Iannarone, Marissa L.; Ku, Tiffany; Larson, Heidi J.; Lim, Stephen S.; Lozano, Rafael; MacIntyre, Michael F.; Margono, Christopher; McLain, Abigail; Mokdad, Ali H.; Mullany, Erin C.; Naghavi, Mohsen; Nguyen, Grant; Pain, Amanda W.; Richardson, Lee; Robinson, Margaret; Sandar, Logan; Stephens, Natalie; Thomson, Blake; Wan, Xia; Wurtz, Brittany; Lopez, Alan D.; Vos, Theo; Murray, Christopher J.] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Ebel, Beth E.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. [Ellenbogen, Richard G.] Univ Washington, Harborview UW Med, Seattle, WA 98195 USA. [Wright, Jonathan L.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Alfonso-Cristancho, Rafael; Anderson, Benjamin O.; Jensen, Paul N.; Quistberg, D. Alex A.; Riederer, Anne; Vavilala, Monica S.; Zunt, Joseph R.] Univ Washington, Seattle, WA 98195 USA. [Anderson, H. Ross] Univ London, St Georges, London, England. [Pourmalek, Farshad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Brauer, Michael; Gotay, Carolyn C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Burnett, Richard; Shin, Hwashin H.; Weichenthal, Scott] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Moradi-Lakeh, Maziar] Iran Univ Med Sci, Dept Community Med, Tehran, Iran. [Knudsen, Ann Kristin] Norwegian Inst Publ Hlth, Dept Hlth Registries, Oslo, Norway. [Aasvang, Gunn Marit; Kinge, Jonas M.; Skirbekk, Vegard; Vollset, Stein Emil] Norwegian Inst Publ Hlth, Oslo, Norway. [Abbafati, Cristiana] Univ Roma La Sapienza, I-00185 Rome, Italy. [Ozgoren, Ayse Abbasoglu; Cavlin, Alanur] Hacettepe Univ, Inst Populat Studies, Ankara, Turkey. [Bicer, Burcu Kucuk] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey. [Abd-Allah, Foad] Cairo Univ, Fac Med, Cairo, Egypt. [Abera, Semaw F.] Mekelle Univ, Sch Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia. [Melaku, Yohannes A.] Mekelle Univ, Mekelle, Ethiopia. [Abera, Semaw F.] Kilte Awlaelo Hlth & Demog Surveillance Site, Mekelle, Ethiopia. [Aboyans, Victor] Dupuytren Univ Hosp, Limoges, France. [Abraham, Biju] Govt Coll Munnar, Munnar, India. [Abraham, Jerry Puthenpurakal] Univ So Calif, Calif Hosp, Family Med Residency Program, Los Angeles, CA USA. [Abraham, Jerry Puthenpurakal] Harvard Univ, Inst Global Hlth, Boston, MA 02115 USA. [Thorne-Lyman, Andrew L.] Harvard Univ, Dept Nutr, Boston, MA 02115 USA. [Ding, Eric L.; Fahimi, Saman; Khatibzadeh, Shahab; Wagner, Gregory R.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Bukhman, Gene] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Campos-Nonato, Ismael R.; Feigl, Andrea B.; Salomon, Joshua A.] Harvard Univ, Boston, MA 02115 USA. [Benzian, Habib] UCL, Dept Epidemiol & Publ Hlth, London, England. [Abubakar, Ibrahim] UCL, London, England. [Abu-Rmeileh, Niveen M. E.] Birzeit Univ, Inst Community & Publ Hlth, Ramallah, Pakistan. [Aburto, Tania C.; Avila, Marco A.; Barquera, Simon; Barrientos-Gutierrez, Tonatiuh; Campos-Nonato, Ismael R.; Campuzano, Julio C.; Cantoral, Alejandra J.; Contreras, Alejandra G.; Cuevas-Nasu, Lucia; De la Cruz-Gongora, Vanessa; Garcia-Guerra, Francisco A.; Dantes, Hector Gomez; de Cosio, Teresita Gonzalez; Gonzalez-Castell, Dinorah; Heredia-Pi, Ileana B.; Hernandez, Lucia; Jauregui, Alejandra; Lozano, Rafael; Medina, Catalina; Mejia-Rodriguez, Fabiola; Hernandez, Julio C. Montaez; Pedraza, Lilia S.; Pedroza, Andrea; Quezada, Amado D.; Salvo, Deborah; Sanchez, Luz Maria; Sanchez-Pimienta, Tania G.; Servan-Mori, Edson E.; Levy, Teresa Shamah; Rojo, Martha M. Tellez; Villalpando, Salvador] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Adelekan, Ademola] Publ Hlth Promot Alliance, Osogbo, Nigeria. [Adofo, Koranteng] Kwame Nkrumah Univ Sci, Kumasi, Ghana. [Adou, Arsene K.] Assoc Ivoirienne Bien Etre Familial, Abidjan, Cote Ivoire. [Adsuar, Jose C.; Paleo, Urbano Fra] Univ Extremadura, Caceres, Spain. [Afshin, Ashkan; Micha, Renata; Arian, Dariush Mozaff] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USA. [Shahraz, Saeid; Shangguan, Siyi] Tufts Univ, Tufts Med Ctr, Boston, MA USA. [Agardh, Emilie E.] Inst Publ Hlth Sci, Stockholm, Sweden. [Al Khabouri, Mazin J.] Minist Hlth, Muscat, Oman. [Al Lami, Faris H.] Baghdad Coll Med, Baghdad, Iraq. [Alam, Sayed Saidul; Naheed, Aliya] icddr b, Dhaka, Bangladesh. [Alasfoor, Deena] Minist Hlth, Al Khuwair, Oman. [Albittar, Mohammed I.] Independent, Damascus, Syria. [Alegretti, Miguel A.] Univ Republica, Dept Prevent & Social Med, Montevideo, Uruguay. [Cavalleri, Fiorella] Univ Republica, Fac Med, Montevideo, Uruguay. [Alemu, Zewdie A.] Debre Markos Univ, Addis Ababa, Ethiopia. [Alhabib, Samia] King Abdullah Bin Abdulaziz Univ Hosp, Riyadh, Saudi Arabia. [Chen, Zhengming] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England. [Gething, Pete] Univ Oxford, Dept Zool, Oxford, England. [Ali, Raghib; Bennett, Derrick A.; Briggs, Adam D. M.; Hay, Simon I.; Rahimi, Kazem; Scarborough, Peter] Univ Oxford, Oxford, England. [Singh, Gitanjali M.] Tufts Univ, Boston, MA USA. [Aleman, Alicia V.; Colistro, Valentina] Univ Republica, Montevideo, Uruguay. [Simard, Edgar P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA USA. [Ali, Mohammed K.; Cunningham, Solveig Argeseanu; Liu, Yang; Narayan, K. M. Venkat; Omer, Saad B.] Emory Univ, Atlanta, GA USA. [Alla, Francois; Guillemin, Francis] Univ Lorraine, Nancy, France. [Allebeck, Peter; Roy, Nobhojit] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Kivipelto, Miia] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden. [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Fereshtehnejad, Seyed-Mohammad] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Havmoeller, Rasmus; Sindi, Shireen] Karolinska Inst, Stockholm, Sweden. [Allen, Peter J.] Minist Hlth, Belmopan, Belize. [Alsharif, Ubai; Endres, Matthias; Nolte, Sandra; Papachristou, Christina] Charite, Berlin, Germany. [Alvarez, Elena] Govt, Madrid, Spain. [Alvis-Guzman, Nelson; Caicedo, Angel J. Paternina] Univ Cartagena, Cartagena De Indias, Colombia. [Amankwaa, Adansi A.] Albany State Univ, Albany, GA 31705 USA. [Amare, Azmeraw T.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Hoek, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Amare, Azmeraw T.] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia. [Yenesew, Muluken] Bahir Dar Univ, Bahir Dar, Ethiopia. [Ameh, Emmanuel A.] Ahmadu Bello Univ, Zaria, Nigeria. [Ameli, Omid] Boston Univ, Boston, MA USA. [Amini, Heresh] Kurdistan Univ Med Sci, Kurdistan Environm Hlth Res Ctr, Sanandaj, Iran. [Amini, Heresh] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Amini, Heresh] Univ Basel, Basel, Switzerland. [Ammar, Walid; Harb, Hilda L.] Minist Publ Hlth, Beirut, Lebanon. [Faraon, Emerito Jose A.] Univ Philippines Manila, Coll Publ Hlth, Manila, Philippines. [Antonio, Carl Abelardo T.] Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, Philippines. [Panelo, Carlo Irwin A.] Univ Philippines Manila, Manila, Philippines. [Arnlov, Johan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Larsson, Anders] Uppsala Univ, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Falun, Sweden. [Arsenijevic, Valentina S. Arsic] Univ Belgrade, Inst Microbiol & Immunol, Sch Med, Belgrade, Serbia. [Arsenijevic, Valentina S. Arsic] Univ Childrens Hosp Belgrade, Belgrade, Serbia. [Asghar, Rana J.] South Asian Publ Hlth Forum, Islamabad, Pakistan. [Assadi, Reza] Mashhad Univ Med Sci, Mashhad, Iran. [Atkins, Lydia S.] Minist Hlth, Wellness Human Serv & Gender Relat, St Lucia, Qld, Australia. [Awuah, Baffour; Laryea, Dennis O.] Komfo Anokye Teaching Hosp, Kumasi, Ghana. [Badawi, Alaa] Publ Hlth Agcy Canada, Toronto, ON, Canada. [Bahit, Maria C.] INECO Neurociencias, Rosario, Argentina. [Bakfalouni, Talal] Minist Hlth, Damascus, Syria. [Balakrishnan, Kalpana] Sri Ramachandra Univ, Madras, Tamil Nadu, India. [Balalla, Shivanthi; Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand. [Ao, Braden J. Te] Auckland Univ Technol, Auckland, New Zealand. [Balu, Ravi Kumar; Dandona, Lalit; Dandona, Rakhi; Goenka, Shifalika; Kumar, G. Anil; Murthy, Kinnari S.; Reddy, K. Srinath] Publ Hlth Fdn India, Delhi, India. [Banerjee, Amitava] Univ Birmingham, Birmingham, W Midlands, England. [Barker-Collo, Suzanne L.] Univ Auckland, Sch Psychol, Auckland, New Zealand. [del Pozo-Cruz, Borja] Univ Auckland, Auckland, New Zealand. [Barregard, Lars] Univ Gothenburg, Dept Occupat & Environm Hlth, Gothenburg, Sweden. [Barrero, Lope H.] Pontificia Univ Javeriana, Dept Ind Engn, Bogota, Colombia. [Basto-Abreu, Ana C.; Ruvalcaba, Carolina Batis; de Castro, E. Filipa; Lopez, Nancy; Texcalac-Sangrador, Jose Luis] Natl Inst Publ Hlth, Mexico City, DF, Mexico. [Basu, Arindam] Univ Canterbury, Sch Hlth Sci, Christchurch, New Zealand. [Gaffikin, Lynne] Stanford Univ, Sch Med, Stanford, CA USA. [Basu, Sanjay] Stanford Univ, Stanford, CA 94305 USA. [Basulaiman, Mohammed O.; Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia. [Beardsley, Justin] Univ Oxford, Ho Hi Minh City, Vietnam. [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia. [Bekele, Tolesa] Madawalabu Univ, Bale Robe, Ethiopia. [Bell, Michelle L.] Yale Univ, New Haven, CT USA. [Benjet, Corina; Borges, Guilherme; Gutierrez, Reyna A.; Orozco, Ricardo] Natl Inst Psychiat Ramon Fuente Muniz, Mexico City, DF, Mexico. [Benzian, Habib] NYU, Coll Dent, Dept Epidemiol & Hlth Promot, New York, NY 10003 USA. [Trasande, Leonardo] NYU, Sch Med, New York, NY USA. [Hagan, Holly] NYU, New York, NY 10003 USA. [Bernabe, Eduardo; Wolfe, Charles D. A.] Kings Coll London, London, England. [Beyene, Tariku J.] Addis Ababa Univ, Debre Zeyit, Ethiopia. [Bhala, Neeraj] Queen Elizabeth Hosp, Birmingham, W Midlands, England. [Bhala, Neeraj] Univ Otago, Capital & Coast District Hlth Board, Wellington, New Zealand. [Derrett, Sarah] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Wellington, New Zealand. [Bhalla, Ashish; Jha, Vivekanand] Postgrad Inst Med Educ & Res, Chandigarh, India. [Bhutta, Zulfi Qar A.] Aga Khan Univ, Med Ctr, Karachi, Pakistan. [Nisar, Muhammad I.] Aga Khan Univ, Karachi, Pakistan. [Bikbov, Boris] AI Evdokimov Moscow State Univ Med & Dent, Moscow, Russia. [Bikbov, Boris] Acad VI Shumakov Fed Res Ctr Transplantol & Artif, Moscow, Russia. [Bin Abdulhak, Aref A.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Vijayakumar, Lakshmi] Univ Melbourne, Ctr Youth Mental Hlth, Melbourne, Vic, Australia. [Chiang, Peggy P.] Univ Melbourne, Gen Practice & Primary Hlth Care Acad Ctr, Melbourne, Vic, Australia. [Blore, Jed D.; Brooks, Peter M.; Colquhoun, Samantha M.; Balaji, Arjun Lakshmana; Weintraub, Robert G.; Lopez, Alan D.] Univ Melbourne, Melbourne, Vic, Australia. [Blyth, Fiona M.] Univ Sydney, Concord, NSW, Australia. [Meretoja, Atte] Univ Melbourne, Dept Florey, Parkville, Vic, Australia. [Meretoja, Atte] Univ Melbourne, Dept Med, Parkville, Vic, Australia. [Bohensky, Megan A.] Univ Melbourne, Parkville, Vic, Australia. [Basara, Berrak Bora; Yentuer, Goekalp K.] Minist Hlth, Gen Directorate Hlth Res, Ankara, Turkey. [Kose, M. Rifat; Pekericli, Ayfer; Uzun, Selen B.] Minist Hlth, Ankara, Turkey. [Bornstein, Natan M.] Tel Aviv Saurasky Med Ctr, Tel Aviv, Israel. [Bose, Dipan] World Bank, Washington, DC USA. [Boufous, Soufiane] Univ New S Wales, Transport & Rd Safety, Sydney, NSW, Australia. [Degenhardt, Louisa] Univ New S Wales, Sydney, NSW, Australia. [Bourne, Rupert R.] Anglia Ruskin Univ, Cambridge, England. [Brainin, Michael] Danube Univ Krems, Krems, Austria. [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Fac Hlth Sci & Social Work, Trnava, Slovakia. [Breitborde, Nicholas J.] Ohio State Univ, Columbus, OH USA. [Breitborde, Nicholas J.] Univ Arizona, Tucson, AZ USA. [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, Heidelberg, Germany. [Broday, David M.] Technion, Haifa, Israel. [Lunevicius, Raimundas] Univ Liverpool, Sch Med, Liverpool, Merseyside, England. [Bruce, Nigel G.; Dherani, Mukesh K.; Pope, Daniel] Univ Liverpool, Liverpool, Merseyside, England. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Brunekreef, Bert; Kromhout, Hans] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands. [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia. [Gabbe, Belinda; Gibney, Katherine B.; Thrift, Amanda G.] Monash Univ, Melbourne, Vic, Australia. [Bui, Linh N.; Nguyen, Nhung T.] Hanoi Sch Publ Hlth, Hanoi, Vietnam. [Bulloch, Andrew G.; Patten, Scott B.; Tonelli, Marcello; Wang, JianLi] Univ Calgary, Calgary, AB, Canada. [Burch, Michael] Great Ormond St Hosp Sick Children, London, England. [Burney, Peter G. J.; Foreman, Kyle J.; Jarvis, Deborah L.; Rodriguez, Alina; Rushton, Lesley; Soljak, Michael; Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, London, England. [Caravanos, Jack; Nash, Denis] CUNY, Sch Publ Hlth, New York, NY USA. [Cardenas, Rosario] Univ Autonoma Metropolitana, Mexico City, DF, Mexico. [Cardis, Elisabeth; Nieuwenhuijsen, Mark J.; Rojas-Rueda, David] Ctr Res Environm Epidemiol, Barcelona, Spain. [Carpenter, David O.; Leung, Ricky] SUNY Albany, Rensselaer, NY USA. [Caso, Valeria] Univ Perugia, Stroke Unit, Perugia, Italy. [Castaneda-Orjuela, Carlos A.] Colombian Natl Hlth Observ, Inst Nacl Salud, Bogota, Colombia. [Castaneda-Orjuela, Carlos A.] Univ Nacl Colombia, Dept Publ Hlth, Epidemiol & Publ Hlth Evaluat Grp, Bogota, Colombia. [Castro, Ruben E.] Univ Diego Portales, Santiago, Chile. [Catala-Lopez, Ferran] Spanish Med & Healthcare Prod Agcy, Minist Hlth, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain. [Catala-Lopez, Ferran] Univ Valencia, Dept Med, CIBERSAM, Valencia, Spain. [Chadha, Vineet K.] Natl TB Inst, Bangalore, Karnataka, India. [Chang, Jung-chen] Natl Taiwan Univ, Taipei, Taiwan. [Scott, James G.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia. [Hoy, Damian G.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Knibbs, Luke D.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia. [Charlson, Fiona J.; Erskine, Holly E.; Ferrari, Alize J.; Gouda, Hebe N.; Veerman, Lennert J.; Whiteford, Harvey A.] Univ Queensland, Brisbane, Qld, Australia. [Chen, Wanqing; Zou, Xiaonong] Chinese Acad Med Sci, Canc Inst, Beijing, Peoples R China. [Wan, Xia] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China. [Chen, Honglei; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA. [Jiang, Ying] Univ Occupat & Environm Hlth, Dept Hlth Dev, Kitakyushu, Fukuoka 807, Japan. [Takahashi, Ken] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka 807, Japan. [Chimed-Ochir, Odgerel] Univ Occupat & Environm Hlth, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Chowdhury, Rajiv; Powles, John] Univ Cambridge, Cambridge, England. [Christophi, Costas A.] Cyprus Univ Technol, Limassol, Cyprus. [Chuang, Ting-Wu] Taipei Med Univ, Taipei, Taiwan. [Chugh, Sumeet S.] Cedars Sinai Med Ctr, Los Angeles, CA USA. [Cirillo, Massimo] Univ Salerno, Baronissi, Italy. [Classen, Thomas K. D.] Univ Bielefeld, Dept Environm & Hlth, Bielefeld, Germany. [Kraemer, Alexander; Tobollik, Myriam] Univ Bielefeld, Sch Publ Hlth, Bielefeld, Germany. [Colomar, Mercedes] UNICEM, Montevideo, Uruguay. [Colquhoun, Samantha M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England. [Cooper, Leslie T.] Mayo Clin, Rochester, MN USA. [Coresh, Josef; Matsushita, Kunihiro] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Tran, Bach X.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Courville, Karen J.] Hosp Dr Gustavo N Collado, Chitre, Panama. [Criqui, Michael H.; Stein, Murray B.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Damsere-Derry, James] Bldg & Rd Res Inst, Kumasi, Ghana. [Danawi, Hadi; Refaat, Amany H.] Walden Univ, Minneapolis, MN USA. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Davis, Adrian; Fay, Derek F. J.; Schmidt, Juergen C.] Publ Hlth England, London, England. [Davitoiu, Dragos V.] Univ Med & Pharm Bucharest, Bucharest, Romania. [Dayama, Anand] Jacobi Med Ctr, Dept Surg, Atlanta, GA USA. [De Leo, Diego] Griffith Univ, Brisbane, Qld, Australia. [de Lima, Graca] Local Hlth Unit Matosinhos, Matosinhos, Portugal. [de Lima, Graca; Machado, Vasco M. P.] Northern Reg Hlth Adm, Dept Publ Hlth, Oporto, Portugal. [Nogueira, Jose R.; Teixeira, Carolina M.] Northern Reg Hlth Adm, Oporto, Portugal. [Dellavalle, Robert P.] Eastern Colorado Healthcare Syst, US Dept Vet Affairs, Denver, CO USA. [Deribe, Kebede] Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Deribe, Kebede] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia. [Mekonnen, Wubegzier] Univ Addis Ababa, Addis Ababa, Ethiopia. [Derrett, Sarah] Massey Univ, Coll Hlth, Sch Publ Hlth, Palmerston North, New Zealand. [Jarlais, Don C. Des] Mt Sinai Beth Israel, New York, NY USA. [Jarlais, Don C. Des] Icahn Sch Med Mt Sinai, New York, NY USA. [Dessalegn, Muluken] Africa Med & Res Fdn Ethiopia, Addis Ababa, Ethiopia. [deVeber, Gabrielle A.] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada. [Lindsay, M. Patrice] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Hu, Howard] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Devries, Karen M.; Larson, Heidi J.; Mckee, Martin; Pearce, Neil; Stoeckl, Heidi; Tillmann, Taavi; Watts, Charlotte H.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Dokova, Klara] Med Univ Varna, Fac Publ Hlth, Dept Social Med, Varna, Bulgaria. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Rochester, NY USA. [Driscoll, Tim R.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia. [Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia. [Leigh, James] Univ Sydney, Sydney, NSW 2006, Australia. [Duan, Leilei; Li, Yichong; Liu, Shiwei; Ma, Jixiang; Wang, Linhong; Ye, Pengpeng; Zhou, Maigeng] Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Durrani, Adnan M.] Natl Inst Hlth, Montgomery Village, MD USA. [Elshrek, Yousef M.] Univ Tripoli, Fac Agr, Dept Food Sci, Tripoli, Libya. [Ermakov, Sergey P.] Russian Acad Sci, Inst Social & Econ Studies Populat, Moscow, Russia. [Ermakov, Sergey P.; Soshnikov, Sergey] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Liang, Xiaofeng] China CDC, Beijing, Peoples R China. [Eshrati, Babak] Arak Univ Med Sci & Hlth Affairs, Arak, Iran. [Farzadfar, Farshad] Univ Tehran Med Sci, NonCommunicable Dis Res Ctr, Tehran, Iran. [Heydarpour, Pouria; Sahraian, Mohammad Ali] Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Neurosci Inst, Tehran, Iran. [Sepanlou, Sadaf G.] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran. [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran. [Ferri, Cleusa P.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Foigt, Nataliya] Acad Med Sci, Inst Gerontol, Kiev, Ukraine. [Franklin, Richard C.] James Cook Univ, Townsville, Qld, Australia. [Gamkrelidze, Amiran; Khonelidze, Irma; Sturua, Lela] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Gankpe, Fortune G.] Leras Afrique, Cotonou, Benin. [Gankpe, Fortune G.] CHU Hassan II, Fes, Morocco. [Gasana, Evariste] Rwanda Biomed Ctr, TB & Other Respir Dis Div, Kigali, Rwanda. [Sabin, Nsanzimana] Rwanda Biomed Ctr, Kigali, Rwanda. [Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Gibney, Katherine B.] Melbourne Hlth, Parkville, Vic, Australia. [Gillum, Richard F.] Howard Univ, Washington, DC USA. [Ginawi, Ibrahim A. M.] Univ Hail, Coll Med, Hailsham, E Sussex, England. [Giroud, Maurice] Univ Hosp Dijon, Dijon, France. [Giussani, Giorgia] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy. [Goginashvili, Ketevan] Minist Labour Hlth & Social Affairs, Tbilisi, Rep of Georgia. [Esteghamati, Alireza; Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Tehran, Iran. [Gona, Philimon] Univ Massachusetts Boston, Boston, MA USA. [Goto, Atsushi] Tokyo Womens Med Univ, Dept Publ Hlth, Tokyo, Japan. [Guerrant, Richard L.] Univ Virginia, Sch Med, Charlottesville, VA USA. [Terkawi, Abdullah S.] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA. [Gugnani, Harish C.] St James Sch Med, Kralendijk, Netherlands. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Gupta, Rahul] West Virginia Bur Publ Hlth, Charleston, WV USA. [Gupta, Rajeev] Fortis Escorts Hosp, Jaipur, Rajasthan, India. [Hagstromer, Maria] Karolinska Inst, Huddinge, Sweden. [Halasa, Yara A.; Idrisov, Bulat T.] Brandeis Univ, Waltham, MA USA. [Hamadeh, Randah R.] Arabian Gulf Univ, Manama, Bahrain. [Hammami, Mouhanad] Wayne Cty Dept Hlth & Human Serv, Detroit, MI USA. [Hankey, Graeme J.] Univ Western Australia, Perth, WA, Australia. [Hao, Yuantao] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China. [Zheng, Yingfeng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China. [Haregu, Tilahun Nigatu; van de Vijver, Steven] African Populat & Hlth Res Ctr, Nairobi, Kenya. [Haro, Josep Maria] CIBERSAM, Parc Sanitari St Joan de Deu, Sant Boi De Llobregat, Spain. [Haro, Josep Maria] Univ Barcelona, Barcelona, Spain. [Hedayati, Mohammad T.] Mazandaran Univ Med Sci, Sari, Mazandaran, Iran. [Hijar, Martha] Fdn Entornos AC, Cuernavaca, Morelos, Mexico. [Hoek, Hans W.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Man, Howard J. Hoff] Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, NIH, Bethesda, MD USA. [Mensah, George A.] NIH, Ctr Translat Res & Implementat Sci, Bethesda, MD USA. [Sampson, Uchechukwu K.] NIH, NHLBI, Bethesda, MD USA. [Hornberger, John C.] Cedar Associates, Menlo Pk, CA USA. [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY USA. [Hsairi, Mohamed] Natl Inst Publ Hlth, Tunis, Tunisia. [Hoy, Damian G.] Secretariat Pacific Community, Publ Hlth Div, Noumea, New Caledonia. [Hu, Guoqing] Cent S Univ, Changsha, Peoples R China. [Huang, Cheng] George Washington Univ, Washington, DC USA. [Hubbell, Bryan J.] US EPA, Res Triangle Pk, NC USA. [Huiart, Laetitia; Racape, Lionel] CHU La Reunion, Saint Denis, France. [Husseini, Abdullatif] Qatar Univ, Doha, Qatar. [Iburg, Kim M.] Aarhus Univ, Aarhus, Denmark. [Ikeda, Nayu] Natl Inst Hlth Nutr, Tokyo, Japan. [Innos, Kaire] Natl Inst Hlth Dev, Tallinn, Estonia. [Inoue, Manami] Univ Tokyo, Grad Sch Med, Tokyo, Japan. [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan. [Shibuya, Kenji] Univ Tokyo, Tokyo, Japan. [Islami, Farhad] Amer Canc Soc, New York, NY USA. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA USA. [Jansen, Henrica A.] UNFPA Asia & Pacific Reg Off, Bangkok, Thailand. [Jassal, Simerjot K.] Univ Calif San Diego, San Diego, CA USA. [Jayaraman, Sudha] Virginia Commonwealth Univ, Richmond, VA USA. [Jeemon, Panniyammakal; Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India. [Jiang, Fan] Shanghai Childrens Med Ctr, Tianjin, Peoples R China. [Jiang, Guohong] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany. [Juel, Knud] Natl Inst Publ Hlth, Copenhagen, Denmark. [She, Jun] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China. [Kan, Haidong] Fudan Univ, Shanghai, Peoples R China. [Roseline, Sidibe S. Kany] MARIKANI, Bamako, Mali. [Karam, Nadim E.] Univ Balamand, Beirut, Lebanon. [Karch, Andre] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany. [Karch, Andre] German Ctr Infect Res, Hannover Braunschweig Site, Braunschweig, Germany. [Karema, Corine K.] Minist Hlth, Malaria & Other Parasit Dis Div, Kigali City, Rwanda. [Karthikeyan, Ganesan; Paul, Vinod K.; Satpathy, Maheswar; Tandon, Nikhil] All India Inst Med Sci, New Delhi, India. [Kaul, Anil] Oklahoma State Univ, Tulsa, OK USA. [Kazi, Dhruv S.] Univ Calif San Francisco, San Francisco, CA USA. [Kemp, Andrew H.; Lotufo, Paulo A.; Polanczyk, Guilherme V.; Santos, Itamar S.] Univ Sao Paulo, Sao Paulo, Brazil. [Kemp, Andrew H.] Univ Sydney, Camperdown, NSW, Australia. [Kengne, Andre P.; Matzopoulos, Richard; Parry, Charles D.] South African Med Res Council, Cape Town, South Africa. [Sliwa, Karen] Univ Cape Town, Fac Hlth Sci, Hatter Inst Cardiovasc Res Africa, Cape Town, South Africa. [Matzopoulos, Richard] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa. [Kengne, Andre P.; Mayosi, Bongani M.; Stein, Dan J.] Univ Cape Town, Cape Town, South Africa. [Keren, Andre] Hadassah Kerem Univ Hosp, Cardiol, Jerusalem, Israel. [Khader, Yousef S.] Jordan Univ Sci & Technol, Irbid, Jordan. [Khalifa, Shams Eldin Ali Hassan] Supreme Council Hlth, Doha, Qatar. [Khan, Ejaz A.] Hlth Serv Acad, Islamabad, Pakistan. [Khan, Ejaz A.] Expanded Programme Immunizat, Islamabad, Pakistan. [Khang, Young-Ho] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Kieling, Christian] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Kim, Daniel] Northeastern Univ, Boston, MA USA. [Kim, Sungroul] Soonchunhyang Univ, Seoul, South Korea. [Kim, Yunjin] Southern Univ Coll, Johor Baharu, Malaysia. [Kimokoti, Ruth W.] Simmons Coll, Boston, MA USA. [Kinfu, Yohannes] Univ Canberra, Canberra, ACT, Australia. [Kissela, Brett M.] Univ Cincinnati, Cincinnati, OH USA. [Kokubo, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan. [Kosen, Soewarta] Minist Hlth Indonesia, NIHRD, Ctr Community Empowerment Hlth Policy & Human, Jakarta, Indonesia. [Warouw, Tati S.] Minist Hlth Indonesia, NIHRD, Jakarta, Indonesia. [Kravchenko, Michael] Res Ctr Neurol, Moscow, Russia. [Krishnaswami, Sanjay] Oregon Hlth & Sci Univ, Portland, OR USA. [Defo, Barthelemy Kuate] Univ Montreal, Montreal, PQ, Canada. [Kuipers, Ernst J.] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands. [Kulkarni, Chanda] Rajrajeswari Med Coll & Hosp, Bangalore, Karnataka, India. [Kulkarni, Veena S.] Arkansas State Univ, State Univ, AR USA. [Kwan, Gene F.] Boston Med Ctr, Boston, MA USA. [Lai, Taavi] Fourth View Consulting, Tallinn, Estonia. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia. [Lalloo, Ratilal] Univ Adelaide, Sch Dent, Australian Res Ctr Populat Oral Hlth, Adelaide, SA, Australia. [Lallukka, Tea] Finnish Inst Occupat Hlth, Disabil Prevent Res Ctr, Helsinki, Finland. [Shiri, Rahman] Finnish Inst Occupat Hlth, Helsinki, Finland. [Lallukka, Tea] Univ Helsinki, Fac Med, Helsinki, Finland. [Lam, Hilton] NIH, Inst Hlth Policy & Dev Studies, Manila, Philippines. [Lan, Qing] NCI, Rockville, MD USA. [Lansingh, Van C.] Help Me See Inc, New York, NY USA. [Lansingh, Van C.] Inst Mexicano Oftalmol, Queretaro, Mexico. [Lavados, Pablo M.] Univ Desarrollo, Serv Neurol, Clin Alemana, Santiago, Chile. [Lawrynowicz, Alicia E.] Inst Nacl Epidemiol Dr Juan H Jara, Mar Del Plata, Buenos Aires, Argentina. [Leasher, Janet L.] Nova SE Univ, Coll Optometry, Ft Lauderdale, FL USA. [Lee, Jong-Tae; Yoon, Seok-Jun] Korea Univ, Seoul, South Korea. [Levi, Miriam] Tuscany Reg Ctr Occupat Injuries & Dis, Florence, Italy. [Li, Yichong] Anolinx LLC, Salt Lake City, UT USA. [Liang, Juan; Wang, Yanping; Zhu, Jun] Sichuan Univ, West China Univ Hosp 2, Natl Off Maternal & Child Hlth Surveillance, Chengdu, Peoples R China. [Lindsay, M. Patrice] Heart & Stroke Fdn Canada, Ottawa, ON, Canada. [Lipshultz, Steven E.] Wayne State Univ, Detroit, MI USA. [Lloyd, Belinda K.] Monash Univ, Eastern Hlth Clin Sch, Fitzroy, Vic, Australia. [Lloyd, Belinda K.; Room, Robin] Eastern Hlth, Turning Point Alcohol & Drug Ctr, Fitzroy, Vic, Australia. [Logroscino, Giancarlo] Univ Bari, Bari, Italy. [Lortet-Tieulent, Joannie] Amer Canc Soc, Atlanta, GA USA. [Lunevicius, Raimundas] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England. [Ma, Stefan; Phua, Hwee Pin] Minist Hlth Singapore, Singapore, Singapore. [Ma, Stefan] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore. [Magis-Rodriguez, Carlos] Secretaria Salud Mexico, Ctr Nacl Prevenc & Control VIH SIDA, Mexico City, DF, Mexico. [Mahdi, Abbas A.] King Georges Med Univ, Lucknow, Uttar Pradesh, India. [Malekzadeh, Reza] Shariati Hosp, Digest Dis Reseach Inst, Tehran, Iran. [Malekzadeh, Reza] Shiraz Univ Med Sci, Shiraz, Iran. [Mangalam, Srikanth] Tech Stand & Safety Author, Toronto, ON, Canada. [Masiye, Felix] Univ Zambia, Lusaka, Zambia. [Marape, Marape] Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana. [Marcenes, Wagner] Queen Mary Univ London, London, England. [Meaney, Peter A.] Univ Penn, Pereleman Sch Med, Philadelphia, PA USA. [Martin, Randall V.] Dalhousie Univ, Halifax, NS, Canada. [Marzan, Melvin B.] Univ East Ramon Magsaysay Memorial, Med Ctr, Quezon City, Philippines. [Mashal, Mohammad T.] Minist Publ Hlth, Kabul, Afghanistan. [Mason-Jones, Amanda J.] Univ York, York, N Yorkshire, England. [Mazorodze, Tasara T.] Automot Ind Dev Ctr Eastern Cape, Port Elizabeth, South Africa. [Mckay, Abigail C.] EmergentCorp, Belize City, Belize. [Meaney, Peter A.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Mehndiratta, Man Mohan] Janakpuri Superspecialty Hosp, New Delhi, India. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA USA. [Mendoza, Walter] United Nations Populat Fund, Lima, Peru. [Meretoja, Atte] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland. [Mhimbira, Francis Apolinary] Ifakara Hlth Inst, Bagamoyo, Tanzania. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Miller, Ted R.] Curtin Univ, Ctr Populat Hlth, Perth, WA, Australia. [Mills, Edward J.] Univ Ottawa, Ottawa, ON, Canada. [Margolis, David J.; Silberberg, Donald H.] Univ Penn, Philadelphia, PA USA. [Mishra, Santosh] SNDT Womens Univ, Populat Educ Resource Ctr, Dept Continuing & Adult Educ & Extens, Bombay, Maharashtra, India. [Ibrahim, Norlinah Mohamed] Univ Kebangsaan Malaysia, Med Ctr, Dept Med, Bandar Tun Razak, Malaysia. [Mohammad, Karzan A.] Univ Salahaddin, Erbil, Iraq. [Mola, Glen L.] Univ Papua New Guinea, Boroko, Papua N Guinea. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca] Inst Maternal & Child Hlth, IRCCS Burlo Garofolo, Trieste, Italy. [Moore, Ami R.] Univ N Texas, Denton, TX USA. [Morawska, Lidia] Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, Australia. [Norman, Rosana E.] Queensland Univ Technol, Inst Hlth Biomed Innovat, Brisbane, Qld, Australia. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo, Japan. [Tsilimbaris, Miltiadis] Univ Crete, Dept Med, Iraklion, Greece. [Moschandreas, Joanna] Univ Crete, Iraklion, Greece. [Moturi, Wilkister N.] Egerton Univ, Egerton, Kenya. [Werdecker, Andrea] Competence Ctr Mortal Follow Up German Natl Cohor, Heidelberg, Germany. [Mueller, Ulrich O.; Westerman, Ronny] Fed Inst Populat Res, Wiesbaden, Germany. [Mukaigawara, Mitsuru] Okinawa Chubu Hosp, Okinawa, Japan. [Nahas, Ziad] Amer Univ Beirut, Med Ctr, Beirut, Lebanon. [Naidoo, Kovin S.] Univ KwaZulu Natal, Durban, South Africa. [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Nand, Devina] Minist Hlth Fiji, Suva, Fiji. [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India. [Neal, Bruce] George Inst Global Hlth, Sydney, NSW, Australia. [Nejjari, Chakib] Fac Med, Fes, Morocco. [Neupane, Sudan P.] Univ Oslo, Oslo, Norway. [Ngalesoni, Frida N.] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Ngirabega, Jean de Dieu] East African Community Hlth Res Commiss, Kigali, Rwanda. [Nolla, Joan M.] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain. [Nolte, Sandra] Deakin Univ, Melbourne, Vic, Australia. [Vollset, Stein Emil] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway. [Norheim, Ole F.] Univ Bergen, Bergen, Norway. [Norrving, Bo] Lund Univ, Dept Clin Sci, Lund, Sweden. [Nyakarahuka, Luke] Makerere Univ, Kampala, Uganda. [Oh, In-Hwan] Kyung Hee Univ, Seoul, South Korea. [Ohkubo, Takayoshi] Teikyo Univ, Sch Med, Tokyo, Japan. [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Ikoyi, Nigeria. [Opio, John Nelson] Lira Municipal Council, Lira Dist Local Govt, Lira, Uganda. [Pagcatipunan, Rodolfo S., Jr.] United Lab Inc, Mandaluyong City, Philippines. [Pandian, Jeyaraj D.] Christian Med Coll Ludhiana, Ludhiana, Punjab, India. [Park, Eun-Kee] Kosin Univ, Coll Med, Busan, South Korea. [Stein, Dan J.] South African Med Res Council, Unit Anxiety & Stress Disorders, Cape Town, South Africa. [Parry, Charles D.] South African Med Res Council, Cape Town, South Africa. [Parry, Charles D.; Seedat, Soraya] Univ Stellenbosch, Cape Town, South Africa. [Stokic, Ljiljana Pejin] Econ Inst, Belgrade, Serbia. [Pereira, David M.] Univ Porto, REQUIMTE, Fac Farm, Dept Quim,Lab Farmacognosia, Oporto, Portugal. [Perez-Padilla, Rogelio] Natl Inst Resp Dis, Mexico City, DF, Mexico. [Perez-Ruiz, Fernando] Hosp Univ Cruces, OSI EE Cruces, Baracaldo, Spain. [Perez-Ruiz, Fernando] Biocruces Hlth Res Inst, Baracaldo, Spain. [Perico, Norberto; Remuzzi, Giuseppe; Trillini, Matias] IRCCS Mario Negri Inst Pharmacol Res, Bergamo, Italy. [Perry, Samuel A. L.] Washington State Dept Hlth, Kent, WA USA. [Pervaiz, Aslam] Postgrad Med Inst, Lahore, Pakistan. [Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA, Australia. [Peterson, Carrie B.] Aalborg Univ, Aalborg Esst, Denmark. [Petzold, Max] Hlth Metr Unit, Gothenburg, Sweden. [Petzold, Max] Univ Witwatersrand, Johannesburg, South Africa. [Phillips, Michael R.] Emory Univ, Atlanta, GA USA. [Plass, Dietrich] Fed Environm Agcy, Sect Exposure Assessment & Environm Hlth Indicato, Berlin, Germany. [Poenaru, Dan] McGill Univ, Montreal Childrens Hosp, Montreal, PQ, Canada. [Poenaru, Dan] MyungSung Med Coll, Addis Ababa, Ethiopia. [Pond, Constance D.] Univ Newcastle, Callaghan, NSW 2308, Australia. [Pope, C. Arden] Brigham Young Univ, Provo, UT USA. [Popova, Svetlana; Rehm, Juergen] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Prasad, Noela M.] Fred Hollows Fdn, Sydney, NSW, Australia. [Qato, Dima M.] Univ Illinois, Coll Pharm, Chicago, IL USA. [Rafay, Anwar; Rana, Saleem M.] Contech Int Hlth Consultants, Lahore, Pakistan. [Rafay, Anwar; Rana, Saleem M.] Contech Sch Publ Hlth, Lahore, Pakistan. [Rahman, Sajjad Ur] Hamad Med Corp, Doha, Qatar. [Raju, Murugesan] Univ Missouri, Columbia, MO USA. [Rakovac, Ivo] WHO Reg Off Europe, Copenhagen, Denmark. [Rao, Mayuree] Brown Univ, Warren Alpert Med Sch, Providence, RI USA. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Refaat, Amany H.] Suez Canal Univ, Ismailia, Egypt. [Ribeiro, Antonio L.] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil. [Velasquez-Melendez, Gustavo] Univ Fed Minas Gerais, Escola Enfermagem, Belo Horizonte, MG, Brazil. [Riccio, Patricia M.; Sposato, Luciano A.] Univ Western Ontario, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON, Canada. [Riederer, Anne] George Washington Univ, Washington, DC USA. [Roca, Anna] MRC Unit, Fajara, Gambia. [Rodriguez, Alina] Mid Sweden Univ, Stersund, Sweden. [Romieu, Isabelle; Straif, Kurt] WHO, IARC, Lyon, France. [Roy, Nobhojit] HBNI Univ, BARC Hosp, Bombay, Maharashtra, India. [Ruhago, George M.; Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Miami, FL USA. [Saha, Sukanta] Pk Ctr Mental Hlth, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Sahathevan, Ramesh] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia. [Sahathevan, Ramesh] Calvary Healthcare Bruce, Canberra, ACT, Australia. [Sanabria, Juan R.] Case Western Reserve Univ, Cleveland, OH USA. [Sanabria, Juan R.] RFU Chicago Med Sch, Canc Treatment Ctr Amer, N Chicago, IL USA. [Sanchez-Riera, Lidia] Univ Zurich, Ctr Ageing & Mobil, Zurich, Switzerland. [Sanchez-Riera, Lidia] City Hosp Waid, Zurich, Switzerland. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, College Pk, MD USA. [Saunders, James E.] Dartmouth Coll, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. [Soneji, Samir] Dartmouth Coll, Lebanon, NH USA. [Sawhney, Monika] Marshall Univ, Huntington, WV USA. [Saylan, Mete I.] Novartis Turkey, Istanbul, Turkey. [Schneider, Ione J. C.] Univ Fed Santa Catarina, Florianopolis, SC, Brazil. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Serdar, Berrin] Univ Colorado, Aurora, CO USA. [Shaddick, Gavin] Univ Bath, Bath BA2 7AY, Avon, England. [Shangguan, Siyi] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan. [Shiri, Rahman] Univ Tampere, Sch Hlth Sci, Tampere, Finland. [Shishani, Kawkab] Washington State Univ, Spokane, WA USA. [Shiue, Ivy] Northumbria Univ, Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England. [Shiue, Ivy] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland. [Sigfusdottir, Inga D.] Reykjavik Univ, Reykjavik, Iceland. [Singh, Abhishek] Int Inst Populat Sci, Bombay, Maharashtra, India. [Soreide, Kjetil] Stavanger Univ Hosp, Stavanger, Norway. [Sreeramareddy, Chandrashekhar T.] Univ Tunku Abdul Rahman, Fac Med & Hlth Sci, Kajang, Cheras, Malaysia. [Stapelberg, Nicolas J. C.] Griffith Univ, Southport, Qld, Australia. [Stathopoulou, Vasiliki] Attikon Univ Hosp, Athens, Greece. [Steckling, Nadine] Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany. [Stroumpoulis, Konstantinos] Alexandra Gen Hosp Athens, Athens, Greece. [Stroumpoulis, Konstantinos] Ctr Hosp Publ Cotentin, Cherbourg, France. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Swaroop, Mamta; Yano, Yuichiro] Northwestern Univ, Chicago, IL USA. [Sykes, Bryan L.] Univ Calif Irvine, Irvine, CA USA. [Tabb, Karen M.] Univ Illinois, Champaign, IL USA. [Talongwa, Roberto T.] Minist Hlth, MINSANTE, Yaounde, Cameroon. [Tanne, David] Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Tanne, David] Tel Aviv Univ, Tel Hashomer, Israel. [Tavakkoli, Mohammad] Westchester Med Ctr, Valhalla, NY USA. [Terkawi, Abdullah S.] Outcomes Res Consortium, Cleveland, OH USA. [Terkawi, Abdullah S.] King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi Arabia. [Thackway, Sarah V.] New South Wales Hlth, Sydney, NSW, Australia. [Thurston, George D.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA. [Topouzis, Fotis] Aristotle Univ Thessaloniki, Thessaloniki, Greece. [Towbin, Jeff Rey A.] Bonheur Childrens Hosp, Memphis, TN USA. [Towbin, Jeff Rey A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN USA. [Toyoshima, Hideaki] Anjo Kosei Hosp, Hlth Care Ctr, Anjo City, Japan. [Traebert, Jeff Erson] Univ Southern Santa Catarina, Palhoca, Brazil. [Tran, Bach X.] Hanoi Med Univ, Hanoi, Vietnam. [Trujillo, Ulises] Serv Canario Salud, Tenerife, Spain. [Dimbuene, Zacharie Tsala] Univ Kinshasa, Fac Econ & Management, Dept Populat Sci & Dev, Kinshasa, Zaire. [Tuzcu, Emin Murat] Cleveland Clin, Cleveland, OH USA. [Uchendu, Uche S.] Dept Vet Affairs, Washington, DC USA. [Ukwaja, Kingsley N.] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria. [Van Dingenen, Rita] European Commiss, Joint Res Ctr, Ispra, Italy. [Van Gool, Coen H.] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands. [Van Os, Jim] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Vasankari, Tommi J.] UKK Inst Hlth Promot Res, Tampere, Finland. [Vasconcelos, Ana Maria N.] Univ Brasilia, Brasilia, DF, Brazil. [Vijayakumar, Lakshmi] VHS SNEHA, Madras, Tamil Nadu, India. [Violante, Francesco S.] Univ Bologna, Bologna, Italy. [Vlassov, Vasiliy Victorovich] Higher Sch Econ, Moscow, Russia. [Wagner, Gregory R.] Natl Inst Occupat Safety & Hlth, Washington, DC USA. [Waller, Stephen G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA. [Wallin, Mitchell T.] Georgetown Univ, Dept Neurol, Arlington, VA USA. [Wallin, Mitchell T.] VA Med Ctr, Washington, DC USA. [Wang, Wenzhi] Beijing Neurosurg Inst, Beijing, Peoples R China. [Weintraub, Robert G.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Wessells, K. Ryan] Univ Calif Davis, Davis, CA USA. [Westerman, Ronny] German Natl Cohort Consortium, Heidelberg, Germany. [Wilkinson, James D.] Wayne State Univ, Detroit, MI USA. [Williams, Hywel C.] Univ Nottingham, Nottingham, England. [Woldeyohannes, Solomon M.] Univ Gondar, Inst Publ Hlth, Gondar, Ethiopia. [Wong, John Q.] Manila Univ, Ateneo Sch Med & Publ Hlth, Pasig, Philippines. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, Cornwall, England. [Xu, Gelin] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing, Peoples R China. [Yan, Lijing L.] Duke Kunshan Univ, Kunshan, Peoples R China. [Yang, Gonghuan] Peking Union Med Coll, Beijing, Peoples R China. [Yano, Yuichiro] Jichi Med Sch, Tochigi, Japan. [Yip, Paul] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Yonemoto, Naohiro] Natl Ctr Neurol & Psychiat, Kodaira, Tokyo, Japan. [Younis, Mustafa Z.] Jackson State Univ, Jackson, MS USA. [Younoussi, Zourkaleini] Univ Niamey, Niamey, Niger. [Yu, Chuanhua] Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China. [Yu, Chuanhua] Wuhan Univ, Global Hlth Inst, Wuhan, Peoples R China. [Zaki, Maysaa E.] Mansoura Fac Med, Mansoura, Egypt. [Zhao, Yong] Chongqing Med Univ, Chongqing, Peoples R China. [Zhu, Shankuan] Zhejiang Univ, Sch Publ Hlth, Hangzhou, Peoples R China. RP Murray, CJ (reprint author), Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI ; Alsharif, Ubai/C-6527-2017; Amini, Heresh/B-3076-2010; Lotufo, Paulo/A-9843-2008; Karch, Andre/D-6973-2017; Hedayati, Mohammad T./E-2304-2017; Scott, James/D-5900-2012; Franklin, Richard/H-1731-2012; Giussani, Giorgia/E-8057-2017; Ermakov, Sergey/G-1709-2016; Pereira, David/M-9286-2013; NORMAN, ROSANA/F-2774-2010; Kravchenko, Michael/B-2596-2012; Nolte, Sandra/B-7498-2008; Stein, Dan/A-1752-2008; Tonelli, Marcello/B-3028-2009; Lalloo, Ratilal/O-5624-2014; Tillmann, Taavi/R-6026-2016; Salomon, Joshua/D-3898-2009; Beyene, Tariku Jibat/A-6875-2017; Varakin, Yuriy/C-8634-2012; Brenner, Hermann/B-4627-2017; Majdan, Marek/K-5017-2012; Cardis, Elisabeth/C-3904-2017; Nieuwenhuijsen, Mark/C-3914-2017; Ferri, Cleusa/B-2922-2010; Devries, Karen/K-1083-2016; Jacobsen, Kathryn/B-5857-2008; LOGROSCINO, GIANCARLO/K-5148-2016; wang, YA XING/K-9671-2016; Ribeiro, Antonio/C-2707-2009; Hay, Simon/F-8967-2015; Naldi, Luigi/K-6343-2016; Thrift, Amanda/I-6251-2012; Weiderpass, Elisabete/M-4029-2016; Dokova, Klara/N-2448-2016; Montico, Marcella/B-5290-2013; Parry, Charles/A-2906-2009; Haro, Josep Maria/D-1423-2011; Degenhardt, Louisa/D-4515-2012; Martin, Randall/C-1205-2014; Hankey, Graeme /H-4968-2014; Kaul, Anil/B-2075-2016; Rakovac, Ivo/A-7678-2013; Fra.Paleo, Urbano/B-8088-2016; Monasta, Lorenzo/B-1388-2012; Sepanlou, Sadaf/H-9343-2016; Banerjee, Amitava/D-4381-2014; Charlson, Fiona/F-5290-2011; Patten, Scott/B-4434-2011 OI Norheim, Ole F./0000-0002-5748-5956; Hoek, Hans/0000-0001-6353-5465; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Aburto, Tania/0000-0002-6932-9344; Bernabe, Eduardo/0000-0002-1858-3713; Derrett, Sarah/0000-0003-2867-0498; London, Stephanie/0000-0003-4911-5290; Santos, Itamar/0000-0003-3212-8466; Erskine, Holly/0000-0003-3119-9211; Aboyans, Victor/0000-0002-0322-9818; Gouda, Hebe/0000-0002-5709-4509; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; Kissela, Brett/0000-0002-9773-4013; Catala-Lopez, Ferran/0000-0002-3833-9312; Broday, David/0000-0002-6525-3979; Alsharif, Ubai/0000-0002-4024-3950; Amini, Heresh/0000-0002-4825-1322; Lotufo, Paulo/0000-0002-4856-8450; Karch, Andre/0000-0003-3014-8543; Hedayati, Mohammad T./0000-0001-6415-4648; Scott, James/0000-0002-0744-0688; Franklin, Richard/0000-0003-1864-4552; Ermakov, Sergey/0000-0003-1072-1162; Pereira, David/0000-0003-0384-7592; NORMAN, ROSANA/0000-0002-9742-1957; Leung, Ricky/0000-0002-2852-6771; Kieling, Christian/0000-0001-7691-4149; Sindi, Shireen/0000-0002-3786-0552; Gething, Peter/0000-0001-6759-5449; Husseini, Abdullatif/0000-0001-8767-5956; Benjet, Corina/0000-0002-4569-6094; Gabbe, Belinda/0000-0001-7096-7688; Prabhakaran, Dorairaj/0000-0002-3172-834X; Neupane, Sudan Prasad/0000-0002-7389-4178; Khang, Young-Ho/0000-0002-9585-8266; Kemp, Andrew/0000-0003-1146-3791; Xu, Gelin/0000-0002-6194-0341; Goto, Atsushi/0000-0003-0669-654X; Soshnikov, Sergey/0000-0002-6983-7066; assadi, reza/0000-0002-5016-2994; Vlassov, Vasiliy/0000-0001-5203-549X; Soreide, Kjetil/0000-0001-7594-4354; Villalpando, Salvador/0000-0001-6429-3816; Borges, Guilherme/0000-0002-3269-0507; Miller, Ted/0000-0002-0958-2639; Giussani, Giorgia/0000-0003-2460-3095; Balakrishnan, Kalpana/0000-0002-5905-1801; Newton, Charles/0000-0002-6999-5507; Mhimbira, Francis/0000-0001-8989-6832; Heredia-Pi, Ileana Beatriz/0000-0002-9998-9239; Sreeramareddy, Chandrashekhar/0000-0002-5693-7631; Kravchenko, Michael/0000-0001-5187-5518; Nolte, Sandra/0000-0001-6185-9423; Stein, Dan/0000-0001-7218-7810; Lalloo, Ratilal/0000-0001-5822-1269; Tillmann, Taavi/0000-0002-8428-3719; Salomon, Joshua/0000-0003-3929-5515; Beyene, Tariku Jibat/0000-0002-7474-1966; Brenner, Hermann/0000-0002-6129-1572; Majdan, Marek/0000-0001-8037-742X; Nieuwenhuijsen, Mark/0000-0001-9461-7981; Ferri, Cleusa/0000-0002-1815-7685; Devries, Karen/0000-0001-8935-2181; Jacobsen, Kathryn/0000-0002-4198-6246; LOGROSCINO, GIANCARLO/0000-0003-0423-3242; wang, YA XING/0000-0003-2749-7793; Ribeiro, Antonio/0000-0002-2740-0042; Hay, Simon/0000-0002-0611-7272; Naldi, Luigi/0000-0002-3160-2835; Thrift, Amanda/0000-0001-8533-4170; Weiderpass, Elisabete/0000-0003-2237-0128; Montico, Marcella/0000-0003-0377-8232; Parry, Charles/0000-0001-9787-2785; Haro, Josep Maria/0000-0002-3984-277X; Degenhardt, Louisa/0000-0002-8513-2218; Martin, Randall/0000-0003-2632-8402; Hankey, Graeme /0000-0002-6044-7328; Rakovac, Ivo/0000-0003-3462-2636; Fra.Paleo, Urbano/0000-0001-6192-7684; Monasta, Lorenzo/0000-0001-7774-548X; Sepanlou, Sadaf/0000-0002-3669-5129; Banerjee, Amitava/0000-0001-8741-3411; Charlson, Fiona/0000-0003-2876-5040; Patten, Scott/0000-0001-9871-4041; Olusanya, Bolajoko/0000-0002-3826-0583; Goenka, Shifalika/0000-0001-6993-2883; Quezada, Amado David/0000-0003-3258-8198; Heydarpour, Pouria/0000-0001-5644-7555; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Stockl, Heidi/0000-0002-0907-8483; Vlassov, Valentin/0000-0003-2845-2992; Davis, Adrian/0000-0001-7134-7528; Paternina-Caicedo, Angel/0000-0002-6332-5174; Leasher, Janet/0000-0002-8779-5162; Hu, Howard/0000-0002-3676-2707 FU Bill AMP; Melinda Gates Foundation FX Funding Bill & Melinda Gates Foundation. NR 86 TC 266 Z9 283 U1 170 U2 369 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 5 PY 2015 VL 386 IS 10010 BP 2287 EP 2323 DI 10.1016/S0140-6736(15)00128-2 PG 37 WC Medicine, General & Internal SC General & Internal Medicine GA CX8ZB UT WOS:000365993200031 ER PT J AU Carey, A Cleary, MM Edwards, DK Eide, CA Traer, E McWeeney, SK Tyner, JW Bagby, GC Druker, BJ Agarwal, A AF Carey, Alyssa Cleary, Megan M. Edwards, David K. Eide, Christopher A. Traer, Elie McWeeney, Shannon K. Tyner, Jeffrey W. Bagby, Grover C. Druker, Brian J. Agarwal, Anupriya TI The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Carey, Alyssa; Cleary, Megan M.; Eide, Christopher A.; Traer, Elie; Bagby, Grover C.; Druker, Brian J.; Agarwal, Anupriya] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA. [Edwards, David K.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Eide, Christopher A.; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Bioinformat & Computat Biol, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002303 ER PT J AU Chin, D Kutny, MA Grim, J Gerbing, RB Miller, K Farrar, JE Auvil, JMG Smith, MA Gerhard, DS Davidsen, TM Gesuwan, P Hermida, LC Marra, MA Mungall, AJ Moore, R Long, W Ma, Y Zong, S Kolb, EA Gamis, AS Alonzo, TA Meshinchi, S AF Chin, Diana Kutny, Matthew A. Grim, Jonathan Gerbing, Robert B. Miller, Kristen Farrar, Jason E. Auvil, Jaime M. Guidry Smith, Malcolm A. Gerhard, Daniela S. Davidsen, Tanja M. Gesuwan, Patee Hermida, Leandro C. Marra, Marco A. Mungall, Andrew J. Moore, Richard Long, William Ma, Yussanne Zong, Stuart Kolb, E. Anders Gamis, Alan S. Alonzo, Todd A. Meshinchi, Soheil TI Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chin, Diana; Miller, Kristen; Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kutny, Matthew A.] Univ Alabama Birmingham, Dept Pediat, Div Hematol Oncol, Birmingham, AL USA. [Grim, Jonathan] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gerbing, Robert B.] Childrens Oncol Grp, Monrovia, CA USA. [Farrar, Jason E.] Univ Arkansas Med Sci, Dept Pediat, Hematol Oncol Sect, Little Rock, AR 72205 USA. [Auvil, Jaime M. Guidry; Gerhard, Daniela S.; Davidsen, Tanja M.; Gesuwan, Patee; Hermida, Leandro C.] NCI, Off Canc Genom, Bethesda, MD 20892 USA. [Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Marra, Marco A.; Moore, Richard] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Mungall, Andrew J.; Long, William; Ma, Yussanne; Zong, Stuart] British Columbia Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Kolb, E. Anders] Alfred I duPont Hosp Children, Nemours Ctr Canc & Blood Disorders, Wilmington, DE USA. [Gamis, Alan S.] Childrens Mercy Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Kansas City, MO USA. [Alonzo, Todd A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000234 ER PT J AU Newell, LF Holtan, SG Rosenzweig, J Yates, J Garbati, M Rathbun, RK Keeble, W Tyner, JW Burd, I Bagby, GC AF Newell, Laura F. Holtan, Shernan G. Rosenzweig, Jason Yates, Jane Garbati, Michael Rathbun, R. K. Keeble, Winifred Tyner, Jeffrey W. Burd, Irina Bagby, Grover C. TI Placental Growth Factor Enhances Toll-like Receptor-Induced Inflammatory Cytokine Gene Expression Transcriptionally in Human Mononuclear Phagocytes SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Newell, Laura F.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Holtan, Shernan G.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Rosenzweig, Jason; Burd, Irina] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD USA. [Yates, Jane; Garbati, Michael; Rathbun, R. K.; Keeble, Winifred] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Yates, Jane] Portland VA Med Ctr, Portland, OR USA. [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. [Bagby, Grover C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003130 ER PT J AU Shatzel, J Azar, S Gay, ND Luo, J Deloughery, TG Recht, M Taylor, JA AF Shatzel, Joseph Azar, Sharl Gay, Nathanael David Luo, Jai Deloughery, Thomas G. Recht, Michael Taylor, Jason A. TI The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shatzel, Joseph] Oregon Hlth & Sci Univ, Dept Hematol Oncol, Portland, OR 97201 USA. [Azar, Sharl; Recht, Michael; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Azar, Sharl] Portland VA Med Ctr, Portland, OR USA. [Gay, Nathanael David; Deloughery, Thomas G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Luo, Jai] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003215 ER PT J AU Callander, NS Freytes, CO Luo, SH Carson, KR AF Callander, Natalie Scott Freytes, Cesar O. Luo, Suhong Carson, Kenneth R. TI Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Callander, Natalie Scott] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Callander, Natalie Scott] Williams S Middleton Mem Vet Hosp, Madison, WI USA. [Freytes, Cesar O.] Audie L Murphy Mem Vet Adm Med Ctr, Med, San Antonio, TX 78284 USA. [Luo, Suhong; Carson, Kenneth R.] St Louis Vet Adm Med Ctr, Res Serv, St Louis, MO USA. [Carson, Kenneth R.] Washington Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801136 ER PT J AU Qiu, HY Sandmaier, BM Storer, BE Chauncey, T Petersen, F Pulsipher, MA Bruno, B Flowers, M Mielcarek, M Storb, R Maloney, DG AF Qiu, Huiying Sandmaier, Brenda M. Storer, Barry E. Chauncey, Thomas Petersen, Finn Pulsipher, Michael A. Bruno, Benedetto Flowers, Mary Mielcarek, Marco Storb, Rainer Maloney, David G. TI A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Qiu, Huiying; Sandmaier, Brenda M.; Flowers, Mary; Mielcarek, Marco; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sandmaier, Brenda M.; Storer, Barry E.; Chauncey, Thomas; Flowers, Mary; Mielcarek, Marco; Storb, Rainer] Univ Washington, Seattle, WA 98195 USA. [Storer, Barry E.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Petersen, Finn] LDS Hosp, Salt Lake City, UT USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Pulsipher, Michael A.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Maloney, David G.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100114 ER PT J AU Kwoh, CK Vina, ER Cloonan, YK Hannon, MJ Boudreau, RM Ibrahim, SA AF Kwoh, C. Kent Vina, Ernest R. Cloonan, Yona K. Hannon, Michael J. Boudreau, Robert M. Ibrahim, Said A. TI Determinants of patient preferences for total knee replacement: African-Americans and whites SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Osteoarthritis; Knee replacement surgery; Race; Health disparity; Treatment preference ID TOTAL JOINT ARTHROPLASTY; RACIAL-DIFFERENCES; ETHNIC-DIFFERENCES; SOCIAL SUPPORT; UNITED-STATES; OSTEOARTHRITIS; HIP; ARTHRITIS; WILLINGNESS; SURGERY AB Introduction: Patient preferences contribute to marked racial disparities in the utilization of total knee replacement (TKR). The objectives of this study were to identify the determinants of knee osteoarthritis (OA) patients' preferences regarding TKR by race and to identify the variables that may mediate racial differences in willingness to undergo TKR. Methods: Five hundred fourteen White (WH) and 285 African-American (AA) patients with chronic knee pain and radiographic evidence of OA participated in the study. Participants were recruited from the community, an academic medical center, and a Veterans Affairs hospital. Structured interviews were conducted to collect socio-demographics, disease severity, socio-cultural determinants, and treatment preferences. Logistic regression was performed, stratified by race, to identify determinants of preferences. Clinical and socio-cultural factors were entered simultaneously into the models. Stepwise selection identified factors for inclusion in the final models (p < 0.20). Results: Compared to WHs, AAs were less willing to undergo TKR (80 % vs. 62 %, respectively). Better expectations regarding TKR surgery outcomes determined willingness to undergo surgery in both AAs (odds ratio (OR) 2.08, 95 % confidence interval (CI) 0.91-4.79 for 4th vs. 1st quartile) and WHs (OR 5.11, 95 % CI 2.31-11.30 for 4th vs. 1st quartile). Among AAs, better understanding of the procedure (OR 1.80, 95 % CI 0.97-3.35), perceiving a short hospital course (OR 0.81, 95 % CI 0.58-1.13), and believing in less post-surgical pain (OR 0.73, 95 % CI 0.39-1.35) and walking difficulties (OR 0.66, 95 % CI 0.37-1.16) also determined willingness. Among WHs, having surgical discussion with a physician (OR 1.96, 95 % CI 1.05-3.68), not ever receiving surgical referral (OR 0.56, 95 % CI 0.32-0.99), and higher trust in the healthcare system (OR 1.58, 95 % CI 0.75-3.31 for 4th vs. 1st quartile) additionally determined willingness. Among the variables considered, only knowledge-related matters pertaining to TKR attenuated the racial difference in knee OA patients' treatment preference. Conclusions: Expectations of surgical outcomes influence preference for TKR in all patients, but clinical and socio-cultural factors exist that shape marked racial differences in preferences for TKR. Interventions to reduce or eliminate racial disparities in the utilization of TKR should consider and target these factors. C1 [Kwoh, C. Kent; Vina, Ernest R.] Univ Arizona, Sch Med, Tucson, AZ 85724 USA. [Kwoh, C. Kent; Vina, Ernest R.] Univ Arizona, Arthrit Ctr, Tucson, AZ 85724 USA. [Cloonan, Yona K.; Boudreau, Robert M.] Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Hannon, Michael J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Kwoh, CK (reprint author), Univ Arizona, Sch Med, 1501 N Campbell Ave,POB 245093, Tucson, AZ 85724 USA. EM CKwoh@arthritis.arizona.edu OI Boudreau, Robert/0000-0003-0162-5187; Cloonan, Yona/0000-0003-3893-3693; Vina, Ernest/0000-0001-8135-1731 FU NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases [P60-AR-054731]; K24 Mid-Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Disorders [K24AR055259] FX This study was supported by the NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases (Grant P60-AR-054731). Dr. Ibrahim is supported in part by a K24 Mid-Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Disorders (K24AR055259). NR 44 TC 4 Z9 4 U1 4 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD DEC 3 PY 2015 VL 17 AR 348 DI 10.1186/s13075-015-0864-2 PG 11 WC Rheumatology SC Rheumatology GA CX3YJ UT WOS:000365635100001 PM 26635132 ER PT J AU Hanlon, CA Dowdle, LT Austelle, CW DeVries, W Mithoefer, O Badran, BW George, MS AF Hanlon, Colleen A. Dowdle, Logan T. Austelle, Christopher W. DeVries, William Mithoefer, Oliver Badran, Bashar W. George, Mark S. TI What goes up, can come down: Novel brain stimulation paradigms may attenuate craving and craving-related neural circuitry in substance dependent individuals SO BRAIN RESEARCH LA English DT Article DE Brain stimulation; Functional MRI; Orbitofrontal cortex; BA 10; Caudate ID TRANSCRANIAL MAGNETIC STIMULATION; MEDIAL PREFRONTAL CORTEX; HUMAN MOTOR CORTEX; HF-RTMS SESSION; SYNAPTIC PLASTICITY; COCAINE DEPENDENCE; ALCOHOL DEPENDENCE; CIGARETTE-SMOKING; BASAL GANGLIA; ADDICTION AB Vulnerability to drug related cues is one of the leading causes for continued use and relapse among substance dependent individuals. Using drugs in the face of cues may be associated with dysfunction in at least two frontal-striatal neural circuits: (1) elevated activity in medial and ventral areas that govern limbic arousal (including the medial prefrontal cortex (MPFC) and ventral striatum) or (2) depressed activity in dorsal and lateral areas that govern cognitive control (including the dorsolateral prefrontal cortex (DLPFC) and dorsal striatum): Transcranial magnetic stimulation (TMS) is emerging as a promising new tool for the attenuation of craving among multiple substance dependent populations. To date however, nearly all repetitive TMS studies in addiction have focused on amplifying activity in frontal-striatal circuits that govern cognitive control. This manuscript reviews recent work using TMS as a tool to decrease craving for multiple substances and provides a theoretical model for how clinical researchers might approach target and frequency selection for TMS of addiction. To buttress this model, preliminary data from a single-blind, sham-controlled, crossover study of 11 cocaine-dependent individuals is also presented. These results suggest that attenuating MPFC activity through theta burst stimulation decreases activity in the striatum and anterior insula. It is also more likely to attenuate craving than sham TMS. Hence, while many TMS studies are focused on applying LTP-like stimulation to the DLPFC, the MPFC might be a new, efficacious, and treatable target for craving in cocaine dependent individuals. This article is part of a Special Issue entitled SI:Addiction circuits. (C) 2015 Published by Elsevier B.V. C1 [Hanlon, Colleen A.; Dowdle, Logan T.; Austelle, Christopher W.; DeVries, William; Mithoefer, Oliver; Badran, Bashar W.; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hanlon, Colleen A.; Dowdle, Logan T.; Badran, Bashar W.; George, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC USA. [Hanlon, Colleen A.; George, Mark S.] Med Univ S Carolina, Ctr Biomed Imaging, Charleston, SC USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM hanlon@musc.edu OI Dowdle, Logan/0000-0002-1879-705X FU NIH [K01DA027756, R01DA036617, P50 DA015369, P50 AA010761] FX This effort was funded directly by NIH Grants K01DA027756 (Hanlon), R01DA036617 (Hanlon), P50 DA015369 (Kalivas), P50 AA010761 (Becker). Additional assistance was given by the South Carolina Translational Research Institute UL1 TR000062 and R25 DA033680. The authors would also like to acknowledge the Neuroscience Institute at the Medical University of South Carolina, the Neurobiology of Addiction Research Center, the Center for Biomedical Imaging, Truman R. Brown, Jayce Doose, James Purl, Melanie Canterberry, and Kathleen Brady, all of whom provided intellectual support and resources for this endeavor. NR 65 TC 9 Z9 9 U1 1 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD DEC 2 PY 2015 VL 1628 SI SI BP 199 EP 209 DI 10.1016/j.brainres.2015.02.053 PN A PG 11 WC Neurosciences SC Neurosciences & Neurology GA CZ9IV UT WOS:000367412200018 PM 25770818 ER PT J AU Vuong, HE Hardi, CN Barnes, S Brecha, NC AF Vuong, Helen E. Hardi, Claudia N. Barnes, Steven Brecha, Nicholas C. TI Parallel Inhibition of Dopamine Amacrine Cells and Intrinsically Photosensitive Retinal Ganglion Cells in a Non-Image-Forming Visual Circuit of the Mouse Retina SO JOURNAL OF NEUROSCIENCE LA English DT Article DE amacrine cells; dopamine; interneuron; melanopsin ipRGCs; microcircuit; somatostatin ID SUBTYPE 2A EXPRESSION; ROD BIPOLAR CELLS; CONE PHOTORECEPTORS; MAMMALIAN RETINA; RABBIT RETINA; RAT RETINA; RECEPTOR ACTIVATION; CALCIUM-CHANNELS; MELANOPSIN CELLS; CIRCADIAN CLOCK AB An inner retinal microcircuit composed of dopamine (DA)-containing amacrine cells and melanopsin-containing, intrinsically photosensitive retinal ganglion cells (M1 ipRGCs) process information about the duration and intensity of light exposures, mediating light adaptation, circadian entrainment, pupillary reflexes, and other aspects of non-image-forming vision. The neural interaction is reciprocal: M1 ipRGCs excite DA amacrine cells, and these, in turn, feed inhibition back onto M1 ipRGCs. We found that the neuropeptide somatostatin [somatotropin release inhibiting factor (SRIF)] also inhibits the intrinsic light response of M1 ipRGCs and postulated that, to tune the bidirectional interaction of M1 ipRGCs and DA amacrine cells, SRIF amacrine cells would provide inhibitory modulation to both cell types. SRIF amacrine cells, DA amacrine cells, and M1 ipRGCs form numerous contacts. DA amacrine cells and M1 ipRGCs express the SRIF receptor subtypes sst(2A) and sst(4) respectively. SRIF modulation of the microcircuit was investigated with targeted patch-clamp recordings of DA amacrine cells in TH-RFP mice and M1 ipRGCs in OPN4-EGFP mice. SRIF increases K+ currents, decreases Ca2+ currents, and inhibits spike activity in both cell types, actions reproduced by the selective sst(2A) agonist L-054,264 (N-[(1R)-2-[[[(1S*,3R*)-3-(aminomethyl)cyclohexyl]methyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]spiro[1H-indene-1,4'-piperidine]-1'-carboxamide) in DA amacrine cells and the selective sst(4) agonist L-803,087 (N-2-[4-(5,7-difluoro-2-phenyl-1H-indol-3-yl)-1-oxobutyl]-l-arginine methyl ester trifluoroacetate) in M1 ipRGCs. These parallel actions of SRIF may serve to counteract the disinhibition of M1 ipRGCs caused by SRIF inhibition of DA amacrine cells. This allows the actions of SRIF on DA amacrine cells to proceed with adjusting retinal DA levels without destabilizing light responses by M1 ipRGCs, which project to non-image-forming targets in the brain. C1 [Vuong, Helen E.; Hardi, Claudia N.; Barnes, Steven; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Vuong, Helen E.; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA 90095 USA. [Vuong, Helen E.; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE: Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Barnes, Steven] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 4R2, Canada. [Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 4R2, Canada. [Barnes, Steven; Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Brecha, NC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM nbrecha@ucla.edu FU National Institutes of Health [R01 EY04067, T32 EY007026, P30 DK41301]; Veterans Administration Merit Review; Plum Foundation; Canadian Institutes of Health Research-Nova Scotia Health Research Foundation Regional Partnership Program [MOP-10968]; Natural Sciences and Engineering Research Council of Canada Discovery Award [194640]; Whitcome Summer Undergraduate Research Fellowship FX This work was supported by National Institutes of Health Grants R01 EY04067 (N.C.B.), T32 EY007026 (H.E.V.), and P30 DK41301 (Imaging and Stem Cell Biology Core; CURE: Digestive Diseases Research Center), a Veterans Administration Merit Review (N.C.B.), the Plum Foundation (S.B. and N.C.B.), Canadian Institutes of Health Research-Nova Scotia Health Research Foundation Regional Partnership Program MOP-10968 (S.B.), a Natural Sciences and Engineering Research Council of Canada Discovery Award 194640 (S.B.), and a Whitcome Summer Undergraduate Research Fellowship (C.N.H.). N.C.B. is a Veterans Administration Career Research Scientist. We thank Dr. Douglas McMahon for providing the TH-RFP mouse line, Dr. David Berson for providing the OPN4-EGFP mouse line, and Drs. Kristopher G. Sheets, Arlene A. Hirano, and Luis Perez de Sevilla Muller for assistance with data interpretation and comments on this manuscript. NR 68 TC 5 Z9 5 U1 3 U2 15 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD DEC 2 PY 2015 VL 35 IS 48 BP 15955 EP 15970 DI 10.1523/JNEUROSCI.3382-15.2015 PG 16 WC Neurosciences SC Neurosciences & Neurology GA CX9WD UT WOS:000366055500017 PM 26631476 ER PT J AU Hope, TA Verdin, EF Bergsland, EK Ohliger, MA Corvera, CU Nakakura, EK AF Hope, Thomas A. Verdin, Emily F. Bergsland, Emily K. Ohliger, Michael A. Corvera, Carlos U. Nakakura, Eric K. TI Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging SO EJNMMI PHYSICS LA English DT Article ID WHOLE-BODY PET/MRI; ATTENUATION CORRECTION; PET QUANTIFICATION; MRI; RESOLUTION; CONTRAST; ONCOLOGY; LESIONS; IMPACT; TUMOR AB Background: The purpose of this study was to evaluate the utility of bellows-based respiratory compensation and navigated hepatobiliary phase imaging to correct for respiratory motion in the setting of dedicated liver PET/MRI. Methods: Institutional review board approval and informed consent were obtained. Six patients with metastatic neuroendocrine tumor were imaged using Ga-68 DOTA-TOC PET/MRI. Whole body imaging and a dedicated 15-min liver PET acquisition was performed, in addition to navigated and breath-held hepatobiliary phase (HBP) MRI. Liver PET data was reconstructed three ways: the entire data set (liver PET), gated using respiratory bellows (RC-liver PET), and a non-gated data set reconstructed using the same amount of data used in the RC-liver PET (shortened liver PET). Liver lesions were evaluated using SUVmax, SUVpeak, SUVmean, and Vol(isocontour). Additionally, the displacement of each lesion between the RC-liver PET images and the navigated and breath-held HBP images was calculated. Results: Respiratory compensation resulted in a 43 % increase in SUVs compared to ungated data (liver vs RC-liver PET SUVmax 26.0 vs 37.3, p < 0.001) and a 25 % increase compared to a non-gated reconstruction using the same amount of data (RC-liver vs shortened liver PET SUVmax 26.0 vs 32.6, p < 0.001). Lesion displacement was minimized using navigated HBP MRI (1.3 +/- 1.0 mm) compared to breath-held HBP MRI (23.3 +/- 1.0 mm). Conclusions: Respiratory bellows can provide accurate respiratory compensation when imaging liver lesions using PET/MRI, and results in increased SUVs due to a combination of increased image noise and reduced respiratory blurring. Additionally, navigated HBP MRI accurately aligns with respiratory compensated PET data. C1 [Hope, Thomas A.; Verdin, Emily F.; Ohliger, Michael A.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Hope, Thomas A.] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Bergsland, Emily K.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA. [Ohliger, Michael A.] San Francisco Gen Hosp, Dept Radiol, San Francisco, CA 94110 USA. [Corvera, Carlos U.; Nakakura, Eric K.] Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA USA. RP Hope, TA (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. EM thomas.hope@ucsf.edu FU NIDDK NIH HHS [P30 DK026743] NR 27 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 2197-7364 J9 EJNMMI PHYS JI EJNMMI Phys. PD DEC PY 2015 VL 2 IS 1 AR 21 DI 10.1186/s40658-015-0125-0 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DQ4XQ UT WOS:000379208500021 PM 26501822 ER PT J AU Hodnett, BL Schmitt, NC Thirumala, PD Duvvuri, U AF Hodnett, Benjamin L. Schmitt, Nicole C. Thirumala, Parthasarathy D. Duvvuri, Umamaheswar TI Intraoperative identification of the human communicating nerve during thyroidectomy SO JOURNAL OF SURGICAL CASE REPORTS LA English DT Article ID SUPERIOR LARYNGEAL NERVE AB The human communicating nerve (HCN) is a connection between the superior and recurrent laryngeal nerves that has been described in cadaveric studies. We report a case of an extralaryngeal variant of the HCN that was identified and stimulated intraoperatively during thyroidectomy. This appears to be the first case of intraoperative identification of this anatomic variant, of which the functional significance remains unclear. C1 [Hodnett, Benjamin L.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Schmitt, Nicole C.] Johns Hopkins Univ, Dept Otorhinolaryngol Head & Neck Surg, NIDCD, NIH, Bethesda, MD USA. [Thirumala, Parthasarathy D.] UPMC Presbyterian Hosp, Dept Neurol Surg & Neurol, Ctr Clin Neurophysiol, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Sch Med, Dept Otolaryngol, VA Pittsburgh Hlth Syst,Eye & Ear Inst, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, VA Pittsburgh Hlth Syst,Eye & Ear Inst, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2042-8812 J9 J SURG CASE REP JI J. Surg. Case Rep. PD DEC PY 2015 IS 12 AR UNSP rjv154 DI 10.1093/jscr/rjv154 PG 4 WC Surgery SC Surgery GA DH2EO UT WOS:000372597200006 ER PT J AU Hobeika, L Hunt, KJ Neely, BA Arthur, JM AF Hobeika, Liliane Hunt, Kelly J. Neely, Benjamin A. Arthur, John M. TI Comparison of the Rate of Renal Function Decline in NonProteinuric Patients With and Without Diabetes SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Diabetes; Renal function decline; Chronic kidney disease; Proteinuria; Hypertension ID GLOMERULAR-FILTRATION-RATE; RISK-FACTORS; KIDNEY-DISEASE; INSUFFICIENCY; MICROALBUMINURIA; ALBUMINURIA; NEPHROPATHY; PREVALENCE; MELLITUS; STAGE AB Background: Patients with diabetes and chronic kidney disease (CKD) without proteinuria are often believed to have a cause of CKD other than diabetes. It was hypothesized that if this is true, the rate of renal function decline should be similar among nonproteinuric patients with and without diabetes. Methods: Patients seen in the nephrology, endocrinology and general internal medicine clinics at the Medical University of South Carolina (MUSC) between 2008 and 2012 with hypertension and diabetes were identified by ICD9 diagnosis codes. Patients with less than 2 measures of serum creatinine, without urine studies over the study period and with proteinuria were excluded. Four hundred seventy-two patients met the inclusion and exclusion criteria and had an initial estimated glomerular filtration rate (eGFR) between 35 and 80 mL/min per 1.73 m(2). The annual rate of decline in eGFR was estimated for each patient from the lowest eGFR in each year by fitting a regression model with random intercept and slope. Results: In unadjusted analyses, the rate of eGFR decline was greater in patients with diabetes than without diabetes (-0.71 versus -0.30 mL.min(-1).yr(-1), P = 0.03). After adjusting for age, race, sex, baseline eGFR and use of renin-angiotensin-aldosterone system blockade, the rate of decline was still greater among patients with diabetes than among those without diabetes (-0.68 versus -0.36 mL.min(-1).yr(-1), P = 0.03). Conclusions: Patients with diabetes had more rapid decline in kidney function compared with individuals without diabetes, despite the absence of proteinuria. These results suggest that even in the absence of proteinuria, diabetes may be associated with CKD. C1 [Hobeika, Liliane] Univ Louisville, Dept Internal Med, Div Nephrol, Louisville, KY 40202 USA. [Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Hunt, Kelly J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Neely, Benjamin A.] Univ S Carolina, Dept Internal Med, Div Nephrol, Charleston, SC USA. [Arthur, John M.] Univ Arkansas Med Sci, Dept Internal Med, Div Nephrol, Little Rock, AR 72205 USA. [Arthur, John M.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. RP Hobeika, L (reprint author), Univ Louisville, Div Nephrol & Hypertens, 615 South Preston St, Louisville, KY 40202 USA. EM liliane.hobeika@louisville.edu OI Neely, Benjamin/0000-0001-6120-7695 FU NIH [R01DK101034]; South Carolina Clinical & Translational Research (SCTR) Institute through NIH [UL1 TR000062] FX Supported by NIH grant R01DK101034 and by the South Carolina Clinical & Translational Research (SCTR) Institute through NIH Grant Number UL1 TR000062. NR 24 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD DEC PY 2015 VL 350 IS 6 BP 447 EP 452 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DF4MQ UT WOS:000371323100005 PM 26624901 ER PT J AU Iyer, SP Pancake, LS Dandino, ES Wells, KB AF Iyer, Sharat P. Pancake, Laura S. Dandino, Elizabeth S. Wells, Kenneth B. TI Consumer-Involved Participatory Research to Address General Medical Health and Wellness in a Community Mental Health Setting SO PSYCHIATRIC SERVICES LA English DT Article ID SCHIZOPHRENIA; MORTALITY; ENGAGEMENT; SERVICES; COHORT AB Barriers to sustainably implementing general medical interventions in community mental health (CMH) settings include role uncertainty, consumer engagement, workforce limitations, and sustainable reimbursement. To address these barriers, this project used a community-partnered participatory research framework to create a stakeholder-based general medical and wellness intervention in a large CMH organization, with consumers involved in all decision-making processes. Consumers faced practical barriers to participating in organizational decision making, but their narratives were critical in establishing priorities and ensuring sustainability. Addressing baseline knowledge and readiness of stakeholders and functional challenges to consumer involvement can aid stakeholder-based approaches to implementing general medical interventions in CMH settings. C1 [Iyer, Sharat P.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, Bronx, NY USA. [Iyer, Sharat P.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Pancake, Laura S.; Dandino, Elizabeth S.] Pacific Clin, Pasadena, CA USA. [Wells, Kenneth B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA. RP Iyer, SP (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, Bronx, NY USA. EM sharat.iyer@mssm.edu FU Robert Wood Johnson Foundation; U.S. Department of Veterans Affairs FX This material is the result of work supported with resources and the use of facilities at the James J. Peters VA Medical Center, Bronx, New York, and the West Los Angeles VA Medical Center, Los Angeles. Funding for Dr. Iyer was provided by the Robert Wood Johnson Foundation Clinical Scholars program and the U.S. Department of Veterans Affairs. The authors thank the members of the Pacific Clinics Physical Health Stakeholder Committee for their efforts in this work: Erika Aguirre-Miyamoto, Angela Crenshaw, Dolly Ehlen, Sandra Escobar, Viola Gaffaney, Joana Garcia, Rosa Hernandez, Samantha James-Perez, Lisa Lansing, Lou Mallory, David Martel, Lana Martin, Yolanda Mendez, Nina Paddock, Irene Pines, Elizabeth Torres, and Wendy Wang. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 10 TC 0 Z9 0 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2015 VL 66 IS 12 BP 1268 EP 1270 DI 10.1176/appi.ps.201500157 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE7WK UT WOS:000370847300011 PM 26174950 ER PT J AU Nelson, CB Zivin, K Walters, H Ganoczy, D Wadsworth, SM Valenstein, M AF Nelson, C. Beau Zivin, Kara Walters, Heather Ganoczy, Dara Wadsworth, Shelley MacDermid Valenstein, Marcia TI Factors Associated With Civilian Employment, Work Satisfaction, and Performance Among National Guard Members SO PSYCHIATRIC SERVICES LA English DT Article ID MENTAL-HEALTH-SERVICES; GENERALIZED ANXIETY DISORDER; TREATMENT-SEEKING; US MILITARY; IRAQ; VETERANS; SOLDIERS; AFGHANISTAN; DEPRESSION; BARRIERS AB Objective: Employment is a vital part of the postdeployment return to civilian life. This study investigated factors associated with employment-related outcomes (employment status, self-reported work performance, and self-reported work satisfaction) among National Guard members returning from Operation Enduring Freedom, Operation Iraqi Freedom, or Operation New Dawn deployments. Methods: The sample consisted of 1,151 National Guard service members who had returned from overseas deployments approximately six months earlier. Bivariate and multivariable analyses were performed to examine associations between predictors and employment-related outcome variables. Results: Higher-risk alcohol use was associated with reduced odds of being employed as well as with lower ratings of work satisfaction, whereas psychiatric symptom load was associated with lower self-reported work performance and work satisfaction ratings. Perceived social resources were associated with higher self-reported work performance and work satisfaction, whereas better physical functioning was associated with better self-reported work performance. Conclusions: Policy makers and clinicians may need to consider and assess alcohol use among unemployed National Guard members. They may also need to consider psychiatric symptom load and physical functioning among employed service members who perceive poor work performance and have low work satisfaction. Further research is needed on causal links between these predictors and employment outcomes. C1 [Nelson, C. Beau] Vet Affairs Ann Arbor Healthcare Syst, Div Mental Hlth Serv, Ann Arbor, MI USA. [Nelson, C. Beau] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Zivin, Kara; Valenstein, Marcia] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA. [Walters, Heather; Ganoczy, Dara; Wadsworth, Shelley MacDermid] Purdue Univ, Ctr Families, W Lafayette, IN 47907 USA. [Walters, Heather; Ganoczy, Dara; Wadsworth, Shelley MacDermid] Purdue Univ, Mil Family Res Inst, W Lafayette, IN 47907 USA. RP Nelson, CB (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Div Mental Hlth Serv, Ann Arbor, MI USA. EM claytonn@med.umich.edu FU Department of Veterans Affairs Health Services Research and Development Service [RRP 09-420, SDP 10-047] FX This study was funded by grants RRP 09-420 and SDP 10-047 from the Department of Veterans Affairs Health Services Research and Development Service. NR 42 TC 0 Z9 0 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2015 VL 66 IS 12 BP 1318 EP 1325 DI 10.1176/appi.ps.201400334 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE7WK UT WOS:000370847300019 PM 26278223 ER PT J AU Ha, Y Collins, ME Martino, D AF Yoonsook Ha Collins, Mary Elizabeth Martino, David TI Child care burden and the risk of child maltreatment among low-income working families SO CHILDREN AND YOUTH SERVICES REVIEW LA English DT Article DE Child care burden; Child maltreatment; Child abuse; Child neglect; Child care issues; Child care subsidies ID COMMUNITY-LEVEL FACTORS; OF-THE-LITERATURE; SUBSTANCE-ABUSE; PHYSICAL ABUSE; SOCIAL-ISOLATION; YOUNG-CHILDREN; NEIGHBORHOODS; NEGLECT; STRESS; RATES AB Studies suggest that a substantial proportion of low-income working mothers experience work disruptions and parental stress related to child care, which may lead to increases in the risk of physical and psychological abuse and neglect of children. However, little research has examined the relationship between child care burden and the risk of child maltreatment among low-income working families. Using the Fragile Families and Child Wellbeing Study 3-year data, this study explores how child care burden is associated with the risk of child maltreatment (physical aggression, psychological aggression, and neglectful behavior) among low-income working mothers. We find that instability in child care arrangements is likely to increase mothers' physical and psychological aggression, while not having someone reliable for emergency child care is likely to increase mothers' neglectful behaviors. Findings also show that the risk of child maltreatment related to child care burden measures is more significant for single mothers than married mothers. Potential policy implications are discussed. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Yoonsook Ha; Collins, Mary Elizabeth] Boston Univ, Boston, MA 02215 USA. [Martino, David] US Dept Vet Affairs, Washington, DC USA. RP Ha, Y (reprint author), Boston Univ, Boston, MA 02215 USA. OI Martino, David/0000-0002-4068-5329 NR 55 TC 1 Z9 1 U1 4 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0190-7409 EI 1873-7765 J9 CHILD YOUTH SERV REV JI Child. Youth Serv. Rev. PD DEC PY 2015 VL 59 BP 19 EP 27 DI 10.1016/j.childyouth.2015.10.008 PG 9 WC Family Studies; Social Work SC Family Studies; Social Work GA DE2MZ UT WOS:000370462700003 ER PT J AU Park, M Shlipak, MG Vittinghoff, E Katz, R Siscovick, D Sarnak, M Lima, JA Hsu, CY Peralta, CA AF Park, Meyeon Shlipak, Michael G. Vittinghoff, Eric Katz, Ronit Siscovick, David Sarnak, Mark Lima, Joao A. Hsu, Chi-yuan Peralta, Carmen A. TI Associations of kidney injury markers with subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis SO CLINICAL NEPHROLOGY LA English DT Letter ID GELATINASE-ASSOCIATED LIPOCALIN; GLOMERULAR-FILTRATION-RATE; LEFT-VENTRICULAR MASS; ARTERIAL COMPLIANCE; MOLECULE-1 KIM-1; FUNCTION DECLINE; NORMAL VALUES; RISK; ABNORMALITIES; ELASTICITY C1 [Park, Meyeon; Shlipak, Michael G.; Vittinghoff, Eric; Hsu, Chi-yuan; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Katz, Ronit] Univ Washington, Seattle, WA 98195 USA. [Siscovick, David] New York Acad Med, New York, NY USA. [Sarnak, Mark] Tufts Med Ctr, Boston, MA USA. [Lima, Joao A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Park, M (reprint author), 521 Parnassus Ave,C443,Box 0532, San Francisco, CA 94143 USA. EM meyeon.park@ucsf.edu FU NCATS NIH HHS [UL1-TR-000040, UL1-TR-001079]; NHLBI NIH HHS [N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; NIA NIH HHS [R01 AG027002]; NIDDK NIH HHS [K24 DK92291, 1K23DK082793, K23 DK099238] NR 23 TC 0 Z9 0 U1 1 U2 1 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD DEC PY 2015 VL 84 IS 6 BP 358 EP 364 DI 10.5414/CN108668 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DC5GQ UT WOS:000369249900007 PM 26558369 ER PT J AU Ramirez, M Groff, S Kowalewski, C AF Ramirez, Mary Groff, Sarah Kowalewski, Catherine TI Eruptive Keratoacanthomas After Photodynamic Therapy SO DERMATOLOGIC SURGERY LA English DT Letter C1 [Ramirez, Mary] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79409 USA. [Groff, Sarah; Kowalewski, Catherine] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol, San Antonio, TX 78229 USA. [Kowalewski, Catherine] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ramirez, M (reprint author), Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79409 USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-0512 EI 1524-4725 J9 DERMATOL SURG JI Dermatol. Surg. PD DEC PY 2015 VL 41 IS 12 BP 1426 EP 1429 PG 5 WC Dermatology; Surgery SC Dermatology; Surgery GA DD5DY UT WOS:000369944000015 PM 26580847 ER PT J AU Reid, MW Cohen, S Wang, H Kaung, A Patel, A Tashjian, V Williams, DL Martinez, B Spiegel, BMR AF Reid, Mark W. Cohen, Samuel Wang, Hank Kaung, Aung Patel, Anish Tashjian, Vartan Williams, Demetrius L., Jr. Martinez, Bibiana Spiegel, Brennan M. R. TI Preventing Patient Absenteeism: Validation of a Predictive Overbooking Model SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID NON-ATTENDANCE; SCREENING COLONOSCOPY; OUTPATIENT ENDOSCOPY; GENERAL-PRACTICE; PRIMARY-CARE; NO-SHOWS; APPOINTMENTS; ACCESS; NONATTENDANCE; TRIAL AB Objectives: To develop a model that identifies patients at high risk for missing scheduled appointments ("no-shows" and cancellations) and to project the impact of predictive overbooking in a gastrointestinal endoscopy clinic-an exemplar resource-intensive environment with a high no-show rate. Study Design: We retrospectively developed an algorithm that uses electronic health record (EHR) data to identify patients who do not show up to their appointments. Next, we prospectively validated the algorithm at a Veterans Administration healthcare network clinic. Methods: We constructed a multivariable logistic regression model that assigned a no-show risk score optimized by receiver operating characteristic curve analysis. Based on these scores, we created a calendar of projected open slots to offer to patients and compared the daily performance of predictive overbooking with fixed overbooking and typical "1 patient, 1 slot" scheduling. Results: Data from 1392 patients identified several predictors of no-show, including previous absenteeism, comorbid disease burden, and current diagnoses of mood and substance use disorders. The model correctly classified most patients during the development (area under the curve [AUC] = 0.80) and validation phases (AUC = 0.75). Prospective testing in 1197 patients found that predictive overbooking averaged 0.51 unused appointments per day versus 6.18 for typical booking (difference = -5.67; 95% CI, -6.48 to -4.87; P < .0001). Predictive overbooking could have increased service utilization from 62% to 97% of capacity, with only rare clinic overflows. Conclusions: Information from EHRs can accurately predict whether patients will no-show. This method can be used to overbook appointments, thereby maximizing service utilization while staying within clinic capacity. C1 [Reid, Mark W.; Cohen, Samuel; Kaung, Aung; Patel, Anish; Williams, Demetrius L., Jr.; Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Reid, Mark W.; Williams, Demetrius L., Jr.; Martinez, Bibiana; Spiegel, Brennan M. R.] Cedars Sinai Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Wang, Hank] Kaiser Permanente No Calif, Oakland, CA USA. [Tashjian, Vartan; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), West Los Angeles VA Med Ctr, Div Gastroenterol, Med & Publ Hlth, 11301 Wilshire Blvd,Bldg 115,Rm 215, Los Angeles, CA 90073 USA. EM brennan.spiegel@cshs.org FU VA Health Services Research and Development Merit Award [IIR 12-055] FX This study was funded by a VA Health Services Research and Development Merit Award (IIR 12-055). NR 40 TC 1 Z9 1 U1 2 U2 10 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD DEC PY 2015 VL 21 IS 12 BP 902 EP 910 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DC7GQ UT WOS:000369388100015 PM 26671702 ER PT J AU Haverhals, LM Sayre, G Helfrich, CD Battaglia, C Aron, D Stevenson, LD Kirsh, S Ho, PM Lowery, J AF Haverhals, Leah M. Sayre, George Helfrich, Christian D. Battaglia, Catherine Aron, David Stevenson, Lauren D. Kirsh, Susan Ho, P. Michael Lowery, Julie TI E-Consult Implementation: Lessons Learned Using Consolidated Framework for Implementation Research SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CONSENSUAL QUALITATIVE RESEARCH; WEIGHT MANAGEMENT PROGRAM; HEALTH-CARE; VETERANS; ACCESS; VA AB Objectives: In 2011, the Veterans Health Administration (VHA) implemented electronic consults (e-consults) as an alternative to in-person specialty visits to improve access and reduce travel for veterans. We conducted an evaluation to understand variation in the use of the new e-consult mechanism and the causes of variable implementation, guided by the Consolidated Framework for Implementation Research (CFIR). Study Design: Qualitative case studies of 3 high-and 5 low-implementation e-consult pilot sites. Participants included e-consult site leaders, primary care providers, specialists, and support staff identified using a modified snowball sample. Methods: We used a 3-step approach, with a structured survey of e-consult site leaders to identify key constructs, based on the CFIR. We then conducted open-ended interviews, focused on key constructs, with all participants. Finally, we produced structured, site-level ratings of CFIR constructs and compared them between high-and low-implementation sites. Results: Site leaders identified 14 initial constructs. We conducted 37 interviews, from which 4 CFIR constructs distinguished high-implementation e-consult sites: compatibility, networks and communications, training, and access to knowledge and information. For example, illustrating compatibility, a specialist at a high-implementation site reported that the site changed the order of consult options so that all specialties listed e-consults first to maintain consistency. High-implementation sites also exhibited greater agreement on constructs. Conclusions: By using the CFIR to analyze results, we facilitate future synthesis with other findings, and we better identify common patterns of implementation determinants common across settings. C1 [Haverhals, Leah M.; Battaglia, Catherine; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [Sayre, George; Helfrich, Christian D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Aron, David; Stevenson, Lauren D.; Kirsh, Susan] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Kirsh, Susan] Off Specialty Care & Specialty Care Transformat, Washington, DC USA. [Lowery, Julie] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. RP Haverhals, LM (reprint author), VA Eastern Colorado Hlth Care Syst, Res A151, 1055 Clermont St, Denver, CO 80220 USA. EM leah.haverhals@va.gov FU US Department of Veterans Affairs; Office of Specialty Care Transformation; Office of Health Services Research FX This work was supported by the US Department of Veterans Affairs, Office of Specialty Care Transformation and Office of Health Services Research, and undertaken by the Specialty Care Transformation Initiative Evaluation Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 26 TC 0 Z9 0 U1 3 U2 4 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD DEC PY 2015 VL 21 IS 12 BP E640 EP + PG 21 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DC7GQ UT WOS:000369388100003 PM 26760426 ER PT J AU Kirsh, S Carey, E Aron, DC Cardenas, O Graham, G Jain, R Au, DH Tseng, CL Franklin, H Ho, PM AF Kirsh, Susan Carey, Evan Aron, David C. Cardenas, Omar Graham, Glenn Jain, Rajiv Au, David H. Tseng, Chin-Lin Franklin, Heather Ho, P. Michael TI Impact of a National Specialty E-Consultation Implementation Project on Access SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID ELECTRONIC HEALTH RECORD; CENTERED MEDICAL HOME; PRIMARY-CARE; REFERRALS; COMMUNICATION; SYSTEM; TRANSFORMATION; PHYSICIANS; LESSONS; SERVICE AB Objective:s To assess the early impact of implementation of the electronic consults (e-consults) initiative by the Veterans Health Administration (VHA), designed to improve specialty care access. Study Design: Observational cohort study exploiting a natural experiment begun in May 2011 at 12 VHA medical centers and expanded to 122 medical centers by December 2013. Methods: The following were assessed: 1) growth of e-consults by VHA regional networks, medical centers, and specialty; 2) location of patient's primary care provider (medical center vs community-based outpatient clinic [CBOC]); 3) potential patient miles needed to travel for a specialty care face-to-face consult in place of the observed e-consults using estimated geodesic distance; 4) use of specialty care subsequent to the e-consult. Results: Of 11,270,638 consults completed in 13 clinics of interest, 217,014 were e-consults (adjusted rate, 1.93 e-consults per 100 consults). The e-consult rate was highest in endocrinology (5.0 per 100), hematology (3.0 per 100), and gastroenterology (3.0 per 100). The percentage of e-consult patients with CBOC-based primary care grew from 28.5% to 44.4% in the first year of implementation and to 45.6% at year 3. Of those e-consult patients from community clinics, the average potential miles needed to travel was 72.1 miles per patient (SD = 72.6; median = 54.6; interquartile range = 17.1-108), translating to a potential savings of 6,875,631 total miles and travel reimbursement costs of $2,853,387. Conclusions: E-consult volume increased significantly since inception within many medical and surgical specialties. For patients receiving primary care at one of more than 800 CBOCs, e-consults may decrease travel burden and direct travel costs for patients. C1 [Kirsh, Susan; Cardenas, Omar; Graham, Glenn] Vet Hlth Adm, Off Specialty Care Serv, Washington, DC USA. [Jain, Rajiv] Vet Hlth Adm, Patient Care Serv, Washington, DC USA. [Kirsh, Susan; Aron, David C.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Kirsh, Susan; Aron, David C.] Case Western Reserve Univ, Sch Med, 10701 East Blvd, Cleveland, OH 44106 USA. [Carey, Evan; Ho, P. Michael] Eastern Colorado VA Med Ctr, Denver, CO USA. [Au, David H.] US Dept Vet Affairs, Puget Sound Hlth Serv, Res & Dev Ctr Innovat, Seattle, WA USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. [Tseng, Chin-Lin; Franklin, Heather] New Jersey Vet Hlth Care Syst, East Orange Campus, E Orange, NJ USA. RP Kirsh, S (reprint author), Case Western Reserve Univ, Sch Med, 10701 East Blvd, Cleveland, OH 44106 USA. EM susan.kirsh@va.gov FU US Department of Veterans Affairs; Office of Research and Development Quality Enhancement Research Initiative; Office of Specialty Care Transformation FX This material is based upon work supported by the US Department of Veterans Affairs, the Office of Specialty Care Transformation and the Office of Research and Development Quality Enhancement Research Initiative. NR 30 TC 4 Z9 4 U1 2 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD DEC PY 2015 VL 21 IS 12 BP E648 EP + PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DC7GQ UT WOS:000369388100004 PM 26760427 ER PT J AU Shields, RK Nguyen, MH Clancy, CJ AF Shields, Ryan K. Nguyen, M. Hong Clancy, Cornelius J. TI Clinical perspectives on echinocandin resistance among Candida species SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE Candida; echinocandin; FKS mutation; resistance; susceptibility testing ID EPIDEMIOLOGIC CUTOFF VALUES; INVASIVE CANDIDIASIS; FKS MUTATIONS; ANTIFUNGAL SUSCEPTIBILITY; MULTIDRUG-RESISTANCE; CASPOFUNGIN MICS; AMPHOTERICIN-B; GLABRATA; BREAKPOINTS; MICAFUNGIN AB Purpose of reviewWe review and offer our clinical perspectives on the emergence of echinocandin-resistant Candida.Recent findingsCandida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, approximate to 4%; other species, <1%). Rates are higher with prior echinocandin exposure, exceeding 50% among C. glabrata or Candida albicans isolates causing breakthrough invasive candidiasis. The median duration of prior echinocandin exposure among FKS mutant isolates is approximate to 100 days. The clinical usefulness of echinocandin susceptibility testing is limited by the low overall prevalence of resistance, and uncertainties surrounding testing methods and interpretation of minimum inhibitory concentrations (MICs). In single-center studies, caspofungin resistance (defined using institution-specific MIC breakpoints) was 32-53% sensitive and 75-95% specific for predicting treatment outcomes of C. glabrata invasive candidiasis; corresponding values for the presence of an FKS mutation were 35-41% and 90-98%. Results were similar using anidulafungin and micafungin MICs. Clinical data are scarce for non-C. glabrata species.SummaryEchinocandins remain preferred agents against invasive Candida infections. Susceptibility testing and FKS genotypic testing do not have roles in routine clinical practice, but may be useful in newly-diagnosed patients who are echinocandin-experienced or those who have not responded to echinocandin treatment. C1 [Shields, Ryan K.; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Med, 3550 Terrace St,S867 Scaife Hall, Pittsburgh, PA 15261 USA. EM cjc76@pitt.edu FU National Institutes of Health [K08AI114883, R21AI107290]; Astellas; Merck; Pfizer; U.S. Department of Veterans Affairs through VA Merit Award [1IO1BX001955] FX R.K.S. is supported by the National Institutes of Health through grant number K08AI114883, and through research grants from Astellas and Merck. M.H.N. is supported by the National Institutes of Health through grant number R21AI107290, and through research grants from Astellas, Merck and Pfizer. C.J.C. is supported by the U.S. Department of Veterans Affairs through VA Merit Award 1IO1BX001955, and through research grants from Astellas, Merck and Pfizer. NR 57 TC 6 Z9 6 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0951-7375 EI 1473-6527 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD DEC PY 2015 VL 28 IS 6 BP 514 EP 522 DI 10.1097/QCO.0000000000000215 PG 9 WC Infectious Diseases SC Infectious Diseases GA DC7TC UT WOS:000369422300003 PM 26524326 ER PT J AU Ozieh, MN Taber, DJ Egede, LE AF Ozieh, Mukoso N. Taber, David J. Egede, Leonard E. TI Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes? SO MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; ALLOGRAFT REJECTION; CARDIOVASCULAR-DISEASE; KIDNEY-TRANSPLANT; CARDIAC OUTCOMES; RECIPIENTS; FLUVASTATIN; TRIAL; MULTICENTER; DISPARITIES AB There is a lack of studies assessing if race impacts the efficacy of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibitor (statin) therapy on renal transplantation (RTx) outcomes. We examined the association between statin therapy and RTx outcomes, while concurrently quantifying the effect modification African American (AA) race has on statin efficacy.This was a retrospective longitudinal cohort study of solitary adult RTx (n=1176) between June 2005 and May 2013. The Cox proportional hazard model was used to examine the impact of statin therapy on graft loss, death, and acute rejection and determine if significant interactions exist between statin therapy and race. Models were adjusted for demographics, socioeconomic status, cardiovascular history, medication use, and transplant characteristics.AAs (n=624) and non-African Americans (n=552) were equally likely to receive statin therapy (P=0.922). Mean LDL and TGs in AA were 94mg/dL and 133mg/dL compared to 90mg/dL and 163mg/dL in non-AA, respectively. After adjusting for confounders, high statin users had 52% lower risk of developing graft loss (HR 0.48, 95% CI 0.29-0.80) and a nonstatistically significant reduction in death (HR 0.50, 95% CI 0.23-1.06) compared to low statin users. Acute rejection was not significantly influenced by statin use (HR 0.77 95% CI 0.46-1.27). There was a significant interaction between race and statin therapy for death (P=0.007), but not for graft loss (P=0.121) or rejection (P=0.605). After stratifying by race, high statin use reduced the risk of death in AAs (HR 0.43, 95% CI 0.20-0.94), but not in non-AAs (HR 1.09, 95% CI 0.49-2.44).High statin use reduces the risk of graft loss in RTx, with a mortality benefit in AAs compared to non-AA, despite similar LDL levels. These results suggest a compelling reason to optimize statin therapy in renal transplant recipients (RTR), especially in AAs. C1 [Ozieh, Mukoso N.] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Ozieh, Mukoso N.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Taber, David J.] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699, K23DK099440, T35 DK007431] FX this study was supported by grants K24DK093699 (PI: Leonard Egede), K23DK099440 (PI: David Taber), and T35 DK007431(PI: Leonard Egede) from The National Institute of Diabetes and Digestive and Kidney Disease. NR 23 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD DEC PY 2015 VL 94 IS 49 AR e2283 DI 10.1097/MD.0000000000002283 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DC9KX UT WOS:000369541600057 PM 26656377 ER PT J AU Singh, N Winston, DJ Limaye, AP Pelletier, S Safdar, N Morris, MI Meneses, K Busuttil, RW Wagener, MM Wheat, LJ AF Singh, Nina Winston, Drew J. Limaye, Ajit P. Pelletier, Shawn Safdar, Nasia Morris, Michele I. Meneses, Katherine Busuttil, Ronald W. Wagener, Marilyn M. Wheat, L. Joseph TI Performance Characteristics of Galactomannan and beta-d-Glucan in High-Risk Liver Transplant Recipients SO TRANSPLANTATION LA English DT Article ID INVASIVE FUNGAL-INFECTIONS; ENZYME-IMMUNOASSAY; EARLY-DIAGNOSIS; DOUBLE-BLIND; ASPERGILLOSIS; ASSAY; ANTIGENEMIA; DISEASES; PLASMA; (1->3)-BETA-D-GLUCAN AB Background. The utility of Aspergillus galactomannan (GM) and beta-D-glucan (BG) in liver transplant recipients remains uncertain. Methods. As part of a randomized, double-blind trial of antifungal prophylaxis in liver transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assessed in 199 patients at baseline (enrollment) and weekly thereafter for the duration of study drug. Receiver operating characteristic (ROC) analysis was used to evaluate the accuracy of these for the diagnosis of IFIs. Results. Overall, 46.4% of the patients at baseline had positive GM(index >= 0.5) and 89.6% had BG of 80 pg/mL or greater with BG level of 500 pg/mL or greater in 31.8%. Patients with invasive aspergillosis (IA) (3/3) had positive GM at baseline as did 45.5% of those without IA (P = 0.098); the area under the ROC curve for the diagnosis of IA was 0.77 (fair test, ie, good sensitivity but poor specificity). Using BG cutoff of 80 pg/mL or higher, 100%(12/12) of the patients with IFI had positive baseline BG and as did 88.9% (160/180) of those without IFI (P = 0.618); the area under the ROC curve for predicting IFIs was 0.56 (poor test). In multivariate analyses, GM positivity was associated with study site (P = 0.041), and BG positivity with renal replacement therapy (P = 0.05) and study site (P = 0.01). The GM and BG levels declined over time; positivity at subsequent time points was lower in comparison with baseline (P < 0.001). Conclusions. The GM and BG tests had significant center variability and limited accuracy for the diagnosis of IFIs in high-risk liver transplant recipients. C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA USA. [Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. [Winston, Drew J.; Meneses, Katherine; Busuttil, Ronald W.] Univ Calif Los Angeles, Med Ctr, Dept Surg, Los Angeles, CA 90024 USA. [Limaye, Ajit P.] Univ Washington, Div Infect Dis, Seattle, WA USA. [Pelletier, Shawn] Univ Michigan, Div Infect Dis, Ann Arbor, MI 48109 USA. [Safdar, Nasia] Univ Wisconsin, Div Infect Dis, Madison, WI USA. [Morris, Michele I.] Univ Miami, Div Infect Dis, Miami, FL USA. [Wagener, Marilyn M.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. [Wheat, L. Joseph] Mira Vista Diagnost, Indianapolis, IN USA. RP Singh, N (reprint author), Vet Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu FU Pfizer Inc. [GA8851MQ] FX The study was supported by an Investigator-Initiated Research Grant from Pfizer Inc. (GA8851MQ). The sponsor had no role in the design and conduct of the study, data collection, analysis and interpretation or preparation of the manuscript. The study was registered at ClinicalTrials.gov NCT00841971. NR 39 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD DEC PY 2015 VL 99 IS 12 BP 2543 EP 2550 DI 10.1097/TP.0000000000000763 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DC7AA UT WOS:000369369500021 PM 26050015 ER PT J AU Aldridge, MD Kelley, AS AF Aldridge, Melissa D. Kelley, Amy S. TI The Myth Regarding the High Cost of End-of-Life Care SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID LONG-TERM TRENDS; LAST YEAR; HEALTH-CARE; MEDICAL EXPENDITURES; REGIONAL-VARIATIONS; COORDINATED CARE; UNITED-STATES; PAYMENTS; QUALITY; SAVINGS AB Health care reform debate in the United States is largely focused on the highly concentrated health care costs among a small proportion of the population and policy proposals to identify and target this "high-cost" group. To better understand this population, we conducted an analysis for the Institute of Medicine Committee on Approaching Death using existing national data sets, peer-reviewed literature, and published reports. We estimated that in 2011, among those with the highest costs, only 11% were in their last year of life, and approximately 13% of the $1.6 trillion spenton personal health care costs in the United States was devoted to care of individuals in their last year of life. Public health interventions to reduce health care costs should target those with long-term chronic conditions and functional limitations. C1 [Aldridge, Melissa D.; Kelley, Amy S.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. [Aldridge, Melissa D.; Kelley, Amy S.] James J Peters VA Med Ctr, Bronx, NY USA. RP Aldridge, MD (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM melissa.aldridge@mssm.edu FU NIA NIH HHS [K23 AG040774] NR 31 TC 5 Z9 5 U1 2 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2015 VL 105 IS 12 BP 2411 EP 2415 DI 10.2105/AJPH.2015.302889 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DC4BB UT WOS:000369163600019 PM 26469646 ER PT J AU Trivedi, RB Post, EP Sun, HL Pomerantz, A Saxon, AJ Piette, JD Maynard, C Arnow, B Curtis, I Fihn, SD Nelson, K AF Trivedi, Ranak B. Post, Edward P. Sun, Haili Pomerantz, Andrew Saxon, Andrew J. Piette, John D. Maynard, Charles Arnow, Bruce Curtis, Idamay Fihn, Stephan D. Nelson, Karin TI Prevalence, Comorbidity, and Prognosis of Mental Health Among US Veterans SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CENTERED MEDICAL HOME; POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE; COLLABORATIVE CARE; BEHAVIORAL HEALTH; DEPRESSION; MORTALITY; ILLNESS; PATIENT; MANAGEMENT AB Objectives. We evaluated the association of mental illnesses with clinical outcomes among US veterans and evaluated the effects of Primary Care-Mental Health Integration (PCMHI). Methods. A total of 4 461 208 veterans were seen in the Veterans Health Administration's patient-centered medical homes called Patient Aligned Care Teams (PACT) in 2010 and 2011, of whom 1 147 022 had at least 1 diagnosis of depression, posttraumatic stress disorder (PTSD), substance use disorder (SUD), anxiety disorder, or serious mental illness (SMI; i.e., schizophrenia or bipolar disorder). We estimated 1-year risk of emergency department (ED) visits, hospitalizations, and mortality by mental illness category and by PCMHI involvement. Results. A quarter of all PACT patients reported 1 or more mental illnesses. Depression, SMI, and SUD were associated with increased risk of hospitalization or death. PTSD was associated with lower odds of ED visits and mortality. Having 1 or more contact with PCMHI was associated with better outcomes. Conclusions. Mental illnesses are associated with poor outcomes, but integrating mental health treatment in primary care may be associated with lower risk of those outcomes. C1 [Arnow, Bruce] Stanford Univ, Dept Psychiat & Behav Sci, 795 Willow Rd MPD-152 Bldg 324, Menlo Pk, CA 94025 USA. [Trivedi, Ranak B.] Vet Affairs VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Sun, Haili; Saxon, Andrew J.; Maynard, Charles; Curtis, Idamay; Nelson, Karin] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Post, Edward P.; Piette, John D.] VA Ann Arbor Hlth Care Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Pomerantz, Andrew] VA Mental Hlth Serv, Washington, DC USA. [Fihn, Stephan D.] Off Analyt & Business Informat, Seattle, WA USA. RP Trivedi, RB (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 795 Willow Rd MPD-152 Bldg 324, Menlo Pk, CA 94025 USA. EM ranak.trivedi@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU National PACT Evaluation Center; VA Office of Analytics and Business Intelligence; VA HSR&D Career Development Award [CDA-09-206]; Michigan Diabetes Translational Research Center [P30DK092926]; National Institute of Diabetes and Digestive and Kidney Diseases [R18DK088294] FX This project was supported by the National PACT Evaluation Center and the VA Office of Analytics and Business Intelligence. R. B. Trivedi is supported by a VA HSR&D Career Development Award (CDA-09-206). J. D. Piette is a VA Senior Research Career Scientist. Other financial support came from the Michigan Diabetes Translational Research Center (grant P30DK092926) and National Institute of Diabetes and Digestive and Kidney Diseases (grant R18DK088294). NR 32 TC 8 Z9 8 U1 4 U2 13 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2015 VL 105 IS 12 BP 2564 EP 2569 DI 10.2105/AJPH.2015.302836 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DC4BB UT WOS:000369163600040 PM 26474009 ER PT J AU Nepomuceno, R Sun, DD AF Nepomuceno, Rachel Sun, Dandan TI Pharmacological inhibition of cation-chloride cotransporters for neurological diseases SO NEURAL REGENERATION RESEARCH LA English DT Editorial Material ID TEMPORAL-LOBE EPILEPSY; BUMETANIDE; MODEL; SEIZURES; TRIAL; BRAIN C1 [Nepomuceno, Rachel; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sun, Dandan] Ctr Geriatr Res Educ & Clin, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Sun, DD (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. EM sund@upmc.edu NR 13 TC 1 Z9 1 U1 2 U2 2 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD DEC PY 2015 VL 10 IS 12 BP 1924 EP 1925 DI 10.4103/1673-5374.172313 PG 2 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA DC0RU UT WOS:000368926200010 PM 26889170 ER PT J AU Luo, C Omelchenko, I Manson, R Robbins, C Oesterle, EC Cao, GZ Shen, IY Hume, CR AF Luo, Chuan Omelchenko, Irina Manson, Robert Robbins, Carol Oesterle, Elizabeth C. Cao, Guo Zhong Shen, I. Y. Hume, Clifford R. TI Direct Intracochlear Acoustic Stimulation Using a PZT Microactuator SO TRENDS IN HEARING LA English DT Article DE Cochlear implant; hearing aid; PZT; cochlea; piezoelectric; perilymph; hybrid; electroacoustic ID BRAIN-STEM RESPONSE; COCHLEAR IMPLANT ELECTRODE; ROUND-WINDOW STIMULATION; INDUCED HEARING-LOSS; GUINEA-PIG; ELECTROACOUSTIC STIMULATION; RESIDUAL HEARING; INNER-EAR; EVOKED-RESPONSES; MOUSE AB Combined electric and acoustic stimulation has proven to be an effective strategy to improve hearing in some cochlear implant users. We describe an acoustic microactuator to directly deliver stimuli to the perilymph in the scala tympani. The 800 mm by 800 mm actuator has a silicon diaphragm driven by a piezoelectric thin film (e.g., lead-zirconium-titanium oxide or PZT). This device could also be used as a component of a bimodal acoustic-electric electrode array. In the current study, we established a guinea pig model to test the actuator for its ability to deliver auditory signals to the cochlea in vivo. The actuator was placed through the round window of the cochlea. Auditory brainstem response (ABR) thresholds, peak latencies, and amplitude growth were calculated for an ear canal speaker versus the intracochlear actuator for tone burst stimuli at 4, 8, 16, and 24 kHz. An ABR was obtained after removal of the probe to assess loss of hearing related to the procedure. In some animals, the temporal bone was harvested for histologic analysis of cochlear damage. We show that the device is capable of stimulating ABRs in vivo with latencies and growth functions comparable to stimulation in the ear canal. Further experiments will be necessary to evaluate the efficiency and safety of this modality in long-term auditory stimulation and its ability to be integrated with conventional cochlear implant arrays. C1 [Luo, Chuan; Manson, Robert; Shen, I. Y.] Univ Washington, Dept Mech Engn, Box 352600, Seattle, WA 98195 USA. [Luo, Chuan] Tsinghua Univ, Dept Precis Instruments, Beijing 100084, Peoples R China. [Omelchenko, Irina; Robbins, Carol; Oesterle, Elizabeth C.; Hume, Clifford R.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA. [Cao, Guo Zhong] Univ Washington, Dept Mat Sci, Seattle, WA 98195 USA. [Hume, Clifford R.] VA Puget Sound, Seattle, WA USA. RP Shen, IY (reprint author), Univ Washington, Dept Mech Engn, Box 352600, Seattle, WA 98195 USA. EM ishen@u.washington; hume@uw.edu RI Cao, Guozhong/E-4799-2011 FU Division of Chemical, Bioengineering, Environmental, and Transport Systems-NSF [CBET-1159623]; National Institute on Deafness and Other Communication Disorders-NIDCD [DC-03944]; NIDCD [DC-006437, P30 DC-04661]; NICHD [P30 HD-02774] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by Division of Chemical, Bioengineering, Environmental, and Transport Systems-NSF CBET-1159623 (to I.-Y. S., G. Z., and C. R. H.)-and by National Institute on Deafness and Other Communication Disorders-NIDCD DC-03944 (to E. C. O.), NIDCD DC-006437 (to C. R. H.), NIDCD P30 DC-04661, and NICHD P30 HD-02774. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the funding agencies. NR 51 TC 0 Z9 0 U1 1 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 2331-2165 J9 TRENDS HEAR JI Trends Hear. PD DEC 1 PY 2015 VL 19 DI 10.1177/2331216515616942 PG 14 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA DB6AQ UT WOS:000368595900003 ER PT J AU Shorter, D Hsieh, J Kosten, TR AF Shorter, Daryl Hsieh, John Kosten, Thomas R. TI Pharmacologic Management of Comorbid Post-Traumatic Stress Disorder and Addictions SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; DRUG-RELATED BEHAVIORS; D-CYCLOSERINE; CANNABIS DEPENDENCE; ALCOHOL DEPENDENCE; COMBAT VETERANS; MILITARY VETERANS; ANXIETY DISORDERS; TREATMENT OPTIONS AB Background and Objectives: Post-traumatic Stress Disorder (PTSD) and substance use disorders (SUD) frequently co-occur, and their combination can increase poor health outcomes as well as mortality. Methods: Using PUBMED and the list of references from key publications, this review article covered the epidemiology, neurobiology and pharmacotherapy of PTSD with comorbid alcohol, opiate, and cannabis use disorders. These SUD represent two with and one without FDA approved pharmacotherapies. Results: SUD is two to three times more likely among individuals with lifetime PTSD, and suicide, which is made more likely by both of these disorders, appears to be additively increased by having this comorbidity of SUD and PTSD. The shared neurobiological features of these two illnesses include amygdalar hyperactivity with hippocampal, medial prefrontal and anterior cingulate cortex dysfunction. Medications for comorbid PTSD and SUD include the PTSD treatment sertraline, often used in combination with anticonvulsants, antipsychotics, and adrenergic blockers. When PTSD is comorbid with alcohol use disorder (AUD), naltrexone, acamprosate or disulfiram may be combined with PTSD treatments. Disulfiram alone may treat both PTSD and AUD. For PTSD combined with opiate use disorder methadone or buprenorphine are most commonly used with sertraline. Marijuana use has been considered by some to be a treatment for PTSD, but no FDA treatment for this addiction is approved. Pregabalin and D-cycloserine are two innovations in pharmacotherapy for PTSD and SUD. Conclusions and Scientific Significance: Comorbid PTSD and SUD amplifies their lethality and treatment complexity. Although they share important neurobiology, these patients uncommonly respond to a single pharmacotherapy such as sertraline or disulfiram and more typically require medication combinations and consideration of the specific type of SUD. C1 [Shorter, Daryl; Kosten, Thomas R.] Michael E DeBakey Med Ctr, Mental Hlth Care Line, Houston, TX USA. [Shorter, Daryl; Hsieh, John; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Shorter, D (reprint author), 2002 Holcombe Blvd,Bldg 121,135, Houston, TX 77030 USA. EM shorter@bcm.edu FU VA grant [VA CS RD CDA-14-001]; NIH [K05-DA0454, P50-DA18197] FX Dr. Shorter is supported by VA grant: VA CS R&D CDA-14-001 and Dr. Kosten is supported by NIH grants K05-DA0454, P50-DA18197. NR 69 TC 6 Z9 6 U1 5 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD DEC PY 2015 VL 24 IS 8 BP 705 EP 712 DI 10.1111/ajad.12306 PG 8 WC Substance Abuse SC Substance Abuse GA DB4TK UT WOS:000368506100003 PM 26587796 ER PT J AU Shields, RK Nguyen, MH Press, EG Cumbie, R Driscoll, E Pasculle, AW Clancy, CJ AF Shields, Ryan K. Nguyen, M. Hong Press, Ellen G. Cumbie, Richard Driscoll, Eileen Pasculle, A. William Clancy, Cornelius J. TI Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ECHINOCANDIN RESISTANCE; INVASIVE CANDIDIASIS; MULTIDRUG-RESISTANCE; CASPOFUNGIN MICS; GLABRATA; SUSCEPTIBILITY; ANIDULAFUNGIN; MANAGEMENT; OUTCOMES; FLUCONAZOLE AB Precise FKS mutation rates among Candida species are undefined because studies have not systematically screened consecutive, disease-causing isolates. The Sensititre YeastOne (SYO) assay measures echinocandin MICs against Candida with less variability than reference broth microdilution methods. However, clinical breakpoint MICs may overstate caspofungin nonsusceptibility compared to other agents. Our objectives were to determine Candida FKS mutation rates by studying consecutive bloodstream isolates and to determine if discrepant susceptibility results were associated with FKS mutations. FKS hot spots were sequenced in echinocandin-intermediate and -resistant isolates and those from patients with breakthrough candidemia or >= 3 days of prior echinocandin exposure. Overall, 453 isolates from 384 patients underwent susceptibility testing; 16% were echinocandin intermediate or resistant. Intermediate susceptibility rates were higher for Candida glabrata than for other species (P<0.0001) and higher for caspofungin than for other agents (P<0.0001). Resistance rates were similar between agents. FKS mutations were detected in 5% of sequenced isolates and 2% of isolates overall. Corresponding rates among C. glabrata isolates were 8% and 4%, respectively. Among Candida albicans isolates, rates were 5% and <1%, respectively. Mutations occurred exclusively with prior echinocandin exposure and were not detected in other species. Isolates with discrepant susceptibility results did not harbor FKS mutations. Mutation rates among isolates resistant to >= 2, 1, and 0 agents were 75%, 13%, and 0%, respectively. In conclusion, FKS mutations were uncommon among non-C. glabrata species, even with prior echinocandin exposure. Discrepancies in echinocandin susceptibility by SYO testing were not driven by mutations and likely reflect imprecise caspofungin clinical breakpoints. C1 [Shields, Ryan K.; Nguyen, M. Hong; Press, Ellen G.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Shields, Ryan K.; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Cumbie, Richard; Driscoll, Eileen; Pasculle, A. William] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. EM mhn5@pitt.edu FU Astellas; Merck; National Institutes of Health [K08AI114883, KL2TR000146] FX This work was supported by investigator-initiated grants from Astellas and Merck and by the National Institutes of Health through grant numbers K08AI114883 and KL2TR000146 awarded to R.K.S. NR 30 TC 3 Z9 4 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 2015 VL 59 IS 12 BP 7465 EP 7470 DI 10.1128/AAC.01973-15 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DB2KO UT WOS:000368337300037 PM 26392494 ER PT J AU Gebremariam, T Wiederhold, NP Fothergill, AW Garvey, EP Hoekstra, WJ Schotzinger, RJ Patterson, TF Filler, SG Ibrahim, AS AF Gebremariam, Teclegiorgis Wiederhold, Nathan P. Fothergill, Annette W. Garvey, Edward P. Hoekstra, William J. Schotzinger, Robert J. Patterson, Thomas F. Filler, Scott G. Ibrahim, Ashraf S. TI VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID LIPOSOMAL AMPHOTERICIN-B; TRANSPLANT RECIPIENTS; IMPROVES SURVIVAL; MOLD INFECTIONS; ZYGOMYCOSIS; MUCORMYCOSIS; EPIDEMIOLOGY; ORYZAE; EFFICACY; CYP51 AB We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis. C1 [Gebremariam, Teclegiorgis; Filler, Scott G.; Ibrahim, Ashraf S.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Infect Dis, Torrance, CA 90509 USA. [Gebremariam, Teclegiorgis; Filler, Scott G.; Ibrahim, Ashraf S.] St Johns Cardiovasc Res Ctr, Torrance, CA 90509 USA. [Wiederhold, Nathan P.; Fothergill, Annette W.; Patterson, Thomas F.] Univ Texas Hlth Sci San Antonio, San Antonio, TX USA. [Garvey, Edward P.; Hoekstra, William J.; Schotzinger, Robert J.] Viamet Pharmaceut Inc, Durham, NC USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Filler, Scott G.; Ibrahim, Ashraf S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Ibrahim, AS (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Infect Dis, Torrance, CA 90509 USA. EM ibrahim@labiomed.org OI Wiederhold, Nathan/0000-0002-2225-5122 FU Public Health Service (NIH) [HHSN272201000038I, R01 AI063503] FX This work was supported by Public Health Service contract HHSN272201000038I (NIH task order A13) and grant R01 AI063503. NR 24 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 2015 VL 59 IS 12 BP 7815 EP 7817 DI 10.1128/AAC.01437-15 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DB2KO UT WOS:000368337300083 PM 26369977 ER PT J AU Niesor, EJ Benghozi, R Amouyel, P Ferdinand, KC Schwartz, GG AF Niesor, Eric J. Benghozi, Renee Amouyel, Philippe Ferdinand, Keith C. Schwartz, Gregory G. TI Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease SO CARDIOVASCULAR DRUGS AND THERAPY LA English DT Review DE Adenylyl cyclase 9; beta 2-adrenergic receptor; High-density lipoprotein; Apolipoprotein A1; Sickle cell disease; Malaria ID REVERSE CHOLESTEROL TRANSPORT; HIGH-DENSITY-LIPOPROTEINS; PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; GENE POLYMORPHISMS; NITRIC-OXIDE; LIPID RAFTS; ERYTHROCYTE-MEMBRANES; SIGNAL-TRANSDUCTION AB Adenylyl cyclase 9 (ADCY9) mediates beta 2-adrenoceptor (beta 2-AR) signalling. Both proteins are associated with caveolae, specialized cholesterol-rich membrane substructures. Apolipoprotein A1 (ApoA1), the major protein component of high-density lipoprotein (HDL), removes cholesterol from cell membrane and caveolae and may thereby influence beta 2-AR signalling, shown in vitro to be modulated by cholesterol. Patients with Sickle Cell Disease (SCD) typically have low HDL and ApoA1 levels. In patients, mainly of African origin, with SCD, beta 2-AR activation may trigger adhesion of red blood cells to endothelial cells, leading to vascular occlusive events. Moreover, ADCY9 polymorphism is associated with risk of stroke in SCD. In recent clinical trials, ADCY9 polymorphism was found to be a discriminant factor associated with the risk of cardiovascular (CV) events in Caucasian patients treated with the HDL-raising compound dalcetrapib. We hypothesize that these seemingly disparate observations share a common mechanism related to interaction of HDL/ApoA1 and ADCY9 on beta 2-AR signalling. This review also raises the importance of characterizing polymorphisms that determine the response to HDL-raising and -mimicking agents in the non-Caucasian population at high risk of CV diseases and suffering from SCD. This may facilitate personalized CV treatments. C1 [Niesor, Eric J.; Benghozi, Renee] F Hoffmann La Roche Ltd, Basel, Switzerland. [Niesor, Eric J.] Pre Ss1 Consulting, CH-1260 Nyon, Switzerland. [Benghozi, Renee] Cerenis Therapeut Holding, Labege, France. [Amouyel, Philippe] Univ Hosp Lille, Lille, France. [Ferdinand, Keith C.] Tulane Univ, Sch Med, New Orleans, LA USA. [Schwartz, Gregory G.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Niesor, EJ (reprint author), F Hoffmann La Roche Ltd, Basel, Switzerland. EM eric.niesor@bluewin.ch FU Roche FX R.B. was an F. Hoffmann-La Roche Ltd. employee and currently CMO of Cerenis Therapeutics; G.G.S. received research funding from Roche through his institution. NR 84 TC 0 Z9 0 U1 1 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-3206 EI 1573-7241 J9 CARDIOVASC DRUG THER JI Cardiovasc. Drugs Ther. PD DEC PY 2015 VL 29 IS 6 BP 563 EP 572 DI 10.1007/s10557-015-6626-1 PG 10 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA DB4AC UT WOS:000368454100008 PM 26619842 ER PT J AU Youngstrom, EA Hameed, A Mitchell, MA Van Meter, AR Freeman, AJ Algorta, GP White, AM Clayton, PJ Gelenberg, AJ Meyer, RE AF Youngstrom, Eric A. Hameed, Ahmad Mitchell, Michael A. Van Meter, Anna R. Freeman, Andrew J. Algorta, Guillermo Perez White, Amanda M. Clayton, Paula J. Gelenberg, Alan J. Meyer, Roger E. TI Direct Comparison of the Psychometric Properties of Multiple Interview and Patient-Rated Assessments of Suicidal Ideation and Behavior in an Adult Psychiatric Inpatient Sample SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; SEVERITY RATING-SCALE; TOWER-OF-BABEL; REVISED NOMENCLATURE; SMOKING-CESSATION; DSM-IV; RISK; RELIABILITY; AGREEMENT; ANTIDEPRESSANTS AB Objective: Compare the accuracy, agreement, internal consistency, and interrater reliability of 3 interviews to assess suicidal ideation and behavior in accordance with US Food and Drug Administration guidance about reporting categories. Method: Adults admitted to a psychiatric inpatient unit (N = 199) completed 3 assessments of past month and lifetime suicidal ideation and behavior-the Columbia Suicide Severity Rating Scale (C-SSRS), the Suicide Tracking Scale (STS), and the Sheehan Suicidality Tracking Scale (S-STS)-in randomized, counterbalanced order. "Missing gold standard" latent class analyses defined categories for ideation and behavior. Analyses also evaluated the S-STS mapping to C-SSRS categories. Three trained judges re-rated 89 randomly selected interview videotapes. Cohen., the primary outcome measure, quantified agreement above chance. Data were collected between November 2011 and June 2013. Results: All 3 assessments showed excellent accuracy for suicidal ideation (kappa = 0.72 to 1.00) and attempts (kappa = 0.82 to 0.95) calibrated against latent classes. Interrater agreement ranged from kappa = 0.52 to 1.00. Interrater agreement about more granular C-SSRS categories varied more widely (kappa = 0.48 to 1.00), and the C-SSRS and S-STS assigned significantly different numbers of cases to many categories. Cronbach a was < 0.55 for the C-SSRS ideation and between 0.78 and 0.92 for the other scales. Conclusions: All 3 assessments showed good accuracy for broad categories of suicidal ideation and behavior. More granular, specific categories usually were rated reliably, but the C-SSRS and S-STS differed significantly in regard to which patients were assigned to these subcategories. Using any of these interviews would improve reliability over unstructured assessment in evaluating suicidal ideation and behavior. Clinical predictive validity of these interviews, and particularly the more granular categories, remains to be shown. (C) Copyright 2015 Physicians Postgraduate Press, Inc. C1 [Youngstrom, Eric A.] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA. [Hameed, Ahmad; White, Amanda M.; Gelenberg, Alan J.; Meyer, Roger E.] Penn State Univ, Coll Med, Dept Psychiat, Hershey, PA USA. [Hameed, Ahmad; White, Amanda M.; Gelenberg, Alan J.; Meyer, Roger E.] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA. [Mitchell, Michael A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Van Meter, Anna R.] Yeshiva Univ, Ferkauf Grad Sch, Bronx, NY USA. [Freeman, Andrew J.] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. [Algorta, Guillermo Perez] Univ Lancaster, Div Hlth Res, Lancaster, England. [Clayton, Paula J.] Univ Minnesota, Minneapolis, MN USA. [Clayton, Paula J.] Univ New Mexico, Albuquerque, NM 87131 USA. RP Youngstrom, EA (reprint author), Univ N Carolina, Dept Psychol, CB 3270,Davie Hall, Chapel Hill, NC 27599 USA. EM eay@unc.edu OI White, Amanda/0000-0002-5747-9257 FU Pfizer; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Addiction Treatment FX This research was supported in part by an investigator initiated grant from Pfizer (PI: Dr Gelenberg) and partially supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Addiction Treatment (Mr Mitchell) and with resources and facilities at the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. NR 46 TC 0 Z9 0 U1 16 U2 18 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2015 VL 76 IS 12 BP 1676 EP 1682 DI 10.4088/JCP.14m09353 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DB2RE UT WOS:000368355900019 PM 26613136 ER PT J AU Siglinsky, E Krueger, D Ward, RE Caserotti, P Strotmeyer, ES Harris, TB Binkley, N Buehring, B AF Siglinsky, E. Krueger, D. Ward, R. E. Caserotti, P. Strotmeyer, E. S. Harris, T. B. Binkley, N. Buehring, B. TI Effect of age and sex on jumping mechanography and other measures of muscle mass and function SO JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS LA English DT Article DE Aging; Skeletal Muscle; Sarcopenia; Jumping Mechanography; Muscle Function Tests ID LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE BATTERY; X-RAY ABSORPTIOMETRY; OLDER-ADULTS; BODY-COMPOSITION; SUBSEQUENT DISABILITY; WALKING SPEED; GAIT SPEED; SARCOPENIA; POWER AB Objectives: Sarcopenia increases falls and fracture risk. Sarcopenia clinical trials require robust quantitative tools to evaluate muscle function; jumping mechanography (JM) is likely one such tool. However, US data comparing JM with traditional tests across the lifespan is limited. This study evaluated the effect of age and sex on JM compared with traditional function tests and lean mass. Methods: US adults (213 women/119 men; mean age 65.4 years, range 27-96) performed functional tests including JM, Short Physical Performance Battery (SPPB) and grip strength (GS). Appendicular lean mass (ALM) was measured using DXA. Results: Men had higher relative jump power [mean (SD) 28.5 (10.52) vs. 21.9 (7.11) W/kg], GS [35.5 (9.84) vs. 22.7 (6.98) kg] and ALM/ht(2) [8.25 (1.35) vs. 6.99 (1.38) kg/m(2)] (all p< 0.0001); no difference was observed for SPPB components. JM parameters were more strongly correlated with age than traditional tests (R-2= 0.38-0.61 vs. R-2= 0.01-0.28) and weakly with GS and chair rise time (R-2= 0.30-0.36). Conclusion: JM parameters are correlated with GS and chair rise time and demonstrate stronger correlations with age. JM shows promise as a valuable tool to evaluate and monitor interventions for sarcopenia as it could potentially detect change in muscle function more precisely than existing tools. C1 [Siglinsky, E.; Krueger, D.; Binkley, N.; Buehring, B.] Univ Wisconsin, Osteoporosis Clin Res Program, Madison, WI 53705 USA. [Ward, R. E.] Spaulding Rehabil Hosp, Cambridge, MA USA. [Ward, R. E.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Caserotti, P.] Univ Southern Denmark, Odense, Denmark. [Strotmeyer, E. S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Ctr Aging & Populat Hlth, Pittsburgh, PA USA. [Harris, T. B.] NIA, Bethesda, MA USA. [Buehring, B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Buehring, B (reprint author), Univ Wisconsin, Osteoporosis Clin Res Program, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA. EM bbuehring@medicine.wisc.edu RI Buehring, Bjoern/L-5581-2013 OI Buehring, Bjoern/0000-0003-3841-624X; Strotmeyer, Elsa/0000-0002-4093-6036 FU National Institute on Aging [P01-AG020166]; General Clinical Research Centers Program; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health [UL1TR000427]; Merck Co., Inc. FX The MIDUS research is supported by a grant from the National Institute on Aging (P01-AG020166). The research was further supported by the General Clinical Research Centers Program and UL1TR000427 (UW) from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health". Jump Validation and Vitamin D studies at the University of Wisconsin sponsored by an investigator initiated research grant from Merck & Co., Inc. NR 43 TC 3 Z9 3 U1 2 U2 7 PU JMNI PI NAFPLION PA 7 SPILIADOU SQ, NAFPLION, 21 100, GREECE SN 1108-7161 J9 J MUSCULOSKEL NEURON JI J. Musculoskelet. Neuronal Interact. PD DEC PY 2015 VL 15 IS 4 BP 301 EP 308 PG 8 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA DB1CF UT WOS:000368244900001 PM 26636275 ER PT J AU Marcum, ZA Perera, S Newman, AB Thorpe, JM Switzer, GE Gray, SL Simonsick, EM Shorr, RI Bauer, DC Castle, NG Studenski, SA Hanlon, JT AF Marcum, Zachary A. Perera, Subashan Newman, Anne B. Thorpe, Joshua M. Switzer, Galen E. Gray, Shelly L. Simonsick, Eleanor M. Shorr, Ronald I. Bauer, Douglas C. Castle, Nicholas G. Studenski, Stephanie A. Hanlon, Joseph T. CA Hlth ABC Study TI Antihypertensive Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Falls; Medication; Epidemiology; Drug related ID BODY-COMPOSITION; DRUG-USE; HYPERTENSION; MEDICATIONS; RISK; PREDICTORS; FRACTURES; PEOPLE; ELDERS; AGE AB Background. Despite wide-spread use of antihypertensives in older adults, the literature is unclear about their association with incident recurrent falls over time. Methods. Health, Aging and Body Composition study participants (n = 2,948) who were well functioning at baseline (1997) were followed to Year 7 (2004). The main outcome was recurrent falls (>= 2) in the ensuing 12 months. Antihypertensive use was examined as: (a) any versus none, (b) long-versus short-term (<= 2 vs <2 years), and by (c) summated standardized daily dose (SDD; 1 = maximum recommended daily dose for one antihypertensive), and (d) subclass. Results. Controlling for potential demographic, health status/behavior and access to care confounders, we found no increase in risk of recurrent falls in antihypertensive users compared to nonusers (adjusted odds ratio [AOR] = 1.13; 95% CI = 0.88-1.46), or those taking higher SDDs or for longer durations. Only those using a loop diuretic were found to have a modest increased risk of recurrent falls (AOR = 1.50; 95% CI = 1.11-2.03). Conclusions. Antihypertensive use overall was not statistically significantly associated with recurrent falls after adjusting for important confounders. Loop diuretic use may be associated with recurrent falls and needs further study. C1 [Marcum, Zachary A.; Perera, Subashan; Newman, Anne B.; Hanlon, Joseph T.; Hlth ABC Study] Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA 15260 USA. [Perera, Subashan; Hanlon, Joseph T.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA. [Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Thorpe, Joshua M.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15260 USA. [Thorpe, Joshua M.; Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Med Gen Internal, Pittsburgh, PA 15260 USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Shorr, Ronald I.] North Florida South Georgia Vet Hlth Syst GRECC, Gainesville, FL USA. [Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Castle, Nicholas G.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. RP Marcum, ZA (reprint author), Univ Washington, Sch Pharm, Dept Pharm, 1959 NE Pacific St,Box 357630, Seattle, WA 98195 USA. EM zmarcum@uw.edu OI Newman, Anne B./0000-0002-0106-1150 FU National Institute on Aging (NIA) [R01AG027017, P30AG024827, T32AG021885, K07AG033174]; Intramural Research program of the National Institutes of Health [N01AG62101, N01AG62103, N01AG62106, R01AG028050]; National Institute of Nursing Research grant [R01NR012459] FX This work was supported by National Institute on Aging (NIA) grants (R01AG027017, P30AG024827, T32AG021885, and K07AG033174). This work was also supported in part by the Intramural Research program of the National Institutes of Health (N01AG62101, N01AG62103, N01AG62106, and R01AG028050) and a National Institute of Nursing Research grant (R01NR012459). NR 33 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2015 VL 70 IS 12 BP 1562 EP 1568 DI 10.1093/gerona/glv095 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DB2UB UT WOS:000368364100014 PM 26265732 ER PT J AU Fishbane, SN Singh, AK Cournoyer, SH Jindal, KK Fanti, P Guss, CD Lin, VH Pratt, RD Gupta, A AF Fishbane, Steven N. Singh, Ajay K. Cournoyer, Serge H. Jindal, Kailash K. Fanti, Paolo Guss, Carrie D. Lin, Vivian H. Pratt, Raymond D. Gupta, Ajay TI Ferric pyrophosphate citrate (Triferic (TM)) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE anemia; erythropoiesis-stimulating agent; ferric pyrophosphate citrate; hemodialysis; iron ID THERAPY; ANEMIA; CKD AB Background. Administration of ferric pyrophosphate citrate (FPC, Triferic (TM)) via hemodialysate may allow replacement of ongoing uremic and hemodialysis-related iron losses. FPC donates iron directly to transferrin, bypassing the reticuloendothelial system and avoiding iron sequestration. Methods. Two identical Phase 3, randomized, placebo-controlled trials (CRUISE 1 and 2) were conducted in 599 iron-replete chronic hemodialysis patients. Patients were dialyzed with dialysate containing 2 mu M FPC-iron or standard dialysate (placebo) for up to 48 weeks. Oral or intravenous iron supplementation was prohibited, and doses of erythropoiesis-stimulating agents were held constant. The primary efficacy end point was the change in hemoglobin (Hgb) concentration from baseline to end of treatment (EoT). Secondary end points included reticulocyte hemoglobin content (CHr) and serum ferritin. Results. In both trials, Hgb concentration was maintained from baseline to EoT in the FPC group but decreased by 0.4 g/dL in the placebo group (P < 0.001, combined results; 95% confidence interval [CI] 0.2-0.6). Placebo treatment resulted in significantly larger mean decreases from baseline in CHr (-0.9 pg versus -0.4 pg, P < 0.001) and serum ferritin (-133.1 mu g/L versus -69.7 mu g/L, P < 0.001) than FPC treatment. The proportions of patients with adverse and serious adverse events were similar in both treatment groups. Conclusions. FPC delivered via dialysate during hemodialysis replaces iron losses, maintains Hgb concentrations, does not increase iron stores and exhibits a safety profile similar to placebo. FPC administered by hemodialysis via dialysate represents a paradigm shift in delivering maintenance iron therapy to hemodialysis patients. C1 [Fishbane, Steven N.] Hofstra North Shore LIJ Sch Med, Great Neck, NY USA. [Singh, Ajay K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Cournoyer, Serge H.] Univ Sherbrooke, Hop Charles LeMoyne, Quebec City, PQ, Canada. [Jindal, Kailash K.] Univ Alberta, Dept Med, Div Nephrol, Edmonton, AB, Canada. [Fanti, Paolo] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Div Nephrol, San Antonio, TX 78229 USA. [Guss, Carrie D.; Lin, Vivian H.; Pratt, Raymond D.; Gupta, Ajay] Rockwell Med Inc, Wixom, MI USA. [Gupta, Ajay] Univ Calif Irvine, Irvine, CA USA. RP Gupta, A (reprint author), Rockwell Med Inc, Wixom, MI USA. EM ajayg1@uci.edu FU Rockwell Medical, Inc. FX This study was funded by Rockwell Medical, Inc. (ClinicalTrials.gov identifiers NCT01320202 and NCT01322347). NR 13 TC 12 Z9 13 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD DEC PY 2015 VL 30 IS 12 BP 2019 EP 2026 DI 10.1093/ndt/gfv277 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DB3ZY UT WOS:000368453700014 PM 26175145 ER PT J AU Newby, TA Graff, JN Ganzini, LK McDonagh, MS AF Newby, Timothy A. Graff, Julie N. Ganzini, Linda K. McDonagh, Marian S. TI Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysis SO PSYCHO-ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; MEN; DIAGNOSIS; IMPACT; EFFICACY; PROGRAM; STYLE AB Objective: Prostate cancer patients are at increased risk of depression yet there is no standard intervention to address this. The purpose of this meta-analysis is to examine the efficacy of interventions in reducing depressive symptoms in men with prostate cancer. Methods: Searches for studies were conducted in four databases and by hand. Randomized controlled trials of any intervention relative to control for depression in prostate cancer patients at any stage of their cancer treatment were included. Results: We identified 11 studies that randomized men with prostate cancer to either an intervention meant to improve some aspect of quality of life or control and reported depressive symptoms scores before and after the intervention or control condition. Two of these were not used in our meta-analysis either for concerns about quality or for lack of depression scores. The interventions identified in the remaining nine articles were exercise (four), information (three), psychotherapy or peer support (three), massage therapy (one), and medication (one). Several publications included more than one type of intervention. A meta-analysis of all studies showed that an intervention of some types significantly improved depressive symptom scores relative to the control condition (improvement in depression score by -0.86 unit (95% CI: -1.42, -0.31)). Isolating the peer support/psychotherapy studies also showed significant improvement (improvement in depression score by -1.09 unit (95% CI: -2.05, -0.13)). Conclusion: Treatments to improve depressive symptoms in men with prostate cancer may be effective, with the best evidence supporting the use of peer support/psychotherapy. Copyright (C) 2015 John Wiley & Sons, Ltd. C1 [Newby, Timothy A.; Graff, Julie N.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Graff, Julie N.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Div Hosp & Specialty Med, Portland, OR 97201 USA. [Ganzini, Linda K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci, Portland, OR USA. [Ganzini, Linda K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Ganzini, Linda K.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [McDonagh, Marian S.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. RP Graff, JN (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,MC P3CHEMO, Portland, OR 97239 USA. EM graffj@ohsu.edu NR 31 TC 3 Z9 3 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD DEC PY 2015 VL 24 IS 12 BP 1686 EP 1693 DI 10.1002/pon.3781 PG 8 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA DB3TP UT WOS:000368435000013 PM 25753507 ER PT J AU Tucker, RP Crowley, KJ Davidson, CL Gutierrez, PM AF Tucker, Raymond P. Crowley, Kevin J. Davidson, Collin L. Gutierrez, Peter M. TI Risk Factors, Warning Signs, and Drivers of Suicide: What Are They, How Do They Differ, and Why Does It Matter? SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID PERCEIVED BURDENSOMENESS; BEHAVIOR; MODEL; INTERNET; CARE AB Research investigating suicide attempts and deaths by suicide has yielded many specific risk factors and warning signs for future suicidal behaviors. Yet, even though these variables are each valuable for suicide prevention efforts, they may be limited in their applicability to clinical practice. The differences among risk factors, warning signs, and "drivers," which are person-specific variables that lead individuals to desire death by suicide, are highlighted. The scarce evidence on drivers is described and specific recommendations for conducting future drivers-focused research and targeting them in clinical practice are suggested. C1 [Tucker, Raymond P.] Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA. [Crowley, Kevin J.] Capital Inst Cognit Therapy, Washington, DC USA. [Davidson, Collin L.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Gutierrez, Peter M.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. RP Tucker, RP (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA. EM raymopt@okstate.edu OI Gutierrez, Peter/0000-0001-8981-8404 NR 43 TC 5 Z9 5 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD DEC PY 2015 VL 45 IS 6 BP 679 EP 689 DI 10.1111/sltb.12161 PG 11 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DB3VS UT WOS:000368441700003 PM 25858332 ER PT J AU Kanzaria, HK McCabe, AM Meisel, ZM LeBlanc, A Schaffer, JT Bellolio, MF Vaughan, W Merck, LH Applegate, KE Hollander, JE Grudzen, CR Mills, AM Carpenter, CR Hess, EP AF Kanzaria, Hemal K. McCabe, Aileen M. Meisel, Zachary M. LeBlanc, Annie Schaffer, Jason T. Bellolio, M. Fernanda Vaughan, William Merck, Lisa H. Applegate, Kimberly E. Hollander, Judd E. Grudzen, Corita R. Mills, Angela M. Carpenter, Christopher R. Hess, Erik P. TI Advancing Patient-centered Outcomes in Emergency Diagnostic Imaging: A Research Agenda SO ACADEMIC EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Academic-Emergency-Medicine (AEM) Consensus Conference CY MAY 12, 2015 CL San Diego, CA SP Acad Emergency Med ID SHARED DECISION-MAKING; HEALTH-CARE DECISIONS; COMPUTED-TOMOGRAPHY; DEPARTMENT UTILIZATION; KNOWLEDGE TRANSLATION; PHYSICIAN PERCEPTIONS; RISK COMMUNICATION; REPORTED OUTCOMES; RANDOMIZED-TRIAL; INVOLVE PATIENTS AB Diagnostic imaging is integral to the evaluation of many emergency department (ED) patients. However, relatively little effort has been devoted to patient-centered outcomes research (PCOR) in emergency diagnostic imaging. This article provides background on this topic and the conclusions of the 2015 Academic Emergency Medicine consensus conference PCOR work group regarding "Diagnostic Imaging in the Emergency Department: A Research Agenda to Optimize Utilization." The goal was to determine a prioritized research agenda to establish which outcomes related to emergency diagnostic imaging are most important to patients, caregivers, and other key stakeholders and which methods will most optimally engage patients in the decision to undergo imaging. Case vignettes are used to emphasize these concepts as they relate to a patient's decision to seek care at an ED and the care received there. The authors discuss applicable research methods and approaches such as shared decision-making that could facilitate better integration of patient-centered outcomes and patient-reported outcomes into decisions regarding emergency diagnostic imaging. Finally, based on a modified Delphi process involving members of the PCOR work group, prioritized research questions are proposed to advance the science of patient-centered outcomes in ED diagnostic imaging. (C) 2015 by the Society for Academic Emergency Medicine C1 [Kanzaria, Hemal K.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Kanzaria, Hemal K.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [McCabe, Aileen M.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schaffer, Jason T.] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA. [Bellolio, M. Fernanda; Hess, Erik P.] Mayo Clin, Dept Emergency Med, Rochester, MN 55905 USA. [Merck, Lisa H.] Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, Providence, RI 02912 USA. [Hollander, Judd E.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Emergency Med, Philadelphia, PA 19107 USA. [Grudzen, Corita R.] NYU, Dept Emergency Med, New York, NY USA. [Kanzaria, Hemal K.] Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Kanzaria, Hemal K.] US Dept Vet Affairs, Los Angeles, CA USA. [Kanzaria, Hemal K.] RAND Hlth, Santa Monica, CA USA. [McCabe, Aileen M.] Royal Coll Surgeons Ireland, Emergency Care Res Unit, Div Populat Hlth Sci, Dublin 2, Ireland. [Meisel, Zachary M.] Univ Penn, Perelman Sch Med, Ctr Emergency Care Policy & Res, Philadelphia, PA 19104 USA. [Meisel, Zachary M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [LeBlanc, Annie] Mayo Clin, Dept Hlth Sci Res, Knowledge & Evaluat Res Unit, Div Hlth Care Policy & Res, Rochester, MN USA. [Bellolio, M. Fernanda; Hess, Erik P.] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA. [Merck, Lisa H.] Brown Univ, Warren Alpert Med Sch, Dept Diagnost Imaging, Providence, RI 02912 USA. [Applegate, Kimberly E.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA. [Hollander, Judd E.] Natl Acad Ctr Telehlth, Philadelphia, PA USA. [Grudzen, Corita R.] NYU, Dept Populat Hlth, New York, NY USA. [Carpenter, Christopher R.] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO USA. [Carpenter, Christopher R.] Washington Univ, Emergency Care Res Core, St Louis, MO USA. [Hess, Erik P.] Mayo Clin, Dept Hlth Sci Res, Div Healthcare Policy Res, Knowledge & Evaluat Res Unit, Rochester, MN USA. RP Hess, EP (reprint author), Mayo Clin, Dept Emergency Med, Rochester, MN 55905 USA. EM hess.erik@mayo.edu RI Carpenter, Christopher/E-3720-2013 OI Carpenter, Christopher/0000-0002-2603-7157; Grudzen, Corita/0000-0003-3039-8497 FU Agency for Healthcare Research and Quality (AHRQ) [1R13HS023498-01]; National Institute of Biomedical Imaging and Bioengineering [1 R13 EB 019813-01] FX Funding for this conference was made possible (in part) by grant number 1R13HS023498-01 from the Agency for Healthcare Research and Quality (AHRQ) and grant number 1 R13 EB 019813-01 from the National Institute of Biomedical Imaging and Bioengineering. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. NR 72 TC 10 Z9 10 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD DEC PY 2015 VL 22 IS 12 SI SI BP 1435 EP 1446 DI 10.1111/acem.12832 PG 12 WC Emergency Medicine SC Emergency Medicine GA DA5FP UT WOS:000367828900010 PM 26574729 ER PT J AU Maughan, BC Baren, JM Shea, JA Merchant, RM AF Maughan, Brandon C. Baren, Jill M. Shea, Judy A. Merchant, Raina M. TI Choosing Wisely in Emergency Medicine: A National Survey of Emergency Medicine Academic Chairs and Division Chiefs SO ACADEMIC EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Academic-Emergency-Medicine (AEM) Consensus Conference CY MAY 12, 2015 CL San Diego, CA SP Acad Emergency Med ID CARE; IMPROVE; LIST AB Objectives: The Choosing Wisely campaign was launched in 2011 to promote stewardship of medical resources by encouraging patients and physicians to speak with each other regarding the appropriateness of common tests and procedures. Medical societies including the American College of Emergency Physicians (ACEP) have developed lists of potentially low-value practices for their members to address with patients. No research has described the awareness or attitudes of emergency physicians (EPs) regarding the Choosing Wisely campaign. The study objective was to assess these beliefs among leaders of academic departments of emergency medicine (EM). Methods: This was a Web-based survey of emergency department (ED) chairs and division chiefs at institutions with allopathic EM residency programs. The survey examined awareness of Choosing Wisely, anticipated effects of the program, and discussions of Choosing Wisely with patients and professional colleagues. Participants also identified factors they associated with the use of potentially low-value services in the ED. Questions and answer scales were refined using iterative pilot testing with EPs and health services researchers. Results: Seventy-eight percent (105/134) of invited participants responded to the survey. Eighty percent of respondents were aware of Choosing Wisely. A majority of participants anticipate the program will decrease costs of care (72% of respondents) and use of ED diagnostic imaging (69%) but will have no effect on EP salaries (94%) or medical-legal risks (65%). Only 45% of chairs have ever addressed Choosing Wisely with patients, in contrast to 88 and 82% who have discussed it with faculty and residents, respectively. Consultant-requested tests were identified by 97% of residents as a potential contributor to low-value services in the ED. Conclusions: A substantial majority of academic EM leaders in our study were aware of Choosing Wisely, but only slightly more than half could recall any ACEP recommendations for the program. Respondents familiar with Choosing Wisely anticipated generally positive effects, but chairs reported only infrequently discussing Choosing Wisely with patients. Future research should identify potentially low-value tests requested by consultants and objectively measure the utility and cost of these tests among ED patient populations. (C) 2015 by the Society for Academic Emergency Medicine C1 [Maughan, Brandon C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Maughan, Brandon C.; Baren, Jill M.; Merchant, Raina M.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Shea, Judy A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Maughan, Brandon C.; Shea, Judy A.; Merchant, Raina M.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Maughan, BC (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM bmaughan@gmail.com FU University of Pennsylvania FX This study was specifically funded by an Eisenberg Scholar Research Grant from the University of Pennsylvania. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The authors have no potential conflicts of interest to disclose, in accordance with ICMJE guidelines. NR 10 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD DEC PY 2015 VL 22 IS 12 SI SI BP 1506 EP 1510 DI 10.1111/acem.12821 PG 5 WC Emergency Medicine SC Emergency Medicine GA DA5FP UT WOS:000367828900018 PM 26568385 ER PT J AU Kohsaka, S Miyata, H Ueda, I Masoudi, FA Peterson, ED Maekawa, Y Kawamura, A Fukuda, K Roe, MT Rumsfeld, JS AF Kohsaka, Shun Miyata, Hiroaki Ueda, Ikuko Masoudi, Frederick A. Peterson, Eric D. Maekawa, Yuichiro Kawamura, Akio Fukuda, Keiichi Roe, Matthew T. Rumsfeld, John S. CA JCD-KiCS NCDR TI An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS) SO AMERICAN HEART JOURNAL LA English DT Article ID IN-HOSPITAL OUTCOMES; MYOCARDIAL-INFARCTION; RISK; IMPACT; MODEL AB Background Details on Japanese patients undergoing percutaneous coronary intervention (PCI) and how they compare to US patients remain unclear. Furthermore, the application of US risk models has not been evaluated internationally. Methods The JCD-KiCS, a multicenter registry of consecutive PCI patients, was launched in 2008, with variables defined in accordance with the US NCDR. Patient and procedural characteristics from patients enrolled from 2008 to 2010 in the JCD-KiCS database (n = 9,941) and those in the NCDR (n = 732,345) were compared. The primary outcomes of this analysis were the hospital-level all-cause mortality and bleeding complications. The NCDR risk models for these 2 outcomes were evaluated in the Japanese data set; from the expected mortality and bleeding rates, the observed/expected ratios were calculated. Results The Japanese patients were older, with a higher proportion of men, diabetes, and smoking than the US patients. The Japanese patients also had a higher rate of complex lesions (26.1 vs 12.7% for bifurcation and 6.2% vs 3.2% for chronic total occlusions, all P < .001), longerprocedure time (29.7 +/- 21.5 vs 14.4 +/- 11.5 minutes, P < .001), and higher mortality (1.6% vs 0.9%, P < .001) and bleeding rates (2.9% vs 1.8%, P < .001) compared with US patients. The observed/expected ratios for mortality and bleeding were 0.921 and 0.467, respectively, in Japanese patients, and 1.002 and 0.981, respectively, for US patients. Conclusions The characteristics of patients undergoing PCI in clinical practice in Japan and the US differ substantially. The NCDR risk models applied well in Japanese patients for prediction of mortality, but not for bleeding, which tended to underestimate the risk. C1 [Kohsaka, Shun; Ueda, Ikuko; Maekawa, Yuichiro; Kawamura, Akio; Fukuda, Keiichi] Keio Univ, Tokyo, Japan. [Miyata, Hiroaki] Univ Tokyo, Tokyo, Japan. [Masoudi, Frederick A.; Rumsfeld, John S.] Univ Colorado, Aurora, CO USA. [Masoudi, Frederick A.; Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Peterson, Eric D.; Roe, Matthew T.] Duke Univ, Durham, NC USA. RP Kohsaka, S (reprint author), Keio Univ, Sch Med, Div Cardiol, 35 Shinanomachi, Tokyo, Japan. EM kohsaka@cpnet.med.keio.ac.jp RI Fukuda, Keiichi/L-3777-2013 OI Kohsaka, Shun/0000-0003-3779-2972 FU Japan Society for the Promotion of Science [25460630, 25460777]; National Cardiovascular Data Registry FX The present study was funded by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (25460630 and 25460777) and the National Cardiovascular Data Registry. The authors disclose no relationship with the industry. Dr Masoudi is a Senior Medical Officer, and Dr. Rumsfeld is the Chief Science Officer for the NCDR. NR 20 TC 4 Z9 4 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD DEC PY 2015 VL 170 IS 6 BP 1077 EP 1085 DI 10.1016/j.ahj.2015.09.017 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB1GH UT WOS:000368255700003 PM 26678628 ER PT J AU Koutroumpakis, E Wu, BCU Bakker, OJ Dudekula, A Singh, VK Besselink, MG Yadav, D van Santvoort, HC Whitcomb, DC Gooszen, HG Banks, PA Papachristou, GI AF Koutroumpakis, Efstratios Wu, Bechien U. Bakker, Olaf J. Dudekula, Anwar Singh, Vikesh K. Besselink, Marc G. Yadav, Dhiraj van Santvoort, Hjalmar C. Whitcomb, David C. Gooszen, Hein G. Banks, Peter A. Papachristou, Georgios I. TI Admission Hematocrit and Rise in Blood Urea Nitrogen at 24 h Outperform other Laboratory Markers in Predicting Persistent Organ Failure and Pancreatic Necrosis in Acute Pancreatitis: A Post Hoc Analysis of Three Large Prospective Databases SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID DETERMINANT-BASED CLASSIFICATION; NECROTIZING PANCREATITIS; SERUM CREATININE; HEMOCONCENTRATION; MORTALITY; SEVERITY; MANAGEMENT; ACCURACY; ATLANTA AB OBJECTIVES: Predicting severe acute pancreatitis (AP) remains a challenge. The present study compares admission blood urea nitrogen (BUN), hematocrit, and creatinine, as well as changes in their levels over 24 h, aiming to determine the most accurate laboratory test for predicting persistent organ failure and pancreatic necrosis. METHODS: Clinical data of 1,612 AP patients, enrolled prospectively in three independent cohorts (University of Pittsburgh, Brigham and Women's Hospital, Dutch Pancreatitis Study Group), were abstracted. The predictive accuracy of the studied laboratories was measured using area under the receiver-operating characteristic curve (AUC) analysis. A pooled analysis was conducted to determine their impact on the risk for persistent organ failure and pancreatic necrosis. Finally, a classification tree was developed on the basis of the most accurate laboratory parameters. RESULTS: Admission hematocrit >= 44% and rise in BUN at 24 h were the most accurate in predicting persistent organ failure (AUC: 0.67 and 0.71, respectively) and pancreatic necrosis (0.66 and 0.67, respectively), outperforming the other laboratory parameters and the acute physiology and chronic health evaluation-II score. In a pooled analysis, admission hematocrit >= 44% and rise in BUN at 24 h were associated with an odds ratio of 3.54 and 5.84 for persistent organ failure, and 3.11 and 4.07, respectively, for pancreatic necrosis. In addition, the classification tree illustrated that when both admission hematocrit was >= 44% and BUN levels increased at 24 h, the rates of persistent organ failure and pancreatic necrosis reached 53.6% and 60.3%, respectively. CONCLUSIONS: Admission hematocrit >= 44% and rise in BUN at 24 h may be the optimal predictive tools in clinical practice among existing laboratory parameters and scoring systems. C1 [Koutroumpakis, Efstratios; Yadav, Dhiraj; Whitcomb, David C.; Papachristou, Georgios I.] Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Wu, Bechien U.; Singh, Vikesh K.; Banks, Peter A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Pancreat Dis,Div Gastroenterol, Boston, MA 02115 USA. [Bakker, Olaf J.; Besselink, Marc G.; van Santvoort, Hjalmar C.; Gooszen, Hein G.] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands. [Dudekula, Anwar] Univ Pittsburgh, Med Ctr, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Dept Med, Div Gastroenterol, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, 200 Lothrop St,3rd Floor, Pittsburgh, PA 15213 USA. EM papachri@pitt.edu FU Veterans Affairs Merit Review Award [PRO00000496] FX The study was financially supported by a Veterans Affairs Merit Review Award (PRO00000496; PI: G.I.P.). The study design as well as the analysis and interpretation of the data were independent of the funding. NR 31 TC 7 Z9 7 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2015 VL 110 IS 12 BP 1707 EP 1716 DI 10.1038/ajg.2015.370 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB1NJ UT WOS:000368274700020 PM 26553208 ER PT J AU Laine, L Kaltenbach, T Barkun, A McQuaid, KR Subramanian, V Soetikno, R AF Laine, Loren Kaltenbach, Tonya Barkun, Alan McQuaid, Kenneth R. Subramanian, Venkataraman Soetikno, Roy TI ACG Guidelines on Management of PTEN-Hamartoma Tumor Syndrome: Does the Evidence Support so Much so Young? Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID SURVEILLANCE C1 [Laine, Loren] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Laine, Loren] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kaltenbach, Tonya; Soetikno, Roy] Vet Affair Palo Alto Healthcare Syst, Palo Alto, CA USA. [Kaltenbach, Tonya; Soetikno, Roy] Stanford Univ, Sch Med Affiliate, Palo Alto, CA 94304 USA. [Barkun, Alan] McGill Univ, Montreal, PQ, Canada. [McQuaid, Kenneth R.] UCSF, San Francisco, CA USA. [McQuaid, Kenneth R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Subramanian, Venkataraman] Univ Leeds, Leeds, W Yorkshire, England. RP Laine, L (reprint author), Yale Univ, Sch Med, Sect Digest Dis, POB 208019, New Haven, CT 06520 USA. EM loren.laine@yale.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2015 VL 110 IS 12 BP 1734 EP 1735 DI 10.1038/ajg.2015.345 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB1NJ UT WOS:000368274700027 PM 26673505 ER PT J AU Tanner, NT Silvestri, GA AF Tanner, Nichole T. Silvestri, Gerard A. TI POINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? Yes SO CHEST LA English DT Editorial Material ID CELL LUNG-CANCER; RANDOMIZED CONTROLLED-TRIAL; SOUTHWEST-ONCOLOGY-GROUP; INDUCTION CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; ENDOBRONCHIAL ULTRASOUND; REPEAT MEDIASTINOSCOPY; NEEDLE ASPIRATION; PHASE-III; THERAPY C1 [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm & Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA. RP Tanner, NT (reprint author), Med Univ S Carolina, Div Pulm & Crit Care Allergy & Sleep Med, 96 Jonathan Lucas St,Ste 812-CSB, Charleston, SC 29425 USA. EM tripici@musc.edu NR 23 TC 1 Z9 1 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2015 VL 148 IS 6 BP 1373 EP 1375 DI 10.1378/chest.15-1194 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DB1NC UT WOS:000368273900019 PM 26110373 ER PT J AU Tanner, NT Silvestri, GA AF Tanner, Nichole T. Silvestri, Gerard A. TI Rebuttal From Drs Tanner and Silvestri SO CHEST LA English DT Editorial Material ID CELL LUNG-CANCER; TRIMODALITY THERAPY C1 [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm & Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA. RP Tanner, NT (reprint author), Med Univ S Carolina, Div Pulm & Crit Care Allergy & Sleep Med, 96 Jonathan Lucas St,Ste 812-CSB, Charleston, SC 29425 USA. EM tripici@musc.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2015 VL 148 IS 6 BP 1379 EP 1380 DI 10.1378/chest.15-1195 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DB1NC UT WOS:000368273900021 PM 26110565 ER PT J AU Cooper, LA Page, ST Amory, JK Anawalt, BD Matsumoto, AM AF Cooper, Lori A. Page, Stephanie T. Amory, John K. Anawalt, Bradley D. Matsumoto, Alvin M. TI The association of obesity with sex hormone-binding globulin is stronger than the association with ageing - implications for the interpretation of total testosterone measurements SO CLINICAL ENDOCRINOLOGY LA English DT Article ID DECREASED ANDROGEN LEVELS; TANDEM MASS-SPECTROMETRY; OLDER MEN; METABOLIC SYNDROME; REFERENCE RANGES; HYPOGONADISM; DEFICIENCY; SERUM; POPULATION; PREVALENCE AB Objective Total testosterone concentrations are influenced by sex hormone-binding globulin (SHBG) concentrations, which are decreased by obesity and increased with ageing. Therefore, we sought to understand and compare the associations of ageing and obesity with SHBG. Design We performed a retrospective, cross-sectional analysis of the associations of obesity and age on SHBG and testosterone measurements in men being evaluated for hypogonadism. Patients, Measurements and Analysis A total of 3671 men who underwent laboratory testing for testosterone deficiency from the Veterans Administration Puget Sound Health Care System from 1997 through 2007 was included. Univariate and multivariate linear regression modelling of the associations between age and body mass index (BMI) and SHBG was performed. Results Obesity was associated with a significantly lower SHBG [beta = -1.26 (95% CI -1.14, -1.38) nmol/l] per unit increase in BMI. In contrast, ageing was associated with a significantly increased SHBG [beta = 0.46 (95% CI 0.39, 0.53) nmol/l per year] (P < 0.001 for both effects). The association of obesity with lower SHBG was two to three times larger than the association of ageing with increased SHBG in both univariate and multivariate modelling. On average, obese men (BMI > 30 kg/m(2)) had significantly lower SHBG and total testosterone concentrations than nonobese men [(mean +/- SD) SHBG: 36 +/- 22 vs 50 +/- 27 nmol/l and total testosterone: 10.5 +/- 5.4 nmol/l vs 14.1 +/- 7.4 nmol/l; (P < 0.001 for both comparisons)], but calculated free testosterone concentrations did not differ between obese and nonobese men. Conclusions We found that the association between obesity and lowered SHBG is greater than the association of ageing with increased SHBG. These competing effects may impact total testosterone measurements for the diagnosis of low testosterone, particularly in obese men. C1 [Cooper, Lori A.; Page, Stephanie T.; Amory, John K.; Anawalt, Bradley D.; Matsumoto, Alvin M.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Cooper, Lori A.; Matsumoto, Alvin M.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA. [Cooper, Lori A.; Page, Stephanie T.; Amory, John K.; Anawalt, Bradley D.; Matsumoto, Alvin M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Anawalt, BD (reprint author), Univ Washington, Dept Med, Box 356420,1959 NE Pacific St, Seattle, WA 98195 USA. EM banawalt@medicine.washington.edu FU National Institutes of Health (NIH) [T32HL0007028]; VA Fellowship in Advanced Geriatrics; National Institute of Aging (NIH) [AG037603A]; Department of Veterans Affairs Puget Sound Health Care System, Geriatric Research Education and Clinical Center FX L.A.C was supported by a training grant from the National Institutes of Health (NIH), T32HL0007028 and a VA Fellowship in Advanced Geriatrics; S.T.P. was supported by the National Institute of Aging (NIH), Grant AG037603A; A.M.M. was supported by the Department of Veterans Affairs Puget Sound Health Care System, Geriatric Research Education and Clinical Center. NR 32 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0300-0664 EI 1365-2265 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD DEC PY 2015 VL 83 IS 6 BP 828 EP 833 DI 10.1111/cen.12768 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DB1TX UT WOS:000368293000012 PM 25777143 ER PT J AU Robinson, JL Barron, DS Kirby, LAJ Bottenhorn, KL Hill, AC Murphy, JE Katz, JS Salibi, N Eickhoff, SB Fox, PT AF Robinson, Jennifer L. Barron, Daniel S. Kirby, Lauren A. J. Bottenhorn, Katherine L. Hill, Ashley C. Murphy, Jerry E. Katz, Jeffrey S. Salibi, Nouha Eickhoff, Simon B. Fox, Peter T. TI Neurofunctional Topography of the Human Hippocampus SO HUMAN BRAIN MAPPING LA English DT Article DE meta-analysis; fMRI; 7T; high field; DTI ID ACTIVATION-BASED PARCELLATION; INFERIOR PREFRONTAL CORTEX; FUNCTIONAL CONNECTIVITY; METAANALYTIC CONNECTIVITY; WORKING-MEMORY; GENDER-DIFFERENCES; EPISODIC MEMORY; SPATIAL MEMORY; HUMAN THALAMUS; BRAIN IMAGES AB Much of what was assumed about the functional topography of the hippocampus was derived from a single case study over half a century ago. Given advances in the imaging sciences, a new era of discovery is underway, with potential to transform the understanding of healthy processing as well as the ability to treat disorders. Coactivation-based parcellation, a meta-analytic approach, and ultra-high field, high-resolution functional and structural neuroimaging to characterize the neurofunctional topography of the hippocampus was employed. Data revealed strong support for an evolutionarily preserved topography along the long-axis. Specifically, the left hippocampus was segmented into three distinct clusters: an emotional processing cluster supported by structural and functional connectivity to the amygdala and parahippocampal gyrus, a cognitive operations cluster, with functional connectivity to the anterior cingulate and inferior frontal gyrus, and a posterior perceptual cluster with distinct structural connectivity patterns to the occipital lobe coupled with functional connectivity to the precuneus and angular gyrus. The right hippocampal segmentation was more ambiguous, with plausible 2- and 5-cluster solutions. Segmentations shared connectivity with brain regions known to support the correlated processes. This represented the first neurofunctional topographic model of the hippocampus using a robust, bias-free, multimodal approach. (C) 2015 Wiley Periodicals, Inc. C1 [Robinson, Jennifer L.; Kirby, Lauren A. J.; Bottenhorn, Katherine L.; Hill, Ashley C.; Murphy, Jerry E.; Katz, Jeffrey S.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Robinson, Jennifer L.; Kirby, Lauren A. J.; Bottenhorn, Katherine L.; Hill, Ashley C.; Murphy, Jerry E.; Katz, Jeffrey S.; Salibi, Nouha] Auburn Univ, Dept Elect & Comp Engn, Magnet Resonance Imaging Res Ctr, Auburn, AL 36849 USA. [Robinson, Jennifer L.] Auburn Univ, Dept Kinesiol, Auburn, AL 36849 USA. [Barron, Daniel S.] Yale Univ, Sch Med, New Haven, CT USA. [Salibi, Nouha] MR Res & Dev, Siemens Healthcare, Malvern, PA USA. [Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Simon B.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Fox, Peter T.] Shenzhen Univ, Sch Med, Neuroimaging Lab, Shenzhen 518060, Guangong, Peoples R China. RP Robinson, JL (reprint author), Auburn Univ, Dept Psychol, 226 Thach Hall, Auburn, AL 36849 USA. EM jrobinson@auburn.edu OI Murphy, Jerry/0000-0002-2841-9087 FU National Institute of Mental Health [R01 074457] FX National Institute of Mental Health; Contract grant number: R01 074457 (Fox PI) NR 71 TC 8 Z9 8 U1 7 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD DEC PY 2015 VL 36 IS 12 BP 5018 EP 5037 DI 10.1002/hbm.22987 PG 20 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA DB1QF UT WOS:000368283100021 PM 26350954 ER PT J AU Kim, H Hung, WW Paik, MC Ross, JS Zhao, ZL Kim, GS Boockvar, K AF Kim, Hongsoo Hung, William W. Paik, Myunghee Cho Ross, Joseph S. Zhao, Zhonglin Kim, Gi-Soo Boockvar, Kenneth TI Predictors and outcomes of unplanned readmission to a different hospital SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE readmissions; hospital care; patient outcomes; health policy ID ADVERSE EVENTS; PREVALENCE; REHOSPITALIZATIONS; RECORDS; MODELS AB Objectives: To examine patient, hospital and market factors and outcomes associated with readmission to a different hospital compared with the same hospital. Design: A population-based, secondary analysis using multilevel causal modeling. Setting: Acute care hospitals in California in the USA. Participants: In total, 509 775 patients aged 50 or older who were discharged alive from acute care hospitals (index hospitalizations), and 59 566 who had a rehospitalization within 30 days following their index discharge. Intervention: No intervention. Main Outcome Measures(s): Thirty-day unplanned readmissions to a different hospital compared with the same hospital and also the costs and health outcomes of the readmissions. Results: Twenty-one percent of patients with a rehospitalization had a different-hospital readmission. Compared with the same-hospital readmission group, the different-hospital readmission group was more likely to be younger, male and have a lower income. The index hospitals of the different-hospital readmission group were more likely to be smaller, for-profit hospitals, which were also more likely to be located in counties with higher competition. The different-hospital readmission group had higher odds for in-hospital death (8.1 vs. 6.7%; P < 0.0001) and greater readmission hospital costs ($15 671.8 vs. $14 286.4; P < 0.001) than the same-hospital readmission group. Conclusions: Patient, hospital and market characteristics predicted different-hospital readmissions compared with same-hospital readmissions. Mortality and cost outcomes were worse among patients with different-hospital readmissions. Strategies for better care coordination targeting people at risk for different-hospital readmissions are necessary. C1 [Kim, Hongsoo] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul, South Korea. [Kim, Hongsoo] Seoul Natl Univ, Inst Hlth & Environm, Seoul, South Korea. [Hung, William W.; Boockvar, Kenneth] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Hung, William W.; Boockvar, Kenneth] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Paik, Myunghee Cho; Kim, Gi-Soo] Seoul Natl Univ, Coll Nat Sci, Dept Stat, Seoul 151742, South Korea. [Ross, Joseph S.] Yale Univ, Sch Med, Gen Internal Med, New Haven, CT USA. [Boockvar, Kenneth] Jewish Home Lifecare, Res Inst Aging, New York, NY USA. RP Kim, H (reprint author), Seoul Natl Univ, Grad Sch Publ Hlth, 1 Gwanak Ro, Seoul, South Korea. EM hk65@snu.ac.kr OI Boockvar, Kenneth/0000-0003-1165-5558 FU University Research Challenge Fund of New York University, NY; National Research Foundation of Korea (NRF) grant - Korean government (MSIP) [2013R1A2A2A01067262]; National Institute on Aging [K08AG032886]; United States Department of Veterans Affairs Health Services Research and Development Service [REA 08-260]; Greenwall Foundation, New York, NY FX This work was supported by the University Research Challenge Fund of New York University, NY (H.K.); a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. 2013R1A2A2A01067262 to M.C.P. and J.K.) and the National Institute on Aging (K08AG032886 to J.S.R.); and the United States Department of Veterans Affairs Health Services Research and Development Service (REA 08-260 to K.B.) and the Greenwall Foundation, New York, NY (K.B.). The contents do not represent the views of any funding agency addressed above. NR 26 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 EI 1464-3677 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD DEC 1 PY 2015 VL 27 IS 6 BP 513 EP 519 DI 10.1093/intqhc/mzv082 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DB1EI UT WOS:000368250400013 PM 26472739 ER PT J AU Mansh, M Katz, KA Linos, E Chren, MM Arron, S AF Mansh, Matthew Katz, Kenneth A. Linos, Eleni Chren, Mary-Margaret Arron, Sarah TI Association of Skin Cancer and Indoor Tanning in Sexual Minority Men and Women SO JAMA DERMATOLOGY LA English DT Article ID UNITED-STATES; CUTANEOUS MELANOMA; RISK BEHAVIORS; PREVALENCE; METAANALYSIS; POPULATION; RADIATION; HISTORY; DEPRESSION; EXPOSURE AB IMPORTANCE Skin cancer, the most common cancer in the United States, is highly associated with outdoor and indoor tanning behaviors. Although indoor tanning has been suggested to be more common among sexual minority (self-reported as homosexual, gay, or bisexual) men compared with heterosexual men, whether rates of skin cancer vary by sexual orientation is unknown. OBJECTIVE To investigate whether skin cancer prevalence and indoor tanning behaviors vary by sexual orientation in the general population. DESIGN, SETTING, AND PARTICIPANTS We performed a cross-sectional study using data from the 2001, 2003, 2005, and 2009 California Health Interview Surveys (CHISs) and the 2013 National Health Interview Survey (NHIS) of population-based samples of the California and US noninstitutionalized civilian population. Participants included 192 575 men and women 18 years or older who identified as heterosexual or a sexual minority. MAIN OUTCOMES AND MEASURES Self-reported lifetime history of skin cancer and 12-month history of indoor tanning. RESULTS The study included 78 487 heterosexual men, 3083 sexual minority men, 107 976 heterosexual women, and 3029 sexual minority women. Sexual minority men were more likely than heterosexual men to report having skin cancer (2001-2005 CHISs: adjusted odds ratio [aOR], 1.56; 95% CI, 1.18-2.06, P < .001; 2013 NHIS: aOR, 2.13; 95% CI, 1.14-3.96, P = .02) and having tanned indoors (2009 CHIS: aOR, 5.80; 95% CI, 2.90-11.60, P < .001; 2013 NHIS: aOR, 3.16; 95% CI, 1.77-5.64, P < .001). Sexual minority women were less likely than heterosexual women to report having had nonmelanoma skin cancer (2001-2005 CHIS: aOR, 0.56; 95% CI, 0.37-0.86, P = .008) and having tanned indoors (2009 CHIS: aOR, 0.43; 95% CI, 0.20-0.92, P = .03; 2013 NHIS: aOR, 0.46; 95% CI, 0.26-0.81, P = .007). CONCLUSIONS AND RELEVANCE Sexual minority men indoor tan more frequently and report higher rates of skin cancer than heterosexual men. Primary and secondary prevention efforts targeted at sexual minority men might reduce risk factors for, and consequences of, skin cancer. C1 [Mansh, Matthew; Linos, Eleni; Chren, Mary-Margaret; Arron, Sarah] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA. [Mansh, Matthew] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Katz, Kenneth A.] Kaiser Permanente, Dept Dermatol, Pleasanton, CA USA. [Chren, Mary-Margaret; Arron, Sarah] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA USA. RP Arron, S (reprint author), Univ Calif San Francisco, Dept Dermatol, 1701 Divisadero St,Third Floor,Box 316, San Francisco, CA 94115 USA. EM sarah.arron@ucsf.edu OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700 FU Stanford Medical Scholars Research Grant; National Center for Advancing Translational Sciences, National Institutes of Health [KL2TR000143]; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health [K24 AR052667] FX This study was supported by a Stanford Medical Scholars Research Grant (Mr Mansh); grant KL2TR000143 from the National Center for Advancing Translational Sciences, National Institutes of Health to the University of California, San Francisco, Clinical and Translational Science Institute (Drs Linos and Arron); and grant K24 AR052667 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (Dr Chren). NR 48 TC 5 Z9 5 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD DEC PY 2015 VL 151 IS 12 BP 1308 EP 1316 DI 10.1001/jamadermatol.2015.3126 PG 9 WC Dermatology SC Dermatology GA DA7OX UT WOS:000367994700006 ER PT J AU Datta, SK Warshaw, EM Edison, KE Kapur, K Thottapurathu, L Moritz, TE Reda, DJ Whited, JD AF Datta, Santanu K. Warshaw, Erin M. Edison, Karen E. Kapur, Kush Thottapurathu, Lizy Moritz, Thomas E. Reda, Domenic J. Whited, John D. TI Cost and Utility Analysis of a Store-and-Forward Teledermatology Referral System A Randomized Clinical Trial SO JAMA DERMATOLOGY LA English DT Article ID HEALTH-STATE UTILITIES; QUALITY-OF-LIFE; CONSULT SYSTEM AB IMPORTANCE The costs and utility of teledermatology are important features of implementation. Such an analysis requires a description of the perspective of the entity that will bear the cost. OBJECTIVE To assess the costs and utility of a store-and-forward teledermatology referral process compared with a conventional referral process from the perspectives of the Department of Veterans Affairs (VA) and society. DESIGN, SETTING, AND PARTICIPANTS Three hundred ninety-one randomized participants were referred from remote sites of primary care to the dermatology services of 2 VA medical facilities for ambulatory skin conditions from December 2008 through June 2010, and follow-up was completed in March 2011. The time trade-off utility measures and costs were collected during a 9-month period among participants in a 2-site parallel group randomized clinical trial. The perspectives of the VA and society were evaluated. The multiple imputation procedure or weighted means were used for missing data elements. Data were analyzed from January to July 2014. INTERVENTIONS Referrals were managed using store-and-forward teledermatology or a conventional text-based referral process. MAIN OUTCOMES AND MEASURES Total costs from the perspectives of the VA and society incurred during the 9-month follow-up were used to derive per-participant costs. Utility, using the time trade-off method, was the measure of effectiveness. RESULTS From the VA perspective, the total cost for conventional referrals was $66 145 (minimum, $58 697; maximum, $71 635), or $338 (SD, $291) per participant (196 participants); the total cost for teledermatology referrals was $59 917 (mimimum, $51 794; maximum, $70 398), or $308 (SD, $298) per participant (195 participants). The $30 difference in per-participant cost was not statistically significant (95% CI, -$79 to $20). From the societal perspective, the total cost for conventional referrals was $106 194 (minimum, $98 746; maximum, $111 684), or $542 (SD, $403) per participant (196 participants); the total cost for teledermatology referrals was $89 523 (minimum, $81 400; maximum, $100 400) or $460 (SD, $428) per participant. This $82 difference in per-participant cost was statistically significant (95% CI, -$12 to -$152). From baseline to the 9-month follow-up, the time trade-off utility value improved by 0.02 in the conventional referral group and 0.03 in the teledermatology group. This difference was not statistically significant (P = .50). CONCLUSIONS AND RELEVANCE Compared with conventional referrals, store-and-forward teledermatology referrals were performed at a comparable cost (VA perspective) or at a lower cost (societal perspective) with no evidence of a difference in utility as measured by the time trade-off method. C1 [Datta, Santanu K.; Whited, John D.] Durham Vet Affairs Med Ctr, Res & Dev, Durham, NC 27705 USA. [Datta, Santanu K.; Whited, John D.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA. [Warshaw, Erin M.] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA. [Warshaw, Erin M.] Minneapolis Vet Affairs Hlth Care Syst, Dermatol Serv, Minneapolis, MN USA. [Edison, Karen E.] Univ Missouri, Dept Dermatol, Columbia, MO 65211 USA. [Kapur, Kush] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Neurol, Boston, MA USA. [Thottapurathu, Lizy; Moritz, Thomas E.; Reda, Domenic J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA. RP Whited, JD (reprint author), Durham Vet Affairs Med Ctr, Res & Dev, Mail Stop 151,508 Fulton St, Durham, NC 27705 USA. EM john.whited@va.gov FU Department of Veterans Affairs Office of Research and Development, Health Services Research and Development [IIR 05-278] FX This study was supported by Service Award IIR 05-278 from the Department of Veterans Affairs Office of Research and Development, Health Services Research and Development. NR 16 TC 7 Z9 8 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD DEC PY 2015 VL 151 IS 12 BP 1323 EP 1329 DI 10.1001/jamadermatol.2015.2362 PG 7 WC Dermatology SC Dermatology GA DA7OX UT WOS:000367994700009 PM 26375589 ER PT J AU Graham, LA Hollis, RH Richman, JS Hawn, MT AF Graham, Laura A. Hollis, Robert H. Richman, Joshua S. Hawn, Mary T. TI Frequency of Surgery Cancellations Associated With Myocardial Infarction or Death 6 Months After Coronary Stent Placement SO JAMA SURGERY LA English DT Letter ID NONCARDIAC SURGERY; RISK C1 [Graham, Laura A.; Hollis, Robert H.; Richman, Joshua S.; Hawn, Mary T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Graham, Laura A.; Hollis, Robert H.; Richman, Joshua S.; Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA. [Hawn, Mary T.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA. RP Hawn, MT (reprint author), Stanford Univ, 300 Pasteur Dr,M121 Alway Bldg, Palo Alto, CA 94306 USA. EM mhawn@stanford.edu NR 6 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD DEC PY 2015 VL 150 IS 12 BP 1199 EP 1201 DI 10.1001/jamasurg.2015.3078 PG 4 WC Surgery SC Surgery GA DA7NJ UT WOS:000367990700024 PM 26443936 ER PT J AU Rostami, R Badran, BW Kazemi, R Habibnezhad, M George, MS AF Rostami, Reza Badran, Bashar W. Kazemi, Reza Habibnezhad, Mohammad George, Mark S. TI Long-lasting analgesic effect of transcranial direct current stimulation in treatment of chronic endometriosis pain SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH LA English DT Article DE endometriosis; motor cortex; pain; transcranial direct current stimulation ID CORTEX; TDCS AB Approximately 10-20% of women of reproductive age suffer from endometriosis, with 70-90% of these women reporting chronic pain symptoms that persist during their menstrual cycle. We are presenting a case in which a novel form of noninvasive brain stimulation called transcranial direct current stimulation was used as an intervention in a 32-year-old woman with persistent, chronic pain symptoms caused by endometriosis for 20 years. Ten daily, 20-min sessions of 2-mA anodal transcranial direct current stimulation were applied over the left primary motor cortex. Acutely, visual analog scale pain symptoms were reduced by 60%. There were also significant decreases in modules of the Endometriosis Health Profile. At the 4-month follow-up, the patient still expressed an overall decrease in pain symptoms of 30%. C1 [Rostami, Reza; Badran, Bashar W.; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Rostami, Reza] Univ Tehran, Fac Psychol & Educ, Tehran, Iran. [Rostami, Reza; Kazemi, Reza; Habibnezhad, Mohammad] Shahid Beheshti Univ, Atieh Clin Neurosci Ctr, Tehran, Iran. [Habibnezhad, Mohammad] Shahid Beheshti Univ, Inst Cognit & Brain Sci, Tehran, Iran. [Kazemi, Reza] Lorestan Univ, Fac Literature & Human Sci, Dept Psychol, Khorramabad, Iran. RP Rostami, R (reprint author), Univ Tehran, Fac Educ & Psychol, Jalal Al Ahmad St, Tehran, Iran. EM rrostami@ut.ac.ir RI Rostami, Reza/G-3181-2017 OI Rostami, Reza/0000-0001-9318-108X NR 12 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1341-8076 EI 1447-0756 J9 J OBSTET GYNAECOL RE JI J. Obstet. Gynaecol. Res. PD DEC PY 2015 VL 41 IS 12 BP 1998 EP 2001 DI 10.1111/jog.12817 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DA7YG UT WOS:000368020900021 PM 26419900 ER PT J AU Raab, PA Mackintosh, MA Gros, DF Morland, LA AF Raab, Phillip A. Mackintosh, Margaret-Anne Gros, Daniel F. Morland, Leslie A. TI Examination of the Content Specificity of Posttraumatic Cognitions in Combat Veterans With Posttraumatic Stress Disorder SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID ADMINISTERED PTSD SCALE; PSYCHOMETRIC PROPERTIES; PROCESSING THERAPY; INVENTORY PTCI; DEPRESSION; SYMPTOMS; ANXIETY; METAANALYSIS; INDIVIDUALS; VALIDATION AB Objective: Cognitive theories have proposed the idea of content specificity, which holds that emotional disorders are associated with unique sets of negative cognitions. The existent research exploring the content specificity related to posttraumatic stress disorder (PTSD) and depression is sparse, and research is especially needed in veteran samples. The purpose of this study was to examine the associations of PTSD symptom clusters and comorbid depressive symptoms with posttraumatic cognitions. Method: This study was cross-sectional in design, and the sample consisted of data from 150 male combat veterans with PTSD drawn from the baseline assessments of a large clinical trial. Analyses involved a series of separate and simultaneous linear regressions to examine the unique associations of comorbid depressive symptoms and PTSD symptom clusters with posttraumatic cognitions, as well as post hoc analyses to examine the mediational role of comorbid depressive symptoms. Results: Findings demonstrated that posttraumatic negative cognitions about the self and self-blame were most strongly associated with comorbid depressive symptoms and the depression-related PTSD numbing cluster. Comorbid depressive symptoms also partially mediated nearly all the relationships between posttraumatic cognitions and PTSD symptom clusters. Conclusions: The findings of this study suggest that posttraumatic cognitions about the self and self-blame are not specific to PTSD but rather are more strongly related to symptoms of depression and negative affect. The results also suggest a potential pathway from posttraumatic cognitions to PTSD through the partially mediating influence of comorbid depression, and highlight the need to assess and treat comorbid depression in veterans with PTSD. C1 [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Dept Vet Affairs Pacific Isl Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Pacific Isl Div, Honolulu, HI USA. [Gros, Daniel F.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Morland, Leslie A.] Univ Hawaii Manoa, Dept Psychiat, John A Burns Sch Med, Honolulu, HI 96822 USA. RP Raab, PA (reprint author), Natl Ctr Posttraumat Stress Disorder, Pacific Isl Div, 3375 Koapaka St,Suite I-560, Honolulu, HI 96819 USA. EM drewraab@gmail.com FU Department of Defense and the Office of Research and Development, Medical Research Service [PT074516]; Department of Veterans Affairs FX This work is partially supported by Grant PT074516 from the Department of Defense and the Office of Research and Development, Medical Research Service, Department of Veterans Affairs. This study's funding organizations had no role in the study's design, in its collection, analysis, and interpretation of data, in writing this report, or the decision to submit this article for publication. All views and opinions expressed herein are those of the authors and do not necessarily reflect those of our respective institutions or the Department of Veterans Affairs. We declare no conflicts of interest. NR 41 TC 0 Z9 0 U1 2 U2 7 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0033-2747 J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PD WIN PY 2015 VL 78 IS 4 BP 328 EP 340 DI 10.1080/00332747.2015.1082337 PG 13 WC Psychiatry SC Psychiatry GA DB3BD UT WOS:000368383600004 PM 26745686 ER PT J AU Lall, C Houshyar, R Landman, J Verma, S Goyenechea, M Bhargava, P Pulford, C Okhunov, Z Siaghani, PJ Menias, C AF Lall, Chandana Houshyar, Roozbeh Landman, Jaime Verma, Sadhna Goyenechea, Martin Bhargava, Puneet Pulford, Christopher Okhunov, Zhamshid Siaghani, Parwiz J. Menias, Christine TI Renal Collision and Composite Tumors: Imaging and Pathophysiology SO UROLOGY LA English DT Article ID OF-THE-LITERATURE; CELL CARCINOMA; METASTASIS; CANCER; ANGIOMYOLIPOMA; KIDNEY AB OBJECTIVE To illustrate the imaging appearances of a spectrum of renal collision and composite tumors. Occurrence of collision and composite tumors in the genitourinary tract is rare compared to the usual occurrence of synchronous tumors. METHODS Case studies were chosen that represent the different tumors. Analysis was made on both the imaging and the pathology if excision was performed. RESULTS Presence of 2 different cell types can lead to confusing imaging findings, and biopsy or excision is typically needed for final diagnosis. Some composite tumors have a characteristic appearance on imaging based on their pathologic features. CONCLUSION Familiarity with imaging findings may help radiologists include these tumors in their differential diagnosis. Published by Elsevier Inc. C1 [Okhunov, Zhamshid] Univ Calif Irvine, Dept Urol, Orange, CA 92868 USA. Univ Cincinnati, Med Ctr, Dept Radiol, Cincinnati, OH 45267 USA. Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Mayo Clin, Dept Radiol, Scottsdale, AZ USA. RP Okhunov, Z (reprint author), Univ Calif Irvine, Dept Urol, 333 City Blvd West,Suite 2100, Orange, CA 92868 USA. EM Zokhunov@uci.edu NR 22 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD DEC PY 2015 VL 86 IS 6 BP 1159 EP 1164 DI 10.1016/j.urology.2015.07.032 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA DB2LD UT WOS:000368339100028 PM 26431891 ER PT J AU Feng, WW Wang, J Chhatbar, PY Doughty, C Landsittel, D Lioutas, VA Kautz, SA Schlaug, G AF Feng, Wuwei Wang, Jasmine Chhatbar, Pratik Y. Doughty, Christopher Landsittel, Douglas Lioutas, Vasileios-Arsenios Kautz, Steven A. Schlaug, Gottfried TI Corticospinal Tract Lesion Load: An Imaging Biomarker for Stroke Motor Outcomes SO ANNALS OF NEUROLOGY LA English DT Article ID ACUTE ISCHEMIC-STROKE; PROGNOSTIC VALUE; RECOVERY; STIMULATION; RELIABILITY; IMPAIRMENT; POSTSTROKE; INTEGRITY; DEPENDS; SIZE AB Objective: The aim of this work was to investigate whether an imaging measure of corticospinal tract (CST) injury in the acute phase can predict motor outcome at 3 months in comparison to clinical assessment of initial motor impairment. Methods: A two-site prospective cohort study followed up a group of first-ever ischemic stroke patients using the Upper-Extremity Fugl-Meyer (UE-FM) Scale to measure motor impairment in the acute phase and at 3 months. A weighted CST lesion load (wCST-LL)was calculated by overlaying the patient's lesion map on magnetic resonance imaging with a probabilistic CST constructed from healthy control subjects. Regression models were fit to assess the predictive value of wCST-LL and compared with initial motor impairment. Results: Seventy-six patients (37 from cohort 1 and 39 from cohort 2) completed the study. wCST-LL as well as assessment of motor impairment (UE-FM) in the acute phase correlated with motor impairment (UE-FM) at 3 months in both cohort 1 (R-2 = 0.69 vs. R-2 = 0.67; p = 0.43) and cohort 2 (R-2 = 0.69 vs. R-2 = 0.62; p = 0.25). In the severely impaired subgroup (defined as UE-FM <= 10 at baseline), wCST-LL correlated with outcomes significantly better than clinical assessment (R-2 = 0.47 vs. R-2 = 0.11; p = 0.03). In the nonseverely impaired subgroup, stroke patients recovered approximately 70% of their maximal recovery potential. All stroke patients in both cohorts had poor motor outcomes at 3 months (defined as UE-FM <= 25) when wCST-LL was >= 7.0 cc (positive predictive value was 100%). Interpretation: wCST-LL, an imaging biomarker determined in the acute phase, can predict poststroke motor outcomes at 3 months, especially in patients with severe impairment at baseline. C1 [Feng, Wuwei; Chhatbar, Pratik Y.] Med Univ S Carolina, Dept Neurol, MUSC Stroke Ctr, Charleston, SC 29425 USA. [Wang, Jasmine; Doughty, Christopher; Lioutas, Vasileios-Arsenios; Schlaug, Gottfried] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Neuroimaging & Stroke Recovery Lab, Boston, MA 02215 USA. [Landsittel, Douglas] Univ Pittsburgh, Dept Med, Sect Biomarkers & Predict Modeling, Pittsburgh, PA USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Feng, Wuwei; Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. RP Schlaug, G (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Neuroimaging & Stroke Recovery Lab, 330 Brookline Ave, Boston, MA 02215 USA. EM gschlaug@bidmc.harvard.edu FU American Heart Association Scientist Development Grant [14SDG1829003]; National Institutes of Health (NIH) [UL1 RR029882, UL1 TR000062, P20GM109040, 1R01 DC008796, R01 DC009823-01]; Rehabilitation Research & Development Service of Department of Veterans Affairs; Mary Crown and William Ellis Fund; Richard and Rosalyn Slifka Family Fund; Tom and Suzanne McManmon Family Fund; Doris Duke Charitable Foundation; South Carolina Clinical & Translational Research Institute/Medical University of South Carolina FX The authors acknowledge grant support from American Heart Association Scientist Development Grant 14SDG1829003 (W.F.) and the South Carolina Clinical & Translational Research Institute/Medical University of South Carolina, through National Institutes of Health (NIH) grant numbers UL1 RR029882 and UL1 TR000062 (W.F.), NIH P20GM109040 (W.F., P.Y.C., and S.K.), Rehabilitation Research & Development Service of the Department of Veterans Affairs (S.K.), NIH 1R01 DC008796 (G.S.), R01 DC009823-01 (G.S.), the Mary Crown and William Ellis Fund (G.S.), the Richard and Rosalyn Slifka Family Fund (G.S.), and the Tom and Suzanne McManmon Family Fund (G.S.) and the Doris Duke Charitable Foundation (C.D.). NR 33 TC 21 Z9 21 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD DEC PY 2015 VL 78 IS 6 BP 860 EP 870 DI 10.1002/ana.24510 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA3DY UT WOS:000367678100004 PM 26289123 ER PT J AU Cassaday, RD Stevenson, PA Gooley, TA Chauncey, TR Pagel, JM Rajendran, J Till, BG Philip, M Orozco, JJ Bensinger, WI Holmberg, LA Shustov, AR Green, DJ Smith, SD Libby, EN Maloney, DG Press, OW Gopal, AK AF Cassaday, Ryan D. Stevenson, Philip A. Gooley, Theodore A. Chauncey, Thomas R. Pagel, John M. Rajendran, Joseph Till, Brian G. Philip, Mary Orozco, Johnnie J. Bensinger, William I. Holmberg, Leona A. Shustov, Andrei R. Green, Damian J. Smith, Stephen D. Libby, Edward N. Maloney, David G. Press, Oliver W. Gopal, Ajay K. TI High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE non-Hodgkin lymphoma; stem cell transplantation; antibody therapy; radiotherapy ID Y-90 IBRITUMOMAB TIUXETAN; PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; NON-HODGKINS-LYMPHOMA; YTTRIUM-90-IBRITUMOMAB TIUXETAN; PHASE-II; MYELOABLATIVE RADIOCHEMOTHERAPY; ALLOGENEIC TRANSPLANTATION; PLUS RITUXIMAB; BEAM AB Autologous stem cell transplant (ASCT) can improve outcomes for mantle cell lymphoma (MCL) patients, yet relapses are frequent. We hypothesized that high-dose anti-CD20 radioimmunotherapy (RIT)-based conditioning could improve results in this setting. We thus assessed 162 consecutive patients with MCL at our centre undergoing ASCT following high-dose RIT-based (n = 61) or standard (n = 101) conditioning. RIT patients were less likely to be in first remission (48% vs. 72%; P = 0.002), be in complete remission (CR) (26% vs. 61%; P < 0.001) and have chemosensitive disease (84% vs. 96%; P = 0.006). Rh-based conditioning was associated with a reduced risk of treatment failure [hazard ratio (HR) 0.40; P = 0.001] and mortality (HR 0.49; P = 0.01) after adjusting for these imbalances. This difference increased as disease status worsened (from CR to partial remission to stable/progressive disease), with respective HRs of 1.14, 0.53 and 0.04 for mortality, and 0.66, 0.36 and 0.14 for treatment failure. RIT-based conditioning appears to improve outcome following ASCT for MCL patients unable to achieve CR after controlling for imbalances in important risk factors. These data support the further study of PIT and radiation-based strategies in a risk-adapted approach to ASCT for persistent MCL. C1 [Cassaday, Ryan D.; Gooley, Theodore A.; Chauncey, Thomas R.; Rajendran, Joseph; Till, Brian G.; Philip, Mary; Orozco, Johnnie J.; Bensinger, William I.; Holmberg, Leona A.; Shustov, Andrei R.; Green, Damian J.; Smith, Stephen D.; Libby, Edward N.; Maloney, David G.; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Cassaday, Ryan D.; Philip, Mary; Orozco, Johnnie J.; Shustov, Andrei R.] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA. [Stevenson, Philip A.; Gooley, Theodore A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Clin Stat Div, Seattle, WA 98195 USA. [Chauncey, Thomas R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Chauncey, Thomas R.; Pagel, John M.; Till, Brian G.; Bensinger, William I.; Holmberg, Leona A.; Green, Damian J.; Smith, Stephen D.; Libby, Edward N.; Maloney, David G.; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA. [Rajendran, Joseph] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA 98195 USA. RP Gopal, AK (reprint author), 825 Eastlake Ave E,Mailstop G3-200, Seattle, WA 98109 USA. EM agopal@uw.edu FU National Institutes of Health [K12 CA076930, P01 CA044991, K24 CA184039]; Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative; Hutchinson Center/University of Washington Cancer Consortium Cancer Center Support Grant [P30 CA015704] FX This work was supported by grants from the National Institutes of Health [K12 CA076930 (R.D.C.), P01 CA044991 (O.W.P.), and K24 CA184039 (A.K.G.)] and the Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative. Support was also provided by Hutchinson Center/University of Washington Cancer Consortium Cancer Center Support Grant (P30 CA015704) and philanthropic gifts from Frank and Betty Vandermeer, Don and Debbie Hunkins, the Mary Aileen Wright Memorial Fund and the David and Patricia Giuliani Family Foundation, A.K.G. is a Scholar in Clinical Research for the Leukemia and Lymphoma Society. NR 37 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD DEC PY 2015 VL 171 IS 5 BP 788 EP 797 DI 10.1111/bjh.13773 PG 10 WC Hematology SC Hematology GA DA4AB UT WOS:000367741400012 PM 26455717 ER PT J AU Inkelas, M Brown, AF Vassar, SD Sankare, IC Martinez, AB Kubicek, K Kuo, T Mahajan, A Gould, M Mittman, BS AF Inkelas, Moira Brown, Arleen F. Vassar, Stefanie D. Sankare, Ibrahima C. Martinez, Arturo B. Kubicek, Katrina Kuo, Tony Mahajan, Anish Gould, Michael Mittman, Brian S. TI Enhancing Dissemination, Implementation, and Improvement Science in CTSAs through Regional Partnerships SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE LA English DT Article DE dissemination; implementation; improvement science; translational research; institutional collaboration ID CLINICAL-RESEARCH ENTERPRISE; HEALTH-CARE; INTEGRATION AB Background and ImportanceChallenges in healthcare policy and practice have stimulated interest in dissemination and implementation science. The Institute of Medicine Committee on the Clinical Translational Science Award (CTSA) program recommended expanding the CTSA program's investment and activity in this domain. Guidance is needed to facilitate successful growth of DII science infrastructure, activity and impacts. ObjectivesSeveral CTSAs in Southern California collaborated to identify and respond to local challenges and opportunities to expand dissemination, implementation and improvement research by strengthening capacity and relationships between DII researchers and community, health system, and population health partners. Main outcomesPlanning and outreach by the Southern California CTSAs increased awareness and interest in DII research and generated recommendations for growth. Recommendations include: increasing strong partnerships with healthcare and population health systems to guide policy research agendas and collaborative DII science; promoting multi-sector partnerships that involve researchers and delivery systems throughout DII processes; bringing together multiple disciplines; and addressing national and international barriers as well as opportunities in DII science. ImplicationsCTSAs through regional collaboration can increase their contributions to improved community health via skill-building, partnership development and enhanced outreach to local healthcare and public health agencies and delivery systems. C1 [Inkelas, Moira] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Clin & Translat Sci Inst, Los Angeles, CA 90095 USA. [Brown, Arleen F.; Vassar, Stefanie D.; Sankare, Ibrahima C.; Martinez, Arturo B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Clin & Translat Sci Inst,Hlth Serv Res, Los Angeles, CA 90095 USA. [Kuo, Tony] Los Angeles Cty Dept Publ Hlth, Div Chron Dis & Injury Prevent, Los Angeles, CA USA. [Kuo, Tony] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Kuo, Tony] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. [Mahajan, Anish] Los Angeles Cty Dept Hlth Serv, Syst Planning Improvement & Data Analyt, Los Angeles, CA USA. [Gould, Michael; Mittman, Brian S.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Kubicek, Katrina] Univ So Calif, Southern Calif Clin & Translat Sci Inst, Los Angeles, CA USA. [Kubicek, Katrina] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, VA Ctr Implementat Practice & Res Support CIPRS, Los Angeles, CA USA. RP Inkelas, M (reprint author), Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Clin & Translat Sci Inst, Los Angeles, CA 90095 USA. EM minkelas@ucla.edu OI Kuo, Tony/0000-0002-4120-8559 FU National Institutes of Health/National Center for Advancing Translational Sciences through UCLA CTSI Grant [UL1TR000124]; Southern California CTSI Grant [UL1TR000130]; Kaiser Permanente Southern California FX The research described was supported, in part, by the National Institutes of Health/National Center for Advancing Translational Sciences through UCLA CTSI Grant Number UL1TR000124, the Southern California CTSI Grant Number UL1TR000130, and Kaiser Permanente Southern California. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 24 TC 1 Z9 1 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1752-8054 EI 1752-8062 J9 CTS-CLIN TRANSL SCI JI CTS-Clin. Transl. Sci. PD DEC PY 2015 VL 8 IS 6 BP 800 EP 806 DI 10.1111/cts.12348 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DA3DL UT WOS:000367676600034 PM 26602191 ER PT J AU Bodison, SC Sankare, I Anaya, H Booker-Vaughns, J Miller, A Williams, P Norris, K AF Bodison, Stefanie C. Sankare, Ibrahima Anaya, Henry Booker-Vaughns, Juanita Miller, Aria Williams, Pluscedia Norris, Keith CA Community Engagement Workgrp TI Engaging the Community in the Dissemination, Implementation, and Improvement of Health-Related Research SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE LA English DT Article DE community-partnered participatory research; community-based participatory research; community engagement; translational research; implementation science ID PARTICIPATORY RESEARCH; PARTNERED RESEARCH; POPULATION HEALTH; STRATEGIES; ENGAGEMENT; SCIENCE; INTEGRATION; EXPERIENCE; DISTRUST; BARRIERS AB To help maximize the real-world applicability of available interventions in clinical and community healthcare practice, there has been greater emphasis over the past two decades on engaging local communities in health-related research. While there have been numerous successful community-academic partnered collaborations, there continues to be a need to articulate the common barriers experienced during the evolution of these partnerships, and to provide a roadmap for best practices that engage healthcare providers, patients, families, caregivers, community leaders, healthcare systems, public agencies and academic medical centers. To this end, this paper presents a summary of a forum discussion from the 2014 Southern California Dissemination, Implementation and Improvement (DII) Science Symposium, sponsored by the University of California Los Angeles (UCLA) Clinical Translational Science Institute (CTSI), University of Southern California (USC) CTSI, and Kaiser Permanente. During this forum, a diverse group of individuals representing multiple constituencies identified four key barriers to success in community-partnered participatory research (CPPR) and discussed consensus recommendations to enhance the development, implementation, and dissemination of community health-related research. In addition, this group identified several ways in which the over 60 NIH funded Clinical and Translational Science Institutes across the country could engage communities and researchers to advance DII science. C1 [Bodison, Stefanie C.] Univ So Calif, Chan Div Occupat Sci & Occupat Therapy, Los Angeles, CA 90095 USA. [Sankare, Ibrahima] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. [Anaya, Henry] US Dept Vet Affairs, Los Angeles, CA USA. [Booker-Vaughns, Juanita; Williams, Pluscedia] Hlth African Amer Families, Los Angeles, CA USA. [Miller, Aria] City Hope Natl Med Ctr, Natl Med Ctr, Dept Populat Sci, Ctr Community Alliance Res & Educ, Duarte, CA USA. [Williams, Pluscedia] Charles R Drew Univ, Los Angeles, CA USA. [Williams, Pluscedia] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Norris, Keith] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bodison, SC (reprint author), Univ So Calif, Chan Div Occupat Sci & Occupat Therapy, Los Angeles, CA 90095 USA. EM bodison@usc.edu FU National Institutes of Health/National Center for Advancing Translational Sciences through UCLA CTSI [UL1TR000124]; Southern California CTSI [UL1TR000130]; Kaiser Permanente Southern California; National Institutes of Health/National Center for Research Resources/National Center for Advancing Translational Sciences [KL2TR000131]; National Institutes of Health [2P20MD000182, 3P30AG021684] FX The research described was supported, in part, by the National Institutes of Health/National Center for Advancing Translational Sciences through UCLA CTSI Grant Number UL1TR000124, the Southern California CTSI Grant Number UL1TR000130, and Kaiser Permanente Southern California. Work on the manuscript was also supported by the National Institutes of Health/National Center for Research Resources/National Center for Advancing Translational Sciences Grant Number KL2TR000131 (SB); and National Institutes of Health Grant Numbers 2P20MD000182 (KN), 3P30AG021684 (KN). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 46 TC 1 Z9 1 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1752-8054 EI 1752-8062 J9 CTS-CLIN TRANSL SCI JI CTS-Clin. Transl. Sci. PD DEC PY 2015 VL 8 IS 6 BP 814 EP 819 DI 10.1111/cts.12342 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DA3DL UT WOS:000367676600036 PM 26546337 ER PT J AU Hanlon, CA DeVries, W Dowdle, LT West, JA Siekman, B Li, XB George, MS AF Hanlon, Colleen A. DeVries, William Dowdle, Logan T. West, Julia A. Siekman, Bradley Li, Xingbao George, Mark S. TI A comprehensive study of sensorimotor cortex excitability in chronic cocaine users: Integrating TMS and functional MRI data SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Addiction; Brain stimulation; Electrophysiology; Recruitment curve; Cortex ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; CORTICAL EXCITABILITY; DEPENDENT PATIENTS; INHIBITION; LAMOTRIGINE; QUESTIONNAIRE; EXCITATION; THRESHOLD; LORAZEPAM AB Background: Disruptions in motor control are often overlooked features of chronic cocaine users. During a simple sensorimotor integration task, for example, cocaine users activate a larger area of cortex than controls but have lower functional connectivity between the cortex and dorsal striatum, which is further correlated with poor performance. The purpose of this study was to determine whether abnormal cortical excitability in cocaine users was related to disrupted inhibitory or excitatory mechanisms, as measured by transcranial magnetic stimulation (TMS). Methods: A battery of TMS measures were acquired from 87 individuals (50 cocaine dependent, 37 controls). Functional MM data were acquired from a subset of 28 individuals who performed a block-design finger tapping task. Results: TMS measures revealed that cocaine users had significantly higher resting motor thresholds and higher intracortical cortical facilitation (ICF) than controls. There was no between-group difference in either measure of cortical inhibition. Task-evoked BOLD signal in the motor cortex was significantly correlated with ICF in the cocaine users. There was no significant difference in brain skull distance between groups. Conclusion: These data demonstrated that cocaine users have disrupted cortical facilitation (as measured with TMS), which is related to elevated BOLD signal. Cortical inhibition, however, is largely intact. Given the relationship between ICF and glutamatergic agents, this may be a potentially fruitful and treatable target in addiction. Finally, among controls the distance from the scalp to the cortex was correlated with the motor threshold which may be a useful parameter to integrate into therapeutic TMS protocols in the future. (C) 2015 Published by Elsevier Ireland Ltd. C1 [Hanlon, Colleen A.; DeVries, William; Dowdle, Logan T.; West, Julia A.; Siekman, Bradley; Li, Xingbao; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Dowdle, Logan T.; West, Julia A.; Siekman, Bradley; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. EM hanlon@musc.edu OI Dowdle, Logan/0000-0002-1879-705X FU NIDA [K01DA027756, R01DA036617]; MUSC's CTSA from the National Center for Research Resources [UL1 RR029882] FX Funding was provided by NIDA K01DA027756 (Hanlon), R01DA036617, and MUSC's CTSA UL1 RR029882 from the National Center for Research Resources. The funding source had no further role in study design, collection, analysis, interpretation or in the decision to submit the paper for publication. NR 54 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 1 PY 2015 VL 157 BP 28 EP 35 DI 10.1016/j.drugalcdep.2015.07.1196 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DA5QM UT WOS:000367857600003 PM 26541870 ER PT J AU Thielke, S Slatore, CG Banks, WA AF Thielke, Stephen Slatore, Christopher G. Banks, William A. TI Association Between Alzheimer Dementia Mortality Rate and Altitude in California Counties SO JAMA PSYCHIATRY LA English DT Letter ID DISEASE C1 [Thielke, Stephen; Banks, William A.] Puget Sound VA Med Ctr, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA. RP Thielke, S (reprint author), Puget Sound VA Med Ctr, Ctr Geriatr Res Educ & Clin, 1660 S Columbian Way,GRECC S-182, Seattle, WA 98108 USA. EM sthielke@u.washington.edu OI Slatore, Christopher/0000-0003-0958-8122 NR 6 TC 2 Z9 2 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD DEC PY 2015 VL 72 IS 12 BP 1253 EP 1254 DI 10.1001/jamapsychiatry.2015.1852 PG 2 WC Psychiatry SC Psychiatry GA DA1UY UT WOS:000367582200018 PM 26502029 ER PT J AU Soni, NJ Franco, R Velez, MI Schnobrich, D Dancel, R Restrepo, MI Mayo, PH AF Soni, Nilam J. Franco, Ricardo Velez, Maria I. Schnobrich, Daniel Dancel, Ria Restrepo, Marcos I. Mayo, Paul H. TI Ultrasound in the Diagnosis and Management of Pleural Effusions SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID PARAPNEUMONIC EFFUSIONS; CHEST RADIOGRAPHY; MEDICAL ICU; THORACIC ULTRASOUND; LUNG ULTRASOUND; ACCURACY; SONOGRAPHY; ULTRASONOGRAPHY; FLUID; PNEUMOTHORAX AB We review the literature on the use of point-of-care ultrasound to evaluate and manage pleural effusions. Point-of-care ultrasound is more sensitive than physical exam and chest radiography to detect pleural effusions, and avoids many negative aspects of computerized tomography. Additionally, point-of-care ultrasound can assess pleural fluid volume and character, revealing possible underlying pathologies and guiding management. Thoracentesis performed with ultrasound guidance has lower risk of pneumothorax and bleeding complications. Future research should focus on the clinical effectiveness of point-of-care ultrasound in the routine management of pleural effusions and how new technologies may expand its clinical utility. (C) 2015 Society of Hospital Medicine C1 [Soni, Nilam J.] South Texas Vet Hlth Care Syst, Sect Hosp Med, San Antonio, TX USA. [Soni, Nilam J.; Velez, Maria I.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Soni, Nilam J.; Velez, Maria I.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Pulm & Crit Care Med Sect, San Antonio, TX USA. [Franco, Ricardo] Med Coll Wisconsin, Div Gen Internal Med, Milwaukee, WI 53226 USA. [Schnobrich, Daniel] Univ Minnesota, Div Gen Internal Med, Minneapolis, MN USA. [Dancel, Ria] Univ N Carolina, Div Gen Med & Epidemiol, Chapel Hill, NC USA. [Mayo, Paul H.] North Shore LIJ Med Ctr, Div Pulm Crit Care & Sleep Med, New Hyde Pk, NY USA. RP Soni, NJ (reprint author), 7703 Floyd Curl Dr,MC 7982, San Antonio, TX 78229 USA. EM sonin@uthscsa.edu FU National Heart, Lung, and Blood Institute [K23HL096054] FX Dr. Restrepo is partially supported by award number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The authors report no conflicts of interest. NR 50 TC 8 Z9 8 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD DEC PY 2015 VL 10 IS 12 BP 811 EP 816 DI 10.1002/jhm.2434 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VQ UT WOS:000367728200009 PM 26218493 ER PT J AU Caster, DJ Korte, EA Merchant, ML Klein, JB Wilkey, DW Rovin, BH Birmingham, DJ Harley, JB Cobb, BL Namjou, B McLeish, KR Powell, DW AF Caster, Dawn J. Korte, Erik A. Merchant, Michael L. Klein, Jon B. Wilkey, Daniel W. Rovin, Brad H. Birmingham, Dan J. Harley, John B. Cobb, Beth L. Namjou, Bahram McLeish, Kenneth R. Powell, David W. TI Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis SO PROTEOMICS CLINICAL APPLICATIONS LA English DT Article DE Autoantibodies; Glomerulonephritis; Lupus nephritis; Systemic lupus erythematosus; Target antigens ID SLIT DIAPHRAGM; ACTIN REORGANIZATION; NEPHROTIC SYNDROME; STATISTICAL-MODEL; ERYTHEMATOSUS; CELLS; CYTOSKELETON; DISEASE; COMPLEX; GLOMERULONEPHRITIS AB Purpose: Patients with systemic lupus erythematosus (SLE) frequently develop lupus nephritis (LN), a complication frequently leading to end stage kidney disease. Immune complex deposition in the glomerulus is central to the development of LN. Using a targeted proteomic approach, we tested the hypothesis that autoantibodies targeting glomerular antigens contribute to the development of LN. Experimental design: Human podocyte and glomerular proteins were separated by SDS-PAGE and immunoblotted with sera from SLE patients with and without LN. The regions of those gels corresponding to reactive bands observed with sera from LN patients were analyzed using LC-MS/MS. Results: LN reactive bands were seen at approximately 50 kDa in podocyte extracts and between 36 and 50 kDa in glomerular extracts. Those bands were analyzed by LC-MS/MS and 102 overlapping proteins were identified. Bioinformatic analysis determined that 36 of those proteins were membrane associated, including a protein previously suggested to contribute to glomerulonephritis and LN, annexin A2. By ELISA, patients with proliferative LN demonstrated significantly increased antibodies against annexin A2. Conclusion and clinical relevance: Proteomic approaches identified multiple candidate antigens for autoantibodies in patients with LN. Serum antibodies against annexin A2 were significantly elevated in subjects with proliferative LN, validating those antibodies as potential biomarkers. C1 [Caster, Dawn J.; Merchant, Michael L.; Klein, Jon B.; Wilkey, Daniel W.; McLeish, Kenneth R.; Powell, David W.] Univ Louisville, Dept Med, Sch Med, Louisville, KY 40202 USA. [Korte, Erik A.; Powell, David W.] Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA. [Caster, Dawn J.; Klein, Jon B.; McLeish, Kenneth R.] Robley Rex Vet Affairs Med Ctr, Louisville, KY USA. [Rovin, Brad H.; Birmingham, Dan J.] Ohio State Univ, Dept Med, Columbus, OH 43210 USA. [Harley, John B.; Cobb, Beth L.; Namjou, Bahram] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Harley, John B.; Cobb, Beth L.; Namjou, Bahram] Univ Cincinnati, Cincinnati, OH USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Caster, DJ (reprint author), Univ Louisville, Dept Med, Sch Med, 570 South Preston St,Baxter Res Bldg 1,102D, Louisville, KY 40202 USA. EM dawn.caster@louisville.edu RI Merchant, Michael/F-7109-2013; McLeish, Kenneth/B-9819-2013 OI McLeish, Kenneth/0000-0002-7816-3286 FU National Institutes of Health [AR063124, AI103980, AI24717, TR000077, HG006828]; Juvenile Diabetes Research Foundation [1-2011-588]; US Department of Veterans Affairs FX The authors were supported by grants from the National Institutes of Health AR063124 (to D.W.P.), AI103980 (to D.W.P. and K.R.M.), AI24717, TR000077, HG006828 (to J.B.H), and the Juvenile Diabetes Research Foundation international grant 1-2011-588 (to D.W.P.). J.B.H. and K.R.M were supported by the US Department of Veterans Affairs. The authors wish to thank Vilius Stribinskis, Ph.D., for the production of recombinant annexin A2. NR 63 TC 6 Z9 6 U1 1 U2 6 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA POSTFACH 101161, 69451 WEINHEIM, GERMANY SN 1862-8346 EI 1862-8354 J9 PROTEOM CLIN APPL JI Proteom. Clin. Appl. PD DEC PY 2015 VL 9 IS 11-12 SI SI BP 1012 EP 1020 DI 10.1002/prca.201400175 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DA3UD UT WOS:000367723600006 PM 25824007 ER PT J AU Klaassen, Z Howard, L Terris, MK Aronson, WJ Cooperberg, MR Amling, CL Kane, CJ Freedland, SJ AF Klaassen, Zachary Howard, Lauren Terris, Martha K. Aronson, William J. Cooperberg, Matthew R. Amling, Christopher L. Kane, Christopher J. Freedland, Stephen J. TI Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer-Results from the SEARCH database SO CANCER EPIDEMIOLOGY LA English DT Article DE Prostate cancer; PSA; Race; Radical prostatectomy; Tumor volume ID AFRICAN-AMERICAN MEN; ANDROGEN RECEPTOR GENE; RADICAL PROSTATECTOMY; RACIAL-DIFFERENCES; WHITE MEN; SPECIMENS; PSA; DISEASE; RISK; CAG AB Objectives: To assess whether larger tumor volume in black men explains higher presurgical PSA levels versus white men with prostate cancer. Methods: We retrospectively analyzed 1904 men from the Shared Equal Access Regional Cancer Hospital database who underwent radical prostatectomy from 1990 to 2013. Geometric mean of tumor volume and preoperative PSA for each race were estimated from multivariable linear regression models. Results: There were 1104 (58%) white men and 800 (42%) black men. Black men were younger (60.2 vs. 62.9 years, p < 0.001) had a higher PSA (6.7 vs. 6.0 ng/mL, p < 0.001), more positive margins (47 vs. 38%, p < 0.001), and seminal vesicle invasion (13 vs. 9%, p = 0.007). White patients had higher clinical stage (p < 0.001) and greater median tumor volume (6.0 vs. 5.3 gm, p = 0.011). After multivariable adjustment (except for PSA), white men had smaller mean tumor volumes (5.2 vs. 5.8 gm, p = 0.011). When further adjusted for PSA, there was no racial difference in mean tumor volume (p = 0.34). After multivariable adjustment, black men had higher mean PSAs vs. white men (7.5 vs. 6.1 ng/mL, p < 0.001). Results were similar after further adjusting for tumor volume: black men had 16% higher mean PSAs versus white men (7.4 vs. 6.2 ng/mL, p < 0.001). Conclusions: In this study of men undergoing radical prostatectomy at multiple equal access medical centers, racial differences in tumor volume did not explain higher presurgical PSA levels in black versus white men. The exact reason for higher PSA values in black men remains unclear. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Klaassen, Zachary; Terris, Martha K.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Howard, Lauren] Duke Univ, Med Ctr, Durham, NC USA. [Terris, Martha K.] Augusta Vet Affairs Med Ctr, Augusta, GA USA. [Aronson, William J.] West Los Angeles Vet Affairs Med Ctr, West Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Cooperberg, Matthew R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cooperberg, Matthew R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kane, Christopher J.] San Diego Vet Affairs Med Ctr, San Diego, CA USA. [Kane, Christopher J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Freedland, Stephen J.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Freedland, Stephen J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, Dept Surg, Div Urol, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA. EM stephen.freedland@cshs.org FU Department of Veterans Affairs, the National Institutes of Health (NIH) [R01CA100938]; NIH Specialized Programs of Research Excellence Grant [P50CA92131-01A1]; Georgia Cancer Coalition; NIH grant [K24CA160653] FX Research support was received from the Department of Veterans Affairs, the National Institutes of Health (NIH) (grant R01CA100938 to Dr. Aronson), NIH Specialized Programs of Research Excellence Grant P50CA92131-01A1 (to Dr. Aronson), the Georgia Cancer Coalition (to Dr. Terris), and NIH grant K24CA160653 (to Dr. Freedland). NR 30 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 EI 1877-783X J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD DEC PY 2015 VL 39 IS 6 BP 1066 EP 1070 DI 10.1016/j.canep.2015.09.007 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CZ9VE UT WOS:000367444300039 PM 26452418 ER PT J AU Agassandian, M Tedrow, JR Sembrat, J Kass, DJ Zhang, YZ Goncharova, EA Kaminski, N Mallampalli, RK Vuga, LJ AF Agassandian, Marianna Tedrow, John R. Sembrat, John Kass, Daniel J. Zhang, Yingze Goncharova, Elena A. Kaminski, Naftali Mallampalli, Rama K. Vuga, Louis J. TI VCAM-1 is a TGF-beta 1 inducible gene upregulated in idiopathic pulmonary fibrosis SO CELLULAR SIGNALLING LA English DT Article DE IPF; VCAM-1; Lung fibroblasts; TGF-beta 1 ID SOLUBLE ADHESION MOLECULES; INTERSTITIAL PNEUMONIAS; SYSTEMIC-SCLEROSIS; EXPRESSION; INHIBITION; THERAPY AB Idiopathic pulmonary fibrosis (IPF) is a chronic lethal interstitial lung disease of unknown etiology. We previously reported that high plasma levels of vascular cell adhesion molecule 1 (VCAM-1) predict mortality in IPF subjects. Here we investigated the cellular origin and potential role of VCAM-1 in regulating primary lung fibroblast behavior. VCAM-1 mRNA was significantly increased in lungs of subjects with IPF compared to lungs from control subjects (p = 0.001), and it negatively correlated with two markers of lung function, forced vital capacity (FVC) and pulmonary diffusion capacity for carbon monoxide (DLco). VCAM-1 protein levels were highly expressed in IPF subjects where it was detected in fibrotic foci and blood vessels of IPF lung. Treatment of human lung fibroblasts with TGF-beta 1 significantly increased steady-state VCAM1 mRNA and protein levels without affecting VCAM1 mRNA stability. Further, cellular depletion of VCAM-1 inhibited fibroblast cell proliferation and reduced G2/M and S phases of the cell cycle suggestive of cell cycle arrest. These effects on cell cycle progression triggered by VCAM1 depletion were associated with reductions in levels of phosphorylaed extracellular regulated kinase 1/2 and cyclin D1. Thus, these observations suggest that VCAM-1 is a TGF-beta 1 responsive mediator that partakes in fibroblast proliferation in subjects with IPF. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Agassandian, Marianna; Tedrow, John R.; Sembrat, John; Kass, Daniel J.; Zhang, Yingze; Vuga, Louis J.] Univ Pittsburgh, Sch Med, Dorothy P & Richard P Simmons Ctr Interstitial Lu, Pittsburgh, PA 15213 USA. [Agassandian, Marianna; Tedrow, John R.; Sembrat, John; Kass, Daniel J.; Zhang, Yingze; Goncharova, Elena A.; Mallampalli, Rama K.; Vuga, Louis J.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Goncharova, Elena A.] Univ Pittsburgh, Pittsburgh Heart Lung Blood & Vasc Med Inst, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Kaminski, Naftali] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Heaven, CT USA. RP Mallampalli, RK (reprint author), NW628 Montefiore Univ Hosp, 3459 Fifth Ave, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu; vugalj@upmc.edu FU National Institutes of Health/National Heart, Lung, and Blood Institute [HL108869, HL073745, HL097376, R01HL095397, RC2HL101715, U01HL108642, P01HL114453, P50HL0894932]; Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research; US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; VA Merit Review Award FX We would like to thank Dr. Mauricio Rojas for his editorial suggestions in the manuscript. This research was supported by the National Institutes of Health/National Heart, Lung, and Blood Institute [HL108869, HL073745, HL097376, R01HL095397, RC2HL101715, U01HL108642, P01HL114453, and P50HL0894932], and the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research. This material is also based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and a VA Merit Review Award. NR 36 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 EI 1873-3913 J9 CELL SIGNAL JI Cell. Signal. PD DEC PY 2015 VL 27 IS 12 BP 2467 EP 2473 DI 10.1016/j.cellsig.2015.09.003 PG 7 WC Cell Biology SC Cell Biology GA DA0KQ UT WOS:000367486400015 PM 26386411 ER PT J AU Boockvar, K AF Boockvar, Kenneth TI Preserving Cognition and Attaining Ideal Anesthesia and Surgical Outcomes in Older Adults SO CLINICAL THERAPEUTICS LA English DT Editorial Material ID POSTOPERATIVE DELIRIUM; HIP FRACTURE; SEVOFLURANE; SURGERY C1 [Boockvar, Kenneth] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Boockvar, Kenneth] New Jewish Home, Res Inst Aging, New York, NY USA. [Boockvar, Kenneth] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. RP Boockvar, K (reprint author), James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 20 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD DEC PY 2015 VL 37 IS 12 BP 2638 EP 2640 DI 10.1016/j.clinthera.2015.11.006 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CZ9MF UT WOS:000367421000004 PM 26621624 ER PT J AU Garcia, PS Duggan, EW McCullough, IL Lee, SC Fishman, D AF Garcia, Paul S. Duggan, Elizabeth W. McCullough, Ian L. Lee, Simon C. Fishman, David TI Postanesthesia Care for the Elderly Patient SO CLINICAL THERAPEUTICS LA English DT Review DE elderly; recovery; delirium; polypharmacy; anesthesia; surgery ID POSTOPERATIVE URINARY RETENTION; OBSTRUCTIVE PULMONARY-DISEASE; CONVERTING ENZYME-INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; NONCARDIAC SURGERY; ALZHEIMERS-DISEASE; UNITED-STATES; OLDER-ADULTS; SLEEP-APNEA; RESPIRATORY COMPLICATIONS AB Purpose: As the general population lives longer, the perioperative physician is more likely to encounter disease states that increase in incidence in an aging population. This review focuses on anesthetic considerations for rational drug choices during the perioperative care of elderly patients. The primary aim of the review was to identify intraoperative and postanesthetic considerations for diseases associated with advancing age; it includes highlights of the commonly impaired major organs (eg, cardiovascular, pulmonary, neurologic, renal, hepatic systems). We also outline an approach to frequent issues that arise in the immediate postsurgical period while caring for these patients. Methods: A systematic review was performed on aspects of the perioperative and postoperative periods that relate to the elderly. A list of pertinent key words was derived from the authors, and a PubMed database search was performed. Findings: The anesthesiologist must account for changes in various organ systems that affect perioperative care, including the cardiovascular, pulmonary, renal, hepatic, and central nervous systems. The pharmacokinetic principles frequently differ and are often unpredictable because of anatomic changes and decreased renal and hepatic function. The most important pharmacodynamic consideration is that elderly patients tend to exhibit an exaggerated hypoactivity after anesthesia. Published by Elsevier HS Journals, Inc. C1 [Garcia, Paul S.; Fishman, David] US Dept Vet Affairs, Atlanta VA Med Ctr, Decatur, GA USA. [Garcia, Paul S.; Duggan, Elizabeth W.; McCullough, Ian L.; Lee, Simon C.; Fishman, David] Emory Univ, Sch Med, Dept Anesthesiol, Decatur, GA 30033 USA. RP Garcia, PS (reprint author), Emory Univ, Sch Med, Dept Vet Affairs, Atlanta VA Med Ctr, 1670 Clairmont Rd NE, Decatur, GA 30033 USA. EM pgarcia@emory.edu FU James S. McDonnell Foundation; Department of Veterans Affairs [CDA BX001677] FX The authors gratefully acknowledge research support from internal departmental and institutional initiatives (Team-Based Science). Dr. Garcia's research efforts are supported in part by funding from the James S. McDonnell Foundation (www.jsmf.org) and from funding from a Career Development Award awarded by the Department of Veterans Affairs (PSG, CDA BX001677). The contents do not represent the views of the US Department of Veterans Affairs or the United States Government. NR 113 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD DEC PY 2015 VL 37 IS 12 BP 2651 EP 2665 DI 10.1016/j.clinthera.2015.10.018 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CZ9MF UT WOS:000367421000006 PM 26598176 ER PT J AU Gencer, ZK Saydam, L Cohen, NA Cingi, C AF Gencer, Zeliha Kapusuz Saydam, Levent Cohen, Noam A. Cingi, Cemal TI N-acetylcysteine effects on sinonasal cilia function SO ENT UPDATES LA English DT Article DE N-acetylcysteine; sinonasal; cilia ID AIRWAY EPITHELIAL-CELLS; SURFACE LIQUID VOLUME; S-NITROSOGLUTATHIONE; CYSTIC-FIBROSIS; BEAT AB Objective: To evaluate the pharmacological effects of the N-acetylcysteine (NAC) on human respiratory epithelial cultures specifically addressing electrolyte transport and cilia beat frequency. Methods: Well-differentiated human bronchial epithelial cultures grown at an air liquid interface were treated on the apical or basolateral surface with varying concentrations of NAC. The best NAC concentration for ideal cilia beat frequency was found. The effects of NAC were evaluated on cilia beat frequency. After the effect of N-acetylcysteine on beat rate was found, its efficiency was investigated by ATP or IBMX to understand its mechanism of action. Changes in ciliary beat frequency were determined using the Sissons-Ammons video analysis system. Results: Maximal stimulatory effect on cilia function was evident at 10 mg/ml NAC concentration. After wash up, cilia movement were increased very dramatically. This increase of cilia beat frequency was even higher after NAC plus IBMX and NAC plus ATP washings. Conclusion: Apical application of NAC prominently stimulates cilia beat frequency and after wash up, cilia movement was increased very dramatically. After NAC use by washing with PBS in clinical efficacy can be enhanced. C1 [Gencer, Zeliha Kapusuz; Saydam, Levent] Univ Bozok, Dept Otorhinolaryngol Head & Neck Surg, Yozgat, Turkey. [Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. [Cingi, Cemal] Osmangazi Univ, Dept Otorhinolaryngol Head & Neck Surg, Eskisehir, Turkey. RP Gencer, ZK (reprint author), Univ Bozok, Dept Otorhinolaryngol Head & Neck Surg, Yozgat, Turkey. EM drzeliha19@hotmail.com NR 18 TC 0 Z9 0 U1 0 U2 0 PU DEOMED PUBL, ISTANBUL PI ISTANBUL PA GUR SOK 7-B, FIKIRTEPE 34720 KADIKOY, ISTANBUL, 00000, TURKEY SN 2149-7109 EI 2149-6498 J9 ENT UPDATES JI ENT Updates PD DEC PY 2015 VL 5 IS 3 BP 87 EP 92 DI 10.2399/jmu.2015003002 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA CZ8UJ UT WOS:000367374300001 ER PT J AU Schure, MB Conte, KP Goins, RT AF Schure, Marc B. Conte, Kathleen P. Goins, R. Turner TI Unmet Assistance Need Among Older American Indians: The Native Elder Care Study SO GERONTOLOGIST LA English DT Article DE American Indians; Functional disability; Unmet assistance need; Social support ID PERSONAL ASSISTANCE; ADULTS; DISABILITY; HEALTH; CONSEQUENCES; IMPUTATION; MORTALITY; HELP AB Purpose: We examined the prevalence and correlates of unmet assistance need with respect to activities of daily living (ADLs) and instrumental activities of daily living (IADLs) among older American Indians. Design and Methods: Data for our analyses were collected in 2006-2008 as part of the Native Elder Care Study, a cross-sectional study of community-dwelling American Indians aged >= 55 years. In-person interviewer-administered surveys were used to collect data on demographic characteristics, physical functioning, mental and physical health, personal assistance needs, and psychosocial resources. Results: Among those with an assistance need, 47.8% reported an unmet need with one or more ADLs or IADLs. Significant adjusted correlates of unmet assistance need included greater number of ADL and IADL difficulties and lower levels of social support. Implications: Initiatives and programs aimed at increasing social support and augmenting informal care networks can support efforts to meet American Indian adults' personal assistance needs. C1 [Schure, Marc B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Conte, Kathleen P.] Oregon State Univ, Sch Social & Behav Hlth Sci, Corvallis, OR 97331 USA. [Goins, R. Turner] Western Carolina Univ, Coll Hlth & Human Sci, Dept Social Work, Cullowhee, NC 28723 USA. RP Schure, MB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Mark.Schure@va.gov RI Conte, Kathleen/G-8348-2016 OI Conte, Kathleen/0000-0002-5429-429X FU National Institute on Aging [AG022336] FX The authors receive support by award AG022336 from the National Institute on Aging. NR 35 TC 0 Z9 0 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 2015 VL 55 IS 6 BP 920 EP 928 DI 10.1093/geront/gnt211 PG 9 WC Gerontology SC Geriatrics & Gerontology GA CZ9XX UT WOS:000367452300005 PM 24451895 ER PT J AU Schofield, H Loewenstein, G Kopsic, J Volpp, KG AF Schofield, Heather Loewenstein, George Kopsic, Jessica Volpp, Kevin G. TI Comparing the effectiveness of individualistic, altruistic, and competitive incentives in motivating completion of mental exercises SO JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Cognitive exercises; Incentives; Social incentives; Behavioral economics; Health behaviors ID RANDOMIZED CONTROLLED-TRIAL; FINANCIAL INCENTIVES; OLDER-ADULTS; SMOKING-CESSATION; DESIGN AB This study examines the impact of individually oriented, purely altruistic, and a hybrid of competitive and cooperative monetary reward incentives on older adults' completion of cognitive exercises and cognitive function. We find that all three incentive structures approximately double the number of exercises completed during the six-week active experimental period relative to a no incentive control condition. However, the altruistic and cooperative/competitive incentives led to different patterns of participation, with significantly higher inter-partner correlations in utilization of the software, as well as greater persistence once incentives were removed. Provision of all incentives significantly improved performance on the incentivized exercises. However, results of an independent cognitive testing battery suggest no generalizable gains in cognitive function resulted from the training. (C) 2015 The Authors. Published by Elsevier B.V. C1 [Schofield, Heather] Harvard Univ, Littauer Ctr, Dept Econ, Cambridge, MA 02138 USA. [Loewenstein, George; Kopsic, Jessica] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, LDI Ctr Hlth Incent & Behav Econ, CHERP,Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Schofield, H (reprint author), Univ Penn, Perelman Sch Med, 1102 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM hschof@upenn.edu; gl20@andrew.cmu.edu; jessica.kopsic@gmail.com; volpp70@mail.med.upenn.edu FU Pennsylvania Department of Health's Commonwealth Universal Research Enhancement Program; NIA FX We gratefully acknowledge financial support from the Pennsylvania Department of Health's Commonwealth Universal Research Enhancement Program and the NIA-funded joint Penn/CMU Roybal P30 Center on Behavioral Economics and Health. We also thank Lumosity and Neurotrax for generously allowing us to use their software, Matt Thompson for his outstanding website development, and Ben Cowan and ASHEcon conference participants for helpful comments. All errors are our own. NR 46 TC 1 Z9 1 U1 1 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6296 EI 1879-1646 J9 J HEALTH ECON JI J. Health Econ. PD DEC PY 2015 VL 44 BP 286 EP 299 DI 10.1016/j.jhealeco.2015.09.007 PG 14 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CZ9HI UT WOS:000367408200020 PM 26595894 ER PT J AU Fu, LW Wei, CC Powell, PC Bradley, WE Collawn, JF Dell'Italia, LJ AF Fu, Lianwu Wei, Chih-Chang Powell, Pamela C. Bradley, Wayne E. Collawn, James F. Dell'Italia, Louis J. TI Volume overload induces autophagic degradation of procollagen in cardiac fibroblasts SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE Volume overload; Cardiac fibroblast; Oxidative stress; Autophagy; Intracellular procollagen; Matrix metalloproteinase ID MATRIX-METALLOPROTEINASE ACTIVITY; OXIDATIVE STRESS; MITRAL REGURGITATION; HEART-FAILURE; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; COLLAGEN PRODUCTION; MITOCHONDRIA; INFLAMMATION; BRADYKININ AB In a pure volume overloaded (VO) heart, interstitial collagen loss is degraded by matrix metalloproteinases (MMPs) that leads to left ventricular (LV) dilatation and heart failure. Cardiac fibroblasts are the primary source of extracellular matrix proteins that connect cardiomyocytes. The goal of this study was to determine how VO affects intracellular procollagen in cardiac fibroblasts. Using the aortocaval fistula (ACF) model in Sprague-Dawley rats, we demonstrate that cardiac fibroblasts isolated from 4 and 12 wk ACF animals have decreased intracellular procollagen I compared to the fibroblasts from age-matched shams. The reduction of procollagen I is associated with increased autophagy as demonstrated by increased autophagic vacuoles and LC3-II expression. To test the relationship between autophagy and procollagen degradation, we treated adult cardiac fibroblasts with either an autophagy inducer, rapamycin, or an inhibitor, wortmannin, and found that procollagen I protein levels were decreased in fibroblasts treated with rapamycin and elevated in wortmannin-treated cells. In addition, we demonstrated that VO induces oxidative stresses in cardiac fibroblasts from 4 and 12 wk ACF rats. Treatment of cultured cardiac fibroblasts with an oxidative stress-inducing agent (DMNQ) induces autophagy and intracellular procollagen I and fibronectin degradation, which is reversed by wortmannin but not by the global MMP inhibitor (PD166793). Mechanical stretch of cardiac fibroblasts also induces oxidative stress and autophagic degradation of procollagen I and fibronectin. Our results suggest that in addition to the well-known effects of MMPs on extracellular collagen degradation in VO, there is a concurrent degradation of intracellular procollagen and fibronectin mediated by oxidative stress-induced autophagy in cardiac fibroblasts. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Fu, Lianwu; Collawn, James F.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Wei, Chih-Chang; Powell, Pamela C.; Dell'Italia, Louis J.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Wei, Chih-Chang; Bradley, Wayne E.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. RP Wei, CC (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham VA Med Ctr, 901 19th St South, Birmingham, AL 35294 USA. EM chih@uab.edu; louis.dellitalia@va.gov FU Department of Veteran Affairs for Merit Review [1BX001050-01, 1CX000993-01]; NIH [P01 HL051952] FX This work was supported by grants from Department of Veteran Affairs for Merit Review (Grant 1BX001050-01 to C.C.W. and Grant 1CX000993-01 to L.J.D.) and NIH (Grant P01 HL051952 to L.J.D). NR 34 TC 3 Z9 3 U1 1 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD DEC PY 2015 VL 89 BP 241 EP 250 DI 10.1016/j.yjmcc.2015.10.027 PN B PG 10 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA CZ9KV UT WOS:000367417400017 PM 26596413 ER PT J AU Nguyen, C Mir, O Vahidy, F Wu, TC Albright, K Boehme, A Delgado, R Savitz, S AF Claude Nguyen Mir, Osman Vahidy, Farhaan Wu, Tzu-Ching Albright, Karen Boehme, Amelia Delgado, Rigoberto Savitz, Sean TI Resource Utilization for Patients with Intracerebral Hemorrhage Transferred to a Comprehensive Stroke Center SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Stroke systems; comprehensive stroke center; hemorrhagic stroke; intracerebral hemorrhage ID INTENSIVE-CARE-UNIT; MORTALITY-RATE; IMPACT; ASSOCIATION; POPULATION; OUTCOMES; COST AB Background: As a comprehensive stroke center (CSC), we accept transfer patients with intracerebral hemorrhage (ICH) in our region. CSC guidelines mandate receipt of patients with ICH for higher level of care. We determined resource utilization of patients accepted from outside hospitals compared with patients directly arriving to our center. Methods: From our stroke registry, we compared patients with primary ICH transferred to those directly arriving to our CSC from March 2011-March 2012. We compared the proportion of patients who utilized at least one of these resources: neurointensive care unit (NICU), neurosurgical intervention, or clinical trial enrollment. Results: Among the 362 patients, 210 (58%) were transfers. Transferred patients were older, had higher median Glasgow Coma Scale scores, and lower National Institutes of Health Stroke Scale scores than directly admitted patients. Transfers had smaller median ICH volumes (20.5 cc versus 15.2 cc; P = .04) and lower ICH scores (2.1 +/- 1.4 versus 1.6 +/- 1.3; P < .01). A smaller proportion of transfers utilized CSC-specific resources compared with direct admits (P = .02). Fewer transferred patients required neurosurgical intervention or were enrolled in trials. No significant difference was found in the proportion of patients who used NICU resources, although transferred patients had a significantly lower length of stay in the NICU. Average hospital stay costs were less for transferred patients than for direct admits. Conclusions: Patients with ICH transferred to our CSC underwent fewer neurosurgical procedures and had a shorter stay in the NICU. These results were reflected in the lower per-patient costs in the transferred group. Our results raise the need to analyze cost-benefits and resource utilization of transferring patients with milder ICH. (C) 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved. C1 [Claude Nguyen; Mir, Osman; Vahidy, Farhaan; Wu, Tzu-Ching; Savitz, Sean] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA. [Albright, Karen] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [Albright, Karen] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Boehme, Amelia] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10027 USA. [Delgado, Rigoberto] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA. RP Savitz, S (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Neurol, 6431 Fannin,MSB 7-125, Houston, TX 77030 USA. EM sean.i.savitz@uth.tmc.edu FU National Institutes of Health [5 T32 NS007412-12] FX This work was supported by National Institutes of Health Training Grant 5 T32 NS007412-12. NR 20 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD DEC PY 2015 VL 24 IS 12 BP 2866 EP 2874 DI 10.1016/j.jstrokecerebrovasdis.2015.08.023 PG 9 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA CZ8ZY UT WOS:000367388800029 PM 26460244 ER PT J AU Yarnykh, VL Tartaglione, EV Ioannou, GN AF Yarnykh, Vasily L. Tartaglione, Erica V. Ioannou, George N. TI Fast macromolecular proton fraction mapping of the human liver in vivo for quantitative assessment of hepatic fibrosis SO NMR IN BIOMEDICINE LA English DT Article DE magnetization transfer; quantification; hepatobiliary; fibrosis; macromolecular proton fraction; biomarker ID MAGNETIC-RESONANCE ELASTOGRAPHY; SELECTIVE INVERSION-RECOVERY; DIFFUSION-WEIGHTED MRI; CROSS-RELAXATION; TRANSIENT ELASTOGRAPHY; NONINVASIVE DIAGNOSIS; WHITE-MATTER; HUMAN BRAIN; STEADY-STATE; PARAMETERS AB The macromolecular proton fraction (MPF) is a quantitative MRI parameter determining the magnetization transfer (MT) effect in tissues, and is defined as the relative amount of immobile macromolecular protons involved in magnetization exchange with mobile water protons. MPF has the potential to provide a quantitative assessment of fibrous tissue because of the intrinsically high MPF specific for collagen. The goal of this study was to investigate the relationship between histologically determined fibrosis stage and MPF in the liver parenchyma measured using a recently developed fast single-point clinically targeted MPF mapping method. Optimal saturation parameters for single-point liver MPF measurements were determined from the analysis of liver Z spectra in vivo based on the error propagation model. Sixteen patients with chronic hepatitis C viral infection underwent 3-T MRI using an optimized liver MPF mapping protocol. Fourteen patients had prior liver biopsy with histologically staged fibrosis (METAVIR scores F0-F3) and two patients had clinically diagnosed cirrhosis (score F4 was assigned). The protocol included four breath-hold three-dimensional scans with 2 x 3 x 6-mm(3) resolution and 10 transverse sections: (1) dynamic acquisition of MT-weighted and reference images; (2) dynamic acquisition of three images for variable flip angle T-1 mapping; (3) dual-echo B-0 map; and (4) actual flip angle imaging B-1 map. The average liver MPF was determined as the mode of the MPF histograms. MPF was significantly increased in patients with clinically significant fibrosis (scores F2-F4, n = 6) relative to patients with no or mild fibrosis (scores F0-F1, n = 10): 6.49 +/- 0.36% versus 5.94 +/- 0.26%, p < 0.01 (Mann-Whitney test). MPF and fibrosis scores were strongly positively correlated, with a Spearman's rank correlation coefficient of 0.80 (p < 0.001). This study demonstrates the feasibility of fast MPF mapping of the human liver in vivo and confirms the hypothesis that MPF is increased in hepatic fibrosis and associated with fibrosis stage. MPF may be useful as a non-invasive imaging biomarker of hepatic fibrosis. Copyright (C) 2015 John Wiley & Sons, Ltd. C1 [Yarnykh, Vasily L.] Univ Washington, Dept Radiol, Seattle, WA 98109 USA. [Yarnykh, Vasily L.] Tomsk State Univ, Res Inst Biol & Biophys, Tomsk 634050, Russia. [Tartaglione, Erica V.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98109 USA. RP Yarnykh, VL (reprint author), Univ Washington, Dept Radiol, Box 358050,850 Republican St,Room 255, Seattle, WA 98109 USA. EM yarnykh@u.washington.edu RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; FU National Institutes of Health [R21EB016135]; University of Washington Bridge Fund; Russian Science Foundation [14-45-00040] FX The authors acknowledge financial support from the National Institutes of Health (grant R21EB016135) for software development, University of Washington Bridge Fund for data acquisition, and the Russian Science Foundation (project no. 14-45-00040) for data analysis and manuscript preparation. NR 69 TC 2 Z9 2 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0952-3480 EI 1099-1492 J9 NMR BIOMED JI NMR Biomed. PD DEC PY 2015 VL 28 IS 12 BP 1716 EP 1725 DI 10.1002/nbm.3437 PG 10 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA CZ7XX UT WOS:000367315100012 PM 26503401 ER PT J AU Hasan, NS Babson, KA Banducci, AN Bonn-Miller, MO AF Hasan, Nadeem S. Babson, Kimberly A. Banducci, Anne N. Bonn-Miller, Marcel O. TI The Prospective Effects of Perceived and Laboratory Indices of Distress Tolerance on Cannabis Use Following a Self-Guided Quit Attempt SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE distress tolerance; cannabis; marijuana; veterans; cessation ID SUBSTANCE USE DISORDERS; MARIJUANA DEPENDENCE; NEGATIVE AFFECT; WITHDRAWAL; INDIVIDUALS; VALIDATION; VALIDITY; MOTIVES; ADULTS; SCALE AB The majority of individuals who attempt to quit using cannabis do not seek formalized treatment. To better understand which malleable factors contribute to cannabis use following a self-guided quit attempt, we concurrently examined 2 measures of distress tolerance (DT) as prospective predictors of cannabis use post quit attempt. We hypothesized that veterans with higher in relation to lower levels of DT would be less likely to use cannabis following a self-guided quit attempt. In this study, we included 103 cannabis-dependent veterans (M-age = 50, 95% male, 37% White, 36% Black, 14% Hispanic, 14% other) who reported being motivated to quit using cannabis. Veterans completed 2 measures of DT, the Distress Tolerance Scale (perceived distress tolerance) and the Mirror-Tracing Persistence Task (laboratory analogue of distress tolerance). Findings indicated that veterans with greater perceived distress tolerance used less cannabis over the quit period than did veterans with less perceived distress tolerance. However, contrary to expectations, baseline performance on a laboratory analogue of distress tolerance was not related to cannabis use over the quit period. Results suggest that veterans' perceived ability to tolerate distress is an important predictor of cannabis use following a self-guided quit attempt. Thus, the Distress Tolerance Scale could serve as an important tool for helping to identify veterans at risk for cannabis use postquit. C1 [Hasan, Nadeem S.] Univ Calif Los Angeles, Counseling Serv, Los Angeles, CA USA. [Hasan, Nadeem S.] Univ Calif Los Angeles, Psychol Serv, Los Angeles, CA USA. [Babson, Kimberly A.; Banducci, Anne N.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Bonn-Miller, Marcel O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Babson, KA (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd,152-MPD, Menlo Pk, CA 94025 USA. EM kimberly.babson@gmail.com OI Banducci, Anne N/0000-0003-1213-7998 FU CSRD VA [IK2 CX001023] NR 36 TC 2 Z9 2 U1 3 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD DEC PY 2015 VL 29 IS 4 BP 933 EP 940 DI 10.1037/adb0000132 PG 8 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA DA0BE UT WOS:000367460900012 PM 26727009 ER PT J AU Kaliyaperuma, K Sharma, AK McDonald, DG Dhindsa, JS Yount, C Singh, AK Won, JS Singh, I AF Kaliyaperuma, Kolanjiappan Sharma, Anand K. McDonald, Daniel G. Dhindsa, Jasdeep S. Yount, Caroline Singh, Avtar K. Won, Je-Seong Singh, Inderjit TI S-nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma SO REDOX BIOLOGY LA English DT Article DE S-Nitrosoglutathione; STAT3; NF-kappa B; Head and neck cancer; Radiotherapy; Cisplatin ID NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; CANCER-CELLS; TRANSCRIPTION FACTOR; MOLECULAR TARGETS; DRUG-RESISTANCE; VEGF EXPRESSION; RAT MODEL; NITROSYLATION AB S-nitrosoglutathione (GSNO) is an endogenous nitric oxide (NO) carrier that plays a critical role in redox based NO signaling. Recent studies have reported that GSNO regulates the activities of STAT3 and NF-kappa B via S-nitrosylation dependent mechanisms. Since STAT3 and NF-kappa B are key transcription factors involved in tumor progression, chemoresistance, and metastasis of head and neck cancer, we investigated the effect of GSNO in cell culture and mouse xenograft models of head and neck squamous cell carcinoma (HNSCC). For the cell culture studies, three HNSCC cell lines were tested (SCC1, SCC14a and SCC22a). All three cell lines had constitutively activated (phosphorylated) STAT3 (Tyr(705)). GSNO treatment of these cell lines reversibly decreased the STAT3 phosphorylation in a concentration dependent manner. GSNO treatment also decreased the basal and cytokine-stimulated activation of NF-kappa B in SCC14a cells and reduced the basal low degree of nitrotyrosine by inhibition of inducible NO synthase (iNOS) expression. The reduced STAT3/NF-kappa B activity by GSNO treatment was correlated with the decreased cell proliferation and increased apoptosis of HNSCC cells. In HNSCC mouse xenograft model, the tumor growth was reduced by systemic treatment with GSNO and was further reduced when the treatment was combined with radiation and cisplatin. Accordingly, GSNO treatment also resulted in decreased levels of phosphorylated STAT3. In summary, these studies demonstrate that GSNO treatment blocks the NF-kappa B and STAT3 pathways which are responsible for cell survival, proliferation and that GSNO mediated mechanisms complement cispaltin and radiation therapy, and thus could potentiate the therapeutic effect in HNSCC. (C) 2015 Published by Elsevier B.V. C1 [Kaliyaperuma, Kolanjiappan; Sharma, Anand K.; McDonald, Daniel G.; Yount, Caroline] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Won, Je-Seong] Med Univ S Carolina, Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC 29401 USA. [Dhindsa, Jasdeep S.; Singh, Inderjit] Med Univ S Carolina, Pediat, Charleston, SC 29425 USA. RP Won, JS (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, Childrens Res Inst, Room 513,173 Ashley Ave, Charleston, SC 29425 USA. EM wonj@musc.edu; singhi@musc.edu FU NIH, United States [NS-37766, NS-72511]; [BX-002829]; [BX-001062] FX In part, this research was supported by grants from VA, United States (BX-002829 and BX-001062) and NIH, United States (NS-37766 and NS-72511). NR 77 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD DEC PY 2015 VL 6 BP 41 EP 50 DI 10.1016/j.redox.2015.07.001 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CZ8GR UT WOS:000367338700005 PM 26177470 ER PT J AU Liu, R Pulliam, DA Liu, YH Salmon, AB AF Liu, Roy Pulliam, Daniel A. Liu, Yuhong Salmon, Adam B. TI Dynamic differences in oxidative stress and the regulation of metabolism with age in visceral versus subcutaneous adipose SO REDOX BIOLOGY LA English DT Article DE Fat; Mitochondria; JNK; MAPK/ERK; Pre-adipocytes; Seahorse ID TERMINAL KINASE JNK; INSULIN-RESISTANCE; HUMAN OBESITY; TISSUE; FAT; MICE; LONGEVITY; PROTEIN; IMPACT; CARBONYLATION AB Once thought only as storage for excess nutrients, adipose tissue has been shown to be a dynamic organ implicated in the regulation of many physiological processes. There is emerging evidence supporting differential roles for visceral and subcutaneous white adipose tissue in maintaining health, although how these roles are modulated by the aging process is not clear. However, the proposed beneficial effects of subcutaneous fat suggest that targeting maintenance of this tissue could lead to healthier aging. In this study, we tested whether alterations in adipose function with age might be associated with changes in oxidative stress. Using visceral and subcutaneous adipose from C57BL16 mice, we discovered effects of both age and depot location on markers of lipolysis and adipogenesis. Conversely, accumulation of oxidative damage and changes in enzymatic antioxidant expression with age were largely similar between these two depots. The activation of each of the stress signaling pathways JNK and MAPK/ERK was relatively suppressed in subcutaneous adipose tissue suggesting reduced sensitivity to oxidative stress. Similarly, pre-adipocytes from subcutaneous adipose were significantly more resistant than visceral-derived cells to cell death caused by oxidative stress. Cellular respiration in visceral-derived cells was dramatically higher than in cells derived from subcutaneous adipose despite little evidence for differences in mitochondrial density. Together, our data identify molecular mechanisms by which visceral and subcutaneous adipose differ with age and suggest potential targetable means to preserve healthy adipose aging. Published by Elsevier B.V. C1 [Liu, Roy; Pulliam, Daniel A.; Liu, Yuhong; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Pulliam, Daniel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Mol Med, San Antonio, TX 78245 USA. [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM salmona@uthscsa.edu FU Medical Student Training in Aging Research (MSTAR) program - American Federation for Aging Research; National Institute on Aging [T35AG038048]; Geriatric Research Education and Clinical Center of the South Texas Veterans Healthcare System; American Federation for Aging Research; San Antonio Area Foundation FX R.L. was supported throughout this project as an awardee of the Medical Student Training in Aging Research (MSTAR) program supported by the American Federation for Aging Research and the National Institute on Aging (T35AG038048). This research was supported in part by the Geriatric Research Education and Clinical Center of the South Texas Veterans Healthcare System, and funding from the American Federation for Aging Research and the San Antonio Area Foundation (to A.B.S.). Mitochondrial bio-energetic assessment was performed with resources provided by the Mitochondrial Function and Oxidative Damage Core Facility of the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. This work was supported using facilities and resources at the Audie L. Murphy Memorial Veterans Hospital of the South Texas Veterans Health Care System. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 41 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD DEC PY 2015 VL 6 BP 401 EP 408 DI 10.1016/j.redox.2015.07.014 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CZ8GR UT WOS:000367338700039 PM 26355396 ER PT J AU Graham, JL Shahani, L Grimes, RM Hartman, C Giordano, TP AF Graham, James L. Shahani, Lokesh Grimes, Richard M. Hartman, Christine Giordano, Thomas P. TI The Influence of Trust in Physicians and Trust in the Healthcare System on Linkage, Retention, and Adherence to HIV Care SO AIDS PATIENT CARE AND STDS LA English DT Article ID UNITED-STATES; PREVENTIVE SERVICES; PATIENT; MORTALITY; PROVIDERS; INFECTION; DISPARITIES; POPULATION; BEHAVIORS; DIAGNOSIS AB Lack of trust by the patient in the physicians or the healthcare system has been associated with poorer health outcomes. The present study was designed to determine if trust in physicians and the healthcare system among persons newly diagnosed with HIV infection was predictive of patients' subsequent linkage, retention, and adherence to HIV care. 178 newly diagnosed HIV infected patients were administered the trust-in-physicians and trust-in-healthcare system scales. Median trust-in-physicians and trust-in-healthcare system scores were compared for all the mentioned subsequent linkage, retention, and adherence to HIV care. Univariate logistic regression using the trust-in-physician scale confirmed significant association with retention in care (p=0.04), which persisted in multivariate analyses (p=0.04). No significant association was found between trust-in-physicians and linkage to care or adherence to antiretroviral therapy. Trust in the healthcare system was not associated with any of the outcomes. Patients with higher trust in physicians were more likely to be retained in HIV care. Trust at diagnosis may not be a barrier to better clinical outcomes, either because trust changes based on subsequent interactions, or because trust is not a determining feature. Interventions to improve retention in care could include improving trust in physicians or target persons with low trust in physicians. C1 [Graham, James L.] Legacy Community Hlth Serv, Houston, TX USA. [Shahani, Lokesh; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Shahani, Lokesh; Hartman, Christine; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr 152, Ctr Innovat Qual Effectiveness & Safety, Houston, TX 77030 USA. [Grimes, Richard M.] Univ Texas Hlth Sci Ctr Houston, Houston Med Sch, Houston, TX 77030 USA. RP Giordano, TP (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM tpg@bcm.edu FU NIMH [R34MH074360]; AHRQ [U18HS016093]; Baylor/UT Houston Center for AIDS Research Grant [P30AI036211] FX This study is supported by NIMH Grant R34MH074360, AHRQ Grant U18HS016093, the Baylor/UT Houston Center for AIDS Research Grant P30AI036211, and the facilities and resources of the Harris Health System and the Michael E. DeBakey VA Medical Center. Dr. Giordano is a researcher at the Michael E. DeBakey VA Medical Center, Houston, TX. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 35 TC 5 Z9 6 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD DEC 1 PY 2015 VL 29 IS 12 BP 661 EP 667 DI 10.1089/apc.2015.0156 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CY7QF UT WOS:000366602800006 PM 26669793 ER PT J AU Niquet, J Gezalian, M Baldwin, R Wasterlain, CG AF Niquet, Jerome Gezalian, Michael Baldwin, Roger Wasterlain, Claude G. TI Neuroprotective effects of deep hypothermia in refractory status epilepticus SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY LA English DT Article ID TARGETED TEMPERATURE MANAGEMENT; HOSPITAL CARDIAC-ARREST; INTENSIVE-CARE-UNIT; THERAPEUTIC HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; MILD HYPOTHERMIA; GENE-EXPRESSION; RISK-FACTORS; BRAIN; SEIZURES AB Objective: Pharmacoresistance develops quickly during repetitive seizures, and refractory status epilepticus (RSE) remains a therapeutic challenge. The outcome of RSE is poor, with high mortality and morbidity. New treatments are needed. Deep hypothermia (20 degrees C) is used clinically during reconstructive cardiac surgery and neurosurgery, and has proved safe and effective in those indications. We tested the hypothesis that deep hypothermia reduces RSE and its long-term consequences. Methods: We used a model of SE induced by lithium and pilocarpine and refractory to midazolam. Several EEG measures were recorded in both hypothermic (n = 17) and normothermic (n = 20) animals. Neuronal injury (by Fluoro-Jade B), cell-mediated inflammation, and breakdown of the blood-brain barrier (BBB) (by immunohistochemistry) were studied 48 h following SE onset. Results: Normothermic rats in RSE seized for 4.1 +/- 1.1 h, and at 48 h they displayed extensive neuronal injury in many brain regions, including hippocampus, dentate gyrus, amygdala, entorhinal and pyriform cortices, thalamus, caudate/putamen, and the frontoparietal neocortex. Deep hypothermia (20 degrees C) of 30 min duration terminated RSE within 12 min of initiation of hypothermia, reduced EEG power and seizure activity upon rewarming, and eliminated SE-induced neuronal injury in most animals. Normothermic rats showed widespread breakdown of the BBB, and extensive macrophage infiltration in areas of neuronal injury, which were completely absent in animals treated with hypothermia. Interpretation: These results suggest that deep hypothermia may open a new therapeutic avenue for the treatment of RSE and for the prevention of its long-term consequences. C1 [Niquet, Jerome; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Niquet, Jerome; Gezalian, Michael; Baldwin, Roger; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Wasterlain, CG (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, West Los Angeles, CA 90073 USA. EM wasterla@ucla.edu FU BLRD VA [I01 BX000273]; NINDS NIH HHS [U01 NS074926] NR 57 TC 4 Z9 4 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2328-9503 J9 ANN CLIN TRANSL NEUR JI Ann. Clin. Transl. Neurol. PD DEC PY 2015 VL 2 IS 12 BP 1105 EP 1115 DI 10.1002/acn3.262 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CZ6WA UT WOS:000367240500005 PM 26734661 ER PT J AU Ashack, KA Burton, KA Kilgour, JM Dellavalle, RP AF Ashack, K. A. Burton, K. A. Kilgour, J. M. Dellavalle, R. P. TI Conflicts of interest in dermatology: a medical student and mentor perspective SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID PHARMACEUTICAL-INDUSTRY; EDUCATION AB Conflict of interest (COI) in medicine is well defined, but is seldom discussed in the field of dermatology. This perspective sheds light on this topic in dermatology and provides suggestions on how better to approach COI in medical school and residency. C1 [Ashack, K. A.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Burton, K. A.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Kilgour, J. M.] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales. [Dellavalle, R. P.] Univ Colorado Anschutz Med Campus, Dept Dermatol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Dellavalle, R. P.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Dellavalle, R. P.] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Dermatol Serv, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado Anschutz Med Campus, Dept Dermatol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. EM robert.dellavalle@ucdenver.edu NR 21 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD DEC PY 2015 VL 173 IS 6 BP 1518 EP 1521 DI 10.1111/bjd.14225 PG 4 WC Dermatology SC Dermatology GA CZ6SX UT WOS:000367232300075 PM 26708549 ER PT J AU Mendez, MF Ringman, JM Shapira, JS AF Mendez, Mario F. Ringman, John M. Shapira, Jill S. TI Impairments in the Face- Processing Network in Developmental Prosopagnosia and Semantic Dementia SO COGNITIVE AND BEHAVIORAL NEUROLOGY LA English DT Article ID RIGHT TEMPORAL-LOBE; PROGRESSIVE PROSOPAGNOSIA; CONGENITAL PROSOPAGNOSIA; ACQUIRED PROSOPAGNOSIA; FRONTOTEMPORAL DEMENTIA; RECOGNITION DISORDERS; FACIAL IDENTITY; FUSIFORM GYRUS; NEURAL SYSTEMS; FAMILIAR FACES C1 [Mendez, Mario F.; Ringman, John M.; Shapira, Jill S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Ringman, John M.; Shapira, Jill S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Ringman, John M.; Shapira, Jill S.] Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU National Institute on Aging [R01AG034499-05] FX Supported in part by National Institute on Aging Grant #R01AG034499-05 (M.F.M.) NR 106 TC 1 Z9 1 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1543-3633 EI 1543-3641 J9 COGN BEHAV NEUROL JI Cogn. Behav. Neurol. PD DEC PY 2015 VL 28 IS 4 BP 188 EP 197 PG 10 WC Behavioral Sciences; Clinical Neurology SC Behavioral Sciences; Neurosciences & Neurology GA CZ5HW UT WOS:000367134400002 PM 26705265 ER PT J AU Liang, TJ Block, TM McMahon, BJ Ghany, MG Urban, S Guo, JT Locarnini, S Zoulim, F Chang, KM Lok, AS AF Liang, T. Jake Block, Timothy M. McMahon, Brian J. Ghany, Marc G. Urban, Stephan Guo, Ju-Tao Locarnini, Stephen Zoulim, Fabien Chang, Kyong-Mi Lok, Anna S. TI Present and Future Therapies of Hepatitis B: From Discovery to Cure SO HEPATOLOGY LA English DT Review ID CLOSED CIRCULAR DNA; TENOFOVIR DISOPROXIL FUMARATE; TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; COMPLEX THERAPEUTIC VACCINE; CHIMERIC ANTIGEN RECEPTOR; ANTIVIRAL IMMUNE-RESPONSE; LARGE SURFACE PROTEIN; D VIRUS ENTRY; T-CELLS; IN-VIVO AB Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million people worldwide. While treatment for HBV has improved, HBV patients often require lifelong therapies and cure is still a challenging goal. Recent advances in technologies and pharmaceutical sciences have heralded a new horizon of innovative therapeutic approaches that are bringing us closer to the possibility of a functional cure of chronic HBV infection. In this article, we review the current state of science in HBV therapy and highlight new and exciting therapeutic strategies spurred by recent scientific advances. Some of these therapies have already entered into clinical phase, and we will likely see more of them moving along the development pipeline. Conclusion: With growing interest in developing and efforts to develop more effective therapies for HBV, the challenging goal of a cure may be well within reach in the near future. C1 [Liang, T. Jake; Ghany, Marc G.] NIDDK, LDB, NIH, Bethesda, MD 20892 USA. [Block, Timothy M.] Baruch S Blumberg Inst, Doylestown, PA USA. [McMahon, Brian J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Urban, Stephan] Univ Heidelberg Hosp, Mol Virol, Dept Infect Dis, Heidelberg, Germany. [Urban, Stephan] Univ Heidelberg Hosp, German Ctr Infect Dis, Heidelberg, Germany. [Locarnini, Stephen] Lyon Univ, Hepatol Dept, Lyon, France. [Locarnini, Stephen] Canc Res Ctr Lyon, INSERM, U1052, Lyon, France. [Zoulim, Fabien] Doherty Inst, Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. [Chang, Kyong-Mi] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Chang, Kyong-Mi] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lok, Anna S.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA. RP Liang, TJ (reprint author), NIDDK, LDB, NIH, Bldg 10-9B16,10 Ctr Dr, Bethesda, MD 20892 USA. EM jliang@nih.gov FU Janssen; Oncore-Tekmira; Gilead; Bristol-Myers Squibb; Roche; Novira; Arrowhead FX Dr. Guo received grants from Janssen. Dr. Block is on the Board of and owns stock in Contravir. He received grants and holds intellectual property rights with Oncore-Tekmira. Dr. Lok consults and received grants from Gilead. She consults from GlaxoSmithKline, Merck, MYR, and Tekmira. She received grants from Bristol-Myers Squibb. Dr. Chang advises Genentech, Arbutus, and Alnylam. Dr. Zoulim consults and received grants from Roche, Gilead, and Novira. He consults for Janssen. Dr. Locarnini received royalties and holds intellectual property rights with Melbourne Health. He consults and received fees from Arrowhead. He consults for Gilead. NR 154 TC 35 Z9 36 U1 5 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD DEC PY 2015 VL 62 IS 6 BP 1893 EP 1908 DI 10.1002/hep.28025 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CZ3OF UT WOS:000367013200059 PM 26239691 ER PT J AU de Almeida, JR Li, R Magnuson, JS Smith, RV Moore, E Lawson, G Remacle, M Ganly, I Kraus, DH Teng, MS Miles, BA White, H Duvvuri, U Ferris, RL Mehta, V Kiyosaki, K Damrose, EJ Wang, SJ Kupferman, ME Koh, Y Genden, EM Holsinger, FC AF de Almeida, John R. Li, Ryan Magnuson, J. Scott Smith, Richard V. Moore, Eric Lawson, Georges Remacle, Marc Ganly, Ian Kraus, Dennis H. Teng, Marita S. Miles, Brett A. White, Hilliary Duvvuri, Umamaheswar Ferris, Robert L. Mehta, Vikas Kiyosaki, Krista Damrose, Edward J. Wang, Steven J. Kupferman, Michael E. Koh, YoonWoo Genden, Eric M. Holsinger, F. Christopher TI Oncologic Outcomes After Transoral Robotic Surgery A Multi-institutional Study SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; PAPILLOMAVIRUS-ASSOCIATED CANCERS; OROPHARYNGEAL CANCER; NECK-CANCER; FUNCTIONAL OUTCOMES; LATERAL OROPHARYNGECTOMY; TONSILLAR REGION; ORAL-CAVITY; HEAD; EXPERIENCE AB IMPORTANCE Large patient cohorts are necessary to validate the efficacy of transoral robotic surgery (TORS) in the management of head and neck cancer. OBJECTIVES To review oncologic outcomes of TORS from a large multi-institutional collaboration and to identify predictors of disease recurrence and disease-specific mortality. DESIGN, SETTING, AND PARTICIPANTS A retrospective review of records from 410 patients undergoing TORS for laryngeal and pharyngeal cancers from January 1, 2007, through December 31, 2012, was performed. Pertinent data were obtained from 11 participating medical institutions. INTERVENTIONS Select patients received radiation therapy and/or chemotherapy before or after TORS. MAIN OUTCOMES AND MEASURES Locoregional control, disease-specific survival, and overall survival were calculated. We used Kaplan-Meier survival analysis with log-rank testing to evaluate individual variable association with these outcomes, followed by multivariate analysis with Cox proportional hazards regression modeling to identify independent predictors. RESULTS Of the 410 patients treated with TORS in this study, 364 (88.8%) had oropharyngeal cancer. Of these 364 patients, information about post-operative adjuvant therapy was known about 338: 106 (31.3) received radiation therapy alone, and 72 (21.3%) received radiation therapy with concurrent chemotherapy. Neck dissection was performed in 323 patients (78.8%). Mean follow-up time was 20 months. Local, regional, and distant recurrence occurred in 18 (4.4%), 15 (3.7%), and 10 (2.4%) of 410 patients, respectively. Seventeen (4.1%) died of disease, and 13 (3.2%) died of other causes. The 2-year locoregional control rate was 91.8% (95% CI, 87.6%-94.7%), disease-specific survival 94.5% (95% CI, 90.6%-96.8%), and overall survival 91% (95% CI, 86.5%-94.0%). Multivariate analysis identified improved survival among women (P = .05) and for patients with tumors arising in tonsil (P = .01). Smoking was associated with worse overall all-cause mortality (P = .01). Although advanced age and tobacco use were associated with locoregional recurrence and disease-specific survival, they, as well as tumor stage and other adverse histopathologic features, did not remain significant on multivariate analysis. CONCLUSIONS AND RELEVANCE This large, multi-institutional study supports the role of TORS within the multidisciplinary treatment paradigm for the treatment of head and neck cancer, especially for patients with oropharyngeal cancer. Favorable oncologic outcomes have been found across institutions. Ongoing comparative clinical trials funded by the National Cancer Institute will further evaluate the role of robotic surgery for patients with head and neck cancers. C1 [de Almeida, John R.] Princess Margaret Canc Ctr, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada. [Li, Ryan; Kiyosaki, Krista; Damrose, Edward J.; Holsinger, F. Christopher] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Surg, Palo Alto, CA 94305 USA. [Magnuson, J. Scott; White, Hilliary] Univ Alabama Birmingham, Dept Otolaryngol Head & Neck Surg, Birmingham, AL USA. [Smith, Richard V.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, New York, NY USA. [Moore, Eric] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN USA. [Lawson, Georges; Remacle, Marc] Catholic Univ Louvain Mont Godinne, Yvoir, Belgium. [Ganly, Ian] Mem Sloan Kettering Canc Ctr, Dept Surg Head & Neck Oncol, New York, NY 10021 USA. [Kraus, Dennis H.] North Shore Hlth Syst, New York Head & Neck Inst, New York, NY USA. [Teng, Marita S.; Miles, Brett A.; Genden, Eric M.] Icahn Sch Med Mt Sinai, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA. [Mehta, Vikas] Univ Pittsburgh, Med Ctr, Vet Affairs Pittsburgh HealthCare Syst, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA. [Wang, Steven J.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA. [Kupferman, Michael E.; Holsinger, F. Christopher] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA. [Koh, YoonWoo] Yonsei Univ, Sch Med, Severance Hosp, Seoul 120749, South Korea. RP Holsinger, FC (reprint author), Stanford Univ, Dept Otolaryngol Head & Neck Surg, 875 Blake Wilbur Dr, Palo Alto, CA 94305 USA. EM holsinger@stanford.edu OI Ganly, Ian/0000-0001-7636-5426 FU Bureau of Labor Statistics, Research and Development; Department of Veterans Affairs FX This study was supported in part by funds from the Bureau of Labor Statistics, Research and Development, Department of Veterans Affairs (Dr Duvvuri). NR 35 TC 19 Z9 19 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD DEC PY 2015 VL 141 IS 12 BP 1043 EP 1051 DI 10.1001/jamaoto.2015.1508 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CZ5MJ UT WOS:000367146400003 PM 26402479 ER PT J AU Maxwell, JH Thompson, LDR Brandwein-Gensler, MS Weiss, BG Canis, M Purgina, B Prabhu, AV Lai, C Shuai, YL Carroll, WR Morlandt, A Duvvuri, U Kim, S Johnson, JT Ferris, RL Seethala, R Chiosea, SI AF Maxwell, Jessica H. Thompson, Lester D. R. Brandwein-Gensler, Margaret S. Weiss, Bernhard G. Canis, Martin Purgina, Bibianna Prabhu, Arpan V. Lai, Chi Shuai, Yongli Carroll, William R. Morlandt, Anthony Duvvuri, Umamaheswar Kim, Seungwon Johnson, Jonas T. Ferris, Robert L. Seethala, Raja Chiosea, Simion I. TI Early Oral Tongue Squamous Cell Carcinoma Sampling of Margins From Tumor Bed and Worse Local Control SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID MICROSCOPIC CUT-THROUGH; FROZEN-SECTION MARGINS; LASER MICROSURGERY; NECK-CANCER; IMPACT; HEAD; CAVITY; RESECTIONS; RATES AB IMPORTANCE Positive margins are associated with poor prognosis among patients with oral tongue squamous cell carcinoma (SCC). However, wide variation exists in the margin sampling technique. OBJECTIVE To determine the effect of the margin sampling technique on local recurrence (LR) in patients with stage I or II oral tongue SCC. DESIGN, SETTING, AND PARTICIPANTS A retrospective study was conducted from January 1, 1986, to December 31, 2012, in 5 tertiary care centers following tumor resection and elective neck dissection in 280 patients with pathologic (p)T1-2 pNO oral tongue SCC. Analysis was conducted from June 1, 2013, to January 20, 2015. INTERVENTIONS In group 1 (n = 119), tumor bed margins were not sampled. In group 2 (n = 61), margins were examined from the glossectomy specimen, found to be positive or suboptimal, and revised with additional tumor bed margins. In group 3 (n = 100), margins were primarily sampled from the tumor bed without preceding examination of the glossectomy specimen. The margin status (both as a binary [positive vs negative] and continuous [distance to the margin in millimeters] variable) and other clinicopathologic parameters were compared across the 3 groups and correlated with LR. MAIN OUTCOMES AND MEASURES Local recurrence. RESULTS Age, sex, pT stage, lymphovascular or perineural invasion, and adjuvant radiation treatment were similar across the 3 groups. The probability of LR-free survival at 3 years was 0.9 and 0.8 in groups 1 and 3, respectively (P = .03). The frequency of positive glossectomy margins was lowest in group 1 (9 of 117 [7.7%]) compared with groups 2 and 3 (28 of 61 [45.9%] and 23 of 95 [24.2%], respectively) (P < .001). Even after excluding cases with positive margins, the median distance to the closest margin was significantly narrower in group 3 (2 mm) compared with group 1 (3 mm) (P = .008). The status (positive vs negative) of margins obtained from the glossectomy specimen correlated with LR (P = .007), while the status of tumor bed margins did not. The status of the tumor bed margin was 24% sensitive (95% CI, 16%-34%) and 92% specific (95% CI, 85%-97%) for detecting a positive glossectomy margin. CONCLUSIONS AND RELEVANCE The margin sampling technique affects local control in patients with oral tongue SCC. Reliance on margin sampling from the tumor bed is associated with worse local control, most likely owing to narrower margin clearance and greater incidence of positive margins. A resection specimen-based margin assessment is recommended. C1 [Maxwell, Jessica H.; Duvvuri, Umamaheswar; Kim, Seungwon; Johnson, Jonas T.; Ferris, Robert L.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Thompson, Lester D. R.] So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA USA. [Brandwein-Gensler, Margaret S.] Univ Alabama Birmingham, Dept Pathol, Div Anat Pathol, Birmingham, AL USA. [Brandwein-Gensler, Margaret S.] SUNY Buffalo, Dept Pathol & Anat Sci, Buffalo, NY 14260 USA. [Brandwein-Gensler, Margaret S.] Erie Cty Med Ctr & Labs, Buffalo, NY USA. [Weiss, Bernhard G.; Canis, Martin] Univ Gottingen, Dept Otorhinolaryngol Head & Neck Surg, D-37073 Gottingen, Germany. [Purgina, Bibianna; Lai, Chi] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada. [Prabhu, Arpan V.; Seethala, Raja; Chiosea, Simion I.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA. [Shuai, Yongli] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA 15213 USA. [Carroll, William R.; Morlandt, Anthony] Univ Alabama Birmingham, Dept Surg Head & Neck Oncol, Birmingham, AL USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol, Pittsburgh, PA USA. RP Chiosea, SI (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 200 Lothrop St,A610 Room 3, Pittsburgh, PA 15213 USA. EM chioseasi@upmc.edu RI Prabhu, Arpan/M-4193-2014; Thompson, Lester/J-8404-2016 OI Prabhu, Arpan/0000-0002-9928-2911; Thompson, Lester/0000-0003-3714-1432 FU [P30CA047904] FX This project used the University of Pittsburgh Cancer Institute Biostatistics Facility that is supported in part by award P30CA047904. NR 27 TC 6 Z9 7 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD DEC PY 2015 VL 141 IS 12 BP 1104 EP 1110 DI 10.1001/jamaoto.2015.1351 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CZ5MJ UT WOS:000367146400012 PM 26225798 ER PT J AU Aydil, U Duvvuri, U Kizil, Y Koybasioglu, A AF Aydil, U. Duvvuri, U. Kizil, Y. Koybasioglu, A. TI Tumour-node-metastasis staging of human papillomavirus negative upper aerodigestive tract cancers: a critical appraisal SO JOURNAL OF LARYNGOLOGY AND OTOLOGY LA English DT Review DE Neoplasm Staging; Head and Neck Neoplasms; Larynx; Mouth; Lymphatic Metastasis ID SQUAMOUS-CELL CARCINOMA; EARLY GLOTTIC CARCINOMA; ANTERIOR COMMISSURE INVOLVEMENT; PRIMARY SUBGLOTTIC CANCER; CAROTID-ARTERY RESECTION; ORAL TONGUE CARCINOMA; EXTRACAPSULAR SPREAD; PROGNOSTIC-FACTORS; RADIATION-THERAPY; LARYNGEAL-CANCER AB Objective: The tumour-node-metastasis staging system has a dynamic structure that is continuously being updated as scientific data develops. This review discusses some suggested revisions on tumour-node-metastasis staging of human papillomavirus negative upper aerodigestive tract cancers. Methods: The seventh edition of The American Joint Committee on Cancer Staging Manual was reviewed and important issues that could be considered for revision were identified and discussed. Results: According to our assessment of the oncological outcomes of previous studies, the following factors should be considered for revision: anterior commissure involvement and subglottic extension in laryngeal cancers; underlying bone involvement in hard palate and upper alveolar ridge cancers; tumour thickness in oral cancers; and extracapsular spread and carotid artery involvement in neck metastases. Conclusion: Sufficient data on the prognostic importance of these issues have been reported. Suggested revisions in line with current knowledge on the clinical behaviour of upper aerodigestive tract cancers would improve the relevancy of staging. C1 [Aydil, U.; Kizil, Y.] Gazi Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, TR-06500 Ankara, Turkey. [Koybasioglu, A.] Mem Ankara Hosp, Dept Otorhinolaryngol Head & Neck Surg, Ankara, Turkey. [Duvvuri, U.] Univ Pittsburgh, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Pittsburgh, PA 15260 USA. [Duvvuri, U.] Vet Affairs Pittsburgh Hlth Syst, Otolaryngol Sect, Pittsburgh, PA USA. RP Aydil, U (reprint author), Gazi Univ, Tip Faku, KBB AD, TR-06500 Ankara, Turkey. EM utkuaydil@yahoo.com NR 101 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0022-2151 EI 1748-5460 J9 J LARYNGOL OTOL JI J. Laryngol. Otol. PD DEC PY 2015 VL 129 IS 12 BP 1148 EP 1155 DI 10.1017/S0022215115002686 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA CZ6ZR UT WOS:000367250200002 PM 26446522 ER PT J AU Cooper, Z Mitchell, SL Gorges, RJ Rosenthal, RA Lipsitz, SR Kelley, AS AF Cooper, Zara Mitchell, Susan L. Gorges, Rebecca J. Rosenthal, Ronnie A. Lipsitz, Stuart R. Kelley, Amy S. TI Predictors of Mortality Up to 1 Year After Emergency Major Abdominal Surgery in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE major abdominal surgery; 1-year mortality; surgical complications; geriatric surgery; emergency surgery ID SELF-REPORTED HEALTH; LONG-TERM OUTCOMES; SURGICAL OUTCOMES; DECISION-MAKING; RISK-FACTORS; MORBIDITY; IMPACT; AGE; DIVERTICULITIS; POPULATION AB ObjectivesTo identify factors associated with mortality in older adults 30, 180, and 365days after emergency major abdominal surgery. DesignA retrospective study linked to Medicare claims from 2000 to 2010. SettingHealth and Retirement Study (HRS). ParticipantsMedicare beneficiaries aged 65.5 enrolled in the HRS from 2000 to 2010 with at least one urgent or emergency major abdominal surgery and a core interview from the HRS within 3years before surgery. MeasurementsSurvival analysis was used to describe all-cause mortality 30, 180, and 365days after surgery. Complementary log-log regression was used to identify participant characteristics and postoperative events associated with poorer survival. ResultsFour hundred individuals had one of the urgent or emergency surgeries of interest, 24% of whom were aged 85 and older, 50% had coronary artery disease, 48% had cancer, 33% had congestive heart failure, and 37% experienced a postoperative complication. Postoperative mortality was 20% at 30days, 31% at 180days, and 34% at 365days. Of those aged 85 and older, 50% were dead 1year after surgery. After multivariate adjustment including postoperative complications, dementia (hazard ratio (HR)=2.02, 95% confidence interval (CI)=1.24-3.31), hospitalization within 6months before surgery (HR=1.63, 95% CI=1.12-2.28), and complications (HR=3.45, 95% CI=2.32-5.13) were independently associated with worse 1-year survival. ConclusionOverall mortality is high in many older adults up to 1year after undergoing emergency major abdominal surgery. The occurrence of a complication is the clinical factor most strongly associated with worse survival. C1 [Cooper, Zara] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Cooper, Zara; Lipsitz, Stuart R.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Mitchell, Susan L.] Inst Aging Res, Hebrew Senior Life, Boston, MA USA. [Mitchell, Susan L.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Gorges, Rebecca J.; Kelley, Amy S.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Rosenthal, Ronnie A.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Cooper, Z (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM zcooper@partners.org FU Jahnigen Career Development Award from American Geriatrics Society; National Institute on Aging (NIA) Grants [1R03AG042361-01]; Mid-Career Mentoring Award [K24AG033640]; Paul B. Beeson Career Development Award in Aging NIA [K23AG040774]; American Federation for Aging Research FX Dr. Cooper is supported by a Jahnigen Career Development Award from the American Geriatrics Society and National Institute on Aging (NIA) Grants for Early Medical/Surgical Specialists' Transition to Aging Research Grant 1R03AG042361-01. Dr. Mitchell is supported by Mid-Career Mentoring Award K24AG033640. Dr. Kelley is supported by Paul B. Beeson Career Development Award in Aging NIA K23AG040774 and the American Federation for Aging Research. NR 34 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2015 VL 63 IS 12 BP 2572 EP 2579 DI 10.1111/jgs.13785 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CZ6EF UT WOS:000367193300020 PM 26661929 ER PT J AU Hanlon, JT Semla, TP Schmader, KE AF Hanlon, Joseph T. Semla, Todd P. Schmader, Kenneth E. TI Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE inappropriate medications; Beers Criteria; medication management ID RANDOMIZED CONTROLLED-TRIAL; HEALTHY MENOPAUSAL WOMEN; VULVO-VAGINAL ATROPHY; OLDER-PEOPLE; PHARMACOLOGICAL MANAGEMENT; POSTMENOPAUSAL WOMEN; PARKINSONS-DISEASE; HOT FLASHES; DEMENTIA; CRITERIA AB The National Committee for Quality Assurance (NCQA) and the Pharmacy Quality Alliance (PQA) use the American Geriatrics Society (AGS) Beers Criteria to designate the quality measure Use of High-Risk Medications in the Elderly (HRM). The Centers for Medicare and Medicaid Services (CMS) use the HRM measure to monitor and evaluate the quality of care provided to Medicare beneficiaries. NCQA additionally uses the AGS Beers Criteria to designate the quality measure Potentially Harmful Drug-Disease Interactions in the Elderly. Medications included in these measures may be harmful to elderly adults and negatively affect a healthcare plan's quality ratings. Prescribers, pharmacists, patients, and healthcare plans may benefit from evidence-based alternative medication treatments to avoid these problems. Therefore the goal of this work was to develop a list of alternative medications to those included in the two measures. The authors conducted a comprehensive literature review from 2000 to 2015 and a search of their personal files. From the evidence, they prepared a list of drug-therapy alternatives with supporting references. A reference list of nonpharmacological approaches was also provided when appropriate. NCQA, PQA, the 2015 AGS Beers Criteria panel, and the Executive Committee of the AGS reviewed the drug therapy alternatives and nonpharmacological approaches. Recommendations by these groups were incorporated into the final list of alternatives. The final product of drug-therapy alternatives to medications included in the two quality measures and some nonpharmacological resources will be useful to health professionals, consumers, payers, and health systems that care for older adults. C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Geriatr Pharmaceut Outcomes & Gero Informat Res &, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Hanlon, Joseph T.] Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Semla, Todd P.] Pharm Benefits Management Serv, Dept Vet Affairs, Hines, IL USA. [Semla, Todd P.] Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Sch Med, Div Geriatr,Dept Med, Durham, NC 27710 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Hanlon, JT (reprint author), Amer Geriatr Soc, Special Projects & Governance, 40 Fulton St,18th Floor, New York, NY 10038 USA. EM msamuel@americangeriatrics.org FU National Institute of Aging [P30AG024827, R01AG037451, P30AG028716]; Donoghue Foundation grant; Department of Veterans Affairs Health Services Research and Development Service Merit Award [IIR12-379, IIR14-297] FX Dr. Hanlon is supported by National Institute of Aging grants P30AG024827 and R01AG037451, a Donoghue Foundation grant, and Department of Veterans Affairs Health Services Research and Development Service Merit Awards IIR12-379 and IIR14-297. Dr. Schmader is supported by National Institute on Aging Grant P30AG028716. NR 40 TC 15 Z9 15 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2015 VL 63 IS 12 BP e8 EP e18 DI 10.1111/jgs.13807 PG 11 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CZ6EF UT WOS:000367193300002 PM 26447889 ER PT J AU Steinman, MA Beizer, JL DuBeau, CE Laird, RD Lundebjerg, NE Mulhausen, P AF Steinman, Michael A. Beizer, Judith L. DuBeau, Catherine E. Laird, Rosemary D. Lundebjerg, Nancy E. Mulhausen, Paul TI How to Use the American Geriatrics Society 2015 Beers Criteria-A Guide for Patients, Clinicians, Health Systems, and Payors SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID POTENTIALLY INAPPROPRIATE MEDICATION; OLDER-PEOPLE; EXPLICIT CRITERIA; ADULTS; CARE; PERSPECTIVE; EVENTS; EUROPE; MISUSE; COSTS AB The Beers Criteria are a valuable tool for clinical care and quality improvement but may be misinterpreted and implemented in ways that cause unintended harms. This article describes the intended role of the 2015 American Geriatrics Society (AGS) Beers Criteria and provides guidance on how patients, clinicians, health systems, and payors should use them. A key theme underlying these recommendations is to use common sense and clinical judgment in applying the 2015 AGS Beers Criteria and to remain mindful of nuances in the criteria. The criteria serve as a warning light to identify medications that have an unfavorable balance of benefits and harms in many older adults, particularly when compared with pharmacological and nonpharmacological alternatives. However, there are situations in which use of medications included in the criteria can be appropriate. As such, the 2015 AGS Beers Criteria work best not only when they identify potentially inappropriate medications, but also when they educate clinicians and patients about the reasons those medications are included and the situations in which their use may be more or less problematic. The criteria are designed to support, rather than supplant, good clinical judgment. C1 [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Beizer, Judith L.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY USA. [DuBeau, Catherine E.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [DuBeau, Catherine E.] Univ Massachusetts, Sch Med, Dept Family Med & Community Hlth, Worcester, MA USA. [DuBeau, Catherine E.] Univ Massachusetts, Sch Med, Dept Obstet & Gynecol, Worcester, MA USA. [Laird, Rosemary D.] Florida Hosp, Winter Pk, FL USA. [Lundebjerg, Nancy E.] Amer Geriatr Soc, New York, NY USA. [Mulhausen, Paul] Telligen, W Des Moines, IA USA. RP Steinman, MA (reprint author), 4150 Clement St,SFVAMC Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [K24 AG049057] NR 33 TC 9 Z9 9 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2015 VL 63 IS 12 BP e1 EP e7 DI 10.1111/jgs.13701 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CZ6EF UT WOS:000367193300001 PM 26446776 ER PT J AU Gold, MC McLaren, JE Reistetter, J Smyk-Pearson, S Ladell, K Swarbrick, GM Yu, YYL Hansen, TH Lund, O Nielsen, M Lewinsohn, DA Price, DA Lewinsohn, DM AF Gold, Marielle C. McLaren, James E. Reistetter, Joe Smyk-Pearson, Sue Ladell, Kristin Swarbrick, Gwendolyn M. Yu, Yik Y. L. Hansen, Ted H. Lund, Ole Nielsen, Morten Lewinsohn, Deborah A. Price, David A. Lewinsohn, David M. TI MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T-cell receptor usage SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 8th International Workshop on Antigen Processing and Presentation CY JUN 10-13, 2014 CL Philadelphia, PA C1 [Gold, Marielle C.; Reistetter, Joe; Smyk-Pearson, Sue; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97239 USA. [Gold, Marielle C.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Gold, Marielle C.; Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Mol Microbiol & Immunol, Portland, OR 97239 USA. [McLaren, James E.; Ladell, Kristin; Price, David A.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales. [Swarbrick, Gwendolyn M.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Pediat, Portland, OR 97239 USA. [Yu, Yik Y. L.; Hansen, Ted H.] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA. [Lund, Ole; Nielsen, Morten] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark. [Nielsen, Morten] Univ Nacl San Martin, Inst Invest Biotecnol, Buenos Aires, DF, Argentina. EM smykpearson@ohsu.edu; swarbric@ohsu.edu; lund@cbs.dtu.dk; mniel@cbs.dtu.dk; lewinsde@ohsu.edu RI Ladell, Kristin/C-8301-2013; Price, David/C-7876-2013; Lund, Ole/F-4437-2014; Nielsen, Morten/E-7754-2011 OI Ladell, Kristin/0000-0002-9856-2938; Price, David/0000-0001-9416-2737; Lund, Ole/0000-0003-1108-0491; Nielsen, Morten/0000-0001-7885-4311 NR 0 TC 0 Z9 0 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2015 VL 68 IS 2 BP 134 EP 134 PN A PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA CZ0AO UT WOS:000366767700022 ER PT J AU McMurtrey, C Harriff, M Liles, L Swarbrick, G Bardet, W Canfield, ET Jackson, K Lewinsohn, D Lewinsohn, D Hildebrand, W AF McMurtrey, Curtis Harriff, Melanie Liles, Lauren Swarbrick, Gwendolyn Bardet, Wilfried Canfield, Elizabeth T. Jackson, Ken Lewinsohn, Deborah Lewinsohn, David Hildebrand, William TI Identification of Mtb peptides presented by the HLA-Ib molecule HLA-E SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 8th International Workshop on Antigen Processing and Presentation CY JUN 10-13, 2014 CL Philadelphia, PA C1 [McMurtrey, Curtis; Liles, Lauren; Bardet, Wilfried; Jackson, Ken; Hildebrand, William] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73140 USA. [Harriff, Melanie; Swarbrick, Gwendolyn; Canfield, Elizabeth T.; Lewinsohn, Deborah; Lewinsohn, David] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. EM William-hildebrand@ouhsc.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2015 VL 68 IS 2 BP 158 EP 158 PN A PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA CZ0AO UT WOS:000366767700092 ER PT J AU Harriff, MJ Moita, LF Canfield, ET Grant, WF Burr, A Lewinsohn, DM AF Harriff, Melanie J. Moita, Luis F. Canfield, Elizabeth T. Grant, Wilmon F. Burr, Ansen Lewinsohn, David M. TI Identification of key determinants of MR1 vesicular trafficking and antigen presentation SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 8th International Workshop on Antigen Processing and Presentation CY JUN 10-13, 2014 CL Philadelphia, PA C1 [Harriff, Melanie J.; Canfield, Elizabeth T.; Burr, Ansen; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Harriff, Melanie J.; Canfield, Elizabeth T.; Grant, Wilmon F.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97239 USA. [Moita, Luis F.] Univ Lisbon, Fac Med, Inst Med Mol, P-1649028 Lisbon, Portugal. [Lewinsohn, David M.] Oregon Hlth & Sci Univ, Mol Microbiol & Immunol, Portland, OR 97239 USA. EM harriffm@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2015 VL 68 IS 2 BP 159 EP 159 PN A PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA CZ0AO UT WOS:000366767700095 ER PT J AU Grant, WF Harriff, MJ Canfield, ET Lewinsohn, DM AF Grant, Wilmon F. Harriff, Melanie J. Canfield, Elizabeth T. Lewinsohn, David M. TI HLA-E dependent antigen processing at the Mycobacterium tuberculosis phagosome SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 8th International Workshop on Antigen Processing and Presentation CY JUN 10-13, 2014 CL Philadelphia, PA C1 [Grant, Wilmon F.; Harriff, Melanie J.; Canfield, Elizabeth T.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97239 USA. [Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA. EM lewinsod@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2015 VL 68 IS 2 BP 160 EP 160 PN A PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA CZ0AO UT WOS:000366767700099 ER PT J AU Hensley, K Harris-White, ME AF Hensley, Kenneth Harris-White, Marni E. TI Redox regulation of autophagy in healthy brain and neurodegeneration SO NEUROBIOLOGY OF DISEASE LA English DT Review DE Autophagy; Alzheimer's disease; Beclin; Brain; Lanthionine; LC3; Neuroinflammation; Nrf2/Keap1; Redox biology; Reactive oxygen species; Sequestosome ID RESPONSE MEDIATOR PROTEIN-2; AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; MOUSE MODEL; OXIDATIVE STRESS; AMYLOID-BETA; PATHWAY; COMPLEX; MICE; NRF2 AB Autophagy and redox biochemistry are two major sub disciplines of cell biology which are both coming to be appreciated for their paramount importance in the etiology of neurodegenerative diseases including Alzheimer's disease (AD). Thus far, however, there has been relatively little exploration of the interface between autophagy and redox biology. Autophagy normally recycles macro-molecular aggregates produced through oxidative-stress mediated pathways, and also may reduce the mitochondria(production of reactive oxygen species through recycling of old and damaged mitochondria. Conversely, dysfunction in autophagy initiation, progression or clearance is evidenced to increase aggregation-prone proteins in neural and extraneural tissues. Redox mechanisms of autophagy regulation have been documented at the level of cross-talk between the Nrf2/Keap1 oxidant and electrophilic defense pathway and p62/sequestosome-1 (SQSTM1)-associated autophagy, at least in extraneural tissue; but other mechanisms of redox autophagy regulation doubtless remain to be discovered and the relevance of such processes to maintenance of neural homeostasis remains to be determined. This review summarizes current knowledge regarding the relationship of redox signaling, autophagy control, and oxidative stress as these phenomena relate to neurodegenerative disease. AD is specifically addressed as an example of the theme and as a promising indication for new therapies that act through engagement of autophagy pathways. To exemplify one such novel therapeutic entity, data is presented that the antioxidant and neurotrophic agent lanthionine ketimine-ethyl ester (LIKE) affects autophagy pathway proteins including beclin-1 in the 3xTg-AD model of Alzheimer's disease where the compound has been shown to reduce pathological features and cognitive dysfunction. (C) 2015 Elsevier Inc. All rights reserved. C1 [Hensley, Kenneth] Univ Toledo, Toledo, OH 43614 USA. [Harris-White, Marni E.] Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Harris-White, Marni E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Hensley, K (reprint author), Univ Toledo, Hlth Sci Campus,3000 Arlington Ave, Toledo, OH 43614 USA. EM Kenneth.hensley@utoledo.edu; Marni@ucla.edu FU University of Toledo Foundation Biomedical Innovation Award; Veterans Administration Merit funding; Muscular Dystrophy Association [MDA217526]; National Institutes of Health [NS082283] FX This work was supported in part by the University of Toledo Foundation Biomedical Innovation Award (KH); Veterans Administration Merit funding (MHW); a grant from the Muscular Dystrophy Association (MDA217526; KH); and the National Institutes of Health (NS082283; KH). KH is the inventor on U.S. patent 7,683,055 (other patents pending) covering composition and use of lanthionine ketimine derivatives including lanthionine ketimine-ester (LICE) and holds equity in a company engaged in commercial development of the technology. NR 68 TC 19 Z9 20 U1 3 U2 18 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD DEC PY 2015 VL 84 SI SI BP 50 EP 59 DI 10.1016/j.nbd.2015.03.002 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CZ3UK UT WOS:000367029300005 PM 25771170 ER PT J AU Harris-White, ME Ferbas, KG Johnson, MF Eslami, P Poteshkina, A Venkova, K Christov, A Hensley, K AF Harris-White, Marni E. Ferbas, Kathie G. Johnson, Ming F. Eslami, Pirooz Poteshkina, Aleksandra Venkova, Kalina Christov, Alexandar Hensley, Kenneth TI A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Autophagy; mTOR complex (mTORC); CRMP2; DPYSL2; Lanthionine ketimine ID RESPONSE MEDIATOR PROTEIN-2; CENTRAL-NERVOUS-SYSTEM; C-LIKE PROTEIN-1; ALZHEIMERS-DISEASE; MOUSE MODEL; MUSCULAR-DYSTROPHY; OXIDATIVE STRESS; BRAIN; RAPAMYCIN; PHOSPHORYLATION AB Autophagy is a fundamental cellular recycling process vulnerable to compromise in neurodegeneration. We now report that a cell-penetrating neurotrophic and neuroprotective derivative of the central nervous system (CNS) metabolite, lanthionine ketimine (LK), stimulates autophagy in RG2 glioma and SH-SY5Y neuroblastoma cells at concentrations within or below pharmacological levels reported in previous mouse studies. Autophagy stimulation was evidenced by increased lipidation of microtubule-associated protein 1 light chain 3 (LC3) both in the absence and presence of bafilomycin-A1 which discriminates between effects on autophagic flux versus blockage of autophagy clearance. LIKE treatment caused changes in protein level or phosphorylation state of multiple autophagy pathway proteins including mTOR; p70S6 kinase; unc-51-like-kinase-1 (ULK1); beclin-1 and LC3 in a manner essentially identical to effects observed after rapamycin treatment. The LICE site of action was near mTOR because neither LIKE nor the mTOR inhibitor rapamycin affected tuberous sclerosis complex (TSC) phosphorylation status upstream from mTOR. Confocal immunofluorescence imaging revealed that LICE specifically decreased mTOR (but not TSC2) colocalization with LAMP2(+) lysosomes in RG2 cells, a necessary event for mTORC1-mediated autophagy suppression, whereas rapamycin had no effect. Suppression of the LK-binding adaptor protein CRMP2 (collapsin response mediator protein-2) by means of shRNA resulted in diminished autophagy flux, suggesting that the LIKE action on mTOR localization may occur through a novel mechanism involving CRMP2-mediated intracellular trafficking. These findings clarify the mechanism-of-action for LIKE in preclinical models of CNS disease, while suggesting possible roles for natural lanthionine metabolites in regulating CNS autophagy. (C) 2015 Elsevier Inc All rights reserved. C1 [Harris-White, Marni E.; Ferbas, Kathie G.; Johnson, Ming F.; Eslami, Pirooz; Poteshkina, Aleksandra] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Harris-White, Marni E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ferbas, Kathie G.] Pepperdine Univ, Seaver Coll, Div Nat Sci, Malibu, CA 90265 USA. [Venkova, Kalina; Christov, Alexandar; Hensley, Kenneth] Univ Toledo, Med Ctr, Dept Pathol, Toledo, OH 43614 USA. [Hensley, Kenneth] Univ Toledo, Med Ctr, Dept Neurosci, Toledo, OH 43614 USA. RP Hensley, K (reprint author), 3000 Arlington Ave, Toledo, OH 43614 USA. EM Kenneth.hensley@utoledo.edu OI Harris-White, Marni/0000-0001-8994-3715 FU University of Toledo Foundation Biomedical Innovation Award; Veterans Administration Merit funding; Muscular Dystrophy Association [MDA217526]; National Institutes of Health [NS082283] FX This work was supported in part by the University of Toledo Foundation Biomedical Innovation Award (KH); Veterans Administration Merit funding (MHW); a grant from the Muscular Dystrophy Association (MDA217526; KH); and the National Institutes of Health (NS082283; KH). KH is the inventor of U.S. patent 7,683,055 covering composition and use of lanthionine ketimine derivatives including lanthionine ketimine-ester (LKE) and holds equity in a company engaged in commercial development of the technology. NR 53 TC 6 Z9 6 U1 1 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD DEC PY 2015 VL 84 SI SI BP 60 EP 68 DI 10.1016/j.nbd.2015.03.007 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CZ3UK UT WOS:000367029300006 PM 25779968 ER PT J AU Blevins, JE Baskin, DG AF Blevins, James E. Baskin, Denis G. TI Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans SO PHYSIOLOGY & BEHAVIOR LA English DT Article; Proceedings Paper CT 22nd Annual Meeting of the Society for the Study of Ingestive Behavior CY JUL 29-AUG 02, 2014 CL Seattle, WA DE Obesity; Food intake; Energy expenditure; Oxytocin ID HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; BROWN ADIPOSE-TISSUE; CAUSES WEIGHT-LOSS; HUMAN GASTROINTESTINAL-TRACT; SUGAR-SWEETENED BEVERAGES; MESSENGER-RNA EXPRESSION; RECEPTOR-DEFICIENT MICE; PRADER-WILLI-SYNDROME; HIGH-AFFINITY BINDING; INDUCED OBESE RATS AB The fact that more than 78 million adults in the US are considered overweight or obese highlights the need to develop new, effective strategies to treat obesity and its associated complications, including type 2 diabetes, kidney disease and cardiovascular disease. While the neurohypophyseal peptide oxytocin (OT) is well recognized for its peripheral effects to stimulate uterine contraction during parturition and milk ejection during lactation, release of OT within the brain is implicated in prosocial behaviors and in the regulation of energy balance. Previous findings indicate that chronic administration of OT decreases food intake and weight gain or elicits weight loss in diet-induced obese (DIO) mice and rats. Furthermore, chronic systemic treatment with OT largely reproduces the effects of central administration to reduce weight gain in DIO and genetically obese rodents at doses that do not appear to result in tolerance. These findings have now been recently extended to more translational models of obesity showing that chronic subcutaneous or intranasal OT treatment is sufficient to elicit body weight loss in DIO nonhuman primates and pre-diabetic obese humans. This review assesses the potential use of OT as a therapeutic strategy for treatment of obesity in rodents, nonhuman primates, and humans, and identifies potential mechanisms that mediate this effect. Published by Elsevier Inc. C1 [Blevins, James E.; Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Off Res & Dev, Med Res Serv, Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Blevins, James E.; Baskin, Denis G.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Blevins, JE (reprint author), VA Puget Sound Hlth Care Syst, Res 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jeblevin@u.washington.edu OI Blevins, James/0000-0002-7587-0380 FU Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA); California National Primate Research Center (CNPRC) Pilot Award [0D011107]; Department of VA Merit Review Research Program; VA Senior Research Career Scientist award FX This review is based on work presented in the symposium titled, "OT in Energy Balance Control" during the XXIInd Annual Meeting of the Society for the Study of Ingestive Behavior, July 29-August 2, 2014, in Seattle, WA. This material is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA). The research in our laboratory has been supported by the California National Primate Research Center (CNPRC) Pilot Award (core grant #0D011107) and the Department of VA Merit Review Research Program. DGB is the recipient of a VA Senior Research Career Scientist award. We also acknowledge the contributions of Dr. Christian Roth and Dr. Karen Bales for their review of this manuscript. In addition, we acknowledge Zachary Roberts for his technical assistance with Fig. 1. NR 242 TC 10 Z9 10 U1 4 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD DEC 1 PY 2015 VL 152 SI SI BP 438 EP 449 DI 10.1016/j.physbeh.2015.05.023 PN B PG 12 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA CZ2SB UT WOS:000366953800016 PM 26013577 ER PT J AU Ithapu, VK Singh, V Okonkwo, OC Chappell, RJ Dowling, NM Johnson, SC AF Ithapu, Vamsi K. Singh, Vikas Okonkwo, Ozioma C. Chappell, Richard J. Dowling, N. Maritza Johnson, Sterling C. CA Alzheimer's Dis Neuroimaging TI Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment SO ALZHEIMERS & DEMENTIA LA English DT Article DE Clinical trials; Sample enrichment; Deep learning; Alzheimer's disease ID ALZHEIMERS-DISEASE; SAMPLE-SIZE; BIOMARKER; CLASSIFICATION; VARIABILITY; DEMENTIA AB The mild cognitive impairment (MCI) stage of Alzheimer's disease (AD) may be optimal for clinical trials to test potential treatments for preventing or delaying decline to dementia. However, MCI is heterogeneous in that not all cases progress to dementia within the time frame of a trial and some may not have underlying AD pathology. Identifying those MCIs who are most likely to decline during a trial and thus most likely to benefit from treatment will improve trial efficiency and power to detect treatment effects. To this end, using multimodal, imaging-derived, inclusion criteria may be especially beneficial. Here, we present a novel multimodal imaging marker that predicts future cognitive and neural decline from [F-18] fluorodeoxyglucose positron emission tomography (PET), amyloid florbetapir PET, and structural magnetic resonance imaging, based on a new deep learning algorithm (randomized denoising autoencoder marker, rDAm). Using ADNI2 MCI data, we show that using rDAm as a trial enrichment criterion reduces the required sample estimates by at least five times compared with the no-enrichment regime and leads to smaller trials with high statistical power, compared with existing methods. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Ithapu, Vamsi K.; Singh, Vikas] Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA. [Ithapu, Vamsi K.; Singh, Vikas; Okonkwo, Ozioma C.; Dowling, N. Maritza; Johnson, Sterling C.] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Singh, Vikas; Chappell, Richard J.; Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Okonkwo, Ozioma C.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Madison, WI USA. [Johnson, Sterling C.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. RP Ithapu, VK (reprint author), Univ Wisconsin, Dept Comp Sci, 1210 W Dayton St, Madison, WI 53706 USA. EM ithapu@wisc.edu FU NIH [R01 AG040396, R01 AG021155]; NSF CAREER award [1252725]; Wisconsin Partnership Program; UW ADRC [P50 AG033514]; UW ICTR [1UL1RR025011] FX NIH R01 AG040396; NSF CAREER award 1252725; NIH R01 AG021155; Wisconsin Partnership Program; UW ADRC P50 AG033514; UW ICTR 1UL1RR025011. NR 28 TC 4 Z9 4 U1 5 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD DEC PY 2015 VL 11 IS 12 BP 1489 EP 1499 DI 10.1016/j.jalz.2015.01.010 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CY9IW UT WOS:000366721600010 PM 26093156 ER PT J AU Koyner, JL Coca, SG Thiessen-Philbrook, H Patel, UD Shlipak, MG Garg, AX Parikh, CR AF Koyner, Jay L. Coca, Steven G. Thiessen-Philbrook, Heather Patel, Uptal D. Shlipak, Michael G. Garg, Amit X. Parikh, Chirag R. CA TRIBE AKI Consortium TI Urine Biomarkers and Perioperative Acute Kidney Injury: The Impact of Preoperative Estimated GFR SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Urine biomarkers; interleukin 18 (IL-18); liver-type fatty acid binding protein (L-FABP); acute renal failure (ARF); acute kidney injury (AKI); perioperative AKI; effect modification; estimated glomerular filtration rate (eGFR); prognosis; cardiac surgery; surgical complication ID GELATINASE-ASSOCIATED LIPOCALIN; GLOMERULAR-FILTRATION-RATE; CYCLE ARREST BIOMARKERS; ACUTE-RENAL-FAILURE; CARDIAC-SURGERY; PREDICT PROGRESSION; CRITICALLY-ILL; POOR OUTCOMES; PERFORMANCE; VALIDATION AB Background: The interaction between baseline kidney function and the performance of biomarkers of acute kidney injury (AKI) on the development of AKI is unclear. Study Design: Post hoc analysis of prospective cohort study. Setting & Participants: The 1,219 TRIBE-AKI Consortium adult cardiac surgery cohort participants. Predictor: Unadjusted postoperative urinary biomarkers of AKI measured within 6 hours of surgery. Outcome: AKI was defined as AKI Network stage 1 (any AKI) or higher, as well as a doubling of serum creatinine level from the preoperative value or the need for post-operative dialysis (severe AKI). Measurements: Stratified analyses by preoperative estimated glomerular filtration rate (eGFR) <= 60 versus >60 mL/min/1.73 m(2). Results: 180 (42%) patients with preoperative eGFRs <= 60 mL/min/1.73 m(2) developed clinical AKI compared with 246 (31%) of those with eGFRs >60 mL/min/1.73 m(2) (P < 0.001). For log(2)-transformed biomarker concentrations, there was a significant interaction between any AKI and baseline eGFR for interleukin 18 (P = 0.007) and borderline significance for liver-type fatty acid binding protein (P = 0.06). For all biomarkers, the adjusted relative risk (RR) point estimates for the risk for any AKI were higher in those with elevated baseline eGFRs compared with those with eGFRs <= 60 mL/min/1.73 m(2). However, the difference in magnitude of these risks was low (adjusted RRs were 1.04 [95% CI, 0.99-1.09] and 1.11 [95% CI, 1.07-1.15] for those with preoperative eGFRs <= 60 mL/min/1.73 m(2) and those with higher eGFRs, respectively). Although no biomarker displayed an interaction for baseline eGFR and severe AKI, log(2)-transformed interleukin 18 and kidney injury molecule 1 had significant adjusted RRs for severe AKI in those with and without baseline eGFRs <= 60 mL/min/1.73 m(2). Limitations: Limited numbers of patients with severe AKI and post-operative dialysis. Conclusions: The association between early postoperative AKI urinary biomarkers and AKI is modified by preoperative eGFR. The degree of this modification and its impact on the biomarker-AKI association is small across biomarkers. Our findings suggest that distinct biomarker cutoffs for those with and without a preoperative eGFR <= 60 mL/min/1.73 m(2) is not necessary. Published by Elsevier Inc. C1 [Koyner, Jay L.] Univ Chicago, Pritzker Sch Med, Nephrol Sect, Dept Med, Chicago, IL 60637 USA. [Coca, Steven G.; Parikh, Chirag R.] Yale Univ, Sch Med, Dept Internal Med, Clin Epidemiol Res Ctr, New Haven, CT 06510 USA. [Thiessen-Philbrook, Heather; Garg, Amit X.] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. [Patel, Uptal D.] Duke Univ, Sch Med, Durham, NC USA. [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Parikh, CR (reprint author), Yale Univ, Program Appl Translat Res, 60 Temple St,Ste 6C, New Haven, CT 06510 USA. EM chirag.parikh@yale.edu FU National Institutes of Health (NIH) [R01HL085757]; NIH Career Development Awards [K23DK081616, K23DK080132]; NIH [K24DK090203, U01DK082185] FX This study was supported by the National Institutes of Health (NIH; R01HL085757 to Dr Parikh) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. Drs Koyner and Coca have been supported by NIH Career Development Awards (K23DK081616 and K23DK080132, respectively). Dr Parikh is supported by the NIH (K24DK090203). Drs Coca, Garg, and Parikh are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01DK082185). Urine biomarker assays were donated by Abbott Diagnostics (IL-18 and NGAL) and Sekisui Diagnostics LLC (cystatin C, KIM-1, and L-FABP). The granting agencies, Abbott Diagnostics, and Sekisui Diagnostics Inc, did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. NR 29 TC 4 Z9 4 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD DEC PY 2015 VL 66 IS 6 BP 1006 EP 1014 DI 10.1053/j.ajkd.2015.07.027 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CZ0ZP UT WOS:000366835700016 PM 26386737 ER PT J AU Hom, J Goldstein, G AF Hom, Jim Goldstein, Gerald TI Introduction to the Special Issue: A Tribute to Ralph M. Reitan SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Editorial Material C1 [Hom, Jim] Neuropsychol Ctr, Plano, TX 75074 USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, VISN IV MIRECC, Pittsburgh, PA USA. RP Hom, J (reprint author), Neuropsychol Ctr, Plano, TX 75074 USA. EM jhom@neuropsych.com NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD DEC PY 2015 VL 30 IS 8 BP 721 EP 723 DI 10.1093/arclin/acv068 PG 3 WC Psychology, Clinical; Psychology SC Psychology GA CY4HD UT WOS:000366368300001 PM 26590071 ER PT J AU Goldstein, G AF Goldstein, Gerald TI Ralph Reitan and Biological Intelligence SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article ID BRAIN-DAMAGE; LESIONS C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, VISN IV MIRECC, Pittsburgh, PA 15260 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, VISN IV MIRECC, Pittsburgh, PA 15260 USA. EM ggold@nb.net NR 23 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD DEC PY 2015 VL 30 IS 8 BP 733 EP 739 DI 10.1093/arclin/acv069 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA CY4HD UT WOS:000366368300003 PM 26590073 ER PT J AU Park, M Kulkarni, A Beatty, A Ganz, P Regan, M Vittinghoff, E Whooley, M AF Park, Meyeon Kulkarni, Ameya Beatty, Alexis Ganz, Peter Regan, Mathilda Vittinghoff, Eric Whooley, Mary TI Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study SO ATHEROSCLEROSIS LA English DT Article DE Atherosclerosis; Endothelium; Kidney disease; Cardiovascular mortality ID GLOMERULAR-FILTRATION-RATE; ARTERY-DISEASE; CYSTATIN-C; THROMBUS FORMATION; SERUM CREATININE; EVENTS; MORTALITY; ALBUMINURIA; ASSOCIATION; FAILURE AB Background and Aims: Endothelial cell-selective adhesion molecule (ESAM) is selectively expressed on vascular endothelium and is postulated to play a role in atherogenesis. We investigated the association of serum soluble ESAM (sESAM) levels with subsequent cardiovascular outcomes in patients with stable ischemic heart disease. Methods: We measured sESAM levels in 981 patients with stable coronary disease enrolled between September 2000 and December 2002 in a prospective cohort study. Poisson regression models were used to define the relationship between baseline sESAM levels and cardiovascular outcomes, including myocardial infarction, heart failure hospitalization, and mortality. Results: There were 293 occurrences of the composite endpoint over a median follow-up of 8.9 years. After adjusting for demographic and clinical risk factors, participants in the highest sESAM quartile (compared to the lower three sESAM quartiles) had a higher rate of the composite endpoint (incident rate ratio (IRR) 1.52 (95% CI 1.16-1.99) as well as of its individual components: myocardial infarction (IRR 1.64 (1.06-2.55)), heart failure hospitalizations (IRR 1.96 (1.32-2.81)), and death (IRR 1.5 (1.2-1.89)). These associations were no longer significant after adjustment for estimated glomerular filtration rate. Conclusions: sESAM levels associate with myocardial infarction, heart failure, and death after adjustment for demographic and clinical risk factors, but not after adjustment for kidney function. sESAM may be involved in the pathogenesis of concurrent kidney and cardiovascular disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Park, Meyeon] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Kulkarni, Ameya] Kaiser Permanente, Mclean, VA USA. [Beatty, Alexis; Ganz, Peter] Univ Washington, VA Puget Sound Hlth Care Syst, Div Cardiol, Seattle, WA 98195 USA. [Ganz, Peter] San Francisco Gen Hosp, San Francisco, CA USA. [Regan, Mathilda; Whooley, Mary] San Francisco VA Hosp, Dept Med, San Francisco, CA USA. [Whooley, Mary] UCSF, Dept Med, San Francisco, CA USA. [Vittinghoff, Eric; Whooley, Mary] UCSF, Dept Epidemiol & Biostat, San Francisco, CA USA. RP Park, M (reprint author), 521 Parnassus Ave,C443,Box 0532, San Francisco, CA 94143 USA. EM meyeon.park@ucsf.edu FU Meyeon Park's NIH/NIDDK [K23 DK099238]; Department of Veteran Affairs (Epidemiology Merit Review Program), Washington, DC; National Heart, Lung, and Blood Institute, Bethesda, MD [R01 HL-079235]; Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), Princeton, NJ; American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), New York, NY; Ischemia Research and Education Foundation, South San Francisco, CA FX This work was supported by Meyeon Park's NIH/NIDDK K23 DK099238. The Heart and Soul Study was funded by the Department of Veteran Affairs (Epidemiology Merit Review Program), Washington, DC; grant R01 HL-079235 from the National Heart, Lung, and Blood Institute, Bethesda, MD; the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), Princeton, NJ; the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), New York, NY; and the Ischemia Research and Education Foundation, South San Francisco, CA. NR 27 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD DEC PY 2015 VL 243 IS 2 BP 546 EP 552 DI 10.1016/j.atherosclerosis.2015.10.092 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CY6QO UT WOS:000366534100028 PM 26523992 ER PT J AU Arnold, SV Spertus, JA Vemulapalli, S Dai, DD O'Brien, SM Baron, SJ Kirtane, AJ Mack, MJ Green, P Reynolds, MR Rumsfeld, JS Cohen, DJ AF Arnold, Suzanne V. Spertus, John A. Vemulapalli, Sreekanth Dai, Dadi O'Brien, Sean M. Baron, Suzanne J. Kirtane, Ajay J. Mack, Michael J. Green, Philip Reynolds, Matthew R. Rumsfeld, John S. Cohen, David J. TI Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement Report From the STS/ACC TVT Registry SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article ID HIGH-RISK PATIENTS; CITY CARDIOMYOPATHY QUESTIONNAIRE; HEART-FAILURE; MYOCARDIAL-INFARCTION; OUTCOMES; IMPLANTATION; STENOSIS; TRIAL; RELIABILITY; PREDICTORS C1 [Arnold, Suzanne V.; Spertus, John A.; Baron, Suzanne J.; Cohen, David J.] St Lukes Mid Amer Heart Inst, Dept Med, Kansas City, MO 64111 USA. [Arnold, Suzanne V.; Spertus, John A.; Baron, Suzanne J.; Cohen, David J.] Univ Missouri Kansas City, Kansas City, MO USA. [Vemulapalli, Sreekanth; Dai, Dadi; O'Brien, Sean M.] Duke Univ, Dept Med, Durham, NC USA. [Kirtane, Ajay J.; Green, Philip] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Med, New York, NY 10027 USA. [Mack, Michael J.] Baylor Scott & White Hlth, Dept Cardiovasc Dis, Plano, TX USA. [Reynolds, Matthew R.] Lahey Hosp & Med Ctr, Dept Med, Boston, MA USA. [Reynolds, Matthew R.] Harvard Clin Res Inst, Boston, MA USA. [Rumsfeld, John S.] Denver VA Med Ctr, Dept Med, Denver, CO USA. RP Arnold, SV (reprint author), St Lukes Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM suz.v.arnold@gmail.com FU American College of Cardiology's National Cardiovascular Data Registry (NCDR); National Heart, Lung, and Blood Institute [K23 HL116799, K23 HL12114] FX The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry is an initiative of the STS and the ACC. This research was supported by the American College of Cardiology's National Cardiovascular Data Registry (NCDR). The study sponsors were not involved in the design and conduct of the study; analysis and interpretation of the data; preparation of the article; or decision to submit the article for publication. Dr Arnold is supported by a Career Development Grant Award (K23 HL116799) from the National Heart, Lung, and Blood Institute. Dr Green is supported by a Career Development Grant Award (K23 HL12114) from the National Heart, Lung, and Blood Institute. NR 29 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7640 EI 1941-7632 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD DEC PY 2015 VL 8 IS 12 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY9VI UT WOS:000366754000001 ER PT J AU Crisp, JG Takhar, SS Moran, GJ Krishnadasan, A Dowd, SE Finegold, SM Summanen, PH Talan, DA AF Crisp, Jonathan G. Takhar, Sukhjit S. Moran, Gregory J. Krishnadasan, Anusha Dowd, Scot E. Finegold, Sydney M. Summanen, Paula H. Talan, David A. CA EMERGEncy ID Net Study Grp TI Inability of Polymerase Chain Reaction, Pyrosequencing, and Culture of Infected and Uninfected Site Skin Biopsy Specimens to Identify the Cause of Cellulitis SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE cellulitis; culture; polymerase chain reaction; PCR; pyrosequencing ID RESISTANT STAPHYLOCOCCUS-AUREUS; FINE-NEEDLE-ASPIRATION; SOFT-TISSUE INFECTIONS; ANTIBACTERIAL PROPERTIES; EMERGENCY-DEPARTMENT; DIAGNOSIS; ERYSIPELAS; MANAGEMENT; ADULTS; PCR AB Background. The cause of cellulitis is unclear. Streptococcus pyogenes, and to a lesser extent, Staphylococcus aureus, are presumed pathogens. Methods. We conducted a study of adults with acute cellulitis without drainage presenting to a US emergency department research network. Skin biopsy specimens were taken from the infected site and a comparable uninfected site on the opposite side of the body. Microbiology was evaluated using quantitative polymerase chain reaction (PCR), pyrosequencing, and standard culture techniques. To determine the cause, the prevalence and quantity of bacterial species at the infected and uninfected sites were compared. Results. Among 50 subjects with biopsy specimens from infected and uninfected sites, culture rarely identified a bacterium. Among 49 subjects with paired specimens from infected and uninfected sites tested with PCR, methicillin- susceptible S. aureus was identified in 20 (41%) and 17 (34%), respectively. Pyrosequencing identified abundant atypical bacteria in addition to streptococci and staphylococci. Among 49 subjects with paired specimens tested by pyrosequencing, S. aureus was identified from 11 (22%) and 15 (31%) and streptococci from 15 (31%) and 20 (41%) of the specimens, respectively. Methicillin-resistant S. aureus was not found by culture or PCR, and S. pyogenes was not identified by any technique. Conclusions. The bacterial cause of cellulitis cannot be determined by comparing the prevalence and quantity of pathogens from infected and uninfected skin biopsy specimens using current molecular techniques. Methicillin-susceptible S. aureus was detected but not methicillin-resistant S. aureus or S. pyogenes from cellulitis tissue specimens. For now, optimal treatment will need to be guided by clinical trials. Noninfectious causes should also be explored. C1 [Crisp, Jonathan G.; Moran, Gregory J.; Krishnadasan, Anusha; Talan, David A.] Olive View UCLA Med Ctr, Dept Emergency Med, Los Angeles, CA USA. [Moran, Gregory J.; Talan, David A.] Olive View UCLA Med Ctr, Dept Med, Div Infect Dis, Los Angeles, CA USA. [Finegold, Sydney M.; Summanen, Paula H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis,VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Takhar, Sukhjit S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med,Div Infect Dis, Boston, MA 02115 USA. [Takhar, Sukhjit S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Infect Dis, Boston, MA 02115 USA. [Dowd, Scot E.] MR DNA, Shallowater, TX USA. RP Talan, DA (reprint author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA. EM dtalan@ucla.edu OI Rothman, Richard/0000-0002-1017-9505 FU Centers for Disease Control and Prevention [U01/CI000353-0] FX This work was supported by the Centers for Disease Control and Prevention (cooperative agreement U01/CI000353-0). NR 51 TC 6 Z9 6 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2015 VL 61 IS 11 BP 1679 EP 1687 DI 10.1093/cid/civ655 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CY5RF UT WOS:000366464200008 PM 26240200 ER PT J AU Abad, CL Safdar, N AF Abad, C. L. Safdar, N. TI The Reemergence of Measles SO CURRENT INFECTIOUS DISEASE REPORTS LA English DT Review DE Acute viral illness; Acute viral illness of childhood; Measles; Measles vaccine ID HUMAN-IMMUNODEFICIENCY-VIRUS; MUMPS-RUBELLA VACCINE; UNITED-STATES; YOUNG-ADULTS; CLINICAL CHARACTERISTICS; MEDIASTINAL EMPHYSEMA; CONTROLLED-TRIAL; LIVE MEASLES; CHILDREN; IMMUNIZATION AB Measles, or rubeola, is a highly infectious, acute viral illness of childhood that is considered eliminated in the USA but has reemerged in the past few years. Globally, an estimated 20 million cases of measles continue to occur, and it remains a leading cause of death among young children. It is rare in the USA and other first world countries, but numerous outbreaks have occurred in the USA recently, due to a combination of factors including poor vaccine coverage and importation of cases among travelers returning from endemic areas. The diagnosis of measles is usually made clinically, when an individual presents with a constellation of symptoms including cough, coryza, conjunctivitis, high fever, and an erythematous maculopapular rash in a cephalocaudal distribution. Complications are common and include otitis media, pneumonia, encephalitis, and rarely death. A measles vaccine is available in two doses and provides excellent protection against the disease. Despite this, vaccination coverage, especially among young adults, remains poor. Given its resurgence in the USA and other countries, interventions are urgently needed to address low vaccination rates and vaccine hesitancy. Measles awareness should also be a priority among young clinicians, who may have never seen a case or are not familiar with the disease. C1 [Abad, C. L.] Univ Philippines, Philippine Gen Hosp, Dept Med, Pasig, Philippines. [Safdar, N.] Univ Wisconsin, Sch Med, William S Middleton Mem Vet Hosp, Madison, WI 53703 USA. [Safdar, N.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin, Sch Med, William S Middleton Mem Vet Hosp, Madison, WI 53703 USA. EM ns2@medicine.wisc.edu NR 95 TC 3 Z9 3 U1 3 U2 32 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3847 EI 1534-3146 J9 CURR INFECT DIS REP JI Curr. Infect. Dis. Rep. PD DEC PY 2015 VL 17 IS 12 AR 51 DI 10.1007/s11908-015-0506-5 PG 8 WC Infectious Diseases SC Infectious Diseases GA CZ0PA UT WOS:000366807000003 PM 26446612 ER PT J AU Felker, GM Mentz, RJ Teerlink, JR Voors, AA Pang, PS Ponikowski, P Greenberg, BH Filippatos, G Davison, BA Cotter, G Prescott, MF Hua, TA Lopez-Pintado, S Severin, T Metra, M AF Felker, G. Michael Mentz, Robert J. Teerlink, John R. Voors, Adriaan A. Pang, Peter S. Ponikowski, Piotr Greenberg, Barry H. Filippatos, Gerasimos Davison, Beth A. Cotter, Gad Prescott, Margaret F. Hua, Tsushung A. Lopez-Pintado, Sara Severin, Thomas Metra, Marco TI Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE High-sensitivity cardiac troponin T; Acute heart failure; Outcomes; mortality; Dyspnoea ID SERELAXIN; BIOMARKERS; OUTCOMES AB AimsTroponin elevation is common in acute heart failure (AHF) and may be useful for prognostication; however, available data are mixed and many previous studies used older, less sensitive assays. We examined the association between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and outcomes in RELAX-AHF. Methods and resultsHs-cTnT was measured at baseline and days 2, 5, and 14. We assessed the relationship between baseline, peak and peak change hs-cTnT with dyspnoea relief by visual analogue scale, cardiovascular death, or HF/renal hospitalization to 60days and cardiovascular mortality to 180days. Models were adjusted for clinical variables and treatment assignment. Whether baseline troponin status affected the treatment effect of serelaxin was assessed using interactions terms. In 1074 patients, the median baseline troponin was 0.033 mu g/L, and 90% of patients were above the 99th upper reference limit (URL). Patients with hs-cTnT >median were more likely to be men with ischaemic heart disease, worse renal function, and higher N-terminal pro-brain natriuretic peptide. Higher baseline or peak hs-cTnT and greater peak change were associated with worse outcomes independent of adjustment for covariates, but relationships were generally strongest for 180-day cardiovascular mortality (hazard ratio per doubling of baseline hs-cTnT=1.36, 95% confidence interval 1.15-1.60). Troponin was most strongly associated with death from heart failure or from other cardiovascular causes. The treatment effect of serelaxin did not differ by baseline troponin levels. ConclusionHs-cTnT was elevated above the 99% URL in the majority of AHF patients. Baseline, peak, and peak change hs-cTnT were associated with worse outcomes, with the strongest relationship with 180-day cardiovascular mortality. C1 [Felker, G. Michael; Mentz, Robert J.] Duke Clin Res Inst, Durham, NC 27710 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Pang, Peter S.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Greenberg, Barry H.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece. [Davison, Beth A.; Cotter, Gad] Momentum Res Inc, Durham, NC USA. [Prescott, Margaret F.; Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA. [Lopez-Pintado, Sara] Columbia Univ, New York, NY USA. [Severin, Thomas] Novartis Pharma AG, Basel, Switzerland. [Metra, Marco] Univ Brescia, Brescia, Italy. RP Felker, GM (reprint author), Duke Clin Res Inst, DUMC Box 3850, Durham, NC 27710 USA. EM michael.felker@duke.edu NR 13 TC 18 Z9 18 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD DEC PY 2015 VL 17 IS 12 BP 1262 EP 1270 DI 10.1002/ejhf.341 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY4YV UT WOS:000366415700011 PM 26333655 ER PT J AU Swenson, ER AF Swenson, Erik R. TI On Receiving the Baton SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Editorial Material C1 [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. [Swenson, Erik R.] Univ Washington, Seattle, WA 98195 USA. RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 EI 1557-8682 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD DEC 1 PY 2015 VL 16 IS 4 BP 270 EP 270 DI 10.1089/ham.2015.29006.ers PG 1 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA CY8XX UT WOS:000366693100002 PM 26544799 ER PT J AU Pasinetti, GM AF Pasinetti, Giulio Maria TI Insulin resistance and obesity in childhood and long term consequences during aging SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE LA English DT Meeting Abstract CT Joint Meeting of the 20th Biennial Meeting of the International-Society-for-Developmental-Neuroscience / 5th Annual NeuroDevNet Brain Development Conference CY JUL 19-24, 2014 CL Montreal, CANADA SP Int Soc Dev Neuroscience C1 [Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Educ & Clin Ctr, Geriatr Res, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0736-5748 EI 1873-474X J9 INT J DEV NEUROSCI JI Int. J. Dev. Neurosci. PD DEC PY 2015 VL 47 SI SI BP 88 EP 88 DI 10.1016/j.ijdevneu.2015.04.241 PN A PG 1 WC Developmental Biology; Neurosciences SC Developmental Biology; Neurosciences & Neurology GA CY6QT UT WOS:000366534600231 PM 26531563 ER PT J AU Kerlikowske, K AF Kerlikowske, Karla TI Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID WOMEN AB IMPORTANCE Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality. OBJECTIVE To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer. PROCESS The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. EVIDENCE SYNTHESIS Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screeningmethod for women at average risk. RECOMMENDATIONS The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation). CONCLUSIONS AND RELEVANCE These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening. C1 [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM karla.kerlikowske@ucsf.edu FU National Cancer Institute [P01CA154292] FX This work was supported by grant P01CA154292 from the National Cancer Institute. NR 5 TC 3 Z9 3 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD DEC PY 2015 VL 175 IS 12 BP 1970 EP 1971 DI 10.1001/jamainternmed.2015.6466 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CY3TE UT WOS:000366332000021 PM 26502319 ER PT J AU Romo, RD Lee, SJ Miao, YH Boscardin, WJ Smith, AK AF Romo, Rafael D. Lee, Sei J. Miao, Yinghui Boscardin, W. John Smith, Alexander K. TI Subjective, Objective, and Observed Long-term Survival: A Longitudinal Cohort Study SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID OLDER-ADULTS C1 [Romo, Rafael D.; Lee, Sei J.; Boscardin, W. John; Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Romo, Rafael D.; Lee, Sei J.; Miao, Yinghui; Smith, Alexander K.] San Francisco VA Med Ctr, Geriatr & Extended Care, San Francisco, CA 94121 USA. RP Romo, RD (reprint author), San Francisco VA Med Ctr, Geriatr & Extended Care, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM rafael.romo@ucsf.edu FU NIA NIH HHS [P30 AG044281, 1K23AG040772, K23 AG040772] NR 6 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD DEC PY 2015 VL 175 IS 12 BP 1986 EP + DI 10.1001/jamainternmed.2015.5542 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CY3TE UT WOS:000366332000028 PM 26502331 ER PT J AU Willette, AA Burns, CM Bendlin, BB AF Willette, Auriel A. Burns, Christine M. Bendlin, Barbara B. TI Insulin Resistance and APOE e4 SO JAMA NEUROLOGY LA English DT Letter ID ADULTS C1 [Willette, Auriel A.] Iowa State Univ, Ames, IA USA. [Burns, Christine M.] US Dept Vet Affairs, Albuquerque, NM USA. [Bendlin, Barbara B.] Univ Wisconsin, Madison, WI 53792 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Ctr Clin Sci, Sect J5-1M,600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu FU NIA NIH HHS [P50 AG033514] NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD DEC PY 2015 VL 72 IS 12 BP 1536 EP + PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA CY8EG UT WOS:000366641000028 PM 26658975 ER PT J AU Stevens, WW Lee, RJ Schleimer, RP Cohen, NA AF Stevens, Whitney W. Lee, Robert J. Schleimer, Robert P. Cohen, Noam A. TI Chronic rhinosinusitis pathogenesis SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Chronic rhinosinusitis; nasal polyps; mucociliary clearance; epithelial cells; inflammation; microbiome ID HUMAN NASAL-MUCOSA; INNATE LYMPHOID-CELLS; TASTE RECEPTOR T2R38; ANTIMICROBIAL PEPTIDE LL-37; UPPER RESPIRATORY-INFECTION; HUMAN AIRWAY EPITHELIA; SURFACTANT PROTEIN-A; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS AB There are a variety of medical conditions associated with chronic sinonasal inflammation, including chronic rhinosinusitis (CRS) and cystic fibrosis. In particular, CRS can be divided into 2 major subgroups based on whether nasal polyps are present or absent. Unfortunately, clinical treatment strategies for patients with chronic sinonasal inflammation are limited, in part because the underlying mechanisms contributing to disease pathology are heterogeneous and not entirely known. It is hypothesized that alterations in mucociliary clearance, abnormalities in the sinonasal epithelial cell barrier, and tissue remodeling all contribute to the chronic inflammatory and tissue-deforming processes characteristic of CRS. Additionally, the host innate and adaptive immune responses are also significantly activated and might be involved in pathogenesis. Recent advancements in the understanding of CRS pathogenesis are highlighted in this review, with special focus placed on the roles of epithelial cells and the host immune response in patients with cystic fibrosis, CRS without nasal polyps, or CRS with nasal polyps. C1 [Stevens, Whitney W.; Schleimer, Robert P.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA. [Schleimer, Robert P.] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA. [Lee, Robert J.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Perelman Sch Med, Philadelphia, PA USA. [Lee, Robert J.] Univ Penn, Dept Physiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Cohen, Noam A.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. RP Schleimer, RP (reprint author), Div Allergy Immunol, 240 E Huron St,McGaw Rm M-318, Chicago, IL 60611 USA. EM rpschleimer@northwestern.edu OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686 FU USPHS grants [R01DC013588, R21DC013886, R03DC013862]; National Institutes of Health [T32 AI083216, R01 AI104733]; Ernest S. Bazley Foundation; Chronic Rhinosinusitis Integrative Studies Program [U19-AI106683]; RLG Foundation FX Some of the research described in this review and effort directed towards writing the review was supported by USPHS grants R01DC013588, R21DC013886 (to N.A.C.), and R03DC013862 (to R.J.L.); National Institutes of Health grants T32 AI083216 and R01 AI104733 (to R.P.S.); the Ernest S. Bazley Foundation (to R.P.S.); the Chronic Rhinosinusitis Integrative Studies Program U19-AI106683 (to R.P.S.), and a philanthropic contribution from the RLG Foundation (to N.A.C.). NR 159 TC 13 Z9 15 U1 2 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD DEC PY 2015 VL 136 IS 6 BP 1442 EP 1453 DI 10.1016/j.jaci.2015.10.009 PG 12 WC Allergy; Immunology SC Allergy; Immunology GA CX9RZ UT WOS:000366044300002 PM 26654193 ER PT J AU Hartling, L Guise, JM Kato, E Anderson, J Belinson, S Berliner, E Dryden, DM Featherstone, R Mitchell, MD Motu'apuaka, M Noorani, H Paynter, R Robinson, KA Schoelles, K Umscheid, CA Whitlock, E AF Hartling, Lisa Guise, Jeanne-Marie Kato, Elisabeth Anderson, Johanna Belinson, Suzanne Berliner, Elise Dryden, Donna M. Featherstone, Robin Mitchell, Matthew D. Motu'apuaka, Makalapua Noorani, Hussein Paynter, Robin Robinson, Karen A. Schoelles, Karen Umscheid, Craig A. Whitlock, Evelyn TI A taxonomy of rapid reviews links report types and methods to specific decision-making contexts SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Review DE Systematic reviews; Rapid reviews; Methodology; Interviews; Stakeholders; Automation ID SYSTEMATIC REVIEWS; PRODUCTS; MAKERS AB Objectives: Describe characteristics of rapid reviews and examine the impact of methodological variations on their reliability and validity. Study Design and Setting: We conducted a literature review and interviews with organizations that produce rapid reviews or related products to identify methods, guidance, empiric evidence, and current practices. Results: We identified 36 rapid products from 20 organizations (production time, 5 minutes to 8 months). Methods differed from systematic reviews at all stages. As time frames increased, methods became more rigorous; however, restrictions on database searching, inclusion criteria, data extracted, and independent dual review remained. We categorized rapid products based on extent of synthesis. "Inventories" list what evidence is available. "Rapid responses" present best available evidence with no formal synthesis. "Rapid reviews" synthesize the quality of and findings from the evidence. "Automated approaches" generate meta-analyses in response to user-defined queries. Rapid products rely on a close relationship with end users and support specific decisions in an identified time frame. Limited empiric evidence exists comparing rapid and systematic reviews. Conclusions: Rapid products have tremendous methodological variation; categorization based on time frame or type of synthesis reveals patterns. The similarity across rapid products lies in the close relationship with the end user to meet time-sensitive decision-making needs. (C) 2015 Elsevier Inc. All rights reserved. C1 [Hartling, Lisa; Dryden, Donna M.; Featherstone, Robin] Univ Alberta, Dept Pediat, Edmonton, AB, Canada. [Guise, Jeanne-Marie; Anderson, Johanna; Motu'apuaka, Makalapua; Paynter, Robin] Portland VA Res Fdn, Sci Resource Ctr, AHRQ Effect Hlth Care Program, Portland VA Med Ctr, Portland, OR USA. [Kato, Elisabeth; Berliner, Elise] Agcy Healthcare Res & Qual, Ctr Outcomes & Evidence, Rockville, MD USA. [Belinson, Suzanne; Noorani, Hussein] Blue Cross Blue Shield Assoc, Off Clin Affairs, Chicago, IL USA. [Mitchell, Matthew D.; Schoelles, Karen; Umscheid, Craig A.] Univ Penn, ECRI Inst, Penn Med AHRQ EPC, Philadelphia, PA 19104 USA. [Mitchell, Matthew D.; Schoelles, Karen; Umscheid, Craig A.] Univ Penn, Ctr Evidence Based Practice, Philadelphia, PA 19104 USA. [Mitchell, Matthew D.; Schoelles, Karen; Umscheid, Craig A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Robinson, Karen A.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Whitlock, Evelyn] Kaiser Permanente Res Affiliates, Portland, OR USA. RP Hartling, L (reprint author), 4-472 ECHA,11405-87 Ave, Edmonton, AB T6G IC9, Canada. EM hartling@ualberta.ca RI Featherstone, Robin/J-5165-2014 OI Featherstone, Robin/0000-0003-2517-2258; Paynter, Robin/0000-0002-6969-4261 FU Agency for Healthcare Research and Quality (AHRQ), Rockville, Maryland [290-2012-00013-I, 290-2012-00010-I, 290-2012-00011-I, 290-2012-00015-I, 290-2012-00007-I, 290201200004C] FX This manuscript is based on a project conducted by a working group with the Evidence-based Practice Center Program supported by the Agency for Healthcare Research and Quality (AHRQ), Rockville, Maryland through contracts to the following Evidence-based Practice Centers: University of Alberta (290-2012-00013-I), Blue Cross Blue Shield (290-2012-00010-I), ECRI- Penn (290-2012-00011-I), Kaiser (290-2012-00015-I), The Johns Hopkins University (290-2012-00007-I), and the Scientific Resource Center for the EPC Program (290201200004C). The findings and conclusions in this manuscript are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. No statement in this manuscript should be construed as an official position of AHRQ or of the US Department of Health and Human Services. NR 21 TC 5 Z9 5 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD DEC PY 2015 VL 68 IS 12 BP 1451 EP 1462 DI 10.1016/j.jclinepi.2015.05.036 PG 12 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CY6TR UT WOS:000366542200010 PM 26278023 ER PT J AU Whitaker, RM Stallons, LJ Kneff, JE Alge, JL Harmon, JL Rahn, JJ Arthur, JM Beeson, CC Chan, SL Schnellmann, RG AF Whitaker, Ryan M. Stallons, L. Jay Kneff, Joshua E. Alge, Joseph L. Harmon, Jennifer L. Rahn, Jennifer J. Arthur, John M. Beeson, Craig C. Chan, Sherine L. Schnellmann, Rick G. TI Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury SO KIDNEY INTERNATIONAL LA English DT Article DE acute kidney injury; ischemia/reperfusion; mitochondria ID CARDIAC-SURGERY; DISEASE; RISK; AKI; PROGRESSION; DIAGNOSIS; RECOVERY; OUTCOMES; BIOGENESIS; SEVERITY AB Recent studies show the importance of mitochondrial dysfunction in the initiation and progression of acute kidney injury (AKI). However, no biomarkers exist linking renal injury to mitochondrial function and integrity. To this end, we evaluated urinary mitochondrial DNA (UmtDNA) as a biomarker of renal injury and function in humans with AKI following cardiac surgery. mtDNA was isolated from the urine of patients following cardiac surgery and quantified by quantitative PCR. Patients were stratified into no AKI, stable AKI, and progressive AKI groups based on Acute Kidney Injury Network (AKIN) staging. UmtDNA was elevated in progressive AKI patients and was associated with progression of patients with AKI at collection to higher AKIN stages. To evaluate the relationship of UmtDNA to measures of renal mitochondrial integrity in AKI, mice were subjected to sham surgery or varying degrees of ischemia followed by 24 h of reperfusion. UmtDNA increased in mice after 10-15 min of ischemia and positively correlated with ischemia time. Furthermore, UmtDNA was predictive of AKI in the mouse model. Finally, UmtDNA levels were negatively correlated with renal cortical mtDNA and mitochondrial gene expression. These translational studies demonstrate that UmtDNA is associated with recovery from AKI following cardiac surgery by serving as an indicator of mitochondrial integrity. Thus UmtDNA may serve as valuable biomarker for the development of mitochondrial-targeted therapies in AKI. C1 [Whitaker, Ryan M.; Stallons, L. Jay; Kneff, Joshua E.; Harmon, Jennifer L.; Rahn, Jennifer J.; Beeson, Craig C.; Chan, Sherine L.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Alge, Joseph L.; Arthur, John M.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Arthur, John M.; Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu OI Alge, Joseph/0000-0002-2491-1066 FU NIDDK NIH HHS [F30 DK096964]; NIGMS NIH HHS [T32 GM008716, R01 GM084147] NR 46 TC 3 Z9 3 U1 3 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2015 VL 88 IS 6 BP 1336 EP 1344 DI 10.1038/ki.2015.240 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CY4RG UT WOS:000366395300019 PM 26287315 ER PT J AU Ozburn, A AF Ozburn, Angela TI Effects of Chronic Alcohol Drinking on Circadian Gene Expression SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 54th Annual Meeting of the American-College-of-Neuropsychopharmacology (ACNP) CY DEC 06-10, 2015 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol DE Alcohol; circadian; gene expression; genetic mouse model C1 [Ozburn, Angela] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2015 VL 40 SU 1 MA W239 BP S596 EP S597 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OI UT WOS:000366597700963 ER PT J AU Tregellas, J Wylie, K Smucny, J Olincy, A Legget, K AF Tregellas, Jason Wylie, Korey Smucny, Jason Olincy, Ann Legget, Kristina TI Altered Insula Between-Network Connectivity in Schizophrenia SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 54th Annual Meeting of the American-College-of-Neuropsychopharmacology (ACNP) CY DEC 06-10, 2015 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol DE schizophrenia; Insula; functional connectivity C1 [Tregellas, Jason; Wylie, Korey; Smucny, Jason; Olincy, Ann; Legget, Kristina] Univ Colorado, Denver VA Med Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2015 VL 40 SU 1 MA W179 BP S558 EP S558 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OI UT WOS:000366597700903 ER PT J AU Hennessy, S Kurichi, JE Pan, Q Streim, JE Bogner, HR Xie, DW Stineman, MG AF Hennessy, Sean Kurichi, Jibby E. Pan, Qiang Streim, Joel E. Bogner, Hillary R. Xie, Dawei Stineman, Margaret G. TI Disability Stage is an Independent Risk Factor for Mortality in Medicare Beneficiaries Aged 65 Years and Older SO PM&R LA English DT Article ID COMMUNITY-DWELLING PERSONS; ACTIVITY LIMITATION; ELDERLY-PEOPLE; HOME ACCESSIBILITY; FUNCTIONAL STATUS; HEALTH-CARE; CASE-MIX; LIFE; POPULATION; HOSPITALIZATION AB Background: Stages of activity limitation based on activities of daily living (ADLs) and instrumental activities of daily living (IADLs) have been found to predict mortality in persons aged 70 years and older but have not been examined in Medicare beneficiaries aged 65 years and older using data that are routinely collected. Objective: To examine the association between functional stages based on items of ADLs and IADLs with 3-year mortality in Medicare beneficiaries aged 65 years and older, accounting for baseline sociodemographics, health status, smoking, subjective health, and psychological well-being. Design: A cohort study using the Medicare Current Beneficiary Survey (MCBS) and associated health care utilization data. Setting: Community administered survey. Participants: The study included 9698 Medicare beneficiaries aged 65 years and older who participated in the MCBS in 2005-2007. Main Outcome Measures: Death within 3 years of cohort entry. Results: The overall mortality rate was 3.6 per 100 person years, and 3-year cumulative mortality was 10.3%. Unadjusted 3-year mortality was monotonically associated with both ADL stage and IADL stage. Adjusted 3-year mortality was associated with ADL and IADL stages, except that in some models the hazard ratio for stage III (which includes persons with atypical activity limitation patterns) was numerically lower than that for stage II. Conclusion: We found nearly monotonic relationships between ADL and IADL stage and adjusted 3-year mortality. These findings could aid in the development of population health approaches and metrics for evaluating the success of alternative economic, social, or health policies on the longevity of older adults with activity limitations. C1 [Hennessy, Sean; Kurichi, Jibby E.; Pan, Qiang; Xie, Dawei] Univ Penn, Perelman Sch Med, Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Hennessy, Sean] Univ Penn, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Perelman Sch Med, Geriatr Psychiat Sect, Dept Psychiat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Bogner, Hillary R.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Stineman, Margaret G.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. RP Hennessy, S (reprint author), Univ Penn, Perelman Sch Med, Clin Epidemiol & Biostat, 803 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM hennessy@upenn.edu FU National Institutes of Health [R01AG040105, R01HD074756, R01AG025152, R01DK102694] FX This research was supported by the National Institutes of Health (R01AG040105, R01HD074756, R01AG025152, and R01DK102694). Neither the National Institutes of Health nor the Centers for Medicare and Medicaid Services (which provided the data) played a role in the design or conduct of the study, in the analysis or interpretation of the data, or in the preparation, review, or approval of the manuscript. NR 27 TC 6 Z9 6 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD DEC PY 2015 VL 7 IS 12 BP 1215 EP 1225 DI 10.1016/j.pmrj.2015.05.014 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CZ1FP UT WOS:000366851600003 PM 26003869 ER PT J AU Suri, P Fry, AL Gellhorn, AC AF Suri, Pradeep Fry, Adrielle L. Gellhorn, Alfred C. TI Do Muscle Characteristics on Lumbar Spine Magnetic Resonance Imaging or Computed Tomography Predict Future Low Back Pain, Physical Function, or Performance? A Systematic Review SO PM&R LA English DT Review ID CROSS-SECTIONAL AREA; PSYCHOPHYSICAL LIFTING STRENGTH; OLDER-ADULTS; PARASPINAL MUSCLES; MULTIFIDUS; ENDURANCE; SIZE; ASSOCIATION; IMPROVEMENT; DISABILITY AB Objective: To determine whether lumbar muscle characteristics on magnetic resonance imaging (MRI) or computed tomography (CT) can inform clinicians as to the course of future low back pain (LBP), functional limitations, or physical performance, in adults with or without LBP. Type: Systematic review. Literature Review: We searched PubMed, Embase, and CINAHL through October 2014 for articles published in English in which authors assessed lumbar muscle characteristics on conventional MRI/CT as predictors of future LBP, functional limitations, or physical performance in adults. Studies with only postsurgical subjects were excluded. Our search identified 3554 articles, of which 6 observational cohort studies were included in the final review. Methodology: We used the Newcastle Ottawa Scale to evaluate potential bias. Data were extracted on study design, study population, sample size, participant characteristics, details of MRI/CT assessments, interventions, study outcomes, analysis methods, and study results. Because of heterogeneity between studies, we conducted a qualitative evidence synthesis. Synthesis: Among high-quality studies, there was limited evidence that, for individuals with or without LBP, greater MRI-detected multifidus cross-sectional area at L5-S1 predicted greater LBP intensity at 1-year follow-up, lesser erector spinae fat infiltration (FI) at L5-S1 predicted greater LBP intensity at 15-year follow-up, and greater erector spinae side-to-side FI asymmetry at L3-L4 predicted lower LBP frequency at 15-year follow-up; however, there was also limited evidence that all other MRI-detected paraspinal muscle characteristics examined were not predictive of LBP incidence, prevalence, frequency, or intensity at follow-up durations ranging from 1 to 15 years. There was limited evidence that greater CT-detected trunk muscle FI predicted worse physical performance in older adults at 3-year follow-up, but that trunk muscle cross-sectional area did not. Conclusion: Few lumbar muscle characteristics have limited evidence for an association with future LBP and physical performance outcomes, and the vast majority have limited evidence for having no association with such outcomes. C1 [Suri, Pradeep] VA Puget Sound Healthcare Syst, Div Rehabil Care Serv, ERIC, Seattle, WA 98108 USA. [Suri, Pradeep; Fry, Adrielle L.; Gellhorn, Alfred C.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Gellhorn, Alfred C.] Weill Cornell Med Coll, Div Rehabil Med, New York, NY USA. RP Suri, P (reprint author), VA Puget Sound Healthcare Syst, Div Rehabil Care Serv, ERIC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM pradeep.suri@va.gov FU VA Puget Sound Health Care System FX Dr. Suri's participation is this study was funded by VA Puget Sound Health Care System. The authors report no financial arrangements that may represent a possible conflict of interest with the work presented. A portion of this research was submitted as an abstract to the American Association of Academic Physiatrists Annual Meeting 2015, in San Antonio, TX. NR 36 TC 4 Z9 4 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD DEC PY 2015 VL 7 IS 12 BP 1269 EP 1281 DI 10.1016/j.pmrj.2015.04.016 PG 13 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CZ1FP UT WOS:000366851600009 PM 25952771 ER PT J AU Rodriguez-Jimenez, R Dompablo, M Bagney, A Santabarbara, J Aparicio, AI Torio, I Moreno-Ortega, M Lopez-Anton, R Lobo, A Kern, RS Green, MF Jimenez-Arriero, MA Santos, JL Nuechterlein, KH Palomo, T AF Rodriguez-Jimenez, R. Dompablo, M. Bagney, A. Santabarbara, J. Aparicio, A. I. Torio, I. Moreno-Ortega, M. Lopez-Anton, R. Lobo, A. Kern, R. S. Green, M. F. Jimenez-Arriero, M. A. Santos, J. L. Nuechterlein, K. H. Palomo, T. TI The MCCB impairment profile in a Spanish sample of patients with schizophrenia: Effects of diagnosis, age, and gender on cognitive functioning SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Cognition; MATRICS; MCCB; Age; Gender ID 1ST-EPISODE SCHIZOPHRENIA; BATTERY; STANDARDIZATION; INDIVIDUALS; PERFORMANCE; DEFICIT AB The MATRICS Consensus Cognitive Battery (MCCB) was administered to 293 schizophrenia outpatients and 210 community residents in Spain. Our first objective was to identify the age-and gender-corrected MCCB cognitive profile of patients with schizophrenia. The profile of schizophrenia patients showed deficits when compared to controls across the seven MCCB domains. Reasoning and Problem Solving and Social Cognition were the least impaired, while Visual Learning and Verbal Learning showed the greatest deficits. Our second objective was to study the effects on cognitive functioning of age and gender, in addition to diagnosis. Diagnosis was found to have the greatest effect on cognition (Cohen's d > 0.8 for all MCCB domains); age and gender also had effects on cognitive functioning, although to a lesser degree (with age usually having slightly larger effects than gender). The effects of age were apparent in all domains (with better performance in younger subjects), except for Social Cognition. Gender had effects on Attention/Vigilance, Working Memory, Reasoning and Problem Solving (better performance in males), and Social Cognition (better performance in females). No interaction effects were found between diagnosis and age, or between diagnosis and gender. This lack of interactions suggests that age and gender effects are not different in patients and controls. (C) 2015 Elsevier B.V. All rights reserved. C1 [Rodriguez-Jimenez, R.; Dompablo, M.; Bagney, A.; Torio, I.; Moreno-Ortega, M.; Jimenez-Arriero, M. A.; Palomo, T.] Inst Invest Hosp 12 Octubre I 12, Dept Psychiat, Madrid 28041, Spain. [Rodriguez-Jimenez, R.; Dompablo, M.; Bagney, A.; Santabarbara, J.; Moreno-Ortega, M.; Lopez-Anton, R.; Lobo, A.; Jimenez-Arriero, M. A.; Palomo, T.] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain. [Rodriguez-Jimenez, R.; Jimenez-Arriero, M. A.; Palomo, T.] Univ Complutense Madrid, Dept Psychiat, E-28040 Madrid, Spain. [Santabarbara, J.] Univ Zaragoza, Dept Prevent Med & Publ Hlth, E-50009 Zaragoza, Spain. [Aparicio, A. I.; Santos, J. L.] Hosp Virgen La Luz, Dept Psychiat, Cuenca, Spain. [Lopez-Anton, R.] Univ Zaragoza, Dept Psychol & Sociol, E-50009 Zaragoza, Spain. [Lobo, A.] Univ Zaragoza, Dept Psychiat, IIS Aragon, E-50009 Zaragoza, Spain. [Kern, R. S.; Green, M. F.; Nuechterlein, K. H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Kern, R. S.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Rodriguez-Jimenez, R (reprint author), Inst Invest Hosp 12 Octubre I 12, Dept Psychiat, Avda Cordoba S-N, Madrid 28041, Spain. EM roberto.rodriguez.jimenez@gmail.com FU Fondo de Investigaciones Sanitarias, FIS [PI080514]; Madrid's Regional Government [S2010/BMD-2422 AGES]; European Union Structural Funds; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III FX This research was supported in part by grant PI080514 (Fondo de Investigaciones Sanitarias, FIS), by Madrid's Regional Government (S2010/BMD-2422 AGES) and European Union Structural Funds, and by the Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III. NR 30 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2015 VL 169 IS 1-3 BP 116 EP 120 DI 10.1016/j.schres.2015.09.013 PG 5 WC Psychiatry SC Psychiatry GA CY5PC UT WOS:000366458600017 PM 26416441 ER PT J AU Schlosser, DA Campellone, TR Biagianti, B Delucchi, KL Gard, DE Fulford, D Stuart, BK Fisher, M Loewy, RL Vinogradov, S AF Schlosser, Danielle A. Campellone, Timothy R. Biagianti, Bruno Delucchi, Kevin L. Gard, David E. Fulford, Daniel Stuart, Barbara K. Fisher, Melissa Loewy, Rachel L. Vinogradov, Sophia TI Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Motivation; Social functioning; Prodromal; Psychosis; Experiential negative symptoms; Expressive negative symptoms ID ULTRA-HIGH RISK; MOTIVATIONAL DEFICITS; SCHIZOPHRENIA; NEUROCOGNITION; DIMENSIONS; PREDICTION; INTERVIEW; PRODROME; OUTCOMES; IMPACT AB A priority for improving outcome in individuals at clinical high risk (CHR) is enhancing our understanding of predictors of psychosis as well as psychosocial functioning. Social functioning, in particular, is a unique indicator of risk as well as an important outcome in itself. Negative symptoms are a significant determinant of social functioning in CHR individuals; yet, it is unclear which specific negative symptoms drive functional outcomeand how these symptoms function relative to other predictors, such as neurocognition and mood/anxiety symptoms. In a sample of 85 CHR individuals, we examined whether a two-factor negative symptom structure that is found in schizophrenia (experiential vs expressive symptoms) would be replicated in a CHR sample; and tested the degree to which specific negative symptoms predict social functioning, relative to neurocognition and mood/anxiety symptoms, which are known to predict functioning. The two-factor negative symptom solution was replicated in this CHR sample. Negative symptom severity was found to be uniquely predictive of social functioning, above and beyond depression/anxiety and neurocognition. Experiential symptoms were more strongly associated with social functioning, relative to expression symptoms. In addition, experiential symptoms mediated the relationship between expressive negative symptoms and social functioning. These results suggest that experiences of motivational impairment are more important in determining social functioning, relative to affective flattening and alogia, in CHR individuals, thereby informing the development of more precise therapeutic targets. Developing novel interventions that stimulate goal-directed behavior and reinforce rewarding experiences in social contexts are recommended. (C) 2015 Elsevier B.V. All rights reserved. C1 [Schlosser, Danielle A.; Campellone, Timothy R.; Biagianti, Bruno; Delucchi, Kevin L.; Stuart, Barbara K.; Fisher, Melissa; Loewy, Rachel L.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Campellone, Timothy R.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Gard, David E.] San Francisco State Univ, San Francisco, CA USA. [Fulford, Daniel] Boston Univ, Boston, MA 02215 USA. [Fisher, Melissa; Vinogradov, Sophia] San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Schlosser, DA (reprint author), 401 Parnassus Ave, San Francisco, CA 94134 USA. EM Danielle.schlosser@ucsf.edu OI Gard, David/0000-0002-0446-4000 FU NIMH [K23 MH097795-01, R34 MH100399, R01 01MH081051] FX This research was supported by the following funding sources: NIMH K23 MH097795-01 (Schlosser); NIMH R34 MH100399 (Schlosser/Vinogradov); and NIMH R01 01MH081051 (Vinogradov). The funding sources had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 33 TC 3 Z9 3 U1 3 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2015 VL 169 IS 1-3 BP 204 EP 208 DI 10.1016/j.schres.2015.10.036 PG 5 WC Psychiatry SC Psychiatry GA CY5PC UT WOS:000366458600031 PM 26530628 ER PT J AU Tregellas, JR Smucny, J Legget, KT Stevens, KE AF Tregellas, Jason R. Smucny, Jason Legget, Kristina T. Stevens, Karen E. TI Effects of a ketogenic diet on auditory gating in DBA/2 mice: A proof-of-concept study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Gating; Ketogenic diet; Hippocampus; P50; Schizophrenia ID NICOTINIC ACETYLCHOLINE-RECEPTORS; CEREBRAL-BLOOD-FLOW; NEUROPHYSIOLOGICAL EVIDENCE; HIPPOCAMPAL-FORMATION; SCHIZOPHRENIA; DYSFUNCTION; EPILEPSY; HYPERACTIVITY; INHIBITION; MECHANISMS AB Although the ketogenic diet has shown promise in a pilot study and case report in schizophrenia, its effects in animal models of hypothesized disease mechanisms are unknown. This study examined effects of treatment with the ketogenic diet on hippocampal P20/N40 gating in DBA/2 mice, a translational endophenotype that mirrors inhibitory deficits in P50 sensory gating in schizophrenia patients. As expected, the diet increased blood ketone levels. Animals with the highest ketone levels showed the lowest P20/N40 gating ratios. These preliminary results suggest that the ketogenic diet may effectively target sensory gating deficits and is a promising area for additional research in schizophrenia. Published by Elsevier B.V. C1 [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Tregellas, Jason R.; Smucny, Jason; Legget, Kristina T.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Tregellas, Jason R.; Smucny, Jason; Legget, Kristina T.; Stevens, Karen E.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. RP Tregellas, JR (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80045 USA. EM Jason.Tregellas@ucdenver.edu OI Smucny, Jason/0000-0001-5656-7987; Legget, Kristina/0000-0002-2948-506X FU VA Biomedical Laboratory and Clinical Science Research and Development Service; Brain and Behavior Research Foundation; NIH [DK-089095, DK-103691, MH-102224, MH-102879] FX This work was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service (grant to Dr. Tregellas), the Brain and Behavior Research Foundation (grant to Dr. Tregellas), NIH grants DK-089095, DK-103691 and MH-102224 (grants to Dr. Tregellas), and NIH fellowship MH-102879 (grant to Mr. Smucny). NR 45 TC 1 Z9 1 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2015 VL 169 IS 1-3 BP 351 EP 354 DI 10.1016/j.schres.2015.09.022 PG 4 WC Psychiatry SC Psychiatry GA CY5PC UT WOS:000366458600054 PM 26453015 ER PT J AU Huang, WL Ojo, KK Zhang, ZS Rivas, K Vidadala, RSR Scheele, S DeRocher, AE Choi, R Hulverson, MA Barrett, LK Bruzual, I Siddaramaiah, LK Kerchner, KM Kurnick, MD Freiberg, GM Kempf, D Hol, WGJ Merritt, EA Neckermann, G de Hostos, EL Isoherranen, N Maly, DJ Parsons, M Doggett, JS Van Voorhis, WC Fang, EK AF Huang, Wenlin Ojo, Kayode K. Zhang, Zhongsheng Rivas, Kasey Vidadala, Rama Subba Rao Scheele, Suzanne DeRocher, Amy E. Choi, Ryan Hulverson, Matthew A. Barrett, Lynn K. Bruzual, Igor Siddaramaiah, Latha Kallur Kerchner, Keshia M. Kurnick, Matthew D. Freiberg, Gail M. Kempf, Dale Hol, Wim G. J. Merritt, Ethan A. Neckermann, Georg de Hostos, Eugenio L. Isoherranen, Nina Maly, Dustin J. Parsons, Marilyn Doggett, J. Stone Van Voorhis, Wesley C. Fang, Erkang TI SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1 SO ACS MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Toxoplasma gondii; calcium-dependent protein kinase-1; enzyme inhibitor; structure-activity relationship studies ID PROTEIN-KINASE 1; CRYPTOSPORIDIUM-PARVUM; HOST-CELLS; T. GONDII; C. PARVUM; CALCIUM; INVASION; TARGET AB We previously discovered compounds based on a 5-aminopyrazole-4-carboxamide scaffold to be potent and selective inhibitors of CDPK1 from T. gondii. The current work, through structure-activity relationship studies, led to the discovery of compounds (34 and 35) with improved characteristics over the starting inhibitor 1 in terms of solubility, plasma exposure after oral administration in mice, or efficacy on parasite growth inhibition. Compounds 34 and 35 were further demonstrated to be more effective than 1 in a mouse infection model and markedly reduced the amount of T. gondii in the brain, spleen, and peritoneal fluid, and 35 given at 20 mg/kg eliminated T. gondii from the peritoneal fluid. C1 [Huang, Wenlin; Zhang, Zhongsheng; Siddaramaiah, Latha Kallur; Kerchner, Keshia M.; Hol, Wim G. J.; Merritt, Ethan A.; Fang, Erkang] Univ Washington, Dept Biochem, Seattle, WA 98195 USA. [Ojo, Kayode K.; Rivas, Kasey; Choi, Ryan; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98109 USA. [Ojo, Kayode K.; Rivas, Kasey; Choi, Ryan; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Ctr Emerging & Reemerging Infect Dis, Seattle, WA 98109 USA. [Vidadala, Rama Subba Rao; Maly, Dustin J.] Univ Washington, Dept Chem, Seattle, WA 98195 USA. [Scheele, Suzanne; DeRocher, Amy E.; Parsons, Marilyn] Ctr Infect Dis Res, Seattle, WA 98109 USA. [Bruzual, Igor] Portland VA Med Ctr, Portland, OR 97239 USA. [Kurnick, Matthew D.; Freiberg, Gail M.; Kempf, Dale] AbbVie, N Chicago, IL 60064 USA. [Neckermann, Georg; de Hostos, Eugenio L.] PATH, San Francisco, CA 94102 USA. [Isoherranen, Nina] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA. [Parsons, Marilyn; Van Voorhis, Wesley C.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. RP Fang, EK (reprint author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA. EM wesley@uw.edu; erkang@uw.edu RI huang, wenlin/H-7572-2016 OI Parsons, Marilyn/0000-0003-3994-8096 FU National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development of the National Institutes of Health [R01AI089441, R01AI111341, R01HD080670]; United States Department of Agriculture [2014-06183]; United States Department of Veterans Affairs Biomedical Laboratory Research and Development [BX002440]; U.S. Department of Energy Office of Basic Energy Sciences [DE-AC02-76SF00515]; National Institutes of Health [P41GM103393] FX Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development of the National Institutes of Health under award numbers R01AI089441, R01AI111341, and R01HD080670. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported in part by Award #2014-06183 from the United States Department of Agriculture and by Career Development Award #BX002440 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development. Crystallography performed in support of the work benefitted from remote access to resources at the Stanford Synchrotron Radiation Lightsource supported by the U.S. Department of Energy Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515 and by the National Institutes of Health (P41GM103393). NR 22 TC 9 Z9 10 U1 0 U2 10 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-5875 J9 ACS MED CHEM LETT JI ACS Med. Chem. Lett. PD DEC PY 2015 VL 6 IS 12 BP 1184 EP 1189 DI 10.1021/acsmedchemlett.5b00319 PG 6 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA CY3XO UT WOS:000366343400003 PM 26693272 ER PT J AU Bullman, T Hoffmire, C Schneiderman, A Bossarte, R AF Bullman, Tim Hoffmire, Claire Schneiderman, Aaron Bossarte, Robert TI Time dependent gender differences in suicide risk among Operation Enduring Freedom and Operation Iraqi Freedom veterans SO ANNALS OF EPIDEMIOLOGY LA English DT Editorial Material DE Veterans; Suicide; Gender C1 [Bullman, Tim; Schneiderman, Aaron; Bossarte, Robert] US Dept Vet Affairs, Off Publ Hlth, Program Epidemiol, Washington, DC 20420 USA. [Hoffmire, Claire] US Dept Vet Affairs, Rocky Mt MIRECC Suicide Prevent, Denver, CO USA. RP Bullman, T (reprint author), US Dept Vet Affairs, Off Publ Hlth, Program Epidemiol, 810 Vermont Ave, Washington, DC 20420 USA. EM tim.bullman@va.gov NR 7 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD DEC PY 2015 VL 25 IS 12 BP 964 EP 965 DI 10.1016/j.annepidem.2015.09.008 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CY5IK UT WOS:000366441100015 PM 26493115 ER PT J AU Pantoja, JL Zhang, ZH Tartibi, M Sun, K Macmillan, W Guccione, JM Ge, L Ratcliffe, MB AF Pantoja, Joe Luis Zhang, Zhihong Tartibi, Mehrzad Sun, Kay Macmillan, Warrick Guccione, Julius M. Ge, Liang Ratcliffe, Mark B. TI Residual Stress Impairs Pump Function After Surgical Ventricular Remodeling: A Finite Element Analysis SO ANNALS OF THORACIC SURGERY LA English DT Article ID REDUCTION SURGERY; MODEL; ANEURYSM; RESTORATION; MECHANICS; MYOCARDIUM; MUSCLE AB Background. Surgical ventricular restoration (Dor procedure) is generally thought to reduce left ventricular (LV) myofiber stress (FS) but to adversely affect pump function. However, the underlying mechanism is unclear. The goal of this study was to determine the effect of residual stress (RS) on LV FS and pump function after the Dor procedure. Methods. Previously described finite element models of the LV based on magnetic resonance imaging data obtained in 5 sheep 16 weeks after anteroapical myocardial infarction were used. Simulated polyethylene terephthalate fiber (Dacron) patches that were elliptical and 25% of the infarct opening area were implanted using a virtual suture technique (VIRTUAL-DOR). In each case, diastole and systole were simulated, and RS, FS, LV volumes, systolic and diastolic function, and pump (Starling) function were calculated. Results. VIRTUAL-DOR was associated with significant RS that was tensile (2.89 +/- 1.31 kPa) in the remote myocardium and compressive (234.15 +/- 65.53 kPa) in the border zone. VIRTUAL-DOR+RS (compared with VIRTUAL-DOR-NO-RS) was associated with further reduction in regional diastolic and systolic FS, with the greatest change in the border zone (43.5-fold and 7.1-fold, respectively; p < 0.0001). VIRTUAL-DOR+RS was also associated with further reduction in systolic and diastolic volumes (7.9%; p = 0.0606, and 10.6%; p = 0.0630, respectively). The resultant effect was a further reduction in pump function after VIRTUAL-DOR+RS. Conclusions. Residual stress that occurs after the Dor procedure is positive (tensile) in the remote myocardium and negative (compressive) in the border zone and associated with reductions in FS and LV volumes. The resultant effect is a further reduction in LV pump (Starling) function. (C) 2015 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov FU NIH grant [R01-HL-63348] FX This study was supported by NIH grant R01-HL-63348 (Dr Ratcliffe). This support is gratefully acknowledged. NR 25 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2015 VL 100 IS 6 BP 2198 EP 2205 DI 10.1016/j.athoracsur.2015.05.119 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CX6QD UT WOS:000365824700041 PM 26341601 ER PT J AU Yu, M O'Leary, RM Kaz, AM Morris, SM Carter, KT Chak, A Chandar, A Willis, JE Moinova, HR Markowitz, SD Brenner, DE Anandabapasathy, S Westerhoff, M Wong, CJ Shaheen, NJ Chen, YW Barnholtz-Sloan, JS Grady, WM AF Yu, Ming O'Leary, Rachele M. Kaz, Andrew M. Morris, Shelli M. Carter, Kelly T. Chak, Amitabh Chandar, Apoorva Willis, Joseph E. Moinova, Helen R. Markowitz, Sanford D. Brenner, Dean E. Anandabapasathy, Sharmila Westerhoff, Maria Wong, Chao-Jen Shaheen, Nicholas J. Chen, Yanwen Barnholtz-Sloan, Jill S. Grady, William M. TI Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID DNA METHYLATION; ADENOCARCINOMA INCIDENCE; GASTROESOPHAGEAL REFLUX; COLORECTAL-CANCER; RISK; SURVEILLANCE; PROGRESSION; SIGNATURES; MORTALITY; SYMPTOMS AB Background: Barrett's esophagus (BE) is a preneoplastic condition in which normal esophageal squamous epithelium (SQ) is replaced by specialized intestinal metaplasia. It is the presumed precursor for esophageal adenocarcinoma (EAC) as well as the strongest risk factor for this cancer. Unfortunately, many patients with BE go undiagnosed under the current BE screening guidelines. The development of noninvasive and accurate BE detection assays could potentially identify many of these undiagnosed BE patients. Methods: DNA methylation is a common epigenetic alteration in BE. Therefore, we conducted a genome-wide methylation screen to identify potential BE biomarkers. Samples from SQ (N = 12), stomach (N = 28), and BE (N = 29) were analyzed and methylation levels at over 485,000 CpG sites were compared. Pyrosequencing assays were used to validate the results and MethyLight assays were developed to detect the methylated alleles in endoscopic brushings. Results: We discovered two genes, B3GAT2 and ZNF793, that are aberrantly methylated in BE. Clinical validation studies confirmed B3GAT2 and ZNF793 methylation levels were significantly higher in BE samples (median = 32.5% and 33.1%, respectively) than in control tissues (median = 2.29% and 2.52%, respectively; P < 0.0001 for both genes). Furthermore, gene-specific MethyLight assays could accurately detect BE (P < 0.0001 for both) in endoscopic brushing samples. Conclusion: B3GAT2 and ZNF793 are hypermethylated in BE, and the methylation status of these genes can be used to detect BE in tissue samples. Impact: These findings support the development of methylated B3GAT2 and ZNF793 as biomarkers for noninvasive assays for the detection of BE. (C)2015 AACR. C1 [Yu, Ming; O'Leary, Rachele M.; Morris, Shelli M.; Carter, Kelly T.; Wong, Chao-Jen; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Chak, Amitabh; Chandar, Apoorva] Univ Hosp Case Med Ctr, Div Gastroenterol, Cleveland, OH USA. [Chak, Amitabh; Chandar, Apoorva] Univ Hosp Case Med Ctr, Div Oncol, Cleveland, OH USA. [Willis, Joseph E.] Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA. [Moinova, Helen R.; Markowitz, Sanford D.] Univ Hosp Case Med Ctr, Dept Med, Cleveland, OH USA. [Markowitz, Sanford D.; Chen, Yanwen; Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA. [Brenner, Dean E.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Anandabapasathy, Sharmila] Baylor Coll Med, Dept Med & Gastroenterol, Houston, TX 77030 USA. [Westerhoff, Maria] Univ Washington, Sch Med, Dept Anat Pathol, Seattle, WA USA. [Shaheen, Nicholas J.] Univ North Carolina Hosp, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA. EM wgrady@fredhutch.org FU NIH [UO1 CA152756, 5P30CA015704, U01CA086402, U01CA182940, U54CA163060, P50CA150964, U01CA86400, T32DK007742] FX These studies were supported by funding from the NIH: UO1 CA152756, 5P30CA015704, U01CA086402, and U01CA182940 to W.M. Grady; U54CA163060 to A. Chak, W.M. Grady, S.D. Markowitz, and J.E. Willis; P50CA150964 to S.D. Markowitz, A. Chak, and J.E. Willis; U01CA86400 to D.E. Brenner; and T32DK007742 to M. Yu. NR 29 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD DEC PY 2015 VL 24 IS 12 BP 1890 EP 1897 DI 10.1158/1055-9965.EPI-15-0370 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CY0XB UT WOS:000366129100011 PM 26545406 ER PT J AU Stewart, IJ Sosnov, JA Howard, JT Orman, JA Fang, R Morrow, BD Zonies, DH Bollinger, M Tuman, C Freedman, BA Chung, KK AF Stewart, Ian J. Sosnov, Jonathan A. Howard, Jeffrey T. Orman, Jean A. Fang, Raymond Morrow, Benjamin D. Zonies, David H. Bollinger, Mary Tuman, Caroline Freedman, Brett A. Chung, Kevin K. TI Retrospective Analysis of Long-Term Outcomes After Combat Injury A Hidden Cost of War SO CIRCULATION LA English DT Article DE coronary disease; diabetes mellitus; hypertension; kidney; mortality ID POSTTRAUMATIC-STRESS-DISORDER; CHRONIC KIDNEY-DISEASE; VA HEALTH-CARE; MILITARY SERVICE; COMPETING RISK; PREVALENCE; SEVERITY; SYSTEM; AKI; HYPERTENSION AB Background During the conflicts in Iraq and Afghanistan, 52087 service members have been wounded in combat. The long-term sequelae of these injuries have not been carefully examined. We sought to determine the relation between markers of injury severity and the subsequent development of hypertension, coronary artery disease, diabetes mellitus, and chronic kidney disease. Methods and Results Retrospective cohort study of critically injured US military personnel wounded in Iraq or Afghanistan from February 1, 2002 to February 1, 2011. Patients were then followed until January 18, 2013. Chronic disease outcomes were assessed by International Classification of Diseases, 9th edition codes and causes of death were confirmed by autopsy. From 6011 admissions, records were excluded because of missing data or if they were for an individual's second admission. Patients with a disease diagnosis of interest before the injury date were also excluded, yielding a cohort of 3846 subjects for analysis. After adjustment for other factors, each 5-point increment in the injury severity score was associated with a 6%, 13%, 13%, and 15% increase in incidence rates of hypertension, coronary artery disease, diabetes mellitus, and chronic kidney disease, respectively. Acute kidney injury was associated with a 66% increase in rates of hypertension and nearly 5-fold increase in rates of chronic kidney disease. Conclusions In Iraq and Afghanistan veterans, the severity of combat injury was associated with the subsequent development of hypertension, coronary artery disease, diabetes mellitus, and chronic kidney disease. C1 [Stewart, Ian J.] David Grant Med Ctr, Travis Afb, CA 94535 USA. [Stewart, Ian J.; Sosnov, Jonathan A.; Morrow, Benjamin D.; Chung, Kevin K.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Sosnov, Jonathan A.; Morrow, Benjamin D.] San Antonio Mil Med Ctr, San Antonio, TX USA. [Howard, Jeffrey T.; Orman, Jean A.; Chung, Kevin K.] US Army Inst Surg Res, San Antonio, TX USA. [Fang, Raymond] US Air Force Ctr Sustainment Trauma & Readiness S, Baltimore, MD USA. [Zonies, David H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bollinger, Mary] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Tuman, Caroline; Freedman, Brett A.] Landstuhl Reg Med Ctr, Landstuhl, Germany. RP Stewart, IJ (reprint author), David Grant Med Ctr, Clin Invest Facil, 101 Bodin Circle, Travis Afb, CA 94535 USA. EM ian.stewart@us.af.mil FU Oak Ridge Institute of Science and Education FX This study was funded in part by a postdoctoral fellowship provided by the Oak Ridge Institute of Science and Education. NR 39 TC 4 Z9 4 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 1 PY 2015 VL 132 IS 22 BP 2126 EP 2133 DI 10.1161/CIRCULATIONAHA.115.016950 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CY1SE UT WOS:000366187100005 PM 26621637 ER PT J AU Leehey, DJ Zhang, JH Emanuele, NV Whaley-Connell, A Palevsky, PM Reilly, RF Guarino, P Fried, LF AF Leehey, David J. Zhang, Jane H. Emanuele, Nicholas V. Whaley-Connell, Adam Palevsky, Paul M. Reilly, Robert F. Guarino, Peter Fried, Linda F. CA VA NEPHRON-D Study Grp TI BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID BLOOD-PRESSURE CONTROL; RANDOMIZED CONTROLLED-TRIAL; ANTIHYPERTENSIVE TREATMENT; HYPERTENSION; PROGRESSION; ALBUMINURIA; INHIBITION; MANAGEMENT AB Background and objectives Proteinuric diabetic kidney disease frequently progresses to ESRD. Control of BP delays progression, but the optimal BP to improve outcomes remains unclear. The objective of this analysis was to evaluate the relationship between BP and renal outcomes in proteinuric diabetic kidney disease. Design, setting, participants, & measurements BP data from all 1448 randomized participants in the Veterans Affairs Nephropathy in Diabetes Trial were included in a post hoc analysis. The associations of mean on treatment BP with the primary end point (decline in eGFR, ESRD, or death), renal end point (decline in eGFR or ESRD), rate of eGFR decline, and mortality were measured. Results The median (25th, 75th percentile) follow-up time was 2.2 (1.2, 3.0) years. There were 284 primary end points. In univariate analyses, both mean systolic and mean diastolic BPs were strongly associated (P<0.001) with the primary end point. After multivariate adjustment, the hazard of developing the primary end point became progressively higher as mean systolic BID rose from <120 to >= 150 mmHg (P=0.02), with a significantly higher hazard ratio for 140-149 versus 120-129 mmHg (1.51 [1.06, 2.15]; P=0.02). There was also a significant association of mean diastolic BP with the hazard of developing the primary end point (P<0.01), with a significantly higher hazard ratio when mean diastolic BP was 80-89 versus 70-79 mmHg (1.54 [1.05, 2.25]; P=0.03); there was also a strong trend when mean diastolic BP was <60 mmHg. Associations between BP and both renal end point and rate of eGFR decline were similar to those with the primary end point. No association of BP with mortality was observed, possibly because of the limited number of mortality events. Conclusions In patients with proteinuric diabetic kidney disease, mean systolic BP >= 140 mmHg and mean diastolic BP mmHg were associated with worse renal outcomes. C1 [Leehey, David J.; Emanuele, Nicholas V.] Vet Affairs Hosp, Dept Med, Hines, IL USA. [Leehey, David J.; Emanuele, Nicholas V.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Zhang, Jane H.; Guarino, Peter] Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA. [Whaley-Connell, Adam] Harry S Truman Mem Vet Affairs Hosp, Dept Med, Columbia, MO USA. [Whaley-Connell, Adam] Univ Missouri, Sch Med, Columbia, MO USA. [Palevsky, Paul M.; Fried, Linda F.] Dept Med Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Palevsky, Paul M.; Fried, Linda F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Palevsky, Paul M.; Reilly, Robert F.; Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. [Reilly, Robert F.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Leehey, DJ (reprint author), Hines Vet Affairs Hosp 111L, Hines, IL 60141 USA. EM david.leehey@va.gov OI Palevsky, Paul/0000-0002-7334-5400; Whaley-Connell, Adam/0000-0001-8955-5560 FU Cooperative Studies Program of Department of Veterans Affairs Office of Research and Development FX This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. NR 32 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD DEC PY 2015 VL 10 IS 12 BP 2159 EP 2169 DI 10.2215/CJN.02850315 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA CX9EF UT WOS:000366007100010 PM 26482258 ER PT J AU Boyko, EJ AF Boyko, Edward J. TI Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725-2728 SO DIABETES CARE LA English DT Letter C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA 98493 USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98493 USA. EM eboyko@uw.edu OI Boyko, Edward/0000-0002-3695-192X NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2015 VL 38 IS 12 BP E214 EP E214 DI 10.2337/dci15-0021 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CY0TK UT WOS:000366118800011 PM 26604290 ER PT J AU Chen, LF Vander, MW Hofmann, DA Reisinger, HS AF Chen, Luke F. Vander, Mark W. Hofmann, David A. Reisinger, Heather Schacht TI The Hawthorne Effect in Infection Prevention and Epidemiology SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Review ID HAND HYGIENE COMPLIANCE; URINARY CATHETER USE; REACTIVITY; FEEDBACK; SYSTEM AB The Hawthorne Effect is a prevalent observer effect that causes behavioral changes among participants of epidemiological studies or infection control interventions. The purpose of the review is to describe the origins of the Hawthorne Effect, to understand the term in relation to current scientific literature, to describe characteristics of the Hawthorne effect, and to discuss methods to quantify and overcome limitations associated with the Hawthorne Effect. Infect. Control Hosp. Epidemiol. 2015;36(12):1444-1450 C1 [Chen, Luke F.] Duke Univ, Program Infect Prevent & Epidemiol, Med Ctr, Durham, NC USA. [Chen, Luke F.] Duke Univ, Duke Infect Control Outreach Network, Med Ctr, Durham, NC USA. [Chen, Luke F.] Duke Univ, CDC Prevent Epictr Program, Durham, NC USA. [Vander, Mark W.; Reisinger, Heather Schacht] Iowa City Vet Affairs Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. [Vander, Mark W.; Reisinger, Heather Schacht] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. [Vander, Mark W.] Univ Iowa, Dept Psychol, Coll Liberal Arts & Sci, Iowa City, IA 52242 USA. [Hofmann, David A.] Univ N Carolina, Kenan Flagler Business Sch, Dept Org Behav & Strategy, Chapel Hill, NC USA. [Reisinger, Heather Schacht] US Dept Vet Affairs, Natl Ctr Occupat Hlth & Infect Control COHIC, Gainesville, FL USA. RP Chen, LF (reprint author), Duke Univ, Durham, NC USA. EM luke.chen@duke.edu NR 56 TC 5 Z9 5 U1 1 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC PY 2015 VL 36 IS 12 BP 1444 EP 1450 DI 10.1017/ice.2015.216 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CY0UV UT WOS:000366123000011 PM 26383964 ER PT J AU Altan, A Shiozawa, A Bancroft, T Singh, JA AF Altan, Aylin Shiozawa, Aki Bancroft, Tim Singh, Jasvinder A. TI A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE comparative effectiveness; gout; medication switching; serum urate; urate-lowering therapy ID ADMINISTRATIVE CLAIMS ANALYSIS; EVIDENCE BASED RECOMMENDATIONS; OF-RHEUMATOLOGY GUIDELINES; SERUM URATE; GOUTY-ARTHRITIS; TASK-FORCE; HYPERURICEMIA; THERAPY; MANAGEMENT; PREVALENCE AB Objective The objective of this study was to assess the real-world comparative effectiveness of continuing on allopurinol versus switching to febuxostat. Methods In a retrospective claims data study of enrollees in health plans affiliated with Optum, we evaluated patients from February 1, 2009, to May 31, 2012, with a gout diagnosis, a pharmacy claim for allopurinol or febuxostat, and at least 1 serum uric acid (SUA) result available during the follow-up period. Univariate and multivariable-adjusted analyses (controlling for patient demographics and clinical factors) assessed the likelihood of SUA lowering and achievement of target SUA of less than 6.0 mg/dL or less than 5.0 mg/dL in allopurinol continuers versus febuxostat switchers. Results The final study population included 748 subjects who switched to febuxostat from allopurinol and 4795 continuing users of allopurinol. The most common doses of allopurinol were 300 mg/d or less in 95% of allopurinol continuers and 93% of febuxostat switchers (prior to switching); the most common dose of febuxostat was 40 mg/d, in 77% of febuxostat switchers (after switching). Compared with allopurinol continuers, febuxostat switchers had greater (1) mean preindex SUA, 8.0 mg/dL versus 6.6 mg/dL (P < 0.001); (2) likelihood of postindex SUA of less than 6.0 mg/dL, 62.2% versus 58.7% (P = 0.072); (3) likelihood of postindex SUA of less than 5.0 mg/dL, 38.9% versus 29.6% (P < 0.001); and (4) decrease in SUA, 1.8 (SD, 2.2)mg/dL versus 0.4 (SD, 1.7)mg/dL (P < 0.001). In multivariable-adjusted analyses, compared with allopurinol continuers, febuxostat switchers had significantly higher likelihood of achieving SUA of less than 6.0 mg/dL (40% higher) and SUA of less than 5.0 mg/dL (83% higher). Conclusions In this real-world setting, many patients with gout not surprisingly were not treated with maximum permitted doses of allopurinol. Patients switched to febuxostat were more likely to achieve target SUA levels than those who continued on generally stable doses of allopurinol. C1 [Altan, Aylin; Bancroft, Tim] Optum, Eden Prairie, MN USA. [Shiozawa, Aki] Takeda Pharmaceut Int Inc, Deerfield, IL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com RI Shiozawa, Aki/O-2443-2014 OI Shiozawa, Aki/0000-0001-9757-6337 FU Takeda Pharmaceuticals International, Inc. FX This study was supported by Takeda Pharmaceuticals International, Inc. EPI-Q, Inc, provided medical writing assistance and editorial services for this manuscript and was compensated by Takeda Pharmaceuticals International, Inc. OptumInsight was hired by Takeda Pharmaceuticals International, Inc, to conduct analyses for this study. NR 23 TC 2 Z9 2 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD DEC PY 2015 VL 21 IS 8 BP 411 EP 418 DI 10.1097/RHU.0000000000000322 PG 8 WC Rheumatology SC Rheumatology GA CX5BK UT WOS:000365715400004 PM 26580304 ER PT J AU Badour, CL Hirsch, RL Zhang, JM Mandel, H Hamner, M Wang, ZW AF Badour, Christal L. Hirsch, R. Louis Zhang, Jingmei Mandel, Howard Hamner, Mark Wang, Zhewu TI Exploring the association between a cholecystokinin promoter polymorphism (rs1799923) and posttraumatic stress disorder in combat veterans SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Cholecystokinin; CCK; Posttraumatic Stress; PTSD; Anxiety ID PANIC DISORDER; DOPAMINE TRANSPORTER; HEALTHY-VOLUNTEERS; GENE POLYMORPHISMS; T POLYMORPHISM; PTSD SYMPTOMS; WAR VETERANS; B-RECEPTOR; DRD2 GENE; TETRAPEPTIDE AB Background: Cholecystokinin (CCK) is a neuropeptide that has been implicated in understanding the acquisition and extinction of fear. Research on CCK in anxiety has primarily focused on understanding panic attacks and panic disorder. Emerging data suggests that CCK may also hold promise in understanding the development and maintenance of posttraumatic stress disorder (PTSD). Method: The present study examined whether a single nucleotide polymorphism in the promoter region of the CCK gene (C > T; rs1799923) was associated with an increased prevalence of PTSD as well as with severity of PTSD symptoms among a sample of 457 combat veterans. Results: Results demonstrated that participants with either the heterozygous or homozygous T allele had an increased prevalence of PTSD relative to participants with the CC genotype (OR=2.17; 95% CI [1.37-3.43]). Limitations: The relatively small sample size precluded examination of racial/ethnic differences. Findings were also limited by the absence of a systematic assessment of comorbid anxiety psychopathology. Conclusions: These data offer preliminary evidence supporting an association between the rs1799923 polymorphism in the CCK gene and PTSD. Additional research is needed to better understand the nature of this relationship. Published by Elsevier Ltd. C1 [Badour, Christal L.; Hirsch, R. Louis; Zhang, Jingmei; Hamner, Mark; Wang, Zhewu] Med Univ S Carolina, Charleston, SC 29425 USA. [Hirsch, R. Louis; Mandel, Howard; Hamner, Mark; Wang, Zhewu] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Wang, ZW (reprint author), 67 President St,South Bldg,MSC 861, Charleston, SC 29425 USA. EM wanzh@musc.edu FU Ralph H. Johnson VA Medical Center; Clinical Sciences Program of the Department of Veterans Affairs [1I01CX000487-01A1]; National Institute of Mental Health [T32 MH018869] FX This work was supported by the Ralph H. Johnson VA Medical Center and the Clinical Sciences Program of the Department of Veterans Affairs (Merit Review grant # 1I01CX000487-01A1), as well as the National Institute of Mental Health (T32 MH018869; Dr. Christal Badour). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the National Institutes of Health, or the United States government. There are no conflicts of interest to disclose. NR 55 TC 1 Z9 1 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD DEC PY 2015 VL 36 BP 78 EP 83 DI 10.1016/j.janxdis.2015.09.009 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CY2GK UT WOS:000366226600009 PM 26454231 ER PT J AU Cigrang, JA Rauch, SAM Mintz, J Brundige, A Avila, LL Bryan, CJ Goodie, JL Peterson, AL AF Cigrang, Jeffrey A. Rauch, Sheila A. M. Mintz, Jim Brundige, Antoinette Avila, Laura L. Bryan, Craig J. Goodie, Jeffrey L. Peterson, Alan L. CA STRONG STAR Consortium TI Treatment of active duty military with PTSD in primary care: A follow-up report SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE PTSD; Military; Primary care; Trauma; Treatment ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE; DEPRESSION; VETERANS; RELIABILITY; VALIDITY; TRIAL AB First-line trauma-focused therapies offered in specialty mental health clinics do not reach many veterans and active duty service members with posttraumatic stress disorder (PTSD). Primary care is an ideal environment to expand access to mental health care. Several promising clinical case series reports of brief PTSD therapies adapted for primary care have shown positive results, but the long-term effectiveness with military members is unknown. The purpose of this study was to determine the long-term outcome of an open trial of a brief cognitive-behavioral primary care-delivered protocol developed specifically for deployment-related PTSD in a sample of 24 active duty military (15 men, 9 women). Measures of PTSD symptom severity showed statistically and clinically significant reductions from baseline to post-treatment that were maintained at the 6-month and 1-year follow-up assessments. Similar reductions were maintained in depressive symptoms and ratings of global mental health functioning. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Cigrang, Jeffrey A.] Wright State Univ, Dayton, OH 45402 USA. [Rauch, Sheila A. M.] Emory Univ, Sch Med, Atlanta, GA USA. [Rauch, Sheila A. M.] Atlanta VA Med Ctr, Atlanta, GA USA. [Mintz, Jim; Brundige, Antoinette; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Avila, Laura L.] San Antonio Mil Med Ctr, Joint Base San Antonio Ft Sam Houston, San Antonio, TX USA. [Bryan, Craig J.] Natl Ctr Vet Studies, Salt Lake City, UT USA. [Bryan, Craig J.] Univ Utah, Salt Lake City, UT USA. [Goodie, Jeffrey L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Peterson, Alan L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Peterson, Alan L.] Univ Texas San Antonio, San Antonio, TX USA. RP Cigrang, JA (reprint author), Wright State Univ, Sch Profess Psychol, Ellis Human Dev Inst 221, 9N Edwin C Moses Blvd, Dayton, OH 45402 USA. EM jeffrey.cigrang@wright.edu; sheila.a.m.rauch@emory.edu; mintz@uthscsa.edu; brundige@uthscsa.edu; laura.l.avila.civ@mail.mil; craig.biyan@utah.edu; jeffrey.goodie@usuhs.edu; petersona3@uthscsa.edu RI Rauch, Sheila/K-4450-2015 OI Rauch, Sheila/0000-0001-9686-4011; Bryan, Craig/0000-0002-9714-0733 FU Department of Defense through the U.S. Army Medical Research and Materiel Command [W81XWH-08-02-0109]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development FX Funding for this work was made possible by the Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program award W81XWH-08-02-0109. Dr. Rauch's work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development. NR 26 TC 3 Z9 3 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD DEC PY 2015 VL 36 BP 110 EP 114 DI 10.1016/j.janxdis.2015.10.003 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CY2GK UT WOS:000366226600014 PM 26519833 ER PT J AU Kearney, LK Smith, CA Pomerantz, AS AF Kearney, Lisa K. Smith, Clifford A. Pomerantz, Andrew S. TI Capturing Psychologists' Work in Integrated Care: Measuring and Documenting Administrative Outcomes SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS LA English DT Article DE Clinic administration; Access; Productivity; Integrated care ID BEHAVIORAL HEALTH-SERVICES; MENTAL-HEALTH; TREATMENT ENGAGEMENT; ADVANCED ACCESS; REFERRAL CARE; MANAGEMENT; SYSTEM AB With the expansion of integrated primary care and the increased focus on fiscal sustainability, it is critical for clinical managers of these innovative systems to have practical methods for measuring administrative outcomes. Administrative outcomes will assist leadership in the development of efficient, streamlined clinics to provide services to the primary care population. Additionally, administrative measures can be utilized to provide information to assist in guiding resource utilization and management decisions. Several administrative outcomes are suggested for integrated primary care managers to consider for application, including: clinic utilization measures, integrated care administrative measures, wait time and access metrics, and productivity monitors. Effective utilization of these measures can help office managers and clinic leadership not only to maximize patient care, but also to enhance essential business operations, which increase the long-term sustainability of integrated primary care programs. C1 [Kearney, Lisa K.] Vet Hlth Adm, VACO Off Mental Hlth Operat, Off Mental Hlth Operat, Dept Vet Affairs,VISN Mental Hlth Off Plaza Lecea, San Antonio, TX 78240 USA. [Smith, Clifford A.] Iron Mt VA Med Ctr, Iron Mountain, MI USA. [Pomerantz, Andrew S.] Mental Hlth Serv, Vet Hlth Adm, Dept Vet Affairs, Washington, DC USA. [Kearney, Lisa K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Smith, Clifford A.] Michigan State Univ, Dept Psychiat, E Lansing, MI 48824 USA. [Pomerantz, Andrew S.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA. RP Kearney, LK (reprint author), Vet Hlth Adm, VACO Off Mental Hlth Operat, Off Mental Hlth Operat, Dept Vet Affairs,VISN Mental Hlth Off Plaza Lecea, 5441 Babcock Rd,Suite 300, San Antonio, TX 78240 USA. EM Lisa.Kearney3@va.gov; Clifford.Smith2@va.gov; Andrew.Pomerantz@va.gov NR 39 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9583 EI 1573-3572 J9 J CLIN PSYCHOL MED S JI J. Clin. Psychol. Med. Settings PD DEC PY 2015 VL 22 IS 4 BP 232 EP 242 DI 10.1007/s10880-015-9442-7 PG 11 WC Psychology, Clinical SC Psychology GA CY4BI UT WOS:000366353200005 PM 26645090 ER PT J AU Petkovic, J Epstein, J Buchbinder, R Welch, V Rader, T Lyddiatt, A Clerehan, R Christensen, R Boonen, A Goel, N Maxwell, LJ Toupin-April, K De Wit, M Barton, J Flurey, C Jull, J Barnabe, C Sreih, AG Campbell, W Pohl, C Duruoz, MT Singh, JA Tugwell, PS Guillemin, F AF Petkovic, Jennifer Epstein, Jonathan Buchbinder, Rachelle Welch, Vivian Rader, Tamara Lyddiatt, Anne Clerehan, Rosemary Christensen, Robin Boonen, Annelies Goel, Niti Maxwell, Lara J. Toupin-April, Karine De Wit, Maarten Barton, Jennifer Flurey, Caroline Jull, Janet Barnabe, Cheryl Sreih, Antoine G. Campbell, Willemina Pohl, Christoph Duruoz, Mehmet Tuncay Singh, Jasvinder A. Tugwell, Peter S. Guillemin, Francis TI Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE HEALTH EQUITY; MUSCULOSKELETAL CONDITIONS; RHEUMATOLOGY; LITERACY; CULTURAL ADAPTATION ID QUALITY-OF-LIFE; LITERACY LEVELS; ADAPTATION; TRANSLATION; INSTRUMENTS; GUIDELINES; PEOPLE AB Objective. The goal of the Outcome Measures in Rheumatology (OMERACT) 12 (2014) equity working group was to determine whether and how comprehensibility of patient-reported outcome measures (PROM) should be assessed, to ensure suitability for people with low literacy and differing cultures. Methods. The English, Dutch, French, and Turkish Health Assessment Questionnaires and English and French Osteoarthritis Knee and Hip Quality of Life questionnaires were evaluated by applying 3 readability formulas: Flesch Reading Ease, Flesch-Kincaid grade level, and Simple Measure of Gobbledygook; and a new tool, the Evaluative Linguistic Framework for Questionnaires, developed to assess text quality of questionnaires. We also considered a study assessing cross-cultural adaptation with/without back-translation and/or expert committee. The results of this preconference work were presented to the equity working group participants to gain their perspectives on the importance of comprehensibility and cross-cultural adaptation for PROM. Results. Thirty-one OMERACT delegates attended the equity session. Twenty-six participants agreed that PROM should be assessed for comprehensibility and for use of suitable methods (4 abstained, 1 no). Twenty-two participants agreed that cultural equivalency of PROM should be assessed and suitable methods used (7 abstained, 2 no). Special interest group participants identified challenges with cross-cultural adaptation including resources required, and suggested patient involvement for improving translation and adaptation. Conclusion. Future work will include consensus exercises on what methods are required to ensure PROM are appropriate for people with low literacy and different cultures. C1 [Petkovic, Jennifer; Maxwell, Lara J.] Univ Ottawa, Ctr Global Hlth, Ottawa, ON K1N 5C8, Canada. [Epstein, Jonathan; Guillemin, Francis] Univ Lorraine, EA Apemac 4360, Nancy, France. [Buchbinder, Rachelle] Cabrini Inst, Melbourne, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Melbourne, Vic 3004, Australia. [Welch, Vivian] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada. [Rader, Tamara] Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada. [Clerehan, Rosemary] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic 3800, Australia. [Christensen, Robin] Copenhagen Univ Hosp, Musculoskeletal Stat Unit, Parker Inst, Dept Rheumatol, Bispebjerg, Denmark. [Christensen, Robin] Copenhagen Univ Hosp, Musculoskeletal Stat Unit, Parker Inst, Dept Rheumatol, Frederiksberg, Denmark. Maastricht Univ, Dept Internal Med, Div Rheumatol, Med Ctr, NL-6200 MD Maastricht, Netherlands. [Boonen, Annelies] Maastricht Univ, Caphri Res Inst, Rheumatol, NL-6200 MD Maastricht, Netherlands. [Goel, Niti] Quintiles Inc, Durham, NC USA. [Goel, Niti] Duke Univ, Sch Med, Dept Med, Div Rheumatol, Durham, NC 27706 USA. [Toupin-April, Karine] Univ Ottawa, Dept Pediat, Childrens Hosp, Eastern Ontario Res Inst, Ottawa, ON K1N 6N5, Canada. [De Wit, Maarten] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Barton, Jennifer] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Flurey, Caroline] Univ W England, Fac Hlth & Appl Sci, Bristol BS16 1QY, Avon, England. [Barnabe, Cheryl] Univ Calgary, Dept Med & Community Hlth Sci, Cumming Sch Med, Calgary, AB, Canada. [Pohl, Christoph] Charite, Dept Internal Med Rheumatol Clin Immunol Osteol P, Schlosspark Klin, Teaching Hosp, D-13353 Berlin, Germany. [Duruoz, Mehmet Tuncay] Univ Marmara, Fac Med, Dept Phys & Rehabil Med, Rheumatol Clin, Istanbul, Turkey. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Sreih, Antoine G.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. Ottawa Hosp Res Inst, Ottawa, ON, Canada. [Campbell, Willemina] Toronto Western Hosp, UHN, Toronto, ON M5T 2S8, Canada. RP Petkovic, J (reprint author), Univ Ottawa, Ctr Global Hlth, 43 Bruyere St,Annex E,Room 302, Ottawa, ON K1N 5C8, Canada. EM jennifer.petkovic@uottawa.ca OI Petkovic, Jennifer/0000-0002-5824-584X; Tugwell, Peter/0000-0001-5062-0556 FU La Mission Recherche de la Direction de la recherche, des etudes, de l'evaluation et des statistiques; Australian National Health and Medical Research Council Practitioner Fellowship; Arthritis Research UK Fellowship; Canadian Rheumatology Association; Arthritis Society Clinician Investigator Award; Oak Foundation; Agency for Health Quality and Research Center for Education and Research on Therapeutics [U19 HS021110]; US National Institute of Arthritis, Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; National Institute on Aging [U01 AG018947]; National Cancer Institute [U10 CA149950]; Patient Centered Outcomes Research Institute [CE-1304-6631] FX As an OMERACT Fellow, J. Epstein received a bursary from the European League Against Rheumatism and support from OMERACT to attend the meeting; F. Guillemin was supported by La Mission Recherche de la Direction de la recherche, des etudes, de l'evaluation et des statistiques as part of financial support provided to Institut de Recherche en Sante Publique, in the domain of handicap and loss of autonomy; R. Buchbinder is supported in part by an Australian National Health and Medical Research Council Practitioner Fellowship; conference attendance for A. Lyddiatt was made possible by The Arthritis Society, Canada; J. Barton received support from the American College of Rheumatology, Rheumatology Research Foundation, to attend the meeting; C. Flurey is funded by an Arthritis Research UK Fellowship and received support from OMERACT to attend the meeting; C. Barnabe receives salary support from the Canadian Rheumatology Association and The Arthritis Society Clinician Investigator Award, and is a Canadian Institutes of Health Research New Investigator; (Community-Based Primary Health Care); R. Christensen is supported by grants from the Oak Foundation; J. A. Singh is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics U19 HS021110, US National Institute of Arthritis, Musculoskeletal and Skin Diseases P50 AR060772 and U34 AR062891, National Institute on Aging U01 AG018947, National Cancer Institute U10 CA149950, the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute. NR 33 TC 2 Z9 2 U1 1 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2015 VL 42 IS 12 BP 2448 EP 2459 DI 10.3899/jrheum.141168 PG 12 WC Rheumatology SC Rheumatology GA CX7VB UT WOS:000365909900034 PM 26077410 ER PT J AU Grainger, R Dalbeth, N Keen, H Durcan, L Edwards, NL Perez-Ruiz, F Diaz-Torne, C Singh, JA Khanna, D Simon, LS Taylor, WJ AF Grainger, Rebecca Dalbeth, Nicola Keen, Helen Durcan, Laura Edwards, N. Lawrence Perez-Ruiz, Fernando Diaz-Torne, Cesar Singh, Jasvinder A. Khanna, Dinesh Simon, Lee S. Taylor, William J. TI Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE GOUT; OUTCOME MEASURES; MEDICAL IMAGING; OMERACT ID RHEUMATOID-ARTHRITIS; CLINICAL-PRACTICE; TOPHACEOUS GOUT; HYPERURICEMIA; TRIALS AB Objective. The gout working group at the Outcome Measures in Rheumatology (OMERACT) 12 meeting in 2014 aimed to determine which imaging modalities show the most promise for use as measurement instruments for outcomes in studies of people with chronic gout and to identify the key foci for future research about the performance of these imaging techniques with respect to the OMERACT filter 2.0. Methods. During the gout session, a systematic literature review of the data addressing imaging modalities including plain radiography (XR), conventional computed tomography (CT), dual-energy computed tomography (DECT), magnetic resonance imaging (MRI), and ultrasound (US) and the fulfillment of the OMERACT filter 2.0 was presented. Results. The working group identified 3 relevant domains for imaging in gout studies: urate deposition (tophus burden), joint inflammation, and structural joint damage. Conclusion. The working group prioritized gaps in the data and identified a research agenda. C1 Univ Otago Wellington, Dept Med, Wellington, New Zealand. Univ Auckland, Dept Med, Auckland 1, New Zealand. Mater Misericordiae Univ Hosp, Dublin, Ireland. Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia. Univ Florida, Dept Med, Gainesville, FL USA. Hosp Univ Cruces, Div Rheumatol, Vizcaya, Spain. BioCruces Hlth Res Inst, Vizcaya, Spain. Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Div Rheumatol, E-08193 Barcelona, Spain. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. Univ Michigan, Dept Med, Div Rheumatol, Ann Arbor, MI 48109 USA. SDG LLC, Cambridge, MA USA. RP Taylor, WJ (reprint author), Univ Otago Wellington, Rehabil Teaching & Res Unit, 23a Mein St,POB 7343, Wellington 6242, New Zealand. EM william.taylor@otago.ac.nz OI Perez-Ruiz, Fernando/0000-0002-5268-1894 FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; US National Institute of Arthritis, Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; US National Institute on Aging [U01 AG018947]; US National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute [CE-1304-6631] FX JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, US National Institute of Arthritis, Musculoskeletal and Skin Diseases P50 AR060772 and U34 AR062891, US National Institute on Aging U01 AG018947; US National Cancer Institute (NCI) U10 CA149950; the resources and use of facilities at the VA Medical Center at Birmingham, Alabama; and research CE-1304-6631 from the Patient Centered Outcomes Research Institute. NR 24 TC 7 Z9 7 U1 1 U2 10 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2015 VL 42 IS 12 BP 2460 EP 2464 DI 10.3899/jrheum.141164 PG 5 WC Rheumatology SC Rheumatology GA CX7VB UT WOS:000365909900035 PM 25641895 ER PT J AU Singh, JA Dohm, M Sprowson, AP Wall, PD Richards, BL Gossec, L Hawker, GA Riddle, DL Buchbinder, R AF Singh, Jasvinder A. Dohm, Michael Sprowson, Andrew P. Wall, Peter D. Richards, Bethan L. Gossec, Laure Hawker, Gillian A. Riddle, Daniel L. Buchbinder, Rachelle TI Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE ARTHROPLASTY; TOTAL JOINT REPLACEMENT; OUTCOME MEASURES; DOMAINS; HARMONIZATION; CONSENSUS ID KNEE ARTHROPLASTY REGISTER; FILTER IMPLICATIONS; UNITED-STATES; TOTAL HIP; MEASUREMENT SETS; PREVALENCE; CONSENSUS; SURGERY; VOLUME AB Objective. To develop a plan for harmonizing outcomes for people undergoing total joint replacement (TJR), to achieve consensus regarding TJR outcome research. Methods. The TJR working group met during the 2014 Outcome Measures in Rheumatology (OMERACT) 12 meeting in Budapest, Hungary. Multiple conference calls preceded the face-to-face meeting. Brief presentations were made during a 1.5-h meeting, which included an overview of published systematic reviews of TJR trials and the results of a recent systematic review of TJR clinical trial outcome domains and measures. This was followed by discussion of potential core set areas/domains for TJR clinical trials (as per OMERACT Filter 2.0) as well as the challenges associated with the measurement of these domains. Results. Working group participants discussed which TJR clinical trial outcome domains/areas map to the inner versus outer core for core domain set. Several challenges were identified with TJR outcomes including how to best measure function after TJR, elucidating the source of the pre- and post-TJR joint pain being measured, joint-specific versus generic quality of life instruments and the importance of patient satisfaction and revision surgery as outcomes. A preliminary core domain set for TJR clinical trials was proposed and included pain, function, patient satisfaction, revision, adverse events, and death. This core domain set will be further vetted with a broader audience. Conclusion. An international effort with active collaboration with the orthopedic community to standardize key outcome domains and measures is under way with the TJR working group. This effort will be further developed with new collaborations. C1 Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. Univ Arizona, Tucson, AZ USA. [Wall, Peter D.] Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England. [Richards, Bethan L.] Royal Prince Alfred Hosp, Inst Rheumatol & Orthoped, Sydney, NSW, Australia. [Richards, Bethan L.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. Univ Paris 06, Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, Paris, France. Grp Hosp Pitie Salpetriere, AP HP, Dept Rheumatol, F-75634 Paris, France. Univ Toronto, Dept Med, Toronto, ON, Canada. [Hawker, Gillian A.] Univ Toronto, Womens Coll Hosp, Toronto, ON, Canada. Virginia Commonwealth Univ, Richmond, VA USA. Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Buchbinder, Rachelle] Cabrini Hosp, Monash Dept Clin Epidemiol, Melbourne, Australia. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com RI Wall, Peter/O-6408-2016 OI Wall, Peter/0000-0003-3149-3373 FU US Agency for Health Quality and Research Center for Education and Research on Therapeutics; National Institute of Arthritis; Musculoskeletal and Skin Diseases [P50]; National Institute of Aging [U01]; National Cancer Institute; Patient Centered Outcomes Research [CE-1304-6631]; Takeda; Savient; Regeneron; Allergan FX JAS is supported by grants from the US Agency for Health Quality and Research Center for Education and Research on Therapeutics, National Institute of Arthritis, Musculoskeletal and Skin Diseases P50, National Institute of Aging U01, National Cancer Institute, the resources and the use of facilities at the Veterans Affair (VA) Medical Center at Birmingham, Alabama, and research contract CE-1304-6631 from the Patient Centered Outcomes Research. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, and Allergan. JAS is a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; the VA Rheumatology Field Advisory Committee; and the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. NR 41 TC 3 Z9 3 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2015 VL 42 IS 12 BP 2496 EP 2502 DI 10.3899/jrheum.141201 PG 7 WC Rheumatology SC Rheumatology GA CX7VB UT WOS:000365909900042 PM 25834208 ER PT J AU Clark, TJ Flood, TF Maximin, ST Sachs, PB AF Clark, Toshimasa J. Flood, Thomas F. Maximin, Suresh T. Sachs, Peter B. TI Lung CT Screening Reporting and Data System Speed and Accuracy Are Increased With the Use of a Semiautomated Computer Application SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Lung-RADS; decision support; lung cancer screening ID IMAGING 3.0; CANCER; NODULES AB Purpose: The Lung CT Screening Reporting and Data System (LungRADS(TM)) is an algorithm that can be used to classify lung nodules in patients with significant smoking histories. It is published in table format but can be implemented as a computer program. The aim of this, study was to assess the efficiency and accuracy of the use of a computer program versus the table in categorizing lung nodules. Methods: The Lung-RADS algorithm was implemented as a computer program. Through the use of a survey tool, respondents were asked to categorize 13 simulated lung nodules using the computer program and the Lung-RADS table as published. Data were gathered regarding time to completion, accuracy of each nodule's categorization, users' subjective categorization confidence, and users' perceived efficiency using-each method. Results: The use of a computer program to categorize lung nodules resulted in significantly increased interpretation speed (80.8 +/- 37.7 vs 156 105 seconds, P < .0001), lung nodule classification accuracy (99.6% vs 76.5%, P < .0001), and perceived confidence and efficiency compared with the use of the table. There were no significant differences in accuracy when comparing thoracic radiologists with the remainder of the group. Conclusions: Radiologists were both more efficient and more accurate in lung nodule categorization when using computerized decision support tools. The authors propose that other institutions use computerized implementations of Lung-RADS in the interests of both efficiency and patient outcomes through proper management. Furthermore, they suggest the ACR design future iterations of the Lung-RADS algorithm with computerized decision support in mind. Copyright (C) 2015 American College of Radiology C1 [Clark, Toshimasa J.; Flood, Thomas F.; Sachs, Peter B.] Univ Colorado Denver, Aurora, CO 80045 USA. [Maximin, Suresh T.] Univ Washington, Seattle, WA 98195 USA. [Maximin, Suresh T.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Clark, TJ (reprint author), Univ Colorado Denver, 12401 E 17th Ave,Mail Stop L-954, Aurora, CO 80045 USA. EM toshimasa.clark@ucdenver.edu NR 9 TC 4 Z9 4 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD DEC PY 2015 VL 12 IS 12 BP 1301 EP 1306 DI 10.1016/j.jacr.2015.07.015 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CY2HU UT WOS:000366230200018 PM 26507823 ER PT J AU Kautza, B Gomez, H Escobar, D Corey, C Ataya, B Luciano, J Botero, AM Gordon, L Brumfield, J Martinez, S Holder, A Ogundele, O Pinsky, M Shiva, S Zuckerbraun, BS AF Kautza, Benjamin Gomez, Hernando Escobar, Daniel Corey, Catherine Ataya, Bilal Luciano, Jason Botero, Ana Maria Gordon, Lisa Brumfield, John Martinez, Silvia Holder, Andre Ogundele, Olufunmilayo Pinsky, Michael Shiva, Sruti Zuckerbraun, Brian S. TI Inhaled, nebulized sodium nitrite protects in murine and porcine experimental models of hemorrhagic shock and resuscitation by limiting mitochondrial injury SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Article DE Nitrite; Mitochondria; Hemorrhage; Shock; Respiration ID VIVO ISCHEMIA-REPERFUSION; MICROVASCULAR INFLAMMATION; DIETARY NITRATE; COMPLEX I; KINASE-A; OXIDE; ACTIVATION; THERAPY; LIVER; ISCHEMIA/REPERFUSION AB Objective: The cellular injury that occurs in the setting of hemorrhagic shock and resuscitation (HS/R) affects all tissue types and can drive altered inflammatory responses. Resuscitative adjuncts hold the promise of decreasing such injury. Here we test the hypothesis that sodium nitrite (NaNO2), delivered as a nebulized solution via an inhalational route, protects against injury and inflammation from HS/R. Methods: Mice underwent HS/R to a mean arterial pressure (MAP) of 20 or 25 mmHg. Mice were resuscitated with Lactated Ringers after 90-120 min of hypotension. Mice were randomized to receive nebulized NaNO2 via a flow through chamber (30 mg in 5 mL PBS). Pigs (30-35 kg) were anesthetized and bled to a MAP of 30-40 mmHg for 90 min, randomized to receive NaNO2 (11 mg in 2.5 mL PBS) nebulized into the ventilator circuit starting 60 min into the hypotensive period, followed by initial resuscitation with Hextend. Pigs had ongoing resuscitation and support for up to four hours. Hemodynamic data were collected continuously. Results: NaNO2 limited organ injury and inflammation in murine hemorrhagic shock. A nitrate/nitrite depleted diet exacerbated organ injury, as well as mortality, and inhaled NaNO2 significantly reversed this effect. Furthermore, NaNO2 limited mitochondrial oxidant injury. In porcine HS/R, NaNO2 had no significant influence on shock induced hemodynamics. NaNO2 limited hypoxia/reoxia or HS/R-induced mitochondrial injury and promoted mitochondrial fusion. Conclusion: NaNO2 may be a useful adjunct to shock resuscitation based on its limitation of mitochondrial injury. Published by Elsevier Inc. C1 [Corey, Catherine; Shiva, Sruti; Zuckerbraun, Brian S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15260 USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), F1267 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM sss43@pitt.edu; zuckerbraunbs@upmc.edu FU National Institutes of Health [R01GM082830, UM1 HL120877-01, 1K12HL109068-02]; Veterans Affairs Merit Award [1I01BX000566]; Department of Defense [DM102439]; Hemophilia Center of Western Pennsylvania; UPMC Center for Military Medicine Research; Center for Metabolism and Mitochondrial Medicine FX This work is supported by National Institutes of Health grants R01GM082830 (BSZ), UM1 HL120877-01 (BSZ), 1K12HL109068-02 (HG), Veterans Affairs Merit Award 1I01BX000566 (BSZ), Department of Defense DM102439 (BSZ), Hemophilia Center of Western Pennsylvania (SS) and UPMC Center for Military Medicine Research (SS), Center for Metabolism and Mitochondrial Medicine (SS). NR 48 TC 0 Z9 0 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 EI 1089-8611 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PD DEC 1 PY 2015 VL 51 BP 7 EP 18 DI 10.1016/j.niox.2015.09.006 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CX9ZK UT WOS:000366065100002 PM 26410351 ER PT J AU Kuhn, E Crowley, JJ Hoffman, JE Eftekhari, A Ramsey, KM Owen, JE Reger, GM Ruzek, JI AF Kuhn, Eric Crowley, Jill J. Hoffman, Julia E. Eftekhari, Afsoon Ramsey, Kelly M. Owen, Jason E. Reger, Greg M. Ruzek, Josef I. TI Clinician Characteristics and Perceptions Related to Use of the PE (Prolonged Exposure) Coach Mobile App SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE posttraumatic stress disorder; mobile phone intervention; prolonged exposure therapy; diffusion of innovations; mobile apps ID DISORDER; MHEALTH; THERAPY; CARE AB Using smartphones in the provision of evidence-based psychotherapy holds tremendous potential for enhancing care. Mental health clinicians' perceptions of smartphone-delivered interventions will affect their decision to adopt these promising innovations. As a follow-up to our early study (Kuhn et al., 2014), here we investigated mental health clinicians' (N = 271) use of a patient-facing smartphone app for prolonged exposure (PE) therapy for posttraumatic stress disorder, called PE Coach. A Web-based survey assessed clinicians' perceptions of the app using diffusion of innovations constructs. Half of the sample practicing PE in the past year reported using PE Coach, with 93.6% intending to continue using it. For clinicians who did not use PE Coach, 77.6% intended to use it in the future. Perceptions of PE Coach were generally favorable regarding its relative advantage over current practices, compatibility with clinicians' values and needs, complexity, trialability, and observability. Younger clinicians (<40 years) had more favorable perceptions of the app's perceived complexity than did older clinicians (>= 40 years). Clinicians owning smartphones, relative to those not, had more favorable perceptions of compatibility, complexity, and trialability. PE Coach users, relative to nonusers, had more favorable perceptions across all constructs, except trialability. Finally, after controlling for number of PE patients seen in the past year, clinician age and perceived complexity of the app significantly predicted use of PE Coach. These findings suggest that clinicians are using PE Coach and have favorable perceptions of it, but enhanced dissemination efforts may be needed to increase adoption for certain clinician groups. C1 [Kuhn, Eric; Crowley, Jill J.; Hoffman, Julia E.; Eftekhari, Afsoon; Ramsey, Kelly M.; Owen, Jason E.; Ruzek, Josef I.] VA Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA 94025 USA. [Reger, Greg M.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. [Reger, Greg M.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. RP Kuhn, E (reprint author), VA Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM eric.kuhn@va.gov RI Emchi, Karma/Q-1952-2016 NR 21 TC 3 Z9 3 U1 0 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 EI 1939-1323 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD DEC PY 2015 VL 46 IS 6 BP 437 EP 443 DI 10.1037/pro0000051 PG 7 WC Psychology, Multidisciplinary SC Psychology GA CY3MQ UT WOS:000366314300008 ER PT J AU Alberti, MO Jones, JJ Miglietta, R Ding, HT Bakshi, RK Edmonds, TG Kappes, JC Ochsenbauer, C AF Alberti, Michael O. Jones, Jennifer J. Miglietta, Riccardo Ding, Haitao Bakshi, Rakesh K. Edmonds, Tara G. Kappes, John C. Ochsenbauer, Christina TI Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; DEPENDENT CELLULAR CYTOTOXICITY; BROADLY NEUTRALIZING ANTIBODIES; INFECTIOUS MOLECULAR CLONES; T-LYMPHOCYTES; IN-VIVO; TRANSLATION INITIATION; VIRAL INFECTIVITY; DOWN-REGULATION AB We previously developed replication-competent reporter HIV-1 (referred to herein as LucR.T2A reporter viruses), utilizing a ribosome skipping T2A peptide strategy to link Renilla luciferase (LucR) with Nef expression. The demonstrated utility for HIV-1 vaccine and transmission study applications included measurement of neutralizing antibody (NAb) activity in vaccine sera, improved cell-mediated virus inhibition assays, such as T cell-mediated virus inhibition and antibody-dependent cell-mediated cytotoxicity (ADCC) assays, and humanized mouse models. Herein, we extend our prior work and introduce reporter virus technology for applications that require fully functional Nef. We demonstrate that in CD4(+) T cells productively infected with LucR.T2A reporter viruses, T2A peptide-driven Nef expression and function, such as down-regulation of surface CD4 and MHC-I, were impaired. We overcame this limitation of LucR.T2A reporter viruses and achieved physiological Nef expression and function by engineering novel LucR reporter HIV-1 comprising 11 different internal ribosome entry site (IRES) elements chosen for size and relative activity. A range of Nef expression was observed in 293T cells transfected with the different LucR.IRES reporter virus constructs. Iteratively, we identified IRES reporter genomes that expressed Nef closest to physiological levels and produced virus with infectivity, titers, and replication kinetics similar to nonreporter viruses. Our results demonstrated that LucR reporter activity was stable over multiple replication cycles in peripheral blood mononuclear cells (PBMCs). Furthermore, we analyzed Nef functionality, i.e., down-modulation of MHC-I and CD4, following infection of T cell lines and PBMCs. Unlike LucR.T2A reporter virus, one of the redesigned LucR.IRES reporter viruses [containing the modified encephalomyocarditis virus (EMCV) 6ATR IRES element, 6ATRi] demonstrated Nef expression and function similar to parental nonreporter virus. In a previously validated (nef-independent) T cell-based NAb neutralization assay, LucR.6ATRi reporter virus performed indistinguishably from LucR.T2A reporter virus. In summary, reporter viruses comprising the 6ATRi element promise to augment HIV-1 vaccine and transmission research approaches requiring a sensitive reporter readout combined with wild-type Nef function. C1 [Alberti, Michael O.; Jones, Jennifer J.; Miglietta, Riccardo; Ding, Haitao; Bakshi, Rakesh K.; Edmonds, Tara G.; Kappes, John C.; Ochsenbauer, Christina] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Kappes, John C.; Ochsenbauer, Christina] Univ Alabama Birmingham, Ctr AIDS Res, Birmingham, AL 35294 USA. [Kappes, John C.; Ochsenbauer, Christina] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. RP Ochsenbauer, C (reprint author), Univ Alabama Birmingham, Dept Med, LHRB 619,701 19th St South, Birmingham, AL 35294 USA. EM ochsenba@uab.edu OI Alberti, Michael/0000-0003-4269-4701 FU Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC) [1032144]; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID) [NIH U01-AI-067854]; Bill & Melinda Gates Foundation; Flow Cytometry cores of the UAB Center for AIDS Research (CFAR) [P30-AI-27767]; facilities of the Virology, Genetic Sequencing FX This work was supported by a subcontract to C.O. from the Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC) (grant #1032144), which is part of the Collaboration for AIDS Vaccine Discovery (CAVD)/CA-VIMC, funded by the Bill & Melinda Gates Foundation; a subcontract to J.C.K. from the Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID), NIH U01-AI-067854; and facilities of the Virology, Genetic Sequencing, and Flow Cytometry cores of the UAB Center for AIDS Research (CFAR), P30-AI-27767. We would also like to acknowledge Dr. Marla Hertz and Dr. Sunnie Thompson for very helpful discussions and the generous provision of IRES reagents; Dr. James Hoxie for insightful discussion and anti-Nef antibodies; Dr. Alok Mulky and Dr. Qun Dai for technical expertise and useful discussions; and Dr. David Montefiori for his support and discussion. NR 85 TC 0 Z9 0 U1 3 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD DEC 1 PY 2015 VL 31 IS 12 BP 1278 EP 1296 DI 10.1089/aid.2015.0074 PG 19 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CX3EH UT WOS:000365578100015 PM 26101895 ER PT J AU Mitsui, Y Chang, I Fukuhara, S Hiraki, M Arichi, N Yasumoto, H Hirata, H Yamamura, S Shahryari, V Deng, G Wong, DK Majid, S Shiina, H Dahiya, R Tanaka, Y AF Mitsui, Yozo Chang, Inik Fukuhara, Shinichiro Hiraki, Miho Arichi, Naoko Yasumoto, Hiroaki Hirata, Hiroshi Yamamura, Soichiro Shahryari, Varahram Deng, Guoren Wong, Darryn K. Majid, Shahana Shiina, Hiroaki Dahiya, Rajvir Tanaka, Yuichiro TI CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma SO BMC CANCER LA English DT Article DE Cytochrome 450 1B1; Renal cell carcinoma; Apoptosis; CDC20; DAPK1 ID SPINDLE ASSEMBLY CHECKPOINT; POOR-PROGNOSIS; PROTEIN-KINASE; CYTOCHROME-P450 1B1; KIDNEY CANCER; IN-VITRO; OVEREXPRESSION; METHYLATION; DEATH; CARCINOGENESIS AB Background: Cytochrome P450 1B1 (CYP1B1) has been shown to be up-regulated in many types of cancer including renal cell carcinoma (RCC). Several reports have shown that CYP1B1 can influence the regulation of tumor development; however, its role in RCC has not been well investigated. The aim of the present study was to determine the functional effects of CYP1B1 gene on tumorigenesis in RCC. Methods: Expression of CYP1B1 was determined in RCC cell lines, and tissue microarrays of 96 RCC and 25 normal tissues. To determine the biological significance of CYP1B1 in RCC progression, we silenced the gene in Caki-1 and 769-P cells by RNA interference and performed various functional analyses. Results: First, we confirmed that CYP1B1 protein expression was significantly higher in RCC cell lines compared to normal kidney tissue. This trend was also observed in RCC samples (p < 0.01). Interestingly, CYP1B1 expression was associated with tumor grade and stage. Next, we silenced the gene in Caki-1 and 769-P cells by RNA interference and performed various functional analyses to determine the biological significance of CYP1B1 in RCC progression. Inhibition of CYP1B1 expression resulted in decreased cell proliferation, migration and invasion of RCC cells. In addition, reduction of CYP1B1 induced cellular apoptosis in Caki-1. We also found that these anti-tumor effects on RCC cells caused by CYP1B1 depletion may be due to alteration of CDC20 and DAPK1 expression based on gene microarray and confirmed by real-time PCR. Interestingly, CYP1B1 expression was associated with CDC20 and DAPK1 expression in clinical samples. Conclusions: CYP1B1 may promote RCC development by inducing CDC20 expression and inhibiting apoptosis through the down-regulation of DAPK1. Our results demonstrate that CYP1B1 can be a potential tumor biomarker and a target for anticancer therapy in RCC. C1 [Mitsui, Yozo; Hiraki, Miho; Arichi, Naoko; Yasumoto, Hiroaki; Shiina, Hiroaki] Shimane Univ, Fac Med, Dept Urol, Izumo, Shimane 6938501, Japan. [Mitsui, Yozo; Hirata, Hiroshi; Yamamura, Soichiro; Shahryari, Varahram; Deng, Guoren; Wong, Darryn K.; Majid, Shahana; Dahiya, Rajvir; Tanaka, Yuichiro] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. [Mitsui, Yozo; Yamamura, Soichiro; Shahryari, Varahram; Deng, Guoren; Wong, Darryn K.; Majid, Shahana; Dahiya, Rajvir; Tanaka, Yuichiro] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Chang, Inik] Yonsei Univ, Coll Dens, Dept Oral Biol, Seoul 120749, South Korea. [Chang, Inik; Fukuhara, Shinichiro] Osaka Univ, Grad Sch Med, Dept Urol, Suita, Osaka 5650871, Japan. RP Mitsui, Y (reprint author), Shimane Univ, Fac Med, Dept Urol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan. EM mitsui@med.shimane-u.ac.jp; Yuichiro.tanaka@ucsf.edu NR 44 TC 3 Z9 3 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD DEC 1 PY 2015 VL 15 AR 942 DI 10.1186/s12885-015-1951-0 PG 12 WC Oncology SC Oncology GA CX1YB UT WOS:000365490600002 PM 26626260 ER PT J AU Nicholas, CR Okonkwo, OC Bendlin, BB Oh, JM Asthana, S Rowley, HA Hermann, B Sager, MA Johnson, SC AF Nicholas, Christopher R. Okonkwo, Ozioma C. Bendlin, Barbara B. Oh, Jennifer M. Asthana, Sanjay Rowley, Howard A. Hermann, Bruce Sager, Mark A. Johnson, Sterling C. TI Posteromedial hyperactivation during episodic recognition among people with memory decline: findings from the WRAP study SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Alzheimer's; Preclinical; Cognition; Functional neuroimaging; Neuropsychological ID MILD COGNITIVE IMPAIRMENT; MIDDLE-AGED ADULTS; ALZHEIMERS-DISEASE; HIPPOCAMPAL ACTIVATION; BRAIN ACTIVATION; GENETIC RISK; OLDER-ADULTS; LIFE-SPAN; PATTERNS; INDIVIDUALS AB Episodic memory decline is one of the earliest preclinical symptoms of AD, and has been associated with an upregulation in the BOLD response in the prodromal stage (e.g. MCI) of AD. In a previous study, we observed upregulation in cognitively normal (CN) subjects with subclinical episodic memory decline compared to non-decliners. In light of this finding, we sought to determine if a separate cohort of Decliners will show increased brain activation compared to Stable subjects during episodic memory processing, and determine whether the BOLD effect was influenced by cerebral blood flow (CBF) or gray matter volume (GMV). Individuals were classified as a "Decliner" if scores on the Rey Auditory Verbal Learning Test (RAVLT) consistently fell a parts per thousand yenaEuro parts per thousand 1.5 SD below expected intra- or inter-individual levels. FMRI was used to compare activation during a facial recognition memory task in 90 Stable (age = 59.1) and 34 Decliner (age = 62.1, SD = 5.9) CN middle-aged adults and 10 MCI patients (age = 72.1, SD = 9.4). Arterial spin labeling and anatomical T1 MRI were used to measure resting CBF and GMV, respectively. Stables and Decliners performed similarly on the episodic recognition memory task and significantly better than MCI patients. Compared to Stables, Decliners showed increased BOLD signal in the left precuneus on the episodic memory task that was not explained by CBF or GMV, familial AD risk factors, or neuropsychological measures. These findings suggest that subtle changes in the BOLD signal reflecting altered neural function may be a relatively early phenomenon associated with memory decline. C1 [Nicholas, Christopher R.; Okonkwo, Ozioma C.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Nicholas, Christopher R.; Okonkwo, Ozioma C.; Bendlin, Barbara B.; Hermann, Bruce; Sager, Mark A.; Johnson, Sterling C.] Univ Wisconsin, Wisconsin Alzheimers Inst, Sch Med & Publ Hlth, Madison, WI USA. [Nicholas, Christopher R.; Okonkwo, Ozioma C.; Bendlin, Barbara B.; Oh, Jennifer M.; Asthana, Sanjay; Rowley, Howard A.; Sager, Mark A.; Johnson, Sterling C.] Univ Wisconsin, Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace,11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU NIA [R01 AG021155, R01 AG027161]; Veterans Administration Merit Review Grant [I01CX000165]; Veterans Administration Geriatrics Research and Clinical Center (GRECC) Advanced Fellowship in Geriatrics and Aging at the William S. Middleton Memorial Veterans Hospital, Madison, WI; Helen Bader Foundation; Northwestern Mutual Foundation; Extendicare Foundation; Veterans Administration FX This research was supported by NIA grants R01 AG021155 and R01 AG027161 (SCJ): by a Veterans Administration Merit Review Grant I01CX000165 (SCJ); and by a Veterans Administration Geriatrics Research and Clinical Center (GRECC) Advanced Fellowship in Geriatrics and Aging at the William S. Middleton Memorial Veterans Hospital, Madison, WI (CRN). Portions of this research were supported by the Helen Bader Foundation, Northwestern Mutual Foundation, Extendicare Foundation, and from the Veterans Administration including facilities and resources at the GRECC, Madison, WI. NR 47 TC 1 Z9 1 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2015 VL 9 IS 4 BP 690 EP 702 DI 10.1007/s11682-014-9322-z PG 13 WC Neuroimaging SC Neurosciences & Neurology GA CX5PX UT WOS:000365755500004 PM 25332108 ER PT J AU Schultz, SA Larson, J Oh, J Koscik, R Dowling, MN Gallagher, CL Carlsson, CM Rowley, HA Bendlin, BB Asthana, S Hermann, BP Johnson, SC Sager, M Larue, A Okonkwo, OC AF Schultz, Stephanie A. Larson, Jordan Oh, Jennifer Koscik, Rebecca Dowling, Maritza N. Gallagher, Catherine L. Carlsson, Cynthia M. Rowley, Howard A. Bendlin, Barbara B. Asthana, Sanjay Hermann, Bruce P. Johnson, Sterling C. Sager, Mark LaRue, Asenath Okonkwo, Ozioma C. TI Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Preclinical Alzheimer's disease; Cognitive activity; Brain imaging; Cognition; AD prevention ID SURFACE-BASED ANALYSIS; LIFE-STYLE ACTIVITIES; MEMORY DECLINE; LEISURE ACTIVITIES; DEVELOP DEMENTIA; ADULTS; RISK; INDIVIDUALS; PERFORMANCE; IMPAIRMENT AB This study tested the hypothesis that frequent participation in cognitively-stimulating activities, specifically those related to playing games and puzzles, is beneficial to brain health and cognition among middle-aged adults at increased risk for Alzheimer's disease (AD). Three hundred twenty-nine cognitively normal, middle-aged adults (age range, 43.2-73.8 years) enrolled in the Wisconsin Registry for Alzheimer's Prevention (WRAP) participated in this study. They reported their current engagement in cognitive activities using a modified version of the Cognitive Activity Scale (CAS), underwent a structural MRI scan, and completed a comprehensive cognitive battery. FreeSurfer was used to derive gray matter (GM) volumes from AD-related regions of interest (ROIs), and composite measures of episodic memory and executive function were obtained from the cognitive tests. Covariate-adjusted least squares analyses were used to examine the association between the Games item on the CAS (CAS-Games) and both GM volumes and cognitive composites. Higher scores on CAS-Games were associated with greater GM volumes in several ROIs including the hippocampus, posterior cingulate, anterior cingulate, and middle frontal gyrus. Similarly, CAS-Games scores were positively associated with scores on the Immediate Memory, Verbal Learning & Memory, and Speed & Flexibility domains. These findings were not modified by known risk factors for AD. In addition, the Total score on the CAS was not as sensitive as CAS-Games to the examined brain and cognitive measures. For some individuals, participation in cognitive activities pertinent to game playing may help prevent AD by preserving brain structures and cognitive functions vulnerable to AD pathophysiology. C1 [Schultz, Stephanie A.; Larson, Jordan; Oh, Jennifer; Gallagher, Catherine L.; Carlsson, Cynthia M.; Bendlin, Barbara B.; Asthana, Sanjay; Johnson, Sterling C.; Okonkwo, Ozioma C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Schultz, Stephanie A.; Larson, Jordan; Oh, Jennifer; Dowling, Maritza N.; Carlsson, Cynthia M.; Rowley, Howard A.; Bendlin, Barbara B.; Asthana, Sanjay; Hermann, Bruce P.; Johnson, Sterling C.; Sager, Mark; LaRue, Asenath; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53705 USA. [Koscik, Rebecca; Dowling, Maritza N.; Bendlin, Barbara B.; Asthana, Sanjay; Hermann, Bruce P.; Johnson, Sterling C.; Sager, Mark; LaRue, Asenath; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53705 USA. [Dowling, Maritza N.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Rowley, Howard A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53705 USA. [Gallagher, Catherine L.; Hermann, Bruce P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53705 USA. [Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53792 USA. RP Okonkwo, OC (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. EM ozioma@medicine.wisc.edu OI Schultz, Stephanie/0000-0001-8460-4415; Bendlin, Barbara/0000-0002-0580-9875 FU National Institute on Aging [K23 AG045957, R01 AG027161, R01 AG021155, P50 AG033514, P50 AG033514-S1]; Veterans Administration Merit Review Grant [I01CX000165]; Clinical and Translational Science Award [UL1RR025011]; Wisconsin Alumni Research Foundation; Helen Bader Foundation; Northwestern Mutual Foundation; Extendicare Foundation; Veterans Administration FX This work was supported by National Institute on Aging grants K23 AG045957 (OCO), R01 AG027161 (MAS), R01 AG021155 (SCJ), P50 AG033514 (SA), and P50 AG033514-S1 (OCO); by a Veterans Administration Merit Review Grant I01CX000165 (SCJ); and by a Clinical and Translational Science Award (UL1RR025011) to the University of Wisconsin, Madison. Portions of this research were supported by the Wisconsin Alumni Research Foundation, the Helen Bader Foundation, Northwestern Mutual Foundation, Extendicare Foundation; and from the Veterans Administration including facilities and resources at the Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 38 TC 4 Z9 4 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2015 VL 9 IS 4 BP 729 EP 736 DI 10.1007/s11682-014-9329-5 PG 8 WC Neuroimaging SC Neurosciences & Neurology GA CX5PX UT WOS:000365755500007 PM 25358750 ER PT J AU Hillard, JR Graham, DY AF Hillard, James Randolph Graham, David Y. TI It is not all black and white: Future incidence of stomach cancer will be substantially higher than projected due to the effects of immigration and increasing Hispanic and Asian populations in the United States SO CANCER LA English DT Letter C1 [Hillard, James Randolph] Michigan State Univ, Coll Osteopath Med, Coll Human Med, Dept Psychiat, E Lansing, MI 48824 USA. [Graham, David Y.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Hillard, JR (reprint author), Michigan State Univ, Coll Osteopath Med, Coll Human Med, Dept Psychiat, E Lansing, MI 48824 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD DEC 1 PY 2015 VL 121 IS 23 BP 4266 EP 4267 DI 10.1002/cncr.29629 PG 2 WC Oncology SC Oncology GA CX3TJ UT WOS:000365621900023 PM 26280930 ER PT J AU Bagai, A Peterson, ED Honeycutt, E Effron, MB Cohen, DJ Goodman, SG Anstrom, KJ Gupta, A Messenger, JC Wang, TY AF Bagai, Akshay Peterson, Eric D. Honeycutt, Emily Effron, Mark B. Cohen, David J. Goodman, Shaun G. Anstrom, Kevin J. Gupta, Anjan Messenger, John C. Wang, Tracy Y. TI In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study SO EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE LA English DT Article DE Adenosine diphosphate receptor inhibitor switching; safety and effectiveness; acute coronary syndrome; percutaneous coronary intervention ID ASSOCIATION TASK-FORCE; HIGH-DOSE CLOPIDOGREL; ST-SEGMENT ELEVATION; ANTIPLATELET THERAPY; PLATELET INHIBITION; PRACTICE GUIDELINES; RANDOMIZED-TRIAL; PRASUGREL; EVENTS; MANAGEMENT AB Aims: While randomized clinical trials have compared clopidogrel with higher potency adenosine diphosphate (ADP) receptor inhibitors among patients with acute myocardial infarction, little is known about the frequency, effectiveness and safety of switching between ADP receptor inhibitors in routine clinical practice. Methods and results: We studied 11,999 myocardial infarction patients treated with percutaneous coronary intervention at 230 hospitals from April 2010 to October 2012 in the TRANSLATE-ACS study. Multivariable Cox regression was used to compare six-month post-discharge risks of major adverse cardiovascular events (MACE: death, myocardial infarction, stroke, or unplanned revascularization) and Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-defined bleeding between in-hospital ADP receptor inhibitor switching versus continuation of the initially selected therapy. Among 8715 patients treated initially with clopidogrel, 994 (11.4%) were switched to prasugrel or ticagrelor; switching occurred primarily after percutaneous coronary intervention (60.9%) and at the time of hospital discharge (26.7%). Among 3284 patients treated initially with prasugrel or ticagrelor, 448 (13.6%) were switched to clopidogrel; 48.2% of switches occurred after percutaneous coronary intervention and 48.0% at hospital discharge. Switching to prasugrel or ticagrelor was not associated with increased bleeding when compared with continuation on clopidogrel (2.7% vs. 3.3%, adjusted hazard ratio 0.96, 95% confidence interval 0.64-1.42, p=0.82). Switching from prasugrel or ticagrelor to clopidogrel was not associated with increased MACE (8.9% vs. 7.7%, adjusted hazard ratio 1.06, 95% confidence interval 0.75-1.49, p=0.76) when compared with continuation on the higher potency agent. Conclusions: In-hospital ADP receptor inhibitor switching occurs in more than one in 10 myocardial infarction patients in contemporary practice. In this observational study, ADP receptor inhibitor switching does not appear to be significantly associated with increased hazard of MACE or bleeding. C1 [Bagai, Akshay; Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Peterson, Eric D.; Honeycutt, Emily; Anstrom, Kevin J.; Wang, Tracy Y.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA. [Effron, Mark B.] Lilly USA LLC, Indianapolis, IN USA. [Cohen, David J.] St Lukes Mid Amer Heart Inst, Kansas City, KS USA. [Gupta, Anjan] Univ Wisconsin, Sch Med & Publ Hlth, Aurora Cardiovasc Serv, Aurora Sinai Med Ctr, Milwaukee, WI 53201 USA. [Gupta, Anjan] Univ Wisconsin, Sch Med & Publ Hlth, Aurora Cardiovasc Serv, Aurora St Lukes Med Ctr, Milwaukee, WI 53201 USA. [Messenger, John C.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Bagai, A (reprint author), Univ Toronto, St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada. EM bagaia@smh.ca NR 25 TC 12 Z9 12 U1 1 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 2048-8726 EI 2048-8734 J9 EUR HEART J-ACUTE CA JI Eur. Heart J.-Acute Cardiovasc. Care PD DEC PY 2015 VL 4 IS 6 BP 499 EP 508 DI 10.1177/2048872614564082 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX3QB UT WOS:000365613000002 PM 25515725 ER PT J AU O'Leary, TJ Dominitz, JA Chang, KM AF O'Leary, Timothy J. Dominitz, Jason A. Chang, Kyong-Mi TI Veterans Affairs Office of Research and Development: Research Programs and Emerging Opportunities in Digestive Diseases Research SO GASTROENTEROLOGY LA English DT Editorial Material ID MILITARY SERVICE MEMBERS; CARE CLINICAL-TRIAL; COLORECTAL-CANCER; UNITED-STATES; MILLENNIUM COHORT; MENTAL-HEALTH; HEPATITIS; RISK; PREVALENCE; DEPLOYMENT C1 [O'Leary, Timothy J.] US EPA, Off Res & Dev, Dept Vet Affairs, Washington, DC 20460 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Chang, Kyong-Mi] Univ Penn, Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA. [Chang, Kyong-Mi] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP O'Leary, TJ (reprint author), US EPA, Off Res & Dev, Dept Vet Affairs, Washington, DC 20460 USA. FU BLRD VA [I01 BX000649]; Intramural VA [VA999999] NR 24 TC 3 Z9 3 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2015 VL 149 IS 7 BP 1652 EP 1661 DI 10.1053/j.gastro.2015.10.021 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CX6JX UT WOS:000365808100011 PM 26526712 ER PT J AU Tache, Y AF Tache, Yvette TI Personal Perspectives on Mentoring SO GASTROENTEROLOGY LA English DT Editorial Material ID MENTORSHIP; GASTROENTEROLOGY C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr,Digest Dis Div, Los Angeles, CA 90095 USA. [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr Neurobiol Stress & Womens Hlth,Digest Dis Div, Los Angeles, CA 90095 USA. [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,CURE Bldg 115,Room 117, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu NR 14 TC 1 Z9 1 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2015 VL 149 IS 7 BP 1662 EP 1665 DI 10.1053/j.gastro.2015.10.037 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CX6JX UT WOS:000365808100012 PM 26515791 ER PT J AU Bordon, JM Fernandez-Botran, R Wiemken, TL Peyrani, P Uriarte, SM Arnold, FW Rodriquez-Hernandez, L Rane, MJ Kelley, RR Binford, LE Uppatla, S Cavallazzi, R Blasi, F Aliberti, S Restrepo, MI Fazeli, S Mathur, A Rahmani, M Ayesu, K Ramirez, J AF Bordon, J. M. Fernandez-Botran, R. Wiemken, T. L. Peyrani, P. Uriarte, S. M. Arnold, F. W. Rodriquez-Hernandez, L. Rane, M. J. Kelley, R. R. Binford, L. E. Uppatla, S. Cavallazzi, R. Blasi, F. Aliberti, S. Restrepo, M. I. Fazeli, S. Mathur, A. Rahmani, M. Ayesu, K. Ramirez, J. TI Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response SO INFECTION LA English DT Article DE Streptococcus pneumoniae; Community-acquired pneumonia; Pneumonia severity; Pneumococcal bacteremia; Outcome; Mortality; Inflammatory response; Cytokines; Chemokines; Biomarkers; Neutrophil functional responses ID COMMUNITY-ACQUIRED-PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; HOSPITALIZED-PATIENTS; RISK-FACTORS; SEVERITY; ORGANIZATION; PATHOGENS; PROGNOSIS; DISEASE AB Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP. This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-alpha, interleukin (IL)-1r alpha, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups. From 833 pneumococcal CAP patients, 394 patients (47 %) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 % CI 0.69-0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 % CI 1.06-2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p < 0.003). Higher plasma levels of CRP, PCT, and BNP were found in bacteremic than in non-bacteremic patients. The bacteremic group had consistently higher plasma levels of both pro- and anti-inflammatory cytokines. The blood neutrophil functional responses were similar in both groups of patients. Bacteremic pneumococcal CAP patients were significantly associated with higher in-hospital mortality, lower TCS, and longer LOS. HIV-infected patients showed a greater mortality which was not statistically significant. Bacteremic pneumococcal CAP patients had higher levels of biomarkers and systemic cytokines. C1 [Bordon, J. M.; Fazeli, S.; Mathur, A.; Rahmani, M.] Providence Hosp, Infect Dis Sect, Washington, DC 20017 USA. [Fernandez-Botran, R.] Univ Louisville, Sch Med, Dept Pathol & Lab Med, Louisville, KY 40292 USA. [Wiemken, T. L.; Peyrani, P.; Arnold, F. W.; Rodriquez-Hernandez, L.; Kelley, R. R.; Binford, L. E.; Uppatla, S.; Cavallazzi, R.; Ramirez, J.] Univ Louisville, Sch Med, Dept Med, Div Infect Dis, Louisville, KY 40292 USA. [Uriarte, S. M.; Rane, M. J.] Univ Louisville, Sch Med, Dept Med, Div Nephrol, Louisville, KY 40292 USA. [Blasi, F.] Univ Milan, Dept Pathophysiol & Transplantat, IRCCS Fdn Ca Granda Osped Maggiore, Milan, Italy. [Aliberti, S.] Univ Milano Bicocca, Resp Unit, Dept Hlth Sci, AO San Gerardo, Monza, Italy. [Restrepo, M. I.] South Texas Vet Hlth Care Syst, Dept Pulm Dis, San Antonio, TX USA. [Restrepo, M. I.] Univ Texas San Antonio, San Antonio, TX USA. [Ramirez, J.] Vet Adm Med Ctr, Louisville, KY 40202 USA. [Ayesu, K.] Orlando Hlth, Dept Internal Med, Orlando, FL USA. RP Bordon, JM (reprint author), Providence Hosp, Infect Dis Sect, Washington, DC 20017 USA. EM jbordon@provhosp.org RI Fernandez-Botran, Rafael/J-3659-2016; Aliberti, Stefano/K-9115-2016 OI Fernandez-Botran, Rafael/0000-0001-8138-8745; Aliberti, Stefano/0000-0002-0090-4531; Blasi, Francesco/0000-0002-2285-9970 NR 29 TC 6 Z9 8 U1 1 U2 1 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD DEC PY 2015 VL 43 IS 6 BP 729 EP 738 DI 10.1007/s15010-015-0837-z PG 10 WC Infectious Diseases SC Infectious Diseases GA CX2FG UT WOS:000365510700013 PM 26424683 ER PT J AU Geng, TY Sutter, A Harland, MD Law, BA Ross, JS Lewin, D Palanisamy, A Russo, SB Chavin, KD Cowart, LA AF Geng, Tuoyu Sutter, Alton Harland, Michael D. Law, Brittany A. Ross, Jessica S. Lewin, David Palanisamy, Arun Russo, Sarah B. Chavin, Kenneth D. Cowart, L. Ashley TI SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes SO JOURNAL OF LIPID RESEARCH LA English DT Article DE sphingolipids; liver, diet and dietary lipids; lipid kinases; steatohepatitis; sphingosine-1-phosphate; lipotoxicity; sphingosine kinase 1; nonalcoholic steatohepatitis; nonalcoholic fatty liver disease ID SPHINGOSINE KINASE 1; PERFORMANCE LIQUID-CHROMATOGRAPHY; INSULIN-RESISTANCE; LIVER-DISEASE; SPHINGOLIPID METABOLISM; ENDOTHELIAL-CELLS; RETICULUM STRESS; ACTIVATION; ACIDS; MICE AB Steatohepatitis occurs in up to 20% of patients with fatty liver disease and leads to its primary disease outcomes, including fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma. Mechanisms that mediate this inflammation are of major interest. We previously showed that overload of saturated fatty acids, such as that which occurs with metabolic syndrome, induced sphingosine kinase 1 (SphK1), an enzyme that generates sphingosine-1-phosphate (S1P). While data suggest beneficial roles for S1P in some contexts, we hypothesized that it may promote hepatic inflammation in the context of obesity. Consistent with this, we observed 2-fold elevation of this enzyme in livers from humans with nonalcoholic fatty liver disease and also in mice with high saturated fat feeding, which recapitulated the human disease. Mice exhibited activation of NF kappa B, elevated cytokine production, and immune cell infiltration. Importantly, SphK1-null mice were protected from these outcomes. Studies in cultured cells demonstrated saturated fatty acid induction of SphK1 message, protein, and activity, and also a requirement of the enzyme for NF kappa B signaling and increased mRNA encoding TNF alpha and MCP1. Moreover, saturated fat-induced NF kappa B signaling and elevation of TNF alpha and MCP1 mRNA in HepG2 cells was blocked by targeted knockdown of S1P receptor 1, supporting a role for this lipid signaling pathway in inflammation in nonalcoholic fatty liver disease. C1 [Geng, Tuoyu; Harland, Michael D.; Law, Brittany A.; Ross, Jessica S.; Russo, Sarah B.; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Sutter, Alton; Palanisamy, Arun; Chavin, Kenneth D.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Lewin, David] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Law, Brittany A.; Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM cowartl@musc.edu FU Veterans Affairs Merit Award; National Institutes of Health [1R01HL117233, 5P30GM103339-03, 1R01DK069369] FX This work was supported by a Veterans Affairs Merit Award, National Institutes of Health Grants 1R01HL117233 and 5P30GM103339-03 (L.A.C.), and National Institutes of Health Grant 1R01DK069369 to K.D.C. The authors acknowledge that there are no conflicts of interest to disclose. NR 41 TC 4 Z9 4 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD DEC PY 2015 VL 56 IS 12 BP 2359 EP 2371 DI 10.1194/jlr.M063511 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CX6XA UT WOS:000365843800012 PM 26482537 ER PT J AU Osier, ND Carlson, SW DeSana, A Dixon, CE AF Osier, Nicole D. Carlson, Shaun W. DeSana, Anthony Dixon, C. Edward TI Chronic Histopathological and Behavioral Outcomes of Experimental Traumatic Brain Injury in Adult Male Animals SO JOURNAL OF NEUROTRAUMA LA English DT Article DE behavior; chronic; function; histopathology; TBI ID CONTROLLED CORTICAL IMPACT; DIFFUSE AXONAL INJURY; LATERAL FLUID-PERCUSSION; CLOSED-HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MARROW STROMAL CELLS; ACUTE NEURONAL DEGENERATION; SYMPATHETIC NERVOUS-SYSTEM; MEDIAL PREFRONTAL CORTEX; CHRONIC-STAGE CONTUSION AB The purpose of this review is to survey the use of experimental animal models for studying the chronic histopathological and behavioral consequences of traumatic brain injury (TBI). The strategies employed to study the long-term consequences of TBI are described, along with a summary of the evidence available to date from common experimental TBI models: fluid percussion injury; controlled cortical impact; blast TBI; and closed-head injury. For each model, evidence is organized according to outcome. Histopathological outcomes included are gross changes in morphology/histology, ventricular enlargement, gray/white matter shrinkage, axonal injury, cerebrovascular histopathology, inflammation, and neurogenesis. Behavioral outcomes included are overall neurological function, motor function, cognitive function, frontal lobe function, and stress-related outcomes. A brief discussion is provided comparing the most common experimental models of TBI and highlighting the utility of each model in understanding specific aspects of TBI pathology. The majority of experimental TBI studies collect data in the acute postinjury period, but few continue into the chronic period. Available evidence from long-term studies suggests that many of the experimental TBI models can lead to progressive changes in histopathology and behavior. The studies described in this review contribute to our understanding of chronic TBI pathology. C1 [Osier, Nicole D.; Carlson, Shaun W.; DeSana, Anthony; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA. [Carlson, Shaun W.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Osier, Nicole D.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA. [DeSana, Anthony] Seton Hill Univ, Greensburg, PA USA. RP Dixon, CE (reprint author), Univ Pittsburgh, Dept Neurol Surg, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM dixonec@upmc.edu FU National Institutes of Health (NIH)-NINDS [R01-NS079061, 5T32HD040686-14]; Department of Veterans Affairs [RRD B1127-I]; NIH-NINR [1F31NR014957-01, T32NR009759]; Pittsburgh Foundation; Sigma Theta Tau International Eta Chapter; International Society for Nurses in Genetics; American Association of Neuroscience Nursing/Neuroscience Nursing Foundation FX This work was supported by three federally sponsored grants: National Institutes of Health (NIH)-NINDS grants R01-NS079061 and 5T32HD040686-14, Department of Veterans Affairs grant RR&D B1127-I, and NIH-NINR grants 1F31NR014957-01 and T32NR009759. Additional support for this work was provided by grants from the following foundations and professional societies: The Pittsburgh Foundation, Sigma Theta Tau International Eta Chapter, International Society for Nurses in Genetics, and the American Association of Neuroscience Nursing/Neuroscience Nursing Foundation. The authors thank Michael Farmer for his time and assistance with the figures, Marilyn Farmer for her editorial support, as well as Lori Beck, Emad Madha, Lan Pham, and Amanda Savarese for their assistance in identifying and managing the long-term publications cited in this review. NR 309 TC 9 Z9 9 U1 7 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD DEC 1 PY 2015 VL 32 IS 23 SI SI BP 1861 EP 1882 DI 10.1089/neu.2014.3680 PG 22 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CX4TW UT WOS:000365694200004 PM 25490251 ER PT J AU Mitchell, JC Edwards, KJ Hunt, SB Poelstra, P AF Mitchell, Joel C. Edwards, Keith J. Hunt, Scott B. Poelstra, Paul TI Relational Commitment as a Mediator of Religiousness to Marital Quality SO JOURNAL OF PSYCHOLOGY AND THEOLOGY LA English DT Article ID RELATIONSHIP STABILITY; PERSONAL RELATIONSHIPS; CLOSE RELATIONSHIPS; COUPLES; MARRIAGE; SPIRITUALITY; SATISFACTION; CONFLICT; RELIGIOSITY AB This study examined the relationship between religiousness, relational commitment, and marital quality, proposing that relational commitment would act as a mediator in the relationship between religiousness and marital quality. Using a causal step approach to testing mediation, zero-order correlates demonstrated significant relationships among all 3 variables. In examining the mediating effects of relational commitment, full mediation for religiousness on marital quality was determined by using a sequential regression analysis. Therefore, religious individuals who had higher levels of relational commitment to their spouses experienced greater marital quality than those who had lower levels of relational commitment. The theoretical and applied implications of these findings are discussed. C1 [Mitchell, Joel C.; Hunt, Scott B.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. [Mitchell, Joel C.; Hunt, Scott B.] Univ Washington, Tacoma, WA 98493 USA. [Edwards, Keith J.; Poelstra, Paul] Biola Univ, Rosemead Sch Psychol, La Mirada, CA 90639 USA. RP Hunt, SB (reprint author), VA Puget Sound Hlth Care Syst, 9600 Vet Dr A-116, Tacoma, WA 98493 USA. EM scott.hunt3@va.gov NR 56 TC 0 Z9 0 U1 1 U2 3 PU ROSEMEAD SCHOOL PSYCHOLOGY PI LA MIRADA PA 13800 BIOLA AVENUE, BIOLA UNIVERSITY, LA MIRADA, CA 90639-0001 USA SN 0091-6471 J9 J PSYCHOL THEOL JI J. Psychol. Theol. PD WIN PY 2015 VL 43 IS 4 BP 263 EP 270 PG 8 WC Psychology, Multidisciplinary; Religion SC Psychology; Religion GA CX6QW UT WOS:000365827400004 ER PT J AU de Caestecker, M Humphreys, BD Liu, KD Fissell, WH Cerda, J Nolin, TD Askenazi, D Mour, G Harrell, FE Pullen, N Okusa, MD Faubel, S AF de Caestecker, Mark Humphreys, Ben D. Liu, Kathleen D. Fissell, William H. Cerda, Jorge Nolin, Thomas D. Askenazi, David Mour, Girish Harrell, Frank E., Jr. Pullen, Nick Okusa, Mark D. Faubel, Sarah CA ASN AKI Advisory Grp TI Bridging Translation by Improving Preclinical Study Design in AKI SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; CISPLATIN-INDUCED NEPHROTOXICITY; CONTRAST-INDUCED NEPHROPATHY; ISCHEMIA-REPERFUSION INJURY; RANDOMIZED CONTROLLED-TRIAL; ANIMAL-MODELS; SODIUM-BICARBONATE; CARDIAC-SURGERY AB Despite extensive research, no therapeutic interventions have been shown to prevent AKI, accelerate recovery of AKI, or reduce progression of AKI to CKD in patients. This failure in translation has led investigators to speculate that the animal models being used do not predict therapeutic responses in humans. Although this issue continues to be debated, an important concern that has not been addressed is whether improvements in preclinical study design can be identified that might also increase the likelihood of translating basic AKI research into clinical practice using the current models. In this review, we have taken an evidence-based approach to identify common weaknesses in study design and reporting in preclinical AKI research that may contribute to the poor translatability of the findings. We focused on use of N-acetylcysteine or sodium bicarbonate for the prevention of contrast-induced AKI and use of erythropoietin for the prevention of AKI, two therapeutic approaches that have been extensively studied in clinical trials. On the basis of our findings, we identified five areas for improvement in preclinical study design and reporting. These suggested and preliminary guidelines may help improve the quality of preclinical research for AKI drug development. C1 [de Caestecker, Mark; Fissell, William H.] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Nashville, TN 37232 USA. [Humphreys, Ben D.] Washington Univ, Sch Med, Div Renal Dis, St Louis, MO USA. [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Cerda, Jorge] Albany Med Coll, Div Nephrol & Hypertens, Albany, NY 12208 USA. [Nolin, Thomas D.; Mour, Girish] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Nolin, Thomas D.; Mour, Girish] Univ Pittsburgh, Sch Med, Ctr Crit Care Nephrol, Pittsburgh, PA USA. [Askenazi, David] Univ Alabama Birmingham, Dept Pediat, Div Nephrol, Birmingham, AL USA. [Harrell, Frank E., Jr.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA. [Pullen, Nick] Pfizer Global Res & Dev, Inflammat & Immunol Res Unit, Cambridge, MA USA. Univ Virginia Hlth Syst, Div Nephol, Charlottesville, VA USA. Univ Virginia Hlth Syst, Ctr Immun Inflammat & Regenerat Med, Charlottesville, VA USA. [Faubel, Sarah] Univ Colorado, Div Renal, Denver, CO 80202 USA. [Faubel, Sarah] Denver Vet Affairs Med Ctr, Aurora, CO USA. RP Okusa, MD (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, 1161 21st Ave South,S3223 Med Ctr North, Nashville, TN 37232 USA. EM mark.de.caestecker@vanderbilt.edu; sarah.faubel@ucdenver.edu NR 102 TC 10 Z9 10 U1 2 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2015 VL 26 IS 12 BP 2905 EP 2916 DI 10.1681/ASN.2015070832 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA CX1OR UT WOS:000365466000006 PM 26538634 ER PT J AU Zhang, WR Garg, AX Coca, SG Devereaux, PJ Eikelboom, J Kavsak, P McArthur, E Thiessen-Philbrook, H Shortt, C Shlipak, M Whitlock, R Parikh, CR AF Zhang, William R. Garg, Amit X. Coca, Steven G. Devereaux, Philip J. Eikelboom, John Kavsak, Peter McArthur, Eric Thiessen-Philbrook, Heather Shortt, Colleen Shlipak, Michael Whitlock, Richard Parikh, Chirag R. CA TRIBE-AKI Consortium TI Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; SERUM CYSTATIN C; CISPLATIN NEPHROTOXICITY; CARDIOVASCULAR EVENTS; DENDRITIC CELLS; INTERLEUKIN-10; BIOMARKERS; DIALYSIS; RISK AB Inflammation has an integral role in the pathophysiology of AKI. We investigated the associations of two biomarkers of inflammation, plasma IL-6 and IL-10, with AKI and mortality in adults undergoing cardiac surgery. Patients were enrolled at six academic centers (n=960). AKI was defined as a >= 50% or >= 0.3-mg/dl increase in serum creatinine from baseline. Pre- and postoperative IL-6 and IL-10 concentrations were categorized into tertiles and evaluated for associations with outcomes of in-hospital AKI or postdischarge all-cause mortality at a median of 3 years after surgery. Preoperative concentrations of IL-6 and IL-10 were not significantly associated with AKI or mortality. Elevated first postoperative IL-6 concentration was significantly associated with higher risk of AKI, and the risk increased in a dose-dependent manner (second tertile adjusted odds ratio [OR], 1.61 [95% confidence interval (95% Cl), 1.10 to 2.36]; third tertile adjusted OR, 2.13 [95% Cl, 1.45 to 3.13]). First postoperative IL-6 concentration was not associated with risk of mortality; however, the second tertile of peak IL-6 concentration was significantly associated with lower risk of mortality (adjusted hazard ratio, 0.75 [95% Cl, 0.57 to 0.99]). Elevated first postoperative IL-10 concentration was significantly associated with higher risk of AKI (adjusted OR, 1.57 [95% CI, 1.04 to 2.38]) and lower risk of mortality (adjusted HR, 0.72 [95% CI, 0.56 to 0.93]). There was a significant interaction between the concentration of neutrophil gelatinase-associated lipocalin, 'an established AKI biomarker, and the association of IL-10 concentration with mortality (P=0.01). These findings suggest plasma IL-6 and IL-10 may serve as bionnarkers for perioperative outcomes. C1 [Zhang, William R.; Coca, Steven G.; Parikh, Chirag R.] Yale Univ, Sch Med, Dept Internal Med, Program Appl Translat Res, New Haven, CT 06510 USA. [Garg, Amit X.; Thiessen-Philbrook, Heather] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. [Garg, Amit X.; McArthur, Eric] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Coca, Steven G.; Parikh, Chirag R.] Vet Affairs CT Healthcare Syst, Nephrol Sect, West Haven, CT USA. [Devereaux, Philip J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Populat Hlth Res Inst, Hamilton, ON, Canada. [Eikelboom, John] McMaster Univ, Div Cardiac Surg, Populat Hlth Res Inst, Hamilton, ON, Canada. [Shortt, Colleen] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada. [Shlipak, Michael] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Parikh, CR (reprint author), Yale Univ, Sch Med, Nephrol Sect, 60 Temple St,Suite 6C, New Haven, CT 06510 USA. EM chirag.parikh@yale.edu FU Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC); National Institutes of Health (NIH) [R01-HL085757]; NIH [K23-DK080132, K24-DK090203, U01-DK082185]; O'Brien Center [P30-DK079310-07] FX This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.; This study was supported by the National Institutes of Health (NIH) (R01-HL085757 to C.R.P.) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. S.G.C. has been supported by an NIH Career Development Award (K23-DK080132). C.R.P. is supported by the NIH (K24-DK090203) and P30-DK079310-07 O'Brien Center Grant. S.G.C., A.X.G., and C.R.P. are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01-DK082185). NR 60 TC 7 Z9 7 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2015 VL 26 IS 12 BP 3123 EP 3132 DI 10.1681/ASN.2014080764 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA CX1OR UT WOS:000365466000026 PM 25855775 ER PT J AU Blevins, CA Weathers, FW Davis, MT Witte, TK Domino, JL AF Blevins, Christy A. Weathers, Frank W. Davis, Margaret T. Witte, Tracy K. Domino, Jessica L. TI The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PTSD CHECKLIST; MISSING DATA; FIT INDEXES; VALIDITY; SCALE; INVENTORY; CRITERIA; PREVALENCE; SYMPTOMS; MODELS AB The Posttraumatic Stress Disorder Checklist (PCL) is a widely used DSM-correspondent self-report measure of PTSD symptoms. The PCL was recently revised to reflect DSM-5 changes to the PTSD criteria. In this article, the authors describe the development and initial psychometric evaluation of the PCL for DSM-5 (PCL-5). Psychometric properties of the PCL-5 were examined in 2 studies involving trauma-exposed college students. In Study 1 (N = 278), PCL-5 scores exhibited strong internal consistency ( = .94), test-retest reliability (r = .82), and convergent (rs = .74 to .85) and discriminant (rs = .31 to .60) validity. In addition, confirmatory factor analyses indicated adequate fit with the DSM-5 4-factor model, (2)(164) = 455.83, p < .001, standardized root mean square residual (SRMR) = .07, root mean squared error of approximation (RMSEA) = .08, comparative fit index (CFI) = .86, and Tucker-Lewis index (TLI) = .84, and superior fit with recently proposed 6-factor, (2) (164) = 318.37, p < .001, SRMR = .05, RMSEA = .06, CFI = .92, and TLI = .90, and 7-factor, (2) (164) = 291.32, p < .001, SRMR = .05, RMSEA = .06, CFI = .93, and TLI = .91, models. In Study 2 (N = 558), PCL-5 scores demonstrated similarly strong reliability and validity. Overall, results indicate that the PCL-5 is a psychometrically sound measure of PTSD symptoms. Implications for use of the PCL-5 in a variety of assessment contexts are discussed. C1 [Blevins, Christy A.] VA Portland Hlth Care Syst, Portland, OR 97239 USA. [Weathers, Frank W.; Davis, Margaret T.; Witte, Tracy K.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Domino, Jessica L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Blevins, CA (reprint author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM christy.blevins@va.gov NR 38 TC 38 Z9 39 U1 10 U2 54 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2015 VL 28 IS 6 BP 489 EP 498 DI 10.1002/jts.22059 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CX6GL UT WOS:000365799100001 PM 26606250 ER PT J AU Hammond, KW Ben-Ari, AY Laundry, RJ Boyko, EJ Samore, MH AF Hammond, Kenric W. Ben-Ari, Alon Y. Laundry, Ryan J. Boyko, Edward J. Samore, Matthew H. TI The Feasibility of Using Large-Scale Text Mining to Detect Adverse Childhood Experiences in a VA-Treated Population SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS; HEALTH; ABUSE; DEPRESSION; EXTRACTION; VETERANS; DISORDER; SERVICE; COMBAT; IMPACT AB Free text in electronic health records resists large-scale analysis. Text records facts of interest not found in encoded data, and text mining enables their retrieval and quantification. The U.S. Department of Veterans Affairs (VA) clinical data repository affords an opportunity to apply text-mining methodology to study clinical questions in large populations. To assess the feasibility of text mining, investigation of the relationship between exposure to adverse childhood experiences (ACEs) and recorded diagnoses was conducted among all VA-treated Gulf war veterans, utilizing all progress notes recorded from 2000-2011. Text processing extracted ACE exposures recorded among 44.7 million clinical notes belonging to 243,973 veterans. The relationship of ACE exposure to adult illnesses was analyzed using logistic regression. Bias considerations were assessed. ACE score was strongly associated with suicide attempts and serious mental disorders (ORs = 1.84 to 1.97), and less so with behaviorally mediated and somatic conditions (ORs = 1.02 to 1.36) per unit. Bias adjustments did not remove persistent associations between ACE score and most illnesses. Text mining to detect ACE exposure in a large population was feasible. Analysis of the relationship between ACE score and adult health conditions yielded patterns of association consistent with prior research. C1 [Hammond, Kenric W.; Laundry, Ryan J.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. [Hammond, Kenric W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Hammond, Kenric W.] Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA. [Ben-Ari, Alon Y.] VA Puget Sound Hlth Care Syst, Dept Anesthesia, Seattle, WA USA. [Ben-Ari, Alon Y.] Univ Washington, Dept Anesthesia, Seattle, WA 98195 USA. [Boyko, Edward J.] Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. [Samore, Matthew H.] George A Whalen VA Med Ctr, Hlth Serv Res & Dev Serv, Salt Lake City, UT USA. [Samore, Matthew H.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA. [Samore, Matthew H.] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA. RP Hammond, KW (reprint author), 152 VA Puget Sound,1660 S Columbian Way, Seattle, WA 98108 USA. EM khammond@uw.edu OI Boyko, Edward/0000-0002-3695-192X FU U.S. Department of Veterans Affairs (VA) [HIR 10-001] FX This work was supported by U.S. Department of Veterans Affairs (VA) HSR&D study, HIR 10-001. The opinions expressed here are those of the authors and do not reflect those of the VA. NR 27 TC 0 Z9 0 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2015 VL 28 IS 6 BP 505 EP 514 DI 10.1002/jts.22058 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CX6GL UT WOS:000365799100003 PM 26579624 ER PT J AU Grubbs, KM Fortney, JC Pyne, JM Hudson, T Moore, WM Custer, P Schneider, R Schnurr, PP AF Grubbs, Kathleen M. Fortney, John C. Pyne, Jeffrey M. Hudson, Teresa Moore, William Mark Custer, Paul Schneider, Ronald Schnurr, Paula P. TI Predictors of Initiation and Engagement of Cognitive Processing Therapy Among Veterans With PTSD Enrolled in Collaborative Care SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE AB Collaborative care (CC) increases access to evidence-based pharmacotherapy and psychotherapy. The study aim was to identify the characteristics of rural veterans receiving a telemedicine-based CC intervention for posttraumatic stress disorder (PTSD) who initiated and engaged in cognitive processing therapy (CPT) delivered via interactive video. Veterans diagnosed with PTSD were recruited from 11 community-based outpatient clinics (N = 133).Chart abstraction identified all mental health encounters received during the 12-month study. General linear mixed models were used to identify characteristics that predicted CPT initiation and engagement (attendance at 8 or more sessions). For initiation, higher PTSD severity according to the Clinician Administered PTSD Scale (d = -0.39, p = .038) and opt-out recruitment (vs. self-referral; d = -0.49, p = .010) were negative predictors. For engagement, major depression (d = -1.32, p = .006) was a negative predictor whereas a pending claim for military service connected disability (d = 2.02, p = .008) was a positive predictor. In general, veterans enrolled in CC initiated and engaged in CPT at higher rates than usual care. Those with more severe symptoms and comorbidity, however, were at risk of not starting or completing CPT. C1 [Grubbs, Kathleen M.; Pyne, Jeffrey M.; Hudson, Teresa; Moore, William Mark] Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev, North Little Rock, AR USA. [Grubbs, Kathleen M.; Pyne, Jeffrey M.; Hudson, Teresa; Moore, William Mark] Cent Arkansas Vet Healthcare Syst, South Cent Mental Illness Educ & Clin Ctr, North Little Rock, AR USA. [Grubbs, Kathleen M.; Pyne, Jeffrey M.; Hudson, Teresa] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA. [Fortney, John C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet, Ctr & Value Driven Care, Hlth Serv Res & Dev, Seattle, WA USA. [Fortney, John C.] Univ Washington, Dept Psychiat, Div Populat Hlth, Seattle, WA 98195 USA. [Custer, Paul] VA Loma Linda Hlth Care Syst, Dept Psychol, Loma Linda, CA USA. [Schneider, Ronald] Overton Brooks VA Med Ctr, Dept Psychol, Shreveport, LA USA. [Schneider, Ronald] Louisiana State Univ, Hlth Sci Ctr, Dept Psychiat, Shreveport, LA 71105 USA. [Schnurr, Paula P.] VA Med Ctr, Natl Ctr PTSD, White River Jct, VT USA. [Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Grubbs, KM (reprint author), 2121 San Diego Ave, San Diego, CA 92110 USA. EM kathleen.grubbs@va.gov NR 19 TC 0 Z9 0 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2015 VL 28 IS 6 BP 580 EP 584 DI 10.1002/jts.22049 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CX6GL UT WOS:000365799100012 PM 26625355 ER PT J AU Rakian, R Block, TJ Johnson, SM Marinkovic, M Wu, JJ Dai, QX Dean, DD Chen, XD AF Rakian, Rubie Block, Travis J. Johnson, Shannan M. Marinkovic, Milos Wu, Junjie Dai, Qiuxia Dean, David D. Chen, Xiao-Dong TI Native extracellular matrix preserves mesenchymal stem cell "stemness" and differentiation potential under serum-free culture conditions SO STEM CELL RESEARCH & THERAPY LA English DT Article DE Mesenchymal stem cells; Extracellular matrix; Serum-free media; Stem cell expansion ID MARROW STROMAL CELLS; BONE-MARROW; OSTEOBLAST DIFFERENTIATION; PROGENITOR CELLS; EXPANSION; TRANSPLANTATION; PROLIFERATION; PROTEOGLYCANS; STABILITY; MIGRATION AB Introduction: Bone marrow-derived mesenchymal stem cells (BM-MSCs) for clinical use should not be grown in media containing fetal bovine serum (FBS), because of serum-related concerns over biosafety and batch-to-batch variability. Previously, we described the preparation and use of a cell-free native extracellular matrix (ECM) made by bone marrow cells (BM-ECM) which preserves stem cell properties and enhances proliferation. Here, we compare colony-forming ability and differentiation of MSCs cultured on BM-ECM with a commercially available matrix (CELLstart (TM)) and tissue culture plastic (TCP) under serum-free conditions. Methods: Primary MSCs from freshly isolated bone marrow-derived mononuclear cells or passaged MSCs (P1) were grown in serum-containing (SCM) or serum-free (SFM) media on BM-ECM, CELLstart (TM), or TCP substrates. Proliferation, cell composition (phenotype), colony-forming unit replication, and bone morphogenetic protein-2 (BMP-2) responsiveness were compared among cells maintained on the three substrates. Results: Proliferation of primary BM-MSCs was significantly higher in SCM than SFM, irrespectively of culture substrate, suggesting that the expansion of these cells requires SCM. In contrast, passaged cells cultured on BM-ECM or CELLstart (TM) in SFM proliferated to nearly the same extent as cells in SCM. However, morphologically, those on BM-ECM were smaller and more aligned, slender, and long. Cells grown for 7 days on BM-ECM in SFM were 20-40 % more positive for MSC surface markers than cells cultured on CELLstart (TM). Cells cultured on TCP contained the smallest number of cells positive for MSC markers. MSC colony-forming ability in SFM, as measured by CFU-fibroblasts, was increased 10-, 9-, and 2-fold when P1 cells were cultured on BM-ECM, CELLstart (TM), and TCP, respectively. Significantly, CFU-adipocyte and -osteoblast replication of cells grown on BM-ECM was dramatically increased over those on CELLstart (TM) (2X) and TCP (4-7X). BM-MSCs, cultured in SFM and treated with BMP-2, retained their differentiation capacity better on BM-ECM than on either of the other two substrates. Conclusions: Our findings indicate that BM-ECM provides a unique microenvironment that supports the colony-forming ability of MSCs in SFM and preserves their stem cell properties. The establishment of a robust culture system, combining native tissue-specific ECM and SFM, provides an avenue for preparing significant numbers of potent MSCs for cell-based therapies in patients. C1 [Rakian, Rubie; Block, Travis J.; Johnson, Shannan M.; Marinkovic, Milos; Dai, Qiuxia; Dean, David D.; Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Johnson, Shannan M.] Joint Base San Antonio, Periodont Grad Program, Lackland AFB, TX 78236 USA. [Wu, Junjie] Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, Xian 710032, Shaanxi Provinc, Peoples R China. [Chen, Xiao-Dong] South Texas Vet Hlth Care Syst, Res Serv, Audie Murphy VA Med Ctr, San Antonio, TX 78229 USA. RP Chen, XD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chenx4@uthscsa.edu OI Dean, David/0000-0002-4512-9065 FU VA Merit Review [1I01BX002145-01]; Baptist Health Foundation FX This research was supported by VA Merit Review (1I01BX002145-01) and Baptist Health Foundation grants to X-DC. NR 36 TC 5 Z9 6 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1757-6512 J9 STEM CELL RES THER JI Stem Cell Res. Ther. PD DEC 1 PY 2015 VL 6 AR 235 DI 10.1186/s13287-015-0235-6 PG 11 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA CY1KH UT WOS:000366164600001 PM 26620283 ER PT J AU Shore, J Vo, A Yellowlees, P Waugh, M Schneck, C Nagamoto, H Thomas, M AF Shore, Jay Vo, Alexander Yellowlees, Peter Waugh, Maryann Schneck, Christopher Nagamoto, Herbert Thomas, Marshall TI Antipsychotic-Induced Movement Disorder: Screening via Telemental Health SO TELEMEDICINE AND E-HEALTH LA English DT Article DE telehealth; telemedicine; drug-induced movement disorder antipsychotics; telemental health; psychiatry; movement disorders ID ASYNCHRONOUS TELEPSYCHIATRY; CARE AB Background:The purpose of this brief report is to make clinical and research recommendations to advance current knowledge and practices related to the assessment of antipsychotic drug-induced movement disorders (DIMDs) via live interactive videoconferencing.Materials and Methods:The authors provide an overview of the frequent neurological side effects of antipsychotic drugs and review relevant telemedicine research. DIMD prevention is critical, but these disorders remain underdetected and under-reported. Although there are not yet formal recommendations for specific screening tools or screening frequency, baseline and annual assessments are generally agreed-upon minimums. As DIMD awareness increases and more specific guidelines are developed to steer assessments, telemental health may aid practitioners in efficiently and regularly monitoring onset and severity. Research shows that videoconferencing can be used for effective psychiatric treatments and assessment, with at least one study validating the use of videoconference assessment for a subset of movement disorders.Results and Conclusions:Clinical recommendations include developing practice-level protocols and procedures that include regular DIMD assessment (either in-person or via telemedicine) for the full spectrum of possible movement disorders for all patients taking antipsychotic medications. Research and evaluation recommendations include replicating and expanding upon the existing study using videoconferencing to assess movement disorder symptoms, using asynchronous telemental health assessments of DIMDs, and pilot-testing facial and movement recognition software to allow for clinical comparison of patients' movement patterns over time. C1 [Shore, Jay; Schneck, Christopher; Nagamoto, Herbert; Thomas, Marshall] Univ Colorado, Aurora, CO 80045 USA. [Shore, Jay; Vo, Alexander; Waugh, Maryann; Thomas, Marshall] Colorado Access, Denver, CO USA. [Yellowlees, Peter] Univ Calif Davis, Dept Psychiat, Sacramento, CA 95817 USA. [Nagamoto, Herbert] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Shore, J (reprint author), Univ Colorado, Anschutz Med Campus,13055 E 17th Ave,F800, Aurora, CO 80045 USA. EM Jay.Shore@ucdenver.edu NR 11 TC 0 Z9 0 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD DEC 1 PY 2015 VL 21 IS 12 BP 1027 EP 1029 DI 10.1089/tmj.2014.0242 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CX4MZ UT WOS:000365676300010 PM 26125084 ER PT J AU Folkesson, M Li, CJ Frebelius, S Swedenborg, J Wagsater, D Williams, KJ Eriksson, P Roy, J Liu, ML AF Folkesson, Maggie Li, Chunjun Frebelius, Siw Swedenborg, Jesper Wagsater, Dick Williams, Kevin Jon Eriksson, Per Roy, Joy Liu, Ming-Lin TI Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE Abdominal aortic aneurysm; ADAM10; ADAM17; intraluminal thrombus; A disintegrin and matrix metalloproteinase; membrane-bound protease; microparticles; microvesicles ID HUMAN ATHEROSCLEROTIC PLAQUES; TUMOR-NECROSIS-FACTOR; INTRALUMINAL THROMBUS; TOBACCO-SMOKE; TISSUE FACTOR; FACTOR-ALPHA; EXPRESSION; CELLS; MICROPARTICLES; DISINTEGRIN AB The intraluminal thrombus (ILT) of human abdominal aortic aneurysm (AAA) has been suggested to damage the underlying aortic wall, but previous work found scant activity of soluble proteases in the abluminal layer of the ILT, adjacent to the aneurysm. We hypothesised that transmembrane proteases carried by membrane microvesicles (MV) from dying cells remain active in the abluminal ILT. ILTs and AAA segments collected from 21 patients during surgical repair were assayed for two major transmembrane proteases, ADAM10 (a disintegrin and metalloprotease-10) and ADAM17. We also exposed cultured cells to tobacco smoke and assessed ADAM10 and ADAM17 expression and release on MVs. Immunohistochemistry showed abundant ADAM10 and ADAM17 protein in the ILT and underlying aneurysmal aorta. Domain-specific antibodies indicated both transmembrane and shed ADAM17. Importantly, ADAM10 and ADAM 17 in the abluminal ILT were enzymatically active. Electron microscopy of abluminal ILT and aortic wall showed MVs with ADAM10 and ADAM17. By flow cytometry, ADAM-positive microvesicles from abluminal ILT carried the neutrophil marker CD66, but not the platelet marker CD61. Cultured HL60 neutrophils exposed to tobacco smoke extract showed increased ADAM10 and ADAM17 content, cleavage of these molecules into active forms, and release of MVs carrying mature ADAM10 and detectable ADAM17. In conclusion, our results implicate persistent, enzymatically active ADAMs on MVs in the abluminal ILT, adjacent to the aneurysmal wall. The production of ADAM10- and ADAM17-positive MVs from smoke-exposed neutrophils provides a novel molecular mechanism for the vastly accelerated risk of AAA in smokers. C1 [Folkesson, Maggie; Wagsater, Dick] Linkoping Univ, Dept Med & Hlth, Div Drug Res, Linkoping, Sweden. [Li, Chunjun] Tianjin Med Univ, Metab Dis Hosp, Tianjin, Peoples R China. [Li, Chunjun] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin, Peoples R China. [Frebelius, Siw; Swedenborg, Jesper; Roy, Joy] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. [Williams, Kevin Jon; Liu, Ming-Lin] Temple Univ, Sch Med, Dept Med, Endocrinol Sect, Philadelphia, PA 19122 USA. [Williams, Kevin Jon] Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden. [Eriksson, Per] Karolinska Inst, Dept Med, Stockholm, Sweden. [Liu, Ming-Lin] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Liu, Ming-Lin] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Folkesson, M (reprint author), Linkoping Univ, Dept Med & Hlth, Div Drug Res, Linkoping, Sweden. EM maggie.m.folkesson@gmail.com; joy.roy@ki.se; mlliu02@gmail.com OI , Dick/0000-0002-3655-2419 NR 38 TC 5 Z9 6 U1 0 U2 3 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD DEC PY 2015 VL 114 IS 6 BP 1165 EP 1174 DI 10.1160/TH14-10-0899 PG 10 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CX5UY UT WOS:000365769200010 PM 26422658 ER PT J AU Laferrier, JZ Teodorski, E Cooper, RA AF Laferrier, Justin Z. Teodorski, Emily Cooper, Rory A. TI Investigation of the Impact of Sports, Exercise, and Recreation Participation on Psychosocial Outcomes in a Population of Veterans with Disabilities A Cross-sectional Study SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Psychosocial Well-being; Adaptive Sports; Recreation; Sports Participation; Rehabilitation; Disability; Self-esteem; Depression; Posttraumatic Growth; Quality of Life; Service Members; Veterans ID QUALITY-OF-LIFE; SPINAL-CORD-INJURY; PHYSICAL-ACTIVITY; MENTAL-HEALTH; CANCER SURVIVORS; CONTROLLED TRIAL; CEREBRAL-PALSY; DOSE-RESPONSE; DEPRESSION; AFGHANISTAN AB Objective The aim of this study was to investigate possible effects that participation in sports, exercise, and recreation may have on self-esteem and quality-of-life in service members/veterans with disabilities. Design Two hundred twenty service members/veterans with disabilities who were participants in one of three annual adaptive sporting events took part in this cross-sectional study. Variables of interest were years of sport, exercise, and recreation participation since the onset of disability as well as the type of activity they engaged in. Main outcome measures were self-esteem and quality-of-life. Results A positive relationship was found between participant quality-of-life and the number of years spent participating in sports, exercise, and recreation since the onset of their disability. A significant difference was found between pre-event and postevent self-esteem scores. A significant difference was also found in self-esteem scores between the levels of years of participation in sports, exercise, and recreation when averaged across activity type. Finally, there were significant differences found on self-esteem scores between the levels of type of activity averaged across years of participation. Conclusions Our results indicate that participation in sports, exercise, and recreation has a positive influence on self-esteem and quality-of-life in individuals with disabilities. C1 [Laferrier, Justin Z.; Teodorski, Emily] Univ Connecticut, Dept Kinesiol, Phys Therapy Program, Storrs, CT 06269 USA. [Laferrier, Justin Z.; Teodorski, Emily; Cooper, Rory A.] VA Rehabil Res & Dev Serv, Human Engn Res Labs, Pittsburgh, PA USA. [Laferrier, Justin Z.; Teodorski, Emily; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Laferrier, JZ (reprint author), Univ Connecticut, 358 Mansfield Rd,Unit 1101, Storrs, CT 06269 USA. FU CPPF grant through the Department of Veterans Affairs FX Funding was provided through a CPPF grant through the Department of Veterans Affairs. NR 47 TC 3 Z9 3 U1 4 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2015 VL 94 IS 12 BP 1026 EP 1034 DI 10.1097/PHM.0000000000000263 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CW7LR UT WOS:000365180800002 PM 25768065 ER PT J AU Cortes-Briones, JA Cahill, JD Skosnik, PD Mathalon, DH Williams, A Sewell, RA Roach, BJ Ford, JM Ranganathan, M D'Souza, DC AF Cortes-Briones, Jose A. Cahill, John D. Skosnik, Patrick D. Mathalon, Daniel H. Williams, Ashley Sewell, R. Andrew Roach, Brian J. Ford, Judith M. Ranganathan, Mohini D'Souza, Deepak Cyril TI The Psychosis-like Effects of Delta(9)-Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Cannabinoids; Electroencephalogram; Neural noise; Nonlinear analysis; Psychosis; Tetrahydrocannabinol ID LEMPEL-ZIV COMPLEXITY; LONGITUDINAL DATA-ANALYSIS; SPONTANEOUS BRAIN ACTIVITY; FUNCTIONAL CONNECTIVITY; AUDITORY HALLUCINATIONS; WORKING-MEMORY; SCHIZOPHRENIA; EEG; SIGNAL; CANNABINOIDS AB BACKGROUND: Drugs that induce psychosis may do so by increasing the level of task-irrelevant random neural activity or neural noise. Increased levels of neural noise have been demonstrated in psychotic disorders. We tested the hypothesis that neural noise could also be involved in the psychotomimetic effects of delta-9-tetrahydrocannabinol (Delta(9)-THC), the principal active constituent of cannabis. METHODS: Neural noise was indexed by measuring the level of randomness in the electroencephalogram during the prestimulus baseline period of an oddball task using Lempel-Ziv complexity, a nonlinear measure of signal randomness. The acute, dose-related effects of Delta(9)-THC on Lempel-Ziv complexity and signal power were studied in humans (n = 24) who completed 3 test days during which they received intravenous Delta(9)-THC (placebo, .015 and .03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design. RESULTS: Delta(9)-THC increased neural noise in a dose-related manner. Furthermore, there was a strong positive relationship between neural noise and the psychosis-like positive and disorganization symptoms induced by Delta 9-THC, which was independent of total signal power. Instead, there was no relationship between noise and negative-like symptoms. In addition, Delta(9)-THC reduced total signal power during both active drug conditions compared with placebo, but no relationship was detected between signal power and psychosis-like symptoms. CONCLUSIONS: At doses that produced psychosis-like effects, Delta(9)-THC increased neural noise in humans in a dose-dependent manner. Furthermore, increases in neural noise were related with increases in Delta(9)-THC-induced psychosis-like symptoms but not negative-like symptoms. These findings suggest that increases in neural noise may contribute to the psychotomimetic effects of Delta(9)-THC. C1 [Cortes-Briones, Jose A.; Cahill, John D.; Skosnik, Patrick D.; Williams, Ashley; Sewell, R. Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] Vet Affairs Connecticut Healthcare Syst, Psychiat Serv, West Haven, CT USA. [Cortes-Briones, Jose A.; Skosnik, Patrick D.; Williams, Ashley; Sewell, R. Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA. [Cortes-Briones, Jose A.; Cahill, John D.; Skosnik, Patrick D.; Sewell, R. Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Mathalon, Daniel H.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mathalon, Daniel H.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP D'Souza, DC (reprint author), Yale Univ, VACHS Psychiat 116A, 950 Campbell Ave, West Haven, CT 06516 USA. EM deepak.dsouza@yale.edu RI Skosnik, Patrick/D-6466-2016 FU National Institute on Drug Abuse [R21 DA020750]; National Alliance for Research on Schizophrenia and Depression Young Investigator Award; Department of Veterans Affairs; National Institute of Mental Health; National Institute of Drug Abuse; National Institute of Alcoholism and Alcohol Abuse; Yale Center for Clinical Investigation; AbbVie; Pfizer Inc. FX This research project was funded in part by grants from the National Institute on Drug Abuse (R21 DA020750 to DCD) and a National Alliance for Research on Schizophrenia and Depression Young Investigator Award to PDS.; We acknowledge support from the 1) Department of Veterans Affairs, 2) National Institute of Mental Health, 3) National Institute of Drug Abuse, 4) National Institute of Alcoholism and Alcohol Abuse, and 5) the Yale Center for Clinical Investigation. We also thank Angelina Genovese, R.N.C., M.B.A.; Michelle San Pedro, R.N.; Elizabeth O'Donnell, R.N.; Brenda Breault, R.N., B.S.N.; Sonah Yoo, R.Ph.; Rachel Galvan, R.Ph.; and Willie Ford of the Neurobiological Studies Unit at the Veterans Affairs Connecticut Healthcare System, West Haven Campus, for their central contributions to the success of this project. Finally, this manuscript is dedicated to the memory of our dear friend and colleague, the late Dr. R. Andrew Sewell.; Deepak Cyril D'Souza has received in the past 3 years and currently receives research grant support administered through Yale University School of Medicine from AbbVie and Pfizer Inc., and he is a consultant for Bristol Myers Squibb and Johnson and Johnson. Dr. Mathalon is a consultant for Bristol Myers Squibb, Roche, and Amgen. All other authors report no biomedical financial interests or potential conflicts of interest. NR 66 TC 3 Z9 3 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 1 PY 2015 VL 78 IS 11 BP 805 EP 813 DI 10.1016/j.biopsych.2015.03.023 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CW5OQ UT WOS:000365046200012 PM 25913109 ER PT J AU Klyuchnikov, E Bacher, U Kroger, NM Hari, PN Ahn, KW Carreras, J Bachanova, V Bashey, A Cohen, JB D'Souza, A Freytes, CO Gale, RP Ganguly, S Hertzberg, MS Holmberg, LA Kharfan-Dabaja, MA Klein, A Ku, GH Laport, GG Lazarus, HM Miller, AM Mussetti, A Olsson, RF Slavin, S Usmani, SZ Vij, R Wood, WA Maloney, DG Sureda, AM Smith, SM Hamadani, M AF Klyuchnikov, Evgeny Bacher, Ulrike Kroeger, Nicolaus M. Hari, Parameswaran N. Ahn, Kwang Woo Carreras, Jeanette Bachanova, Veronika Bashey, Asad Cohen, Jonathon B. D'Souza, Anita Freytes, Cesar O. Gale, Robert Peter Ganguly, Siddhartha Hertzberg, Mark S. Holmberg, Leona A. Kharfan-Dabaja, Mohamed A. Klein, Andreas Ku, Grace H. Laport, Ginna G. Lazarus, Hillard M. Miller, Alan M. Mussetti, Alberto Olsson, Richard F. Slavin, Shimon Usmani, Saad Z. Vij, Ravi Wood, William A. Maloney, David G. Sureda, Anna M. Smith, Sonali M. Hamadani, Mehdi TI Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Grade 1 and 2 follicular lymphoma; Reduced-intensity allogeneic hematopoietic cell transplantation; Autologous hematopoietic cell transplantation; Long-time survival ID STEM-CELL TRANSPLANTATION; PROGRESSION-FREE SURVIVAL; NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; FOLLOW-UP; ALLOGENEIC TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; RITUXIMAB; EBMT; RELAPSE AB This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P <.0001); relapse/progression: 54% versus 20% (P <.0001); progression-free survival (PFS): 41% versus 58% (P <.001), and overall survival (OS): 74% versus 66% (P =.05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P <.0001) and worse PFS (RR, 2.9; P <.0001) beyond 11 months after HCT. In the first 24 months after HO', auto-HCT was associated with improved OS (RR,.41; P <.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P =.006). A landmark analysis of patients alive and progression-free at 2 years after HO' confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P <.0001) and inferior PFS (RR, 3.2; P <.0001) and OS (RR, 2.1; P =.04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors. (C) 2015 American Society for Blood and Marrow Transplantation. C1 [Klyuchnikov, Evgeny; Kroeger, Nicolaus M.] Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany. [Bacher, Ulrike] Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany. [Hari, Parameswaran N.; Ahn, Kwang Woo; Carreras, Jeanette; D'Souza, Anita; Hamadani, Mehdi] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. [Hari, Parameswaran N.; Ahn, Kwang Woo; Carreras, Jeanette; D'Souza, Anita; Hamadani, Mehdi] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. [Ahn, Kwang Woo] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Bachanova, Veronika] Univ Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA. [Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. [Cohen, Jonathon B.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Freytes, Cesar O.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. [Ganguly, Siddhartha] Univ Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA. [Hertzberg, Mark S.] Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia. [Holmberg, Leona A.; Maloney, David G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kharfan-Dabaja, Mohamed A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. [Klein, Andreas] Tufts Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA USA. [Ku, Grace H.] Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, San Diego, CA 92103 USA. [Laport, Ginna G.] Stanford Hosp & Clin, Div Bone Marrow Transplantat, Stanford, CA USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Miller, Alan M.] Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA. [Mussetti, Alberto] Fdn IRCCS Ist Nazl Tumori, SC Ematol & Trapianto Midollo Osseo, Milan, Italy. [Mussetti, Alberto] Univ Milan, Milan, Italy. [Olsson, Richard F.] Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden. [Olsson, Richard F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Slavin, Shimon] Int Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel. [Usmani, Saad Z.] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol, Med Oncol, Charlotte, NC USA. [Vij, Ravi] Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA. [Wood, William A.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA. [Sureda, Anna M.] Hosp Duran & Reynals, Inst Catala Oncol, Serv Hematol, Barcelona, Spain. [Sureda, Anna M.] European Grp Blood & Marrow Transplantat, Milan, Italy. [Smith, Sonali M.] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA. RP Hamadani, M (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA. EM mhamadani@mcw.edu RI Mussetti, Alberto/C-9500-2017 OI Mussetti, Alberto/0000-0002-4088-036X; D'Souza, Anita/0000-0002-1092-5643; Hari, Parameswaran/0000-0002-8800-297X FU Public Health Service grant from the National Cancer Institute (NCI) [U24-CA076518]; National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); NHLBI [5U10HL069294]; NCI; Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]; Office of Naval Research [N00014-13-1-0039, N00014-14-1-0028]; Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen, Inc. FX The CIBMTR is supported by Public Health Service grant/cooperative agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;*Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the US Government. NR 35 TC 10 Z9 11 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD DEC PY 2015 VL 21 IS 12 BP 2091 EP 2099 DI 10.1016/j.bbmt.2015.07.028 PG 9 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CW4SF UT WOS:000364981700009 PM 26253007 ER PT J AU Gatewood, MO Wemple, M Greco, S Kritek, PA Durvasula, R AF Gatewood, Medley O'Keefe Wemple, Matthew Greco, Sheryl Kritek, Patricia A. Durvasula, Raghu TI A quality improvement project to improve early sepsis care in the emergency department SO BMJ QUALITY & SAFETY LA English DT Article ID CLINICAL DECISION-SUPPORT; SEPTIC SHOCK; RANDOMIZED-TRIAL; MANAGEMENT; OUTCOMES; BUNDLE; ALERTS; IMPLEMENTATION; MORTALITY; THERAPY AB Background Sepsis causes substantial morbidity and mortality in hospitalised patients. Although many studies describe the use of protocols in the management of patients with severe sepsis and septic shock, few have addressed emergency department (ED) screening and management for patients initially presenting with uncomplicated sepsis (ie, patients without organ failure or hypotension). Objective A quality improvement task force at a large, quaternary care referral hospital sought to develop a protocol focusing on early identification of patients with uncomplicated sepsis, in addition to severe sepsis and septic shock. Intervention The three-tiered intervention consisted of (1) a nurse-driven screening tool and management protocol to identify and initiate early treatment of patients with sepsis, (2) a computer-assisted screening algorithm that generated a 'Sepsis Alert' pop-up screen in the electronic medical record for treating clinical healthcare providers and (3) automated suggested sepsis-specific order sets for initial workup and resuscitation, antibiotic selection and goal-directed therapy. Design A before and after retrospective cohort study was undertaken to determine the intervention's impact on compliance with recommended sepsis management, including serum lactate measured in the ED, 2 L of intravenous fluid administered within 2 h of triage, antibiotics administered within 3 h of triage and blood cultures drawn before antibiotic administration. Mortality rates for patients in the ED with a sepsis-designated ICD-9 code present on admission were also analysed. Results Overall bundle compliance increased by 154%, from 28% at baseline to 71% in the last quarter of the study (p<0.001). Bundle, antibiotic and intravenous fluid compliance all increased significantly after launch of the sepsis initiative (eg, bundle and intravenous fluid compliance increased by 74% and 54%, respectively; p<0.001). Bundle and antibiotic compliance both showed further significant increases after implementation of suggested order sets (31 /0 and 25% increases, respectively; p<0.001). The mortality rate for patients in the ED admitted with sepsis was 13.3% before implementation and fell to 11.1 /0 after (p=0.230); mortality in the last two quarters of the study was 9.3% (p=0.107). Conclusions The new protocol demonstrates that early screening interventions can lead to expedited delivery of care to patients with sepsis in the ED and could serve as a model for other facilities. Mortality was not significantly improved by our intervention, which included patients with uncomplicated sepsis. C1 [Gatewood, Medley O'Keefe] Univ Washington, Med Ctr, Div Emergency Med, Seattle, WA 98195 USA. [Wemple, Matthew] VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA USA. [Greco, Sheryl] Univ Washington, Med Ctr, Patient Care Serv, Div Crit Care, Seattle, WA 98195 USA. [Greco, Sheryl] Univ Washington, Med Ctr, Patient Care Serv, Div Cardiol, Seattle, WA 98195 USA. [Kritek, Patricia A.] Univ Washington, Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Durvasula, Raghu] Univ Washington, Med Ctr, Div Nephrol, Seattle, WA 98195 USA. RP Gatewood, MO (reprint author), Univ Washington, Med Ctr, Div Emergency Med, Seattle, WA 98195 USA. EM medley@uw.edu NR 22 TC 5 Z9 5 U1 1 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD DEC PY 2015 VL 24 IS 12 BP 787 EP 795 DI 10.1136/bmjqs-2014-003552 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CW9TI UT WOS:000365340700008 PM 26251506 ER PT J AU Hempel, S Shekelle, PG Liu, JL Danz, MS Foy, R Lim, YW Motala, A Rubenstein, LV AF Hempel, Susanne Shekelle, Paul G. Liu, Jodi L. Danz, Margie Sherwood Foy, Robbie Lim, Yee-Wei Motala, Aneesa Rubenstein, Lisa V. TI Development of the Quality Improvement Minimum Quality Criteria Set (QI-MQCS): a tool for critical appraisal of quality improvement intervention publications SO BMJ QUALITY & SAFETY LA English DT Article ID BIAS; COMMUNITY; TRIALS; RISK AB Objective Valid, reliable critical appraisal tools advance quality improvement (QI) intervention impacts by helping stakeholders identify higher quality studies. QI approaches are diverse and differ from clinical interventions. Widely used critical appraisal instruments do not take unique QI features into account and existing QI tools (eg, Standards for QI Reporting Excellence) are intended for publication guidance rather than critical appraisal. This study developed and psychometrically tested a critical appraisal instrument, the QI Minimum Quality Criteria Set (QI-MQCS) for assessing Ql-specific features of QI publications. Methods Approaches to developing the tool and ensuring validity included a literature review, in-person and online survey expert panel input, and application to empirical examples. We investigated psychometric properties in a set of diverse QI publications (N=54) by analysing reliability measures and item endorsement rates and explored sources of disagreement between reviewers. Results The QI-MQCS includes 16 content domains to evaluate QI intervention publications: Organisational Motivation, Intervention Rationale, Intervention Description, Organisational Characteristics, Implementation, Study Design, Comparator Description, Data Sources, Timing, Adherence/Fidelity, Health Outcomes, Organisational Readiness, Penetration/Reach, Sustainability, Spread and Limitations. Median inter-rater agreement for QI-MQCS items was x 0.57 (83% agreement). Item statistics indicated sufficient ability to differentiate between publications (median quality criteria met 67%). Internal consistency measures indicated coherence without excessive conceptual overlap (absolute mean interitem correlation=0.19). The critical appraisal instrument is accompanied by a user manual detailing What to consider, Where to look and How to rate. Conclusions We developed a ready-to-use, valid and reliable critical appraisal instrument applicable to healthcare QI intervention publications, but recognise scope for continuing refinement. C1 [Hempel, Susanne; Shekelle, Paul G.; Liu, Jodi L.; Danz, Margie Sherwood; Motala, Aneesa; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA 90407 USA. [Shekelle, Paul G.] Vet Affairs West Los Angeles Med Ctr, Los Angeles, CA USA. [Danz, Margie Sherwood; Rubenstein, Lisa V.] Vet Affairs Greater Los Angeles, North Hills, CA USA. [Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England. [Lim, Yee-Wei] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Hempel, S (reprint author), RAND Corp, RAND Hlth, 1776 Main St, Santa Monica, CA 90407 USA. EM susanne_hempel@rand.org FU Robert Wood Johnson (RWJ) Foundation [65113]; Veterans Affairs (VA) Greater Los Angeles Healthcare System; RAND Corporation; Agency for Healthcare Research and Quality (AHRQ) [1R13HS018139-01] FX The project was funded by a grant from the Robert Wood Johnson (RWJ) Foundation (ID 65113), the Veterans Affairs (VA) Greater Los Angeles Healthcare System, the RAND Corporation, and the Agency for Healthcare Research and Quality (AHRQ, 1R13HS018139-01). The funding agencies had no role in the study design, collection, analysis and interpretation of the data; the writing and the decision to submit the manuscript for publication. The findings and conclusions are those of the authors; the content of the manuscript should not be construed as the official position of the RWJ Foundation, the Department of Veteran Affairs, the RAND Corporation, or AHRQ. NR 36 TC 4 Z9 4 U1 1 U2 6 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD DEC PY 2015 VL 24 IS 12 BP 796 EP 804 DI 10.1136/bmjqs-2014-003151 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CW9TI UT WOS:000365340700009 PM 26311020 ER PT J AU Bishu, K Armstrong, EJ AF Bishu, Kalkidan Armstrong, Ehrin J. TI Endovascular revascularization of a surgically ligated superficial femoral artery: A case report SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE angiography; peripheral; renal; endovascular intervention; peripheral intervention ID FAILED ANTEGRADE ANGIOPLASTY; POPLITEAL APPROACH; SUPINE PATIENT; RECANALIZATION; OCCLUSION; DISEASE; ACCESS AB We present a case of a patient with left lower extremity ischemic rest pain who initially underwent surgical profundaplasty requiring ligation of his superficial femoral artery (SFA). The patient developed continued rest pain due to diffuse disease of his profunda and inadequate collaterals. Endovascular intervention was therefore performed to the oversewn SFA. Retrograde left SFA access was obtained and the origin of the SFA was recanalized with true lumen re-entry using an ultrasound guided re-entry catheter. Angioplasty was performed at the origin of the SFA and self-expanding stents were deployed in the proximal and mid left SFA. Hemostasis at the distal left SFA access site was obtained by balloon inflation at the access site and manual compression. This case illustrates the feasibility of endovascular repair of a ligated SFA. (c) 2015 Wiley Periodicals, Inc. C1 [Bishu, Kalkidan; Armstrong, Ehrin J.] Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. [Bishu, Kalkidan; Armstrong, Ehrin J.] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA. RP Armstrong, EJ (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM Ehrin.armstrong@gmail.com NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD DEC 1 PY 2015 VL 86 IS 7 BP 1236 EP 1241 DI 10.1002/ccd.26082 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CW9MS UT WOS:000365323400015 PM 26108345 ER PT J AU Hage, FG Ghimire, G Lester, D Mckay, J Bleich, S El-Hajj, S Iskandrian, AE AF Hage, Fadi G. Ghimire, Gopal Lester, Davis Mckay, Joshua Bleich, Steven El-Hajj, Stephanie Iskandrian, Ami E. TI The prognostic value of regadenoson myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Myocardial perfusion imaging; regadenoson; prognosis; quantitative analysis ID EMISSION COMPUTED-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; ADENOSINE RECEPTOR AGONIST; NUCLEAR CARDIOLOGY; DIAGNOSTIC CATHETERIZATION; HEART-DISEASE; ANGIOGRAPHY; APPROPRIATENESS; SCINTIGRAPHY; TRIAL AB Background. Regadenoson (REGA), a selective adenosine A(2A) receptor agonist, is the most widely used stress agent for SPECT myocardial perfusion imaging (MPI) in the United States. The diagnostic accuracy of REGA MPI is comparable to Adenosine MPI, but its prognostic value is not well defined. Methods. We categorized 1,400 patients (700 consecutive normal and 700 consecutive abnormal REGA-MPIs) into 4 groups based on the perfusion defect size using automated quantitative analysis: Group 1: normal perfusion; Group 2: < 10% of left ventricle; Group 3: 10%-20%; Group 4: > 20%. The primary outcome was a composite of cardiac death, myocardial infarction (MI), and late coronary revascularization (CR > 90 days after MPI). Results. Of the 1,400 patients (42% male, 37% diabetes, 21% heart failure, 26% end-stage renal disease), the primary outcome occurred in 23% (17% cardiac death, 4% MI, 6% late CR) during 46 +/- A 18 months of follow-up and 8% had early CR (within 90 days of MPI). Early CR occurred in 0.4%, 9%, 17%, and 17% and the primary outcome in 10%, 27%, 31%, and 43% in Groups 1-4, respectively (P < .001 for both). In an adjusted Cox proportional model, the hazard ratio for the primary outcome was 2.68 (1.77-4.06), 3.32 (2.28-4.83), and 4.05 (2.78-5.91) for Groups 2-4 compared to Group 1. Conclusion. REGA MPI provides powerful prognostic information that has important implications in patient management and can guide clinical practice. C1 [Hage, Fadi G.; Ghimire, Gopal; Mckay, Joshua; Bleich, Steven; Iskandrian, Ami E.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Lester, Davis] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [El-Hajj, Stephanie] Louisiana State Univ, Dept Med, Baton Rouge, LA 70803 USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU Astellas Pharma USA FX Drs Hage and Iskandrian have received research grants from Astellas Pharma USA. NR 28 TC 10 Z9 10 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD DEC PY 2015 VL 22 IS 6 BP 1214 EP 1221 DI 10.1007/s12350-014-0050-y PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CW9FD UT WOS:000365303100007 PM 25677160 ER PT J AU Almassi, GH Carr, BM Bishawi, M Shroyer, AL Quin, JA Hattler, B Wagner, TH Collins, JF Ravichandran, P Cleveland, JC Grover, FL Bakaeen, FG AF Almassi, G. Hossein Carr, Brendan M. Bishawi, Muath Shroyer, A. Laurie Quin, Jacquelyn A. Hattler, Brack Wagner, Todd H. Collins, Joseph F. Ravichandran, Pasala Cleveland, Joseph C. Grover, Frederick L. Bakaeen, Faisal G. CA Vet Affairs 517 Randomized On Off TI Resident versus attending surgeon graft patency and clinical outcomes in on- versus off-pump coronary artery bypass surgery SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE CABG; on-pump; off-pump; education; resident training; graft patency ID ON-PUMP; PERFORMANCE; ANASTOMOSIS; IMPROVEMENT; EXPERIENCE; SIMULATION; QUALITY; IMPACT; LEVEL; CABG AB Objective: Controversy exists regarding ideal approaches in teaching residents complex and/or new surgical techniques in part because consequences on patient outcomes are largely unknown. This study compared patient outcomes for cases in which residents (rather than attending surgeons) performed most of the distal anastomoses as primary surgeons, during on- and off-pump coronary artery bypass grafting (CABG). Methods: This preapproved substudy of the Randomized On/Off Bypass (ROOBY) trial compared clinical outcomes and 1-year graft patency for cases in which residents versus attending surgeons were the primary operator. Comparisons were made between on-pump and off-pump techniques. Results: From July 2003 through May 2007, a total of 1272 ROOBY nonemergent CABG patients were randomized at 16 Veterans Affairs centers where residents were active participants. Residents were the primary surgeon (ie, performed >= 50% of the distal anastomoses) more frequently in on-pump (77.9%) than in off-pump (67.4%) cases. Between these 2 techniques, no were found differences in baseline patient characteristics; short-term and 1-year morbidity and mortality rates were no different for residents versus attendings in CABG cases. FitzGibbon A graft patency rates were similar for resident versus attendings completed distal anastomoses for on-pump (83.0% vs 82.4%) compared with off-pump (77.2% vs 76.6%) procedures. Conclusions: In the ROOBY trial, short-term and 1-year patient outcomes and graft patency rates did not differ between resident and attending surgeons, demonstrating that with appropriate patient selection and resident supervision, residents can perform advanced, novel surgical techniques with outcomes similar to those of attending surgeons. C1 [Almassi, G. Hossein] Med Coll Wisconsin, Dept Cardiothorac Surg, Milwaukee, WI 53226 USA. [Almassi, G. Hossein] Vet Affairs Med Ctr, Milwaukee, WI USA. [Carr, Brendan M.; Shroyer, A. Laurie] Northport Vet Affairs Med Ctr, Dept Surg, Stony Brook, NY USA. [Carr, Brendan M.; Shroyer, A. Laurie] Stony Brook Sch Med, Stony Brook, NY USA. [Bishawi, Muath] Duke Univ, Med Ctr, Dept Cardiovasc & Thorac Surg, Durham, NC USA. [Quin, Jacquelyn A.] Vet Affairs Boston Healthcare Syst, Dept Cardiac Surg, West Roxbury, MA USA. [Hattler, Brack; Cleveland, Joseph C.; Grover, Frederick L.] Vet Affairs Eastern Colorado Hlth Care Syst, Dept Cardiol, Denver, CO USA. [Hattler, Brack; Cleveland, Joseph C.; Grover, Frederick L.] Univ Colorado, Sch Med, Aurora, CO USA. [Wagner, Todd H.] Vet Affairs Palo Alto Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Wagner, Todd H.] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Collins, Joseph F.] Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [Collins, Joseph F.] Vet Affairs Med Ctr, Perry Point, MD USA. [Ravichandran, Pasala] Portland VA Med Ctr, Dept Surg, Portland, OR USA. [Ravichandran, Pasala] Oregon Hlth & Sci Univ, Portland, OR USA. [Bakaeen, Faisal G.] Baylor Coll Med, Cardiothorac Surg, Houston, TX 77030 USA. [Bakaeen, Faisal G.] Houston Vet Affairs Med Ctr, Houston, TX USA. RP Almassi, GH (reprint author), Med Coll Wisconsin, Cardiothorac Surg, FEC, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. EM halmassi@mcw.edu RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 FU Offices of Research and Development; Zablocki VA Medical Center; Eastern Colorado Health Care System, Denver Department of Veterans Affairs Medical Center FX This ROOBY trial substudy was supported, in part, by the Offices of Research and Development staff and resources at the Northport VA Medical Center, the Zablocki VA Medical Center, and the Eastern Colorado Health Care System, Denver Department of Veterans Affairs Medical Center. Special appreciation is given to both Ms. Annette Wiseman and Ms. Xiaoli (Shirley) Lu for their extraordinary assistance at the Cooperative Studies Program Coordinating Center in Perry Point, Maryland. NR 28 TC 3 Z9 3 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD DEC PY 2015 VL 150 IS 6 BP 1428 EP + DI 10.1016/j.jtcvs.2015.08.124 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CW5MX UT WOS:000365040700022 PM 26470910 ER PT J AU Rajaram, R Ju, MH Bilimoria, KY Ko, CY DeCamp, MM AF Rajaram, Ravi Ju, Mila H. Bilimoria, Karl Y. Ko, Clifford Y. DeCamp, Malcolm M. TI National evaluation of hospital readmission after pulmonary resection SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE Patient readmission; postoperative complications; thoracic surgery; video-assisted; pulmonary surgical procedures; quality indicators; health care; pneumonectomy; Centers for Medicare and Medicaid Services; risk factors ID LENGTH-OF-STAY; SURGICAL COMPLICATIONS; RISK-FACTORS; ACS-NSQIP; SURGERY; QUALITY; RATES; PREVALENCE; LOBECTOMY; OUTCOMES AB Objectives: Our objectives were to (1) assess readmission rates and timing after pulmonary resection, (2) report the most common reasons for rehospitalization, and (3) identify risk factors for unplanned readmission after pulmonary resection. Methods: Patients who underwent pulmonary resection were identified from the 2011 American College of Surgeons National Surgical Quality Improvement Program database. We examined readmission within 30 days of surgery for all resections and 3 subgroups: open lobectomy, video-assisted thoracoscopic lobectomy, and pneumonectomy. Regression models were developed to identify factors associated with readmission. Results: In 1847 patients, there were 899 open lobectomies (49%), 724 video-assisted thoracoscopic lobectomies (39%), and 85 pneumonectomies (5%). The overall readmission rate was 9.3% with no significant difference found among patients undergoing open lobectomy (9.1%), video-assisted thoracoscopic lobectomy (8.4%), or pneumonectomy (11.8%) (P = .576). The median time from operation to readmission was similar among patients undergoing open (14 days) or video-assisted thoracoscopic lobectomy (13 days). The most common cause of readmission for all groups examined was pulmonary related. In multivariable analyses, the strongest factor associated with readmission was an inpatient complication after the initial surgery in all resections (hazard ratio [HR], 4.29; 95% confidence interval [CI], 3.05-6.04), open lobectomy (HR, 4.36; 95% CI, 2.75-6.94), and video-assisted thoracoscopic lobectomy (HR, 4.60; 95% CI, 2.65-7.97). Surgical approach was not associated with readmission (video-assisted thoracoscopic vs open lobectomy: HR, 1.07; 95% CI, 0.75-1.52). Conclusions: Experiencing a postoperative complication was strongly associated with unplanned readmission. Increased attention toward reducing postoperative complications and earlier outpatient follow-up in these patients may be a viable strategy for decreasing readmissions after pulmonary resection. C1 [Rajaram, Ravi; Ju, Mila H.; Bilimoria, Karl Y.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Rajaram, Ravi; Ju, Mila H.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, Chicago, IL 60611 USA. [Rajaram, Ravi; Ju, Mila H.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [DeCamp, Malcolm M.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Thorac Surg, Chicago, IL 60611 USA. [DeCamp, Malcolm M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. RP Rajaram, R (reprint author), Northwestern Univ, Sch Med, Dept Surg, 251 E Huron St Galter 3-150, Chicago, IL 60611 USA. EM Ravi-Rajaram@fsm.northwestern.edu FU American College of Surgeons Clinical Scholars in Residence Program; American Cancer Society; National Institutes of Health [5T32HL094293]; Merck; Agency for Healthcare Research and Quality [T32HS000078] FX This work was supported by the American College of Surgeons Clinical Scholars in Residence Program to RR and MHJ; American Cancer Society to KYB; National Institutes of Health 5T32HL094293 to MHJ; an unrestricted educational grant from Merck to RR; and the Agency for Healthcare Research and Quality T32HS000078 to RR. Funding sources did not have any input into the selection of research topic, study interpretation, or any resulting presentation or publication of the submitted work. NR 29 TC 5 Z9 5 U1 2 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD DEC PY 2015 VL 150 IS 6 BP 1508 EP U207 DI 10.1016/j.jtcvs.2015.05.047 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CW5MX UT WOS:000365040700040 PM 26092506 ER PT J AU Kilpatrick, LA Istrin, JJ Gupta, A Naliboff, BD Tillisch, K Labus, JS Mayer, EA AF Kilpatrick, Lisa A. Istrin, Joshua J. Gupta, Arpana Naliboff, Bruce D. Tillisch, Kirsten Labus, Jennifer S. Mayer, Emeran A. TI Sex commonalities and differences in the relationship between resilient personality and the intrinsic connectivity of the salience and default mode networks SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Resilience; NEO personality inventory; Resting state networks; Default mode network; Salience network; Sex differences ID POSTERIOR CINGULATE CORTEX; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; TEMPORO-PARIETAL JUNCTION; FUNCTIONAL CONNECTIVITY; INDEPENDENT COMPONENTS; COGNITIVE CONTROL; TRAIT RESILIENCE; LIFE EVENTS; HUMAN BRAIN; DSM-IV AB Increased resilience is associated with better health outcomes and reduced morbidity in response to injury and homeostatic perturbations. Proper functioning of the salience network (SN) and modulation of the default mode network (DMN) by SN may play a role in adaptively responding to stress. Here, we demonstrate that resilient personality in healthy subjects is associated with SN and DMN connectivity patterns and that these patterns are influenced by sex. While connectivity of SN with several brain regions including right anterior insula was significantly associated with resilient personality in both men and women, results suggest that increased functional integration of anterior DMN preferentially benefits women while increased functional integration of posterior DMN preferentially benefits men in terms of resilience. These findings may relate to previous demonstrations that men and women engage different information processing and behavioral strategies to achieve resilience and highlight the importance of considering sex in resilience research. (C) 2015 Elsevier B.V. All rights reserved. C1 [Kilpatrick, Lisa A.; Istrin, Joshua J.; Gupta, Arpana; Naliboff, Bruce D.; Tillisch, Kirsten; Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Oppenheimer Family Ctr Neurobiol Stress, Los Angeles, CA USA. [Kilpatrick, Lisa A.; Gupta, Arpana; Naliboff, Bruce D.; Tillisch, Kirsten; Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Naliboff, Bruce D.; Tillisch, Kirsten; Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Naliboff, Bruce D.; Tillisch, Kirsten; Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Kilpatrick, Lisa A.; Naliboff, Bruce D.; Tillisch, Kirsten; Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Pain & Interocept Network PAIN, Los Angeles, CA USA. [Tillisch, Kirsten] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Kilpatrick, LA (reprint author), Oppenheimer Family Ctr Neurobiol Stress, 10833 Le Conte Ave,CHS 42-210 MC 737818, Los Angeles, CA 90095 USA. EM lisa@lisakilpatrick.com FU NIH [DK048351, DK64539, K01 DK085133, P30 DK041301] FX Supported by NIH grants DK048351, DK64539, K01 DK085133, P30 DK041301. NR 77 TC 1 Z9 1 U1 2 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 EI 1873-6246 J9 BIOL PSYCHOL JI Biol. Psychol. PD DEC PY 2015 VL 112 BP 107 EP 115 DI 10.1016/j.biopsycho.2015.09.010 PG 9 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA CW5ON UT WOS:000365045800011 PM 26440126 ER PT J AU Rosenberg, PB Drye, LT Porsteinsson, AP Pollock, BG Devanand, DP Frangakis, C Ismail, Z Marano, C Meinert, CL Mintzer, JE Munro, CA Pelton, G Rabins, PV Schneider, LS Shade, DM Weintraub, D Newell, J Yesavage, J Lyketsos, CG AF Rosenberg, Paul B. Drye, Lea T. Porsteinsson, Anton P. Pollock, Bruce G. Devanand, D. P. Frangakis, Constantine Ismail, Zahinoor Marano, Christopher Meinert, Curtis L. Mintzer, Jacobo E. Munro, Cynthia A. Pelton, Gregory Rabins, Peter V. Schneider, Lon S. Shade, David M. Weintraub, Daniel Newell, Jeffery Yesavage, Jerome Lyketsos, Constantine G. CA CitAD Res Grp TI Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE Alzheimer's disease; agitation; randomized clinical trial; neuropsychiatric symptoms ID RANDOMIZED CLINICAL-TRIAL; NEUROPSYCHIATRIC SYMPTOMS; CACHE COUNTY; BEHAVIORAL DISTURBANCES; DRUG-TREATMENT; DOUBLE-BLIND; DEMENTIA; CITALOPRAM; RISK; DEPRESSION AB Background: Placebo responses raise significant challenges for the design of clinical trials. We report changes in agitation outcomes in the placebo arm of a recent trial of citalopram for agitation in Alzheimer's disease (CitAD). Methods: In the CitAD study, all participants and caregivers received a psychosocial intervention and 92 were assigned to placebo for nine weeks. Outcomes included Neurobehavioral Rating Scale agitation subscale (NBRS-A), modified AD Cooperative Study-Clinical Global Impression of Change (CGIC), Cohen-Mansfield Agitation Inventory (CMAI), the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (NPI A/A) and Total (NPI-Total) and ADLs. Continuous outcomes were analyzed with mixed-effects modeling and dichotomous outcomes with logistic regression. Results: Agitation outcomes improved over nine weeks: NBRS-A mean (SD) decreased from 7.8 (3.0) at baseline to 5.4 (3.2), CMAI from 28.7 (6.7) to 26.7 (7.4), NPI A/A from 8.0 (2.4) to 4.9 (3.8), and NPI-Total from 37.3 (17.7) to 28.4 (22.1). The proportion of CGI-C agitation responders ranged from 21 to 29% and was significantly different from zero. MMSE improved from 14.4 (6.9) to 15.7 (7.2) and ADLs similarly improved. Most of the improvement was observed by three weeks and was sustained through nine weeks. The major predictor of improvement in each agitation measure was a higher baseline score in that measure. Conclusions: We observed significant placebo response which may be due to regression to the mean, response to a psychosocial intervention, natural course of symptoms, or nonspecific benefits of participation in a trial. C1 [Rosenberg, Paul B.; Marano, Christopher; Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Psychiat & Behav Sci, Baltimore, MD 21224 USA. [Drye, Lea T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Alzheimers Dis Care Res & Educ Program AD CARE, Rochester, NY USA. [Pollock, Bruce G.] Univ Toronto, Campbell Inst, CAMH, Toronto, ON, Canada. [Devanand, D. P.; Pelton, Gregory] Columbia Univ, Coll Phys & Surg, Psychiat & Neurol, Div Geriatr Psychiat, New York, NY USA. [Frangakis, Constantine] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA. [Ismail, Zahinoor] Univ Calgary, Psychiat & Neurol, Hotchkiss Brain Inst, Calgary, AB, Canada. [Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Epidemiol & Biostat, Baltimore, MD USA. [Mintzer, Jacobo E.] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC USA. [Munro, Cynthia A.] Johns Hopkins Bayview, Dept Neurol, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Munro, Cynthia A.] Johns Hopkins Sch Med, Baltimore, MD USA. [Rabins, Peter V.] Johns Hopkins Univ Hosp, Johns Hopkins Sch Med, Psychiat & Behav Sci, Baltimore, MD 21287 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Psychiat Neurol & Gerontol, Los Angeles, CA 90033 USA. [Shade, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Pulm Med, Ctr Clin Trials, Baltimore, MD USA. [Shade, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Clin Trials, Dept Epidemiol, Baltimore, MD USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Parkinsons Dis Res Educ & Clin Ctr PADRECC,MIRECC, Philadelphia Vet Affairs Med Ctr,Psychiat & Neuro, Philadelphia, PA 19104 USA. [Pollock, Bruce G.] Univ Toronto, Campbell Family Mental Hlth Res Inst, Div Geriatr Psychiat, Ctr Addict & Mental Hlth,Fac Med, Toronto, ON, Canada. [Ismail, Zahinoor] Univ Toronto, Psychiat, Toronto, ON, Canada. [Mintzer, Jacobo E.] Med Univ S Carolina, Dept Hlth Studies, Charleston, SC 29425 USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Newell, Jeffery] Univ So Calif, Clin Sci, Culture & Mental Hlth Lab, Los Angeles, CA USA. [Yesavage, Jerome] VA Palo Alto Hlth Care Syst, Aging Clin Res Ctr, Director Mental Illness Res Educ & Clin Ctr, Richmond, VA USA. [Yesavage, Jerome] Stanford Univ, Sch Med, Psychiat & Behav Sci, Palo Alto, CA 94304 USA. RP Rosenberg, PB (reprint author), Johns Hopkins Bayview Med Ctr, Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Psychiat & Behav Sci, 5300 Alpha Commons Dr 429, Baltimore, MD 21224 USA. EM prosenb9@jhmi.edu FU NIA; NIMH [R01AG031348]; NIH [P50, AG05142] FX Funding/Support: This work was supported by NIA and NIMH, R01AG031348 and in part by NIH P50, AG05142 (USC, LSS). NR 38 TC 2 Z9 3 U1 4 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD DEC PY 2015 VL 27 IS 12 BP 2059 EP 2067 DI 10.1017/S1041610215001106 PG 9 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CW4CH UT WOS:000364938400015 PM 26305876 ER PT J AU Zhou, XY Liu, Z Shapiro, L Yang, J Burton, GF AF Zhou, Xueyuan Liu, Zhu Shapiro, Leland Yang, Jun Burton, Gregory F. TI Low-density lipoprotein receptor-related protein 1 mediates alpha 1-antitrypsin internalization in CD4(+) T lymphocytes SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE clathrin-dependent endocytosis; endosome; lysosome; HIV-1; NF-kappa B; I kappa B alpha ID CLATHRIN-INDEPENDENT ENDOCYTOSIS; IMMUNODEFICIENCY-VIRUS TYPE-1; RAT PERITONEAL-MACROPHAGES; LYSOSOMAL PERMEABILIZATION; HIV-INFECTION; SEC RECEPTOR; COMPLEXES; EXPRESSION; APOPTOSIS; PATHWAYS AB In alpha 1-antitrypsin-deficient HIV patients, an accelerated decline of CD4(+) T cell numbers is observed, suggesting that alpha 1-antitrypsin is a potential endogenous HIV inhibitor. In infected T lymphocytes, alpha 1-antitrypsin potently blocks NF-kappa B activation and HIV-1 replication by directly interacting with I kappa B alpha in the cytosol, thereby altering its ubiquitination pattern. However, the mechanism of alpha 1-antitrypsin entry into the cytosol, where I kappa B alpha locates, remains unclear. In the present study, we investigated the mechanism of alpha 1-antitrypsin internalization in CD4(+) T cells. Thus, primary CD4(+) T cells were infected with HIV-1 and then incubated with alpha 1-antitrypsin to detect its internalization. We found that CD4(+) T cells internalized alpha 1-antitrypsin through a clathrin-dependent endocytosis process. Next, intracellular a1-antitrypsin exerted the inhibitory effect on NF-kappa B activation and HIV-1 replication. On primary CD4(+) T cells, alpha 1-antitrypsin interacted with low-density lipoprotein receptor-related protein 1 to initiate the internalization. Inside CD4(+) T lymphocytes, alpha 1-antitrypsin was transported from the endosome to the lysosome and then released into the cytosol, where it is possible for alpha 1-antitrypsin to directly interact with I kappa B alpha. These results together suggest that alpha 1-antitrypsin internalization is a clathrin-dependent and low-density lipoprotein receptor-related protein 1-mediated endocytosis process. Internalized alpha 1-antitrypsin is transported through the endosome-lysosome-cytosol routine to interact with cytosolic IkB alpha and block NF-kappa B activation and HIV-1 replication. C1 [Zhou, Xueyuan; Yang, Jun] Leidos Biomed Res Inc, Clin Serv Program, Frederick, MD 21702 USA. [Zhou, Xueyuan; Burton, Gregory F.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA. [Liu, Zhu] Hainan Univ, Coll Agr, Hainan Key Lab Sustainable Utilizat Trop Bioresou, Haikou, Hainan, Peoples R China. [Shapiro, Leland] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. [Shapiro, Leland] Univ Colorado, Dept Med, Div Infect Dis, Denver, CO USA. RP Zhou, XY (reprint author), Leidos Biomed Res Inc, Clin Serv Program, Frederick, MD 21702 USA. EM xueyuan.zhou@nih.gov; zhuliu@hainu.edu.cn FU U.S. Public Health Service Grant from U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Disease [AI91517]; Brigham Young University grant from the College of Physical and Mathematical Sciences; International Science and Technology Cooperation Project of China [2015DFR31060]; Science and Technology Program of Hainan Province [KJHZ2015-24, ZDZX2013023]; central government finance support for enhancing the comprehensive strengths of universities in Midwest China; NIH National Cancer Institute (NCI) [HHSN261200800001E] FX This work was partially supported by U.S. Public Health Service Grant AI91517 from the U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Disease (to G.F.B.) and by a Brigham Young University grant from the College of Physical and Mathematical Sciences (to G.F.B.). This work was also partially supported by International Science and Technology Cooperation Project of China Grant 2015DFR31060 (to Z.L.); the Science and Technology Program of Hainan Province Grants KJHZ2015-24 and ZDZX2013023 (to Z.L.); and the central government finance support for enhancing the comprehensive strengths of universities in Midwest China. The work was also partially supported by the NIH National Cancer Institute (NCI) Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the reviews or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. Funding for open access was provided by NIH NCI Contract No. HHSN261200800001E. The authors thank Drs. Karen J. Merrell, John T. Prince, Richard A. Lempicki, Tomozumi Imamichi, and Ryan Taylor for their technical advice and help. NR 38 TC 2 Z9 2 U1 4 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD DEC PY 2015 VL 98 IS 6 BP 1027 EP 1035 DI 10.1189/jlb.2A0515-209R PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA CW3SL UT WOS:000364912000018 PM 26206901 ER PT J AU Bai, XY Dinarello, CA Chan, ED AF Bai, Xiyuan Dinarello, Charles A. Chan, Edward D. TI The role of interleukin-32 against tuberculosis SO CYTOKINE LA English DT Article DE Interleukin-32; Tuberculosis; Cytokine ID MYCOBACTERIUM-TUBERCULOSIS; PROINFLAMMATORY CYTOKINE; IL-32 EXPRESSION; DISEASE; CELLS; MICE AB IL-32 is increasingly recognized to be an important host-protective molecule against tuberculosis. In this commentary, we highlight some of the potential mechanisms by which the immunomodulatory effect of IL-32 occurs against mycobacterial infections but also areas where mechanistic clarifications are needed. Published by Elsevier Ltd. C1 [Bai, Xiyuan; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO 80206 USA. [Bai, Xiyuan; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Bai, Xiyuan; Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Denver, CO 80206 USA. [Bai, Xiyuan; Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Dinarello, Charles A.] Univ Colorado, Div Infect Dis, Aurora, CO 80045 USA. RP Chan, ED (reprint author), Natl Jewish Hlth, Dept Med, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org FU Department of Veterans Affairs Veterans Health Administration, Office of Research and Development [1 I01 BX001028-01A2]; NIH [AI15614] FX Study funded by Department of Veterans Affairs Veterans Health Administration, Office of Research and Development 1 I01 BX001028-01A2 (EDC) and NIH AI15614 (CAD). NR 20 TC 0 Z9 0 U1 1 U2 3 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 EI 1096-0023 J9 CYTOKINE JI Cytokine PD DEC PY 2015 VL 76 IS 2 BP 585 EP 587 DI 10.1016/j.cyto.2015.06.013 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA CV4NS UT WOS:000364244400066 PM 26144292 ER PT J AU Bancks, MP Pletcher, MJ Kertesz, SG Sidney, S Rana, JS Schreiner, PJ AF Bancks, Michael P. Pletcher, Mark J. Kertesz, Stefan G. Sidney, Stephen Rana, Jamal S. Schreiner, Pamela J. TI Marijuana use and risk of prediabetes and diabetes by middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study SO DIABETOLOGIA LA English DT Article DE Diabetes; Incidence; Longitudinal; Marijuana use; Prediabetes ID DIETARY PATTERNS; CANNABIS SMOKING; TRENDS AB Aims/hypothesis The impact of marijuana use on metabolic health is largely unknown. This study sought to clarify the cross-sectional and longitudinal associations between self-reported marijuana use, and prediabetes (defined as fasting glucose 5.6-6.9 mmol/l, 2 h glucose post OGTT 7.8-11.0 mmol/l or HbA(1c) 5.7-6.4% [39-47 mmol/mol]) and diabetes. Methods Data from the community-based Coronary Artery Risk Development in Young Adults (CARDIA) study were used to determine marijuana use and the presence of prediabetes and diabetes among participants. The association between marijuana use and the prevalence of prediabetes and diabetes was examined in 3,034 participants at CARDIA examination year 25 (2010-2011), while the incidence of prediabetes and diabetes according to previous marijuana use was assessed in 3,151 individuals who were free from prediabetes/diabetes at year 7 (1992-1993) and who returned for at least one of the four subsequent follow-up examinations over 18 years. Results The percentage of individuals who self-reported current use of marijuana declined over the course of the study's follow-up. After multivariable adjustment, higher odds of prediabetes were found for individuals who reported current use of marijuana (OR 1.65 [95% CI 1.15, 2.38]) and a lifetime use of 100 times or more (OR 1.49 [95% CI 1.06, 2.11]), compared with individuals who reported never using marijuana. There was no association between marijuana use and diabetes at CARDIA examination year 25. Over 18 years of follow-up, a greater risk of prediabetes (but not diabetes) was found for individuals who reported a lifetime use of marijuana of 100 times or more (HR 1.39 [95% CI 1.13, 1.71]), compared with individuals who had never used marijuana. Conclusions/interpretation Marijuana use in young adulthood is associated with an increased risk of prediabetes by middle adulthood, but not with the development of diabetes by this age. C1 [Bancks, Michael P.; Schreiner, Pamela J.] Univ Minnesota, Sch Publ Hlth, Dept Epidemiol & Community Hlth, Minneapolis, MN 55454 USA. [Pletcher, Mark J.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Pletcher, Mark J.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Sidney, Stephen; Rana, Jamal S.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. [Rana, Jamal S.] Kaiser Permanente No Calif, Dept Cardiol, Oakland, CA USA. [Rana, Jamal S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Bancks, MP (reprint author), Univ Minnesota, Sch Publ Hlth, Dept Epidemiol & Community Hlth, 1300 South Second St,Suite 300, Minneapolis, MN 55454 USA. EM banck005@umn.edu FU National Institutes of Health (NIH) [T32HL007779]; National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA; NHLBI [AG0005] FX MPB was supported by the National Institutes of Health (NIH) Training Grant T32HL007779 to conduct the current work. The CARDIA study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), the University of Minnesota (HHSN268201300028C), the Kaiser Foundation Research Institute (HHSN268201300029C) and Johns Hopkins University School of Medicine (HHSN268200900041C). The CARDIA study is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between the NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for scientific content. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 26 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD DEC PY 2015 VL 58 IS 12 BP 2736 EP 2744 DI 10.1007/s00125-015-3740-3 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CV4FC UT WOS:000364221200007 PM 26364621 ER PT J AU Vickers, Z Damodhar, H Grummer, C Mendenhall, H Banaszynski, K Hartel, R Hind, J Joyce, A Kaufman, A Robbins, J AF Vickers, Z. Damodhar, H. Grummer, C. Mendenhall, H. Banaszynski, K. Hartel, R. Hind, J. Joyce, A. Kaufman, A. Robbins, J. TI Relationships Among Rheological, Sensory Texture, and Swallowing Pressure Measurements of Hydrocolloid-Thickened Fluids SO DYSPHAGIA LA English DT Article DE Fluid rheology; Swallowing pressure; Thickness; Mouthcoating; Sensory evaluation; Flow behavior ID COMMERCIAL THICKENERS; DYSPHAGIA DIETS; VISCOSITY; FOOD; BEVERAGES; ACCEPTANCE; PERCEPTION; AGENTS; VOLUME; FORCE AB The objective of this study was to examine the relationships among three categories of measurements (rheological, sensory texture, and swallowing pressure) from fluids thickened to two different viscosities with 15 different hydrocolloids. Fluids at viscosities of 300 and 1500 cP (at 30 s(-1)) were targeted because these are the viscosities corresponding to the barium standards used in radiographic dysphagia diagnosis. Within the low viscosity (nectar) fluids (300 cP), the sensory properties thickness, stickiness, adhesiveness, mouth coating, and number of swallows were highly positively correlated with each other and highly positively correlated with the flow behavior index, n value (an indicator of shear-thinning behavior). Within the higher viscosity (thin honey) fluids (1500 cP), the sensory textures of adhesiveness, stickiness, mouth coating, and number of swallows correlated positively with rheological measures of n value. Swallowing pressures measured in the anterior oral cavity correlated negatively with the consistency coefficient k [shear stress/(shear rate) (n) ]. Samples that were more shear thinning (lower n values, higher k values) were generally perceived as less thick, with less adhesive properties (stickiness, adhesiveness, mouthcoating, and number of swallows). This information can be useful for selecting thickeners for people with dysphagia. A desirable thickener for many dysphagic patients would be one that allowed for a safe swallow by being viscous enough to reduce airway penetration, yet pleasant to drink, having the minimal perceived thickness and mouthcoating associated with greater shear thinning. C1 [Vickers, Z.; Damodhar, H.] Univ Minnesota, Dept Food Sci & Nutr, St Paul, MN 55112 USA. [Grummer, C.; Mendenhall, H.; Banaszynski, K.; Hartel, R.] Univ Wisconsin, Dept Food Sci, Madison, WI 53706 USA. [Hind, J.; Joyce, A.; Kaufman, A.; Robbins, J.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Hind, J.; Joyce, A.; Kaufman, A.; Robbins, J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53706 USA. RP Vickers, Z (reprint author), Univ Minnesota, Dept Food Sci & Nutr, 1334 Eckles Ave, St Paul, MN 55112 USA. EM zvickers@umn.edu OI Vickers, Zata/0000-0002-4509-7956 FU National Research Initiative Grant from the USDA Cooperative state Research, Education and Extension Service [12143]; Wm. S. Middleton Memorial Veterans Hospital Geriatric Research, Education and Clinical Center (GRECC); Minnesota Agricultural Experiment Station FX This project was supported by National Research Initiative Grant 12143 from the USDA Cooperative state Research, Education and Extension Service, and the Wm. S. Middleton Memorial Veterans Hospital Geriatric Research, Education and Clinical Center (GRECC). This manuscript was partially prepared at the William S. Middleton Veteran Affairs Hospital in Madison, WI; GRECC manuscript #2015-015. The views and content expressed in this article are solely the responsibility of the authors and do not necessarily reflect the position, policy, or official views of the Department of Veteran Affairs or the U.S. government. This research was partly supported by the Minnesota Agricultural Experiment Station. NR 45 TC 4 Z9 4 U1 13 U2 39 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD DEC PY 2015 VL 30 IS 6 BP 702 EP 713 DI 10.1007/s00455-015-9647-9 PG 12 WC Otorhinolaryngology SC Otorhinolaryngology GA CV8FE UT WOS:000364515500006 PM 26289079 ER PT J AU Minzenberg, MJ Lesh, TA Niendam, TA Yoon, JH Cheng, YA Rhoades, RN Carter, CS AF Minzenberg, Michael J. Lesh, Tyler A. Niendam, Tara A. Yoon, Jong H. Cheng, Yaoan Rhoades, Remy N. Carter, Cameron S. TI Control-related frontal-striatal function is associated with past suicidal ideation and behaviior in patients with recent-onset psychotic major mood disorders SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar I disorder; Major depressive disorder; Psychosis; Suicide risk; Cognitive control; Frontal cortex ID PREFRONTAL CORTEX; COGNITIVE CONTROL; DEPRESSIVE DISORDER; BIPOLAR DISORDER; NEURAL CIRCUITRY; DECISION-MAKING; WORST-POINT; RISK; BRAIN; ADOLESCENTS AB Objective: Suicide is highly-prevalent in major mood disorders, yet it remains unclear how suicidal ideation and suicidal behavior relate to brain functions, especially those that support control processes. We evaluated how prefrontal cortex (PFC) activity during goal-representation (an important component of cognitive control) relates to past suicidal ideation and behavior in patients with psychotic major mood disorders. Method: 30 patients with recent-onset of either DSM-IV-TR-defined bipolar disorder type I (n=21) or major depressive disorder (n=9) with psychotic features, but neither in a major mood episode nor acutely psychotic at study, were evaluated for past suicidal ideation and behavior (Columbia Suicide Severity Rating Scale) and functional MRI during cognitive control task performance. Group-level regression models of brain activation accounted for current depression, psychosis and trait impulsivity. Results: Intensity of past suicidal ideation was associated with higher control-related activation in right-hemisphere regions including the ventrolateral PFC (VLPFC) and orbitofrontal cortex, rostral insula, and dorsal striatum. Among those with past suicidal ideation (n=16), past suicidal behavior (n=8) was associated with higher control-related activation in right-hemisphere regions including VLPFC, rostrolateral PFC, and frontal operculum/rostral insula: and relatively lower activity in midline parietal regions, including cuneus and precuneus. Limitations: The sample size of subjects with past suicidal behavior was modest, and all subjects were taking psychotropic medication. Conclusions: This study provides unique evidence that in early-course psychotic major mood disorders, suicidal ideation and behavior histories directly relate to PFC-based circuit function in support of cognitive control. Published by Elsevier B.V. C1 [Minzenberg, Michael J.; Cheng, Yaoan] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Minzenberg, Michael J.; Cheng, Yaoan] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Lesh, Tyler A.; Niendam, Tara A.; Carter, Cameron S.] Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA. [Carter, Cameron S.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA. [Yoon, Jong H.; Rhoades, Remy N.] Stanford Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA USA. [Yoon, Jong H.; Rhoades, Remy N.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Minzenberg, MJ (reprint author), San Francisco VA Med Ctr, Outpatient Mental Hlth, 116C,4150 Clement St, San Francisco, CA 94121 USA. EM Michael.minzenberg@ucsf.edu NR 58 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD DEC 1 PY 2015 VL 188 BP 202 EP 209 DI 10.1016/j.jad.2015.08.049 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CV3OI UT WOS:000364168100028 PM 26363618 ER PT J AU Hall, DE Hanusa, BH Ling, BS Stone, RA Switzer, GE Fine, MJ Arnold, RM AF Hall, Daniel E. Hanusa, Barbara H. Ling, Bruce S. Stone, Roslyn A. Switzer, Galen E. Fine, Michael J. Arnold, Robert M. TI Using the IRB Researcher Assessment Tool to Guide Quality Improvement SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS LA English DT Article DE research ethics committee; Institutional Review Board; quality improvement; engineering AB Institutional Review Boards (IRBs) are intended to protect those who participate in research. However, because there is no established measure of IRB quality, it is unclear whether these committees achieve their goal. The IRB Researcher Assessment Tool is a previously validated, internally normed, proxy measure of IRB quality that assesses 45 distinct IRB activities and functions. We administered this instrument to a sample of investigators and IRB members at a large urban VA Medical Center. We describe a systematic approach to analyze and interpret survey responses that can identify the IRB activities and functions most in need of quality improvement. The proposed approach to empirical data analysis and presentation could inform local initiatives to improve the quality of IRB review. C1 [Hall, Daniel E.; Hanusa, Barbara H.; Ling, Bruce S.; Stone, Roslyn A.; Switzer, Galen E.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Hanusa, Barbara H.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Hall, Daniel E.] Univ Pittsburgh, Surg, Pittsburgh, PA 15260 USA. [Ling, Bruce S.; Fine, Michael J.; Arnold, Robert M.] Univ Pittsburgh, Med, Pittsburgh, PA 15260 USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Biostat, Pittsburgh, PA 15260 USA. [Switzer, Galen E.] Univ Pittsburgh, Med & Psychiat, Pittsburgh, PA 15260 USA. RP Hall, DE (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. EM hallde@upmc.edu OI Hall, Daniel/0000-0001-6382-0522 FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CDA 08-281, SDR 11-399-1] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (CDA 08-281 and SDR 11-399-1). NR 9 TC 0 Z9 0 U1 3 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1556-2646 EI 1556-2654 J9 J EMPIR RES HUM RES JI J. Empir. Res. Hum. Res. Ethics PD DEC PY 2015 VL 10 IS 5 BP 460 EP 469 DI 10.1177/1556264615612195 PG 10 WC Ethics; Medical Ethics SC Social Sciences - Other Topics; Medical Ethics GA CW3EK UT WOS:000364874600005 PM 26527369 ER PT J AU Bishu, KG Gebregziabher, M Dismuke, CE Egede, LE AF Bishu, Kinfe G. Gebregziabher, Mulugeta Dismuke, Clara E. Egede, Leonard E. TI Quantifying the Incremental and Aggregate Cost of Missed Workdays in Adults with Diabetes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE diabetes; cost; work absenteeism ID UNITED-STATES; PRODUCTIVITY; ABSENTEEISM; US; AGREEMENT; WORKFORCE; EMPLOYEES; WORKERS; ABSENCE; BURDEN AB Although the national cost of missed workdays associated with diabetes has been estimated previously, we use the most recent available national data and methodology to update the individual and national estimates for the U.S population. We identified 14,429 employed individuals a parts per thousand yen 18 years of age in 2011 Medical Expenditure Panel Survey (MEPS) data. Diabetes and missed workdays were based on self-report, and cost was based on multiplying the daily wage rate for each individual by the number of missed days. Adjusted total national burden of missed workdays associated with diabetes was calculated using a novel two-part model to simultaneously estimate the association of diabetes with the number and cost of missed workdays. The unadjusted annual mean 2011 cost of missed workdays was $277 (95 % CI 177.0-378.0) for individuals with diabetes relative to $160 (95 % CI $130-$189) for those without. The incremental cost of missed workdays associated with diabetes was $120 (95 % CI $30.7-$209.1). Based on the US population in 2011, the unadjusted national burden of missed workdays associated with diabetes was estimated to be $2.7 billion, while the fully adjusted incremental national burden was estimated to be $1.1 billion. We provide more precise estimates of the cost burden of diabetes due to missed workdays on the U.S population. The high incremental and total cost burden of missed workdays among Americans with diabetes suggests the need for interventions to improve diabetes care management among employed individuals. C1 [Gebregziabher, Mulugeta; Dismuke, Clara E.; Egede, Leonard E.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Hlth Equity & Rural Outreach Innovat Ctr, Charleston, SC 29403 USA. [Bishu, Kinfe G.; Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX 1. This study was supported by Grant K24DK093699-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 29 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2015 VL 30 IS 12 BP 1773 EP 1779 DI 10.1007/s11606-015-3338-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CV8VQ UT WOS:000364566600013 PM 25986134 ER PT J AU Leykum, LK Chesser, H Lanham, HJ Carla, P Palmer, R Ratcliffe, T Reisinger, H Agar, M Pugh, J AF Leykum, Luci K. Chesser, Hannah Lanham, Holly J. Carla, Pezzia Palmer, Ray Ratcliffe, Temple Reisinger, Heather Agar, Michael Pugh, Jacqueline TI The Association Between Sensemaking During Physician Team Rounds and Hospitalized Patients' Outcomes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE complexity science; sensemaking; length of stay; complication rates; inpatient teams ID HIGH-RELIABILITY; CARE; ORGANIZATIONS; QUALITY AB Sensemaking is the social act of assigning meaning to ambiguous events. It is recognized as a means to achieve high reliability. We sought to assess sensemaking in daily patient care through examining how inpatient teams round and discuss patients. Our purpose was to assess the association between inpatient physician team sensemaking and hospitalized patients' outcomes, including length of stay (LOS), unnecessary length of stay (ULOS), and complication rates. Eleven inpatient medicine teams' daily rounds were observed for 2 to 4 weeks. Rounds were audiotaped, and field notes taken. Four patient discussions per team were assessed using a standardized Situation, Task, Intent, Concern, Calibrate (STICC) framework. Inpatient physician teams at the teaching hospitals affiliated with the University of Texas Health Science Center at San Antonio participated in the study. Outcomes of patients admitted to the teams were included. Sensemaking was assessed based on the order in which patients were seen, purposeful rounding, patient-driven rounding, and individual patient discussions. We assigned teams a score based on the number of STICC elements used in the four patient discussions sampled. The association between sensemaking and outcomes was assessed using Kruskal-Wallis sum rank and Dunn's tests. Teams rounded in several different ways. Five teams rounded purposefully, and four based rounds on patient-driven needs. Purposeful and patient-driven rounds were significantly associated with lower complication rates. Varying the order in which patients were seen and purposefully rounding were significantly associated with lower LOS, and purposeful and patient-driven rounds associated with lower ULOS. Use of a greater number of STICC elements was associated with significantly lower LOS (4.6 vs. 5.7, p = 0.01), ULOS (0.3 vs. 0.6, p = 0.02), and complications (0.2 vs. 0.5, p = 0.0001). Improving sensemaking may be a strategy for improving patient outcomes, fostering a shared understanding of a patient's clinical trajectory, and enabling high reliability. C1 [Leykum, Luci K.; Lanham, Holly J.; Ratcliffe, Temple; Pugh, Jacqueline] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Leykum, Luci K.; Lanham, Holly J.; Carla, Pezzia; Ratcliffe, Temple; Pugh, Jacqueline] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Leykum, Luci K.; Lanham, Holly J.] Univ Texas Austin, McCombs Sch Business, San Antonio, TX USA. [Chesser, Hannah] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Carla, Pezzia] Univ Dallas, Dallas, TX USA. [Palmer, Ray] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Reisinger, Heather] Iowa City VA Hlth Care Syst, Iowa City, IA USA. [Agar, Michael] Ethknoworks LLC, Santa Fe, NM USA. RP Leykum, LK (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter, San Antonio, TX 78229 USA. EM Leykum@uthscsa.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [CDA 07-022]; South Texas Veterans Health Care System FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CDA 07-022). Investigator salary support is provided through this funding, and through the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 28 TC 0 Z9 0 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2015 VL 30 IS 12 BP 1821 EP 1827 DI 10.1007/s11606-015-3377-4 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CV8VQ UT WOS:000364566600019 PM 26014891 ER PT J AU Jones, AL Cochran, SD Leibowitz, A Wells, KB Kominski, G Mays, VM AF Jones, Audrey L. Cochran, Susan D. Leibowitz, Arleen Wells, Kenneth B. Kominski, Gerald Mays, Vickie M. TI Usual Primary Care Provider Characteristics of a Patient-Centered Medical Home and Mental Health Service Use SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient-centered medical home; primary care; mental health services; Affordable Care Act; race ID COMORBIDITY SURVEY REPLICATION; NATIONAL COMORBIDITY; PSYCHOLOGICAL DISTRESS; MAJOR DEPRESSION; UNITED-STATES; DISORDERS; EXPENDITURES; POPULATION; OUTCOMES; ILLNESS AB The benefits of the patient-centered medical home (PCMH) over and above that of a usual source of medical care have yet to be determined, particularly for adults with mental health disorders. To examine qualities of a usual provider that align with PCMH goals of access, comprehensiveness, and patient-centered care, and to determine whether PCMH qualities in a usual provider are associated with the use of mental health services (MHS). Using national data from the Medical Expenditure Panel Survey, we conducted a lagged cross-sectional study of MHS use subsequent to participant reports of psychological distress and usual provider and practice characteristics. A total of 2,358 adults, aged 18-64 years, met the criteria for serious psychological distress and reported on their usual provider and practice characteristics. We defined "usual provider" as a primary care provider/practice, and "PCMH provider" as a usual provider that delivered accessible, comprehensive, patient-centered care as determined by patient self-reporting. The dependent variable, MHS, included self-reported mental health visits to a primary care provider or mental health specialist, counseling, and psychiatric medication treatment over a period of 1 year. Participants with a usual provider were significantly more likely than those with no usual provider to have experienced a primary care mental health visit (marginal effect [ME] = 8.5, 95 % CI = 3.2-13.8) and to have received psychiatric medication (ME = 15.5, 95 % CI = 9.4-21.5). Participants with a PCMH were additionally more likely than those with no usual provider to visit a mental health specialist (ME = 7.6, 95 % CI = 0.7-14.4) and receive mental health counseling (ME = 8.5, 95 % CI = 1.5-15.6). Among those who reported having had any type of mental health visit, participants with a PCMH were more likely to have received mental health counseling than those with only a usual provider (ME = 10.0, 95 % CI = 1.0-19.0). Access to a usual provider is associated with increased receipt of needed MHS. Patients who have a usual provider with PCMH qualities are more likely to receive mental health counseling. C1 [Jones, Audrey L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Cochran, Susan D.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Cochran, Susan D.] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA USA. [Cochran, Susan D.; Mays, Vickie M.] Univ Calif Los Angeles, Ctr Bridging Res Innovat, Training & Educ Minor Hlth Dispar Solut, Los Angeles, CA USA. [Leibowitz, Arleen] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA USA. [Wells, Kenneth B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wells, Kenneth B.] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Los Angeles, CA USA. [Wells, Kenneth B.; Kominski, Gerald; Mays, Vickie M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Kominski, Gerald] Univ Calif Los Angeles, Ctr Hlth Policy Res, Los Angeles, CA USA. [Mays, Vickie M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Jones, AL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. EM Audrey.Jones3@va.gov OI Kominski, Gerald/0000-0001-5214-7133 FU Agency for Healthcare Research and Quality [1R36HS021721]; National Institutes of Health National Institute on Minority Health and Health Disparities [MD006923]; National Institute of Drug Abuse [DA20826] FX This research was supported by funding from the Agency for Healthcare Research and Quality (1R36HS021721) and from the National Institutes of Health National Institute on Minority Health and Health Disparities (MD006923) and National Institute of Drug Abuse (DA20826). Dr. Jones is supported as a VA Office of Academic Affiliations Associated Health Professions Post-Doctoral Fellow in Health Services Research at the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 70 TC 5 Z9 5 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2015 VL 30 IS 12 BP 1828 EP 1836 DI 10.1007/s11606-015-3417-0 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CV8VQ UT WOS:000364566600020 PM 26037232 ER PT J AU Moreira, DM Howard, LE Sourbeer, KN Amarasekara, HS Chow, LC Cockrell, DC Hanyok, BT Pratson, CL Aronson, WJ Kane, CJ Terris, MK Amling, CL Cooperberg, MR Liede, A Freedland, SJ AF Moreira, D. M. Howard, L. E. Sourbeer, K. N. Amarasekara, H. S. Chow, L. C. Cockrell, D. C. Hanyok, B. T. Pratson, C. L. Aronson, W. J. Kane, C. J. Terris, M. K. Amling, C. L. Cooperberg, M. R. Liede, A. Freedland, S. J. TI Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article ID ANTIGEN DOUBLING TIME; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; SEARCH DATABASE; METASTATIC-DISEASE; SIPULEUCEL-T; NAIVE MEN; PHASE-II; THERAPY; FAILURE AB BACKGROUND: To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. METHODS: Retrospective analysis of 531 bone scans of 312 clinically CRPC patients with no known metastases at baseline treated with a variety of primary treatment types in the SEARCH database. The association of patients' demographics, pathological features, PSA levels and kinetics with risk of a positive scan was tested using generalized estimating equations. RESULTS: A total of 149 (28%) scans were positive. Positive scans were associated with younger age (odds ratio (OR) = 0.98; P = 0.014), higher Gleason scores (relative to Gleason 2-6, Gleason 3+4: OR = 2.03, P = 0.035; Gleason 4+3 and 8-10: OR = 1.76, P = 0.059), higher prescan PSA (OR = 2.11; P<0.001), shorter prescan PSA doubling time (PSADT; OR = 0.53; P < 0.001), higher PSA velocity (OR = 1.74; P<0.001) and more remote scan year (OR = 0.92; P = 0.004). Scan positivity was 6, 14, 29 and 57% for men with PSA < 5, 5-14.9, 15-49.9 and >= 50 ng ml(-1), respectively (P-trend < 0.001). Men with PSADT >= 15, 9-14.9, 3-8.9 and < 3 months had a scan positivity of 11, 22, 34 and 47%, correspondingly (P-trend < 0.001). Tables were constructed using PSA and PSADT to predict the likelihood of a positive bone scan. CONCLUSIONS: PSA levels and kinetics were associated with positive bone scans. We developed tables to predict the risk of positive bone scans by PSA and PSADT. Combining PSA levels and kinetics may help select patients with CRPC for bone scans. C1 [Moreira, D. M.] Mayo Clin, Dept Urol, Rochester, MN 55905 USA. [Howard, L. E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA. [Howard, L. E.; Sourbeer, K. N.; Amarasekara, H. S.; Chow, L. C.; Cockrell, D. C.; Hanyok, B. T.; Pratson, C. L.; Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Howard, L. E.; Sourbeer, K. N.; Amarasekara, H. S.; Chow, L. C.; Cockrell, D. C.; Hanyok, B. T.; Pratson, C. L.; Freedland, S. J.] Duke Univ, Sch Med, Dept Surg, Div Urol, Durham, NC USA. [Howard, L. E.; Sourbeer, K. N.; Amarasekara, H. S.; Chow, L. C.; Cockrell, D. C.; Hanyok, B. T.; Pratson, C. L.; Freedland, S. J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC USA. [Aronson, W. J.] W Los Angeles Vet Affairs Med Ctr, Dept Surg, Urol Sect, Los Angeles, CA 90073 USA. [Aronson, W. J.] Univ Calif Los Angeles, Med Ctr, Dept Urol, Los Angeles, CA 90024 USA. [Kane, C. J.] Univ Calif San Diego, Med Ctr, Dept Surg, Div Urol, San Diego, CA 92103 USA. [Terris, M. K.] Vet Affairs Med Ctr, Div Surg, Urol Sect, Augusta, GA USA. [Terris, M. K.] Med Coll Georgia, Dept Surg, Div Urol Surg, Augusta, GA 30912 USA. [Amling, C. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR 97201 USA. [Cooperberg, M. R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. [Cooperberg, M. R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cooperberg, M. R.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA. [Liede, A.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA. [Freedland, S. J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA. RP Moreira, DM (reprint author), Mayo Clin, Dept Urol, 200 First St SW, Rochester, MN 55905 USA. EM Moreira.Daniel@mayo.edu OI Hanyok, Brian/0000-0003-1079-8821; Terris, Martha/0000-0002-3843-7270 FU Department of Veterans Affairs, National Institutes of Health [R01CA100938]; NIH Specialized Programs of Research Excellence [P50 CA92131-01A1]; Georgia Cancer Coalition; NIH [K24 CA160653]; Amgen FX This study was funded by the Department of Veterans Affairs, National Institutes of Health grant R01CA100938 (WJA), NIH Specialized Programs of Research Excellence grant P50 CA92131-01A1 (WJA), the Georgia Cancer Coalition (MKT), NIH K24 CA160653 (SJF) and Amgen. NR 22 TC 7 Z9 7 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 EI 1476-5608 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD DEC PY 2015 VL 18 IS 4 BP 333 EP 337 DI 10.1038/pcan.2015.25 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA CW2XY UT WOS:000364857600006 PM 26171882 ER PT J AU Ahluwalia, SC Bekelman, DB Huynh, AK Prendergast, TJ Shreve, S Lorenz, KA AF Ahluwalia, Sangeeta C. Bekelman, David B. Huynh, Alexis K. Prendergast, Thomas J. Shreve, Scott Lorenz, Karl A. TI Barriers and Strategies to an Iterative Model of Advance Care Planning Communication SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE advance care planning; goals of care; patient preference; electronic health record; continuity of care; primary health care ID END-OF-LIFE; HEALTH INFORMATION EXCHANGE; VETERANS-AFFAIRS; DECISION-MAKING; INTENSIVE COMMUNICATION; CLINICAL REMINDERS; PALLIATIVE CARE; NATIONAL-SURVEY; NEAR-DEATH; DIRECTIVES AB Background: Early and repeated patient-provider conversations about advance care planning (ACP) are now widely recommended. We sought to characterize barriers and strategies for realizing an iterative model of ACP patient-provider communication. Methods: A total of 2 multidisciplinary focus groups and 3 semistructured interviews with 20 providers at a large Veterans Affairs medical center. Thematic analysis was employed to identify salient themes. Results: Barriers included variation among providers in approaches to ACP, lack of useful information about patient values to guide decision making, and ineffective communication between providers across settings. Strategies included eliciting patient values rather than specific treatment choices and an increased role for primary care in the ACP process. Conclusions: Greater attention to connecting providers across the continuum, maximizing the potential of the electronic health record, and linking patient experiences to their values may help to connect ACP communication across the continuum. C1 [Ahluwalia, Sangeeta C.] Oregon State Univ, Corvallis, OR 97331 USA. [Ahluwalia, Sangeeta C.; Huynh, Alexis K.; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bekelman, David B.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA. [Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO USA. [Prendergast, Thomas J.] Portland VA Med Ctr, Portland, OR USA. [Prendergast, Thomas J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Shreve, Scott] Lebanon VA Med Ctr, Lebanon, PA USA. [Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Ahluwalia, SC (reprint author), Oregon State Univ, Coll Publ Hlth & Human Sci, 418 Waldo Hall, Corvallis, OR 97331 USA. EM sangeeta.c.ahluwalia@oregonstate.edu FU Department of Veterans Affairs Comprehensive End-of-Life Care Initiative, Office of Patient Care Services; National Palliative Care Research Center; Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University in St Louis, through the National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the Department of Veterans Affairs Comprehensive End-of-Life Care Initiative, Office of Patient Care Services. Dr Ahluwalia is supported in part by a Career Development Grant from the National Palliative Care Research Center. The preparation of this article was supported in part by the Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University in St Louis, through the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). NR 47 TC 5 Z9 5 U1 3 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD DEC PY 2015 VL 32 IS 8 BP 817 EP 823 DI 10.1177/1049909114541513 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CV3OR UT WOS:000364169000005 PM 24988894 ER PT J AU Smith, JA Frueh, BC Campbell, J Egede, L AF Smith, Jeffrey A. Frueh, B. Christopher Campbell, Jennifer Egede, Leonard TI RACIAL DIFFERENCES IN DIABETES AMONG UNION FORCES DURING THE US CIVIL WAR SO ETHNICITY & DISEASE LA English DT Editorial Material DE Diabetes; Military; Civil War ID ETHNIC-DIFFERENCES; UNITED-STATES; VETERANS; END AB Diabetes is the seventh leading cause of death in the United States and disproportionately affects ethnic minorities. While research examining health disparities is well-established, an historical understanding of how the disparities evolved over time may be warranted. This article examined racial differences in prevalence of diabetes and associated mortality in Blacks and Whites during the US Civil War. Data were extracted from the Medical and Surgical History of the War of Rebellion, 18611865, representing segregated White and Black Union Forces who served during the war. Data were collapsed by war theater (Atlantic, Central, Pacific). Results by race show that, from 1861 to 1866, the rates of Whites diagnosed with diabetes ranged overall from 0% to .11% and was distributed throughout the war theaters as: Atlantic 0.3% to .05%; Central 0.3% to .08%, and Pacific 0% to .11%. For Blacks, Atlantic ranged from .02% to .07% and Central .03% to .06%. None were reported for Pacific. Mortality was approximately .01% for both Blacks and Whites. These data suggest no racial differences in diabetes prevalence and mortality existed between Blacks and Whites during this time, implying that disparities may have evolved more recently. C1 [Smith, Jeffrey A.] Univ Hawaii, Dept Hist, Hilo, HI 96720 USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Campbell, Jennifer; Egede, Leonard] Med Univ S Carolina, Charleston, SC 29425 USA. [Egede, Leonard] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Egede, L (reprint author), Med Univ S Carolina, Ctr Hlth Disparities Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu NR 12 TC 0 Z9 0 U1 0 U2 3 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD WIN PY 2015 VL 25 IS 1 BP 104 EP 107 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU7KV UT WOS:000363717600018 PM 25812260 ER PT J AU Noerager, BD Xu, X Davis, VA Jones, CW Okafor, S Whitehead, A Blalock, JE Jackson, PL AF Noerager, Brett D. Xu, Xin Davis, Virginia A. Jones, Caleb W. Okafor, Svetlana Whitehead, Alicia Blalock, J. Edwin Jackson, Patricia L. TI A Potential Role for Acrolein in Neutrophil-Mediated Chronic Inflammation SO INFLAMMATION LA English DT Article DE acrolein; neutrophils; inflammation; chronic obstructive pulmonary disease ID OBSTRUCTIVE PULMONARY-DISEASE; BRONCHIAL EPITHELIAL-CELLS; PROLINE-GLYCINE-PROLINE; CIGARETTE-SMOKE; CYSTIC-FIBROSIS; ALPHA,BETA-UNSATURATED ALDEHYDES; AIRWAY INFLAMMATION; RELEASE; CHEMOATTRACTANT; MACROPHAGES AB Neutrophils (PMNs) are key mediators of inflammatory processes throughout the body. In this study, we investigated the role of acrolein, a highly reactive aldehyde that is ubiquitously present in the environment and produced endogenously at sites of inflammation, in mediating PMN-mediated degradation of collagen facilitating proline-glycine-proline (PGP) production. We treated peripheral blood neutrophils with acrolein and analyzed cell supernatants and lysates for matrix metalloproteinase-9 (MMP-9) and prolyl endopeptidase (PE), assessed their ability to break down collagen and release PGP, and assayed for the presence of leukotriene A4 hydrolase (LTA4H) and its ability to degrade PGP. Acrolein treatment induced elevated production and functionality of collagen-degrading enzymes and generation of PGP fragments. Meanwhile, LTA4H levels and triaminopeptidase activity declined with increasing concentrations of acrolein thereby sparing PGP from enzymatic destruction. These findings suggest that acrolein exacerbates the acute inflammatory response mediated by neutrophils and sets the stage for chronic pulmonary and systemic inflammation. C1 [Noerager, Brett D.; Davis, Virginia A.] Univ Montevallo, Dept Biol Chem & Math, Montevallo, AL 35115 USA. [Xu, Xin; Jones, Caleb W.; Blalock, J. Edwin; Jackson, Patricia L.] Univ Alabama Birmingham, Dept Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Jones, Caleb W.; Okafor, Svetlana; Whitehead, Alicia] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Blalock, J. Edwin; Jackson, Patricia L.] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL 35294 USA. [Jackson, Patricia L.] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA. [Jackson, Patricia L.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Noerager, BD (reprint author), Univ Montevallo, Dept Biol Chem & Math, Montevallo, AL 35115 USA. EM noeragerb@montevallo.edu OI Blalock, J. Edwin/0000-0001-5303-8123 FU NIH [HL07783, HL090999, HL087824]; Cystic Fibrosis Foundation [R464-CR11]; NIH/NIDDK [P30 DKO72482] FX JEB is funded through NIH (HL07783, HL090999, and HL087824). PLJ is supported by Cystic Fibrosis Foundation R464-CR11 "Research Development Program-Component II" and NIH/NIDDK P30 DKO72482. The authors wish to thank Dr. Mike Wells for thoughtful input on many drafts of the manuscript. NR 41 TC 3 Z9 3 U1 0 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0360-3997 EI 1573-2576 J9 INFLAMMATION JI Inflammation PD DEC PY 2015 VL 38 IS 6 BP 2279 EP 2287 DI 10.1007/s10753-015-0213-2 PG 9 WC Cell Biology; Immunology SC Cell Biology; Immunology GA CV4GA UT WOS:000364223800029 PM 26208604 ER PT J AU Barrows, RJ Barsuglia, J Paholpak, P Eknoyan, D Sabodash, V Lee, GJ Mendez, MF AF Barrows, Robin J. Barsuglia, Joseph Paholpak, Pongsatorn Eknoyan, Donald Sabodash, Valeriy Lee, Grace J. Mendez, Mario F. TI Executive Abilities as Reflected by Clock Hand Placement: Frontotemporal Dementia Versus Early-Onset Alzheimer Disease SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE Alzheimer disease; frontotemporal dementia; executive functioning ID MILD COGNITIVE IMPAIRMENT; TENSOR-BASED MORPHOMETRY; DRAWING-TEST; QUALITATIVE ANALYSES; BEHAVIORAL VARIANT; DIAGNOSTIC-CRITERIA; WORKING-MEMORY; OLDER-ADULTS; TASK; CONNECTIVITY AB The clock-drawing test (CDT) is widely used in clinical practice to diagnose and distinguish patients with dementia. It remains unclear, however, whether the CDT can distinguish among the early-onset dementias. Accordingly, we examined the ability of both quantitative and qualitative CDT analyses to distinguish behavioral variant frontotemporal dementia (bvFTD) and early-onset Alzheimer disease (eAD), the 2 most common neurodegenerative dementias with onset <65 years of age. We hypothesized that executive aspects of the CDT would discriminate between these 2 disorders. The study compared 15 patients with bvFTD and 16 patients with eAD on the CDT using 2 different scales and correlated the findings with neuropsychological testing and magnetic resonance imaging. The total CDT scores did not discriminate bvFTD and eAD; however, specific analysis of executive hand placement items successfully distinguished the groups, with eAD exhibiting greater errors than bvFTD. The performance on those executive hand placement items correlated with measures of naming as well as visuospatial and executive function. On tensor-based morphometry of the magnetic resonance images, executive hand placement correlated with right frontal volume. These findings suggest that lower performance on executive hand placement items occurs with involvement of the right dorsolateral frontal-parietal network for executive control in eAD, a network disproportionately affected in AD of early onset. Rather than the total performance on the clock task, the analysis of specific errors, such as executive hand placement, may be useful for early differentiation of eAD, bvFTD, and other conditions. C1 [Barrows, Robin J.; Barsuglia, Joseph; Paholpak, Pongsatorn; Sabodash, Valeriy; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Barrows, Robin J.; Barsuglia, Joseph; Paholpak, Pongsatorn; Eknoyan, Donald; Sabodash, Valeriy; Mendez, Mario F.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Fac Med, Dept Psychiat, Khon Kaen, Thailand. [Eknoyan, Donald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. [Lee, Grace J.] Loma Linda Univ, Dept Psychol, Sch Behav Hlth, Loma Linda, CA 92350 USA. RP Barrows, RJ (reprint author), VA Greater Los Angeles Healthcare Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM drbarrowsrobinjoyce@gmail.com FU National Institute of Aging [5R01AG034499-05] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute of Aging (grant number 5R01AG034499-05). NR 52 TC 2 Z9 3 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 EI 1552-5708 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2015 VL 28 IS 4 BP 239 EP 248 DI 10.1177/0891988715598228 PG 10 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA CV1AX UT WOS:000363986300002 PM 26251109 ER PT J AU Slade, EP Goldman, HH Dixon, LB Gibbons, B Stuart, EA AF Slade, Eric P. Goldman, Howard H. Dixon, Lisa B. Gibbons, Brent Stuart, Elizabeth A. TI Assessing the Representativeness of Medical Expenditure Panel Survey Inpatient Utilization Data for Individuals With Psychiatric and Nonpsychiatric Conditions SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE mental health; psychiatric inpatient hospitalization; serious mental illness; measurement error; stigma ID SERIOUS MENTAL-ILLNESS; HEALTH; SERVICES; DEPRESSION; HIV; COMORBIDITY; ASSOCIATION; PREVALENCE; ACCURACY; SAMPLE AB Sampling and reporting biases in the Medical Expenditure Panel Survey (MEPS) survey could render data on inpatient utilization that are not representative for individuals with severe psychiatric conditions. The authors assessed the representativeness of MEPS data on psychiatric inpatient utilization, by comparing MEPS estimates of total annual psychiatric and nonpsychiatric inpatient admissions and bed days, and mean length of stay, for nonelderly U.S. adults in calendar years 2005 to 2010 (N = 9,288) to estimates from the Nationwide Inpatient Sample (NIS), a nationally representative inpatient care database derived from hospitals' administrative records (N = 21,934,378). Compared with the NIS, the MEPS indicated 34% as many psychiatric admissions and 86% as many nonpsychiatric admissions, while mean psychiatric length of stay was greater in MEPS than in NIS. In MEPS data, underrepresentation of psychiatric inpatient utilization at community hospitals may result in measurement distortions for commonly used statistics on psychiatric inpatient utilization and costs. C1 [Slade, Eric P.] US Dept Vet Affairs, Baltimore, MD USA. [Slade, Eric P.; Goldman, Howard H.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Dixon, Lisa B.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Dixon, Lisa B.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Gibbons, Brent] Univ Maryland Baltimore Cty, Baltimore, MD 21228 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Slade, EP (reprint author), Univ Maryland, Sch Med, Dept Psychiat, Div Res Serv, 737 W Lombard St, Baltimore, MD 21201 USA. EM eslade@psych.umaryland.edu FU National Institute of Mental Health/National Institutes of Health Common Fund [R21-MH096285] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute of Mental Health/National Institutes of Health Common Fund R21-MH096285. NR 32 TC 0 Z9 0 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 EI 1552-6801 J9 MED CARE RES REV JI Med. Care Res. Rev. PD DEC PY 2015 VL 72 IS 6 BP 736 EP 755 DI 10.1177/1077558715592745 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CV6YF UT WOS:000364417500005 PM 26149973 ER PT J AU Miller, A Moon, B Anders, S Walden, R Brown, S Montella, D AF Miller, Anne Moon, Brian Anders, Shilo Walden, Rachel Brown, Steven Montella, Diane TI Integrating computerized clinical decision support systems into clinical work: A meta-synthesis of qualitative research SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE Computerized clinical decision support; Workflow integration; Clinical decision making; Meta-synthesis; Qualitative research; Human-system interaction; Human computer interaction; Usability ID ELECTRONIC HEALTH RECORDS; INTENSIVE INSULIN THERAPY; MEANINGFUL USE; METASYNTHESIS; PERFORMANCE; ALERTS AB Purpose: Computerized clinical decision support systems (CDSS) are an emerging means for improving healthcare safety, quality and efficiency, but meta-analyses findings are mixed. This meta-synthesis aggregates qualitative research findings as possible explanations for variable quantitative research outcomes. Inclusion criteria: Qualitative studies published between 2000 and 2013 in English, involving physicians, registered and advanced practice nurses' experience of CDSS use in clinical practice were included. Search strategy: PubMed and CINAHL databases were searched. Study titles and abstracts were screened against inclusion criteria. Retained studies were appraised against quality criteria. Findings were extracted iteratively from studies in the 4th quartile of quality scores. Two reviewers constructed themes inductively. A third reviewer applied the defined themes deductively achieving 92% agreement. Results: 3798 unique records were returned; 56 met inclusion criteria and were reviewed against quality criteria. 9 studies were of sufficiently high quality for synthetic analysis. Five major themes (clinician-patient-system integration; user interface usability; the need for better 'algorithms'; system maturity; patient safety) were defined. Conclusions: Despite ongoing development, CDSS remains an emerging technology. Lack of understanding about and lack of consideration for the interaction between human decision makers and CDSS is a major reason for poor system adoption and use. Further high-quality qualitative research is needed to better understand human-system interaction issues. These issues may continue to confound quantitative study results if not addressed. (C) 2015 Published by Elsevier Ireland Ltd. C1 [Miller, Anne; Anders, Shilo; Walden, Rachel; Brown, Steven; Montella, Diane] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA. [Moon, Brian] Perigean Technol, Fredericksburg, VA USA. [Miller, Anne; Brown, Steven; Montella, Diane] US Dept Vet Affairs, Fredericksburg, VA USA. RP Miller, A (reprint author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA. EM Anne.miller@vanderbilt.edu OI Walden, Rachel/0000-0003-4140-9446 FU United States Department of Veteran's Affairs FX This project was funded by the United States Department of Veteran's Affairs. It was conceived as part of a broader program of research coordinated by the Knowledge Based System's Group within the Department of Veteran's Affair's Office of Informatics and Analytics. NR 35 TC 2 Z9 3 U1 3 U2 26 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 EI 1872-8243 J9 INT J MED INFORM JI Int. J. Med. Inform. PD DEC PY 2015 VL 84 IS 12 BP 1009 EP 1018 DI 10.1016/j.ijmedinf.2015.09.005 PG 10 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA CU9IL UT WOS:000363858100002 PM 26391601 ER PT J AU Almario, CV Chey, WD Iriana, S Dailey, F Robbins, K Patel, AV Reid, M Whitman, C Fuller, G Bolus, R Dennis, B Encarnacion, R Martinez, B Soares, J Modi, R Agarwal, N Lee, A Kubomoto, S Sharma, G Bolus, S Chang, L Spiegel, BMR AF Almario, Christopher V. Chey, William D. Iriana, Sentia Dailey, Francis Robbins, Karen Patel, Anish V. Reid, Mark Whitman, Cynthia Fuller, Garth Bolus, Roger Dennis, Buddy Encarnacion, Rey Martinez, Bibiana Soares, Jennifer Modi, Rushaba Agarwal, Nikhil Lee, Aaron Kubomoto, Scott Sharma, Gobind Bolus, Sally Chang, Lin Spiegel, Brennan M. R. TI Computer versus physician identification of gastrointestinal alarm features SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE Alarm features; Checklists; Patient-provider portal ID SAFETY CHECKLISTS; GUIDELINES; MANAGEMENT; RECORDS; DISEASE; DIAGNOSIS; SYMPTOMS; QUALITY; CANCER; SYSTEM AB Objective: It is important for clinicians to inquire about "alarm features" as it may identify those at risk for organic disease and who require additional diagnostic workup. We developed a computer algorithm called Automated Evaluation of Gastrointestinal Symptoms (AEGIS) that systematically collects patient gastrointestinal (GI) symptoms and alarm features, and then "translates" the information into a history of present illness (HPI). Our study's objective was to compare the number of alarms documented by physicians during usual care vs. that collected by AEGIS. Methods: We performed a cross-sectional study with a paired sample design among patients visiting adult GI clinics. Participants first received usual care by their physicians and then completed AEGIS. Each individual thus contributed both a physician-documented and computer-generated HPI. Blinded physician reviewers enumerated the positive alarm features (hematochezia, melena, hematemesis, unintentional weight loss, decreased appetite, and fevers) mentioned in each HPI. We compared the number of documented alarms within patient using the Wilcoxon signed-rank test. Results: Seventy-five patients had both physician and AEGIS HPIs. AEGIS identified more patients with positive alarm features compared to physicians (53% vs. 27%; p<.001). AEGIS also documented more positive alarms (median 1, interquartile range [IQR] 0-2) vs. physicians (median 0, IQR 0-1; p<.001). Moreover, clinicians documented only 30% of the positive alarms self-reported by patients through AEGIS. Conclusions: Physicians documented less than one-third of red flags reported by patients through a computer algorithm. These data indicate that physicians may under report alarm features and that computerized "checklists" could complement standard HPIs to bolster clinical care. (C) 2015 Published by Elsevier Ireland Ltd. C1 [Almario, Christopher V.; Iriana, Sentia; Dailey, Francis; Robbins, Karen; Patel, Anish V.; Whitman, Cynthia; Fuller, Garth; Martinez, Bibiana; Soares, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Lee, Aaron; Kubomoto, Scott; Sharma, Gobind; Spiegel, Brennan M. R.] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA. [Almario, Christopher V.; Reid, Mark; Martinez, Bibiana; Soares, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. [Almario, Christopher V.; Modi, Rushaba; Agarwal, Nikhil; Chang, Lin] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. [Almario, Christopher V.; Reid, Mark; Whitman, Cynthia; Fuller, Garth; Bolus, Roger; Martinez, Bibiana; Soares, Jennifer; Bolus, Sally; Spiegel, Brennan M. R.] CS CORE, Los Angeles, CA 90048 USA. [Chey, William D.] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Dennis, Buddy; Encarnacion, Rey] Univ Calif Los Angeles, CTRL, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), CS CORE, 116 Robertson Blvd,4th Floor, Los Angeles, CA 90048 USA. EM Brennan.Spiegel@cshs.org FU National Institutes of Health through the NIH Roadmap for Medical Research Grant [AR052177]; National Institutes of Health T32 training grant [NIH T32DK07180-40] FX NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). Dr. Almario was supported by a National Institutes of Health T32 training grant (NIH T32DK07180-40) during his gastroenterology and health services research training at UCLA. Support for the My GI Health portal used in this study was obtained from Ironwood Pharmaceuticals. The above funding sources did not play any role in the conduct of this study. NR 24 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 EI 1872-8243 J9 INT J MED INFORM JI Int. J. Med. Inform. PD DEC PY 2015 VL 84 IS 12 BP 1111 EP 1117 DI 10.1016/j.ijmedinf.2015.07.006 PG 7 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA CU9IL UT WOS:000363858100013 PM 26254875 ER PT J AU Workman, AD Palmer, JN Adappa, ND Cohen, NA AF Workman, Alan D. Palmer, James N. Adappa, Nithin D. Cohen, Noam A. TI The Role of Bitter and Sweet Taste Receptors in Upper Airway Immunity SO CURRENT ALLERGY AND ASTHMA REPORTS LA English DT Review DE T2R38; Bitter taste receptor; Sweet taste receptor; Solitary chemosensory cell; Airway immune function; Upper airway immunity ID SOLITARY CHEMOSENSORY CELLS; UPPER RESPIRATORY-INFECTION; CHRONIC RHINOSINUSITIS; NITRIC-OXIDE; PSEUDOMONAS-AERUGINOSA; INDIVIDUAL-DIFFERENCES; INNATE IMMUNITY; SINUS SURGERY; UMAMI TASTES; EPITHELIUM AB Over the past several years, taste receptors have emerged as key players in the regulation of innate immune defenses in the mammalian respiratory tract. Several cell types in the airway, including ciliated epithelial cells, solitary chemosensory cells, and bronchial smooth muscle cells, all display chemoresponsive properties that utilize taste receptors. A variety of bitter products secreted by microbes are detected with resultant downstream inflammation, increased mucous clearance, antimicrobial peptide secretion, and direct bacterial killing. Genetic variation of bitter taste receptors also appears to play a role in the susceptibility to infection in respiratory disease states, including that of chronic rhinosinusitis. Ongoing taste receptor research may yield new therapeutics that harness innate immune defenses in the respiratory tract and may offer alternatives to antibiotic treatment. The present review discusses taste receptor-protective responses and analyzes the role these receptors play in mediating airway immune function. C1 [Workman, Alan D.; Palmer, James N.; Adappa, Nithin D.; Cohen, Noam A.] Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Workman, Alan D.; Palmer, James N.; Adappa, Nithin D.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Monell Smell & Taste Ctr, Philadelphia, PA USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM gnoam.cohen@gmail.com OI Cohen, Noam/0000-0002-9462-3932 FU NIDCD NIH HHS [R01 DC013588]; NIH HHS [S10 OD018125] NR 85 TC 6 Z9 6 U1 1 U2 21 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1529-7322 EI 1534-6315 J9 CURR ALLERGY ASTHM R JI Curr. Allergy Asthma Rep. PD DEC PY 2015 VL 15 IS 12 AR 72 DI 10.1007/s11882-015-0571-8 PG 8 WC Allergy; Immunology SC Allergy; Immunology GA CU1AT UT WOS:000363252100005 PM 26492878 ER PT J AU Hebenstreit, CL Madden, E Koo, KH Maguen, S AF Hebenstreit, Claire L. Madden, Erin Koo, Kelly H. Maguen, Shira TI Minimally adequate mental health care and latent classes of PTSD symptoms in female Iraq and Afghanistan veterans SO PSYCHIATRY RESEARCH LA English DT Article DE Women; Veterans; Service utilization; Posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSES; UNITED-STATES; DEPRESSION; DIAGNOSES; WAR; VA; SERVICES; EXPOSURE; ILLNESS AB Female veterans of Operations Enduring and Iraqi Freedom, and Operation New Dawn (OEF/OIF/OND) represent a growing segment of Department of Veterans Affairs (VA) health care users. A retrospective analysis used national VA medical records to identify factors associated with female OEF/OIF/OND veterans' completion of minimally adequate care (MAC) for PTSD, defined as the completion of at least nine mental health outpatient visits within a 15-week period or at least twelve consecutive weeks of medication use. The sample included female OEF/OIF/OND veterans with PTSD who initiated VA health care between 2007-2013, and were seen in outpatient mental health (N=2183). Multivariable logistic regression models examined factors associated with completing MAC for PTSD, including PTSD symptom expression (represented by latent class analysis), sociodemographic, military, clinical, and VA access factors. Within one year of initiating mental health care, 48.3% of female veterans completed MAC. Race/ethnicity, age, PTSD symptom class, additional psychiatric diagnoses, and VA primary care use were significantly associated with completion of MAC for PTSD. Results suggest that veterans presenting for PTSD treatment should be comprehensively evaluated to identify factors associated with inadequate completion of care. Treatments that are tailored to PTSD symptom class may help to address potential barriers. Published by Elsevier Ireland Ltd. C1 [Hebenstreit, Claire L.; Madden, Erin; Koo, Kelly H.; Maguen, Shira] San Francisco VA Med Ctr, Gen Med, San Francisco, CA 94121 USA. [Hebenstreit, Claire L.; Koo, Kelly H.; Maguen, Shira] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. RP Hebenstreit, CL (reprint author), San Francisco VA Med Ctr, Gen Med, 4150 Clement St, San Francisco, CA 94121 USA. EM Claire.hebenstreit@va.gov FU San Francisco VA Medical Center; University of California, San Francisco; U.S. Department of Defense [W81XWH-11-2-0189]; VA Advanced Fellowship Program in Women's Health FX This research has been supported by the San Francisco VA Medical Center, the University of California, San Francisco, the U.S. Department of Defense Award Grant (W81XWH-11-2-0189), and the VA Advanced Fellowship Program in Women's Health. NR 39 TC 1 Z9 1 U1 0 U2 15 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD NOV 30 PY 2015 VL 230 IS 1 BP 90 EP 95 DI 10.1016/j.psychres.2015.08.028 PG 6 WC Psychiatry SC Psychiatry GA CS5SK UT WOS:000362138100014 PM 26330305 ER PT J AU Murray, CJL Barber, RM Foreman, KJ Ozgoren, AA Abd-Allah, F Abera, SF Aboyans, V Abraham, JP Abubakar, I Abu-Raddad, LJ Abu-Rmeileh, NM Achoki, T Ackerman, IN Ademi, Z Adou, AK Adsuar, JC Afshin, A Agardh, EE Alam, SS Alasfoor, D Albittar, MI Alegretti, MA Alemu, ZA Alfonso-Cristancho, R Alhabib, S Ali, R Alla, F Allebeck, P Almazroa, MA Alsharif, U Alvarez, E Alvis-Guzman, N Amare, AT Ameh, EA Amini, H Ammar, W Anderson, HR Anderson, BO Antonio, CAT Anwari, P Arnlov, J Arsenijevic, VSA Artaman, A Asghar, RJ Assadi, R Atkins, LS Avila, MA Awuah, B Bachman, VF Badawi, A Bahit, MC Balakrishnan, K Banerjee, A Barker-Collo, SL Barquera, S Barregard, L Barrero, LH Basu, A Basu, S Basulaiman, MO Beardsley, J Bedi, N Beghi, E Bekele, T Bell, ML Benjet, C Bennett, DA Bensenor, IM Benzian, H Bernabe, E Bertozzi-Villa, A Beyene, TJ Bhala, N Bhalla, A Bhutta, ZA Bienhoff, K Bikbov, B Biryukov, S Blore, JD Blosser, CD Blyth, FM Bohensky, MA Bolliger, IW Basara, BB Bornstein, NM Bose, D Boufous, S Bourne, RRA Boyers, LN Brainin, M Brayne, CE Brazinova, A Breitborde, NJK Brenner, H Briggs, AD Brooks, PM Brown, JC Brugha, TS Buchbinder, R Buckle, GC Budke, CM Bulchis, A Bulloch, AG Campos-Nonato, IR Carabin, H Carapetis, JR Cardenas, R Carpenter, DO Caso, V Castaneda-Orjuela, CA Castro, RE Catala-Lopez, F Cavalleri, F Cavlin, A Chadha, VK Chang, JC Charlson, FJ Chen, HL Chen, WQ Chiang, PP Chimed-Ochir, O Chowdhury, R Christensen, H Christophi, CA Cirillo, M Coates, MM Coffeng, LE Coggeshall, MS Colistro, V Colquhoun, SM Cooke, GS Cooper, C Cooper, LT Coppola, LM Cortinovis, M Criqui, MH Crump, JA Cuevas-Nasu, L Danawi, H Dandona, L Dandona, R Dansereau, E Dargan, PI Davey, G Davis, A Davitoiu, DV Dayama, A De Leo, D Degenhardt, L Del Pozo-Cruz, B Dellavalle, RP Deribe, K Derrett, S Des Jarlais, DC Dessalegn, M Dharmaratne, SD Dherani, MK Diaz-Torne, C Dicker, D Ding, EL Dokova, K Dorsey, ER Driscoll, TR Duan, L Duber, HC Ebel, BE Edmond, KM Elshrek, YM Endres, M Ermakov, SP Erskine, HE Eshrati, B Esteghamati, A Estep, K Faraon, EJA Farzadfar, F Fay, DF Feigin, VL Felson, DT Fereshtehnejad, SM Fernandes, JG Ferrari, AJ Fitzmaurice, C Flaxman, AD Fleming, TD Foigt, N Forouzanfar, MH Fowkes, FGR Paleo, UF Franklin, RC Furst, T Gabbe, B Gaffikin, L Gankpe, FG Geleijnse, JM Gessner, BD Gething, P Gibney, KB Giroud, M Giussani, G Dantes, HG Gona, P Gonzalez-Medina, D Gosselin, RA Gotay, CC Goto, A Gouda, HN Graetz, N Gugnani, HC Gupta, R Gupta, R Gutierrez, RA Haagsma, J Hafezi-Nejad, N Hagan, H Halasa, YA Hamadeh, RR Hamavid, H Hammami, M Hancock, J Hankey, GJ Hansen, GM Hao, YT Harb, HL Haro, JM Havmoeller, R Hay, SI Hay, RJ Heredia-Pi, IB Heuton, KR Heydarpour, P Higashi, H Hijar, M Hoek, HW Hoffman, HJ Hosgood, HD Hossain, M Hotez, PJ Hoy, DG Hsairi, M Hu, GQ Huang, C Huang, JJ Husseini, A Huynh, C Iannarone, ML Iburg, KM Innos, K Inoue, M Islami, F Jacobsen, KH Jarvis, DL Jassal, SK Jee, SH Jeemon, P Jensen, PN Jha, V Jiang, GH Jiang, Y Jonas, JB Juel, K Kan, HD Karch, A Karema, CK Karimkhani, C Karthikeyan, G Kassebaum, NJ Kaul, A Kawakami, N Kazanjan, K Kemp, AH Kengne, AP Keren, A Khader, YS Khalifa, SEA Khan, EA Khan, G Khang, YH Kieling, C Kim, D Kim, S Kim, Y Kinfu, Y Kinge, JM Kivipelto, M Knibbs, LD Knudsen, AK Kokubo, Y Kosen, S Krishnaswami, S Defo, BK Bicer, BK Kuipers, EJ Kulkarni, C Kulkarni, VS Kumar, GA Kyu, HH Lai, T Lalloo, R Lallukka, T Lam, H Lan, Q Lansingh, VC Larsson, A Lawrynowicz, AEB Leasher, JL Leigh, J Leung, R Levitz, CE Li, B Li, YC Li, YM Lim, SS Lind, M Lipshultz, SE Liu, SW Liu, Y Lloyd, BK Lofgren, KT Logroscino, G Looker, KJ Lortet-Tieulent, J Lotufo, PA Lozano, R Lucas, RM Lunevicius, R Lyons, RA Ma, S Macintyre, MF Mackay, MT Majdan, M Malekzadeh, R Marcenes, W Margolis, DJ Margono, C Marzan, MB Masci, JR Mashal, MT Matzopoulos, R Mayosi, BM Mazorodze, TT Mcgill, NW Mcgrath, JJ Mckee, M McLain, A Meaney, PA Medina, C Mehndiratta, MM Mekonnen, W Melaku, YA Meltzer, M Memish, ZA Mensah, GA Meretoja, A Mhimbira, FA Micha, R Miller, TR Mills, EJ Mitchell, PB Mock, CN Ibrahim, NM Mohammad, KA Mokdad, AH Mola, GLD Monasta, L Hernandez, JCM Montico, M Montine, TJ Mooney, MD Moore, AR Moradi-Lakeh, M Moran, AE Mori, R Moschandreas, J Moturi, WN Moyer, ML Mozaffarian, D Msemburi, WT Mueller, UO Mukaigawara, M Mullany, EC Murdoch, ME Murray, J Murthy, KS Naghavi, M Naheed, A Naidoo, KS Naldi, L Nand, D Nangia, V Narayan, KMV Nejjari, C Neupane, SP Newton, CR Ng, M Ngalesoni, FN Nguyen, G Nisar, MI Nolte, S Norheim, OF Norman, RE Norrving, B Nyakarahuka, L Oh, IH Ohkubo, T Ohno, SL Olusanya, BO Opio, JN Ortblad, K Ortiz, A Pain, AW Pandian, JD Panelo, CIA Papachristou, C Park, EK Park, JH Patten, SB Patton, GC Paul, VK Pavlin, BI Pearce, N Pereira, DM Perez-Padilla, R Perez-Ruiz, F Perico, N Pervaiz, A Pesudovs, K Peterson, CB Petzold, M Phillips, MR Phillips, BK Phillips, DE Piel, FB Plass, D Poenaru, D Polinder, S Pope, D Popova, S Poulton, RG Pourmalek, F Prabhakaran, D Prasad, NM Pullan, RL Qato, DM Quistberg, DA Rafay, A Rahimi, K Rahman, SU Raju, M Rana, SM Razavi, H Reddy, KS Refaat, A Remuzzi, G Resnikoff, S Ribeiro, AL Richardson, L Richardus, JH Roberts, DA Rojas-Rueda, D Ronfani, L Roth, GA Rothenbacher, D Rothstein, DH Rowley, JT Roy, N Ruhago, GM Saeedi, MY Saha, S Sahraian, MA Sampson, UKA Sanabria, JR Sandar, L Santos, IS Satpathy, M Sawhney, M Scarborough, P Schneider, IJ Schottker, B Schumacher, AE Schwebel, DC Scott, JG Seedat, S Sepanlou, SG Serina, PT Servan-Mori, EE Shackelford, KA Shaheen, A Shahraz, S Levy, TS Shangguan, S She, J Sheikhbahaei, S Shi, PL Shibuya, K Shinohara, Y Shiri, R Shishani, K Shiue, I Shrime, MG Sigfusdottir, ID Silberberg, DH Simard, EP Sindi, S Singh, A Singh, JA Singh, L Skirbekk, V Slepak, EL Sliwa, K Soneji, S Soreide, K Soshnikov, S Sposato, LA Sreeramareddy, CT Stanaway, JD Stathopoulou, V Stein, DJ Stein, MB Steiner, C Steiner, TJ Stevens, A Stewart, A Stovner, LJ Stroumpoulis, K Sunguya, BF Swaminathan, S Swaroop, M Sykes, BL Tabb, KM Takahashi, K Tandon, N Tanne, D Tanner, M Tavakkoli, M Taylor, HR Te Ao, BJ Tediosi, F Temesgen, AM Templin, T Ten Have, M Tenkorang, EY Terkawi, AS Thomson, B Thorne-Lyman, AL Thrift, AG Thurston, GD Tillmann, T Tonelli, M Topouzis, F Toyoshima, H Traebert, J Tran, BX Trillini, M Truelsen, T Tsilimbaris, M Tuzcu, EM Uchendu, US Ukwaja, KN Undurraga, EA Uzun, SB Van Brakel, WH Van De Vijver, S van Gool, CH Van Os, J Vasankari, TJ Venketasubramanian, N Violante, FS Vlassov, VV Vollset, SE Wagner, GR Wagner, J Waller, SG Wan, X Wang, HD Wang, JL Wang, LH Warouw, TS Weichenthal, S Weiderpass, E Weintraub, RG Wang, WZ Werdecker, A Westerman, R Whiteford, HA Wilkinson, JD Williams, TN Wolfe, CD Wolock, TM Woolf, AD Wulf, S Wurtz, B Xu, GL Yan, LJL Yano, Y Ye, PP Yentur, GK Yip, P Yonemoto, N Yoon, SJ Younis, MZ Yu, CH Zaki, ME Zhao, Y Zheng, YF Zonies, D Zou, XN Salomon, JA Lopez, AD Vos, T AF Murray, Christopher J. L. Barber, Ryan M. Foreman, Kyle J. Ozgoren, Ayse Abbasoglu Abd-Allah, Foad Abera, Semaw F. Aboyans, Victor Abraham, Jerry P. Abubakar, Ibrahim Abu-Raddad, Laith J. Abu-Rmeileh, Niveen M. Achoki, Tom Ackerman, Ilana N. Ademi, Zanfina Adou, Arsene K. Adsuar, Jose C. Afshin, Ashkan Agardh, Emilie E. Alam, Sayed Saidul Alasfoor, Deena Albittar, Mohammed I. Alegretti, Miguel A. Alemu, Zewdie A. Alfonso-Cristancho, Rafael Alhabib, Samia Ali, Raghib Alla, Francois Allebeck, Peter Almazroa, Mohammad A. Alsharif, Ubai Alvarez, Elena Alvis-Guzman, Nelson Amare, Azmeraw T. Ameh, Emmanuel A. Amini, Heresh Ammar, Walid Anderson, H. Ross Anderson, Benjamin O. Antonio, Carl Abelardo T. Anwari, Palwasha Arnlov, Johan Arsenijevic, Valentina S. Arsic Artaman, Al Asghar, Rana J. Assadi, Reza Atkins, Lydia S. Avila, Marco A. Awuah, Baffour Bachman, Victoria F. Badawi, Alaa Bahit, Maria C. Balakrishnan, Kalpana Banerjee, Amitava Barker-Collo, Suzanne L. Barquera, Simon Barregard, Lars Barrero, Lope H. Basu, Arindam Basu, Sanjay Basulaiman, Mohammed O. Beardsley, Justin Bedi, Neeraj Beghi, Ettore Bekele, Tolesa Bell, Michelle L. Benjet, Corina Bennett, Derrick A. Bensenor, Isabela M. Benzian, Habib Bernabe, Eduardo Bertozzi-Villa, Amelia Beyene, Tariku J. Bhala, Neeraj Bhalla, Ashish Bhutta, Zulfiqar A. Bienhoff, Kelly Bikbov, Boris Biryukov, Stan Blore, Jed D. Blosser, Christopher D. Blyth, Fiona M. Bohensky, Megan A. Bolliger, Ian W. Basara, Berrak Bora Bornstein, Natan M. Bose, Dipan Boufous, Soufiane Bourne, Rupert R. A. Boyers, Lindsay N. Brainin, Michael Brayne, Carol E. Brazinova, Alexandra Breitborde, Nicholas J. K. Brenner, Hermann Briggs, Adam D. Brooks, Peter M. Brown, Jonathan C. Brugha, Traolach S. Buchbinder, Rachelle Buckle, Geoffrey C. Budke, Christine M. Bulchis, Anne Bulloch, Andrew G. Campos-Nonato, Ismael R. Carabin, Helene Carapetis, Jonathan R. Cardenas, Rosario Carpenter, David O. Caso, Valeria Castaneda-Orjuela, Carlos A. Castro, Ruben E. Catala-Lopez, Ferran Cavalleri, Fiorella Cavlin, Alanur Chadha, Vineet K. Chang, Jung-Chen Charlson, Fiona J. Chen, Honglei Chen, Wanqing Chiang, Peggy P. Chimed-Ochir, Odgerel Chowdhury, Rajiv Christensen, Hanne Christophi, Costas A. Cirillo, Massimo Coates, Matthew M. Coffeng, Luc E. Coggeshall, Megan S. Colistro, Valentina Colquhoun, Samantha M. Cooke, Graham S. Cooper, Cyrus Cooper, Leslie T. Coppola, Luis M. Cortinovis, Monica Criqui, Michael H. Crump, John A. Cuevas-Nasu, Lucia Danawi, Hadi Dandona, Lalit Dandona, Rakhi Dansereau, Emily Dargan, Paul I. Davey, Gail Davis, Adrian Davitoiu, Dragos V. Dayama, Anand De Leo, Diego Degenhardt, Louisa Del Pozo-Cruz, Borja Dellavalle, Robert P. Deribe, Kebede Derrett, Sarah Des Jarlais, Don C. Dessalegn, Muluken Dharmaratne, Samath D. Dherani, Mukesh K. Diaz-Torne, Cesar Dicker, Daniel Ding, Eric L. Dokova, Klara Dorsey, E. Ray Driscoll, Tim R. Duan, Leilei Duber, Herbert C. Ebel, Beth E. Edmond, Karen M. Elshrek, Yousef M. Endres, Matthias Ermakov, Sergey P. Erskine, Holly E. Eshrati, Babak Esteghamati, Alireza Estep, Kara Faraon, Emerito Jose A. Farzadfar, Farshad Fay, Derek F. Feigin, Valery L. Felson, David T. Fereshtehnejad, Seyed-Mohammad Fernandes, Jefferson G. Ferrari, Alize J. Fitzmaurice, Christina Flaxman, Abraham D. Fleming, Thomas D. Foigt, Nataliya Forouzanfar, Mohammad H. Fowkes, F. Gerry R. Paleo, Urbano Fra Franklin, Richard C. Fuerst, Thomas Gabbe, Belinda Gaffikin, Lynne Gankpe, Fortune G. Geleijnse, Johanna M. Gessner, Bradford D. Gething, Peter Gibney, Katherine B. Giroud, Maurice Giussani, Giorgia Gomez Dantes, Hector Gona, Philimon Gonzalez-Medina, Diego Gosselin, Richard A. Gotay, Carolyn C. Goto, Atsushi Gouda, Hebe N. Graetz, Nicholas Gugnani, Harish C. Gupta, Rahul Gupta, Rajeev Gutierrez, Reyna A. Haagsma, Juanita Hafezi-Nejad, Nima Hagan, Holly Halasa, Yara A. Hamadeh, Randah R. Hamavid, Hannah Hammami, Mouhanad Hancock, Jamie Hankey, Graeme J. Hansen, Gillian M. Hao, Yuantao Harb, Hilda L. Maria Haro, Josep Havmoeller, Rasmus Hay, Simon I. Hay, Roderick J. Heredia-Pi, Ileana B. Heuton, Kyle R. Heydarpour, Pouria Higashi, Hideki Hijar, Martha Hoek, Hans W. Hoffman, Howard J. Hosgood, H. Dean Hossain, Mazeda Hotez, Peter J. Hoy, Damian G. Hsairi, Mohamed Hu, Guoqing Huang, Cheng Huang, John J. Husseini, Abdullatif Huynh, Chantal Iannarone, Marissa L. Iburg, Kim M. Innos, Kaire Inoue, Manami Islami, Farhad Jacobsen, Kathryn H. Jarvis, Deborah L. Jassal, Simerjot K. Jee, Sun Ha Jeemon, Panniyammakal Jensen, Paul N. Jha, Vivekanand Jiang, Guohong Jiang, Ying Jonas, Jost B. Juel, Knud Kan, Haidong Karch, Andre Karema, Corine K. Karimkhani, Chante Karthikeyan, Ganesan Kassebaum, Nicholas J. Kaul, Anil Kawakami, Norito Kazanjan, Konstantin Kemp, Andrew H. Kengne, Andre P. Keren, Andre Khader, Yousef S. Khalifa, Shams Eldin A. Khan, Ejaz A. Khan, Gulfaraz Khang, Young-Ho Kieling, Christian Kim, Daniel Kim, Sungroul Kim, Yunjin Kinfu, Yohannes Kinge, Jonas M. Kivipelto, Miia Knibbs, Luke D. Knudsen, Ann Kristin Kokubo, Yoshihiro Kosen, Soewarta Krishnaswami, Sanjay Defo, Barthelemy Kuate Bicer, Burcu Kucuk Kuipers, Ernst J. Kulkarni, Chanda Kulkarni, Veena S. Kumar, G. Anil Kyu, Hmwe H. Lai, Taavi Lalloo, Ratilal Lallukka, Tea Lam, Hilton Lan, Qing Lansingh, Van C. Larsson, Anders Lawrynowicz, Alicia E. B. Leasher, Janet L. Leigh, James Leung, Ricky Levitz, Carly E. Li, Bin Li, Yichong Li, Yongmei Lim, Stephen S. Lind, Maggie Lipshultz, Steven E. Liu, Shiwei Liu, Yang Lloyd, Belinda K. Lofgren, Katherine T. Logroscino, Giancarlo Looker, Katharine J. Lortet-Tieulent, Joannie Lotufo, Paulo A. Lozano, Rafael Lucas, Robyn M. Lunevicius, Raimundas Lyons, Ronan A. Ma, Stefan Macintyre, Michael F. Mackay, Mark T. Majdan, Marek Malekzadeh, Reza Marcenes, Wagner Margolis, David J. Margono, Christopher Marzan, Melvin B. Masci, Joseph R. Mashal, Mohammad T. Matzopoulos, Richard Mayosi, Bongani M. Mazorodze, Tasara T. Mcgill, Neil W. Mcgrath, John J. Mckee, Martin McLain, Abigail Meaney, Peter A. Medina, Catalina Mehndiratta, Man Mohan Mekonnen, Wubegzier Melaku, Yohannes A. Meltzer, Michele Memish, Ziad A. Mensah, George A. Meretoja, Atte Mhimbira, Francis A. Micha, Renata Miller, Ted R. Mills, Edward J. Mitchell, Philip B. Mock, Charles N. Ibrahim, Norlinah Mohamed Mohammad, Karzan A. Mokdad, Ali H. Mola, Glen L. D. Monasta, Lorenzo Montanez Hernandez, Julio C. Montico, Marcella Montine, Thomas J. Mooney, Meghan D. Moore, Ami R. Moradi-Lakeh, Maziar Moran, Andrew E. Mori, Rintaro Moschandreas, Joanna Moturi, Wilkister N. Moyer, Madeline L. Mozaffarian, Dariush Msemburi, William T. Mueller, Ulrich O. Mukaigawara, Mitsuru Mullany, Erin C. Murdoch, Michele E. Murray, Joseph Murthy, Kinnari S. Naghavi, Mohsen Naheed, Aliya Naidoo, Kovin S. Naldi, Luigi Nand, Devina Nangia, Vinay Narayan, K. M. Venkat Nejjari, Chakib Neupane, Sudan P. Newton, Charles R. Ng, Marie Ngalesoni, Frida N. Nguyen, Grant Nisar, Muhammad I. Nolte, Sandra Norheim, Ole F. Norman, Rosana E. Norrving, Bo Nyakarahuka, Luke Oh, In-Hwan Ohkubo, Takayoshi Ohno, Summer L. Olusanya, Bolajoko O. Opio, John Nelson Ortblad, Katrina Ortiz, Alberto Pain, Amanda W. Pandian, Jeyaraj D. Panelo, Carlo Irwin A. Papachristou, Christina Park, Eun-Kee Park, Jae-Hyun Patten, Scott B. Patton, George C. Paul, Vinod K. Pavlin, Boris I. Pearce, Neil Pereira, David M. Perez-Padilla, Rogelio Perez-Ruiz, Fernando Perico, Norberto Pervaiz, Aslam Pesudovs, Konrad Peterson, Carrie B. Petzold, Max Phillips, Michael R. Phillips, Bryan K. Phillips, David E. Piel, Frederic B. Plass, Dietrich Poenaru, Dan Polinder, Suzanne Pope, Daniel Popova, Svetlana Poulton, Richie G. Pourmalek, Farshad Prabhakaran, Dorairaj Prasad, Noela M. Pullan, Rachel L. Qato, Dima M. Quistberg, D. Alex Rafay, Anwar Rahimi, Kazem Rahman, Sajjad U. Raju, Murugesan Rana, Saleem M. Razavi, Homie Reddy, K. Srinath Refaat, Amany Remuzzi, Giuseppe Resnikoff, Serge Ribeiro, Antonio L. Richardson, Lee Richardus, Jan Hendrik Roberts, D. Allen Rojas-Rueda, David Ronfani, Luca Roth, Gregory A. Rothenbacher, Dietrich Rothstein, David H. Rowley, Jane T. Roy, Nobhojit Ruhago, George M. Saeedi, Mohammad Y. Saha, Sukanta Sahraian, Mohammad Ali Sampson, Uchechukwu K. A. Sanabria, Juan R. Sandar, Logan Santos, Itamar S. Satpathy, Maheswar Sawhney, Monika Scarborough, Peter Schneider, Ione J. Schoettker, Ben Schumacher, Austin E. Schwebel, David C. Scott, James G. Seedat, Soraya Sepanlou, Sadaf G. Serina, Peter T. Servan-Mori, Edson E. Shackelford, Katya A. Shaheen, Amira Shahraz, Saeid Levy, Teresa Shamah Shangguan, Siyi She, Jun Sheikhbahaei, Sara Shi, Peilin Shibuya, Kenji Shinohara, Yukito Shiri, Rahman Shishani, Kawkab Shiue, Ivy Shrime, Mark G. Sigfusdottir, Inga D. Silberberg, Donald H. Simard, Edgar P. Sindi, Shireen Singh, Abhishek Singh, Jasvinder A. Singh, Lavanya Skirbekk, Vegard Slepak, Erica Leigh Sliwa, Karen Soneji, Samir Soreide, Kjetil Soshnikov, Sergey Sposato, Luciano A. Sreeramareddy, Chandrashekhar T. Stanaway, Jeffrey D. Stathopoulou, Vasiliki Stein, Dan J. Stein, Murray B. Steiner, Caitlyn Steiner, Timothy J. Stevens, Antony Stewart, Andrea Stovner, Lars J. Stroumpoulis, Konstantinos Sunguya, Bruno F. Swaminathan, Soumya Swaroop, Mamta Sykes, Bryan L. Tabb, Karen M. Takahashi, Ken Tandon, Nikhil Tanne, David Tanner, Marcel Tavakkoli, Mohammad Taylor, Hugh R. Te Ao, Braden J. Tediosi, Fabrizio Temesgen, Awoke M. Templin, Tara Ten Have, Margreet Tenkorang, Eric Y. Terkawi, Abdullah S. Thomson, Blake Thorne-Lyman, Andrew L. Thrift, Amanda G. Thurston, George D. Tillmann, Taavi Tonelli, Marcello Topouzis, Fotis Toyoshima, Hideaki Traebert, Jefferson Tran, Bach X. Trillini, Matias Truelsen, Thomas Tsilimbaris, Miltiadis Tuzcu, Emin M. Uchendu, Uche S. Ukwaja, Kingsley N. Undurraga, Eduardo A. Uzun, Selen B. Van Brakel, Wim H. Van De Vijver, Steven van Gool, Coen H. Van Os, Jim Vasankari, Tommi J. Venketasubramanian, N. Violante, Francesco S. Vlassov, Vasiliy V. Vollset, Stein Emil Wagner, Gregory R. Wagner, Joseph Waller, Stephen G. Wan, Xia Wang, Haidong Wang, Jianli Wang, Linhong Warouw, Tati S. Weichenthal, Scott Weiderpass, Elisabete Weintraub, Robert G. Wang Wenzhi Werdecker, Andrea Westerman, Ronny Whiteford, Harvey A. Wilkinson, James D. Williams, Thomas N. Wolfe, Charles D. Wolock, Timothy M. Woolf, Anthony D. Wulf, Sarah Wurtz, Brittany Xu, Gelin Yan, Lijing L. Yano, Yuichiro Ye, Pengpeng Yentur, Goekalp K. Yip, Paul Yonemoto, Naohiro Yoon, Seok-Jun Younis, Mustafa Z. Yu, Chuanhua Zaki, Maysaa E. Zhao, Yong Zheng, Yingfeng Zonies, David Zou, Xiaonong Salomon, Joshua A. Lopez, Alan D. Vos, Theo CA GBD 2013 DALYs Collaborator HALE Collaborator TI Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition SO LANCET LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; LOW SOCIOECONOMIC-STATUS; SELF-RATED HEALTH; SYSTEMATIC ANALYSIS; MORTALITY TRENDS; NONCOMMUNICABLE DISEASES; ECONOMIC-DEVELOPMENT; CHANGING RELATION; EUROPEAN-UNION; RISK-FACTORS AB Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age-sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic development. Methods We used the published GBD 2013 data for age-specific mortality, years of life lost due to premature mortality (YLLs), and years lived with disability (YLDs) to calculate DALYs and HALE for 1990, 1995, 2000, 2005, 2010, and 2013 for 188 countries. We calculated HALE using the Sullivan method; 95% uncertainty intervals (UIs) represent uncertainty in age-specific death rates and YLDs per person for each country, age, sex, and year. We estimated DALYs for 306 causes for each country as the sum of YLLs and YLDs; 95% UIs represent uncertainty in YLL and YLD rates. We quantified patterns of the epidemiological transition with a composite indicator of sociodemographic status, which we constructed from income per person, average years of schooling after age 15 years, and the total fertility rate and mean age of the population. We applied hierarchical regression to DALY rates by cause across countries to decompose variance related to the sociodemographic status variable, country, and time. Findings Worldwide, from 1990 to 2013, life expectancy at birth rose by 6.2 years (95% UI 5.6-6.6), from 65.3 years (65.0-65.6) in 1990 to 71.5 years (71.0-71.9) in 2013, HALE at birth rose by 5.4 years (4.9-5.8), from 56.9 years (54.5-59.1) to 62.3 years (59.7-64.8), total DALYs fell by 3.6% (0.3-7.4), and age-standardised DALY rates per 100 000 people fell by 26.7% (24.6-29.1). For communicable, maternal, neonatal, and nutritional disorders, global DALY numbers, crude rates, and age-standardised rates have all declined between 1990 and 2013, whereas for non-communicable diseases, global DALYs have been increasing, DALY rates have remained nearly constant, and age-standardised DALY rates declined during the same period. From 2005 to 2013, the number of DALYs increased for most specific non-communicable diseases, including cardiovascular diseases and neoplasms, in addition to dengue, food-borne trematodes, and leishmaniasis; DALYs decreased for nearly all other causes. By 2013, the five leading causes of DALYs were ischaemic heart disease, lower respiratory infections, cerebrovascular disease, low back and neck pain, and road injuries. Sociodemographic status explained more than 50% of the variance between countries and over time for diarrhoea, lower respiratory infections, and other common infectious diseases; maternal disorders; neonatal disorders; nutritional deficiencies; other communicable, maternal, neonatal, and nutritional diseases; musculoskeletal disorders; and other non-communicable diseases. However, sociodemographic status explained less than 10% of the variance in DALY rates for cardiovascular diseases; chronic respiratory diseases; cirrhosis; diabetes, urogenital, blood, and endocrine diseases; unintentional injuries; and self-harm and interpersonal violence. Predictably, increased sociodemographic status was associated with a shift in burden from YLLs to YLDs, driven by declines in YLLs and increases in YLDs from musculoskeletal disorders, neurological disorders, and mental and substance use disorders. In most country-specific estimates, the increase in life expectancy was greater than that in HALE. Leading causes of DALYs are highly variable across countries. Interpretation Global health is improving. Population growth and ageing have driven up numbers of DALYs, but crude rates have remained relatively constant, showing that progress in health does not mean fewer demands on health systems. The notion of an epidemiological transition-in which increasing sociodemographic status brings structured change in disease burden-is useful, but there is tremendous variation in burden of disease that is not associated with sociodemographic status. This further underscores the need for country-specific assessments of DALYs and HALE to appropriately inform health policy decisions and attendant actions. C1 [Murray, Christopher J. L.; Barber, Ryan M.; Foreman, Kyle J.; Achoki, Tom; Afshin, Ashkan; Bachman, Victoria F.; Bertozzi-Villa, Amelia; Bienhoff, Kelly; Biryukov, Stan; Blore, Jed D.; Bolliger, Ian W.; Brown, Jonathan C.; Bulchis, Anne; Coates, Matthew M.; Coffeng, Luc E.; Coggeshall, Megan S.; Dandona, Lalit; Dansereau, Emily; Dicker, Daniel; Duber, Herbert C.; Estep, Kara; Fitzmaurice, Christina; Flaxman, Abraham D.; Fleming, Thomas D.; Forouzanfar, Mohammad H.; Gonzalez-Medina, Diego; Graetz, Nicholas; Haagsma, Juanita; Hamavid, Hannah; Hancock, Jamie; Hansen, Gillian M.; Hay, Simon I.; Heuton, Kyle R.; Higashi, Hideki; Huynh, Chantal; Iannarone, Marissa L.; Kassebaum, Nicholas J.; Kyu, Hmwe H.; Levitz, Carly E.; Lim, Stephen S.; Lind, Maggie; Lofgren, Katherine T.; Lozano, Rafael; Macintyre, Michael F.; Margono, Christopher; McLain, Abigail; Mokdad, Ali H.; Mooney, Meghan D.; Moradi-Lakeh, Maziar; Moyer, Madeline L.; Msemburi, William T.; Mullany, Erin C.; Naghavi, Mohsen; Ng, Marie; Nguyen, Grant; Ohno, Summer L.; Ortblad, Katrina; Pain, Amanda W.; Phillips, Bryan K.; Phillips, David E.; Richardson, Lee; Roberts, D. Allen; Roth, Gregory A.; Sandar, Logan; Schumacher, Austin E.; Serina, Peter T.; Shackelford, Katya A.; Singh, Lavanya; Slepak, Erica Leigh; Stanaway, Jeffrey D.; Steiner, Caitlyn; Stevens, Antony; Stewart, Andrea; Temesgen, Awoke M.; Templin, Tara; Thomson, Blake; Wagner, Joseph; Wan, Xia; Wang, Haidong; Wolock, Timothy M.; Wulf, Sarah; Wurtz, Brittany; Vos, Theo] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Ebel, Beth E.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. [Kassebaum, Nicholas J.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Alfonso-Cristancho, Rafael; Anderson, Benjamin O.; Blosser, Christopher D.; Jensen, Paul N.; Mock, Charles N.; Montine, Thomas J.; Quistberg, D. Alex] Univ Washington, Seattle, WA 98195 USA. [Fuerst, Thomas] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Foreman, Kyle J.; Cooke, Graham S.; Jarvis, Deborah L.; Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, London, England. [Ozgoren, Ayse Abbasoglu; Cavlin, Alanur] Hacettepe Univ, Inst Populat Studies, Ankara, Turkey. [Bicer, Burcu Kucuk] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey. [Abd-Allah, Foad] Cairo Univ, Fac Med, Cairo, Egypt. [Abera, Semaw F.] Mekelle Univ, Coll Hlth Sci, Sch Publ Hlth, Mekelle, Ethiopia. [Abera, Semaw F.] Kilte Awlaelo Hlth & Demog Surveillance Site, Mekelle, Ethiopia. [Aboyans, Victor] Dupuytren Univ Hosp, Limoges, France. [Abraham, Jerry P.] Univ So Calif, Calif Hosp, Family Med Residency Program, Los Angeles, CA USA. [Abraham, Jerry P.] Harvard Univ, Inst Global Hlth, Boston, MA 02115 USA. [Thorne-Lyman, Andrew L.] Harvard Univ, Dept Nutr, Boston, MA USA. [Abraham, Jerry P.; Ding, Eric L.; Wagner, Gregory R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Campos-Nonato, Ismael R.; Shrime, Mark G.; Salomon, Joshua A.] Harvard Univ, Boston, MA 02115 USA. [Benzian, Habib] UCL, Dept Epidemiol & Publ Hlth, London, England. [Abu-Raddad, Laith J.] Weill Cornell Med Coll Ar Rayyan Qatar, Doha, Qatar. [Abu-Rmeileh, Niveen M.] Birzeit Univ, Inst Community & Publ Hlth, Ramallah, Israel. [Chiang, Peggy P.] Univ Melbourne, Gen Practice & Primary Hlth Care Acad Ctr, Melbourne, Vic, Australia. [Meretoja, Atte] Univ Melbourne, Dept Med, Melbourne, Vic, Australia. [Meretoja, Atte] Univ Melbourne, Dept Florey, Melbourne, Vic, Australia. [Ackerman, Ilana N.; Ademi, Zanfina; Blore, Jed D.; Bohensky, Megan A.; Brooks, Peter M.; Colquhoun, Samantha M.; Patton, George C.; Taylor, Hugh R.; Weintraub, Robert G.; Lopez, Alan D.] Univ Melbourne, Melbourne, Vic, Australia. [Ademi, Zanfina; Amini, Heresh] Univ Basel, Basel, Switzerland. [Tanner, Marcel; Tediosi, Fabrizio] Univ Basel, Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Ademi, Zanfina] Univ Basel, Basel, Switzerland. [Adou, Arsene K.] Assoc Ivoirienne Bien Etre Familial, Abidjan, Cote Ivoire. [Adsuar, Jose C.; Paleo, Urbano Fra] Univ Extremadura, Caceres, Spain. [Afshin, Ashkan; Micha, Renata; Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Shangguan, Siyi; Shi, Peilin] Tufts Univ, Boston, MA 02111 USA. [Agardh, Emilie E.] Inst Publ Hlth Sci, Stockholm, Sweden. [Alam, Sayed Saidul; Naheed, Aliya] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Alasfoor, Deena] Minist Hlth, Al Khuwair, Oman. [Alegretti, Miguel A.] Univ Republica, Fac Med, Dept Med Prevent & Social, Montevideo, Uruguay. [Cavalleri, Fiorella] Univ Republica, Fac Med, Montevideo, Uruguay. [Alemu, Zewdie A.] Debre Markos Univ, Addis Ababa, Ethiopia. [Alhabib, Samia] King Abdullah Bin Abdulaziz Univ Hosp, Riyadh, Saudi Arabia. [Gething, Peter] Univ Oxford, Dept Zool, Oxford, England. [Ali, Raghib; Bennett, Derrick A.; Briggs, Adam D.; Hay, Simon I.; Piel, Frederic B.; Rahimi, Kazem; Scarborough, Peter] Univ Oxford, Oxford, England. [Gibney, Katherine B.] Melbourne Hlth, Parkville, Vic, Australia. [Alla, Francois] Univ Lorraine, Sch Publ Hlth, Nancy, France. [Allebeck, Peter; Roy, Nobhojit] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Fereshtehnejad, Seyed-Mohammad] Karolinska Inst, Dept Neurobiol Care Sci & Soc NVS, Stockholm, Sweden. [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Kivipelto, Miia] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden. [Havmoeller, Rasmus; Sindi, Shireen] Karolinska Inst, Stockholm, Sweden. [Almazroa, Mohammad A.; Basulaiman, Mohammed O.; Saeedi, Mohammad Y.] Minist Hlth, Riyadh, Saudi Arabia. [Alsharif, Ubai; Endres, Matthias] Charite, D-13353 Berlin, Germany. [Alvarez, Elena] Govt, Madrid, Spain. [Alvis-Guzman, Nelson] Univ Cartagena, Cartagena De Indias, Colombia. [Amare, Azmeraw T.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Hoek, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Amare, Azmeraw T.] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia. [Ameh, Emmanuel A.] Ahmadu Bello Univ, Zaria, Nigeria. [Amini, Heresh] Kurdistan Univ Med Sci, Kurdistan Environm Hlth Res Ctr, Sanandaj, Iran. [Harb, Hilda L.] Minist Publ Hlth, Beirut, Lebanon. [Anderson, H. Ross] Univ London, St Georges, London, England. [Antonio, Carl Abelardo T.] Univ Philippines Manila, Coll Publ Hlth, Dept Hlth Policy & Adm, Manila, Philippines. [Panelo, Carlo Irwin A.] Univ Philippines Manila, Manila, Philippines. [Arnlov, Johan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Falun, Sweden. [Arsenijevic, Valentina S. Arsic] Univ Belgrade, Inst Microbiol & Immunol, Sch Med, Belgrade, Serbia. [Arsenijevic, Valentina S. Arsic] Univ Childrens Hosp Belgrade, Belgrade, Serbia. [Asghar, Rana J.] South Asian Publ Hlth Forum, Islamabad, Pakistan. [Assadi, Reza] Mashhad Univ Med Sci, Mashhad, Iran. [Atkins, Lydia S.] Minist Hlth, Wellness Human Serv & Gender Relat, St Lucia, Qld, Australia. [Avila, Marco A.; Barquera, Simon; Campos-Nonato, Ismael R.; Cuevas-Nasu, Lucia; Gomez Dantes, Hector; Gonzalez-Medina, Diego; Heredia-Pi, Ileana B.; Lozano, Rafael; Montanez Hernandez, Julio C.; Servan-Mori, Edson E.; Levy, Teresa Shamah] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Awuah, Baffour] Komfo Anokye Teaching Hosp, Kumasi, Ghana. [Badawi, Alaa] Publ Hlth Agcy Canada, Toronto, ON, Canada. [Bahit, Maria C.] INECO Neurociencias, Rosario, Argentina. [Balakrishnan, Kalpana] Sri Ramachandra Univ, Madras, Tamil Nadu, India. [Banerjee, Amitava] Univ Birmingham, Birmingham, W Midlands, England. [Barker-Collo, Suzanne L.] Univ Auckland, Sch Psychol, Auckland 1, New Zealand. [Del Pozo-Cruz, Borja] Univ Auckland, Auckland 1, New Zealand. [Barregard, Lars] Univ Gothenburg, Dept Occupat & Environm Hlth, Gothenburg, Sweden. [Barrero, Lope H.] Pontificia Univ Javeriana, Dept Ind Engn, Bogota, Colombia. [Basu, Arindam] Univ Canterbury, Sch Hlth Sci, Christchurch 1, New Zealand. [Gaffikin, Lynne] Stanford Univ, Sch Med, Stanford, CA USA. [Basu, Sanjay] Stanford Univ, Stanford, CA 94305 USA. [Beardsley, Justin] Univ Oxford, Ho Chi Minh City, Vietnam. [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia. [Beghi, Ettore; Cortinovis, Monica; Giussani, Giorgia] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy. [Bekele, Tolesa] Madawalabu Univ, Bale Goba, Ethiopia. [Bell, Michelle L.; Huang, John J.] Yale Univ, New Haven, CT USA. [Benjet, Corina; Gutierrez, Reyna A.] Natl Inst Psychiat Ramon Fuente Muniz, Mexico City, DF, Mexico. [Bensenor, Isabela M.; Kemp, Andrew H.; Lotufo, Paulo A.; Santos, Itamar S.] Univ Sao Paulo, Sao Paulo, Brazil. [Benzian, Habib] NYU, Coll Dent, Dept Epidemiol & Hlth Promot, New York, NY USA. [Thurston, George D.] NYU, Sch Med, Nelson Inst Environm Med, New York, NY USA. [Hagan, Holly] NYU, New York, NY USA. [Bernabe, Eduardo; Hay, Roderick J.; Wolfe, Charles D.] Kings Coll London, London, England. [Deribe, Kebede] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia. [Beyene, Tariku J.; Mekonnen, Wubegzier] Univ Addis Ababa, Addis Ababa, Ethiopia. [Bhala, Neeraj] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England. [Bhala, Neeraj] Univ Otago, Sch Med, Dunedin, New Zealand. [Bhalla, Ashish; Jha, Vivekanand] Postgrad Inst Med Educ & Res, Chandigarh 160012, India. [Bhutta, Zulfiqar A.] Aga Khan Univ, Med Ctr, Karachi, Pakistan. [Nisar, Muhammad I.] Aga Khan Univ, Karachi, Pakistan. [Bikbov, Boris] AI Evdokimov Moscow State Univ Med & Dent, Moscow, Russia. [Bikbov, Boris] Acad VI Shumakov Fed Res Ctr Transplantol & Artif, Moscow, Russia. [Driscoll, Tim R.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Blyth, Fiona M.; Kemp, Andrew H.; Leigh, James] Univ Sydney, Sydney, NSW 2006, Australia. [Basara, Berrak Bora; Yentur, Goekalp K.] Minist Hlth, Gen Directorate Hlth Res, Ankara, Turkey. [Uzun, Selen B.] Minist Hlth, Ankara, Turkey. [Bornstein, Natan M.] Tel Aviv Saurasky Med Ctr, Tel Aviv, Israel. [Bose, Dipan] World Bank, Washington, DC 20433 USA. [Boufous, Soufiane] Univ New S Wales, Transport & Rd Safety TARS Res, Kensington, NSW 2033, Australia. [Resnikoff, Serge] Univ New S Wales, BHVI, Kensington, NSW 2033, Australia. [Degenhardt, Louisa; Mitchell, Philip B.] Univ New S Wales, Kensington, NSW 2033, Australia. [Bourne, Rupert R. A.] Anglia Ruskin Univ, Cambridge, England. [Boyers, Lindsay N.] Georgetown Univ, Washington, DC USA. [Brainin, Michael] Danube Univ Krems, Krems, Austria. [Brayne, Carol E.] Cambridge Inst Publ Hlth, Cambridge, England. [Brazinova, Alexandra] Trnava Univ, Fac Hlth Sci & Social Work, Trnava, Slovakia. [Majdan, Marek] Trnava Univ, Dept Publ Hlth, Trnava, Slovakia. [Breitborde, Nicholas J. K.] Ohio State Univ, Columbus, OH 43210 USA. [Breitborde, Nicholas J. K.] Univ Arizona, Tucson, AZ USA. [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, Heidelberg, Germany. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Lloyd, Belinda K.] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia. [Gabbe, Belinda; Gibney, Katherine B.; Thrift, Amanda G.] Monash Univ, Melbourne, Vic 3004, Australia. [Buckle, Geoffrey C.; Gosselin, Richard A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Budke, Christine M.] Texas A&M Univ, College Stn, TX USA. [Bulloch, Andrew G.; Patten, Scott B.; Tonelli, Marcello; Wang, Jianli] Univ Calgary, Calgary, AB, Canada. [Carabin, Helene] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Carapetis, Jonathan R.] Telethon Inst Child Hlth Res, Subiaco, WA, Australia. [Cardenas, Rosario] Univ Autonoma Metropolitana, Mexico City, DF, Mexico. [Carpenter, David O.] SUNY Albany, Albany, NY 12222 USA. [Caso, Valeria] Univ Perugia, I-06100 Perugia, Italy. [Castaneda-Orjuela, Carlos A.] Colombian Natl Hlth Observ, Bogota, Colombia. [Castaneda-Orjuela, Carlos A.] Univ Nacl Colombia, Dept Publ Hlth, Epidemiol & Publ Hlth Evaluat Grp, Bogota, Colombia. [Castro, Ruben E.] Univ Diego Portales, Santiago, Chile. [Catala-Lopez, Ferran] Spanish Med & Healthcare Prod Agcy AEMPS, Minist Hlth, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain. [Catala-Lopez, Ferran] Univ Valencia, Dept Med, CIBERSAM, Valencia, Spain. [Chadha, Vineet K.] Natl TB Inst, Bengaluru, India. [Chang, Jung-Chen] Natl Taiwan Univ, Coll Med, Taipei, Taiwan. [Hoy, Damian G.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Knibbs, Luke D.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia. [Scott, James G.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia. [Charlson, Fiona J.; Erskine, Holly E.; Ferrari, Alize J.; Gouda, Hebe N.; Mcgrath, John J.; Whiteford, Harvey A.] Univ Queensland, Brisbane, Qld, Australia. [Chen, Honglei] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Jiang, Ying] Univ Occupat & Environm Hlth, Dept Hlth Dev, Kitakyushu, Fukuoka 807, Japan. [Jiang, Ying; Takahashi, Ken] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka 807, Japan. [Chimed-Ochir, Odgerel; Jiang, Ying; Takahashi, Ken] Univ Occupat & Environm Hlth, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Chowdhury, Rajiv; Murray, Joseph] Univ Cambridge, Cambridge, England. [Christensen, Hanne] Bispebjerg Hosp, Copenhagen, Denmark. [Christophi, Costas A.] Cyprus Univ Technol, Limassol, Cyprus. [Cirillo, Massimo] Univ Salerno, I-84081 Baronissi, Italy. [Colistro, Valentina] Univ Republica, Montevideo, Uruguay. [Colistro, Valentina] Minist Salud Publ, Montevideo, Uruguay. [Colquhoun, Samantha M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England. [Criqui, Michael H.; Jassal, Simerjot K.; Stein, Murray B.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Cooper, Leslie T.] Mayo Clin, Rochester, MN USA. [Coppola, Luis M.] Hosp Municipal Ramon Santamarina, Tandil, Argentina. [Crump, John A.] Univ Otago, Dunedin Sch Med, Ctr Int Hlth, Dunedin, New Zealand. [Derrett, Sarah] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand. [Poulton, Richie G.] Univ Otago, Dunedin, New Zealand. [Derrett, Sarah] Massey Univ, Coll Hlth, Sch Publ Hlth, Palmerston North, New Zealand. [Danawi, Hadi] Walden Univ, Minneapolis, MN USA. [Dandona, Lalit; Dandona, Rakhi; Kumar, G. Anil; Murthy, Kinnari S.; Reddy, K. Srinath] Publ Hlth Fdn India, New Delhi, India. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Davey, Gail] Wellcome Trust Brighton, Brighton, E Sussex, England. [Davey, Gail] Sussex Ctr Global Hlth Res, Brighton, E Sussex, England. [Davis, Adrian; Fay, Derek F.] Publ Hlth England, London, England. [Davitoiu, Dragos V.] Univ Med & Pharm Bucharest, Bucharest, Romania. [Dayama, Anand] Jacobi Med Ctr, Dept Surg, Atlanta, GA USA. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Brisbane, Qld 4111, Australia. [De Leo, Diego] Griffith Univ, Brisbane, Qld 4111, Australia. [Dellavalle, Robert P.] Eastern Colorado Healthcare Syst, US Dept Vet Affairs, Denver, CO USA. [Deribe, Kebede] Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Des Jarlais, Don C.] Mt Sinai Beth Israel, New York, NY USA. [Des Jarlais, Don C.] Icahn Sch Med Mt Sinai, New York, NY USA. [Dessalegn, Muluken] Africa Med & Res Fdn Ethiopia, Addis Ababa, Ethiopia. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Lunevicius, Raimundas] Univ Liverpool, Sch Med, Liverpool L69 3BX, Merseyside, England. [Dherani, Mukesh K.; Pope, Daniel] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Dokova, Klara] Med Univ Varna, Fac Publ Hlth, Dept Social Med, Varna, Bulgaria. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Edmond, Karen M.; Hankey, Graeme J.] Univ Western Australia, Perth, WA 6009, Australia. [Elshrek, Yousef M.] Univ Tripoli, Fac Agr, Dept Food Sci, Tripoli, Libya. [Ermakov, Sergey P.] Russian Acad Sci, Inst Social & Econ Studies Populat, Moscow, Russia. [Ermakov, Sergey P.] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Eshrati, Babak] Arak Univ Med Sci & Hlth Affairs, Arak, Iran. [Esteghamati, Alireza; Farzadfar, Farshad; Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Univ Tehran Med Sci, Communicable Dis Res Ctr, Endocrinol & Metab Res Inst, Tehran, Iran. [Heydarpour, Pouria; Sahraian, Mohammad Ali] Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Neurosci Inst, Tehran, Iran. [Sepanlou, Sadaf G.] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran. [Faraon, Emerito Jose A.] UP Coll Publ Hlth, DHPA, Manila, Philippines. [Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand. [Te Ao, Braden J.] Auckland Univ Technol, Auckland, New Zealand. [Felson, David T.] Boston Univ, Boston, MA 02215 USA. [Fernandes, Jefferson G.] German Hosp Oswaldo Cruz, Inst Educ & Sci, Sao Paulo, Brazil. [Foigt, Nataliya] Acad Med Sci, Inst Gerontol, Kiev, Ukraine. [Fowkes, F. Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Franklin, Richard C.] James Cook Univ, Townsville, Qld 4811, Australia. [Gankpe, Fortune G.] Leras Afrique, Cotonou, Benin. [Gankpe, Fortune G.] CHU Hassan II, Fes, Morocco. [Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, NL-6700 AP Wageningen, Netherlands. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Giroud, Maurice] Univ Hosp Dijon, Dijon, France. [Gona, Philimon] Univ Massachusetts, Boston, MA 02125 USA. [Pourmalek, Farshad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Gotay, Carolyn C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Goto, Atsushi] Tokyo Womens Med Univ, Dept Publ Hlth, Tokyo, Japan. [Gugnani, Harish C.] St James Sch Med, Kralendijk, Netherlands. [Gupta, Rahul] West Virginia Bur Publ Hlth, Charleston, WV USA. [Gupta, Rajeev] Fortis Escorts Hosp, Jaipur, Rajasthan, India. [Halasa, Yara A.; Undurraga, Eduardo A.] Brandeis Univ, Waltham, MA USA. [Hamadeh, Randah R.] Arabian Gulf Univ, Manama, Bahrain. [Hammami, Mouhanad] Wayne Cty Dept Hlth & Human Serv, Detroit, MI USA. [Hao, Yuantao] Sun Yae Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China. [Zheng, Yingfeng] Sun Yae Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China. [Maria Haro, Josep] Parc Sanitari St Joan Deu CIBERSAM, Barcelona, Spain. [Maria Haro, Josep] Univ Barcelona, Barcelona, Spain. [Hay, Roderick J.] Int Fdn Dermatol, London, England. [Hijar, Martha] Fdn Entornos AC, Cuernavaca, Morelos, Mexico. [Hoek, Hans W.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Moran, Andrew E.] Columbia Univ, New York, NY USA. [Hoffman, Howard J.] Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, NIH, Bethesda, MD USA. [Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bethesda, MD 20892 USA. [Sampson, Uchechukwu K. A.] NHLBI, NIH, Bethesda, MD 20892 USA. [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Hossain, Mazeda; Mckee, Martin; Pearce, Neil; Pullan, Rachel L.; Tillmann, Taavi] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Hotez, Peter J.] Baylor Coll Med, Houston, TX 77030 USA. [Hoy, Damian G.] Secretariat Pacific Community, Publ Hlth Div, Noumea, New Caledonia. [Hsairi, Mohamed] Natl Inst Publ Hlth, Tunis, Tunisia. [Hu, Guoqing] Cent S Univ, Sch Publ Hlth, Changsha, Hunan, Peoples R China. [Huang, Cheng] George Washington Univ, Washington, DC USA. [Husseini, Abdullatif] Qatar Univ, Doha, Qatar. [Iburg, Kim M.] Aarhus Univ, Aarhus, Denmark. [Innos, Kaire] Natl Inst Hlth Dev, Tallinn, Estonia. [Inoue, Manami] Univ Tokyo, Grad Sch Med, Tokyo, Japan. [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan. [Shibuya, Kenji] Univ Tokyo, Tokyo, Japan. [Islami, Farhad] Amer Canc Soc, New York, NY USA. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA 22030 USA. [Jee, Sun Ha] Yonsei Univ, Grad Sch Publ Hlth, Seoul 120749, South Korea. [Jeemon, Panniyammakal; Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India. [Jiang, Guohong] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany. [Juel, Knud] Natl Inst Publ Hlth, Copenhagen, Denmark. [She, Jun] Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China. [Kan, Haidong] Fudan Univ, Shanghai 200433, Peoples R China. [Karch, Andre] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany. [Karch, Andre] German Ctr Infect Res DZIF, Hannover Braunschweig Site, Braunschweig, Germany. [Karema, Corine K.] Minist Hlth, Malaria & Other Parasit Dis Div, Kigali City, Rwanda. [Karimkhani, Chante] Case Western Univ Hosp, Cleveland, OH USA. [Karthikeyan, Ganesan; Paul, Vinod K.; Satpathy, Maheswar; Tandon, Nikhil] All India Inst Med Sci, New Delhi, India. [Kaul, Anil] Oklahoma State Univ, Tulsa, OK USA. [Kazanjan, Konstantin] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Kengne, Andre P.; Matzopoulos, Richard; Msemburi, William T.; Stein, Dan J.] South African Med Res Council, Cape Town, South Africa. [Sliwa, Karen] Univ Cape Town, Fac Hlth Sci, Hatter Inst Cardiovasc Res Africa, ZA-7925 Cape Town, South Africa. [Matzopoulos, Richard] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa. [Kengne, Andre P.; Mayosi, Bongani M.; Stein, Dan J.] Univ Cape Town, ZA-7925 Cape Town, South Africa. [Keren, Andre] Hadassah Kerem Univ Hosp, Cardiol, Jerusalem, Israel. [Khader, Yousef S.] Jordan Univ Sci & Technol, Irbid, Jordan. [Khalifa, Shams Eldin A.] Supreme Council Hlth, Doha, Qatar. [Khan, Ejaz A.] Hlth Serv Acad, Islamabad, Pakistan. [Khan, Ejaz A.] Expanded Programme Immunizat, Islamabad, Pakistan. [Khan, Gulfaraz] UAE Univ, Al Ain, U Arab Emirates. [Khang, Young-Ho] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Kieling, Christian] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Kim, Daniel] Northeastern Univ, Boston, MA 02115 USA. [Kim, Sungroul] Soonchunhyang Univ, Seoul, South Korea. [Kim, Yunjin] Southern Univ Coll, Johor Baharu, Malaysia. [Kinfu, Yohannes] Univ Canberra, Canberra, ACT 2601, Australia. [Knudsen, Ann Kristin] Norwegian Inst Publ Hlth, Dept Hlth Registries, Oslo, Norway. [Kinge, Jonas M.; Skirbekk, Vegard; Vollset, Stein Emil] Norwegian Inst Publ Hlth, Oslo, Norway. [Kokubo, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan. [Kosen, Soewarta] NIHRD, Ctr Community Empowerment Hlth Policy & Humanitie, Jakarta, Indonesia. [Krishnaswami, Sanjay; Zonies, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Defo, Barthelemy Kuate] Univ Montreal, Montreal, PQ, Canada. [Kuipers, Ernst J.; Polinder, Suzanne; Richardus, Jan Hendrik] Univ Med Ctr Rotterdam, Erasmus MC, Rotterdam, Netherlands. [Kulkarni, Chanda] Rajrajeswari Med Coll & Hosp, Bangalore, Karnataka, India. [Kulkarni, Veena S.] Arkansas State Univ, Jonesboro, AR USA. [Lai, Taavi] Fourth View Consulting, Tallinn, Estonia. [Lalloo, Ratilal] Univ Adelaide, Sch Dent, Australian Res Ctr Populat Oral Hlth, Adelaide, SA, Australia. [Lallukka, Tea] Finnish Inst Occupat Hlth, Disabil Prevent Res Ctr, Helsinki, Finland. [Shiri, Rahman] Finnish Inst Occupat Hlth, Helsinki, Finland. [Lallukka, Tea] Univ Helsinki, Fac Med, Helsinki, Finland. [Lam, Hilton] Natl Inst Hlth, Inst Hlth Policy & Dev Studies, Manila, Philippines. [Lan, Qing] NCI, Rockville, MD USA. [Lansingh, Van C.] Help Me See Inc, New York, NY USA. [Lansingh, Van C.] Inst Mexicano Oftalmol, Queretaro, Mexico. [Larsson, Anders] Uppsala Univ, Uppsala, Sweden. [Lawrynowicz, Alicia E. B.] Inst Nacl Epidemiol Dr Juan H Jara, Mar Del Plata, Buenos Aires, Argentina. [Leasher, Janet L.] Nova SE Univ, Coll Optometry, Ft Lauderdale, FL 33314 USA. [Leung, Ricky] SUNY Albany, Rensselaer, NY USA. [Li, Bin] Jinan Cent Hosp, Jinan, Peoples R China. [Duan, Leilei; Li, Yichong; Liu, Shiwei; Wang, Linhong; Ye, Pengpeng] China CDC, Natl Ctr Chron & Noncommunible Dis Control Preven, Beijing, Peoples R China. [Li, Yichong] Anolinx LLC, Salt Lake City, UT USA. [Lipshultz, Steven E.] Wayne State Univ, Miami, FL USA. [Simard, Edgar P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Liu, Yang; Narayan, K. M. Venkat] Emory Univ, Atlanta, GA 30322 USA. [Lloyd, Belinda K.] Eastern Hlth, Turning Point, Melbourne, Vic, Australia. [Logroscino, Giancarlo] Univ Bari, Bari, Italy. [Looker, Katharine J.] Univ Bristol, Bristol, Avon, England. [Lortet-Tieulent, Joannie] Amer Canc Soc, Atlanta, GA 30329 USA. [Lucas, Robyn M.] Australian Natl Univ, Canberra, ACT, Australia. [Lunevicius, Raimundas] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England. [Lyons, Ronan A.] Swansea Univ, Swansea, W Glam, Wales. [Ma, Stefan] Minist Hlth Singapore, Singapore, Singapore. [Ma, Stefan] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore. [Weintraub, Robert G.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Mackay, Mark T.] Royal Childrens Hosp, Melbourne, Vic, Australia. [Malekzadeh, Reza] Shariati Hosp, Digest Dis Reseach Inst, Tehran, Iran. [Malekzadeh, Reza] Shiraz Univ Med Scinces, Shiraz, Iran. [Marcenes, Wagner] Queen Mary Univ London, London, England. [Meaney, Peter A.] Univ Penn, Pereleman Sch Med, Philadelphia, PA 19104 USA. [Margolis, David J.; Silberberg, Donald H.] Univ Penn, Philadelphia, PA 19104 USA. [Marzan, Melvin B.] Univ East Ramon Magsaysay Mem, Med Ctr, Quezon City, Philippines. [Masci, Joseph R.] Elmhurst Hosp Ctr, Mt Sinai Serv, Elmhurst, NY USA. [Mashal, Mohammad T.] Minist Publ Hlth, Kabul, Afghanistan. [Mazorodze, Tasara T.] AIDC EC, Port Elizabeth, South Africa. [Mcgill, Neil W.] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia. [Meaney, Peter A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Mehndiratta, Man Mohan] Janakpuri Superspecialty Hosp, New Delhi, India. [Melaku, Yohannes A.] Mekelle Univ, Mekelle, Ethiopia. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Memish, Ziad A.] Saudi Minist Hlth, Riyadh, Saudi Arabia. [Meretoja, Atte] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland. [Mhimbira, Francis A.] Ifakara Hlth Inst, Bagamoyo, Tanzania. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Miller, Ted R.] Curtin Univ, Ctr Populat Hlth, Perth, WA 6845, Australia. [Mills, Edward J.] Univ Ottawa, Ottawa, ON, Canada. [Ibrahim, Norlinah Mohamed] Univ Kebangsaan Malaysia, Med Ctr, Dept Med, Bandar Tun Razak, Malaysia. [Mohammad, Karzan A.] Univ Salahaddin, Erbil, Iraq. [Mola, Glen L. D.] Univ Papua New Guinea, Boroko, Papua N Guinea. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy. [Moore, Ami R.] Univ N Texas, Denton, TX 76203 USA. [Moradi-Lakeh, Maziar] Iran Univ Med Sci, Dept Community Med, Tehran, Iran. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo, Japan. [Tsilimbaris, Miltiadis] Univ Crete, Dept Med, Iraklion, Greece. [Moschandreas, Joanna] Univ Crete, Iraklion, Greece. [Moturi, Wilkister N.] Egerton Univ, Egerton, Kenya. [Mueller, Ulrich O.] Univ Marburg, Marburg, Germany. [Mukaigawara, Mitsuru] Okinawa Chubu Hosp, Okinawa, Japan. [Murdoch, Michele E.] West Herts Hosp NHS Trust, Watford, England. [Naidoo, Kovin S.] Univ KwaZulu Natal, Durban, South Africa. [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Nand, Devina] Minist Hlth, Suva, Fiji. [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India. [Nejjari, Chakib] Fac Med, Fes, Morocco. [Neupane, Sudan P.] Univ Oslo, Oslo, Norway. [Ngalesoni, Frida N.] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Nolte, Sandra; Papachristou, Christina] Charite, D-13353 Berlin, Germany. [Nolte, Sandra] Deakin Univ, Melbourne, Vic, Australia. [Vollset, Stein Emil] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway. [Norheim, Ole F.] Univ Bergen, Bergen, Norway. [Norman, Rosana E.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. [Norrving, Bo] Lund Univ, Dept Clin Sci, Lund, Sweden. [Nyakarahuka, Luke] Makerere Univ, Kampala, Uganda. [Oh, In-Hwan] Kyung Hee Univ, Seoul, South Korea. [Ohkubo, Takayoshi] Teikyo Univ, Sch Med, Tokyo 173, Japan. [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Ikoyi, Nigeria. [Opio, John Nelson] Lira Municipal Council, Lira Dist Local Govt, Lira, Uganda. [Ortiz, Alberto] IIS Fdn Jimenez Diaz, Madrid, Spain. [Pandian, Jeyaraj D.] Christian Med Coll Ludhiana, Ludhiana, Punjab, India. [Park, Eun-Kee] Kosin Univ, Coll Med, Busan, South Korea. [Park, Jae-Hyun] Sungkyunkwan Univ, Sch Med, Suwon, South Korea. [Pereira, David M.] Univ Porto, Fac Farm, Dept Quim, REQUIMTE LAQV,Lab Farmacognosia, P-4100 Oporto, Portugal. [Perez-Padilla, Rogelio] Natl Inst Resp Dis, Mexico City, DF, Mexico. [Perez-Ruiz, Fernando] Hopsital Univ Cruces, OSI EE Cruces, Baracaldo, Spain. [Perez-Ruiz, Fernando] Biocruces Hlth Res Inst, Baracaldo, Spain. [Perico, Norberto; Trillini, Matias] Mario Negri Inst Pharmacol Res, Ranica, Italy. [Pervaiz, Aslam] Postgrad Med Inst, Lahore, Pakistan. [Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA 5001, Australia. [Peterson, Carrie B.] Aalborg Univ, Aalborg Esst, Denmark. [Petzold, Max] Hlth Metr Unit, Gothenburg, Sweden. [Petzold, Max] Univ Witwatersrand, Johannesburg, South Africa. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China. [Phillips, Michael R.] Emory Univ, Atlanta, GA 30322 USA. [Plass, Dietrich] Fed Environm Agcy, Sect Exposure Assessment & Environm Hlth Indicato, Berlin, Germany. [Poenaru, Dan] McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada. [Poenaru, Dan] MyungSung Med Coll, Addis Ababa, Ethiopia. [Popova, Svetlana] Ctr Addict & Mental Hlth CAMH, Toronto, ON, Canada. [Prasad, Noela M.] Fred Hollows Fdn, Sydney, NSW, Australia. [Qato, Dima M.] Univ Illinois, Chicago, IL USA. [Rafay, Anwar; Rana, Saleem M.] Contech Int Hlth Consultants, Lahore, Pakistan. [Rahman, Sajjad U.] Hamad Med Corp, Doha, Qatar. [Raju, Murugesan] Univ Missouri, Columbia, MO USA. [Rafay, Anwar; Rana, Saleem M.] Contech Sch Publ Hlth, Lahore, Pakistan. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Refaat, Amany] Suez Canal Univ, Ismailia, Egypt. [Remuzzi, Giuseppe] IRCCS Mario Negri Inst Pharmacol Res, Centro Anna Maria Astori, Bergamo, Italy. [Resnikoff, Serge] Int Hlth & Dev, Geneva, Switzerland. [Ribeiro, Antonio L.] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil. [Rojas-Rueda, David] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Rothenbacher, Dietrich] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany. [Rothstein, David H.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA. [Roy, Nobhojit] HBNI Univ, BARC Hosp, Bombay, Maharashtra, India. [Ruhago, George M.; Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Saha, Sukanta] Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Brisbane, Qld, Australia. [Sanabria, Juan R.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Sanabria, Juan R.] Chicago Med Sch, Canc Treatment Ctr Amer RFU, N Chicago, IL USA. [Sawhney, Monika] Marshall Univ, Huntington, WV USA. [Schneider, Ione J.] Univ Fed Santa Catarina, Florianopolis, SC, Brazil. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Seedat, Soraya] Univ Stellenbosch, Cape Town, South Africa. [Shaheen, Amira] An Najah Univ, Nablus, Israel. [Shahraz, Saeid] Tufts Med Ctr, Boston, MA USA. [Shangguan, Siyi] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan. [Shiri, Rahman] Finnish Inst Occupat Hlth, Helsinki, Finland. [Shishani, Kawkab] Washington State Univ, Spokane, WA USA. [Shiue, Ivy] Northumbria Univ, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England. [Shiue, Ivy] Univ Edinburgh, Alzheimers Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland. [Sigfusdottir, Inga D.] Reykjavik Univ, Reykjavik, Iceland. [Singh, Abhishek] Int Inst Populat Sci, Bombay, Maharashtra, India. [Soneji, Samir] Dartmouth Coll, Lebanon, NH 03756 USA. [Soreide, Kjetil] Stavanger Univ Hosp, Stavanger, Norway. [Soshnikov, Sergey] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Sposato, Luciano A.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada. [Sreeramareddy, Chandrashekhar T.] Univ Tunku Abdul Rahman, Fac Med & Hlth Sci, Kajang, Cheras, Malaysia. [Stathopoulou, Vasiliki] Attikon Univ Hosp, Athens, Greece. [Stovner, Lars J.] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway. [Steiner, Timothy J.] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway. [Stovner, Lars J.] St Olavs Hosp, Norwegian Advisory Unit Headache, Trondheim, Norway. [Stroumpoulis, Konstantinos] Alexandra Gen Hosp Athens, Athens, Greece. [Stroumpoulis, Konstantinos] Ctr Hosp Publ Cotentin, Cherbourg, France. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Swaroop, Mamta; Yano, Yuichiro] Northwestern Univ, Chicago, IL 60611 USA. [Sykes, Bryan L.] Univ Calif Irvine, Irvine, CA USA. [Tabb, Karen M.] Univ Illinois, Champaign, IL USA. [Tanne, David] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Tanne, David] Tel Aviv Univ, IL-69978 Tel Aviv, Israel. [Tavakkoli, Mohammad] Westchester Med Ctr, Valhalla, NY USA. [Ten Have, Margreet] Netherlands Inst Mental Hlth & Addict, Utrecht, Netherlands. [Tenkorang, Eric Y.] Mem Univ Newfoundland, St John, NF, Canada. [Terkawi, Abdullah S.] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA. [Terkawi, Abdullah S.] Outcomes Res Consortium, Cleveland, OH USA. [Terkawi, Abdullah S.] King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi Arabia. [Thorne-Lyman, Andrew L.] WorldFish, George Town, Malaysia. [Topouzis, Fotis] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece. [Toyoshima, Hideaki] Anjo Kosei Hosp, Hlth Care Ctr, Anjo City, Japan. [Traebert, Jefferson] Univ Southern Santa Catarina, Palhoca, Brazil. [Tran, Bach X.] Johns Hopkins Univ, Baltimore, MD USA. [Tran, Bach X.] Hanoi Med Univ, Hanoi 100803, Vietnam. [Truelsen, Thomas] Univ Copenhagen, Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark. [Tuzcu, Emin M.] Cleveland Clin, Cleveland, OH 44106 USA. [Uchendu, Uche S.] Dept Vet Affairs, Washington, DC USA. [Ukwaja, Kingsley N.] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria. [Van Brakel, Wim H.] Netherlands Leprosy Relief, Amsterdam, Netherlands. [Van De Vijver, Steven] African Populat & Hlth Res Ctr, Nariobi, Kenya. [van Gool, Coen H.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Van Os, Jim] Maastricht Univ, Med Ctr, NL-6200 MD Maastricht, Netherlands. [Vasankari, Tommi J.] UKK Inst Hlth Promot Res, Tampere, Finland. [Venketasubramanian, N.] Raffles Hosp, Neurosci Ctr, Singapore, Singapore. [Violante, Francesco S.] Univ Bologna, Bologna, Italy. [Vlassov, Vasiliy V.] Higher Sch Econ, Moscow, Russia. [Wagner, Gregory R.] Natl Inst Occupat Safety & Hlth, Washington, DC USA. [Waller, Stephen G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Wan, Xia] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100730, Peoples R China. [Chen, Wanqing] Chinese Acad Med Sci, Inst Canc, Beijing 100021, Peoples R China. [Warouw, Tati S.] Minist Hlth Indonesia, NIHRD, Jakarta, Indonesia. [Weichenthal, Scott] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Wang Wenzhi] Beijing Neurosurg Inst, Beijing, Peoples R China. [Werdecker, Andrea] Inst Med Sociol & Social Med, Marburg, Germany. [Westerman, Ronny] Fed Inst Populat Res, Wiesbaden, Germany. [Westerman, Ronny] German Natl Cohort Consortium, Heidelberg, Germany. [Wilkinson, James D.] Wayne State Univ, Detroit, MI USA. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, England. [Xu, Gelin] Nanjing Univ, Sch Med, Nanjing 210008, Jiangsu, Peoples R China. [Yan, Lijing L.] Duke Kunshan Univ, Kunshan, Peoples R China. [Yano, Yuichiro] Jichi Med Sch, Simotsuke, Tochigi, Japan. [Yip, Paul] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Yonemoto, Naohiro] Natl Ctr Neurol & Psychiat, Kodaira, Tokyo, Japan. [Yoon, Seok-Jun] Korea Univ, Seoul, South Korea. [Younis, Mustafa Z.] Jackson State Univ, Jackson, MS USA. [Yu, Chuanhua] Sch Publ Hlth, Wuhan, Peoples R China. [Yu, Chuanhua] Wuhan Univ, Global Hlth Inst, Wuhan 430072, Peoples R China. [Zaki, Maysaa E.] Mansoura Fac Med, Mansoura, Egypt. [Zhao, Yong] Chongqing Med Univ, Chongqing, Peoples R China. RP Murray, CJL (reprint author), Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. RI ; Undurraga, Eduardo/I-3739-2014; Higashi, Hideki/D-3797-2011; Santos, Itamar/K-7055-2012; Patton, George/B-5246-2013; Scott, James/D-5900-2012; Brenner, Hermann/B-4627-2017; Majdan, Marek/K-5017-2012; Alsharif, Ubai/C-6527-2017; Amini, Heresh/B-3076-2010; Lotufo, Paulo/A-9843-2008; Karch, Andre/D-6973-2017; Franklin, Richard/H-1731-2012; Giussani, Giorgia/E-8057-2017; Ermakov, Sergey/G-1709-2016; NORMAN, ROSANA/F-2774-2010; Sepanlou, Sadaf/H-9343-2016; Bolliger, Ian/C-4207-2016; LOGROSCINO, GIANCARLO/K-5148-2016; Naldi, Luigi/K-6343-2016; Thrift, Amanda/I-6251-2012; Weiderpass, Elisabete/M-4029-2016; Dokova, Klara/N-2448-2016; Jacobsen, Kathryn/B-5857-2008; Nolte, Sandra/B-7498-2008; Tonelli, Marcello/B-3028-2009; Lalloo, Ratilal/O-5624-2014; Tillmann, Taavi/R-6026-2016; Salomon, Joshua/D-3898-2009; Rahimi, Kazem/Q-1279-2015; Charlson, Fiona/F-5290-2011; Patten, Scott/B-4434-2011; Monasta, Lorenzo/B-1388-2012; Adsuar, Jose C/C-6558-2008; Pereira, David/M-9286-2013; Ribeiro, Antonio/C-2707-2009; Haro, Josep Maria/D-1423-2011; Degenhardt, Louisa/D-4515-2012; Hankey, Graeme /H-4968-2014; Kaul, Anil/B-2075-2016; Carabin, Helene/B-7600-2016; Whiteford, Harvey/A-4840-2009 OI Moradi-Lakeh, Maziar/0000-0001-7381-5305; Stein, Dan/0000-0001-7218-7810; Olusanya, Bolajoko/0000-0002-3826-0583; Heydarpour, Pouria/0000-0001-5644-7555; Norheim, Ole F./0000-0002-5748-5956; Hoek, Hans/0000-0001-6353-5465; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Bernabe, Eduardo/0000-0002-1858-3713; Derrett, Sarah/0000-0003-2867-0498; Taylor, Hugh/0000-0002-9437-784X; Khang, Young-Ho/0000-0002-9585-8266; Ortiz Arduan, Alberto/0000-0002-9805-9523; Kemp, Andrew/0000-0003-1146-3791; Erskine, Holly/0000-0003-3119-9211; Aboyans, Victor/0000-0002-0322-9818; Gouda, Hebe/0000-0002-5709-4509; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; Catala-Lopez, Ferran/0000-0002-3833-9312; Piel, Frederic B./0000-0001-8131-7728; Giussani, Giorgia/0000-0003-2460-3095; Leung, Ricky/0000-0002-2852-6771; Kieling, Christian/0000-0001-7691-4149; Sindi, Shireen/0000-0002-3786-0552; Gething, Peter/0000-0001-6759-5449; Husseini, Abdullatif/0000-0001-8767-5956; Benjet, Corina/0000-0002-4569-6094; Gabbe, Belinda/0000-0001-7096-7688; Prabhakaran, Dorairaj/0000-0002-3172-834X; Neupane, Sudan Prasad/0000-0002-7389-4178; Deribe, Kebede/0000-0002-8526-6996; Xu, Gelin/0000-0002-6194-0341; Goto, Atsushi/0000-0003-0669-654X; Soshnikov, Sergey/0000-0002-6983-7066; assadi, reza/0000-0002-5016-2994; Mitchell, Philip/0000-0002-7954-5235; Vlassov, Vasiliy/0000-0001-5203-549X; Soreide, Kjetil/0000-0001-7594-4354; Tediosi, Fabrizio/0000-0001-8671-9400; Miller, Ted/0000-0002-0958-2639; Undurraga, Eduardo/0000-0002-4425-1253; Balakrishnan, Kalpana/0000-0002-5905-1801; Montico, Marcella/0000-0003-0377-8232; Vlassov, Valentin/0000-0003-2845-2992; Mhimbira, Francis/0000-0001-8989-6832; Higashi, Hideki/0000-0002-5534-0905; Heredia-Pi, Ileana Beatriz/0000-0002-9998-9239; Hay, Simon/0000-0002-0611-7272; Sreeramareddy, Chandrashekhar/0000-0002-5693-7631; Gibney, Katherine/0000-0001-5851-5339; Leasher, Janet/0000-0002-8779-5162; Davis, Adrian/0000-0001-7134-7528; Banerjee, Amitava/0000-0001-8741-3411; Hotez, Peter/0000-0001-8770-1042; Santos, Itamar/0000-0003-3212-8466; Patton, George/0000-0001-5039-8326; Scott, James/0000-0002-0744-0688; Brenner, Hermann/0000-0002-6129-1572; Majdan, Marek/0000-0001-8037-742X; Alsharif, Ubai/0000-0002-4024-3950; Amini, Heresh/0000-0002-4825-1322; Lotufo, Paulo/0000-0002-4856-8450; Karch, Andre/0000-0003-3014-8543; Franklin, Richard/0000-0003-1864-4552; Ermakov, Sergey/0000-0003-1072-1162; NORMAN, ROSANA/0000-0002-9742-1957; Sepanlou, Sadaf/0000-0002-3669-5129; Bolliger, Ian/0000-0001-8055-297X; LOGROSCINO, GIANCARLO/0000-0003-0423-3242; Naldi, Luigi/0000-0002-3160-2835; Thrift, Amanda/0000-0001-8533-4170; Weiderpass, Elisabete/0000-0003-2237-0128; Jacobsen, Kathryn/0000-0002-4198-6246; Nolte, Sandra/0000-0001-6185-9423; Lalloo, Ratilal/0000-0001-5822-1269; Tillmann, Taavi/0000-0002-8428-3719; Salomon, Joshua/0000-0003-3929-5515; Rahimi, Kazem/0000-0002-4807-4610; Charlson, Fiona/0000-0003-2876-5040; Patten, Scott/0000-0001-9871-4041; Monasta, Lorenzo/0000-0001-7774-548X; Adsuar, Jose C/0000-0001-7203-3168; Pereira, David/0000-0003-0384-7592; Ribeiro, Antonio/0000-0002-2740-0042; Haro, Josep Maria/0000-0002-3984-277X; Degenhardt, Louisa/0000-0002-8513-2218; Hankey, Graeme /0000-0002-6044-7328; Whiteford, Harvey/0000-0003-4667-6623 FU Bill & Melinda Gates Foundation; Graduate School of Medical Sciences, University Medical Center Groningen (UMCG); National Health and Medical Research Council; National Natural Sciences Foundation of China; German National Cohort Consortium; Brien Holden Vision Institute; National Health and Medical Research Council Public Health (Australian) Early Career Fellowship; Wellcome Trust Fellowship in Public Health and Tropical Medicine [099876]; National Natural Science Foundation for Young Scholars of China [81200051]; Research Fund for the Doctoral Program of Higher Education of China [20110071120060]; Science Foundation for Young Scholars in Zhongshan Hospital [2012ZSQN04]; Scientific Project for Fudan University [20520133474]; Australian National Health and Medical Research Council Senior Principal Research Fellow; Swiss National Science Foundation [PBBSP3-146869, P300P3-154634]; Korean Health Technology R&D Project (Ministry of Health & Welfare, Republic of Korea) [HI13C0729]; CGIAR Research Program on Aquatic Agricultural Systems FX Bill & Melinda Gates Foundation.; On behalf of the GBD 2010 Genitourinary Diseases Expert Group, GR, NoP, and BB would like to acknowledge that their activities within the GBD 2013 have been made on the behalf of the International Society of Nephrology (ISN). ATA received institutional support and grants from the Graduate School of Medical Sciences, University Medical Center Groningen (UMCG). JM has received support from the National Health and Medical Research Council. LLY is also supported by the National Natural Sciences Foundation of China. UOM would like to acknowledge his funding by the German National Cohort Consortium. RB was provided funding support by the Brien Holden Vision Institute. INA would like to acknowledge her funding support from the National Health and Medical Research Council Public Health (Australian) Early Career Fellowship. KD is supported by a Wellcome Trust Fellowship in Public Health and Tropical Medicine (grant number 099876). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. JS was supported by the National Natural Science Foundation for Young Scholars of China, (number 81200051); Research Fund for the Doctoral Program of Higher Education of China (number 20110071120060); Science Foundation for Young Scholars in Zhongshan Hospital (number 2012ZSQN04); and the Scientific Project for Fudan University (number 20520133474). RB is funded by an Australian National Health and Medical Research Council Senior Principal Research Fellow. TF is grateful to the Swiss National Science Foundation for an Early and an Advanced Postdoc Mobility fellowship (project numbers PBBSP3-146869 and P300P3-154634). SJY and IHO received funding for their work in a grant from the Korean Health Technology R&D Project (Ministry of Health & Welfare, Republic of Korea; grant number HI13C0729). ALT-L was supported by the CGIAR Research Program on Aquatic Agricultural Systems. NR 60 TC 223 Z9 239 U1 79 U2 265 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD NOV 28 PY 2015 VL 386 IS 10009 BP 2145 EP 2191 DI 10.1016/S0140-6736(15)61340-X PG 47 WC Medicine, General & Internal SC General & Internal Medicine GA CX8YW UT WOS:000365992600030 ER PT J AU Brautigam, H Moreno, CL Steele, JW Bogush, A Dickstein, DL Kwok, JBJ Schofield, PR Thinakaran, G Mathews, PM Hof, PR Gandy, S Ehrlich, ME AF Brautigam, Hannah Moreno, Cesar L. Steele, John W. Bogush, Alexey Dickstein, Dara L. Kwok, John B. J. Schofield, Peter R. Thinakaran, Gopal Mathews, Paul M. Hof, Patrick R. Gandy, Sam Ehrlich, Michelle E. TI Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1-/- phenotype and forms complexes with wildtype PS1 and nicastrin SO SCIENTIFIC REPORTS LA English DT Article ID GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; MUTATIONS; PLAQUES; MOUSE; ASPARTATES; INSIGHTS; MUTANT; MICE AB The presenilin 1 (PSEN1) L271V mutation causes early-onset familial Alzheimer's disease by disrupting the alternative splicing of the PSEN1 gene, producing some transcripts harboring the L271V point mutation and other transcripts lacking exon 8 (PS1(Delta exon8)). We previously reported that PS1 L271V increased amyloid beta (A beta) 42/40 ratios, while PS1(Delta exon8) reduced A beta 42/40 ratios, indicating that the former and not the exon 8 deletion transcript is amyloidogenic. Also, PS1(Delta exon8) did not rescue A beta generation in PS1/2 double knockout cells indicating its identity as a severe loss-of-function splice form. PS1(Delta exon8) is generated physiologically raising the possibility that we had identified the first physiological inactive PS1 isoform. We studied PS1(Delta exon8) in vivo by crossing PS1(Delta exon8) transgenics with either PS1-null or Dutch APP(E693Q) mice. As a control, we crossed APP(E693Q) with mice expressing a deletion in an adjacent exon (PS1(Delta exon9)). PS1(Delta exon8) did not rescue embryonic lethality or Notch-deficient phenotypes of PS1-null mice displaying severe loss of function in vivo. We also demonstrate that this splice form can interact with wildtype PS1 using cultured cells and - co-immunoprecipitation (co-IP)/bimolecular fluorescence complementation. Further co-IP demonstrates that PS1(Delta exon8) interacts with nicastrin, participating in the gamma-secretase complex formation. These data support that catalytically inactive PS1(Delta exon8) is generated physiologically and participates in protein-protein interactions. C1 [Brautigam, Hannah; Moreno, Cesar L.; Dickstein, Dara L.; Hof, Patrick R.; Gandy, Sam] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Brautigam, Hannah; Moreno, Cesar L.; Dickstein, Dara L.; Hof, Patrick R.; Gandy, Sam] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Moreno, Cesar L.; Steele, John W.; Gandy, Sam; Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Moreno, Cesar L.; Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Moreno, Cesar L.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Brautigam, Hannah; Steele, John W.; Dickstein, Dara L.; Hof, Patrick R.; Gandy, Sam; Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Brautigam, Hannah; Dickstein, Dara L.; Hof, Patrick R.; Gandy, Sam; Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA. [Brautigam, Hannah; Moreno, Cesar L.; Dickstein, Dara L.; Hof, Patrick R.; Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA. [Brautigam, Hannah] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Steele, John W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92037 USA. [Steele, John W.] OrPhi Therapeut, Dept Preclin Biol, Carlsbad, CA 92008 USA. [Bogush, Alexey] Univ Penn, Perelman Sch Med, Dept Physiol, Philadelphia, PA 19104 USA. [Kwok, John B. J.; Schofield, Peter R.] Neurosci Res Australia, Sydney, NSW 2031, Australia. [Kwok, John B. J.; Schofield, Peter R.] Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia. [Thinakaran, Gopal] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA. [Thinakaran, Gopal] Univ Chicago, Dept Neurol & Pathol, Chicago, IL 60637 USA. [Mathews, Paul M.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA. [Mathews, Paul M.] Nathan Kline Inst Ctr Dementia Res, Orangeburg, NY 10962 USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. EM samuel.gandy@mssm.edu OI moreno, cesar/0000-0002-0876-0341; Mathews, Paul/0000-0003-1742-7687 FU NIH [F31 AG039890, F31 AG042299, P50 AG005138, P01 AG0717617, U01 AG046170, I01 RX000684, R01NS075685, R34 AG049649] FX This work was supported by NIH grants F31 AG039890 (HB), F31 AG042299 (CLM), P50 AG005138 (to Mary Sano with SG, PRH, DLD, MEE), P01 AG0717617 (PM) U01 AG046170 (SG), I01 RX000684 (SG), R01NS075685 (SG), and R34 AG049649 (SG). A portion of this work was used in a dissertation by HB in partial fulfillment of requirements for the PhD degree at the Icahn School of Medicine at Mount Sinai in New York. We thank Drs Miguel Gama Sosa and Gregory Elder for PS1 +/- mice. We also thank: Dr. Chang-Deng Hu, Purdue University for BiFC vectors; Dr. Mark Baxter for advice on statistical analysis; Drs Maitane Ortiz-Virumbrales and Rachel Lane for technical assistance; Jennifer Short and William G.M. Janssen for advice with confocal imaging; Carlos Thomas and Ari Stock for assistance with embryo photographs; and members of the Dickstein, Hof, Ehrlich, and Gandy laboratories for advice and discussion. NR 25 TC 1 Z9 1 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 26 PY 2015 VL 5 AR 17042 DI 10.1038/srep17042 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX0LR UT WOS:000365388600001 PM 26608390 ER PT J AU Banks, WA Gray, AM Erickson, MA Salameh, TS Damodarasamy, M Sheibani, N Meabon, JS Wing, EE Morofuji, Y Cook, DG Reed, MJ AF Banks, William A. Gray, Alicia M. Erickson, Michelle A. Salameh, Therese S. Damodarasamy, Mamatha Sheibani, Nader Meabon, James S. Wing, Emily E. Morofuji, Yoichi Cook, David G. Reed, May J. TI Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Blood-brain barrier; Neurovascular unit; Neuroinflammation; Brain endothelial cells; Indomethacin; Lipopolysaccharide ID ENDOTHELIAL-CELLS; N-ACETYLCYSTEINE; NITRIC-OXIDE; IN-VITRO; CUTTING EDGE; PERMEABILITY; RECEPTOR; ACTIVATION; TRANSPORT; ENDOTOXIN AB Background: Disruption of the blood-brain barrier (BBB) occurs in many diseases and is often mediated by inflammatory and neuroimmune mechanisms. Inflammation is well established as a cause of BBB disruption, but many mechanistic questions remain. Methods: We used lipopolysaccharide (LPS) to induce inflammation and BBB disruption in mice. BBB disruption was measured using C-14-sucrose and radioactively labeled albumin. Brain cytokine responses were measured using multiplex technology and dependence on cyclooxygenase (COX) and oxidative stress determined by treatments with indomethacin and N-acetylcysteine. Astrocyte and microglia/macrophage responses were measured using brain immunohistochemistry. In vitro studies used Transwell cultures of primary brain endothelial cells co-or tri-cultured with astrocytes and pericytes to measure effects of LPS on transendothelial electrical resistance (TEER), cellular distribution of tight junction proteins, and permeability to C-14-sucrose and radioactive albumin. Results: In comparison to LPS-induced weight loss, the BBB was relatively resistant to LPS-induced disruption. Disruption occurred only with the highest dose of LPS and was most evident in the frontal cortex, thalamus, pons-medulla, and cerebellum with no disruption in the hypothalamus. The in vitro and in vivo patterns of LPS-induced disruption as measured with C-14-sucrose, radioactive albumin, and TEER suggested involvement of both paracellular and transcytotic pathways. Disruption as measured with albumin and C-14-sucrose, but not TEER, was blocked by indomethacin. N-acetylcysteine did not affect disruption. In vivo, the measures of neuroinflammation induced by LPS were mainly not reversed by indomethacin. In vitro, the effects on LPS and indomethacin were not altered when brain endothelial cells (BECs) were cultured with astrocytes or pericytes. Conclusions: The BBB is relatively resistant to LPS-induced disruption with some brain regions more vulnerable than others. LPS-induced disruption appears is to be dependent on COX but not on oxidative stress. Based on in vivo and in vitro measures of neuroinflammation, it appears that astrocytes, microglia/macrophages, and pericytes play little role in the LPS-mediated disruption of the BBB. C1 [Banks, William A.; Erickson, Michelle A.; Salameh, Therese S.; Wing, Emily E.; Morofuji, Yoichi; Cook, David G.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.; Erickson, Michelle A.; Damodarasamy, Mamatha; Morofuji, Yoichi; Reed, May J.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Gray, Alicia M.] Univ Washington, Sch Med, Seattle, WA USA. [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Ophthalmol & Visual Sci, Madison, WI USA. [Meabon, James S.] VA Puget Sound Hlth Care Syst, Mental Hlth Res Educ & Clin Ctr, Seattle, WA USA. [Morofuji, Yoichi] Nagasaki Univ, Dept Neurosurg, Nagasaki 852, Japan. RP Banks, WA (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU VA; [R01 AG029839] FX We would like to thank Dr. Jessica Hamerman (University of Washington) for TREM2 KO mouse materials and the rat anti-TREM2 antibody. Supported by the VA and R01 AG029839 (WAB). NR 59 TC 15 Z9 16 U1 2 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD NOV 25 PY 2015 VL 12 AR 223 DI 10.1186/s12974-015-0434-1 PG 15 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CX5ZU UT WOS:000365781800001 PM 26608623 ER PT J AU Tsai, TT Rehring, TF Rogers, RK Shetterly, SM Wagner, NM Gupta, R Jazaeri, O Hedayati, N Jones, WS Patel, MR Ho, PM Go, AS Magid, DJ AF Tsai, Thomas T. Rehring, Thomas F. Rogers, R. Kevin Shetterly, Susan M. Wagner, Nicole M. Gupta, Rajan Jazaeri, Omid Hedayati, Nasim Jones, W. Schuyler Patel, Manesh R. Ho, P. Michael Go, Alan S. Magid, David J. TI The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease SO CIRCULATION LA English DT Article DE comparative effectiveness research; lower extremity bypass surgery; peripheral arterial disease ID QUALITY-OF-LIFE; WALKING IMPAIRMENT QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL; INTERMITTENT CLAUDICATION; OCCLUSIVE DISEASE; LIMB ISCHEMIA; EXERCISE; ENDARTERECTOMY; MULTICENTER; STENOSIS AB Background Treatment for symptomatic peripheral artery disease includes lower extremity bypass surgery (LEB) and peripheral endovascular interventions (PVIs); however, limited comparative effectiveness data exist between the 2 therapies. We assessed the safety and effectiveness of LEB and PVI in patients with symptomatic claudication and critical limb ischemia. Methods and Results In a community-based clinical registry at 2 large integrated healthcare delivery systems, we compared 883 patients undergoing PVI and 975 patients undergoing LEB between January 1, 2005 and December 31, 2011. Rates of target lesion revascularization were greater for PVI than for LEB in patients presenting with claudication (12.32.7% and 19.0 +/- 3.5% at 1 and 3 years versus 5.2 +/- 2.4% and 8.3 +/- 3.1%, log-rank P<0.001) and critical limb ischemia (19.1 +/- 4.8% and 31.6 +/- 6.3% at 1 and 3 years versus 10.8 +/- 2.5% and 16.0 +/- 3.2%, log-rank P<0.001). However, in comparison with PVI, LEB was associated with increased rates of complications up to 30 days following the procedure (37.1% versus 11.9%, P<0.001). There were no differences in amputation rates between the 2 groups. Findings remained consistent in sensitivity analyses by using propensity methods to account for treatment selection. Conclusions In patients with symptomatic peripheral artery disease, in comparison with LEB, PVI was associated with fewer 30-day procedural complications, higher revascularization rates at 1 and 3 years, and no difference in subsequent amputations. C1 [Tsai, Thomas T.; Rehring, Thomas F.; Shetterly, Susan M.; Wagner, Nicole M.; Ho, P. Michael; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA. [Tsai, Thomas T.; Rehring, Thomas F.; Rogers, R. Kevin; Gupta, Rajan; Jazaeri, Omid; Ho, P. Michael; Magid, David J.] Univ Colorado, Denver, CO 80202 USA. [Hedayati, Nasim] UC Davis Hlth Syst, Davis, CA USA. [Jones, W. Schuyler; Patel, Manesh R.] Duke Clin Res Inst, Durham, NC USA. [Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. RP Tsai, TT (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 East Harvard Suite 300, Denver, CO 80231 USA. EM thomas.tsai@coloradooutcomes.org FU Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program [290201000008I] FX This project was funded under Contract No. 290201000008I from the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services. NR 27 TC 3 Z9 3 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 24 PY 2015 VL 132 IS 21 BP 1999 EP 2011 DI 10.1161/CIRCULATIONAHA.114.013440 PG 13 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX3DB UT WOS:000365574600010 PM 26362632 ER PT J AU Ventura, MI Edwards, JD Barnes, DE AF Ventura, Maria I. Edwards, Jerri D. Barnes, Deborah E. TI More than just a movement disorder Why cognitive training is needed in Parkinson disease SO NEUROLOGY LA English DT Editorial Material ID SYMPTOMS; PERFORMANCE AB Parkinson disease (PD) is a movement disorder with cardinal motor symptoms of resting tremor, bradykinesia, freezing of gait, and rigidity.(1) Most PD treatments aim to manage motor symptoms through pharmacologic and surgical interventions such as deep brain stimulation. Although these treatments can improve or slow decline in motor symptoms, they can also have adverse side effects, such as debilitating motor fluctuations, and costs are an estimated $25 billion per year in the United States alone.(2,3) In addition, nonmotor symptoms, including cognitive impairments, can be as troublesome as motor symptoms, but are not responsive to current PD treatments.(4) Results from an extensive review by Seppi et al.(4) show a lack of evidence for the effectiveness of pharmacologic treatments for cognitive decline in PD, with the exception of rivastigmine for the treatment of dementia. Cognitive difficulties in domains such as speed of processing, memory, and visuospatial and attentional executive functioning are common in PD, may appear before motor symptom onset, and can affect approximately 25% of patients at disease onset.(5) Even subtle cognitive decline can negatively affect quality of life. Furthermore, those experiencing cognitive difficulties early in disease progression are at higher risk for cognitive decline, with 80% developing dementia.(6) Therefore, there is a great need to explore nonpharmacologic, noninvasive interventions that are effective in treating cognitive symptoms in order to help patients with PD maintain daily functioning, independence and quality of life. C1 [Ventura, Maria I.] Univ Calif San Francisco, Dept Geriatr, San Francisco, CA 94143 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94117 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Stat, San Francisco, CA 94143 USA. [Edwards, Jerri D.] Univ S Florida, Sch Aging Studies, Tampa, FL USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94117 USA. EM Deborah.Barnes@ucsf.edu FU NIA NIH HHS [T32 AG000212] NR 10 TC 0 Z9 0 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD NOV 24 PY 2015 VL 85 IS 21 BP 1828 EP 1829 DI 10.1212/WNL.0000000000002158 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA CW9HJ UT WOS:000365309500002 PM 26519546 ER PT J AU Kaup, AR Nettiksimmons, J LeBlanc, ES Yaffe, K AF Kaup, Allison R. Nettiksimmons, Jasmine LeBlanc, Erin S. Yaffe, Kristine TI Memory complaints and risk of cognitive impairment after nearly 2 decades among older women SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; DECLINE; BIOMARKERS; DEMENTIA; ADULTS AB Objectives:To investigate the association between subjective memory complaints (SMCs) and long-term risk of cognitive impairment in aging because most previous studies have followed individuals for only a few years.Methods:Participants were 1,107 cognitively normal, community-dwelling older women (aged 65 years and older at baseline) in a prospective study of aging. SMCs were assessed shortly after baseline and repeatedly over time with the yes/no question, Do you feel you have more problems with memory than most? Cognitive status 18 years later (normal or impaired with mild cognitive impairment or dementia) was determined by an expert panel. Using logistic regression, we investigated the association between SMCs over time and risk of cognitive impairment, adjusting for demographics, baseline cognition, and characteristics that differed between those with and without SMCs.Results:At baseline, 8.0% of participants (n = 89) endorsed SMCs. Baseline SMCs were associated with increased risk of cognitive impairment 18 years later (adjusted odds ratio [OR] = 1.7, 95% confidence interval 1.1-2.8). Results were unchanged after excluding participants with depression. The association between SMCs and cognitive impairment was greatest at the last SMC assessment time point (18 years before diagnosis: adjusted OR = 1.7 [1.1-2.9]; 14 years before diagnosis: adjusted OR = 1.6 [0.9-2.7]; 10 years before diagnosis: adjusted OR = 1.9 [1.1-3.1]; 4 years before diagnosis: adjusted OR = 3.0 [1.8-5.0]).Conclusions:SMCs are associated with cognitive impairment nearly 2 decades later among older women. SMCs may be a very early symptom of an insidious neurodegenerative disease process, such as Alzheimer disease. C1 [Kaup, Allison R.] Univ Calif San Francisco, Res Serv, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Kaup, Allison R.; Nettiksimmons, Jasmine; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [LeBlanc, Erin S.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. RP Kaup, AR (reprint author), Univ Calif San Francisco, Res Serv, San Francisco, CA 94143 USA. EM allison.kaup@ucsf.edu FU NIH; National Institute on Aging (NIA) [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576]; NIA grant [K24AG031155]; US Department of Veterans Affairs, Rehabilitation Research and Development Service [1IK2RX001629]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the San Francisco Veterans Affairs Medical Center; Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) FX The Study of Osteoporotic Fractures (SOF) is supported by NIH funding. The National Institute on Aging (NIA) provides support under the following grants: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. The research described here was also supported in part by NIA grant K24AG031155 (awarded to Kristine Yaffe, MD); by Career Development Award 1IK2RX001629 (awarded to Allison Kaup, PhD) from the US Department of Veterans Affairs, Rehabilitation Research and Development Service; and the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). The contents of this manuscript do not represent the views of the US Department of Veterans Affairs or the United States Government. NR 25 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD NOV 24 PY 2015 VL 85 IS 21 BP 1852 EP 1858 DI 10.1212/WNL.0000000000002153 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CW9HJ UT WOS:000365309500007 PM 26511452 ER PT J AU Heo, SJ Thorpe, SD Driscoll, TP Duncan, RL Lee, DA Mauck, RL AF Heo, Su-Jin Thorpe, Stephen D. Driscoll, Tristan P. Duncan, Randall L. Lee, David A. Mauck, Robert L. TI Biophysical Regulation of Chromatin Architecture Instills a Mechanical Memory in Mesenchymal Stem Cells SO SCIENTIFIC REPORTS LA English DT Article ID INDUCED OSTEOGENIC DIFFERENTIATION; MECHANOTRANSDUCTION PATHWAY; LINEAGE SPECIFICATION; HISTONE MODIFICATIONS; GENE-EXPRESSION; FLUID-FLOW; NUCLEUS; ATP; CHONDROCYTES; CYTOSKELETON AB Mechanical cues direct the lineage commitment of mesenchymal stem cells (MSCs). In this study, we identified the operative molecular mechanisms through which dynamic tensile loading (DL) regulates changes in chromatin organization and nuclear mechanics in MSCs. Our data show that, in the absence of exogenous differentiation factors, short term DL elicits a rapid increase in chromatin condensation, mediated by acto-myosin based cellular contractility and the activity of the histone-lysine N-methyltransferase EZH2. The resulting change in chromatin condensation stiffened the MSC nucleus, making it less deformable when stretch was applied to the cell. We also identified stretch induced ATP release and purinergic calcium signaling as a central mediator of this chromatin condensation process. Further, we showed that DL, through differential stabilization of the condensed chromatin state, established a 'mechanical memory' in these cells. That is, increasing strain levels and number of loading events led to a greater degree of chromatin condensation that persisted for longer periods of time after the cessation of loading. These data indicate that, with mechanical perturbation, MSCs develop a mechanical memory encoded in structural changes in the nucleus which may sensitize them to future mechanical loading events and define the trajectory and persistence of their lineage specification. C1 [Heo, Su-Jin; Driscoll, Tristan P.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Heo, Su-Jin; Driscoll, Tristan P.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA. [Thorpe, Stephen D.; Lee, David A.] Queen Mary Univ London, Inst Bioengn, Sch Engn & Mat Sci, London, England. [Driscoll, Tristan P.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Duncan, Randall L.] Univ Delaware, Dept Biol Sci, Newark, DE USA. RP Mauck, RL (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu OI Driscoll, Tristan/0000-0002-2426-5551; Thorpe, Stephen/0000-0002-4707-7756 FU National Institutes of Health [R01 AR056624, R01 EB02425, T32 AR007132, P30 AR050950]; Marie Curie Intra European Fellowship (GENOMICDIFF) [301509]; Montague Research Award from the Perelman School of Medicine; University of Pennsylvania University Research Foundation Award FX This work was supported by the National Institutes of Health (R01 AR056624, R01 EB02425, T32 AR007132, and P30 AR050950) and a Marie Curie Intra European Fellowship (GENOMICDIFF, grant No. 301509). Additional support was provided by a Montague Research Award from the Perelman School of Medicine and a University of Pennsylvania University Research Foundation Award. The authors would like to gratefully acknowledge Dr. Woojin Han for assistance in calcium imaging studies. NR 54 TC 7 Z9 7 U1 5 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 23 PY 2015 VL 5 AR 16895 DI 10.1038/srep16895 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CW6EC UT WOS:000365089300001 PM 26592929 ER PT J AU Chen, LJ Hambright, WS Na, R Ran, QT AF Chen, Liuji Hambright, William Sealy Na, Ren Ran, Qitao TI Ablation of the Ferroptosis Inhibitor Glutathione Peroxidase 4 in Neurons Results in Rapid Motor Neuron Degeneration and Paralysis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; NONAPOPTOTIC CELL-DEATH; TRANSGENIC MICE; OXIDATIVE DAMAGE; APOPTOSIS; GPX4; GENERATION; PROTECTS; PHGPX AB Glutathione peroxidase 4 (GPX4), an antioxidant defense enzyme active in repairing oxidative damage to lipids, is a key inhibitor of ferroptosis, a non-apoptotic form of cell death involving lipid reactive oxygen species. Here we show that GPX4 is essential for motor neuron health and survival in vivo. Conditional ablation of Gpx4 in neurons of adult mice resulted in rapid onset and progression of paralysis and death. Pathological inspection revealed that the paralyzed mice had a dramatic degeneration of motor neurons in the spinal cord but had no overt neuron degeneration in the cerebral cortex. Consistent with the role of GPX4 as a ferroptosis inhibitor, spinal motor neuron degeneration induced by Gpx4 ablation exhibited features of ferroptosis, including no caspase-3 activation, no TUNEL staining, activation of ERKs, and elevated spinal inflammation. Supplementation with vitamin E, another inhibitor of ferroptosis, delayed the onset of paralysis and death induced by Gpx4 ablation. Also, lipid peroxidation and mitochondrial dysfunction appeared to be involved in ferroptosis of motor neurons induced by Gpx4 ablation. Taken together, the dramatic motor neuron degeneration and paralysis induced by Gpx4 ablation suggest that ferroptosis inhibition by GPX4 is essential for motor neuron health and survival in vivo. C1 [Chen, Liuji; Hambright, William Sealy; Na, Ren; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ran, Qitao] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA. RP Ran, QT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ran@uthscsa.edu FU Department of Veterans Affairs; Alzheimer's Association; William and Ella Owens Medical Research Foundation FX Supported by a merit review grant from the Department of Veterans Affairs, a grant from the Alzheimer's Association, and an award from The William and Ella Owens Medical Research Foundation. To whom correspondence should be addressed: Dept. of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229. Tel.: 210-567-3842; Fax: 210-567-6781; E-mail: ran@uthscsa.edu. NR 23 TC 13 Z9 14 U1 4 U2 20 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 20 PY 2015 VL 290 IS 47 BP 28097 EP 28106 DI 10.1074/jbc.M115.680090 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CX5SD UT WOS:000365761900006 PM 26400084 ER PT J AU Li, RS Jen, N Wu, L Lee, J Fang, K Quigley, K Lee, K Wang, S Zhou, B Vergnes, L Chen, YR Li, ZP Reue, K Ann, DK Hsiai, TK AF Li, Rongsong Jen, Nelson Wu, Lan Lee, Juhyun Fang, Karen Quigley, Katherine Lee, Katherine Wang, Sky Zhou, Bill Vergnes, Laurent Chen, Yun-Ru Li, Zhaoping Reue, Karen Ann, David K. Hsiai, Tzung K. TI Disturbed Flow Induces Autophagy, but Impairs Autophagic Flux to Perturb Mitochondrial Homeostasis SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID WALL SHEAR-STRESS; OXIDATIVE STRESS; DNA-DAMAGE; ENDOTHELIAL FUNCTION; NADPH OXIDASE; MN-SOD; ATHEROSCLEROSIS; CELLS; DISEASE; PROTEINS AB Aim: Temporal and spatial variations in shear stress are intimately linked with vascular metabolic effects. Autophagy is tightly regulated in intracellular bulk degradation/recycling system for maintaining cellular homeostasis. We postulated that disturbed flow modulates autophagy with an implication in mitochondrial superoxide (mtO(2)(center dot-)) production. Results: In the disturbed flow or oscillatory shear stress (OSS)-exposed aortic arch, we observed prominent staining of p62, a reverse marker of autophagic flux, whereas in the pulsatile shear stress (PSS)-exposed descending aorta, p62 was attenuated. OSS significantly increased (i) microtubule-associated protein light chain 3 (LC3) II to I ratios in human aortic endothelial cells, (ii) autophagosome formation as quantified by green fluorescent protein (GFP)-LC3 dots per cell, and (iii) p62 protein levels, whereas manganese superoxide dismutase (MnSOD) overexpression by recombinant adenovirus, N-acetyl cysteine treatment, or c-Jun N-terminal kinase (JNK) inhibition reduced OSS-mediated LC3-II/LC3-I ratios and mitochondrial DNA damage. Introducing bafilomycin to Earle's balanced salt solution or to OSS condition incrementally increased both LC3-II/LC3-I ratios and p62 levels, implicating impaired autophagic flux. In the OSS-exposed aortic arch, both anti-phospho-JNK and anti-8-hydroxy-2-deoxyguanosine (8-OHdG) staining for DNA damage were prominent, whereas in the PSS-exposed descending aorta, the staining was nearly absent. Knockdown of ATG5 with siRNA increased OSS-mediated mtO(2)(center dot-), whereas starvation or rapamycin-induced autophagy reduced OSS-mediated mtO(2)(center dot-), mitochondrial respiration, and complex II activity. Innovation: Disturbed flow-mediated oxidative stress and JNK activation induce autophagy. Conclusion: OSS impairs autophagic flux to interfere with mitochondrial homeostasis. Antioxid. Redox Signal. 23, 1207-1219. C1 [Li, Rongsong; Wu, Lan; Fang, Karen; Quigley, Katherine; Lee, Katherine; Wang, Sky; Zhou, Bill; Hsiai, Tzung K.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Dept Med, Los Angeles, CA 90095 USA. [Jen, Nelson; Lee, Juhyun; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Bioengn, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA 90095 USA. [Vergnes, Laurent; Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Chen, Yun-Ru; Ann, David K.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA. [Li, Zhaoping; Hsiai, Tzung K.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90095 USA. RP Hsiai, TK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Henry Samueli Sch Engn & Appl Sci, Dept Med Cardiol, Los Angeles, CA 90095 USA. EM thsiai@mednet.ucla.edu FU National Institutes of Health [HL083015, HL118650, HL111437, DE010742, DE014183] FX The authors are grateful to Dr. Junichi Sadoshima from Rutgers New Jersey Medical School for providing recombinant GFP-LC3 adenoviruses. The authors thank Dr. Peixiang Zhang from UCLA for the Seahorse assay. This project was supported by National Institutes of Health, HL083015 (T.K.H.), HL118650 (T.K.H.), HL111437 (T.K.H.), DE010742 (D.K.A.), and DE014183 (D.K.A.). NR 79 TC 6 Z9 6 U1 1 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD NOV 20 PY 2015 VL 23 IS 15 BP 1207 EP 1219 DI 10.1089/ars.2014.5896 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA CX2HJ UT WOS:000365517400001 PM 26120766 ER PT J AU Mufson, EJ Mahady, L Waters, D Counts, SE Perez, SE Dekosky, ST Ginsberg, SD Ikonomovic, MD Scheff, SW Binder, LI AF Mufson, E. J. Mahady, L. Waters, D. Counts, S. E. Perez, S. E. Dekosky, S. T. Ginsberg, S. D. Ikonomovic, M. D. Scheff, S. W. Binder, L. I. TI HIPPOCAMPAL PLASTICITY DURING THE PROGRESSION OF ALZHEIMER'S DISEASE SO NEUROSCIENCE LA English DT Article DE hippocampus; Alzheimer's disease; neurotrophins; mild cognitive impairment; plasticity degeneration ID MILD COGNITIVE IMPAIRMENT; NERVE GROWTH-FACTOR; CHOLINERGIC BASAL FOREBRAIN; ENDOSOMAL-LYSOSOMAL SYSTEM; AMYLOID PRECURSOR PROTEIN; POSTSYNAPTIC GLUTAMATERGIC FUNCTION; VITRO AUTORADIOGRAPHIC ANALYSIS; LESION-INDUCED SYNAPTOGENESIS; PERFORANT-PATH TRANSECTION; ENTORHINAL CORTEX NEURONS AB Neuroplasticity involves molecular and structural changes in central nervous system (CNS) throughout life. The concept of neural organization allows for remodeling as a compensatory mechanism to the early pathobiology of Alzheimer's disease (AD) in an attempt to maintain brain function and cognition during the onset of dementia. The hippocampus, a crucial component of the medial temporal lobe memory circuit, is affected early in AD and displays synaptic and intraneuronal molecular remodeling against a pathological background of extracellular amyloid-beta (A beta) deposition and intracellular neurofibrillary tangle (NFT) formation in the early stages of AD. Here we discuss human clinical pathological findings supporting the concept that the hippocampus is capable of neural plasticity during mild cognitive impairment (MCI), a prodromal stage of AD and early stage AD. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Mufson, E. J.; Mahady, L.; Waters, D.] St Josephs Med Ctr, Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA. [Counts, S. E.; Binder, L. I.] Michigan State Univ, Coll Human Med, Dept Translat Sci & Mol Med, Grand Rapids, MI USA. [Perez, S. E.] Rush Univ, Med Ctr, Div Neurol Sci, Chicago, IL 60612 USA. [Dekosky, S. T.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. [Ginsberg, S. D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Psychiat, Orangeburg, NY USA. [Ginsberg, S. D.] NYU, Langone Med Ctr, Dept Physiol & Neurosci, Orangeburg, NY USA. [Ikonomovic, M. D.] Univ Pittsburgh, Geriatr Res Educ & Clin Ctr, VA Pittsburgh Healthcare Syst, Dept Neurol, Pittsburgh, PA USA. [Ikonomovic, M. D.] Univ Pittsburgh, Geriatr Res Educ & Clin Ctr, VA Pittsburgh Healthcare Syst, Dept Psychiat, Pittsburgh, PA USA. [Scheff, S. W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. RP Mufson, EJ (reprint author), Barrow Neurol Inst, Alzheimers Dis Res Lab, 350 W Thomas St, Phoenix, AZ 85013 USA. EM elliott.mufson@dignityhealth.org OI Ginsberg, Stephen /0000-0002-1797-4288 FU National Institute on Aging, National Institutes of Health [PO1AG014449, RO1AG043375, RO1AG042475, PO1AG025204, PO1AG107617, P30AG019610, P30AG10161]; Alzheimer's Association FX This study was supported by grants PO1AG014449, RO1AG043375, RO1AG042475, PO1AG025204, PO1AG107617, P30AG019610 and P30AG10161 from the National Institute on Aging, National Institutes of Health and the Alzheimer's Association. We are indebted to the Catholic nuns, priests, and lay brothers who participated in the Rush Religious Orders Study, the University of Kentucky RADC clinical cohort and to all ADC center participants that provided clinical and pathological data to the various studies discussed in this review. NR 232 TC 17 Z9 17 U1 6 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD NOV 19 PY 2015 VL 309 BP 51 EP 67 DI 10.1016/j.neuroscience.2015.03.006 PG 17 WC Neurosciences SC Neurosciences & Neurology GA CV3EV UT WOS:000364142300004 PM 25772787 ER PT J AU Hedgpeth, DC Zhang, XM Jin, JF Leite, RS Krayer, JW Huang, Y AF Hedgpeth, Dustin C. Zhang, Xiaoming Jin, Junfei Leite, Renata S. Krayer, Joe W. Huang, Yan TI Periodontal CD14 mRNA expression is downregulated in patients with chronic periodontitis and type 2 diabetes SO BMC ORAL HEALTH LA English DT Article DE Periodontitis; CD14; TLR4; Diabetes; Gene expression ID MATRIX METALLOPROTEINASE-1 EXPRESSION; TOLL-LIKE RECEPTORS; UP-REGULATION; CARDIOVASCULAR-DISEASE; BINDING-PROTEIN; LIPOPOLYSACCHARIDE; TLR4; LPS; INFLAMMATION; ENDOTOXIN AB Background: Patients with type 2 diabetes mellitus (T2DM) have increased severity of periodontitis. Toll-like receptor (TLR) 4, its co-receptors CD14 and MD-2, and adaptor MyD88 play pivotal roles in lipopolysaccharide (LPS)-triggered tissue inflammation and periodontitis. This study investigated the effects of T2DM and periodontitis on TLR4, CD14, MD-2 and MyD88 mRNA expression in surgically removed periodontal tissues. Methods: Periodontal tissue specimens were collected from 14 patients without periodontitis and T2DM (Group 1), 15 patients with periodontitis alone (Group 2), and 7 patients with both periodontitis and T2DM (Group 3). The mRNA of TLR4, CD14, MD-2 and MyD88 was quantified using real-time PCR and compared between the groups. Results: Statistical analysis showed that periodontal expression of CD14 mRNA was significantly reduced across Groups 1, 2 and 3 (p = 0.02) whereas the mRNA expression of TLR4, MD-2 and MyD88 was not significantly different among the groups. Furthermore, when patients in Groups 1 and 2 were combined (n = 22), the CD14 mRNA expression was significantly lower than that in patients of Group 1 (p = 0.04). Conclusions: CD14 mRNA expression was downregulated across patients with neither periodontitis nor T2DM, patients with periodontitis alone and patients with both diseases, suggesting that CD14 mRNA expression is associated with a favorable host response or subjected to a negative feedback regulation. C1 [Hedgpeth, Dustin C.; Leite, Renata S.; Krayer, Joe W.] Med Univ S Carolina, James B Edwards Coll Dent Med, Dept Stomatol, Charleston, SC 29425 USA. [Leite, Renata S.] Med Univ S Carolina, James B Edwards Coll Dent Med, Ctr Oral Hlth Res, Charleston, SC 29425 USA. [Zhang, Xiaoming; Jin, Junfei; Huang, Yan] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Huang, Yan] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Jin, Junfei] Guilin Med Univ, Affiliated Hosp, Lab Hepatobiliary & Pancreat Surg, Guilin 541001, Guangxi, Peoples R China. RP Huang, Y (reprint author), Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, 114 Doughty St, Charleston, SC 29425 USA. EM huangyan@musc.edu FU National Institute of Dental and Craniofacial Research (NIDCR)/National Institutes of Health (NIH) [DE016353]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development [5I01BX000854] FX This work was supported by National Institute of Dental and Craniofacial Research (NIDCR)/National Institutes of Health (NIH) grant DE016353 and Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development grant 5I01BX000854 (to Y.H.). NR 47 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6831 J9 BMC ORAL HEALTH JI BMC Oral Health PD NOV 18 PY 2015 VL 15 AR 145 DI 10.1186/s12903-015-0118-3 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CW4ZM UT WOS:000365005200001 PM 26581717 ER PT J AU Pindyck, T Prochazka, AV AF Pindyck, Talia Prochazka, Allan V. TI Review: Screening identifies women having intimate partner violence, but effects are unclear SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Pindyck, Talia; Prochazka, Allan V.] Denver VA Med Ctr, Aurora, CO USA. RP Pindyck, T (reprint author), Denver VA Med Ctr, Aurora, CO USA. NR 3 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 17 PY 2015 VL 163 IS 10 BP JC3 EP JC3 DI 10.7326/ACPJC-2015-163-10-003 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CX5MQ UT WOS:000365746400004 PM 26571257 ER PT J AU Wang, R Stone, RL Kaelber, JT Rochat, RH Nick, AM Vijayan, KV Afshar-Kharghan, V Schmid, MF Dong, JF Sood, AK Chiu, W AF Wang, Rui Stone, Rebecca L. Kaelber, Jason T. Rochat, Ryan H. Nick, Alpa M. Vijayan, K. Vinod Afshar-Kharghan, Vahid Schmid, Michael F. Dong, Jing-Fei Sood, Anil K. Chiu, Wah TI Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE electron; cryotomography; platelet; microtubule; cancer ID CRYOELECTRON TOMOGRAPHY; TUMOR-METASTASIS; THROMBOCYTOSIS; VISUALIZATION; MICROSCOPY; ACQUISITION; CELLS AB Thrombocytosis and platelet hyperreactivity are known to be associated with malignancy; however, there have been no ultrastructure studies of platelets from patients with ovarian cancer. Here, we used electron cryotomography (cryo-ET) to examine frozen-hydrated platelets from patients with invasive ovarian cancer (n = 12) and control subjects either with benign adnexal mass (n = 5) or free from disease (n = 6). Qualitative inspections of the tomograms indicate significant morphological differences between the cancer and control platelets, including disruption of the microtubule marginal band. Quantitative analysis of subcellular features in 120 platelet electron tomograms from these two groups showed statistically significant differences in mitochondria, as well as microtubules. These structural variations in the platelets from the patients with cancer may be correlated with the altered platelet functions associated with malignancy. Cryo-ET of platelets shows potential as a noninvasive biomarker technology for ovarian cancer and other platelet-related diseases. C1 [Wang, Rui; Rochat, Ryan H.; Schmid, Michael F.; Chiu, Wah] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA. [Wang, Rui; Kaelber, Jason T.; Rochat, Ryan H.; Schmid, Michael F.; Chiu, Wah] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA. [Stone, Rebecca L.; Nick, Alpa M.; Afshar-Kharghan, Vahid; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA. [Kaelber, Jason T.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Vijayan, K. Vinod] Baylor Coll Med, Michael E DeBakey Vet Affair Med Ctr, Dept Med, Houston, TX 77030 USA. [Dong, Jing-Fei] Michael E DeBakey Vet Affair Med Ctr, Ctr Translat Res Inflammat, Houston, TX 77030 USA. [Dong, Jing-Fei] Univ Washington, Sch Med, Dept Med, Puget Sound Blood Ctr, Seattle, WA 98104 USA. [Dong, Jing-Fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98104 USA. [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA. [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA. RP Sood, AK (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA. EM asood@mdanderson.org; wah@bcm.edu OI Kaelber, Jason/0000-0001-9426-1030 FU NIH [P41GM103832, HL071895, HL085769, HL081613, CA177909]; Department of Defense [OC120547, OC093416]; Ovarian Cancer Research Fund Program Project Development Grant; Bettyann Asche Murray Distinguished Professorship; Baylor College of Medicine; MD Anderson Cancer Center Collaborative Award FX This research has been supported by NIH Grants P41GM103832, HL071895, HL085769, HL081613, and CA177909; Department of Defense Grants OC120547 and OC093416; an Ovarian Cancer Research Fund Program Project Development Grant; the Bettyann Asche Murray Distinguished Professorship; and a Baylor College of Medicine and MD Anderson Cancer Center Collaborative Award. NR 37 TC 6 Z9 6 U1 2 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 17 PY 2015 VL 112 IS 46 BP 14266 EP 14271 DI 10.1073/pnas.1518628112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CW7IA UT WOS:000365170400056 PM 26578771 ER PT J AU Silkoff, PE Strambu, I Laviolette, M Singh, D FitzGerald, JM Lam, S Kelsen, S Eich, A Ludwig-Sengpiel, A Hupp, GC Backer, V Porsbjerg, C Girodet, PO Berger, P Leigh, R Kline, JN Dransfield, M Calhoun, W Hussaini, A Khatri, S Chanez, P Susulic, VS Barnathan, ES Curran, M Das, AM Brodmerkel, C Baribaud, F Loza, MJ AF Silkoff, P. E. Strambu, I. Laviolette, M. Singh, D. FitzGerald, J. M. Lam, S. Kelsen, S. Eich, A. Ludwig-Sengpiel, A. Hupp, G. C. Backer, V. Porsbjerg, C. Girodet, P. O. Berger, P. Leigh, R. Kline, J. N. Dransfield, M. Calhoun, W. Hussaini, A. Khatri, S. Chanez, P. Susulic, V. S. Barnathan, E. S. Curran, M. Das, A. M. Brodmerkel, C. Baribaud, F. Loza, M. J. TI Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study SO RESPIRATORY RESEARCH LA English DT Article DE Asthma; Severity; Phenotypes; Profiling; Biomarkers; Personalized ID EXHALED NITRIC-OXIDE; RESEARCH-PROGRAM; EOSINOPHILIC ASTHMA; PERSISTENT ASTHMA; CLUSTER-ANALYSIS; SPUTUM; INFLAMMATION; PHENOTYPES; ADULTS; LUNG AB Background: Asthma is a heterogeneous disease and development of novel therapeutics requires an understanding of pathophysiologic phenotypes. The purpose of the ADEPT study was to correlate clinical features and biomarkers with molecular characteristics, by profiling asthma (NCT01274507). This report presents for the first time the study design, and characteristics of the recruited subjects. Methods: Patients with a range of asthma severity and healthy non-atopic controls were enrolled. The asthmatic subjects were followed for 12 months. Assessments included history, patient questionnaires, spirometry, airway hyper-responsiveness to methacholine, fractional exhaled nitric oxide (FENO), and biomarkers measured in induced sputum, blood, and bronchoscopy samples. All subjects underwent sputum induction and 30 subjects/cohort had bronchoscopy. Results: Mild (n = 52), moderate (n = 55), severe (n = 51) asthma cohorts and 30 healthy controls were enrolled from North America and Western Europe. Airflow obstruction, bronchodilator response and airways hyperresponsiveness increased with asthma severity, and severe asthma subjects had reduced forced vital capacity. Asthma control questionnaire-7 (ACQ7) scores worsened with asthma severity. In the asthmatics, mean values for all clinical and biomarker characteristics were stable over 12 months although individual variability was evident. FENO and blood eosinophils did not differ by asthma severity. Induced sputum eosinophils but not neutrophils were lower in mild compared to the moderate and severe asthma cohorts. Conclusions: The ADEPT study successfully enrolled asthmatics across a spectrum of severity and non-atopic controls. Clinical characteristics were related to asthma severity and in general asthma characteristics e.g. lung function, were stable over 12 months. Use of the ADEPT data should prove useful in defining biological phenotypes to facilitate personalized therapeutic approaches. C1 [Silkoff, P. E.; Susulic, V. S.; Barnathan, E. S.; Curran, M.; Das, A. M.; Brodmerkel, C.; Baribaud, F.; Loza, M. J.] Janssen Res & Dev LLC, Spring House, PA 19477 USA. [Strambu, I.] Arensia Exploratory Med, Bucharest 050159, Romania. [Laviolette, M.] IUCPQ, Quebec City, PQ G1V 4G5, Canada. [Singh, D.] Univ Manchester, Univ Hosp South Manchester Fdn Trust, Med Evaluat Unit, Manchester M23 9QZ, Lancs, England. [FitzGerald, J. M.; Lam, S.] Inst Heart & Lung Hlth, Lung Ctr, Gordon, ON, Canada. [FitzGerald, J. M.; Lam, S.] Leslie Diamond Hlth Care Ctr, Vancouver, BC V5Z 1M9, Canada. [Kelsen, S.] Temple Univ, Dept Thorac Med & Surg, Sch Med, Philadelphia, PA 19140 USA. [Eich, A.] IKF Pneumol Frankfurt, Inst Klin Forsch Pneumol, Clin Res Ctr Resp Dis, D-360596 Frankfurt, Germany. [Ludwig-Sengpiel, A.] KLB Gesundheitsforsch Lubeck GmbH, D-23552 Lubeck, Germany. [Hupp, G. C.] Yale Univ, Sch Med, Div Pulm & Crit Care & Sleep Med, Yale Ctr Asthma & Airway Dis, New Haven, CT 06520 USA. [Backer, V.; Porsbjerg, C.] Bispebjerg Hosp, Resp Res Unit, Dept Resp Med, DK-2400 Copenhagen NV, Denmark. [Girodet, P. O.; Berger, P.] Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, INSERM, U1045, F-33000 Bordeaux, France. [Leigh, R.] Univ Calgary, Cumming Sch Med, Calgary, AB T2N 4Z6, Canada. [Kline, J. N.] Univ Iowa, Div Pulm Crit Care & Occupat Med, Iowa City, IA 52242 USA. [Dransfield, M.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Dransfield, M.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Calhoun, W.] Univ Texas Med Branch, Galveston, TX 77555 USA. [Hussaini, A.] Parexel Int, Shelton Simmons MD, Brooklyn, MD 21225 USA. [Khatri, S.] Cleveland Clin, Dept Pulm & Crit Care, Cleveland, OH 44195 USA. [Chanez, P.] Aix Marseille Univ, Dept Resp Dis, Marseille, France. [Chanez, P.] Aix Marseille Univ, CNRS 7733, INSERM, UMR U1067,CIC Nord AP HM, Marseille, France. RP Silkoff, PE (reprint author), Janssen Res & Dev LLC, 1400 McKean Rd, Spring House, PA 19477 USA. EM psilkoff@its.jnj.com NR 42 TC 6 Z9 6 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD NOV 17 PY 2015 VL 16 AR 142 DI 10.1186/s12931-015-0299-y PG 15 WC Respiratory System SC Respiratory System GA CW1VS UT WOS:000364780500001 PM 26576744 ER PT J AU Libert, T Grande, D Asch, DA AF Libert, Timothy Grande, David Asch, David A. TI What web browsing reveals about your health SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID INFORMATION AB Advertisers can learn a lot from our digital footprints, including about our health. Timothy Libert and colleagues argue that we need to tighten restrictions on such data for marketing purposes while looking at their potential to improve health C1 [Libert, Timothy] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Grande, David; Asch, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Asch, DA (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. EM asch@wharton.upenn.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD NOV 16 PY 2015 VL 351 AR h5974 DI 10.1136/bmj.h5974 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CW9XU UT WOS:000365352300004 PM 26572794 ER PT J AU Delgado, RN Lim, DA AF Delgado, Ryan N. Lim, Daniel A. TI Embryonic Nkx2.1-expressing neural precursor cells contribute to the regional heterogeneity of adult V-SVZ neural stem cells SO DEVELOPMENTAL BIOLOGY LA English DT Article DE Stem cell heterogeneity; Neural stem cells; Adult neurogenesis; V-SVZ; Positional identity; Regional patterning; Nkx2.1 ID OLFACTORY-BULB; MAMMALIAN BRAIN; SUBVENTRICULAR ZONE; NEURONAL MIGRATION; TELENCEPHALON; INTERNEURONS; ORGANIZATION; DIVERSITY; GRANULE; ORIGIN AB The adult ventricular-subventricular zone (V-SVZ) of the lateral ventricle produces several subtypes of olfactory bulb (OB) interneurons throughout life. Neural stem cells (NSCs) within this zone are heterogeneous, with NSCs located in different regions of the lateral ventricle wall generating distinct OB interneuron subtypes. The regional expression of specific transcription factors appears to correspond to such geographical differences in the developmental potential of V-SVZ NSCs. However, the transcriptional definition and developmental origin of V-SVZ NSC regional identity are not well understood. In this study, we found that a population of NSCs in the ventral region of the V-SVZ expresses the transcription factor Nkx2.1 and is derived from Nkx2.1-expressing (Nkx2.1 +) embryonic precursors. To follow the fate of Nkx2.1 + cells and their progeny in vivo, we used mice with an Nkx2.1-CreER "knock-in" allele. Nkx2.1 + V-SVZ NSCs labeled in adult mice generated interneurons for the deep granule cell layer of the OB. Embryonic brain Nkx2.1 + precursors labeled at embryonic day 12.5 gave rise to Nkx2.1 + NSCs of the ventral V-SVZ in postnatal and adult mice. Thus, embryonic Nkx2.1 + neural precursors give rise to a population of Nkx2.1 + NSCs in the ventral V-SVZ where they contribute to the regional heterogeneity of V-SVZ NSCs. Published by Elsevier Inc. C1 [Delgado, Ryan N.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Delgado, Ryan N.; Lim, Daniel A.] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA. [Delgado, Ryan N.] Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA. [Delgado, Ryan N.] Univ Calif San Francisco, Med Scientist Training Program, San Francisco, CA 94143 USA. [Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 35 Med Ctr Way, San Francisco, CA 94143 USA. EM Daniel.Lim@ucsf.edu FU NIH [DP2-OD006505-01]; VA [2101 BX000252-04]; CIRM Predoctoral Fellowship [TG2-01153]; MSTP training grant [2T32GM007618-34] FX We thank L. Fuentealba and A. Alvarez-Buylla for helpful comments and suggestions, R. Andersen for careful review of the manuscript, and M. Bedolli for assisting in the caesarean delivery of tamoxifen-treated embryos. This work was funded by: NIH DP2-OD006505-01, VA 2101 BX000252-04, CIRM Predoctoral Fellowship (TG2-01153), MSTP training grant 2T32GM007618-34.. NR 45 TC 2 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 EI 1095-564X J9 DEV BIOL JI Dev. Biol. PD NOV 15 PY 2015 VL 407 IS 2 BP 265 EP 274 DI 10.1016/j.ydbio.2015.09.008 PG 10 WC Developmental Biology SC Developmental Biology GA CY0AK UT WOS:000366068100008 PM 26387477 ER PT J AU Lavine, JA Kibbe, CR Baan, M Sirinvaravong, S Umhoefer, HM Engler, KA Meske, LM Sacotte, KA Erhardt, DP Davis, DB AF Lavine, Jeremy A. Kibbe, Carly R. Baan, Mieke Sirinvaravong, Sirinart Umhoefer, Heidi M. Engler, Kimberly A. Meske, Louise M. Sacotte, Kaitlyn A. Erhardt, Daniel P. Davis, Dawn Belt TI Cholecystokinin expression in the beta-cell leads to increased beta-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE cholecystokinin; islet; beta-cell; apoptosis; aging; streptozotocin ID FAT-FED MICE; INSULIN-SECRETION; GENE-EXPRESSION; MOUSE MODELS; ALPHA-CELLS; IN-VIVO; RECEPTOR; PANCREAS; ISLETS; LOCALIZATION AB Cholecystokinin (CCK) is a peptide hormone produced in the gut and brain with beneficial effects on digestion, satiety, and insulin secretion. CCK is also expressed in pancreatic beta-cells, but only in models of obesity and insulin resistance. Whole body deletion of CCK in obese mice leads to reduced beta-cell mass expansion and increased apoptosis. We hypothesized that islet-derived CCK is important in protection from beta-cell apoptosis. To determine the specific role of beta-cell-derived CCK in beta-cell mass dynamics, we generated a transgenic mouse that expresses CCK in the beta-cell in the lean state (MIP-CCK). Although this transgene contains the human growth hormone minigene, we saw no expression of human growth hormone protein in transgenic islets. We examined the ability of MIP-CCK mice to maintain beta-cell mass when subjected to apoptotic stress, with advanced age, and after streptozotocin treatment. Aged MIP-CCK mice have increased beta-cell area. MIP-CCK mice are resistant to streptozotocin- induced diabetes and exhibit reduced beta-cell apoptosis. Directed CCK overexpression in cultured beta-cells also protects from cytokine-induced apoptosis. We have identified an important new paracrine/autocrine effect of CCK in protection of beta-cells from apoptotic stress. Understanding the role of beta-cell CCK adds to the emerging knowledge of classic gut peptides in intraislet signaling. CCK receptor agonists are being investigated as therapeutics for obesity and diabetes. While these agonists clearly have beneficial effects on body weight and insulin sensitivity in peripheral tissues, they may also directly protect beta-cells from apoptosis. C1 [Lavine, Jeremy A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Kibbe, Carly R.; Baan, Mieke; Sirinvaravong, Sirinart; Umhoefer, Heidi M.; Engler, Kimberly A.; Meske, Louise M.; Sacotte, Kaitlyn A.; Erhardt, Daniel P.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ Ctr, Madison, WI USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Clin Ctr, Madison, WI USA. RP Davis, DB (reprint author), 4147 MFCB,1685 Highland Ave, Madison, WI 53705 USA. EM dbd@medicine.wisc.edu FU Medical Scientist Training Program [T32 GM-08692]; National Institute on Aging [5T32 AG-000213]; National Institutes of Health [T32 RR-023916, T32 OD-010423]; National Institute of Diabetes and Digestive and Kidney Diseases [DK-083442]; US Department of Veterans Affairs [1I01BX001880]; University of Wisconsin; Wisconsin Partnership Program FX J. A. Lavine was supported by the Medical Scientist Training Program (T32 GM-08692). C. R. Kibbe is funded by National Institute on Aging (5T32 AG-000213). M. Baan was supported by the National Institutes of Health training grants T32 RR-023916 and T32 OD-010423. D. B. Davis has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-083442), US Department of Veterans Affairs (1I01BX001880), the University of Wisconsin, and the Wisconsin Partnership Program. NR 51 TC 3 Z9 3 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD NOV 15 PY 2015 VL 309 IS 10 BP E819 EP E828 DI 10.1152/ajpendo.00159.2015 PG 10 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA CX7JP UT WOS:000365878300001 PM 26394663 ER PT J AU Vu, JP Goyal, D Luong, L Oh, S Sandhu, R Norris, J Parsons, W Pisegna, JR Germano, PM AF Vu, John P. Goyal, Deepinder Luong, Leon Oh, Suwan Sandhu, Ravneet Norris, Joshua Parsons, William Pisegna, Joseph R. Germano, Patrizia M. TI PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE pituitary adenylate cyclase-activating peptide; PAC1 receptor; appetite; ghrelin; GLP-1; leptin ID CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; STIMULATES ADENYLATE-CYCLASE; GASTRIC-ACID-SECRETION; IN-SITU HYBRIDIZATION; PARAVENTRICULAR NUCLEUS; INSULIN SENSITIVITY; TISSUE DISTRIBUTION; GLUCOSE-TOLERANCE; MOLECULAR-CLONING AB Pituitary adenylate cyclase-activating peptide (PACAP) is expressed within the gastroenteric system, where it has profound physiological effects. PACAP was shown to regulate food intake and thermogenesis centrally; however, PACAP peripheral regulation of appetite and feeding behavior is unknown. Therefore, we studied PACAP's effect on appetite and food intake control by analyzing feeding behavior and metabolic hormones in PAC1-deficient (PAC1-/-) and age-matched wild-type (WT) mice intraperitoneally injected with PACAP(1-38) or PACAP(1-27) before the dark phase of feeding. Food intake and feeding behavior were analyzed using the BioDAQ system. Active ghrelin, glucagon-like peptide-1 (GLP-1), leptin, peptide YY, pancreatic polypeptide, and insulin were measured following PACAP(1-38) administration in fasted WT mice. PACAP(1-38)/PACAP(1-27) injected into WT mice significantly decreased in a dose-dependent manner cumulative food intake and reduced bout and meal feeding parameters. Conversely, PACAP(1-38) injected into PAC1-/- mice failed to significantly change food intake. Importantly, PACAP(1-38) reduced plasma levels of active ghrelin compared with vehicle in WT mice. In PAC1-/- mice, fasting levels of active ghrelin, GLP-1, insulin, and leptin and postprandial levels of active ghrelin and insulin were significantly altered compared with levels in WT mice. Therefore, PAC1 is a novel regulator of appetite/satiety. PACAP(1-38)/PACAP(1-27) significantly reduced appetite and food intake through PAC1. In PAC1-/- mice, the regulation of anorexigenic/orexigenic hormones was abolished, whereas active ghrelin remained elevated even postprandially. PACAP significantly reduced active ghrelin in fasting conditions. These results establish a role for PACAP via PAC1 in the peripheral regulation of appetite/satiety and suggest future studies to explore a therapeutic use of PACAP or PAC1 agonists for obesity treatment. C1 [Vu, John P.; Oh, Suwan; Sandhu, Ravneet; Norris, Joshua; Parsons, William; Pisegna, Joseph R.; Germano, Patrizia M.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Goyal, Deepinder] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Luong, Leon; Parsons, William; Pisegna, Joseph R.] Univ Calif Los Angeles, Mol Cellular & Integrat Physiol Program, Los Angeles, CA USA. [Pisegna, Joseph R.] Vet Affairs Greater Angeles Healthcare Syst, Div Gastroenterol Hepatol & Parenteral Nutr, Los Angeles, CA USA. [Pisegna, Joseph R.; Germano, Patrizia M.] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Germano, Patrizia M.] Vet Affairs Greater Angeles Healthcare Syst, Div Pulm & Crit Care, Los Angeles, CA USA. RP Germano, PM (reprint author), Univ Calif Los Angeles, Dept Vet Affairs, CURE, Greater Los Angeles Med Ctr, Bldg 115,Rm 313, Los Angeles, CA USA. EM pgermano@ucla.edu FU two Department of Veterans Affairs Merit Review Awards; Department of Veterans Affairs Merit Review Shared Equipment Evaluation Program; National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK-41301] FX This work was supported by two Department of Veterans Affairs Merit Review Awards (to P. Germano and J. R. Pisegna), the Department of Veterans Affairs Merit Review Shared Equipment Evaluation Program (to P. Germano), and National Institute of Diabetes and Digestive and Kidney Diseases Grant P30 DK-41301 (to CURE: Digestive Diseases Research Center, Models of Gastrointestinal Function and Disease Core). NR 62 TC 2 Z9 2 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD NOV 15 PY 2015 VL 309 IS 10 BP G816 EP G825 DI 10.1152/ajpgi.00190.2015 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA CX7JL UT WOS:000365877900004 PM 26336928 ER PT J AU Wells, JM Gaggar, A Nicod, LP AF Wells, J. Michael Gaggar, Amit Nicod, Laurent P. TI A Fragment in Time Elastin Peptides and Progression of Emphysema SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID OBSTRUCTIVE PULMONARY-DISEASE; SMOKERS; COPD; CT C1 [Wells, J. Michael; Gaggar, Amit] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Birmingham, AL 35233 USA. [Wells, J. Michael; Gaggar, Amit] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Gaggar, Amit] Birmingham VA Med Ctr, Birmingham, AL USA. [Nicod, Laurent P.] Univ Lausanne Hosp, Serv Pneumol, Lausanne, Switzerland. RP Wells, JM (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Birmingham, AL 35233 USA. FU NHLBI NIH HHS [K08 HL123940] NR 15 TC 1 Z9 1 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 15 PY 2015 VL 192 IS 10 BP 1141 EP 1143 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CW6XY UT WOS:000365142900001 PM 26568233 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI High-Volume Hemofiltration in Post-Cardiac Surgery Shock A Heroic Therapy? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID ACUTE KIDNEY INJURY; RENAL REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; INITIATION; STANDARD; METAANALYSIS; BYPASS C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Med Serv, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Med Serv, Pittsburgh, PA 15240 USA. OI Palevsky, Paul/0000-0002-7334-5400 NR 14 TC 0 Z9 0 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 15 PY 2015 VL 192 IS 10 BP 1143 EP 1144 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CW6XY UT WOS:000365142900002 PM 26568234 ER PT J AU Tanner, NT Silvestri, GA AF Tanner, Nichole T. Silvestri, Gerard A. TI What's in a Number? When It Comes to Pulmonary Nodules, It's All About the Number SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID LUNG-CANCER; DIAGNOSTIC EVALUATION; MANAGEMENT; PHYSICIANS; VOLUME C1 [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, HEROIC, Charleston, SC 29401 USA. [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA. RP Tanner, NT (reprint author), Ralph H Johnson Vet Affairs Hosp, HEROIC, Charleston, SC 29401 USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 15 PY 2015 VL 192 IS 10 BP 1149 EP 1150 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CW6XY UT WOS:000365142900005 PM 26568237 ER PT J AU Amalakuhan, B Maselli, DJ Martinez-Garcia, MA AF Amalakuhan, Bravein Maselli, Diego J. Martinez-Garcia, Miguel A. TI Update in Bronchiectasis 2014 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID CYSTIC FIBROSIS BRONCHIECTASIS; RANDOMIZED CONTROLLED-TRIAL; AIRWAY EPITHELIAL-CELLS; OF-LIFE QUESTIONNAIRE; LUNG CLEARANCE INDEX; RHEUMATOID-ARTHRITIS; EXACERBATIONS; MACROLIDES; CHILDREN; METAANALYSIS C1 [Amalakuhan, Bravein; Maselli, Diego J.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis Crit Care Med, Dept Med, San Antonio, TX 78229 USA. [Amalakuhan, Bravein; Maselli, Diego J.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Martinez-Garcia, Miguel A.] Univ & Polytech La Fe Hosp, Pneumol Serv, Valencia, Spain. RP Amalakuhan, B (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp, Pulm Dis Sect, 5th Floor,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM amalakuhan@uthscsa.edu NR 49 TC 3 Z9 3 U1 1 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 15 PY 2015 VL 192 IS 10 BP 1155 EP 1161 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CW6XY UT WOS:000365142900008 PM 26568240 ER PT J AU Russo, M Mahon, K Shanahan, M Ramjas, E Solon, C Purcell, SM Burdick, KE AF Russo, Manuela Mahon, Katie Shanahan, Megan Ramjas, Elizabeth Solon, Carly Purcell, Shaun M. Burdick, Katherine E. TI The relationship between sleep quality and neurocognition in bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Sleep disruption; Sleep quality; Neurocognition; Bipolar disorder ID CLOCK GENES; COGNITIVE DYSFUNCTION; CIRCADIAN-RHYTHMS; SOCIAL COGNITION; RATING-SCALE; DEPRESSION; PREFERENCE; RISK; SCHIZOPHRENIA; INDIVIDUALS AB Backgrounds: Sleep and circadian rhythm disruptions are prominent, trait-like features of bipolar disorder (BD) which precede the onset of mood episodes. Neurocognitive impairments also characterize BD not only during acute phases of the illness but also during remission. Although the relationship between these two debilitating aspects of the illness might seem intuitive, very little is known about their relationship. We examined the association between sleep dysfunction and neurocognition in BD. Methods: In a sample of 117 BD patients (mean age =45.0 +/- 10.7; 59.0% (n=69) male), neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery (MCCB). Sleep quality data were collected using the Epworth Sleepiness Scale (ESS) and the Pittsburgh Sleep Quality Index (PSQI). Partial Pearson correlations tested for a relationship between sleep and neurocognition. Path analyses were conducted to examine the hypothesized direct influence of sleep disruption on neurocognition. Results: Higher levels of sleep disruptions were associated with a more severe clinical presentation and poorer performance in social cognition, visual learning and working memory. Social cognition and working memory were directly (negatively) predicted by sleep disruptions. Limitations: The study was limited by a relatively small sample size and the lack of behavioral and biological objectives measure of activity/rest cycles. Conclusions: Our study suggests that in patients with BD, sleep disruptions have a detrimental effect on general level of psychopathology and contribute directly to impaired cognitive functioning in the domains of social cognition and working memory. More research using objective measurement of sleep should be pursued to support these data and to further investigate the causal relationship between these disabling aspects of the illness. Published by Elsevier B.V. C1 [Russo, Manuela; Mahon, Katie; Shanahan, Megan; Ramjas, Elizabeth; Solon, Carly; Purcell, Shaun M.; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Russo, Manuela; Mahon, Katie; Shanahan, Megan; Ramjas, Elizabeth; Solon, Carly; Purcell, Shaun M.; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Burdick, Katherine E.] James J Peters VA Med Ctr Bronx, Bronx, NY USA. RP Burdick, KE (reprint author), 1 Gustave L Levy Pl Box 1230, New York, NY 10029 USA. EM Katherine.burdick@mssm.edu FU CSRD VA [I01 CX000995]; NIMH NIH HHS [R01 MH100125, R34 MH101267] NR 46 TC 2 Z9 2 U1 1 U2 35 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD NOV 15 PY 2015 VL 187 BP 156 EP 162 DI 10.1016/j.jad.2015.08.009 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CS1RL UT WOS:000361845300023 PM 26339925 ER PT J AU Coati, I Fassan, M Farinati, F Graham, DY Genta, RM Rugge, M AF Coati, Irene Fassan, Matteo Farinati, Fabio Graham, David Y. Genta, Robert M. Rugge, Massimo TI Autoimmune gastritis: Pathologist's viewpoint SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Autoimmune gastritis; Metaplasia; Carcinoids; Operative link for gastritis assessment staging ID CHRONIC ATROPHIC GASTRITIS; PYLORIC GLAND ADENOMA; PERNICIOUS-ANEMIA; SYDNEY SYSTEM; T-CELLS; CANCER; METAPLASIA; STOMACH; CLASSIFICATION; PREVALENCE AB Western countries are seeing a constant decline in the incidence of Helicobacter pylori-associated gastritis, coupled with a rising epidemiological and clinical impact of autoimmune gastritis. This latter gastropathy is due to autoimmune aggression targeting parietal cells through a complex interaction of auto-antibodies against the parietal cell proton pump and intrinsic factor, and sensitized T cells. Given the specific target of this aggression, autoimmune gastritis is typically restricted to the gastric corpus-fundus mucosa. In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and (intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of the phenotypic changes or cascades occurring in this autoimmune setting, no reliable biomarkers are available for identifying patients at higher risk of developing a gastric neoplasm. The standardization of autoimmune gastritis histology reports and classifications in diagnostic practice is a prerequisite for implementing definitive secondary prevention strategies based on multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling. C1 [Coati, Irene; Fassan, Matteo; Rugge, Massimo] Univ Padua, Dept Med DIMED, Surg Pathol Unit, I-35121 Padua, Italy. [Farinati, Fabio] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterol Unit, I-35121 Padua, Italy. [Graham, David Y.] Baylor Coll Med, Dept Med, Vet Adm Hosp, Houston, TX 77030 USA. [Genta, Robert M.] Miraca Life Sci Res Inst, Irving, TX 75039 USA. [Genta, Robert M.] VA North Texas Hlth Care Syst, Dept Pathol, Dallas, TX 75390 USA. [Genta, Robert M.] VA North Texas Hlth Care Syst, Dept Med, Dallas, TX 75390 USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Fassan, M (reprint author), Univ Padua, Dept Med DIMED, Pathol, Surg Pathol Unit, Via Gabelli 61, I-35121 Padua, Italy. EM matteo.fassan@unipd.it RI Rugge, Massimo/K-7525-2016 FU Italian Association for Cancer Research (AIRC Regional grant) [6421]; Healthy Stomach Initiative (HIS) FX Supported by A grant from the Italian Association for Cancer Research (partly, AIRC Regional grant 2008 No. 6421); and published under the auspices of the Healthy Stomach Initiative (HIS) NR 60 TC 6 Z9 8 U1 2 U2 6 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD NOV 14 PY 2015 VL 21 IS 42 BP 12179 EP 12189 DI 10.3748/wjg.v21.i42.12179 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CW5HC UT WOS:000365025300026 PM 26576102 ER PT J AU Dixit, R Kemp, C Kulich, S Seethala, R Chiosea, S Ling, SZ Ha, PK Duvvuri, U AF Dixit, Ronak Kemp, Carolyn Kulich, Scott Seethala, Raja Chiosea, Simion Ling, Shizhang Ha, Patrick K. Duvvuri, Umamaheswar TI TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation SO SCIENTIFIC REPORTS LA English DT Article ID CANCER GENOMICS; IDENTIFICATION; SCCHN AB Head and neck squamous cell carcinoma (HNSCC) has a variety of causes. Recently, the human papilloma virus (HPV) has been implicated in the rising incidence of oropharyngeal cancer and has led to variety of studies exploring the differences between HPV-positive and HPV-negative HNSCC. The calcium-activated chloride channel TMEM16A is overexpressed in a variety of cancers, including HNSCC, but whether or not it plays different roles in HPV-positive and HPV-negative HNSCC is unknown. Here, we demonstrate that TMEM16A is preferentially overexpressed in HPV-negative HNSCC and that this overexpression of TMEM16A is associated with decreased patient survival. We also show that TMEM16A expression is decreased in HPV-positive HNSCC at the DNA, RNA, and protein levels in patient samples as well as cell lines. We demonstrate that the lower levels of TMEM16A expression in HPV-positive tumors can be attributed to both a combination of copy number alteration and promoter methylation at the DNA level. Additionally, our cellular data show that HPV-negative cell lines are more dependent on TMEM16A for survival than HPV-positive cell lines. Therefore, we suspect that the down-regulation of TMEM16A in HPV-positive HNSCC makes TMEM16A a poor therapeutic target in HPV-positive HNSCC, but a potentially useful target in HPV-negative HNSCC. C1 [Dixit, Ronak; Kemp, Carolyn; Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Kulich, Scott; Duvvuri, Umamaheswar] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Seethala, Raja; Chiosea, Simion] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Ling, Shizhang; Ha, Patrick K.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. EM duvvuriu@upmc.edu FU Department of Veterans Affairs; PNC Foundation; University of Pittsburgh; NIH CCSG [P30 CA047904] FX We would like to acknowledge Alyssa Luvison of the Department of Pathology at the University of Pittsburgh for running the FISH analysis and providing the respective images. This work was funded in part by a Career Development Award from the Department of Veterans Affairs, the PNC Foundation, and the Competitive Medical Research Fund from the University of Pittsburgh (U.D.). We acknowledge support from the NIH CCSG P30 CA047904 for Tissue Core Facilities. This work does not represent the views of US Government or the Department of Veterans Affairs. NR 19 TC 3 Z9 3 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 13 PY 2015 VL 5 AR 16657 DI 10.1038/srep16657 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CW0AU UT WOS:000364652100001 PM 26563938 ER PT J AU D'Souza, A Dispenzieri, A Wirk, B Zhang, MJ Huang, JX Gertz, MA Kyle, RA Kumar, S Comenzo, RL Gale, RP Lazarus, HM Savani, BN Cornell, RF Weiss, BM Vogl, DT Freytes, CO Scott, EC Landau, HJ Moreb, JS Costa, LJ Ramanathan, M Callander, NS Kamble, RT Olsson, RF Ganguly, S Nishihori, T Kindwall-Keller, TL Wood, WA Mark, TM Hari, P AF D'Souza, Anita Dispenzieri, Angela Wirk, Baldeep Zhang, Mei-Jie Huang, Jiaxing Gertz, Morie A. Kyle, Robert A. Kumar, Shaji Comenzo, Raymond L. Gale, Robert Peter Lazarus, Hillard M. Savani, Bipin N. Cornell, Robert F. Weiss, Brendan M. Vogl, Dan T. Freytes, Cesar O. Scott, Emma C. Landau, Heather J. Moreb, Jan S. Costa, Luciano J. Ramanathan, Muthalagu Callander, Natalie S. Kamble, Rammurti T. Olsson, Richard F. Ganguly, Siddhartha Nishihori, Taiga Kindwall-Keller, Tamila L. Wood, William A. Mark, Tomer M. Hari, Parameswaran TI Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PRIMARY SYSTEMIC AMYLOIDOSIS; HIGH-DOSE MELPHALAN; AL AMYLOIDOSIS; CARDIAC BIOMARKERS; MULTIPLE-MYELOMA; STAGING SYSTEM; DEXAMETHASONE; BORTEZOMIB; SURVIVAL; CYCLOPHOSPHAMIDE AB Purpose Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America. Patients and Methods Between 1995 and 2012, 1,536 patients with AL who underwent autotransplantation at 134 centers were identified in the Center for International Blood and Marrow Transplant Research database. EM and overall survival (OS) were analyzed in three time cohorts: 1995 to 2000 (n = 140), 2001 to 2006 (n = 596), and 2007 to 2012 (n = 800). Hematologic and renal responses and factors associated with EM, relapse and/or progression, progression-free survival and OS were analyzed in more recent subgroups from 2001 to 2006 (n = 197) and from 2007 to 2012 (n = 157). Results Mortality at 30 and 100 days progressively declined over successive time periods from 11% and 20%, respectively, in 1995 to 2000 to 5% and 11%, respectively, in 2001 to 2006, and to 3% and 5%, respectively, in 2007 to 2012. Correspondingly, 5-year OS improved from 55% in 1995 to 2000 to 61% in 2001 to 2006 and to 77% in 2007 to 2012. Hematologic response to transplantation improved in the latest cohort. Renal response rate was 32%. Centers performing more than four AL transplantations per year had superior survival outcomes. In the multivariable analysis, cardiac AL was associated with high EM and inferior progression-free survival and OS. Autotransplantation in 2007 to 2012 and use of higher dosages of melphalan were associated with a lowered relapse risk. A Karnofsky score less than 80 and creatinine levels 2 mg/m(2) or greater were associated with worsened OS. Conclusion Post-transplantation survival in AL has improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year survival. The risk-benefit ratio for autotransplantation has changed, and randomized comparison with nontransplantation approaches is again warranted. (C) 2015 by American Society of Clinical Oncology C1 [D'Souza, Anita; Zhang, Mei-Jie; Huang, Jiaxing; Hari, Parameswaran] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Zhang, Mei-Jie] Med Coll Wisconsin, Inst Hlth & Soc, Milwaukee, WI 53226 USA. [Callander, Natalie S.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Dispenzieri, Angela; Gertz, Morie A.; Kyle, Robert A.; Kumar, Shaji] Mayo Clin, Rochester, MN USA. [Wirk, Baldeep] Seattle Canc Care Alliance, Seattle, WA USA. [Comenzo, Raymond L.] Tufts Med Ctr, Boston, MA USA. [Ramanathan, Muthalagu] Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Hematol Res Ctr, London, England. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Savani, Bipin N.; Cornell, Robert F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Weiss, Brendan M.; Vogl, Dan T.] Univ Penn, Med Ctr, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kamble, Rammurti T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Scott, Emma C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Landau, Heather J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Mark, Tomer M.] Weill Cornell Med Coll, New York, NY USA. [Moreb, Jan S.] Shands HealthCare, Gainesville, FL USA. [Moreb, Jan S.] Univ Florida, Gainesville, FL USA. [Nishihori, Taiga] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Costa, Luciano J.] Univ Alabama Birmingham, Birmingham, AL USA. [Olsson, Richard F.] Karolinska Inst, Stockholm, Sweden. [Olsson, Richard F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Ganguly, Siddhartha] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Kindwall-Keller, Tamila L.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Wood, William A.] Univ N Carolina, Chapel Hill, NC USA. RP D'Souza, A (reprint author), Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave,Ste C5500, Milwaukee, WI 53226 USA. EM andsouza@mcw.edu OI Dispenzieri, Angela/0000-0001-8780-9512; Hari, Parameswaran/0000-0002-8800-297X FU Celgene; Millennium Pharmaceuticals; Janssen Oncology; Pfizer; Novartis; Onyx; Millennium; Sanofi Pasteur; Janssen Pharmaceuticals; Prothena; Takeda Pharmaceuticals; Jannsen Pharmaceuticals; Array BioPharma; Karyopharm; Janssen Research Development; Acetylon Pharmaceuticals; GlaxoSmithKline; Calithera Biosciences; Constellation Pharmaceuticals; Merck; Takeda; Pharmacyclics; Gilead Sciences; Sanofi; Celldex; US Biotest FX Celgene (Inst), Millennium Pharmaceuticals (Inst), Janssen Oncology (Inst), Pfizer (Inst); Celgene, Novartis, Onyx, Millennium, Sanofi Pasteur, Janssen Pharmaceuticals; Prothena, Takeda Pharmaceuticals, Jannsen Pharmaceuticals, Array BioPharma, Karyopharm; Prothena, Janssen Research & Development; Millennium Pharmaceuticals, Acetylon Pharmaceuticals, GlaxoSmithKline, Calithera Biosciences, Constellation Pharmaceuticals; Merck; Millennium Pharmaceuticals, Takeda; Onyx, Takeda; Celgene, Gilead Sciences, Millennium Pharmaceuticals, Pharmacyclics; Janssen Pharmaceuticals, Sanofi, Celgene; Celldex, US Biotest; Celgene (Inst), Onyx (Inst); Millennium Pharmaceuticals (Inst), Celgene (Inst) NR 30 TC 15 Z9 15 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 10 PY 2015 VL 33 IS 32 BP 3741 EP + DI 10.1200/JCO.2015.62.4015 PG 12 WC Oncology SC Oncology GA CX9IX UT WOS:000366020100013 PM 26371138 ER PT J AU Kim, YH Tavallaee, M Sundram, U Salva, KA Wood, GS Li, SF Rozati, S Nagpal, S Krathen, M Reddy, S Hoppe, RT Nguyen-Lin, A Weng, WK Armstrong, R Pulitzer, M Advani, RH Horwitz, SM AF Kim, Youn H. Tavallaee, Mahkam Sundram, Uma Salva, Katrin A. Wood, Gary S. Li, Shufeng Rozati, Sima Nagpal, Seema Krathen, Michael Reddy, Sunil Hoppe, Richard T. Nguyen-Lin, Annie Weng, Wen-Kai Armstrong, Randall Pulitzer, Melissa Advani, Ranjana H. Horwitz, Steven M. TI Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID STEM-CELL TRANSPLANTATION; LIGHT-CHAIN AMYLOIDOSIS; PRIMARY SYSTEMIC AMYLOIDOSIS; HIGH-DOSE MELPHALAN; AL AMYLOIDOSIS; CARDIAC BIOMARKERS; STAGING SYSTEM; DEXAMETHASONE; BORTEZOMIB; SURVIVAL AB Purpose In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Szary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS. Tissue and blood biomarkers of clinical response were explored. Patients and Methods In this phase II study, patients with MF or SS with negligible to 100% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses. The primary end point was overall global response rate. Secondary end points included correlation of tissue CD30 expression level with clinical response, time to response, duration of response, progression-free and event-free survivals, and safety. Results Of the 32 patients enrolled and treated, 30 patients had available efficacy evaluations. Objective global response was observed in 21 (70%) of 30 patients (90% CI, 53% to 83%). CD30 expression assessed by immunohistochemistry was highly variable, with a median CD30max of 13% (range, 0% to 100%). Those with <5% CD30 expression had a lower likelihood of global response than did those with 5% or greater CD30 expression (P < .005). CD163 positive tumor-associated macrophages, many of which coexpress CD30, were abundant in tissue. Peripheral neuropathy was the most common adverse event. Conclusion Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF or SS with a wide range of CD30 expression levels. Additional biomarker studies may help optimize rational design of combination therapies with brentuximab vedotin. (C) 2015 by American Society of Clinical Oncology C1 [Kim, Youn H.; Tavallaee, Mahkam; Sundram, Uma; Li, Shufeng; Rozati, Sima; Nagpal, Seema; Krathen, Michael; Reddy, Sunil; Hoppe, Richard T.; Nguyen-Lin, Annie; Weng, Wen-Kai; Armstrong, Randall; Advani, Ranjana H.] Stanford Univ, Stanford, CA 94305 USA. [Salva, Katrin A.; Wood, Gary S.] Univ Wisconsin, Madison, WI USA. [Salva, Katrin A.; Wood, Gary S.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Pulitzer, Melissa; Horwitz, Steven M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Kim, YH (reprint author), Stanford Canc Inst, Multidisciplinary Cutaneous Lymphoma Program, 780 Welch Rd,CJ220J, Stanford, CA 94305 USA. EM younkim@stanford.edu FU Seattle Genetics; Haas Family Foundation FX Supported by Seattle Genetics and the Haas Family Foundation. NR 30 TC 27 Z9 28 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 10 PY 2015 VL 33 IS 32 BP 3750 EP + DI 10.1200/JCO.2014.60.3969 PG 11 WC Oncology SC Oncology GA CX9IX UT WOS:000366020100014 PM 26195720 ER PT J AU Xiang, Y Kiseleva, R Reukov, V Mulligan, J Atkinson, C Schlosser, R Vertegel, A AF Xiang, Yun Kiseleva, Raisa Reukov, Vladimir Mulligan, Jennifer Atkinson, Carl Schlosser, Rodney Vertegel, Alexey TI Relationship between Targeting Efficacy of Liposomes and the Dosage of Targeting Antibody Using Surface Plasmon Resonance SO LANGMUIR LA English DT Article ID DRUG-DELIVERY; IN-VITRO; NANOPARTICLES; BINDING; RECEPTOR; AVIDITY; CELLS; SIZE; IMMUNOLIPOSOMES; NANOCARRIERS AB Surface plasmon resonance (SPR) was used in this research to investigate the targeting efficacy (i.e., the binding affinity) of antibody-modified liposomes. The results indicated that liposomes modified by targeting antibodies exhibited an increase in apparent binding affinity, a result attributed to the avidity effect. More specifically, the targeting effect improved as the surface density of the targeting antibody increased, an increase primarily attributed to the decrease of the dissociation rate. However, this trend stopped when the surface density reached a threshold of approximately 1.5 x 10(8) antibody/mm(2). This surface density was found to be quite consistent regardless of the liposome size and the type of targeting antibody. In addition, a traditional cell binding experiment was conducted to confirm the saturation point obtained from SPR. C1 [Xiang, Yun; Kiseleva, Raisa; Reukov, Vladimir; Vertegel, Alexey] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. [Mulligan, Jennifer; Atkinson, Carl; Schlosser, Rodney] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Vertegel, A (reprint author), Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. EM vertege@clemson.edu FU VA Grant [101 CX000377]; NIH [2P20RR016461-10] FX The authors gratefully acknowledge the assistance from the Biomolecular Interactions Lab and Biomolecular Modeling Lab, Department of Bioengineering, Clemson University. This project was supported by a VA Grant (Merit Award 101 CX000377). Partial support was provided by NIH Grant No. 2P20RR016461-10 (INBRE), awarded to the South Carolina Research Foundation. NR 38 TC 2 Z9 2 U1 3 U2 11 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0743-7463 J9 LANGMUIR JI Langmuir PD NOV 10 PY 2015 VL 31 IS 44 BP 12177 EP 12186 DI 10.1021/acs.langmuir.5b01386 PG 10 WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science, Multidisciplinary SC Chemistry; Materials Science GA CV9NY UT WOS:000364615100027 PM 26484937 ER PT J AU Antonucci, L Fagman, JB Kim, JY Todoric, J Gukovsky, I Mackey, M Ellisman, MH Karin, M AF Antonucci, Laura Fagman, Johan B. Kim, Ju Youn Todoric, Jelena Gukovsky, Ilya Mackey, Mason Ellisman, Mark H. Karin, Michael TI Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE autophagy; ATG7; pancreatitis; protein synthesis ID ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; CANCER; MICE; PATHWAY; P53; INFLAMMATION; INVOLVEMENT; ROLES AB Pancreatic acinar cells possess very high protein synthetic rates as they need to produce and secrete large amounts of digestive enzymes. Acinar cell damage and dysfunction cause malnutrition and pancreatitis, and inflammation of the exocrine pancreas that promotes development of pancreatic ductal adenocarcinoma (PDAC), a deadly pancreatic neoplasm. The cellular and molecular mechanisms that maintain acinar cell function and whose dysregulation can lead to tissue damage and chronic pancreatitis are poorly understood. It was suggested that autophagy, the principal cellular degradative pathway, is impaired in pancreatitis, but it is unknown whether impaired autophagy is a cause or a consequence of pancreatitis. To address this question, we generated Atg7(Delta pan) mice that lack the essential autophagy-related protein 7 (ATG7) in pancreatic epithelial cells. Atg7(Delta pan) mice exhibit severe acinar cell degeneration, leading to pancreatic inflammation and extensive fibrosis. Whereas ATG7 loss leads to the expected decrease in autophagic flux, it also results in endoplasmic reticulum (ER) stress, accumulation of dysfunctional mitochondria, oxidative stress, activation of AMPK, and a marked decrease in protein synthetic capacity that is accompanied by loss of rough ER. Atg7(Delta pan) mice also exhibit spontaneous activation of regenerative mechanisms that initiate acinar-to-ductal metaplasia (ADM), a process that replaces damaged acinar cells with duct-like structures. C1 [Antonucci, Laura; Fagman, Johan B.; Kim, Ju Youn; Todoric, Jelena; Karin, Michael] Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Moores Canc Ctr,Dept Pharmacol, La Jolla, CA 92093 USA. [Antonucci, Laura; Fagman, Johan B.; Kim, Ju Youn; Todoric, Jelena; Karin, Michael] Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Moores Canc Ctr,Dept Pathol, La Jolla, CA 92093 USA. [Fagman, Johan B.] Univ Gothenburg, Inst Clin Sci, Dept Surg, Sahlgrenska Canc Ctr, SE-41345 Gothenburg, Sweden. [Todoric, Jelena] Med Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria. [Gukovsky, Ilya] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Gukovsky, Ilya] Univ Calif Los Angeles, Los Angeles, CA 90073 USA. [Mackey, Mason; Ellisman, Mark H.] Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA. RP Karin, M (reprint author), Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Moores Canc Ctr,Dept Pharmacol, La Jolla, CA 92093 USA. EM karinoffice@ucsd.edu FU Istituto Pasteur-Fondazione Cenci Bolognetti; Swedish Research Council [524-2011-6817]; Swedish Society for Medical Research; Superfund Basic Research Project (SBRP) [ES010337]; Austrian Science Fund [J3233]; Austrian Association for Laboratory Medicine and Clinical Chemistry (OGLMKC); Austrian Program for Advanced Research and Technology of the Austrian Academy of Sciences; NIH [AA019730, DK098108, GM103412, GM103426, CA163798, P01 DK098108]; International Community Foundation, San Diego; SBRP [ES010337]; Lustgarten Foundation [RFP-B-007] FX We thank Guy Perkins and Tom Deerinck for advice and helpful suggestions and thank Santa Cruz Biotechnology and Cell Signaling for antibody samples. L.A. was supported by a fellowship from Istituto Pasteur-Fondazione Cenci Bolognetti; J.B.F. was supported by post-doctoral fellowships from the Swedish Research Council (524-2011-6817) and the Swedish Society for Medical Research. J.Y.K. was supported by the Superfund Basic Research Project (SBRP; ES010337); J.T. was supported by the Erwin Schroedinger Fellowship from the Austrian Science Fund (J3233) and Univ. Prof. Dr. 17 Matthias M. Muller Fellowship from the Austrian Association for Laboratory Medicine and Clinical Chemistry (OGLMKC) and the Austrian Program for Advanced Research and Technology of the Austrian Academy of Sciences; I.G. was supported by NIH Grants AA019730 and DK098108; M.M. and M.H.E. were supported by grants from the International Community Foundation, San Diego, the NIH (GM103412 and GM103426). M.K. is an American Cancer Society Research Professor and the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases. Research in his lab was supported by grants from the NIH (CA163798), the SBRP (ES010337), the Lustgarten Foundation (RFP-B-007), and NIH Program Project Grant P01 DK098108. NR 44 TC 18 Z9 18 U1 1 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 10 PY 2015 VL 112 IS 45 BP E6166 EP E6174 DI 10.1073/pnas.1519384112 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CV7QY UT WOS:000364470300014 PM 26512112 ER PT J AU Urayama, A Dohgu, S Robinson, SM Sly, WS Grubb, JH Banks, WA AF Urayama, Akihiko Dohgu, Shinya Robinson, Sandra M. Sly, William S. Grubb, Jeffery H. Banks, William A. TI Alpha Adrenergic Induction of Transport of Lysosomal Enzyme across the Blood-Brain Barrier SO PLoS One LA English DT Article ID MANNOSE 6-PHOSPHATE RECEPTOR; MEDIATED TRANSPORT; INTERNALIZATION; SUBTYPES; STORAGE; VII AB The impermeability of the adult blood-brain barrier (BBB) to lysosomal enzymes impedes the ability to treat the central nervous system manifestations of lysosomal storage diseases. Here, we found that simultaneous stimulation of the alpha1 and alpha2 adrenoreceptor restores in adult mice the high rate of transport for the lysosomal enzyme P-GUS that is seen in neonates but lost with development. Beta adrenergics, other monoamines, and acetylcholine did not restore this transport. A high dose (500 microg/mouse) of clonidine, a strong alpha2 and weak alpha1 agonist, was able to act as monotherapy in the stimulation of P-GUS transport. Neither use of alpha1 plus alpha2 agonists nor the high dose clonidine disrupted the BBB to albumin. In situ brain perfusion and immunohistochemistry studies indicated that adrengerics act on transporters already at the luminal surface of brain endothelial cells. These results show that adrenergic stimulation, including monotherapy with clonidine, could be key for CNS enzyme replacement therapy. C1 [Urayama, Akihiko] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA. [Dohgu, Shinya] Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka, Japan. [Robinson, Sandra M.] St Louis Univ, Div Geriatr Med, Dept Internal Med, St Louis, MO 63103 USA. [Sly, William S.; Grubb, Jeffery H.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98493 USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98493 USA. EM wabanks1@uw.edu FU National Institutes of Health [Ro1 NS081134]; Veterans Affairs; Shire; NIH [R01 NS081134] FX National Institutes of Health (WAB) Ro1 NS081134, Veterans Affairs (WAB) (no number), Shire (WAB; WSS) (no number). The funders had no role in the study, design, data collection and analysis, decision to publish, or preparation of the manuscript.; Supported by Veterans Affairs (WAB), Shire, and NIH R01 NS081134 (WAB). The contents do not represent the views of the US Department of Veterans Affairs or the United States Government. NR 25 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 6 PY 2015 VL 10 IS 11 AR e0142347 DI 10.1371/journal.pone.0142347 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CV6RT UT WOS:000364398700116 PM 26545208 ER PT J AU Murray, SG Wachter, RM Cho, KC Dhaliwal, G AF Murray, Sara G. Wachter, Robert M. Cho, Kerry C. Dhaliwal, Gurpreet TI A Breakthrough Diagnosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID BLADDER RUPTURE; URINARY ASCITES; RENAL-FAILURE; MULTIPLE-SCLEROSIS C1 [Murray, Sara G.; Wachter, Robert M.; Cho, Kerry C.; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Murray, Sara G.; Wachter, Robert M.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Cho, Kerry C.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Murray, SG (reprint author), Univ Calif San Francisco, 533 Parnassus Ave,U125, San Francisco, CA 94143 USA. EM sara.murray@ucsf.edu FU Governance Institute; Optima Health; QuantiaMD; IPC Healthcare; PatientSafe Solutions; Twine Health; EarlySense; QPID Health; Amino.com FX Dr. Wachter reports receiving fees paid to his institution for his membership on the board of directors and his service as chair of the quality committee for IPC Healthcare, receiving fees for serving on advisory boards for and holding stock options in PatientSafe Solutions, Twine Health, EarlySense, QPID Health, and Amino.com, receiving lecture fees from the Governance Institute and Optima Health, and receiving fees for developing and presenting patient safety educational material from QuantiaMD. No other potential conflict of interest relevant to this article was reported. NR 12 TC 0 Z9 0 U1 1 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 5 PY 2015 VL 373 IS 19 BP 1866 EP 1871 DI 10.1056/NEJMcps1402621 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CV3FK UT WOS:000364144000012 ER PT J AU Smith, CS Gerrish, WG Nash, M Fisher, A Brotman, A Smith, D Student, A Green, M Donovan, J Dreffin, M AF Smith, C. Scott Gerrish, Winslow G. Nash, Melanie Fisher, Amber Brotman, Adam Smith, Deborah Student, Ami Green, Melissa Donovan, Jodie Dreffin, Melissa TI Professional equipoise: Getting beyond dominant discourses in an interprofessional team SO JOURNAL OF INTERPROFESSIONAL CARE LA English DT Article DE Education; interprofessional education; interprofessional relations; interprofessional research; qualitative method ID CLINICAL-PSYCHOLOGY; PRIMARY-CARE; EDUCATION; COLLABORATION; PHARMACISTS; AMERICA AB In 2011, the US Department of Veterans Affairs established five Centers of Excellence to study training in the patient-centered medical home clinical microsystem. Early on, our center began a discourse analysis in order to better understand each profession's assumptions about roles, responsibilities, and the basis for truth in clinical care. We discovered that these different discourses were pervasive and led to unhelpful stereotypes of each other. This article describes the evidence we identified that led us to hypothesize these conflicting discourses and stereotypes. Specifically, we report on our attempts to identify the traditional discourses of four post-graduate professionsmedicine, nurse practitioner, psychology, and pharmacy. We also share lessons from our efforts to defuse participants from their identified discursive assumptions, and develop appreciation and value for the discursive contributions of other professionsa process we call professional equipoise. We conclude that we can change these discourses and the professional identity formation of novices if we provide sustained, integrated interprofessional education curriculum. This implies that we need: embedded, longitudinal training; faculty role modeling of inquisitiveness, respectful relationships, and risk taking; and safe and honest discussion about our differences. C1 [Smith, C. Scott; Nash, Melanie; Fisher, Amber; Brotman, Adam; Donovan, Jodie; Dreffin, Melissa] Boise VA Med Ctr, Boise, ID 83702 USA. [Gerrish, Winslow G.] Family Med Residency Idaho, Boise, ID USA. [Smith, Deborah] Gonzaga Univ, Dept Nursing, Spokane, WA 99258 USA. [Student, Ami] San Francisco VA Med Ctr, San Francisco, CA USA. [Green, Melissa] Salt Lake City VA, Salt Lake City, UT USA. RP Smith, CS (reprint author), Boise VA Med Ctr, 500 W Ft St, Boise, ID 83702 USA. EM scott.smith2@va.gov NR 42 TC 1 Z9 1 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1356-1820 EI 1469-9567 J9 J INTERPROF CARE JI J. Interprofessional Care PD NOV 3 PY 2015 VL 29 IS 6 BP 603 EP 609 DI 10.3109/13561820.2015.1051216 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CY5LX UT WOS:000366450200015 PM 26652633 ER PT J AU Yetish, G Kaplan, H Gurven, M Wood, B Pontzer, H Manger, PR Wilson, C McGregor, R Siegel, JM AF Yetish, Gandhi Kaplan, Hillard Gurven, Michael Wood, Brian Pontzer, Herman Manger, Paul R. Wilson, Charles McGregor, Ronald Siegel, Jerome M. TI Natural Sleep and Its Seasonal Variations in Three Pre-industrial Societies SO CURRENT BIOLOGY LA English DT Article ID SKIN-TEMPERATURE; HUNTER-GATHERER; KUNG-SAN; INFECTION; ENTRAINMENT; DURATION; LIGHT; DAWN AB How did humans sleep before the modern era? Because the tools to measure sleep under natural conditions were developed long after the invention of the electric devices suspected of delaying and reducing sleep, we investigated sleep in three preindustrial societies [1-3]. We find that all three show similar sleep organization, suggesting that they express core human sleep patterns, most likely characteristic of pre-modern era Homo sapiens. Sleep periods, the times from onset to offset, averaged 6.9-8.5 hr, with sleep durations of 5.7-7.1 hr, amounts near the low end of those industrial societies [4-7]. There was a difference of nearly 1 hr between summer and winter sleep. Daily variation in sleep duration was strongly linked to time of onset, rather than offset. None of these groups began sleep near sunset, onset occurring, on average, 3.3 hr after sunset. Awakening was usually before sunrise. The sleep period consistently occurred during the night-time period of falling environmental temperature, was not interrupted by extended periods of waking, and terminated, with vasoconstriction, near the nadir of daily ambient temperature. The daily cycle of temperature change, largely eliminated from modern sleep environments, may be a potent natural regulator of sleep. Light exposure was maximal in the morning and greatly decreased at noon, indicating that all three groups seek shade at midday and that light activation of the suprachiasmatic nucleus is maximal in the morning. Napping occurred on <7% of days in winter and <22% of days in summer. Mimicking aspects of the natural environment might be effective in treating certain modern sleep disorders. C1 [Yetish, Gandhi; Kaplan, Hillard] Univ New Mexico, Dept Anthropol, Albuquerque, NM 87131 USA. [Gurven, Michael] Univ Calif Santa Barbara, Dept Anthropol, Santa Barbara, CA 93106 USA. [Wood, Brian] Yale Univ, Dept Anthropol, New Haven, CT 06511 USA. [Pontzer, Herman] CUNY Hunter Coll, Dept Anthropol, New York, NY 10065 USA. [Manger, Paul R.] Univ Witwatersrand, Sch Anat Sci, ZA-2193 Johannesburg, South Africa. [Wilson, Charles] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Wilson, Charles] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Siegel, Jerome M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 91343 USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. EM jsiegel@ucla.edu FU National Research Foundation of South Africa; National Science Foundation [1062879]; NIH/NIA [R01AG024119]; [MH064109]; [DA034748] FX We thank Oma Tsamkgao for translation, assistance with the Actiwatch, and iButton application, and various associated tasks; Adhil Bhagwandin, Leigh-Anne Dell, and Josh Davimes for assistance with setup of studies in Namibia; Alfredo Maito Nose and Basilio Vie Tayo for translation, long hours of hard work, and comprehensive field guidance in Bolivia; Keng-Tee Chew and Ming-Fung Wu for help with data analysis; Eus Van Someren for advice on the use of iButtons; and Craig Heller for advice on ambient temperature recording. J.M.S. was supported by MH064109 and DA034748. M.G., H.K., and G.Y. were supported by NIH/NIA grant no. R01AG024119. P.R.M. was supported by funding from the National Research Foundation of South Africa. B.W. received support from the National Science Foundation grant no. 1062879. An abstract of this work was submitted to the World Federation of Sleep Research Societies meeting on April 6, 2015. NR 37 TC 24 Z9 25 U1 7 U2 33 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0960-9822 EI 1879-0445 J9 CURR BIOL JI Curr. Biol. PD NOV 2 PY 2015 VL 25 IS 21 BP 2862 EP 2868 DI 10.1016/j.cub.2015.09.046 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CV4UR UT WOS:000364262500031 PM 26480842 ER PT J AU Mavandadi, S Jacques, N Sayers, SL Oslin, DW AF Mavandadi, Shahrzad Jacques, Natacha Sayers, Steven L. Oslin, David W. TI Health-related social control among older men with depressive symptomatology SO AGING & MENTAL HEALTH LA English DT Article DE social support; depression; age; health behavior ID PSYCHOLOGICAL DISTRESS; MARITAL-STATUS; SHORT-FORM; BEHAVIOR; SUPPORT; GENDER; INFORMATION; RELIABILITY; SYMPTOMS; MARRIAGE AB Objectives: Social control attempts, or attempts by social network members to influence a person's behavior, significantly predict men's health behaviors and psychological well-being. Despite the fact that depression is associated with compromised interpersonal functioning and poor health behaviors, the association between social control processes and depression has not been studied. Thus, this pilot study explored differential vulnerability to spouses' social control attempts among older, male primary care patients with varying levels of depression symptom severity and the degree to which these attempts predicted patients' behavioral and affective responses.Method: Participants included 88 older men referred by their primary care providers for a behavioral health assessment at a Veterans Affairs Medical Center. Data on sociodemographics, depressive symptomatology, health behaviors, spouses' positive and negative social control attempts, and patients' behavioral and affective responses to attempts were collected by telephone.Results: The sample was primarily Caucasian (mean age = 65.3 (SD = 8.1) years). Patients' higher depressive symptoms were significantly associated with positive and negative affective responses to their spouses' social control attempts. The frequency of control attempts and patients' behavioral responses, however, were unrelated to patients' depressive symptoms. Multiple regression models revealed that while spouses' control attempts were unrelated to patients' positive behavioral responses, more frequent negative attempts predicted greater negative behavioral responses (e.g., ignoring spouses' attempts). Moreover, negative control attempts predicted greater negative affective responses (e.g., resentment, sadness).Conclusion: The findings highlight the value of identifying effective social control strategies that maximize positive behavioral change, emotional responses, and health outcomes among older men with depressive symptoms. C1 [Mavandadi, Shahrzad; Jacques, Natacha; Sayers, Steven L.; Oslin, David W.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Mavandadi, Shahrzad; Sayers, Steven L.; Oslin, David W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Mavandadi, S (reprint author), Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. EM shahrzad.mavandadi@va.gov FU US Department of Veterans Affairs-VISN 4 Competitive Pilot Project Fund FX This work was supported by the US Department of Veterans Affairs-VISN 4 Competitive Pilot Project Fund. The content of this article does not reflect the views of the VHA or of the Government. NR 38 TC 0 Z9 0 U1 2 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 EI 1364-6915 J9 AGING MENT HEALTH JI Aging Ment. Health PD NOV 2 PY 2015 VL 19 IS 11 BP 997 EP 1004 DI 10.1080/13607863.2014.986646 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CP4JR UT WOS:000359848300005 PM 25506653 ER PT J AU Blanchard, EH Castle, S Cheng, J Roberts, C Ines, E Lee, C AF Blanchard, E. H. Castle, S. Cheng, J. Roberts, C. Ines, E. Lee, C. TI PROMOTING FITNESS AND FUNCTION AS A LIFELONG PROCESS FOR OLDER VETERANS IN GEROFIT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Blanchard, E. H.; Castle, S.; Cheng, J.; Roberts, C.; Ines, E.; Lee, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Castle, S.; Lee, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 4 EP 4 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222700015 ER PT J AU Dodge, HH Zhu, J Erten-Lyons, D Silbert, L Abner, EL Kryscio, R Schmitt, FA Kaye, J AF Dodge, H. H. Zhu, J. Erten-Lyons, D. Silbert, L. Abner, E. L. Kryscio, R. Schmitt, F. A. Kaye, J. TI RISK OF ALZHEIMER'S DISEASE INCIDENCE ATTRIBUTABLE TO PATHOLOGY-CONFIRMED VASCULAR DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dodge, H. H.; Erten-Lyons, D.; Silbert, L.; Kaye, J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Dodge, H. H.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Zhu, J.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Erten-Lyons, D.; Silbert, L.; Kaye, J.] Portland VA Med Ctr, Portland, OR USA. [Kryscio, R.] Univ Kentucky, Dept Biostat, Lexington, KY USA. [Kryscio, R.] Univ Kentucky, Dept Stat, Lexington, KY USA. [Abner, E. L.] Univ Kentucky, Dept Epidemiol, Lexington, KY USA. [Schmitt, F. A.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 6 EP 6 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222700026 ER PT J AU Atanous, AM Sherman, A Howe, JL AF Atanous, A. M. Sherman, A. Howe, J. L. TI REFLECTIVE PRACTICE ACROSS DISCIPLINES: STUDENT JOURNALING AS A LEARNING STRATEGY ABOUT THE LIFELONG PROCESS OF AGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Atanous, A. M.; Sherman, A.; Howe, J. L.] James J Peters VA Med Ctr, Bronx, NY USA. [Howe, J. L.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 49 EP 49 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222700202 ER PT J AU Zhou, Y Chen, Y Musi, N AF Zhou, Y. Chen, Y. Musi, N. TI TRANSCRIPTOMIC AND METABOLOMIC ANALYSIS OF AGING MUSCLE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Zhou, Y.; Musi, N.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Musi, N.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Zhou, Y.; Musi, N.] Sam & Ann Barshop Inst Aging & Longev Studies, San Antonio, TX USA. [Chen, Y.] Greehey Childrens Canc Res Inst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 67 EP 67 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222700262 ER PT J AU Carpenter, J Berry, PH Ersek, M AF Carpenter, J. Berry, P. H. Ersek, M. TI POST-DISCHARGE CARE IN NURSING FACILITIES AFTER HOSPITAL BASED PALLIATIVE CARE CONSULT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Carpenter, J.] Univ Utah, Salt Lake City, UT USA. [Berry, P. H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Ersek, M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Ersek, M.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 172 EP 172 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701089 ER PT J AU Howe, JL Fernandez, H Ko, FC Ganta, N Deering, J Sun, D Dumorne, D Atanous, AM AF Howe, J. L. Fernandez, H. Ko, F. C. Ganta, N. Deering, J. Sun, D. Dumorne, D. Atanous, A. M. TI PREPARING GERIATRICS FELLOWS TO EDUCATE PRIMARY CARE PROVIDERS: A MENTORED E-LEARNING CURRICULUM DEVELOPMENT AND ASSESSMENT TRACK SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Howe, J. L.; Ko, F. C.; Sun, D.; Dumorne, D.; Atanous, A. M.] James J Peters VAMC, Bronx GRECC, Bronx, NY USA. [Howe, J. L.; Fernandez, H.; Ko, F. C.; Ganta, N.; Deering, J.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 191 EP 192 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701158 ER PT J AU Peterson, D Dijkstra, BW Horak, FB AF Peterson, D. Dijkstra, B. W. Horak, F. B. TI THE EFFECTS OF AGE ON POSTURAL MOTOR LEARNING IN COMPENSATORY STEPPING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Peterson, D.; Horak, F. B.] Portland VA Med Ctr, Portland, OR USA. [Peterson, D.; Horak, F. B.] Oregon Hlth & Sci Univ, Neurol, Portland, OR 97201 USA. [Dijkstra, B. W.] Univ Groningen, Groningen, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 217 EP 217 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701244 ER PT J AU Creekmur, B Cote, S Mitchell, MN Kramer, B AF Creekmur, B. Cote, S. Mitchell, M. N. Kramer, B. TI ACCESS TO VA HOME-BASED PRIMARY CARE EXPANSION PROGRAMS IN COLLABORATION WITH INDIAN HEALTH SERVICE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Creekmur, B.; Cote, S.; Mitchell, M. N.; Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 256 EP 256 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701375 ER PT J AU Byers, AL Lai, AX Boscardin, J Nelson, JC Arean, PA Yaffe, K AF Byers, A. L. Lai, A. X. Boscardin, J. Nelson, J. C. Arean, P. A. Yaffe, K. TI PREDICTORS OF MENTAL HEALTH SERVICES USE ACROSS THE LIFESPAN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A. L.; Boscardin, J.; Nelson, J. C.; Arean, P. A.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, A. L.; Lai, A. X.; Boscardin, J.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 279 EP 280 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701462 ER PT J AU Rothrock, AG Bearden, D Simmons, E Booth, K Viles, A Sawyer, P Brown, CJ Flood, K AF Rothrock, A. G. Bearden, D. Simmons, E. Booth, K. Viles, A. Sawyer, P. Brown, C. J. Flood, K. TI HOURLY ROUNDING ON OLDER ADULTS IN ACUTE CARE SETTINGS: SIMULATION TRAINING FOR ACUTE CARE PROVIDERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rothrock, A. G.; Bearden, D.; Simmons, E.; Booth, K.; Viles, A.; Sawyer, P.; Brown, C. J.; Flood, K.] Univ Alabama Birmingham, Birmingham, AL USA. [Booth, K.; Brown, C. J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 303 EP 303 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701551 ER PT J AU Hung, WW AF Hung, W. W. TI INTEGRATED CARE: ESTABLISHING CARE PLANS TO MOVE RELEVANT CLINICAL INFORMATION ACROSS SILOS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.] Mt Sinai Sch Med, Geriatr, New York, NY USA. [Hung, W. W.] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 328 EP 328 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222701648 ER PT J AU Cigolle, C Quinones, AR Nagel, CL AF Cigolle, C. Quinones, A. R. Nagel, C. L. TI INCONSISTENCY IN THE SELF-REPORT OF DIABETES IN PANEL SURVEYS: LIMITATIONS OF MEDICATION DATA IN RESOLVING PROBLEMATIC RESPONSES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Cigolle, C.] Univ Michigan, Ann Arbor, MI 48109 USA. [Cigolle, C.] VAAAHS, GRECC, Ann Arbor, MI USA. [Quinones, A. R.; Nagel, C. L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Quinones, A. R.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 522 EP 523 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222702513 ER PT J AU Madigan, B Saliba, D Gassoumis, ZD Wilber, KH AF Madigan, B. Saliba, D. Gassoumis, Z. D. Wilber, K. H. TI COLLECTING CAREGIVER DATA DURING UNIVERSAL ASSESSMENT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Madigan, B.] Univ Calif Los Angeles, VA Geriatr Social Work Educ Consortium, Los Angeles, CA USA. [Saliba, D.] Univ Calif Los Angeles, JH Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Saliba, D.] RAND Corp, Santa Monica, CA USA. [Gassoumis, Z. D.; Wilber, K. H.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 535 EP 535 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222702556 ER PT J AU Ray, LM Wilber, K Newcomer, R Fulbright, KA Saliba, D AF Ray, L. M. Wilber, K. Newcomer, R. Fulbright, K. A. Saliba, D. TI TRANSFORMING EXISTING STATE MODELS INTO AN ASSESSMENT FRAMEWORK AND RECOMMENDATIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Ray, L. M.; Saliba, D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ray, L. M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Wilber, K.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA. [Newcomer, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fulbright, K. A.; Saliba, D.] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, D.] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 535 EP 535 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222702554 ER PT J AU Wilber, K Gassoumis, ZD Fulbright, KA Ray, LM Saliba, D AF Wilber, K. Gassoumis, Z. D. Fulbright, K. A. Ray, L. M. Saliba, D. TI CALIFORNIA: WHERE ARE WE STARTING FROM? SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Wilber, K.; Gassoumis, Z. D.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA. [Fulbright, K. A.; Saliba, D.] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA USA. [Ray, L. M.; Saliba, D.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Ray, L. M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Saliba, D.] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 535 EP 535 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222702555 ER PT J AU Allison, TA Ventura, M AF Allison, T. A. Ventura, M. TI HOW ARTS CLASSES CREATE NORMALCY IN THE CONTEXT OF NEURODEGENERATIVE DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Allison, T. A.; Ventura, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Allison, T. A.; Ventura, M.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 546 EP 546 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222702595 ER PT J AU Bouldin, E Trivedi, R Reiber, GE Nelson, K AF Bouldin, E. Trivedi, R. Reiber, G. E. Nelson, K. TI DO CAREGIVERS IMPROVE SELF-CARE AMONG ADULTS WITH POORLY CONTROLLED DIABETES? SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bouldin, E.; Reiber, G. E.; Nelson, K.] VA Puget Sound, HSR&D, Seattle, WA USA. [Bouldin, E.; Reiber, G. E.; Nelson, K.] Univ Washington, Seattle, WA 98195 USA. [Trivedi, R.] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Trivedi, R.] Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 652 EP 652 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222703156 ER PT J AU LaRocca, MA Scogin, F Lichstein, KL Mieskowski, L Moran, C Woosley, JA DiNapoli, EA Thomas, SJ AF LaRocca, M. A. Scogin, F. Lichstein, K. L. Mieskowski, L. Moran, C. Woosley, J. A. DiNapoli, E. A. Thomas, S. J. TI PREDICTORS OF QUALITY OF LIFE AMONG RURAL OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [LaRocca, M. A.; Scogin, F.; Lichstein, K. L.; Mieskowski, L.; Moran, C.; Woosley, J. A.] Univ Alabama, Clin Psychol, Tuscaloosa, AL USA. [DiNapoli, E. A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Thomas, S. J.] AL VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 681 EP 681 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222703254 ER PT J AU Kramer, B Frank, JC Creekmur, B Melendez, L Douglas, J Lee, D Mitchell, MN AF Kramer, B. Frank, J. C. Creekmur, B. Melendez, L. Douglas, J. Lee, D. Mitchell, M. N. TI THE IMPACT OF THE VA GERIATRIC SCHOLARS PROGRAM: INTEGRATING GERIATRICS IN PRIMARY CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, B.; Creekmur, B.; Melendez, L.; Douglas, J.; Lee, D.; Mitchell, M. N.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.; Frank, J. C.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 716 EP 716 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222703371 ER PT J AU Huh, J Gould, CE Shah, S Brown, K AF Huh, J. Gould, C. E. Shah, S. Brown, K. TI INCREASING SOCIALIZATION AND REDUCING LONELINESS IN OLDER RURAL VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Huh, J.; Gould, C. E.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA. [Huh, J.; Gould, C. E.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Shah, S.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. [Brown, K.] Episcopal Senior Communities, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 815 EP 816 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704234 ER PT J AU Trivedi, R Slightam, C Piette, JD Nelson, K Rosland, A Heidenreich, P Asch, S Timko, C AF Trivedi, R. Slightam, C. Piette, J. D. Nelson, K. Rosland, A. Heidenreich, P. Asch, S. Timko, C. TI SUCCEED: A PILOT STUDY OF A HEART FAILURE SELF-MANAGEMENT PROGRAM FOR COUPLES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Trivedi, R.; Slightam, C.; Heidenreich, P.; Asch, S.; Timko, C.] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Trivedi, R.; Heidenreich, P.; Asch, S.; Timko, C.] Stanford Univ, Stanford, CA 94305 USA. [Piette, J. D.; Rosland, A.] Ann Arbor VA, Ann Arbor, VA USA. [Piette, J. D.; Rosland, A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Nelson, K.] VA Puget Sound HCS, Seattle, WA USA. [Nelson, K.] Univ Washington, Seattle, WA 98195 USA. RI Rosland, Annmarie/B-7750-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 BP 822 EP 823 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704263 ER PT J AU Apelo, SA Lamming, D AF Apelo, Sebastian Arriola Lamming, Dudley TI Alternative Rapamycin Treatment Regimens Promote Longevity While Minimizing Side Effects SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Wisconsin, Med, Madison, WI 53706 USA. William S Middleton Mem VA Hosp, Madison, WI USA. [Apelo, Sebastian Arriola; Lamming, Dudley] Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Med, Madison, WI 53706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 MA 340 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704460 ER PT J AU Cortes, J Shrestha, S Ramos, K Cummings, J Armento, M Kunik, ME Stanley, MA Bush, A AF Cortes, Jose Shrestha, Srijana Ramos, Katherine Cummings, Jeremy Armento, Maria Kunik, Mark E. Stanley, Melinda A. Bush, Amy TI Psychometric Properties of Worry/Anxiety Measures in an Urban, Racially Diverse, Underserved Sample of Older Adults SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Cortes, Jose; Shrestha, Srijana; Armento, Maria; Kunik, Mark E.; Stanley, Melinda A.; Bush, Amy] Baylor Coll Med, Psychiat & Behav Sci, Houston, TX 77030 USA. [Cortes, Jose; Kunik, Mark E.; Stanley, Melinda A.; Bush, Amy] Houston VA Med Ctr, HSR&D, Houston, TX USA. [Shrestha, Srijana] Univ St Thomas, Psychol, St Paul, MN USA. [Ramos, Katherine] Durham VA Med Ctr, GRECC, Durham, NC USA. [Cummings, Jeremy] Southeastern Univ, Lakeland, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 MA 332 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704508 ER PT J AU Perez, K Ramos, K Wilson, NL Bush, A Kunik, ME Stanley, MA AF Perez, Kateri Ramos, Katherine Wilson, Nancy L. Bush, Amy Kunik, Mark E. Stanley, Melinda A. TI Vida Calma: Spanish-adapted CBT intervention for Spanish Elder with GAD SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Perez, Kateri] Univ Houston, Psychol Hlth & Learning Sci, Houston, TX 77004 USA. [Perez, Kateri; Wilson, Nancy L.; Bush, Amy; Kunik, Mark E.; Stanley, Melinda A.] Houston VA Med Ctr, HSR & D, Houston, TX USA. [Perez, Kateri; Wilson, Nancy L.; Bush, Amy; Kunik, Mark E.; Stanley, Melinda A.] Baylor Coll Med, Psychiat & Behav Sci, Houston, TX 77030 USA. [Ramos, Katherine] Durham VA Med Ctr, GRECC, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 MA 359 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704479 ER PT J AU Rogus-Pulia, N Zielinski, JJ Rusche, N Divyak, E Gangnon, R Safdar, N Robbins, J AF Rogus-Pulia, Nicole Zielinski, Jill J. Rusche, Nicole Divyak, Elizabeth Gangnon, Ronald Safdar, Nasia Robbins, Joanne TI Outcomes from the Swallow STRengthening OropharyNGeal (Swallow STRONG) Program and Expansion sites: An Update SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rogus-Pulia, Nicole; Zielinski, Jill J.; Rusche, Nicole; Divyak, Elizabeth; Safdar, Nasia; Robbins, Joanne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, Joanne] Univ Wisconsin, Med, Madison, WI 53706 USA. [Gangnon, Ronald] Univ Wisconsin, Biostat & Med Informat, Madison, WI 53706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 MA 342 PG 1 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704462 ER PT J AU Thorpe, C Fowler, N Zhao, XH Harrigan, K Kang, YH Thorpe, JM Hanlon, JT Gellad, WF AF Thorpe, Carolyn Fowler, Nicole Zhao, Xinhua Harrigan, Katherine Kang, Yihuang Thorpe, Joshua M. Hanlon, Joseph T. Gellad, Walid F. TI Initiation and Discontinuation of Antidementia Drugs in a National Sample of Medicare Beneficiaries SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Thorpe, Carolyn; Harrigan, Katherine; Thorpe, Joshua M.] Univ Pittsburgh, Pharm & Therapeut, Pittsburgh, PA 15260 USA. [Thorpe, Carolyn; Zhao, Xinhua; Thorpe, Joshua M.; Hanlon, Joseph T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fowler, Nicole] Indiana Univ Sch Med, Gen Internal Med, Indianapolis, IN 46202 USA. [Zhao, Xinhua; Kang, Yihuang; Hanlon, Joseph T.; Gellad, Walid F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2015 VL 55 SU 2 MA 343 PG 2 WC Gerontology SC Geriatrics & Gerontology GA DJ5BV UT WOS:000374222704519 ER EF